<SEC-DOCUMENT>0001493152-22-008703.txt : 20220401
<SEC-HEADER>0001493152-22-008703.hdr.sgml : 20220401
<ACCEPTANCE-DATETIME>20220401095855
ACCESSION NUMBER:		0001493152-22-008703
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220401
DATE AS OF CHANGE:		20220401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hillstream BioPharma Inc.
		CENTRAL INDEX KEY:			0001861657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				842642541
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41210
		FILM NUMBER:		22796218

	BUSINESS ADDRESS:	
		STREET 1:		1200 ROUTE 22 EAST
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		302-743-2995

	MAIL ADDRESS:	
		STREET 1:		245 MAIN STREET
		STREET 2:		SUITE 204
		CITY:			CHESTER
		STATE:			NJ
		ZIP:			07930
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:HILS="http://hillstreambio.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_HILS_hillstreambio.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001861657 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Percent_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey">0001861657</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2020-12-31" id="xdx2ixbrl0061" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2020-12-31" id="xdx2ixbrl0103" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HILS:AcquiredInprocessResearchAndDevelopment1" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0138" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0191" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HILS:DeemedDividendUponDebtExchange" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HILS:DeemedDividendUponDebtExchange" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HILS:RepaymentsOfDeferredOfferingCosts" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HILS:DeemedDividend" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HILS:DueToFounderConvertedToNotePayable" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HILS:UnpaidDeferredOfferingCosts" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0468" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0470" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0472" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0474" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0485" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0487" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0489" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0491" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0559" unitRef="Percent" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0560" unitRef="Percent" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hils-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-13</xbrli:startDate>
        <xbrli:endDate>2022-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-13</xbrli:startDate>
        <xbrli:endDate>2022-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-152021-09-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-15</xbrli:startDate>
        <xbrli:endDate>2021-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">HILS:FarringtonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-112020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">HILS:FarringtonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-11</xbrli:startDate>
        <xbrli:endDate>2020-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-05-012017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-01</xbrli:startDate>
        <xbrli:endDate>2017-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-13</xbrli:startDate>
        <xbrli:endDate>2022-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-042020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-04</xbrli:startDate>
        <xbrli:endDate>2020-09-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_SeptemberExchangeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:FiveNotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:SeptemberExchangeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_ExchangeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:FiveNotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-12-31_custom_RolledOverMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RolledOverMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_RolledOverMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RolledOverInToNewNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverInToNewNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RolledOverInToNewNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverInToNewNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentySeventeenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwentySeventeenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentySeventeenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentySeventeenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentySeventeenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-31_custom_TwentyNineteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-30_custom_TwentyNineteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_TwentyNineteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-302021-05-31_custom_TwentyNineteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-30</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwentyNineteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_FounderAndChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HILS:FounderAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-292019-12-30_custom_AssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:AssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-29</xbrli:startDate>
        <xbrli:endDate>2019-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:AssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:RestatedEmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-30</xbrli:startDate>
        <xbrli:endDate>2021-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-032022-01-06_us-gaap_SubsequentEventMember_custom_PromissoryNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">HILS:PromissoryNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-03</xbrli:startDate>
        <xbrli:endDate>2022-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-13</xbrli:startDate>
        <xbrli:endDate>2022-01-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-202022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HILS:BoardOfDirectorsAndScientificAdvisoryBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-20</xbrli:startDate>
        <xbrli:endDate>2022-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HILS:BoardOfDirectorsAndScientificAdvisoryBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_904_edei--DocumentType_c20210101__20211231_zRiB7sO75KOk"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span id="xdx_908_edei--DocumentAnnualReport_c20210101__20211231_zx4UROvMzTAg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <span id="xdx_903_edei--DocumentPeriodEndDate_c20210101__20211231_z16ONWPOLDfl"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_904_edei--CurrentFiscalYearEndDate_c20210101__20211231_zlUIQHQJqa5a"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, 2021</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span id="xdx_904_edei--DocumentTransitionReport_c20210101__20211231_zZWAYBIeCs5l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from ________ to _________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number <span id="xdx_90E_edei--EntityFileNumber_c20210101__20211231_zrEi6oXjOe5f"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityFileNumber">001-41210</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_900_edei--EntityRegistrantName_c20210101__20211231_zxYYf1hg0zvh" style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName">HILLSTREAM
BIOPHARMA, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zm360myv9v8k"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20210101__20211231_zIIv1gpGPnt7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">84-2642541</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or jurisdiction of<br />
    Incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.R.S.
    Employer<br />
    Identification No.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_900_edei--EntityAddressAddressLine1_c20210101__20211231_z5hkNbBc08Q2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1">1200
    Route 22 East</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_907_edei--EntityAddressAddressLine2_c20210101__20211231_znmpeZNCMcsf"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2">Suite
    2000</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_906_edei--EntityAddressCityOrTown_c20210101__20211231_zIuMI5h2Wsv5"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown">Bridgewater</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20210101__20211231_zEjDHsDoUrEg"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_907_edei--EntityAddressPostalZipCode_c20210101__20211231_z6T7mkvME7V7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode">08807</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_90B_edei--CityAreaCode_c20210101__20211231_zpXfGJP79dja" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:CityAreaCode">(908)</ix:nonNumeric>
</b></span><b><span id="xdx_90A_edei--LocalPhoneNumber_c20210101__20211231_zxyXHW9y0nAj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber">955-3140</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_edei--Security12bTitle_c20210101__20211231_zrkZX7IF3MG6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:Security12bTitle">Common
    stock, $0.0001 par value</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_edei--TradingSymbol_c20210101__20211231_zlm80OdvXUe1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:TradingSymbol">HILS</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_906_edei--SecurityExchangeName_c20210101__20211231_zSrcPZEmKiq1"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: <b>None.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.<br />
Yes &#9744; <span id="xdx_901_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_zq89QhINs0Z1"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_904_edei--EntityVoluntaryFilers_c20210101__20211231_zYp01HIzc6z7"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes &#9744; <span id="xdx_907_edei--EntityCurrentReportingStatus_c20210101__20211231_zHJmMBQSph83"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus">No</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).<br />
<span id="xdx_901_edei--EntityInteractiveDataCurrent_c20210101__20211231_z9Hmj0vD1cll"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90D_edei--EntityFilerCategory_c20210101__20211231_zPkTz3JC3pf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--EntitySmallBusiness_c20210101__20211231_z4ujOF3y8HLc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20210101__20211231_zGWjRwDYY3dk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_906_edei--EntityExTransitionPeriod_c20210101__20211231_zQgvy8wE4VQk"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_903_edei--IcfrAuditorAttestationFlag_c20210101__20211231_zr9aBWA9ayA2"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_908_edei--EntityShellCompany_c20210101__20211231_zxyzNFe2nfw4"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant completed the initial offering of its common stock on January 14, 2022. Accordingly, there was <span id="xdx_90F_edei--EntityPublicFloat_iI_do_c20210630_zddpYnUhl6ed">no
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public market for the registrant&#8217;s
common stock as of June 30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of common shares outstanding as of March 21, 2022 was <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_pid_c20220321_zX6g1livFcB8"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-03-21" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,364,444</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents
Incorporated by Reference: <span id="xdx_900_edei--DocumentsIncorporatedByReferenceTextBlock_c20210101__20211231_zGUrt1jVjN6i"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">None.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><br /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 0.5in">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; vertical-align: bottom; width: 0.6in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_001">Part I</a></b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_002">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_003">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_004">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_005">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_006">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_007">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_008">Part II</a></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_009">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_010">[Reserved]</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">90</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_012">Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_013">Financial Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_014">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_015">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_016">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_017">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_018">Part III</a></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_019">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_020">Executive Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_022">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_023">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#c_024">Part IV</a></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_025">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_026">Form 10-K Summary</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_027">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE ON FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as
amended (the &#8220;Exchange Act&#8221;). These statements may be identified by such forward-looking terminology as &#8220;may,&#8221;
&#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other
comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections
about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually
achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements
involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    projected financial position and estimated cash burn rate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, future revenues and capital requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    need to raise substantial additional capital to fund our operation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success, cost and timing of our clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties in the conduct of our clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ultimate impact of the current COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research
    programs, healthcare systems or the global economy as a whole;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential that results of pre-clinical and clinical trials indicate our current product candidates or any future product candidates
    we may seek to develop are unsafe or ineffective;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of market research conducted by us or others;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our current and future product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce
    or protect our intellectual property rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility that a third party may claim we or our third-party licensors have infringed, misappropriated or otherwise violated their
    intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against
    claims against us;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third-party suppliers and manufacturers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competing therapies and products that are or become available;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product
    liability lawsuits to cause us to limit our commercialization of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    acceptance of our product candidates, the size and growth of the potential markets for our current product candidates and any future
    product candidates we may seek to develop, and our ability to serve those markets; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful development of our commercialization capabilities, including sales and marketing capabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our forward-looking statements are as of the date of this Annual Report on Form 10-K only. In each case, actual results may differ
materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will
prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties
referred to in this Annual Report on Form 10-K or included in our other public disclosures or our other periodic reports or other documents
or filings filed with or furnished to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) could materially and adversely
affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan
to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections
or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report on Form 10-K, even if
such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements
or disclosures by us following this Annual Report on Form 10-K that modify or impact any of the forward-looking statements contained
in this Annual Report on Form 10-K will be deemed to modify or supersede such statements in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K may include market data and certain industry data and forecasts, which we may obtain from internal company
surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications,
articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained
therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed.
While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party
sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>RISK
FACTOR SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what
we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider
the full discussion of our risk factors in the section titled &#8220;Risk Factors,&#8221; together with the other information in this
Annual Report on Form 10-K. If any of the following risks actually occurs (or if any of those listed elsewhere in this Annual Report
on Form 10-K occur), our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously
harmed. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important
factors that adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Additional Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
    have a limited operating history, and we have not initiated, conducted or completed any clinical trials, and have no products approved
    for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient
    revenue to achieve and maintain profitability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
    will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when
    needed, or on acceptable terms, we may be forced to curtail, delay or discontinue one or more of development programs or future commercialization
    efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Discovery and Development of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are substantially dependent on the success of our product candidates. If we are unable to complete development of, obtain approval
    for and commercialize our product candidates in a timely manner, our business may be harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    delays in the commencement or completion, or termination or suspension, of our ongoing, planned or future clinical trials could result
    in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the
    results of our clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration or other comparable foreign
    regulatory authorities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory
    approval could be delayed or prevented.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing
    requirements to maintain regulatory approval. If our candidates prove to be ineffective, unsafe or commercially unviable, our entire
    technology platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business,
    financial condition, results of operations and prospects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
    side effects or other safety risks associated with our drug candidates could delay or preclude approval, cause us to suspend or discontinue
    clinical trials or abandon further development, limit the commercial profile of an approved label, or result in significant negative
    consequences following marketing approval, if any.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    products may never achieve market acceptance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that
    are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business may be adversely affected by the ongoing coronavirus pandemic.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to manufacture our product candidates and conduct our pre-clinical studies and clinical trials. If these third
    parties do not successfully perform their contractual and regulatory duties or meet expected deadlines, we may not be able to obtain
    regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently depend on a sole source supplier and manufacturer for the active ingredient in HSB-1216, and the inability to obtain the
    active ingredient in HSB-1216 as required could harm our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of Our Drug Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are successful in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one
    or more of our drug candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory
    approvals for our drug candidates on a timely basis, or at all.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    inability to protect our intellectual property and proprietary rights may have a material adverse effect on our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Managing Our Business and Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter difficulties in managing our growth, which could adversely affect our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other
    improper activities, including noncompliance with regulatory standards and requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Common Stock </b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock
    exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be
    impaired and it may be more difficult for our stockholders to sell their securities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over
    matters subject to stockholder approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial
    amounts of our outstanding shares may be sold into the market when lock-up or market standoff periods end. If there are substantial
    sales of shares of our common stock, the price of our common stock could decline.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Throughout
this Annual Report on Form 10-K, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; &#8220;Hillstream,&#8221;
or &#8220;Hillstream BioPharma&#8221; refer to Hillstream BioPharma, Inc., individually, or as the context requires, collectively with
its subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="c_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death (&#8220;IMCD&#8221;) for treatment resistant cancers. The most advanced product candidate
which we own is HSB-1216, an IMCD inducer, targeting a variety of solid tumors. In a clinical pilot study conducted in Germany by the
University of Heidelberg, the active drug in HSB-1216 was found to reduce tumor burden in treatment resistant cancers, including triple
negative breast cancer (&#8220;TNBC&#8221;) and epithelial carcinomas. Our goal is to submit an investigational new drug application
(&#8220;IND&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in 2023 and start a clinical study with HSB-1216 in
2023; however, no assurance can be provided that our IND will be accepted by the FDA in 2023, if at all. If our IND is accepted by the
FDA, our HSB-1216 clinical study will focus on expanding upon the clinical pilot study conducted in Germany. If we are able to start
our clinical study with HSB-1216 in 2023, we anticipate that initial clinical data from such trial will be released either the end of
2023 or early 2024. We use Quatramer&#8482;, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor
microenvironment (&#8220;TME&#8221;) with an extended duration of action and minimal off-target toxicity. In addition, TridentAI, our
artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target specific patient
segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target discovery for drug development.
Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular iron or the Labile Iron Pool (&#8220;LIP&#8221;).
Cancer cells increase the LIP leading to unregulated cell growth and metabolism. Decreasing the LIP, induces iron-led ROS production
and lipid peroxidation, two key hallmarks of ferroptosis/IMCD. HSB-1216 binds iron in the cytoplasm of cancer cells and decreases the
LIP, thereby inducing ferroptosis/IMCD, leading to regulated cell death. Areas of interest for the development of HSB-1216 are as a treatment
of solid tumors, including TNBC, uveal melanoma, glioblastoma multiforme, head and neck squamous cell carcinoma and other treatment resistant
cancers with high unmet need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramer
is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate
the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as
well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes
a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer
drug candidates using our Quatramer platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
uses an artificial intelligence precision medicine platform to identify novel biomarkers. TridentAI integrates diverse public datasets,
including The Cancer Genome Atlas (&#8220;TCGA&#8221;) to identify novel gene signatures to stratify patients prospectively in clinical
trials. Quatramer tumor targeting also allows us to segment patients by exploiting TridentAI&#8217;s findings by (i) synthetic lethal
sensitivities with novel combinations, (ii) pursue undruggable targets such as <i>c-myc </i>and (iii) target tumors with a high degree
of cell plasticity indicative of recurrent/drug resistant phenotype.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates and Research Programs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our proprietary technologies and developing multiple product candidates with differentiated profiles designed to address
rare and treatment resistant cancers, as shown below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
1: Pipeline Chart</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_001.jpg" alt="" style="height: 254px; width: 624px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to submit an IND with the FDA for HSB-1216 in 2023, for HSB-888 in 2024, for HSB-510 in 2024 and for HSB-114 in 2025; however,
no assurance can be provided that our INDs will be accepted by the FDA based on our anticipated timeline, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Lead Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">HSB-1216</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216,
our most advanced product candidate which we intend to develop in the clinic in 2022 for multiple high unmet need solid tumors, is an
IMCD inducer delivered using our proprietary carrier, Quatramer. We intend to submit an IND application to the FDA and obtain clinical
data to support our strategy in 2023; however, no assurance can be provided that our IND will be accepted by the FDA in 2023, if at all.
HSB-1216 exploits a key feature of certain tumors that rely on an excessive LIP within the cell to modify the dysregulated iron microenvironment
of cancer. We have received orphan drug designation (&#8220;ODD&#8221;) in small cell lung cancer (&#8220;SCLC&#8221;) and uveal melanoma
for HSB-1216&#8217;s active drug. In a clinical pilot study conducted in Germany by the University of Heidelberg, HSB-1216&#8217;s active
drug was studied in 7 patients with positive results in heavily pre-treated and therapy resistant cancers. By design, HSB-1216 circulates
systemically after an intravenous injection and concentrates in the TME of solid tumor masses. The localization of HSB-1216 has been
demonstrated in multiple <i>in vivo</i> models with pharmacodynamic signals showing significant decreases in tumor size after multiple
weekly injections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
2: HSB-1216 - IMCD Mechanism of Action: Shifting the Intracellular Redox Balance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_002.jpg" alt="" style="height: 487px; width: 624px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a tumor concentrating therapeutic, HSB-1216 has the potential to be used in cancer patients who have failed standard-of-care therapies
for treatment resistant tumors without any approved therapies. We intend to submit an IND to the FDA for approval in 2023 and, if such
IND is timely submitted and approved, we anticipate initial data either the end of 2023 or early 2024; however, no assurance can be provided
that our IND will be accepted by the FDA in 2023, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-888</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapy,
an important part of antitumor treatment, exerts anticancer effects by killing cancer cells, and anthracycline-based regimens have been
and continue to be the mainstay of treatment for a vast majority of tumors. The clinical applications of anthracycline regimens, above
certain dose ranges have limited use due to adverse events, including cumulative lifetime doses resulting in cardiotoxicity. The nonspecific
accumulation of anthracyclines, such as doxorubicin and similar agents in non-target tissues such as cardiac cells, continues
to be a problem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second product candidate, HSB-888, is a dual-loaded IMCD inducer coupled with our ultra-low dose next generation anthracycline analogue
for solid tumors. HSB-888 is in IND-enabling studies, and we intend to develop such product candidate in the clinic in 2024 for multiple
sarcomas after we submit an IND to the FDA for HSB-888 in 2024; however, no assurance can be provided that our IND will be accepted by
the FDA in 2024, if at all. The components of HSB-888 are two anticancer drugs with complementary mechanisms of actions. The FDA
has granted one of the drug components of HSB-888 a Rare Pediatric Disease Designation and ODD for pediatric osteosarcoma. The
other drug component in HSB-888 is our next generation anthracycline analogue approved and marketed in China and Japan which has
potent antitumor activity and is indicated for multiple tumor types, with an improved therapeutic index compared to doxorubicin.
We believe targeting the agent in our proprietary dual-loaded Quatramer with our novel IMCD inducer may confer key benefits for multiple
reasons, including a synergistic ultra-low-dose approach as well as leveraging a key differentiating mechanism of iron-mediation to kill
the tumor and reduce off target toxicities simultaneously.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
3: HSB-888 &#8211; Structure &amp; Mechanism</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" style="height: 292px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
has the potential to be used in solid tumors whereby a potent anthracycline may be effective but prohibitive in current available forms
due to their off-target effects. We intend to include data from our own pre-clinical studies as well as the human data available from
Japanese and Chinese studies in our IND which we intend to submit in 2024 and, if such IND is timely submitted and approved, we anticipate
top-line clinical data in 2024; however, no assurance can be provided that our IND will be accepted by the FDA in 2024, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Other Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">HSB-510</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own HSB-510, which is a novel highly targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against
PI3K-delta and HDAC6, which is also known to downregulate <i>c-myc</i>, a highly pursued and yet undruggable cancer drug target. The
Quatramer platform achieves optimal tumor targeting and bioavailability of the highly potent targeted small molecule. Through an ongoing
Cooperative Research and Development Agreement with the National Center for Advancing Translational Sciences (&#8220;NCATS&#8221;), part
of the National Institutes of Health (&#8220;NIH&#8221;), we analyzed novel dual Class I phosphoinositide 3-kinases (&#8220;PI3K&#8221;)/histone
deacetylases (&#8220;HDAC&#8221;) inhibitors and a lead compound which showed good antiproliferative activity against multiple oncology
cell lines. This compound obtained ideal pharmacokinetic properties in our proprietary Quatramer, while maintaining specific HDAC6-PI3K-delta
specificity. We intend to continue our collaborative effort with NCATS through our collaboration. In addition, we intend to submit an
IND to the FDA for HSB-510 in 2024; however, no assurance can be provided that our IND will be accepted by the FDA in 2024, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
4: HSB-510 - Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="" style="height: 278px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-114</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own HSB-114, which is a novel immunotherapeutic agent that uses our proprietary Quatramer platform to deliver the human tumor
necrosis factor-alpha (&#8220;TNF-alpha&#8221; or &#8220;TNF-&#945;&#8221;) gene into cancer cells. Finding ways to selectively increase
intratumoral TNF-alpha levels in tumors while managing the toxicity associated with such approaches remains a major unmet need. We believe
we have developed a novel approach to include a peptide-DNA complex, which preferentially releases genetic material and localizes
into the nucleus of the delivered cancer cell and has been demonstrated to be highly effective in achieving a desired tumor
response in our pre-clinical oncology models using TNF-alpha. We believe this intratumoral expression of secreted cytokines, such as
TNF-alpha, represents a novel approach for inducing anti-tumor activity and potentially reprogramming the tumor immune microenvironment,
and we intend to develop this technology further to strengthen our pipeline. We intend to submit an IND to the FDA for HSB-114 in 2025;
however, no assurance can be provided that our IND will be accepted by the FDA in 2025, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
5: HSB-114 - Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt="" style="height: 265px; width: 592px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology platform enables us to generate a pipeline of early-stage product candidates spanning multiple targets in oncology utilizing
diverse payloads to treat rare and treatment resistant tumors. While the payloads in our most advanced product candidates, HSB-1216 and
HSB-888, are novel, and have pilot and extensive human data in multiple solid tumors, any solid tumor or non-oncologic disease requiring
delivery of a peptide, protein or biologic is conceivably a candidate for our technology. Our early-stage product candidates are focused
on rare and treatment resistant diseases; however, we believe our technology could potentially deliver meaningful benefit across a wide
range of oncologic and viral diseases. We have tested several peptides, nucleic acids, proteins, small molecules and antibody constructs
against multiple targets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Platform Technologies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Quatramer
Technology</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key aspect of oncology treatment is that effective anticancer agents do not penetrate the tumor bed in order to kill cancer cells due
to the limitation of the microenvironment of the tumor. The TME is protected by stromal tissue comprised of multiple layers of collagen,
proteoglycans, hyaluronans and laminin layers shielding the tumor from the deployment of traditional treatments, including chemotherapy
(novel small molecule and immunotherapies). Parts of the tumor create an environment to survive despite reduced nutrient sources whereby
hypoxic regions of the tumor continue to thrive by incorporating a shift in metabolism, including iron dysregulation. Any drug that reaches
the tumor is effluxed out of the cell by transporter pumps upregulated by the cancer cells rendering any such drug that reaches the tumor
ineffective. The TME continues to thrive by the inability of immune cells normally designed to infiltrate and kill the tumor made ineffective
by a reduction in their ability to activate their killing effect of the cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
6: Tumor Vasculature</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt="" style="height: 401px; width: 602px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary Quatramer technology overcomes the limitations that have hampered development of nanoscale and liposome derived products
as cancer therapeutics. Limitations include, but are not limited to, drug efflux, toxicity, eluding phagocytosis, physiological barrier
penetrance and immune responses. Our Quatramer technology incorporates a therapeutic payload and is designed to be tunable while having
a prolonged circulation within the blood, allowing a targeting of diseased tissue or cells, while providing a controlled and timely release
of the therapeutic payload.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characteristics
of our Quatramer technology include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prolonged
    circulation</b>: the stealth nature of Quatramer allows for a prolonged circulation time resulting in accumulation at the site of
    disease prior to being cleared.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted</b>:
    the size, shape and surface of Quatramer allows it to escape via gaps in the blood vessels in the TME allowing for release of the
    payload directly into cancerous cells.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Blocks
    drug efflux</b>: Quatramer composition offers reversal of p-glycoprotein mediated drug resistance in cells via generation of poloxamers
    (breakdown products comprised of small co-polymers).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tunability</b>:
    Quatramer physicochemical characterization allows for optimizing size, shape and surface chemistry based on payload characteristics
    to render enhanced permeation and retention into the TME.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ease
    of manufacturing</b>: large scale production efficiency and analysis for uniform chemistry, manufacturing and control capability
    at lower costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Established
    regulatory path</b>: chemical compositions listed in the FDA Inactive Ingredients Database with known profile.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payload
    versatility and flexibility</b>: combined with the tunability of Quatramer, the technology allows for a variety of delivery payloads
    including peptides, small molecules, nucleic acids and antibodies with the added flexibility of dual-loaded payload therapeutics.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Biodegradable</b>:
    Quatramers ultimately breakdown into known metabolites such as lactic acid and ethanol.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trident
Artificial Intelligence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
uses an artificial intelligence precision medicine platform to identify novel biomarkers. TridentAI integrates diverse public datasets,
including TCGA to identify novel gene signatures to stratify patients prospectively in clinical trials. Quatramer tumor targeting also
allows us to segment patients by exploiting TridentAI&#8217;s findings by (i) synthetic lethal sensitivities with novel combinations,
(ii) pursue undruggable targets such as <i>c-myc</i> and (iii) target tumors with a high degree of cell plasticity indicative of recurrent/drug
resistant phenotype.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
TridentAI platform:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to create a Ferroptomics Atlas which integrates diverse multi-omics datasets including not only genomics, epigenetics
    and transcriptomics but also emerging proteomics data which enable identification of dynamical re-wiring of intra-tumoral signaling
    circuitry designed to target IMCD;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to identify biomarkers that potentially differentiate between progression of cancer plasticity and correlate it to degree
    of sensitivity to a synthetically lethal target that is induced with standard-of-care treatment and development of resistance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    designed to classify and select patients that are most likely to respond to treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
7: TridentAI is designed to establish clinical development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_007.jpg" alt="" style="height: 192px; width: 609px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Key Programs: HSB-1216 and HSB-888</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have leveraged our proprietary technologies and are developing multiple product candidates with differentiated profiles designed to address
rare and treatment resistant cancers. Our HSB-1216 product candidate is an IMCD inducer delivered by our proprietary Quatramer platform.
We intend to submit an IND to the FDA for approval in 2023 and, if such IND is timely submitted and approved, we anticipate initial data
either at the end of 2023 or early 2024; however, no assurance can be provided that our IND will be accepted by the FDA in 2023,
if at all. Our HSB-888 product candidate is a dual-loaded IMCD inducer that is coupled with our ultra-low dose next generation anthracycline
analogue for solid tumors. We intend to include data from our own pre-clinical studies as well as the human data available from Japanese
and Chinese studies to submit an IND to the FDA in 2024 and, if such IND is timely submitted and approved, we anticipate top-line clinical
data in 2024; however, no assurance can be provided that our IND will be accepted by the FDA in 2024, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-1216:
Our Novel Iron-Medicated Cell Death Inducer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iron,
an important factor of many organisms, satisfies an assortment of vital living processes including DNA replication, protein synthesis
and cellular respiration, essential for normal growth and propagation. However, iron also produces reactive oxygen species (&#8220;ROS&#8221;)
via a chemical process in which there is a catalytic decomposition of hydrogen peroxide by ferrous ions, known as the Fenton reaction.
This process may cause damage to the membrane lipid and DNA caused by ROS, known as lysosomal membrane permeabilization (&#8220;LMP&#8221;)
rupturing and killing the cell by spilling its contents into the surrounding microenvironment and causing degradation in the surrounding
extracellular milieu. Emerging evidence suggests iron may have a twofold role on cells, both stimulating cell growth and causing cell
death, particularly a new form named ferroptosis, first described by the accumulation of iron-dependent lipid peroxides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
8: Role of Iron</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_008.jpg" alt="" style="height: 385px; width: 602px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
that has been published by us with respect to the active drug of HSB-1216 targeting chemotherapy resistant tumors suggests that it sequesters
iron in the lysosomes of resistant tumor cells causing LMP of hard-to-treat cancer cells known as persister cells causing them to rupture
and stop replicating. We believe an area of high interest for the development of HSB-1216 could be SCLC or TNBC or other rare cancers
with high unmet need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
9: HSB-1216 Mechanism of Action</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="" style="height: 487px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the standard limitations to achieving successful cancer therapies is the manifestation of multidrug resistance (&#8220;MDR&#8221;)
which is a cross-resistance to many commonly used drugs after repeat dosing. Extensive evidence to this point has shown that the mechanisms
related to tumor MDR are complex and there is an urgent need to decipher the nuances of this phenomenon and discover new agents capable
of evading resistance which can be applied to a clinical strategy in cancer. MDR can be developed by various ATP-binding cassette (&#8220;ABC&#8221;)
transporters, including the well characterized ABCB1, also known as p-glycoprotein, which has been shown to be an important protein of
the cell membrane and can transport a variety of molecules across extra- and intra-cellular membranes. The protein is an <span style="background-color: white">adenosine
triphosphate (&#8220;</span>ATP&#8221;) dependent drug efflux pump that transports foreign substances out of the cell including drugs
and xenobiotics with broad substrate specificity. HSB-1216&#8217;s active drug has been shown to block this ABC transporter in numerous
studies as evidenced by drug efflux assays in MDR cell lines overexpressing these proteins by inducing a conformational change on the
transporter protein itself rendering it ineffective. Furthermore, the byproduct of the Quatramer bio-degradable process results in formation
of poloxamers which blocks the p-glycoprotein transporter system. This evidence may also allow other traditional chemotherapies, such
as paclitaxel which is highly effected by these transporters, to stay in the cell and elicit anti-tumor effects in combination with HSB-1216.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-1216
in Oncology Indications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidate, HSB-1216, has novel characteristics which may benefit patients with hard-to-treat recurrent tumors, such as TNBC in a
number of ways. HSB-1216&#8217;s active drug, traditionally used as an anti-coccidial drug in livestock and poultry, has been shown to
possess anti-cancer effects in a chemical screen on the basis that it has more than 100-fold potency compared to paclitaxel, a commonly
used FDA-approved anti-cancer drug. The active compound is a monocarboxylic polyether compound first isolated from <i>Streptomyces albus
</i>strain (Strain No. 80614) shown to eliminate self-renewing cancer cells which may remain dormant or undetectable in the presence
of traditional chemotherapeutics, such as paclitaxel or other agents commonly used as first-line agents in a variety of tumors. Salinomycin
alone could not be advanced further after its discovery as an anti-cancer agent for a variety reasons, including a short half-life along
with a relatively narrow therapeutic index and potential toxicities. Subsequently, other groups have shown cytotoxicity of the compound
on human neuronal cells showing it had an increase on cytosolic Na<sup>+ </sup>concentrations consequently resulting in elevated cytosolic
Ca<sup>2+</sup>. In addition, overdose or accidental ingestion of similar compounds has shown undesirable effects in cats, dogs, pigs,
horses, as well as humans<span style="background-color: white">. </span>These results and other data from third parties suggest it may
be prudent to develop tissue-specific strategies to deliver the drug and prevent neuro-specific adverse events and capitalize on the
specific mechanisms of HSB-1216&#8217;s active drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
data from third parties suggest that the specific mechanisms of HSB-1216&#8217;s active drug are three-fold which include a novel selective
iron-induced cell death known as ferroptosis, an ability to reverse a phenomenon known as epithelial-mesenchymal transition (&#8220;EMT&#8221;),
as well as an ability to evade the ABC transporters, of which the latter two are linked to multidrug resistance to commonly used cancer
chemotherapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Data with HSB-1216&#8217;s Active Drug</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
several reasons, HSB-1216&#8217;s active drug was not established as a human drug due to several reports published by third parties in
the past decades which reveal considerable toxicity in mammals such as horses, pigs, cats and alpacas after accidental oral ingestion
or inhalation. It has been relegated to use in livestock as a coccidiostat and growth promoter. The European Food Safety Authority has
declared an acceptable daily intake of 5 <span style="background-color: white">&#181;g/kg</span>. Based on these findings, the compound
was therapeutically used in a &#8220;first-in-man&#8221; clinical pilot study conducted in Germany by the University of Heidelberg with
a cohort of 7 patients with metastatic breast, ovarian and head and neck cancers in which tumor and metastatic regression were observed
clinically in 4 patients with metastatic breast cancer, 1 patient with metastatic ovarian cancer, and 2 patients with squamous cell carcinoma
(1 of the head and neck and the other of the vulva). Administration of 200&#8211; 250 <i>&#956;</i>g&#183;kg<sup>&#8722;1 </sup>of active
drug intravenously every second day for three weeks in these patients resulted in partial regression of tumor metastasis. Intravenous
active drug therapy resulted in tachycardia and mild tremor for 30&#8211;60 minutes after administration but lacked side effects observed
with conventional chemotherapeutic drugs, such as myelodepression, neutropenia, alopecia, nausea and vomiting, or gastrointestinal, thromboembolic,
and neurological side effects. Only 2 of the 7 cases are described in the publication relating to this trial, both of which are detailed
below showing that these promising results inducing cancer regression of heavily pretreated and therapy-resistant tumor types may define
HSB-1216&#8217;s active drug to have novel effects as a clinically significant anticancer agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thirty
months prior to treatment with the HSB-1216&#8217;s active drug, a 40-year-old female patient was diagnosed with unilateral ductal breast
carcinoma (post-mastectomy and axillary lymph node dissection) and subsequently experienced a recurrence of the subcutaneous multifocal
thoracic tumor that was ER, PR, and HER2 negative (i.e., &#8220;triple negative&#8221;) with vertebral bone metastasis. After all therapeutic
options were exhausted, experimental treatment with HSB-1216&#8217;s active drug was recommended. The patient received 12 systemic administrations
of intravenous (&#8220;IV&#8221;) treatment at a dose of 200 &#181;g&#183;kg<sup>-1</sup> given every other day. After 12 cycles, there
was a marked regression of the subcutaneous thoracic metastases (Figure 10). A biopsy of the metastatic tissue, as investigated by molecular
histopathology, demonstrated that approximately 85% of the cells had undergone apoptosis. Additionally, serum levels of the tumor marker
Ca 15-3 decreased from 14.3 U/mL before therapy to 7.2 U/mL after therapy. Similarly, serum levels of Carcinoembryonic antigen, another
tumor marker, declined from 50.8 ng/mL to 15.5 ng/mL posttreatment. These results demonstrate that the drug was not only able to kill
hard-to-treat cancers, but also more differentiated tumor cells and more importantly, highly indolent tumor cells displaying efficient
mechanisms of resistance to cytotoxic drugs, radiation, and induction of apoptosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
10: Clinical Pilot Study</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_009.jpg" alt="" style="height: 217px; width: 554px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a second case study, 18 months prior to treatment with HSB-1216&#8217;s active drug, an 82-year-old female patient was diagnosed with
advanced and metastatic (pelvic lymphatic metastasis) squamous cell carcinoma of the vulva (after radical vulvectomy and bilateral lymph
node dissection). Given a poor therapeutic response to existing treatments at the time and exhaustion of therapeutic options, experimental
treatment of HSB-1216&#8217;s active drug in combination with erlotinib was recommended for this patient. The patient received 14 IV
administrations of the drug at a dose of 200 &#181;g&#183;kg<sup>-1</sup> given every other day plus erlotinib 150 mg daily for 30 days.
Significant tumor regression was observed 30 days after combination therapy, based on clinical inspection of the tumor, as well as decreased
serum level of squamous cell carcinoma (&#8220;SCC&#8221;) antigen from 11.3 ng/mL before combination therapy to 0.13 ng/mL after therapy.
Three months post-treatment, SCC levels increased to 3.2 ng/mL, and clinical inspection demonstrated significant tumor progression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
experiencing numerous marked adverse effects with erlotinib (including fatigue, anorexia, nausea, and inappetence), the patient refused
further treatment with erlotinib and was retreated with HSB-1216&#8217;s active drug as monotherapy. The patient received 12 IV administrations
at a dose of 200 &#181;g&#183;kg<sup>-1 </sup>given every other day, which resulted in no progression and stable disease for 2 weeks,
4 weeks, and 4 months post-treatment, based on clinical inspection of the local tumor and no marked changes in SCC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
11: 2012 &#8211; Human Serum Levels of the Tumor Marker Squamous Cell Carcinoma <i>in vitro</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_010.jpg" alt="" style="height: 214px; width: 397px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
results demonstrate that the drug is able to induce partial clinical regression of heavily pretreated and therapy-resistant cancers,
particularly in combination with novel tumor-targeted drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-1216
Pre-Clinical Data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216&#8217;s
active drug has been shown to target elusive cancer cells in different types of human cancers, including gastric cancer, lung adenocarcinoma,
osteosarcoma, colorectal cancer, squamous cell carcinoma, and prostate, suggesting that the drug may be effective against side populations
of many types of human cancers. The drug is able to enhance the cytotoxic effects of conventional chemotherapeutics and novel tumor-targeted
drugs in regular cancer cells, potentially playing a central role for HSB-1216-based combination therapies in the future treatment of
cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
12: HSB-1216 Inhibits Tumor Growth in SCLC Mouse Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_011.jpg" alt="" style="height: 363px; width: 434px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">According
to the National Cancer Institute&#8217;s Surveillance, Epidemiology and End Results, there are anticipated to be more than 230,000 new
cases of lung cancer in the United States in 2021, and according to the American Cancer Society, SCLC comprises approximately</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-15% <span style="background-color: white">of all lung cancers.
Although SCLC is responsive to chemotherapy, recurrence occurs rapidly, with less than 7% of patients surviving over five years. SCLC
has shown to be responsive to immunotherapy with approximately </span>one-third <span style="background-color: white">of patients responding
to</span> PD-1/PD-L1 <span style="background-color: white">therapy and achieving a median overall survival of approximately eight months.
The need to rapidly advance therapeutics is an urgent, unmet medical need in these recurrent cases. In one pre-clinical mouse model of
SCLC conducted by a third party in Asia, both HSB-1216&#8217;s active drug as well as HSB-1216 showed no antitumor activity <i>in vivo</i>,
believed to be due to lab dilution errors of the test articles. The same articles showed marked antitumor activity in a tumor sphere
model owing to the potent effects of both compounds. Our previous studies with HSB-1216 has shown a profound inhibition of tumor growth
as a once-weekly injectable product in a nude mouse xenograft models utilizing an N-H69 SCLC cell line, with three 5 mg/kg doses administered
over three weeks when compared to placebo.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
13: HSB-1216 is 2x-4x more potent against chemo-resistant SCLC cell <i>in vitro</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_012.jpg" alt="" style="height: 312px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216
is two to four times more potent in chemoresistant SCLC. Using chemoresistant cell lines for SCLC (NCI-H69AR), our approach demonstrates
an increased potency of our compound using our Quatramer formulation when compared to standard-of-care therapies for these resistant
tumor types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-1216
Clinical Plan in Solid Tumors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to submit an IND for our HSB-1216 product candidate for solid tumors to the FDA in 2023, and, if approved, we plan to conduct
a Phase 1 clinical trial to obtain human pharmacokinetic data and dose optimization data on our formulation thereafter; however, no assurance
can be provided that our IND will be accepted by the FDA in 2023, if at all. Based on the data obtained from pre-clinical studies, we
believe a Phase 1 basket trial can be conducted in the US with HSB-1216 where there are limited therapies. Even with the advent of immune
checkpoint inhibitors (&#8220;ICIs&#8221;), there remains a large patient population which either does not benefit from allowing HSB-1216
to potentially prolong survival in ICI failures as well as recurrent disease patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-888:
Our Dual-Loaded IMCD inducer and Ultra-Low Dose Next Generation Anthracycline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
HSB-888 product candidate has a component selected in pre-clinical screens for its similar cytotoxic activity to doxorubicin accompanied
by its reduced cardiac toxicity. The component drug has been in use in Japan for more than two decades, and our clinical studies support
its claim of similar efficacy to doxorubicin but with reduced toxicity. We intend to obtain approval of this product in the United States
as a drug that can be used in the treatment protocol of recurrent osteosarcoma. HSB-888 combination could be a more tolerable therapy
which may improve response rates, overall survival, and quality of life. We intend to submit an IND to the FDA in 2024 and, if approved,
we plan to initiate a clinical trial in recurrent pediatric osteosarcoma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
active drugs of HSB-888 have been used clinically to treat tumors such as osteosarcoma, breast cancer, lymphoma and acute myeloid leukemia
(&#8220;AML&#8221;) in countries outside the US such as Germany, Japan, China and India. One component compound has shown lower cardiotoxicity
and greater antitumor effect than other anthracycline agents, commonly used in these tumors, due to the fact that it is taken up by tumor
cells to a higher degree than other drugs in its class. This rapid uptake into tumor cells causes targeted incorporation into the cell&#8217;s
DNA and causes cell cycle arrest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
in multidrug-resistant cells, we believe HSB-888 can disrupt cell cycle kinetics. Currently, the most important impediment to improving
outcomes of patients with osteosarcoma is the clinical resistance to the primary chemotherapy, MAP, which is widely used. One of HSB-888&#8217;s
active drugs has been shown to be taken up by tumor cells approximately 170 times faster than doxorubicin and distributes its DNA into
tumor nucleus and intercalates. In MDR osteosarcoma cell lines (MG63/DOX), the drug was shown to have a marked cell inhibitory effect
in both resistant and sensitive cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a retrospective Chinese study of relapsed and refractory osteosarcoma conducted by a third party, 3 of 23 evaluable patients who received
only one of the active drugs of HSB-888 with cisplatin, had partial responses, with 1 patient after 7 cycles achieving disease free progression
for more than 29 months. In another Chinese study, the <span style="background-color: white">5-year disease-free survival (&#8220;DFS&#8221;)
rate of the patients treated with the drug was 70.2%, significantly higher than that of the DOX-based regimen-treated group (53.1%).
The drug decreased the lung metastatic rate significantly compared with the DOX-based regimen (19.1% vs. 36.7%, </span><i>p</i><span style="background-color: white">=0.045),
as well as the relapse rate (31.9% vs. 49.0%, </span><i>p</i><span style="background-color: white">=0.067). The compound also showed
lower rates of alopecia (63.8% vs. 85.7%, </span><i>P</i><span style="background-color: white">=0.012), nausea and vomiting (51.1% vs.
79.6%, </span><i>p</i><span style="background-color: white">=0.003), and mucositis (48.9% vs. 75.6%, </span><i>p</i><span style="background-color: white">=0.003).
It also resulted in lower cardiac toxicity and demonstrated that it is better than the DOX-based regimen in terms of the 5-year DFS rate,
pulmonary metastasis rate, relapse rate and side effects</span>. These data suggest that an updated regimen utilizing HSB-888 delivering
two active drugs in refractory cases in a setting that would use high-dose methotrexate along with a platinum-drug may be warranted,
and we intend to study these patients in a clinical trial, due to the high unmet need in this population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-888
Low Dose Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemotherapies
like anthracyclines, including doxorubicin and others in its class, have been used for decades as mainstay therapy in combination with
other drugs for multiple tumor types, including osteosarcoma as first-line therapy. The most important issue is that although the regimen
may benefit patients in this setting, there is a dose-limiting cumulative effect on the patient with these cytotoxic approaches whereby,
after a maximum accumulation of dose over multiple cycles, the class of drug can longer be used in the recurrent setting for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
components of our HSB-888 product candidate are two anticancer drugs with distinct and complementary mechanisms of actions (ferroptosis
and DNA intercalation) which together constitute an active combination for treating osteosarcoma. We investigated whether the efficacy
of this combination could be improved by controlling drug ratios following <i>in vitro and vivo </i>administration. The combinations
were evaluated systematically for drug ratio-dependent synergy <i>in vitro </i>using multiple tumor cell lines. <i>In vitro </i>screening
informatics on drug ratio-dependent cytotoxicity identified a consistently antagonistic region between active drugs at various molar
ratios, which also showed multiple synergistic ratios, dependent on the chemical characteristics of either DNA intercalating active drugs
combined with a ferroptosis inducer. Co-formulations of these two agents were developed that maintained a fixed drug ratio for stability
and release profiling over broad timelines. Drug ratio-dependent antitumor activity was demonstrated <i>in vitro </i>and <i>in vivo </i>for
these ratios and improved antitumor activity was observed for the Quatramer 1:3 molar ratio of DNA intercalator:ferroptosis inducer (designated
HSB-888) compared to drug cocktails in models tested. HS-888, is a fixed-ratio formulation of DNA intercalator and ferroptosis inducer,
and a near-clinical candidate for development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Furthermore,
our proprietary molar ratio as seen by its <i>in vitro</i> and <i>in vivo</i> efficacy profile enables a low dose to be administered
that is presumably 5-fold to 10-fold less than the traditional DNA intercalator therapy that is currently utilized in multiple high unmet
need tumor types. This low dose strategy may allow clinicians to treat a variety of tumor types requiring cytotoxic chemotherapy without
the burden of dose-limiting toxicities for traditional chemotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-888
Synergy and Combination Index</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Extensive
research suggests cancer drug combination may act in synergy, additively or antagonistic based on drug ratios of the separate compounds
combined. While this relationship can be evaluated readily</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>in
vitro</i> <span style="background-color: white">where drug ratios can be controlled, the translation of such information</span> <i>in vivo
is </i><span style="background-color: white">complex due to the fact that individual drugs administered separately may be distributed,
metabolized and eliminated differently. This prevents control of the drug ratio following administration and may result in exposure of
cancer cells to antagonistic drug ratios with a corresponding loss of therapeutic activity.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
approach with a combination of two drugs in HSB-888 as a dual drug-loaded formulation with our Quatramer strategy circumvents multiple
hurdles when compared with administering compounds separately. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
distinguishing feature of our technology is our proprietary Quatramer delivery platform which maintains drug combinations at the desired
ratio after <i>in-vivo </i>administration. Drug combinations used to treat cancer are often encompassed with drugs which are highly varied
in chemical and physical composition as well as properties. Subsequently, formulating such drug combinations with unrelated features
into a single pharmaceutical approach that discharges both agents at the same or pre-determined different rates in the body as well as
in the tumor tissue of choice presents a significant technical challenge. We have developed the Quatramer platform to provide versatility
in controlling drug loading to specified drug loading and release rates with the precise retention properties for therapeutic agents
from drug classes important for unmet need pharmaceutical development to benefit cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have specifically identified cell-based screens and identified synergistic drug combinations of HSB-1216 and HSB-888 which have markedly
different chemical attributes. With respect to our combination approach, we have controlled the ratio of the compounds in the delivery
when prepared, maintained the ratio of the compounds within the carrier system while circulating in the blood and have ensured the release
at the proper synergistic ratios when delivered to the tumor. This approach allows for the combination product HSB-888 to have different
physicochemical properties of the original drugs and allows for the co-formulation and coordinated release of both drugs with widely
different properties from the same particle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
14: HSB-888 is 5 times more potent in synergy with HSB - 1216 <i>in vitro</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_013.jpg" alt="" style="height: 233px; width: 580px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-888
Combination Drug Clinical Development Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to submit an IND to the FDA for HSB-888 in 2024 and, if approved, thereafter progress our program into a Phase 1 study to identify
the dose of our formulation that would optimize the pharmacokinetic profile of the drug in line with the known cellular and human kinetic
profiles in Japanese and Chinese studies; however, no assurance can be provided that our IND will be accepted by the FDA in 2024, if
at all. We intend to work with the FDA to further progress a Phase 2 trial in a refractory sarcoma setting in patients who would benefit
due to the cumulative doses of anthracycline regimens these patients have already received. We intend to develop our combination strategy
that incorporates our Quatramer platform using HSB-888, a dual drug-loaded formulation that may be synergistic in mechanism to explore
improved outcomes in these patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recurrent
Sarcoma Market Potential</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarcomas
in a broad sense are tumors which are mesenchymal in nature capable of forming in connective tissue, blood, lymphatic and vessels, believed
to also effect bone and soft tissue. They are rare and account for 1% of cancers, yet encompass about 13% of cases under the age of 20.
Most common in bone are osteosarcoma and Ewing&#8217;s sarcoma, while those arising from soft tissue are commonly rhabdomyosarcomas.
Other sarcomas, such as desmoplastic small round cell and synovial sarcoma are more common into adolescence and young adulthood. All
of these tumors are treated with combination strategies including surgery, radiotherapy and traditional chemotherapy of various kinds
with 5-year survival rates of 60-70% depending on histology and metastatic disease at diagnosis. Metastatic disease has a poor prognosis
at about 20-30% 5-year survival, while recurrent disease is even worse at less than 20%. Recurrent osteosarcoma, either initially non-respondent
to treatment or returning after an initial response, occurs in about 30-50% of patients with local disease and upwards of 80% in metastatic
disease. The most frequent site of metastasis as well as recurrence is the lungs, and often times these patients undergo surgical resection
of the tumor prior to continuing on therapy. Research has suggested that patients can benefit from multiple surgeries, but this does
not obviate the need for systemic treatments to mitigate or eradicate the disease in recurrent cases, a significant high unmet need.
Other than palliative approaches using bone-seeking radiopharmaceuticals, limited agents have been approved for this high unmet need
tumor, predominantly in children and young adults. <span style="background-color: white">Vascular endothelial growth factor</span> inhibitors
as well as <span style="background-color: white">mechanistic target of rapamycin</span> inhibitors and immunotherapy have been studied
but none have been conclusive in elucidating a regimen that could be FDA-approved for this disease. Ewing&#8217;s sarcoma, the second
most common bone sarcoma when it recurs, has a dismal prognosis with a 5-year overall survival less than 10%. Frontline therapy consists
of vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide in alternating cycles of interval compressed treatment. While
chemotherapy regimens are used in frontline treatment, there remains no standard backbone therapy for recurrent or refractory cases.
Rhabdomyosarcoma, the most common soft tissue tumor in young adults, has been historically treated with vincristine, actinomycin D, and
cyclophosphamide as standard-of-care for the last 50 years. Desmoplastic round cell tumors as well synovial sarcomas are much more aggressive
sarcomas and have had no new interventions in recurrent and refractory disease. All of these sarcomas, effecting younger patients, share
the commonality of very poor prognoses when the cancer recurs or becomes refractory to standard-of-care treatment protocols, creating
a vital urgency for novel treatments in these tumor types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-510:
Our Novel Bifunction HDAC6-PI3K-Delta Inhibitor Downregulates &#172;c-myc</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
HSB-510 product candidate is a novel highly targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against
PI3K-delta and HDAC6, which is also known to downregulate <i>c-myc</i>, a highly pursued and yet undruggable cancer drug target. The
Quatramer platform achieves optimal tumor targeting and bioavailability of the highly potent targeted small molecule. In October 2020,
we renewed our Cooperative Research and Development Agreement with NCATS. The agreement enables NCATS to use our Quatramer drug delivery
platform in formulations of HDAC-PI3K-delta dual inhibitors for the treatment of rare cancers, including AML and acute lymphoid leukemia
(&#8220;ALL&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
series of compounds were rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating a <span style="background-color: white">histone
deacetylase</span> pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker. Several of these dual inhibitors were highly
potent (IC50 &lt; 10 nM) and selective against PI3K&#947;, -delta and HDAC6 enzymes and exhibited good antiproliferative activity against
multiple cancer cell lines. The lead compound induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts
from AML patients, while showing no cytotoxicity against several select normal cells. Target engagement of PI3K-delta and HDAC6 by the
lead were demonstrated in specific cells using the cellular thermal shift assay. The compound also showed ideal pharmacokinetic properties
in mice via intraperitoneal administration which provides a means to examine the biological effects of inhibiting these two enzymes with
a single molecule, either <i>in vitro</i> or <i>in vivo</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
conducted by NCATS have shown that by disrupting multiple compensatory cytoprotective pathways, HDAC6-PI3K-delta dual inhibitors have
therapeutic value. Our primary objective in conjunction with NCATS was encapsulation of NCATS&#8217; developed HDAC6-PI3K-delta dual
inhibitors into our proprietary, tumor infiltrating Quatramer platform to enhance delivery to malignant cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue our collaborative effort with NCATS through our Cooperative Research and Development Agreement, and we intend to expand
such agreement and execute a license to this novel HDAC-PI3K-delta dual inhibitor to move the compound through further pre-clinical testing
and into IND-enabling work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HSB-510
HDAC6 &amp; PI3K-delta Inhibitor</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HDACs
are an important class of epigenetic enzymes that regulate gene expression by removing acetyl groups from &#949;-amino lysine residues
on histones. HDACs play an important role in regulating expression of various proteins, including tumor suppressors and transcription
factors. Dysregulation of HDACs is involved in cancer initiation and proliferation. HDAC inhibition has emerged as a therapeutic approach
for cancer and several inhibitors, including Vorinostat (&#8220;SAHA&#8221;), Romidepsin, Belinostat, Panobinostat, and Chidamide, have
been approved in recent years Pan-HDAC inhibitors, such as Panobinostat and SAHA, modulate the acetylation status of a wide range of
protein targets leading to a therapeutic response; however, these molecules also have undesirable side-effects, including hematological,
gastrointestinal, and cardiac toxicity with less than disable efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
I PI3Ks are lipid kinase enzymes that transduce signals from cell surface receptors (RTK, GPCR, etc.) to downstream effectors (AKT, mTOR,
etc.), leading to a variety of cellular processes, including cell proliferation, survival, differentiation, metabolism, and angiogenesis.
Specifically, class I PI3Ks phosphorylate phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2 or PIP2) in vivo to form the secondary messenger
phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3 or PIP3). The PI3K&#945; and PI3K&#946; isoforms are ubiquitously expressed,
whereas PI3K&#947; and PI3K-delta expression is limited to leukocytes. Aberrant regulation of class I PI3Ks has been implicated in several
cancer types, and their inhibition continues to be an active cancer therapeutic area with at least four approved PI3K inhibitor drugs
(Idelalisib, Copanlisib, Duvelisib, and Alpelisib) and several others in ongoing clinical trials. Despite tremendous progress in the
discovery of PI3K inhibitors (&#8220;PI3Ki&#8221;) over the past decade, clinical trials conducted by third parties with PI3Ki as a monotherapy
have shown poor efficacy prompting their evaluation in combination therapies and/or developing PI3K-based multitarget drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
both PI3K and HDAC inhibitor drugs are limited by insufficient efficacy and resistance mutations, there is strong evidence that simultaneous
inhibition of both PI3K and HDAC can synergistically inhibit tumor growth and address these limitations by improving efficacy, limiting
resistance, and providing a better therapeutic window than single inhibitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
15: HSB-510 - Mechanism</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_014.jpg" alt="" style="height: 298px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-114
(TNF-alpha DNA) for Metastatic Soft Tissue Sarcoma</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TNF-&#945;,
identified in 1975, cloned in 1984 and named for its ability to induce necrosis of induced-sarcomas in mice, is a chemokine with potent
tumoricidal properties. However, severe systemic toxicity (capillary leakage, disseminated coagulopathy, acidosis and shock) limited
its use as an anticancer agent, until procedures were developed to use the cytokine in the clinic where high concentrations were infused
into isolated limbs of sarcoma and melanoma subjects. It has since been shown that direct intratumoral injection can augment ICIs by
slowing progression of tumors in various models, with unreliable efficacy due to the fact that levels of TNF produced must be sufficient
to attract specific T cells to the tumor via signaling, notwithstanding TNF&#8217;s direct antitumor necrotic effects. Despite the potential
to activate tumor cell death, physiological intratumoral levels of sufficient TNF concentrations are unlikely to induce cancer regression
in patients utilizing the current strategies available to deliver this potent cytokine. Finding ways to selectively increase intratumoral
TNF levels in tumors while managing the toxicity associated with such approaches remains a major unmet need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
HSB-114 product candidate is a novel immunotherapeutic agent which uses our proprietary Quatramer technology to deliver the human TNF-&#945;
gene to cancer cells. Previous immunotherapeutic strategies, including the payload of HSB-114, pHSB-114, used adenovector technology
requiring replication deficient gene deletions and complex manufacturing controls in order to deliver the gene to the desired cells,
although posed a theoretical risk of systemic toxicity and adjacent tissue damage due to overflow of TNF-&#945; in blood from the tumor,
had some dose-limited toxicities. <span style="background-color: white">In early phase trials of pHSB-114 in combination with radiotherapy
conducted by GenVec Inc. (&#8220;GenVec&#8221;), significant clinical activity was observed in patients with metastatic melanoma, soft
tissue sarcoma and locally advanced esophageal cancer. Anti-tumor activity was also observed in patients with pancreatic, rectal, and
head and neck cancers. However, a Phase 3 trial conducted by GenVec in patients with locally advanced pancreatic cancer failed to demonstrate
a survival benefit prompting discontinuation of the development of this agent.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our novel non-viral immunotherapeutic TNF-&#945; gene therapy, HSB-114, builds on the pHSB-114 clinical development program with
improved scalability and tunability providing efficacy with an overall enhanced safety profile to potentially minimize dose-limited toxicities.
We <span style="background-color: white">have developed HSB-114 via a modified Quatramer delivery system which includes a peptide-DNA
complex designed for maintaining the balance of DNA condensation and intracellular release and nuclear localization. For delivery <i>in
vivo</i>, the system circumvents the challenge of DNA-nanoparticle serum interactions that have limited this field from progressing without
use of a viral vector delivery scheme. Our results demonstrate that this approach is highly effective in conferring TNF-induced anti-tumor
activity in the absence of toxicity (</span>Figure 5<span style="background-color: white">). Our findings further indicate that this
system maybe broadly applicable for expression of intratumoral cytokines that promote immune recognition and destruction.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
16: 2017 &#8211; Antitumor Activity of HSB-114 in Mouse Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_015.jpg" alt="" style="height: 147px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Data with pHSB-114</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
Phase 1 studies conducted by a third party evaluated TNF-&#945; gene transfer therapy using a radiation-inducible polymer combined with
ionizing radiation therapy in patients with soft tissue sarcoma and solid tumors. This combination therapy optimizes the therapeutic
index of TNF-&#945; by facilitating a synergistic supra-additive interaction between the two therapeutic modalities by selective destruction
of the tumor vasculature leading to tumor necrosis. Further, this strategy allows for direct cellular toxicity by locally targeted induction
of high concentrations of TNF-&#945; within the tumor with minimal systemic toxicity. The studies, summarized below, provide preliminary
evidence that pHSB-114 + radiotherapy is feasible, well tolerated, and provides a potential alternative to isolated limb perfusion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
I Study in Soft Tissue Sarcoma of the Extremities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 1 dose-escalation study evaluated pHSB-114 and concomitant ionizing radiation therapy for up to 5 weeks in 14 adult patients with
soft tissue sarcoma of an extremity. pHSB-114 was administered by intratumoral injection, twice weekly during the first week and once
weekly during weeks 2-5 of radiation therapy. Three escalating dose levels of pHSB-114 were administered, with 3-6 patients treated per
dose level, starting with a dose of 4 &#215; 10<sup>9</sup> particle units (&#8220;pu&#8221;) and escalating in 1-log increments to a
dose of 4 &#215; 10<sup>11 </sup>pu or until the maximal tolerated dose (&#8220;MTD&#8221;) was reached. There was no intrapatient dose
escalation. Concomitant single-daily fractionated radiation was administered 5 days per week (total dose, 36-50.4 Gy). Surgery was performed
in 11 patients whose tumor was resectable 3&#8211;9 weeks after radiotherapy ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
objective tumor response was observed in 11 patients, or 85%; of these, 2 were complete responses and 9 were partial responses. Of the
11 patients who had surgery, all were resected with negative margins. Pathological complete response was observed in 2 of the 11 patients.
Of the 8 patients who had partial response, 4 had &#8805; 95% tumor necrosis, which prognostically carries an improved long-term survival.
Of the 2 patients who did not have surgery and received pHSB-114 for palliation, 1 had stable disease and the other had partial response.
Tumor response assessment was not consistent between results obtained via computed tomography (&#8220;CT&#8221;) and those obtained via
histological assessment after resection, whereby CT scans showed less response than pathological assessment in 9 of the 11 patients who
had surgery, suggesting that the magnitude of the true anti-tumor response rate of pHSB-114 with ionizing radiation may be underestimated
by CT scans, particularly if performed shortly after the end of treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HSB-1218:
Research in Treating COVID-19</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coronaviruses
(&#8220;CoVs&#8221;) are important human and animal pathogens, and at the end of 2019, a novel coronavirus emerged as the cause of a
cluster of pneumonia cases in Wuhan, China. Since then the virus identified as severe acute respiratory syndrome coronavirus 2 (&#8220;SARS-CoV-2&#8221;)
has been identified to causes the designated as COVID-19. According to Johns Hopkins Coronavirus Resource Center, the global cases of
COVID-19 have reached over 446 million confirmed cases and more than 6 million reported deaths as of March 7, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there are no specific clinical features which can reliably distinguish COVID-19 from other viral respiratory infections, development
of dyspnea, anosmia and myalgias were strongly associated with a positive microbiologic test. There has been much research on finding
effective vaccines and therapeutics against SARS-COV-2, including remdesivir, chloroquine or hydroxychloroquine, convalescent plasma
and other antibody based therapies, as well as IL-6 inhibitors, direct and indirect acting antivirals, immunomodulatory agents as well
as antibiotics including azithromycin, and anti-helminthics such as ivermectin are all in various stages of testing and clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
has been reported that CoVs present and adhere to host cells via Angiotensin-Converting Enzyme-2 (&#8220;ACE-2&#8221;) receptor-mediated
endocytosis, which is a pH-dependent process. In this process, Spike (S) protein plays a major role in receptor binding and membrane
fusion of SARS-CoV-2 for access into host cells. It is a large transmembrane protein on the surface of the virus consisting of two subunits,
including the S1 subunit necessary to fit with the ACE-2 receptor for viral entry. Subsequent to binding, SARS-CoV-2 enters the cytosol
of the host cell, by pH-dependent proteolytic cleavage of spike protein by transmembrane protease serine 2, a plasma membrane-anchored
protease that participates in proteolytic cascades of several human proteins, including those relevant to the normal function of the
human prostate. This host protein primes the S1 subunit and promotes viral uptake and host cell entry. Then, the combination of viral
and host cell membranes occurs in acidified endosomes, permitting viral genomes to affect host cells with the aid of the S2 subunit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
HSB-1218 product candidates uses our Quatramer tunable technology to encapsulate a potent antiviral and deploy the agent either systemically
or in an inhaled formulation to target SARS-CoV-2. Evidence suggests the payload of HSB-1218&#8217;s active drug inhibits replication
of viral RNA in the cytoplasm by altering the pH. We believe this product candidate has the potential to prevent the entry of SARS-CoV-2
into the cytosol and prevent membrane fusion (a pH-dependent process). Further, it has been reported to interact with the S-protein,
and impact ACE-2 attachment and impede the release of viral RNA into the cytoplasm identifying the active component as a <span style="background-color: white">potential
antiviral agent against SARS-CoV-2.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #222222"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
2021 we conducted studies in BSL3 laboratory to assess activity of HSB-1218 against SARS-CoV-2 virus grown in Vero E6 cells. The results
demonstrated that treating tissue culture cells with HSB-1218 either before or after challenge with SARS-CoV-2 virus can protect cells
from virus induced cytotoxicity and significantly reduce the accumulation of virus titers in culture supernatants. In pre-treatment experiments,
treatment of cells with 5 micromolar HSB-1218 had the most significant impact on both inhibition of virus induced cytotoxicity and virus
titers at 72 hours post-infection and treatment with as little as 1 micromolar HSB-1218 reduced virus titers below the limit of detection
at 24 hours post-infection. Treatment of cells with 10 micromolar HSB-1218 following infection reduced virus titers in the culture supernatant
below the level of detection and inhibited virus induced cytotoxicity. We are continuing further mechanistic studies in order to identify
the antiviral effect of HSB-1218 against SARS-CoV-2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
17: HSB-1218 - Dose dependent effect of HSB-1218 in an <i>in vitro</i> COVID-19 Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_016.jpg" alt="" style="height: 147px; width: 624px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
believe HSB-1218, which utilizes our Quatramer delivery technology, may offer an approach for effective use of this agent as an antiviral
delivered to the site of infection in attacking SARS-CoV-2, and we intend to continue to develop this compound and seek government and
other funding to further develop this program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Iron
Mediated Cell Death Inducer Analogues Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, we acquired intellectual property and data related to analogues of HSB-1216&#8217;s active drug with varying molecular
constructs with increased efficacy against a subgroup of tumors consisting of breast, pancreatic and prostate cancers. Several lead analogues
have demonstrated increased potency when compared to HSB-1216&#8217;s active drug, whereby the increased potency of these compounds is
expected to have ferroptotic effects greater than HSB-1216&#8217;s active drug at micro-dosage levels, creating an increased therapeutic
index as novel small molecules. We expect to develop these advanced compounds as follow-on therapeutics to HSB-1216 to treat a variety
of high unmet needs, including orphan cancers, which are sensitive to the ferroptotic pathway.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quatramer
Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
proprietary Quatramer technology is based on know-how and permits manufacture of uniform size polymer aggregates that can be packaged
and tuned specifically to interact with pharmaceutical drugs, biological molecules and/or combinations of molecules to bypass delivery
problems. The system is biocompatible and can be tailored to form therapeutics which solubilize the drug in aqueous media such as human
plasma and blood which dramatically increases the amount of drug available at the disease site while administering a lower dose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
18: Quatramer Platform - Disintegration</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_017.jpg" alt="" style="height: 552px; width: 602px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
studies have shown that targeted delivery of drugs to a site of action, including tumors, is directly related to the length of time of
a circulating therapeutic in the bloodstream. This is an expected outcome as most drug delivery formulations delivering payloads to sites
of action are cleared extremely rapidly by the reticuloendothelial system (&#8220;RES&#8221;) in the liver. The stealth nature of our
technology allows for a prolonged circulation time whereby there is accumulation at the site of disease prior to being cleared.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
19: Scanning electron microscopy (SEM) of Quatramer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_018.jpg" alt="" style="height: 176px; width: 153px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
size, shape and surface of our Quatramer allows it to escape via gaps in the blood vessels in the TME allowing for release of the payload
directly into cancerous cells. Furthermore, the system functions as a &#8220;peeling onion&#8221; in coordinated and precise acidic versus
basic conditions depending on the TME as well as inside cancerous cells. Certain portions of the technology release a payload due to
its own physicochemical characteristics while the core of the Quatramer system would release a different payload depending on its own
chemical and physical properties. This type of a profile for certain of our Quatramer therapeutics, particularly our combination products,
are specifically designed to cleave or disperse in response to external stimuli causing internal changes for delivery and is a designed
approach to our size tunable vehicles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
designed size tunable feature of certain of our Quatramer compositions offer further advantages, as certain cleaved materials create
a reversal of drug resistance in cells. <span style="background-color: white">Drug resistance can be classified into two categories:
<i>de novo</i> resistance or acquired resistance. Cancer patients that exhibit <i>de novo</i> resistance do not respond to chemotherapy
from the start. However, in acquired resistance, the cancer cells initially respond to a drug but eventually acquire resistance to it
and the cells might also show cross-resistance to other structurally and mechanistically unrelated drugs, a phenomenon commonly known
as MDR whereby treatment regimens that combine multiple agents with different targets are no longer effective. Our Quatramer technology
circumvents this phenomenon upon cleavage of the payload from the system, whereby the remnants of the system, such as certain hydrophobic
chains flanked by hydrophilic chains which are not related to therapeutic efficacy, cause drug efflux pump blockage and allow the payload
to continue to be effective in MDR cellular systems both <i>in vitro</i> and <i>in vivo</i>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramer
physicochemical characterization allows for optimizing size, shape and surface chemistry based on payload characteristics to render enhanced
permeation and retention into the TME. Our scientific know-how and scientific expertise in developing Quatramer based therapeutics has
led to understanding the optimal conditions for encapsulating therapeutics of different physicochemical characteristics into our proprietary
delivery, and the combination of multiple materials used varies depending on the drug itself, causing a highly specific tunability platform
that can be scaled. The proprietary know-how behind our Quatramer structures with multiple layering allows for therapeutics of different
levels of hydrophilicity and hydrophobicity to interact within aqueous mediums of varied acid-base conditions, including human serum
and blood. The importance of the Quatramer structure extends the certain aspects of the core and thereby has the capacity to increase
drug uptake and sustain its release over long periods of time, including over many days and weeks in both <i>in vitro</i> and <i>in vivo
</i>systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quatramer technology has been designed to be a scalable process with production efficiency whereby the analysis of the output of a designed
chemistry, manufacturing and controls system creates a predictable and uniform product with controllable capability and cost efficiency.
Chemical compositions listed in the FDA Inactive Ingredients Database with known profile. Combined with the tunability of Quatramer,
the technology allows for a variety of delivery payloads including peptides, small molecules, nucleic acids and antibodies with the added
flexibility of dual-loaded payload therapeutics. The payload diversity and flexibility of the system coupled with its numerous advantages
allows for a targeted system with prolonged circulation time, which takes advantage of an efficient EPR effect with numerous mechanistic
features deployed at various conditions with the TME as well as in intracellular environments, which makes the methodology of Quatramer
therapeutics, a highly advantageous platform to deliver low doses of therapeutics directly to tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trident
Artificial Intelligence Platform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
cells are constantly undergoing phenotypic switching that may or may not be dependent on the drug target and without additional secondary
genetic mutations but are now understood to engage three different mechanisms: EMT, Dedifferentiation/Trans differentiation and Treatment-induced
tolerance. These stepwise phenotypic transitions through a slow cycling state potentially induce a synthetic lethal sensitivity of key
driver functional pathways making them amenable to novel therapeutic strategies. These phenotypic transitions present novel opportunities
for targeting specific drug pathways and gene circuits which none of the conventional approaches are designed to do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize these dynamical aspects which make cancer a constantly evolving progressive disease and are taking a biomarker-guided approach
to drug development that will maximize treatment benefit for patients. We are developing TAI, a drug targeting technology platform, to
enable the development of rational therapeutic strategies to target the plasticity of cancer cells associated with drug resistance. TAI
aims to establish clinical development by applying state-of-the-art deep learning artificial intelligence technologies to patient-based
multi-modal datasets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
TridentAI platform:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to create a Ferroptomics Atlas which integrates diverse multi-omics datasets including not only genomics, epigenetics
    and transcriptomics but also emerging proteomics data which enable identification of dynamical re-wiring of intra-tumoral signaling
    circuitry designed to target IMCD;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    the ability to identify biomarkers that potentially differentiate between progression of cancer plasticity and correlate it to degree
    of sensitivity to a synthetically lethal target that is induced with standard-of-care treatment and development of resistance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    designed to classify and select patients that are most likely to respond to treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
is based on a deep learning engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity using biomarkers
that can be translated for patient selection. TridentAI is designed to maximize enrichment for patients who are most likely to respond
to treatment and thus de-risks clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cell
plasticity is a leading contributor to drug resistance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
cells are constantly undergoing phenotypic switching that may or may not be dependent on the drug target and without additional secondary
genetic mutations. Three critical mechanisms are understood to be involved which are engaged more or less simultaneously.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
are EMT, dedifferentiation and transdifferentiation, and transient drug-induced tolerance. EMT is characterized by both morphological
and molecular changes characterized by loss of apical-basal polarity and epithelial cell junctions leading to changes in cellular composition
of basement membrane, altering intra- and inter- cellular signaling, and eventually resulting in metastasis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the same time, distinct compartments of the epithelium maintained by different pools of resident stem cells begin to transdifferentiate
or even reverse completely and dedifferentiate upon treatment. For instance, <span style="background-color: white">epidermal growth factor
receptor</span> (&#8220;EGFR&#8221;)-driven non-SCLC are observed to convert towards a SCLC phenotype upon EGFR inhibition and melanoma
cells dedifferentiate progressively through transitory and neural crest-like states under <span style="background-color: white">v-raf
murine sarcoma viral oncogene homolog B1 </span>inhibitor treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
20: Cell plasticity is a leading contributor to drug resistance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_019.jpg" alt="" style="height: 319px; width: 595px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
tumor cells undergo a slow-proliferating drug-tolerant state, called drug-tolerant persisters, before further developing secondary mutational
drug-resistance. This phenomenon has been observed in glioblastomas, melanomas and non-SCLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collectively,
these stepwise transitions through a slow cycling state potentially induce a synthetic lethal sensitivity of key driver functional pathways
making them amenable to novel therapeutic strategies. This presents a novel opportunity for drug targeting to identifying treatment-induced,
state-specific, synthetically lethal drug-target pairs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conventional
approaches to drug targeting are limiting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conventional
approaches to drug targeting are not equipped to handle the challenges of identifying synthetic lethal drug-target pairs. Signature-reversion
principles or guilt-by-association strategies used to uncover drug-drug or drug-disease similarity have yielded few successes due to
large transcriptional differences between in vitro long-lived cell lines and in vivo TME. Chemical similarity approaches have their pitfalls
- errors in chemical structures as well as physiological effects that exist beyond the structural relationship limit the use for drug
targeting. Structure-based molecular docking virtual screens, for predicting drug-target pairs, are limited by lack of widespread availability
of 3D protein structures for drug targets and poor predictability of target binding affinity. Pathway or network-based approaches to
integrate gene expression patterns, protein interactions and genome-wide association study data help identify enrichment of drug targets
but do not yield biomarkers that can be translated for patient selection. None of these approaches are designed to search for context-specific
synthetic lethal targets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
21: Conventional approaches to drug repurposing are limiting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_020.jpg" alt="" style="height: 179px; width: 606px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TridentAI
is a Deep Learning Engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
takes a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses namely EMT, dedifferentiation/transdifferentiation,
and transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation of diverse multi-modal and multi-omic
private and public datasets which include not only genomic and transcriptomic data from patient derived blood or biopsy samples and sublines,
and pan-cancer epigenetic and transcriptional drug response data from TCGA, Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity
in Cancer, but also human cancer proteome datasets from emerging global efforts that include Human Cancer Proteome Project, The Cancer
Proteome Atlas and The National Cancer Institute&#8217;s Clinical Proteomic Tumor Analysis Consortium. Inclusion of proteomics data is
very critical for identifying dynamical re-wiring of intra-tumoral signaling circuitry which is likely to be missed if one looks at the
genomic and transcriptomic level alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
is a deep learning engine that integrates <i>in vitro</i> and <i>in vivo</i> epigenetic, transcriptomic and proteomic data characterizing
genomic alterations, methylation states, cellular differentiation, and drug tolerance to identify:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomarker
    fingerprints that deconvolve a heterogenous tumor biopsy into a discrete phenotypic state along a gradient of progressive cellular
    plasticity;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Network
    of dis-regulated functional pathways that underscore a patient&#8217;s pathology; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indication-specific
    synthetic-lethal sensitivities to drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
utilizes state-of-the-art convolutional neural networks to classify and select patients based on their tumor-derived multi-comic profiles
thus enabling a targeted synthetic-lethal approach to kill persistent tumor cell populations and treat patients in select indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
22: TridentAI identifies synthetic legal sensitivities associated with degree of cell plasticity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_021.jpg" alt="" style="height: 317px; width: 605px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TridentAI
maps the phenotypic tumor transition from a high-dimensional landscape onto a quantitative, measurable one-dimensional scale</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
traces the complex high-dimensional landscape of tumor progression to identify biomarkers that mark milestones in this continuum and
enable quantification of degree of plasticity along the trajectory. TridentAI&#8217;s deep learning engine trains a model that can reduce
this high-dimensional information into a one-dimensional quantitative and measurable scale which provides the degree of plasticity in
a biopsy sample or cell line dataset. TridentAI&#8217;s unbiased search in the vast repository of multi-modal datasets enables identification
of synthetic lethal sensitivities that correlate linearly but contrast with degree of plasticity. This biomarker-guided, state-specific
approach enables to successfully deconvolve signals from a heterogenous tumor biopsy into a discrete phenotypic state along a gradient
of progressive and divergent cellular plasticity and complementary synthetic lethal sensitivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
23: TridentAI maps the phenotypic transition of tumor onto a quantitative, measurable one-dimensional scale</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_022.jpg" alt="" style="height: 226px; width: 595px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TridentAI
is designed to establish clinical development and deliver on the promise of precision medicine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
is designed to deliver on our ultimate goal, which is to identify and treat the right patients that are most likely to benefit from treatment.
Using TridentAI, biomarkers measured in patient blood/biopsy samples will assist in determining the degree of plasticity for a specific
patient, which will then directly inform about a patient&#8217;s sensitivity to activation/inhibition of the synthetically lethal target
and probability of successful treatment. More than just de-risking clinical development, TridentAI aspires to deliver on the promise
of precision medicine by building a platform based on the robust foundation of patient-based biomarker research and deep learning artificial
intelligence technologies. TridentAI has successfully identified biomarkers correlating dedifferentiation in melanoma with sensitivity
to inhibitors of ferroptosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
24: TridentAI is designed to establish clinical development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_023.jpg" alt="" style="height: 191px; width: 605px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to disrupt the biotechnology landscape by developing novel therapeutics by leveraging both our targeted-delivery Quatramer platform-based
therapeutics and our TAI platform to address significant unmet medical needs, with a focus on treatments for cancer. We believe that
our technology has the potential to generate differentiated products that have the potential to treat rare and treatment resistant tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    drug candidate, HSB-1216, in solid tumors.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a clinical pilot study conducted in Germany by the University of Heidelberg led us to progress HSB-1216 into IND-enabling studies
with the goal of submitting an IND to the FDA in 2023. These IND-enabling trials are pre-clinical in nature and include toxicology and
pharmacokinetic profiling as well as bioanalytical assay development. We engaged in discussions with the FDA in 2020 and expect to use
the 505(b)(1) FDA approval pathway and conduct a Phase 1 trial to obtain initial pharmacokinetic and dosing information in patients.
We intend to evaluate the development of HSB-1216 in other high-unmet need oncology indications, including certain brain, breast and
prostate cancers, and in combination with other cancer therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    our combination drug candidate, HSB-888, for pediatric sarcomas.</i></b></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is in IND-enabling trials with the goal of submitting an IND to the FDA in 2024. These trials are pre-clinical in nature and include
toxicology and pharmacokinetic profiling as well as bioanalytical assay development. Based on this data we plan to initiate discussions
with the FDA in 2024 and intend to use the 505(b)(1) FDA approval pathway and conduct a Phase 1 trial for obtaining initial pharmacokinetic
data and determine the optimized dose in patients. We intend to demonstrate the safety and efficacy in a Phase 2 program in a basket
trial enrolling patients with recurrent cancers due to multiple sarcomas, including Ewing&#8217;s sarcoma, rhabdomyosarcoma and eligible
osteosarcoma patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging
    our Trident Artificial Intelligence Platform.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a computational intelligence platform that identifies synthetic lethal sensitivities associated with degree of cell plasticity. We
undertake a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses including epithelial
to EMT, dedifferentiation/transdifferentiation, and transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation
of diverse multi-modal and multi-omic private and public datasets which include not only genomic and transcriptomic data from patient
derived blood or biopsy samples and sublines, and pan-cancer epigenetic and transcriptional drug response data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    and commercializing Quatramer in collaboration with leading pharmaceutical companies.</i></b></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies
to develop Quatramer incorporating therapeutic payloads from their proprietary product portfolios. We intend to establish collaborations
with industry leaders and strategic pharmaceutical organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging
    our novel platform to develop a pipeline of high value Quatramer leads.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tunability of our technology allows us to efficiently expand our pipeline of Quatramer, both on our own and in collaboration with others,
through various combinations of targeted DNA encoded for anti-tumor cytokines and therapeutic payloads, which enables us to move into
other areas of oncology, including immuno-oncology whereby we could potentially increase the effectiveness of ICIs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commercializing
    proprietary Quatramer based products, including HSB-1216, directly in the United States and with collaborators outside the United
    States.</i></b></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own HSB-1216 and our other proprietary pipeline and expect to maintain similar rights with respect to other proprietary Quatramer we
develop. We intend to build a focused oncology sales organization to market Quatramer in the United States following FDA approval. Outside
the United States, we expect to rely on collaborators to commercialize proprietary approved Quatramer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing
    to extend and protect our product technology and Quatramer through our intellectual property portfolio.</i></b></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our novel platform through U.S. and international patents as well as know-how and trade secrets relating to the design
and manufacturing of our technology. We expect to continue to file patent applications as we apply our technology to new targets and
therapeutic payloads. In addition, we believe the heightened regulatory requirements for generics of this technology may strengthen the
protection afforded by our intellectual property portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Team</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
Chief Executive Officer and directors have extensive scientific, drug development, and commercialization experience across pertinent
disciplines including oncology; small molecule, peptide and antibody drug manufacturing and quality; clinical drug development, and commercialization.
Our Chief Executive Officer and directors have held various research, clinical development, artificial intelligence, strategy, corporate
development and operational positions at large biopharmaceutical companies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
<span style="background-color: white">public biotechnology companies, and universities having worked at companies such as DuPont Merck
Pharmaceuticals, Amgen Inc., Exelixis, Inc., Salix Pharmaceuticals, Inc., Global Cancer Research Institute, Sanofi and UCLA School of
Medicine. Our Chief Executive Officer and directors have been involved in the discovery, development, manufacturing and commercialization
of multiple marketed products across various therapeutic areas, including, but not limited to, Cabometyx<sup>&#174; </sup>(cabozantinib),
Remicade<sup>&#174;</sup> (infliximab) and Clolar<sup>&#174; </sup>(clofarabine).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products and intellectual property. We face competition from m</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ajor
multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up
companies, universities and other research institutions both in the United States and internationally. Any drug candidates that we successfully
develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions
in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number
of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. Earlier stage companies, such as smaller discovery phase biotechnology companies, may also prove
to be significant competitors, particularly through collaborative arrangements with large and established companies. Some of our competitors
include BridgeBio Pharma, Inc. (Ferro Therapeutic, Inc.), Kojin Therapeutics, Inc., Bayer AG and The Broad Institute of MIT and Harvard,
Moderna Inc. and Takeda Pharmaceutical Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors
also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our
ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products.
Generic products are currently on the market, including the therapeutics payload in HSB-1216 and HSB-888, for the indications that we
are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our drug candidates
achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy and targeted drug
therapy. There are a variety of available drug therapies marketed for solid tumors. In many cases, these drugs are administered in combination
to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis, including
drugs in the same therapeutic class as the payloads contained in HSB-1216 and/or HSB-888. Many of these approved drugs are well established
therapies and are widely accepted by physicians, patients and third-party payers. In general, although there has been considerable progress
over the past few decades in the treatment of solid tumors and the currently marketed therapies provide benefits to many patients, these
therapies all are limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating
all patients. As a result, the level of morbidity and mortality from solid tumor cancers remains high.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are also a number of products in late-stage clinical development to treat solid tumors including, but not limited to, Merck &amp; Co
Inc. (Keytruda), Bristol-Myers Squibb Co. (Opdivo), AbbVie Inc. (Imbruvica), Roche Group (Tecentiq), Regeneron Pharmaceuticals, Inc.
(Libtayo) and Eli Lilly &amp; Co (sintilimab). These products in development may provide efficacy, safety, convenience and other benefits
that are not provided by currently marketed therapies. As a result, they may provide significant competition for our product candidates
for which we obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends on our intellectual property, and we strive to protect it, by, among other things, obtaining, maintaining,
defending, and enforcing our patents in the United States and internationally for our proprietary technology, improvements, platforms,
products and components thereof, novel biological discoveries, new therapeutic approaches and potential indications, and other inventions
that are important to our business. For our product candidates, generally we initially pursue patent protection covering compositions
of matter, methods of production, and methods of use. Throughout the development of our product candidates and technologies, we will
seek to identify additional means of obtaining patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 21, 2022, our utility patent portfolio includes six patent families, as set forth below. These families include issued patents
and pending applications related generally to our polymeric nanoparticle technologies, methods of making our polymeric nanoparticle technologies,
and methods of using our polymeric nanoparticles therapeutically (<i>e.g</i>., for delivery of therapeutic compounds). We own all of
the patents set forth below and currently do not out-license any of our patents to third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
Family #1 (HSB-1216; HSB-510; HSB-888; HSB-407; and HSB-114):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validated
    CH, DE, ES, FR, GB, IT, NL</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and A Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and a Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2034</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and a Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2033</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles and a Process of Preparation Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
Family #2 (HSB-1216):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Korea</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Salinomycin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
Family #3 (HSB-384):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
Family #4 (HSB-114):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Korea</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
Family #5 (HSB-407):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Korea</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polymeric
    Nanoparticles Comprising Bortezomib</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
Family #6 (HSB-1216):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salinomycin
    Derivatives and Therapeutic Uses Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of individual patents depends on the legal term for patents in the countries in which they are obtained. In most countries, including
the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the U.S., the term of
a patent may be lengthened by patent term adjustment (&#8220;PTA&#8221;), which compensates a patentee for administrative delays by the
USPTO in examining and granting a patent or the term of a patent may be shortened if a patent is terminally disclaimed over an earlier
filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension (&#8220;PTE&#8221;)
after FDA approval for a portion of the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations
and provided statutory and regulatory requirements are met. PTE can be for no more than five years, typically only one patent per approved
product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering
the approved drug, a method for using it or a method for manufacturing it may be extended. In addition, the length of the adjustment
or extension granted could be less than that requested, and we may not receive the full PTA or PTE available if we fail to exercise due
diligence during the testing phase or regulatory review process, fails to apply within applicable deadlines, fails to apply prior to
expiration of relevant patents, or otherwise fails to satisfy applicable requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how and continuing technological innovation to develop and maintain our competitive
position. However, trade secrets and know-how can be difficult to protect. We take measures to protect and maintain the confidentiality
of proprietary information in order to protect aspects of the business that are not amenable to, or that we do not consider appropriate
for, patent protection. We require employees, consultants, outside scientific partners, sponsored researchers and other advisors to execute
confidentiality agreements with us on or prior to the commencement of employment or consulting relationships with us. These agreements
also require such individuals to assign to us any inventions conceived in the course of employment or consulting relationships with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also filed a trademark applications with the USPTO for &#8220;HILLSTREAM BIOPHARMA&#8221; for pharmaceutical preparations for use
in cancer treatment and therapies&#8221; and for &#8220;QUATRAMER&#8221; for nano particle technologies and nanoparticle technologies
for cancer therapy and treatment, namely, drug delivery agents in the form of nanoparticles that provide controlled release of active
ingredients for a wide variety of pharmaceuticals for the treatment of cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate any facilities in which we can formulate or manufacture our product candidates. We intend to rely on contract manufacturers
to produce all materials required to conduct pre-clinical studies and clinical trials under current good manufacturing practice (&#8220;cGMP&#8221;),
with oversight of these activities by our management team. We have identified alternate sources of supply and other contract manufacturers
that can produce materials for our pre-clinical and clinical trial requirements on a timely basis. However, if an existing or future
contract manufacture fails to deliver on schedule, or at all, it may delay or interrupt the development process for our product candidates
which may have an adverse effect on our operating results and estimated timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, we closed the initial public offering of our common stock pursuant to which we issued and sold an aggregate of 3,750,000
shares of our common stock for a purchase price of $4.00 per share. We received net proceeds of approximately $13.0 million, after deducting
underwriting discounts and commissions and offering expenses borne by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of our initial public offering, in January 2022, notes in the aggregate amount of $3,920,640, including interest
accrued thereon, were converted into an aggregate of 1,225,384 shares of our common stock. As of March 21, 2022, we have no outstanding
convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Government
Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in the U.S. and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion,
advertising, distribution and marketing of pharmaceutical products such as those being developed by us. In the U.S., the FDA regulates
such products under the FDCA and its implementing regulations. Failure to comply with applicable FDA requirements, both before
and after approval, may subject us to administrative and judicial sanctions, such as a delay in approving or refusal by the FDA to approve
pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions and/or criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Food and Drug Administration Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>United
States Drug Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs, medical devices and combinations of drugs and devices, or combination products, under the
FDCA and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process
of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any
time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial
sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of
an approval, a clinical hold, untitled or warning letters, requests for voluntary product recalls or withdrawals from the market, product
seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution,
disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of extensive pre-clinical laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including
    the FDA&#8217;s Good Laboratory Practice regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with an applicable IND and clinical study related regulations,
    referred to as Good Clinical Practice (&#8220;GCP&#8221;), to establish the safety and efficacy of the proposed drug for its
    proposed indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a new drug application (&#8220;NDA&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product, or components thereof,
    are produced to assess compliance with the FDA&#8217;s cGMP requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the clinical trial sites that generated the data in support of the NDA; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA prior to any commercial marketing or sale.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a pharmaceutical product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include
laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor must submit
the results of the pre-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature,
to the FDA as part of the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the initial
clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical
trial lends itself to an efficacy evaluation. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions related to a proposed clinical trial
and places the trial on a clinical hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve any outstanding
concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials
due to safety concerns or non-compliance, and may be imposed on all drug products within a certain class of drugs. The FDA also can impose
partial clinical holds, for example, prohibiting the initiation of clinical trials of a certain duration or for a certain dose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These
regulations include the requirement that all research subjects provide informed consent in writing before their participation in any
clinical trial. Further, an institutional review board (&#8220;IRB&#8221;) must review and approve the plan for any clinical trial before
it commences at any institution, and the IRB must conduct continuing review and reapprove the study at least annually. An IRB considers,
among other things, whether the risks to individuals participating in the clinical trial are minimized and are reasonable in relation
to anticipated benefits. The IRB also approves the information regarding the clinical trial and the consent form that must be provided
to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
new clinical protocol and any amendments to the protocol must be submitted for FDA review, and to the IRBs for approval. Protocols detail,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1. The product is initially introduced into a small number of healthy human subjects or patients and tested for safety, dosage tolerance,
    absorption, metabolism, distribution and excretion and, if possible, to gain early evidence on effectiveness. In the case of some
    products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the
    initial human testing may be conducted in patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2. Involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily
    evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically
    dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit relationship of the product
    and provide an adequate basis for product labeling.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to
gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase 4 trials. Companies that conduct certain clinical trials also are required to register them and post the results
of completed clinical trials on a government-sponsored database, <i>www.clinicaltrials.gov</i>, in the United States, within certain
timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written
IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings from other
studies that suggest a significant risk to humans exposed to the product, findings from animal or in vitro testing that suggest a significant
risk to human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in
the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified
period, if at all. The FDA or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including
a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate
approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements
or if the product has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an
independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee.
This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from
the study. The clinical trial sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive
climate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
and FDA Review Process</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical
tests conducted on the drug, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA, which request
approval to market a new drug product. The submission of an NDA is subject to the payment of a substantial user fee, and the sponsor
of an approved NDA is also subject to an annual program user fee; although a waiver of such fee may be obtained under certain limited
circumstances. For example, the agency will waive the application fee for the first human drug application that a small business or its
affiliate submits for review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA
for filing. The FDA typically makes a decision on accepting an NDA for filing within 60 days of receipt. The decision to accept the NDA
for filing means that the FDA has made a threshold determination that the application is sufficiently complete to permit a substantive
review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA&#8217;s
goal to complete its substantive review of a standard NDA and respond to the applicant is ten months from the receipt of the NDA. The
FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional
information or clarification and may go through multiple review cycles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is
safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve
the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products that
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA
will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review
process. The review and evaluation of an NDA by the FDA is extensive and time consuming and may take longer than originally planned to
complete, and we may not receive a timely approval, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether
they comply with cGMP. The FDA will not approve the product unless it determines that the manufacturing processes and facilities
are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After
the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete
Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.
A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in
its present form. A Complete Response Letter describes specific deficiencies in the NDA identified by the FDA. The Complete Response
Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming
requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant
may either resubmit the NDA, addressing all the deficiencies identified in the letter, or withdraw the application. Even if such data
and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from
clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties
or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific diseases
and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the
FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval
of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct
post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require
Phase 4 clinical trials to further assess drug safety and effectiveness and may require testing and surveillance programs to monitor
the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals, including the requirement
for a REMS to assure the safe use of the drug. If the FDA concludes a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) is
needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A
REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial
promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory
requirements or if problems occur following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Orange
Book Listing and Paragraph IV Certification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
NDA submissions, including those under Section 505(b)(2), applicants are required to list with the FDA certain patents with claims that
cover the applicant&#8217;s product. Upon approval, each of the patents listed in the application is published in <i>Approved Drug Products
with Therapeutic Equivalence Evaluations</i>, commonly referred to as the Orange Book. Any applicant who subsequently files an abbreviated
new drug application (&#8220;ANDA&#8221;) or 505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that
(1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has
expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use
or sale of the drug product for which the application is submitted. This last certification is known as a Paragraph IV Certification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an applicant has provided a Paragraph IV Certification to the FDA, the applicant must also send notice of the Paragraph IV Certification
to the holder of the NDA for the approved drug and the patent owner once the application has been accepted for filing by the FDA. The
NDA holder or patent owner may then initiate a patent infringement lawsuit in response to notice of the Paragraph IV Certification. The
filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV Certification prevents the FDA from approving
the ANDA or 505(b)(2) application until the earlier of 30 months from the date of the lawsuit, the applicant&#8217;s successful defense
of the suit, or expiration of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reimbursement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
sales of any of our product candidates, if approved, will depend, at least in part, on the extent to which such products will be covered
by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party
payors are increasingly limiting coverage and/or reducing reimbursements for medical products and services. A third-party payor&#8217;s
decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s
determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product.
In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our future
revenues and results of operations. Decreases in third-party reimbursement or a decision by a third-party payor to not cover a product
candidate, if approved, or any future approved products could reduce physician usage of our products, and have a material adverse effect
on our sales, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Part D program provides a voluntary outpatient drug benefit to Medicare beneficiaries for certain products.
We do not know whether our product candidates, if approved, will be eligible for coverage under Medicare Part D, but individual Medicare
Part D plans offer coverage subject to various factors such as those described above. Furthermore, private payors often follow Medicare
coverage policies and payment limitations in setting their own coverage policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Healthcare
Laws and Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement
by the federal government and the states and foreign governments in which we might conduct our business. The healthcare industry is highly
regulated under both state and federal laws and regulations. Our operations and relationships with healthcare plans and providers are
subject to extensive and increasing regulation by numerous federal, state, and local government agencies including the FDA, the Office
of Inspector General (&#8220;OIG&#8221;), the DOJ, the CMS, the Office of Civil Rights, and various state authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare laws and regulations that may affect our ability to operate include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>False
Claims Acts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be subject to numerous federal and state laws that prohibit the presentation of false information, or the failure to disclose information,
in connection with the submission and payment of medical claims for reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil and criminal false claims laws and civil monetary penalties laws, such as the federal False Claims Act, 31 U.S.C. &#167;&#167;
3729&#8212;3733, impose civil liability on individuals or entities that submit false or fraudulent claims for payment to the federal
government. The False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes
has knowingly or recklessly: presented, or caused to be presented, a false or fraudulent claim for payment or approval to the federal
government; made, used or caused to be made or used a false statement or a false record to get a claim for payment approved, including
a false or fraudulent claim; concealed, or knowingly and improperly avoided or decreased, an obligation to pay or transmit money or property
to the federal government; or conspired to commit any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal government has used the False Claims Act to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated
against Medicare and state healthcare programs. The federal government, including as a result of the passage of the ACA, and a number
of courts have taken the position that claims presented in violation of certain other statutes, including the federal Anti-Kickback Statute
(&#8220;AKS&#8221;) or the federal physician referral law, 42 U.S.C. 1395nn (the &#8220;Stark Law&#8221;), can also be considered a violation
of the False Claims Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of states have enacted laws that are similar to the federal False Claims Act. Under Section 6031 of the Deficit Reduction Act
of 2005, as amended, if a state enacts a false claims act that is at least as stringent as the federal statute and that also meets certain
other requirements, the state will be eligible to receive a greater share of any monetary recovery obtained pursuant to certain actions
brought under the state&#8217;s false claims act. As a result, many states have enacted laws that are similar to the federal
False Claims Act and there has been a concomitant increase in state false claims enforcement efforts. Violations of federal
and state fraud and abuse laws may be punishable by criminal and/or civil sanctions, including significant penalties, fines, disgorgement,
additional reporting requirements and oversight under a corporate integrity agreement or similar agreement to resolve allegations of
noncompliance with these laws, and/or exclusion or suspension from federal healthcare programs, such as Medicare, and debarment from
contracting with the U.S. government. Penalties for False Claims Act violations include fines ranging from $11,803 to $23,607 for each
false claim, plus up to three times the amount of damages sustained by the government. In addition to the provisions of the False Claims
Act, which provide for civil enforcement, the federal government also can use several criminal statutes to prosecute persons who are
alleged to have submitted false or fraudulent claims to the government for payments. Additionally, private parties may initiate <i>qui
tam</i> whistleblower lawsuits against any person or entity under the False Claims Act in the name of the federal government, as well
as under the false claims laws of several states, and may share in the proceeds of a successful suit. Generally, federal and state governments
have made investigating and prosecuting healthcare fraud and abuse a priority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Federal &#8220;Stark&#8221; Law</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Stark Law (42 U.S.C. &#167; 1395nn) prohibits referrals or ordering by a physician of &#8220;designated health services,&#8221;
which include pharmaceuticals and drugs that are payable, in whole or in part, by Medicare or Medicaid, to an entity in which the
physician or the physician&#8217;s immediate family member has an investment interest or other financial relationship, subject to several
exceptions. Financial relationships that are implicated by the Stark Law can include arrangements ranging from marketing arrangements
and consulting agreements to medical director agreements with physicians who order our products. The Stark Law also prohibits billing
for services rendered pursuant to a prohibited referral. Several states have enacted laws similar to the Stark Law. These state laws
may cover all (not just Medicare and Medicaid) patients. Many federal healthcare reform proposals in the past few years have attempted
to expand the Stark Law to cover all patients as well. If we violate the Stark Law, our financial results and operations could be adversely
affected. Penalties for violations include denial of payment for the services, significant civil monetary penalties, and exclusion from
the Medicare and Medicaid programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
and State Anti-Kickback Statutes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
AKS, set forth in Section 1128B of the Social Security Act, prohibits the knowing and willful offer, payment, solicitation or receipt
of any form of remuneration in return for, or to induce, (i) the referral of a person for items or services reimbursable under federal
healthcare programs, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under federal healthcare programs
or (iii) the purchase, lease or order or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable
under federal healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
core of a violation of the AKS is an &#8220;inducement&#8221; to refer patients for services or items that are reimbursed under a federal
healthcare program, such as Medicare, Medicaid, or Tricare (which covers military personnel). The ACA amended the AKS to make it clear
that a person need not have actual knowledge of the statute, or specific intent to violate the statute, as a predicate for a violation.
Court cases have resulted in the interpretation that a violation may occur where even one purpose of the remuneration is to induce or
reward referrals, and the OIG, which has the authority to impose administrative sanctions for violation of the statute, has adopted a
similar standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain AKS &#8220;safe harbors&#8221; which, if the respective requirements are met, would afford protection from the AKS. Failure
to meet all requirements of an AKS safe harbor does not necessarily mean the arrangement violates the AKS, but it may be subject to scrutiny
by legal authorities, in light of the parties&#8217; intent and arrangements. In other words, if an arrangement does not fit within a
safe harbor, it does not necessarily mean that the arrangement is <i>per se</i> illegal&#8212;only that it is not shielded from regulatory
scrutiny. The federal AKS provides criminal penalties for individuals or entities that knowingly and willfully solicit or receive any
remuneration. A violation of the AKS is punishable by imprisonment of up to ten years, fines of up to $100,000 per offense, or both.
Violation can also give rise to federal healthcare program exclusion, liability under the False Claims Act and civil penalties, which
may include monetary penalties of up to $100,000 per offense, repayments of up to three times the total payments between the parties
to the arrangement and suspension from future participation in Medicare and Medicaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
some states have enacted statutes and regulations similar to the AKS, but which may be applicable regardless of the payor source for
the patient. These state laws may contain exceptions and safe harbors that are different from and/or more limited than those of federal
law and that may vary from state to state.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
Care Fraud Statute</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Health Care Fraud Statute, 18 U.S.C. &#167; 1347, prohibits any person from knowingly and willfully executing, or attempting to execute,
a scheme to defraud any healthcare benefit program, which can be either a government or private payor plan. Violation of this statute,
even in the absence of actual knowledge of or specific intent to violate the statute, may be charged as a felony offense and may result
in fines, imprisonment or both. The Health Care False Statement Statute, 18 U.S.C. &#167; 1035, prohibits, in any matter involving a
federal healthcare program, anyone from knowingly and willfully falsifying, concealing or covering up, by any trick, scheme or device,
a material fact, or making any materially false, fictitious, or fraudulent statement or representation, or making or using any materially
false writing or document knowing that it contains a materially false or fraudulent statement. A violation of this statute may be charged
as a felony offense and may result in fines, imprisonment, or both.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Civil
Monetary Penalties Statute</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Civil Monetary Penalties Law (&#8220;CMPL&#8221;), 42 U.S.C. &#167; 1320a-7a, authorizes the imposition of civil monetary penalties,
assessments, and exclusions against an individual or entity based on a variety of prohibited conduct, including, but not limited to:
(i) presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payors that the individual
or entity knows or should know are for an item or service that was not provided as claimed or is false or fraudulent; (ii) offering remuneration
to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to influence the beneficiary
to order or receive healthcare items or services from a particular provider; (iii) arranging contracts with an entity or individual excluded
from participation in a federal healthcare program; (iv) violating the federal AKS; (v) making, using, or causing to be made or used,
a false record or statement material to a false or fraudulent claim for payment for items and services furnished under a federal healthcare
program; (vi) making, using, or causing to be made any false statement, omission, or misrepresentation of a material fact in any application,
bid, or contract to participate or enroll as a provider of services or a supplier under a federal healthcare program; and (vii) failing
to report and return an overpayment owed to the federal government. We could be exposed to a wide range of allegations to which the federal
CMPL would apply. We cannot foreclose the possibility that we will face allegations subject to the CMPL with the potential for a material
adverse impact on our business, results of operations and financial condition. Substantial civil monetary penalties may be imposed under
the federal Civil Monetary Penalty Statute and may vary, depending on the underlying violation. In addition, an assessment of not more
than three times the total amount claimed for each item or service may also apply, and a violator may be subject to exclusion from federal
and state healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 21, 2022, we employed 1 full-time employee and 1 part-time employee. We are not a party to any collective bargaining agreements,
and we believe that we maintain good relations with our employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Corporate History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma Inc. (&#8220;HBI&#8221;) was incorporated on March 28, 2017, as a Delaware C-corporation. On July 16, 2019, Hillstream BioPharma
Holdings, Inc. (&#8220;Holdco&#8221;) was formed as a Delaware C-corporation. On July 24, 2019, Holdco entered into a Contribution and
Exchange Agreement with Nanoproteagen LLC (&#8220;Nanoproteagen&#8221;) whereby the members of Nanoproteagen exchanged 100% of their
membership interests in Nanoproteagen for shares of Holdco common stock. Also on July 24, 2019, the stockholders of HBI exchanged 100%
of their shares of common stock for shares of common stock of Holdco. HBI and Nanoproteagen became wholly-owned subsidiaries of Holdco.
On August 7, 2019, pursuant to a certificate of amendment, Holdco&#8217;s name was changed to Hillstream BioPharma, Inc. and HBI&#8217;s
name was changed to HB Pharma Corp. On November 12, 2020, Hillstream BioPharma, Inc. entered into a Share Exchange Agreement with Farrington
Therapeutics LLC (&#8220;Farrington&#8221;), whereby the members of Farrington exchanged their membership interest in Farrington for
shares of common stock of Hillstream BioPharma, Inc., and Farrington became a wholly-owned subsidiary of Hillstream BioPharma, Inc. At
December 31, 2021, Hillstream BioPharma, Inc. has two wholly-owned subsidiaries: HB Pharma Corp. and Farrington.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website address is <i>www.hillstreambio.com</i>. The contents of, or information accessible through, our website are not part of this
Annual Report on Form 10-K, and our website address is included in this document as an inactive textual reference only. We make our filings
with the SEC, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments
to those reports, available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish
such reports to, the SEC. The public may read and copy the materials we file with the SEC at the SEC&#8217;s Public Reference Room at
100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the
SEC at 1-800-SEC-0330. Additionally, the SEC maintains an internet site that contains reports, proxy and information statements and other
information. The address of the SEC&#8217;s website is <i>www.sec.gov</i>. The information contained in the SEC&#8217;s website is not
intended to be a part of this filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_003"></span>ITEM
1A. RISK FACTORS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and the other
information in this Annual Report on Form 10-K before investing in our common stock. Our business and results of operations could be
seriously harmed by any of the following risks. The risks set out below are not the only risks we face. Additional risks and uncertainties
not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition
and/or operating results. If any of the following events occur, our business, financial condition and results of operations could be
materially adversely affected. In such case, the value and trading price of our common stock could decline, and you may lose all or part
of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Additional Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects.
We commenced operations in 2017, have no products approved for commercial sale and have not generated any revenue. Drug development is
a highly uncertain undertaking and involves a substantial degree of risk. Since our inception, we have spent the first three years developing
and refining our Quatramer technology, and since 2019, we have focused our efforts on advancing the development of our product candidates,
HSB-1216, HSB-888 and HSB-510.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Quatramer technology is new and unproven. We have not yet commenced human clinical trials for any of our product candidates, nor have
we demonstrated an ability to initiate or successfully complete any large-scale or pivotal clinical trials, obtain marketing approvals,
manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our likelihood
of success and viability than it could be if we had a longer operating history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan on submitting an IND to the FDA for HSB-1216 in 2023; however, no assurance can be provided that our IND will be accepted by the
FDA in 2023, if at all. Our other programs are in pre-clinical discovery and research stages. As a result, we expect that it will take
several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving
marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial
research and development and other expenses in order to discover, develop and market additional potential products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our TridentAI platform in an attempt to identify synthetic lethal sensitivities associated with degree of cell plasticity
using biomarkers that can be translated for patient selection and stratification for the development of oncology drugs. While we believe
that applying our TridentAI platform is a precision oncology approach that identifies the mechanism of action, potential combination
drug usage and potentially responsive patient population, our approach is both innovative and in the early stages of development and
therefore, the cost and time needed to develop such platform difficult to predict, and our efforts may not result in the successful discovery
and development of biomarkers. We may also be incorrect about the effects of the biomarkers on our drug candidates on the diseases of
our defined patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore,
our estimates of our defined patient populations available for study and treatment may be lower than expected, which could adversely
affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully
commercialize. Our approach may not result in time savings, higher success rates or reduced costs as we expect it to, and if not, we
may not attract collaborators or develop new drugs as quickly or cost effectively as expected and therefore we may not be able to commercialize
our approach as originally expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
TridentAI platform may fail to help us discover and develop appropriate biomarkers for our potential drug candidates which would limit
our commercialization prospects and cause our losses to continue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
biomarker discovery or drug development that we are conducting using our TridentAI platform may not be successful in identifying biomarkers
that have commercial value for our products or therapeutic utility. Our TridentAI platform may initially show promise in identifying
potential biomarkers for our drug candidates, yet fail to stratify patients for clinical development or commercialization for a number
of reasons, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    programs to identify new biomarkers will require substantial technical, financial and human resources, and we may be unsuccessful
    in our efforts to identify biomarkers. If we are unable to identify suitable biomarkers for pre-clinical and clinical development,
    our ability to stratify patients could be compromised, which could result in significant harm to our financial position and adversely
    impact our stock price;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">biomarkers
    identified through our TridentAI platform may not demonstrate correlation to efficacy, safety or tolerability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data available for our TridentAI platform that seeks to correlate genomic or biomarker signatures with certain cancers may be influenced
    by the race of the patient which may limit the efficacy of our drug candidates;</span></td></tr>
</table>

<p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    regulatory pathway for the biomarkers may be too complex, expensive or otherwise difficult to navigate successfully; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors
    may develop alternative approaches that render our potential biomarkers non-competitive or less attractive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development
of, and seek regulatory approvals for, our product candidates, and begin to commercialize approved drugs, if any. Typically, it takes
many years to develop a new drug from the time it is discovered to when it is available for treating patients. We may encounter unforeseen
expenses, difficulties, complications, delays and other unknown factors that may increase our expenses and adversely affect our ability
to generate revenue. The size of our future net losses will depend, in part, on our ability to manage these aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient
revenue to achieve and maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never been profitable and have incurred significant losses in each year since inception. For the years ended December 31, 2021 and
2020, we reported a net loss of $2.2 million and $2.4 million, respectively. As of December 31, 2021, we had an accumulated deficit
of $6.9 million. We have funded our operations primarily with proceeds from the sale of our equity and debt securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur
may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a
good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our
expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse
effect on our working capital, our ability to achieve and maintain profitability and the performance of our stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to generate revenue and achieve profitability depends significantly on our ability to achieve several milestones relating to
the discovery, development and commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial condition and operating results have varied significantly in the past and are expected to continue to fluctuate significantly
due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue our current research and development programs, including conducting laboratory, pre-clinical studies for product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to initiate clinical trials for product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our clinical trials through all phases of clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrollment and timing of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure and maintain collaborations, licensing or other arrangements for the future development and/or commercialization
    of our product candidates, as well as the terms of those arrangements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, as well as the timeliness of obtaining, additional funding to develop our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials or marketing applications for product candidates that may compete with our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing products or new products that may receive marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    side effects of our product candidates that could delay or prevent approval or cause an approved drug to be taken off the market;</span></td></tr>
  </table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays in regulatory review and approval of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and develop additional product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and the ability of third parties such as Clinical Research Organizations (&#8220;CROs&#8221;) to adhere to clinical study
    and other regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of third-party manufacturers to manufacture our product candidates and key ingredients needed to conduct clinical trials
    and, if approved, successfully commercialize our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to us, and our ability as well as the ability of any third-party collaborators, to obtain, maintain and protect our intellectual
    property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to and outcomes of potential intellectual property litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support future growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key personnel to manage our business effectively; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build our finance infrastructure and, to the extent required, improve our accounting systems and controls.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
new products and services is a speculative and risky endeavor. Products or services that initially show promise may fail to achieve the
desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our products in
development and repeat clinical studies before we identify a potentially successful product or service. Product development is expensive,
may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. If, after development,
a product or service appears successful, we may, depending on the nature of the product or service, still need to obtain FDA and other
regulatory clearances, authorizations or approvals before we can market it. The FDA&#8217;s clearance, authorization or approval pathways
are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA may not
clear, authorize or approve any future product or service we develop. Even if we develop a product or service that receives regulatory
clearance, authorization or approval, we would need to commit substantial resources to commercialize, sell and market it before it could
be profitable, and the product or service may never be commercially successful. Additionally, development of any product or service may
be disrupted or made less viable by the development of competing products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
potential products and services may fail any stage of development or commercialization and if we determine that any of our current or
future products or services are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful
in developing additional products or services, our potential for growth may be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
cases where we are successful in obtaining regulatory approval to market one or more of our drug candidates, our revenue will be dependent,
in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the
ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment
population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of
such products, even if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to continue to be significant in connection with our continued investment in our ongoing
and planned clinical trials for our current product candidates and any future product candidates we may develop. Furthermore, if we obtain
regulatory approval for our product candidates, we expect to incur increased sales and marketing expenses. As a result, we expect to
continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have had
and will continue to have a material adverse effect on our stockholders&#8217; equity, financial position, cash flows and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional funding. If we are unable to raise capital on favorable terms when needed, we could be forced to
curtail, delay or discontinue our research or drug development programs or any future commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently advancing our product candidates, HSB-1216 and HSB-888, through pre-clinical stage development. Developing cancer drugs
is expensive and we expect our research and development expenses to increase substantially in connection with our ongoing activities,
particularly as we advance our product candidates in clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had cash of $4,356 and we received net proceeds of approximately $13.0 million, after deducting underwriting
discounts and commissions and offering expenses borne by us in connection with our initial public offering in January 2022; however,
we will require additional capital to obtain regulatory approval for, and to commercialize, our product candidates. Raising funds may
present challenges including, but not limited to, as a result of the novel Coronavirus (&#8220;COVID-19&#8221;). Even if we believe we
have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or
if we have specific strategic considerations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights
of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may
cause the market price of our shares to decline. The sale of additional equity or convertible securities may dilute our stockholders.
The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive
covenants, such as limitations on our ability to make certain dividends, incur additional debt, limitations on our ability to acquire,
sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our
business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than
otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise
capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Discovery and Development of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are substantially dependent on the success of our product candidates, HSB-1216 and HSB-888, which are currently in pre-clinical trials.
If we are unable to complete development of, obtain approval for and commercialize HSB-1216 or HSB-888 for one or more indications in
a timely manner, our business may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on our ability to timely and successfully complete clinical trials, obtain marketing approval for and successfully
commercialize HSB-1216 and HSB-888, our product candidates which are in the pre-clinical stages of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products approved for sale. The success of our business, including our ability to finance our Company and generate any revenue
in the future, will primarily depend on the successful development, regulatory approval and commercialization of HSB-1216 and HSB-888
as well as other product candidates, which may never occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may also become dependent on other product candidates that we may develop or acquire; however, no product candidates based
on our Quatramer technology have been tested in humans and given our early stage of development, it may be many years, if at all, before
we may be able to demonstrate the safety and efficacy of our product candidates to warrant approval for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise any additional required capital on acceptable terms, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to complete IND-enabling studies and successfully submit an IND to the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
    completion of our pre-clinical studies and clinical trials, which may be slower or cost more than we currently anticipate and will
    depend substantially upon the performance of third-party contractors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to
    support approval of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the
    FDA and similar foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to consistently manufacture our product candidates on a timely basis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop,
    validate and maintain commercially viable manufacturing processes that are compliant with cGMP;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable
    risk-benefit profile of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future
    approved products, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual
    obligations and with all regulatory requirements applicable to our current and future product candidates or approved products, if
    any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop a commercial strategy and thereafter commercialize our product candidates in the United States and
    internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration
    with others;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare
    and Medicaid) and other third-party payors for any of our product candidates that may be approved;</span></td></tr>
  </table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    convenience of our treatment or dosing regimen;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    by physicians, payors and patients of the benefits, safety and efficacy of our product candidates, if approved, including relative
    to alternative and competing treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our cancer therapeutics approach;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    demand for our current or future product candidates, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and enforce intellectual property rights in and to our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals
or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully
commercialize our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through
the sale of our product candidates to continue our business or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Quatramer approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes
us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory
approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our Quatramer technology to develop product candidates to treat cancer. Our foundational science and product development approach
are based on our ability to target specified cells or tissues and converge a therapeutic payload at the site of disease to boost efficacy
while abating adverse effects on healthy tissue. We believe that this approach may offer an improved therapeutic effect by driving an
intense, focused attack selectively upon a patient&#8217;s tumor. However, this approach to treating cancer is novel and the clinical
research that results in a product candidate has had limited testing in humans. We are currently in the process of validating different
tumor-specific therapeutic product candidates. We may spend substantial funds attempting to develop these products with the Quatramer
approach and never succeed in developing a marketable therapeutic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, we cannot assure you that even if we are able to develop product candidates to treat cancer, such therapies would safely and effectively
treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic.
We are unable to predict when or if our drug candidates will prove effective or safe in humans or if we will obtain marketing approval.
Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete pre-clinical development
and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing
is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one
or more clinical trials can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive
of the success of later clinical trials, and interim or preliminary results of a clinical trial do not necessarily predict final results.
In particular, the small number of patients in our early clinical trials may make the results of these trials less predictive of the
outcome of later clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to obtain
marketing approval or commercialize our drug candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or IRBs/ethics committees (&#8220;ECs&#8221;) may not authorize us or our investigators to commence a clinical trial or conduct a
    clinical trial at a prospective trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
    with prospective trial sites;</span></td></tr>
  </table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials for our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to
    conduct additional clinical trials, delay clinical trials or abandon product development programs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical
    trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or
    the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    for clinical trial participants from investigational and approved therapies may make it more difficult to enroll patients in our
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or third-party collaborators may fail to obtain the clearance or approval of companion diagnostic tests, if required, on a timely
    basis, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply
    with regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have to suspend or terminate clinical trials for our drug candidates for various reasons, including a finding that the participants
    are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    drug candidates may have undesirable or unexpected side effects or other unexpected characteristics, causing us or our investigators,
    regulators or IRBs/ECs to suspend or terminate the trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials for our drug candidates may be greater than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our drug candidates or other materials necessary to conduct clinical trials for our drug candidates may be insufficient
    or inadequate and result in delays or suspension of our clinical trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or a diagnostic development partner may fail to receive regulatory approval of a companion diagnostic for use with a marketed product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product development costs will increase if we experience delays in pre-clinical studies or clinical trials or in obtaining marketing
approvals. We do not know whether any of our planned pre-clinical studies or clinical trials will begin on a timely basis or at all,
will need to be restructured or will be completed on schedule, or at all. For example, the FDA may place a partial or full clinical hold
on any of our clinical trials for a variety of reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
pre-clinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our
drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
our drug candidates and may harm our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
delays in the commencement or completion, or termination or suspension, of our ongoing, planned or future clinical trials could result
in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can initiate clinical trials of a drug candidate in any indication, we must submit the results of pre-clinical studies to the FDA
along with other information, including information about the drug candidate&#8217;s chemistry, manufacturing and controls and our proposed
clinical trial protocol, as part of an IND or similar regulatory filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from the FDA for the sale of our product candidate in any indication, we must conduct extensive clinical
studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we
expect to rely in part on pre-clinical, clinical and quality data generated by our CROs and other third parties for regulatory submissions
for our drug candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence
over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions
in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may
need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. We
still need to receive FDA clearance of our IND for HSB-1216 and HSB-888 before we can begin clinical trials and would require the same
acceptance by the FDA prior to initiating any clinical trials in the United States for any of our other drug candidates. The FDA may
require us to conduct additional pre-clinical studies for any drug candidate before it allows us to initiate clinical trials under any
IND, which may lead to additional delays and increase the costs of our pre-clinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly affect our product development
costs. We do not know whether our planned trials will begin on time or at all, or be completed on schedule, if at all. The commencement
and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA disagreeing as to the design or implementation of our clinical trials or with our recommended dose for any of our pipeline programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    FDA authorization to commence a trial or reaching a consensus with the FDA on trial design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
    to obtain regulatory clearance or approval of companion diagnostics we may use to identify patients for enrollment in our clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    approval from one or more IRBs/ECs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRBs/ECs
    refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects,
    or withdrawing their approval of the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to clinical trial protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol or dropping out of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
    to manufacture or obtain sufficient quantities of drug candidate or, if applicable, combination therapies for use in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    failing to enroll or remain enrolled in our trials at the rates we expect, or failing to return for post-treatment follow-ups;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    choosing an alternative treatment, or participating in competing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    experiencing severe or unexpected drug-related adverse effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events in trials of the same class of agents conducted by other companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    or being required to use clinical end points that require prolonged periods of clinical observation or analysis of the resulting
    data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    facility manufacturing our drug candidates or any of their components being ordered by the FDA to temporarily or permanently shut
    down due to violations of cGMP regulations or other applicable requirements, or infections or cross-contaminations of drug candidates
    in the manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes to our manufacturing process that may be necessary or desired;</span></td></tr>
  </table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials
    on our anticipated schedule or consistent with the clinical trial protocol GCP or other regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">us,
    or our third-party contractors not performing data collection or analysis in a timely or accurate manner or improperly disclosing
    data prematurely or otherwise in violation of a clinical trial protocol; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations
    of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all
    of the data produced by such contractors in support of our marketing applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials
are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or
termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or
our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical
hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental
regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory
requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require
us to resubmit our clinical trial protocols to IRBs/ECs for reexamination, which may impact the costs, timing or successful completion
of a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our scientific advisors or consultants who receive compensation from us are investigators for our clinical trial. Under certain circumstances,
we may be required to report some of these relationships to the FDA. Although we believe our existing relationships are within the FDA&#8217;s
guidelines, the FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest
or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable
clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection,
of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. If we
experience delays in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects of such
drug candidate will be harmed, and our ability to generate product revenues will be delayed. Moreover, any delays in completing our clinical
trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and
generate revenues which may harm our business, financial condition, results of operations and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results
of our clinical trials may not satisfy the requirements of the FDA, European Medicines Agency (&#8220;EMA&#8221;) or other comparable
foreign regulatory authorities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe
and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in pre-clinical
studies and early-stage clinical trials does not mean that future clinical trials will be successful. Product candidates in later-stage
clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign
regulatory authorities despite having progressed through pre-clinical studies and early-stage clinical trials. Regulatory authorities
may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval,
limit the size of the patient population to which we may market our product candidates, or prevent regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences
in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants.
Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using
other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product
candidates. As a result, assessments of efficacy can vary widely for a particular patient and from patient to patient and site to site
within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain
approval to market any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes
available, and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as the interim data from our
Phase 1 clinical trial of HSB-1216 or HSB-888. These interim updates are based on a preliminary analysis of then-available data, and
the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the
particular study or trial. For example, we may report tumor responses in certain patients that are unconfirmed at the time and which
do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim
analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the
risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.
Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure
of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a
more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with
respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If
the preliminary or topline data that we report differs from late, final or actual results, or if others, including regulatory authorities,
disagree with the conclusions reached, our ability to obtain approval for, and commercialize, HSB-1216 or HSB-888 or any other product
candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory
approval could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or continue our ongoing or planned clinical trials for our product candidates if we are unable to identify
and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. Patient enrollment is a significant
factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than
we anticipate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment may be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications
as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of
our competitors&#8217; programs. Patient enrollment for our current or any future clinical trials may be affected by other factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    and efficacy of approved drugs for the disease under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    eligibility criteria for the trial in question as defined in the protocol;</span></td></tr>
  </table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidate under study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
    and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available
    therapies, including any new products that may be approved or other product candidates being investigated for the indications we
    are investigating;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
    willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical trial sites for prospective patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer
    patients and will not survive the full terms of the clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon
one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product
candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are
able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical
trials through the treatment and any follow-up periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
no regulatory authority has granted approval for a cancer therapeutic based on a Quatramer approach. We may never receive approval to
market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications,
lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant
use or distribution restrictions or safety warnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously submitted an NDA to the FDA or similar regulatory approval filings to comparable foreign authorities, for any product
candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval.
Further, any future product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not
receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain
regulatory approvals to market a product candidate, our revenue will be dependent, in part, upon the size of the markets in the territories
for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as
significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries.
While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other
countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries
also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution
of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing
regulations in these jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements
to maintain regulatory approval. If our candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform
and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results
of operations and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-1216,
HSB-888 and HSB-510 are novel technologies, making it difficult to predict the time, cost and potential success of these product candidates.
We have not yet been able to assess the safety and efficacy of any product candidates in humans. Our success depends on our ability to
develop and commercialize product candidates using our novel Quatramer technology. The novel nature of our technology makes it difficult
to accurately predict the developmental challenges we may face for product candidates as they proceed through research, pre-clinical
or greenhouse studies and clinical or field trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been a limited number of clinical trials of products created with induced ferroptosis and reverse EMT, none of which has utilized
our Quatramer technology, and no therapeutic product candidates created with induced ferroptosis and reverse EMT technology have received
marketing approval in the United States or Europe. Because our therapeutic research programs are all in research or pre-clinical stages,
we have not yet been able to assess the safety or efficacy of any product candidates in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes,
the further development or commercialization of such product candidates may be delayed, and our business may be harmed. Current or future
product candidates may not meet safety and efficacy requirements for continued development or ultimate approval in humans and may cause
significant adverse events or toxicities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
side effects or other safety risks associated with our drug candidates could delay or preclude approval, cause us to suspend or discontinue
clinical trials or abandon further development, limit the commercial profile of an approved label, or result in significant negative
consequences following marketing approval, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.
Undesirable side effects caused by our drug candidates could result in the delay, suspension or termination of clinical trials by us
or the FDA for a number of reasons. Additionally, due to the high mortality rates of the cancers for which we are initially pursuing
development and the pretreated nature of many patients in our planned clinical trials of HSB-1216, a material percentage of patients
in these clinical trials may die during a trial, which could impact development of HSB-1216. If we elect or are required to delay, suspend
or terminate any clinical trial, the commercial prospects of our drug candidates will be harmed and our ability to generate product revenues
from this drug candidate will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market
acceptance of our drug candidates. Any of these occurrences may harm our business, prospects, financial condition and results of operations
significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
if our drug candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we
may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations
for our drug candidates, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many
drugs that initially showed promise in early stage testing have later been found to cause side effects that prevented further development.
In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that as we test our drug candidates in larger, longer and more extensive clinical trials, including with different dosing
regimens, or as the use of our drug candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts
and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous
trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings
may harm our business, financial condition, results of operations and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our drug candidates receive marketing approval, and we or others later identify undesirable side effects caused by
treatment with such drug, a number of potentially significant negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approval of the drug;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall a product or change the way the drug is administered to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication, or issue
    safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information
    about the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product
    or any component thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    drug could become less competitive; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of our drug candidates, if approved, and could significantly
harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory
and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific
studies or clinical trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization
objectives.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
achievement of milestones such as the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other
product development objectives may be outside of our control. All of these milestones are based on a variety of assumptions, including
assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt
of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from
our estimates. If we or our collaborators fail to achieve announced milestones in the expected timeframes, the commercialization of our
product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the price
of our common stock may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage,
we could be forced to pay substantial damage awards that could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of any of our existing or future product candidates in clinical trials and the sale of any approved pharmaceutical products may expose
us to significant product liability claims. We currently do not have product liability insurance coverage but we intend to obtain such
insurance. Such insurance coverage may not protect us against any or all of the product liability claims that may be brought against
us in the future. We may not be able to acquire or maintain adequate product liability insurance coverage at a commercially reasonable
cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against
us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim
brought successfully against us. In the event our product candidate is approved for sale by the FDA or other regulatory agency and commercialized,
we may need to substantially increase the amount of our product liability coverage. Defending any product liability claim or claims could
require us to expend significant financial and managerial resources, which could have an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future products may never achieve significant commercial market acceptance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on the market&#8217;s confidence that we can provide therapeutic products that improve clinical outcomes, lower healthcare
costs and enable better biopharmaceutical development. Failure of our products, or those jointly developed with our collaborators, to
perform as expected could significantly impair our operating results and our reputation. We believe patients, clinicians, academic institutions
and biopharmaceutical companies are likely to be particularly sensitive to defects, errors, inaccuracies, delays and toxicities in or
associated with our products. Furthermore, inadequate performance of these products may result in lower confidence in our Quatramer platform
in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not succeed in achieving significant commercial market acceptance for our current or future products due to a number of factors,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate the clinical utility of our Quatramer platform and related products and their potential advantages over existing
    drug products to academic institutions, biopharmaceutical companies and the medical community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, and that of our collaborators, to secure and maintain FDA and other regulatory clearance, authorization or approval for
    our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    agreement by third-party payors to reimburse our products, the scope and extent of which will affect patients&#8217; willingness
    or ability to pay for our products and will likely heavily influence physicians&#8217; decisions to recommend our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of adoption of our Quatramer platform and related products by academic institutions, clinicians, key opinion leaders, advocacy
    groups and biopharmaceutical companies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of our investments in product innovation and commercial growth.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our customers and collaborators may decide to decrease or discontinue their use of our products due to changes in their research and
development plans, failures in their clinical trials, financial constraints, the regulatory environment, negative publicity about our
products, competing products or the reimbursement landscape, all of which are circumstances outside of our control. We may not be successful
in addressing these or other factors that might affect the market acceptance of our products and Quatramer technology. Failure to achieve
widespread market acceptance of our Quatramer platform and related products would materially harm our business, financial condition and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may be adversely affected by the coronavirus pandemic.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak of COVID-19 evolved into a global pandemic as COVID-19 spread to many regions of the world. The extent to which COVID-19 impacts
our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including
new information that may emerge concerning COVID-19, including variants, and the actions to contain COVID-19 or treat its impact, among
others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the continuing spread of COVID-19, our business operations could be delayed or interrupted. For example, to date, as a result
of COVID-19 we have experienced delays from our manufacturers with respect to the shipping of our materials as well as delays in completion
of analytical testing as a result of the shelter-in-place order restrictions. In addition, our research and development may be affected
as a result of delays in study monitoring and data analysis. Furthermore, if COVID-19 continues to spread, some participants and clinical
investigators may not be able to comply with clinical trial protocols. For example, any quarantines or other travel limitations (whether
voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we
may be unable to conduct our research activities, including our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
continuing infections and deaths related to the pandemic may disrupt the United States&#8217; healthcare and healthcare regulatory systems.
Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval of our product candidates.
It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of clinical trials or
delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a shelter-in-place order or other mandated local travel restrictions, our employees conducting research and development
or manufacturing activities may not be able to access their laboratory or manufacturing space, and our core activities may be significantly
limited or curtailed, possibly for an extended period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place
by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and
the duration of the pandemic may be difficult to assess or predict, it has already caused, and may result in further, disruption of global
financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression
or other sustained adverse market event resulting from the continued spread of COVID-19 could materially and adversely affect our business
and the value of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate impact of the COVID-19 pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know
the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the
global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the
situation closely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications
that may be more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify for specific indications.
As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to
have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific
indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market
for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such drug candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in our efforts to design additional potential drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to apply our knowledge and our understanding of the structure, biology and activity of ferroptosis to
develop drug candidates. The therapeutic design and development activities that we are conducting may not be successful in developing
drug candidates that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying
potential drug candidates, yet fail to yield drug candidates for clinical development for a number of reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    research methodology used may not be successful in identifying potential drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    drug candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are
    unlikely to be drugs that will obtain marketing approval or achieve market acceptance; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    drug candidates may not be effective in treating their targeted diseases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
programs to identify and design new drug candidates require substantial technical, financial and human resources. We may choose to focus
our efforts and resources on a potential drug candidate that ultimately proves to be unsuccessful. If we are unable to identify and design
suitable drug candidates for pre-clinical and clinical development, we will not be able to obtain revenues from the sale of products
in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are
more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product
candidates and processes competitive with ours. Any product candidates that we successfully develop and commercialize will compete with
existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently
under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop
product candidates. In addition, our products may need to compete with drugs physicians use off-label to treat the indications for which
we seek approval. This may make it difficult for us to replace existing therapies with our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, there is intense competition in the field of oncology. We have competitors both in the United States and internationally,
including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging
and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management,
scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business
plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and
in-licensing new product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer side effects, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are
less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable
foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing
approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced
competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our
products we develop may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to healthcare laws and regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement
by the federal government and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations
that may affect our ability to operate include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit,
    receive, offer, or pay any remuneration that is in exchange for or to induce the referral of business, including the purchase, order,
    lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or
    Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    false claims and false statement laws, including the federal civil False Claims Act and the CMPL, prohibits, among other things,
    any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including
    Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created additional federal criminal statutes that prohibit
    among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program,
    including private third-party payors or making any false, fictitious or fraudulent statement in connection with the delivery of or
    payment for healthcare benefits, items or services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their implementing regulations,
    impose obligations on certain types of individuals and entities regarding the electronic exchange of information in common healthcare
    transactions, as well as standards relating to the privacy and security of individually identifiable health information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
    payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report
    annually to the Centers for Medicare &amp; Medicaid Services information related to payments or other transfers of value made to
    physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply
regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, we may be subject
to state laws that require pharmaceutical companies to comply with the federal government&#8217;s and/or pharmaceutical industry&#8217;s
voluntary compliance guidelines, state laws that require drug manufacturers to report information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures, as well as state and foreign laws governing the privacy
and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws and regulations applicable to our business are complex, changing and often subject to varying interpretations. As a result, we may
not be able to adhere to all applicable laws and regulations. Any violation or alleged violation of any of these laws or regulations
by us could have a material adverse effect on our business, financial condition, cash flows and results of operations. We may be a party
to various lawsuits, demands, claims, <i>qui tam</i> suits, government investigations and audits, of which any could result in, among
other things, substantial financial penalties or awards against us, reputational harm, termination of relationships or contracts related
to our business, mandated refunds, substantial payments made by us, required changes to our business practices, exclusion from future
participation in Medicare and other healthcare programs and possible criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found in violation of applicable laws or regulations, we could suffer severe consequences that would have a material adverse effect
on our business, results of operations, financial condition, cash flows, reputation and stock price, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or termination of our participation in federal healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    or civil liability, fines, damages or monetary penalties for violations of healthcare fraud and abuse laws, including the federal
    False Claims Act, CMPL, and Anti-Kickback Statute;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
    actions by governmental agencies or claims for monetary damages by patients under federal or state patient privacy laws, including
    HIPAA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">repayment
    of amounts received in violation of law or applicable payment program requirements, and related monetary penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
    changes to our practices or procedures that materially increase operating expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of corporate integrity agreements that could subject us to ongoing audits and reporting requirements as well as increased scrutiny
    of our business practices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of various relationships or contracts related to our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">harm
    to our reputation which could negatively affect our business relationships, decrease our ability to attract or retain patients and
    physicians, decrease access to new business opportunities and impact our ability to obtain financing, among other things.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Responding
to lawsuits and other proceedings as well as defending ourselves in such matters will continue to require management&#8217;s attention
and cause us to incur significant legal expense. It is also possible that criminal proceedings may be initiated against us or individuals
in our business in connection with investigations by the federal government.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting
the U.S. healthcare reform, our business may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal,
state and local legislative bodies frequently pass legislation and promulgate regulations relating to healthcare reform or that affect
the healthcare industry. We anticipate that there will continue to be increased government oversight and regulation of the healthcare
industry in the future. We cannot predict the ultimate content, timing or effect of any new healthcare legislation or regulations, nor
is it possible at this time to estimate the impact of potential new legislation or regulations on our business. It is possible that future
legislation enacted by Congress or state legislatures, or regulations promulgated by regulatory authorities at the federal or state level,
could adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and if we are
found to have improperly promoted off-label uses of our drugs or drug candidates, if approved, we may become subject to significant liability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have improperly promoted off-label uses of our drugs or drug candidates, we may become subject to significant liability.
The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products, such
as our drug candidates. In particular, a drug may not be promoted for uses that are not approved by the FDA or such other regulatory
agencies as reflected in the drug&#8217;s approved labeling. If we receive marketing approval for our drug candidates for our proposed
indications, physicians may nevertheless use our drugs for their patients in a manner that is inconsistent with the approved label. However,
if we are found to have promoted our drugs for any off-label uses, the federal government could levy civil, criminal and/or administrative
penalties, and seek fines against us. The FDA or other regulatory authorities could also request that we enter into a consent decree
or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored,
changed or curtailed. If we cannot successfully manage the promotion of our drug candidates, we could become subject to significant liability,
which would materially adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to obtain or maintain Fast Track designation or accelerated approval for our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet
medical need for this condition, a drug sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a drug
candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure
that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster
development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition,
the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as &#8220;orphan
drugs.&#8221; Under the Orphan Drug Act, the FDA may designate a drug candidate as an orphan drug if it is intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if the disease
or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing
and making a drug product available in the United States for the type of disease or condition will be recovered from sales of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax
advantages and user-fee waivers. Additionally, if a product that has orphan designation subsequently receives the first FDA approval
for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the
FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except
in certain circumstances, including proving clinical superiority (i.e., another product is safer, more effective or makes a major contribution
to patient care) to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication
for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication than that for which
the orphan product has exclusivity. In addition, exclusive marketing rights in the United States may be limited if we seek approval for
an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation
was materially defective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
Breakthrough Therapy designation by the FDA for our drug candidates may not lead to a faster development or regulatory review or approval
process, and it does not increase the likelihood that our drug candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria
for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive
Breakthrough Therapy designation, the receipt of such designation for a drug candidate may not result in a faster development process,
review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our drug candidates qualify as breakthrough therapies, the FDA may later decide that
the drugs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
We may seek a breakthrough therapy designation for some of our drug candidates. A breakthrough therapy is defined as a drug that is intended,
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated
as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient
path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough
therapies by the FDA are also eligible for accelerated approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully perform their
contractual and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our
drug candidates and our business could be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have the ability to independently conduct all aspects of our pre-clinical testing or clinical trials. As a result, we have relied
upon and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and other third
party CROs to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for the execution
of our pre-clinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards,
and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with current
GCP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European
Economic Area and comparable foreign regulatory authorities for all of our drugs in clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities enforce these current GCP through periodic inspections of trial sponsors, principal investigators and trial sites.
If we or any of our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed
unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority
will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products
produced under cGMP. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under
our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical
and pre-clinical or clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results
of operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate
revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the
third parties conducting our pre-clinical studies or our clinical trials do not perform their contractual duties or obligations, experience
work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy
of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to GCP, or for
any other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work.
As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully
manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
pharmaceutical products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture
of our drug candidates for pre-clinical testing and clinical trials and expect to continue to do so for commercialization. This reliance
on third parties increases the risk that we will not have sufficient quantities of our drug candidates or products or such quantities
at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any manufacturing facilities. We produce very small quantities of small molecules for evaluation in our research programs
in our laboratory. We rely, and expect to continue to rely, on third parties for the manufacture of our drug candidates for pre-clinical
and clinical testing, as well as for commercial manufacture if any of our drug candidates obtain marketing approval. This reliance on
third parties increases the risk that we will not have sufficient quantities of our drug candidates or products or such quantities at
an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to establish any agreements with third-party manufacturers or to do so on favorable terms. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
    on the third party for regulatory, compliance and quality assurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations
    of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including
    the bankruptcy of the manufacturer or supplier or the issuance of an FDA Form 483 notice or warning letter;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible breach of the manufacturing agreement by the third party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible misappropriation of our proprietary information, including our trade secrets and know how;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">carrier
    disruptions or increased costs that are beyond our control; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to deliver our drugs under specified storage conditions and in a timely manner.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited supply arrangements in place with respect to our drug candidates, and these arrangements do not extend to commercial
supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect
to our drug candidates and other materials. If we obtain marketing approval for any of our drug candidates, we will need to establish
an agreement for commercial manufacture with a third party; however, no assurance can be provided that we will be able to enter into
a commercial manufacture agreement on reasonable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
manufacturers may not be able to comply with cGMP or similar regulatory requirements outside of the United States. Our failure,
or the failure of our third-party manufacturers and suppliers, to comply with applicable regulations could result in sanctions being
imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license
revocation, seizures or recalls of drug candidates or products, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect supplies of our products. In addition, our third-party manufacturers and suppliers are subject to
numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal
of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal
fines and penalties for such third parties. Based on the severity of regulatory actions that may be brought against these third parties
in the future, our clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates and any products that we may develop may compete with other drug candidates and products for access to manufacturing
facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers
that operate under cGMP and that may be capable of manufacturing our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we prepare for later-stage clinical trials and potential commercialization, we will need to take steps to increase the scale of production
of our drug candidates. Even minor deviations from normal manufacturing processes could result in reduced production yields, product
defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our drug candidates or in the manufacturing
facilities in which our drug candidates are made, such manufacturing facilities may need to be closed for an extended period of time
to investigate and remedy the contamination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do
not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current contract manufacturers
for pre-clinical and clinical testing cannot perform as agreed, we may be required to replace such manufacturers. Although we believe
that there are several potential alternative manufacturers who could manufacture our drug candidates, we may incur added costs and delays
in identifying and qualifying any such replacement manufacturer or be able to reach agreement with any alternative manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated future dependence upon others for the manufacture of our drug candidates or products may adversely affect our
future profit margins and our ability to commercialize any products that obtain marketing approval on a timely and competitive basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently depend on a sole source supplier and manufacturer for the active ingredient in HSB-1216, and the
inability to obtain the active ingredient in HSB-1216 as required could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently source the active ingredient in HSB-1216 from one supplier and manufacturer. Although we believe that we can obtain the active
ingredient in HSB-1216 from other suppliers, supply shortages for this particular raw material has and may in the future delay our clinical
trials. If we are unable to procure the active ingredient in HSB-1216 as needed, our business may be harmed.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to find third party collaborators to assist or share in the costs of drug development could materially harm our business, financial
condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy for the development and commercialization of our proprietary drug candidates may include the execution of collaborative arrangements
with third parties. Existing and future collaborators have significant discretion in determining the efforts and resources they apply
and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical and
biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">funding
    research, pre-clinical development, clinical trials and manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
    and obtaining regulatory approvals; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    commercializing any future drug candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to establish further collaboration agreements, we may be required to undertake drug development and commercialization
at our own expense. Such an undertaking may limit the number of drug candidates that we will be able to develop, significantly increase
our capital requirements and place additional strain on our internal resources. Our failure to enter into additional collaborations could
materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dependence on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These
agreements may not be on terms that prove favorable to us and may require us to relinquish certain rights in our drug candidates. To
the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could
be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization
of drug candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to develop
or commercialize successfully any drug candidate to which they have obtained rights from us could materially harm our business, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of Our Drug Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are successful in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one or more
of our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and
uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates. If we are not
able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our drug candidates,
and our ability to generate revenue will be materially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture,
safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject
to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities
outside of the United States. Failure to obtain marketing approval for a drug candidate will prevent us from commercializing the drug
candidate. We have not submitted an application for or received marketing approval for any of our drug candidates in the United States
or in any other jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party
clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval
requires the submission of extensive pre-clinical and clinical data and supporting information to regulatory authorities for each therapeutic
indication to establish the drug candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information
about the drug manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our drug candidates
may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are
indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of our drug candidates
receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the
drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years, if approval is obtained
at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates
involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or
regulations, or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an
application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may
decide that our data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition, varying
interpretations of the data obtained from pre-clinical studies and clinical trials could delay, limit or prevent marketing approval of
a drug candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments
that render the approved drug not commercially viable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of any of
our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is
expensive and time-consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a
sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily
incurred these commercialization expenses. These efforts are expected to be costly, and our investment would be lost if we cannot retain
or reposition our sales and marketing personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to collaborate with a third party to market our drugs or may seek to market and sell our drugs by ourselves. If we seek to collaborate
with a third party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that we will be able to acquire, or establish third party relationships to provide, any or all of these marketing and
sales capabilities. The establishment of a direct sales force or a contract sales force or a combination direct and contract sales force
to market our drugs will be expensive and time-consuming and could delay any drug launch. Further, we can give no assurances that we
may be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient to generate
or to grow our revenues or that our sales efforts will ever lead to profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals
for our drug candidates on a timely basis, or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval or other marketing authorizations by the FDA is unpredictable, and it typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval
for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to
develop in the future. Neither we nor any current or future collaborator is permitted to market any drug product candidates in the United
States until we receive regulatory approval from the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining approval to commercialize any drug product candidate in the United States, we must demonstrate with substantial evidence
from well-controlled clinical trials, and to the satisfaction of the FDA, that such product candidates are safe, pure and effective for
their intended uses. Results from pre-clinical studies and clinical trials can be interpreted in different ways. Even if we believe the
pre-clinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA.
The FDA may also require us to conduct additional pre-clinical studies or clinical trials for our product candidates either prior to
or after approval, or it may object to elements of our clinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical
    and commercial supplies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of products in development, only a small percentage successfully complete the FDA approval processes and are commercialized.
The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result
in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly
harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have invested a significant portion of our time and financial resources in the development of our pre-clinical product candidates. Our
business is dependent on our ability to successfully complete pre-clinical and clinical development, obtain regulatory approval for,
and, if approved, successfully commercialize HSB-1216, HSB-888, HSB-510 and any future product candidates in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually complete clinical testing and receive approval for HSB-1216, HSB-888, HSB-510 and any future product candidates, the
FDA, may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including
post-marketing clinical trials. The FDA, also may approve or authorize for marketing a product candidate for a more limited indication
or patient population than we originally request, and the FDA may not approve or authorize the labeling that we believe is necessary
or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable
regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially
adversely impact our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA may change their policies, issue additional regulations or revise existing regulations, or take other actions, which
may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose
additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability
to maintain any marketing authorizations we may have obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market and sell our drugs in the European Union and many other foreign jurisdictions, we or our potential third-party collaborators
must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies
among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required
to obtain FDA marketing approval. The regulatory approval process outside of the United States generally includes all of the risks associated
with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for
reimbursement before the drug can be approved for sale in that country. We or our potential third-party collaborators may not obtain
approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure
approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United
States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay
in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be
able to file for marketing approvals and may not receive necessary approvals to commercialize our drugs in any market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
drug candidate that we obtain marketing approval for could be subject to post-marketing restrictions or withdrawal from the market and
we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems
with our drugs, when and if any of them are approved.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it is possible that one or more of our drug candidates may require a companion diagnostic to select the patients who will likely respond
to a cancer therapy involving one of our drug candidates as a condition of approval, it is too early in our drug candidates development
to identify which drug candidate, if any, would require a companion diagnostic. According to FDA guidance, if the FDA determines that
a companion diagnostic device is essential to the safe and effective use of a novel therapeutic drug or indication, the FDA generally
will not approve the therapeutic drug or new therapeutic drug indication if the companion diagnostic is not also approved or cleared
for that indication. Under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), companion diagnostics are regulated as medical
devices, and the FDA has generally required companion diagnostics intended to select the patients who will respond to cancer treatment
to obtain Premarket Approval (&#8220;PMA&#8221;) for the diagnostic. The PMA process, including the gathering of clinical and pre-clinical
data and the submission to and review by the FDA, involves a rigorous premarket review during which the applicant must prepare and provide
the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components
regarding, among other things, device design, manufacturing and labeling. A PMA is not guaranteed and may take considerable time, and
the FDA may ultimately respond to a PMA submission with a &#8220;not approvable&#8221; determination based on deficiencies in the application
and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay
approval. As a result, if we are required by the FDA to obtain approval of a companion diagnostic for a therapeutic drug candidate, and
we do not obtain or there are delays in obtaining FDA approval of a diagnostic device, we may not be able to commercialize the drug candidate
on a timely basis or at all and our ability to generate revenue will be materially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling,
advertising and promotional activities for such drug, will be subject to continual requirements of and review by the FDA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing
requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records
and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug
candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions
of approval, including the requirement to implement a REMS. New cancer drugs frequently are indicated only for patient populations that
have not responded to an existing therapy or have relapsed. If any of our drug candidates receives marketing approval, the accompanying
label may limit the approved use of our drug in this way, which could limit sales of the drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of the drug, including the adoption and implementation of REMS. The FDA and other agencies, including the Department of Justice (&#8220;DOJ&#8221;),
closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only for
the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions
on manufacturers&#8217; communications regarding off-label use, and if we do not market our drugs for their approved indications, we
may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, including the False Claims Act,
relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations
of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. In addition, later discovery of previously
unknown adverse events or other problems with our drugs, manufacturers or manufacturing processes, or failure to comply with regulatory
requirements, may have various consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on such drugs, manufacturers or manufacturing processes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    and warnings on the labeling or marketing of a drug;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on drug distribution or use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or untitled letters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of the drugs from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications that we submit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
    of drugs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of marketing approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
    to relationships with any potential collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    press coverage and damage to our reputation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our drugs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug
    seizure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    involving patients using our drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform in the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare
system that could affect the future results of pharmaceutical manufactures&#8217; operations. In particular, there have been and continue
to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. On the federal level, the Affordable
Care Act (&#8220;ACA&#8221;) was enacted in March 2010, and included measures to significantly change the way healthcare is financed
by both governmental and private insurers. Among the provisions of the ACA that have been of greatest importance to the pharmaceutical
and biotechnology industry are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned
    among these entities according to their market share in certain government healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementation
    of the federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act&#8221;;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    licensure framework for follow-on biologic products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">creation
    of Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
    research, along with funding for such research;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery
    models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the
    average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs
    at 100% of the Average Manufacturer Price;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption
    of methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and
    biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension
    of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed
    care organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
    and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby
    potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">creation
    of a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated
    prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s
    outpatient drugs to be covered under Medicare Part D; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
    of the entities eligible for discounts under the Public Health program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there have been legal and political challenges to certain aspects of the ACA, the Biden Administration has affirmed support for the law,
entered its own executive orders to enforce and strengthen it, and committed to examining and, where appropriate, reversing contrary
Trump Administration policies. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based
shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &#8220;individual mandate.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the volatility surrounding the implementation and enforcement of the ACA since its passage, and at this time, the full effect that
the ACA would have on a pharmaceutical manufacturer remains unclear. This uncertainty is heightened by President Biden&#8217;s January
28, 2021 Executive Order on Strengthening Medicaid and the Affordable Care Act which indicates that the Biden Administration may significantly
modify the ACA and further reform the ACA and other federal programs in manner that may impact our operations. The Biden Administration
has indicated that a goal of its administration is to expand and support Medicaid and the ACA and to make high-quality healthcare accessible
and affordable. The potential increase in patients covered by government funded insurance may impact our pricing. Further, it is possible
that the Biden Administration may further increase scrutiny of drug pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Additionally,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in <span style="background-color: white">December </span>2019,
a federal appeals court held <span style="background-color: white">that the individual mandate</span> portion of the ACA <span style="background-color: white">was
unconstitutional and </span>left open the question <span style="background-color: white">whether the remaining provisions of the ACA
</span>would be valid without the individual mandate. However, on appeal, the <span style="background-color: white">Supreme Court </span>ruled
in June 2021 that the parties challenging the law lacked standing, leaving the ACA in place. <span style="background-color: white">It
is unclear how any other potential litigation challenging the ACA and the healthcare reform measures of the Biden administration will
impact the ACA. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform
measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care
products and services.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Moreover,
prescription drug pricing has been a recent focus of federal policymaking. The Trump Administration issued a series of executive orders
and rules related to prescription drug pricing, including executive orders in July and September 2020 focused on reducing drug prices
and rules in November 2020 establishing a &#8216;Most Favored Nation&#8217; rule tying Medicare Part B drug pricing to prices in other
countries, as well as a rule effectively banning rebates from Medicare Part D. The Biden Administration has indicated that lowering prescription
drug prices is a priority for the Biden Administration as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there is uncertainty surrounding the applicability of the biosimilars provisions under the ACA. The FDA has issued several guidance documents,
but no implementing regulations, on biosimilars. A number of biosimilar applications have been approved over the past few years. The
regulations that are ultimately promulgated and their implementation are likely to have considerable impact on the way pharmaceutical
manufacturers conduct their business and may require changes to current strategies. A biosimilar is a biological product that is highly
similar to an approved drug notwithstanding minor differences in clinically inactive components, and for which there are no clinically
meaningful differences between the biological product and the approved drug in terms of the safety, purity, and potency of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access,
and marketing cost disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally
mandated price controls on payment amounts by third-party payors or other restrictions could harm a pharmaceutical manufacturer&#8217;s
business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. This could reduce ultimate demand for certain products or put pressure product pricing, which could
negatively affect a pharmaceutical manufacturer&#8217;s business, results of operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state
legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare
and Medicaid programs. While no one cannot predict the full outcome of any such legislation, it may result in decreased reimbursement
for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm a pharmaceutical
manufacturer&#8217;s ability to generate revenue. Increases in importation or re-importation of pharmaceutical products from foreign
countries into the United States could put competitive pressure on a pharmaceutical manufacturer&#8217;s ability to profitably price
products, which, in turn, could adversely affect business, results of operations, financial condition and prospects. A pharmaceutical
manufacturer might elect not to seek approval for or market products in foreign jurisdictions in order to minimize the risk of re-importation,
which could also reduce the revenue generated from product sales. It is also possible that other legislative proposals having similar
effects will be adopted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and
can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency
funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable
to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety
of factors, including budget and funding levels and statutory, regulatory and policy changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing
laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve
the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste
products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination
or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held
liable for any resulting damages, and any liability could exceed our resources, including any available insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or regulations. Under
existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed
or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating
or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to
comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal
injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering
our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or
production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension for any drug candidates we may develop, our business may be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, depending upon the timing, duration, and specifics of any FDA marketing approval of a drug candidate, the patent term
of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration
as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration
Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent.
The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot
extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, and only one patent applicable to an
approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing
it may be extended. Similar provisions are available in Europe and other non-United States jurisdictions to extend the term of a patent
that covers an approved drug. While, in the future, if and when our drug candidates receive FDA approval, we expect to apply for patent
term extensions on patents covering those drug candidates, there is no guarantee that the applicable authorities will agree with our
assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted an
extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to expiration of the relevant patents, or otherwise failing to satisfy applicable
requirements. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors
may obtain approval of competing drugs following the expiration of our patent rights, and our business, financial condition, results
of operations, and prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability
to protect our drugs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming
and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase
the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Recent
patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act)
signed into law in September 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant
changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide
more efficient and cost-effective avenues for competitors to challenge the validity of patents. For example, the Leahy-Smith Act allows
third-party submission of prior art to the United States Patent and Trademark Office (&#8220;USPTO&#8221;) during patent prosecution
and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review,
inter parties review, and derivation proceedings. In addition, the Leahy-Smith Act has transformed the U.S. patent system from a &#8220;first-to-invent&#8221;
system to a &#8220;first-to-file&#8221; system in which, assuming that other requirements for patentability are met, the first inventor
to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. The first-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear
what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation
could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the
prosecution of our or our collaboration partners&#8217; patent applications and the enforcement or defense of our or our collaboration
partners&#8217; issued patents, all of which could harm our business, results of operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened
the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and
enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws
and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and
our ability to protect, defend and enforce our patent rights in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or our future licensors may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which
could be expensive, time-consuming and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
and other third parties may infringe, misappropriate or otherwise violate our or our future licensors&#8217; issued patents or other
intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property
related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties
to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition,
in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or
unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute
such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
re-examination, post-grant review, inter parties review, interference proceedings, derivation proceedings, and equivalent proceedings
in foreign jurisdictions (e.g., opposition proceedings).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted
narrowly, and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also
refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents
do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this
type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products
and have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our drug
candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property
and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical
and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our technology and drug candidates, including interference proceedings, post grant review, inter parties
review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European
Patent Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability
of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive
and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting
these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our drug candidates
near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement
claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of
all such intellectual property rights potentially relating to our technology and drug candidates and their uses. Thus, we do not know
with certainty that our technology and drug candidates, or our development and commercialization thereof, do not and will not infringe,
misappropriate or otherwise violate any third party&#8217;s intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we believe that third party intellectual property claims are without merit, there is no assurance that a court would find in our favor
on questions of misappropriation, infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold these
third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any
technology or drug candidate covered by the asserted third-party patents. In order to successfully challenge the validity of any such
U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present
clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction
would invalidate the claims of any such U.S. patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be required
to obtain a license from such third party to continue developing, manufacturing and marketing our technology and drug candidates. However,
we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license,
it could be non-exclusive; thereby giving our competitors and other third parties access to the same technologies licensed to us and
could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing,
manufacturing and commercializing the infringing technology or drug. In addition, we could be found liable for significant monetary damages,
including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property
right and could be forced to indemnify our collaborators or others. A finding of infringement could prevent us from commercializing our
drug candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be
forced to redesign our drug candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse
effect on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract
our personnel from their normal responsibilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future
sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual
property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings
could compromise our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations in our future intellectual property licenses and funding arrangements with third parties, we could
lose rights that are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be party to license and funding agreements that impose diligence, development and commercialization timelines, milestone payment,
royalty, insurance and other obligations on us. If we fail to comply with such obligations, our counterparties may have the right to
terminate our agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of
any drug candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights
under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose
our rights under these agreements, including our rights to important intellectual property or technology, which would have a material
adverse effect on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
these and other license agreements may not provide exclusive rights to use the licensed intellectual property and technology in all relevant
fields of use and in all territories in which we may wish to develop or commercialize our technology and drugs in the future. As a result,
we may not be able to prevent competitors from developing and commercializing competitive products and technology in fields of use and
territories not included in such agreements. In addition, we may not have the right to control the preparation, filing, prosecution,
maintenance, enforcement, and defense of patents and patent applications covering the technology that we may license from third parties.
Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, and defended
in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such
patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right
to develop and commercialize any of our drugs that are the subject of such licensed rights could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to obtain additional licenses from others to advance our research or allow commercialization of our drug candidates. It is possible
that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all, or such licenses may be non-exclusive.
The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies
may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These
established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make
an appropriate return on our investment or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights
we have, we may be required to expend significant time and resources to redesign our technology, drug candidates, or the methods for
manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis.
If we are unable to do so, we may be unable to develop or commercialize the affected technology and drug candidates, which could harm
our business, financial condition, results of operations, and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise regarding intellectual property subject to a licensing agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation related issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any agreements under which we license intellectual property or technology from third parties may be complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what
we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect
on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected technology and drug candidates, which could have a material adverse effect
on our business, financial conditions, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our licensors are not
the sole and exclusive owners of the patents and patent applications we in-licensed. If other third parties have ownership rights to
our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products
and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our future licensors might conclude that we have materially breached our license agreements and might therefore
terminate our license agreements, thereby removing our ability to develop and commercialize drug candidates and technology covered by
such agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity,
competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could
have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property and proprietary rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive, and the
laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be
able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing
products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to
territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products
may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary
rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and
our business, financial condition, results of operations, and prospects may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Managing Our Business and Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter difficulties in managing our growth, which could adversely affect our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 21, 2022, we had 1 full-time employee and 1 part-time employee. As our clinical development and commercialization plans and
strategies develop, we will need to expand our managerial, clinical, regulatory, sales, marketing, financial, development, manufacturing
and legal capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that
we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future growth
would impose significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining and motivating additional employees;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our development and commercialization efforts effectively, including the clinical and FDA review process for our product candidates,
    while complying with our contractual obligations to contractors and other third parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively
manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities
in order to devote a substantial amount of time to managing these growth activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services, including contract manufacturers and companies focused on research and development and discovery
activities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available
to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage
our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical
trials may be extended, delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory
approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing
consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly,
may not achieve our research, development and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially
harm our business, including the diversion of management&#8217;s attention from core business concerns, failure to effectively exploit
acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees
from either our business or the acquired businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which
could result in a material disruption of our product development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause
interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due
to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial
data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover
or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed
and the further development and commercialization of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of
information maintained in the information systems and networks of our company and our vendors, including personal information of our
employees and study subjects, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems
or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order
to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious codes and viruses,
phishing and other cyberattack. The number and complexity of these threats continue to increase over time. If a material breach of, or
accidental or intentional loss of data from, our information technology systems or those of our vendors occurs, the market perception
of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required
to expend significant amounts of money and other resources to repair or replace information systems or networks. In addition, we could
be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related
to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure
of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events
from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and
processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become
increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As
we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more
on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect
our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those
of our third-party contractors, or our consultants&#8217; efforts to implement adequate security and control measures, will be sufficient
to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data
from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks
which could result in financial, legal, business or reputational harm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes
or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster,
including earthquakes, outbreak of disease or other natural disasters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication
failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing
facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business,
particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to
these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations.
Earthquakes or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business,
financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented
us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities
or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult
or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event.
We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could
have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that
we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you
that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities
of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for
a short period of time, any or all of our research and development programs may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
global economic conditions could adversely affect our business, financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions
of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening
of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, the most recent global financial crisis caused
extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, including due to the impact
of the COVID-19 pandemic, could result in a variety of risks to our business, including a reduced ability to raise additional capital
when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our suppliers,
some of which are located outside of the United States, possibly resulting in supply disruption. Any of the foregoing could harm our
business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely
impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
increasing use of social media platforms presents new risks and challenges.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed
to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of our
product candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve and regulations and regulatory
guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations
applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to
off-label marketing or other prohibited activities. For example, patients may use social media channels to comment on their experience
in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment
may be adversely impacted, we fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able
to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social
media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive
information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur
or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 10-K may prove to be inaccurate,
and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
opportunity estimates and growth forecasts included in this Annual Report on Form 10-K are subject to significant uncertainty and are
based on assumptions and estimates which may not prove to be accurate. The estimates and forecasts included in this Annual Report on
Form 10-K relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete
meet the size estimates and growth forecasts included in this Annual Report on Form 10-K, our business may not grow at similar rates,
or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial
partners, collaborators and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails
to comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the
FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud
and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately
or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those
products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance
with such laws will also increase. These laws may impact, among other things, our current activities with principal investigators and
research patients, as well as proposed and future sales, marketing and education programs. Although we have adopted a code of business
conduct and ethics, it is not always possible to identify and deter misconduct by our employees, independent contractors, consultants,
commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from
a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves
or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary
fines, imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations
and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with
these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil
or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and any potential collaborators may be subject to federal, state and foreign data protection laws and regulations (i.e., laws and regulations
that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health
information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection
laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related
and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health
information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy
and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to criminal
penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity
in a manner that is not authorized or permitted by HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (&#8220;GDPR&#8221;) may also apply
to health-related and other personal information obtained outside of the United States. The GDPR went into effect on May 25, 2018. The
GDPR introduced new data protection requirements in the European Union, as well as potential fines for noncompliant companies of up to
the greater of &#8364;20 million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection,
use and disclosure of personal information, including more stringent requirements relating to consent and the information that must be
shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals
of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals
in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes
restrictions on cross-border data transfer. The GDPR will increase our responsibility and liability in relation to personal data that
we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules.
Further, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard
to data protection regulation in the United Kingdom. In particular, it is unclear whether the United Kingdom will enact data protection
legislation equivalent to the GDPR and how data transfers to and from the United Kingdom will be regulated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts,
restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure
to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could
include civil, criminal, and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating
results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the
providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we
have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations,
even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. tax law could adversely affect our financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive
application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes
are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business,
cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the
implications of potential changes in U.S. tax laws on an investment in our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our stock may be volatile, and you could lose all or part of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some
of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221;
section and elsewhere in this Annual Report on Form 10-K, these factors include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment or results of clinical trials and pre-clinical studies of our drug candidates or those of our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in identifying and advancing a clinical candidate for our other development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our regulatory filings for our drug candidates and any adverse development or perceived adverse development with respect
    to the applicable regulatory authority&#8217;s review of such filings, including, without limitation, the FDA&#8217;s issuance of
    a &#8220;refusal to file&#8221; letter or a request for additional information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    results or delays in future clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory decisions, including failure to receive regulatory approval of for our drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations applicable to our drug candidates, including, but not limited to, clinical trial requirements for approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    developments concerning our manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to establish collaborations, if needed;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to commercialize our product candidates, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key scientific or management personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    serious safety concerns related to the use of our drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
    of new products offered by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively manage our growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in quarterly operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
    of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal
    of research coverage by securities analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuations of similar companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of the healthcare payment systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
    performance of the equity markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us or our stockholders in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting practices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffectiveness
    of our internal controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection
    for our technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    lawsuits, including patent or stockholder litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    political and economic conditions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which are beyond our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including as
a result of the COVID-19 pandemic. Broad market and industry factors may negatively affect the market price of our common stock, regardless
of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following
periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial
costs and a diversion of management&#8217;s attention and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange,
our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and
it may be more difficult for our stockholders to sell their securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our common stock is currently listed on The Nasdaq Capital Market, we may not be able to continue to meet the exchange&#8217;s minimum
listing requirements or those of any other national exchange. If we are unable to maintain listing on Nasdaq or if a liquid market for
our common stock does not develop or is sustained, our common stock may remain thinly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Listing Rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any
reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from trading on its
exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may
occur, each of which could have a material adverse effect on our shareholders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidity of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market price of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financing for the continuation of our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of investors that will consider investing in our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of market makers in our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of information concerning the trading prices and volume of our common stock; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of broker-dealers willing to execute trades in shares of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain
terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will
therefore be limited to the appreciation of their stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters
subject to stockholder approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 21, 2022, our executive officers, directors and their affiliates will beneficially hold, in the aggregate, approximately 40.10%
of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence all matters requiring
stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of
our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage
unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our
common stock. If our internal controls are not effective, we may not be able to accurately report our financial results or prevent fraud.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In connection
with the audit of our financial statements for the years ended December 31, 2020 and 2019, our independent registered
public accounting firm identified a material weakness. A material weakness is a significant deficiency, or a combination of significant
deficiencies, in internal controls over financial reporting such that it is reasonably possible that a material misstatement of
the annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness that has been identified
by our independent registered public accounting firm relates to the design and implementation of control(s) to review the completeness
and accuracy of contracts with financial reporting implications. In addition, the terms and conditions related to these contracts were
not communicated to the financial reporting function for analysis and reporting implications in a timely manner. While we intend to take
steps to remediate the material weakness in our internal control over financial reporting by formalizing certain accounting policies
and internal control documentation and adding staff members with requisite experience to oversee the review of contracts, we may not
be successful in remediating such weaknesses in a timely manner, if at all, which may undermine our ability to provide accurate, timely
and reliable reports on our financial and operating results. Furthermore, if we remediate our current material weakness but identify
new material weaknesses in our internal control over financial reporting in the future, investors may lose confidence in the accuracy
and completeness of our financial reports and the market price of our common stock may be negatively affected. As a result of such failures,
we could also become subject to investigations by Nasdaq, the SEC, or other regulatory authorities, and become subject to litigation
from investors and stockholders, which could harm our reputation, financial condition or divert financial and management resources from
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Substantial
amounts of our outstanding shares may be sold into the market when lock-up or market standoff periods end. If there are substantial sales
of shares of our common stock, the price of our common stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of common stock held by our directors, executive officers and our stockholders are subject to contractual lock-up
restrictions on resale. Specifically, in connection with our initial public offering, <span style="background-color: white">our executive
officers and directors agreed to a 365 day </span>lock-up restriction from the date of our prospectus in connection with our initial
public offering and other stockholders <span style="background-color: white">agreed to a 180 day </span>lock-up restriction from the
date of our prospectus in connection with our initial public offering. If these stockholders sell, or indicate an intent to sell, substantial
amounts of our common stock in the public market after the expiration of the applicable lock-up period, the trading price of our common
stock could decline significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation, as amended (&#8220;Certificate of Incorporation&#8221;) provides that the Court of Chancery of the State
of Delaware will be the sole and exclusive forum for substantially all disputes between the Company and its stockholders, which could
limit stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers or employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the State of Delaware
is the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim
of breach of a fiduciary duty owed by any director, officer or other employee of our Company to us or our stockholders, (iii) any action
asserting a claim arising pursuant to any provision of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) or our Certificate
of Incorporation or Bylaws, or (iv) any action governed by the internal affairs doctrine. This exclusive forum provision would not apply
to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the
federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the
Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act
or the rules and regulations thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder. However, our Certificate of Incorporation contains a federal forum
provision which provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the
Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers or other employees and may result in increased costs to our stockholders, which may discourage such
lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find our choice of forum provisions
contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated
with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation, Bylaws and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change
in control, which may cause our stock price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, our Bylaws and Delaware law could make it more difficult for a third party to acquire us, even if closing
such a transaction would be beneficial to our stockholders. We are authorized to issue up to 10 million shares of preferred stock. This
preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors
without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to
vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions.
The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce
the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict
our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our Certificate of Incorporation, our Bylaws and Delaware law also could have the effect of discouraging potential acquisition proposals
or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such
provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, our Certificate
of Incorporation, our Bylaws and Delaware law, as applicable, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    the board of directors with the ability to alter the Bylaws without stockholder approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon
    at stockholder meetings; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
and economic conditions may negatively impact our business, financial condition and share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerns
over inflation, energy costs, geopolitical issues, the U.S. mortgage market and a declining real estate market, unstable global credit
markets and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity
and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and
expectations of slower global economic growth going forward, increased unemployment rates, and increased credit defaults in recent years.
Our general business strategy may be adversely affected by any such economic downturns, volatile business environments and continued
unstable or unpredictable economic and market conditions. If these conditions continue to deteriorate or do not improve, it may make
any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing
in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance, and share
price and could require us to delay or abandon development or commercialization plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause
our share price to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that significant additional capital will be needed in the future to continue our planned operations, including research and development,
increased marketing, hiring new personnel, commercializing our products, and continuing activities as an operating public company. To
the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell
common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from
time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may
be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing shareholders, and new investors
could gain rights superior to our existing shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
will make our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth
companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act,
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the
requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments
not previously approved. We could be an emerging growth company for up to five years following the year in which we completed our initial
public offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the
earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering,
(b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer,
which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th
and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to take advantage of some, but not all, of the available exemptions. We cannot predict whether investors will find our common
stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a
result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting
pronouncements as of public company effective dates. We have chosen to take advantage of the extended transition periods available to
emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise
apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies
that comply with public company effective dates for complying with new or revised accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to
devote substantial time to compliance matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company we incur significant additional legal, accounting and other expenses. The obligations of being a public company
in the U.S. require significant expenditures and place significant demands on our management and other personnel, including costs resulting
from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance practices,
including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and The Nasdaq Capital Market.
These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control
over financial reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement,
monitor and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS Act, the reporting requirements, rules,
and regulations will make some activities more time-consuming and costly, particularly after we are no longer an &#8220;emerging growth
company&#8221; or a &#8220;smaller reporting company.&#8221; Our management and other personnel will need to devote a substantial amount
of time to ensure that we comply with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance
and risk becoming subject to litigation or being delisted, among other potential problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our
stock price and trading volume may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us,
our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock,
the lack of research coverage may adversely affect the market price of our common stock. Furthermore, if one or more of the analysts
who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, our stock price
would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose
visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline
and may also impair our ability to expand our business with existing customers and attract new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be subject to securities class action litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility
in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and
resources, which could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="c_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive office which we lease is located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807. We believe that our existing
facilities are suitable and adequate to meet our current needs. We intend to add new facilities or expand existing facilities as we add
employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion
of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_006"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business.
We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse
effect on our business, financial condition or operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_007"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="c_008"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="c_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2022, our common stock began trading on The Nasdaq Capital Market under the symbol &#8220;HILS.&#8221; Prior to that time,
there was no public market for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Proceeds from Initial Public Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, we closed the initial public offering of our common stock pursuant to which we issued and sold 3,750,000 shares of
our common stock at a price to the public of $4.00 per share. All of the shares of common stock issued and sold in our initial public
offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-259821), which was declared
effective by the SEC on January 11, 2022. We received net proceeds of approximately $13.0 million, after deducting underwriting discounts
and commissions and offering expenses borne by us. None of the expenses incurred by us were direct or indirect payments to any of (i)
our directors or officers or their associates, (ii) persons owning 10% or more of our common stock, or (iii) our affiliates. There has
been no material change in the planned use of proceeds from our initial as described in our final prospectus filed with the SEC on January
13, 2022 pursuant to Rule 424(b)(4). ThinkEquity acted as sole book-running manager for the offering. The offering commenced on January
11, 2022 and did not terminate before all securities registered in the registration statement were sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 21, 2022, there were 25 stockholders of record of our common stock. The actual number of holders of our common stock
is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street
name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held
in trust by other entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common
stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion
of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a
number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions
imposed by applicable law and other factors our board of directors deems relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January 2021 to December 15, 2021, we issued convertible promissory notes in an aggregate principal amount of $1,716,992 to certain investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January 2021 to June 15, 2021, we granted stock options to purchase an aggregate of 227,737 shares of our common stock at a weighted-average
exercise price of $7.756 per share to employees, directors and non-employee service providers pursuant to our 2019 Stock Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing offers, sales and issuances were exempt from registration under Section 4(a)(2) of the Securities Act or Rule 701 of the Securities
Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_010"></span>ITEM
6. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="c_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and plan of operations together with and our accompanying
consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical
information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our
actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include,
but are not limited to, those identified below, and those discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere
in this Annual Report on Form 10-K. All amounts in this report are in U.S. dollars, unless otherwise noted.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism
resulting in IMCD for treatment resistant cancers. Our most advanced product candidate is HSB-1216, an IMCD modulator, targeting a variety
of solid tumors. In a clinical pilot study conducted in Germany by the University of Heidelberg, the active drug in HSB-1216 was found
to reduce tumor burden in treatment resistant cancers, including TNBC and epithelial carcinomas. Our goal is to submit an IND to the
FDA in 2023 and start a clinical study with HSB-1216 in 2023; however, no assurance can be provided that our IND will be accepted by
the FDA in 2023, if at all. If our IND is accepted by the FDA, our HSB-1216 clinical study will focus on expanding upon the clinical
pilot study conducted in Germany. If we are able to start our clinical study with HSB-1216 in 2023, we anticipate that initial clinical
data from such trial will be released either the end of 2023 or early 2024. We use Quatramer&#8482;, our proprietary tumor targeting
platform, to enhance the uptake of HSB-1216 in the TME with an extended duration of action and minimal off-target toxicity. In addition,
TridentAI, our artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target
specific patient segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target discovery for drug development.
Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular iron or the LIP. Cancer cells
increase the LIP leading to unregulated cell growth and metabolism. Decreasing the LIP induces iron-led ROS production and lipid peroxidation,
two key hallmarks of ferroptosis/IMCD. HSB-1216 binds iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD,
leading to regulated cell death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quatramer
is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate
the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as
well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes
a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer
drug candidates using the Quatramer platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TridentAI
uses an artificial intelligence precision medicine platform to identify novel biomarkers. TridentAI integrates diverse public datasets,
including TCGA to identify novel gene signatures to stratify patients prospectively in clinical trials. Quatramer tumor targeting also
allows us to segment patients by exploiting TridentAI&#8217;s findings by (i) synthetic lethal sensitivities with novel combinations,
(ii) pursue undruggable targets such as <i>c-myc</i> and (iii) target tumors with a high degree of cell plasticity indicative of recurrent/drug
resistant phenotype.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical components of our business strategy to achieve our goals include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    our drug candidate, HSB-1216, in solid tumors.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from a clinical pilot use study in Germany led us to progress HSB-1216 into IND-enabling studies with the ultimate goal of submitting
an IND to the FDA in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    our combination drug candidate, HSB-888, for pediatric sarcomas.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSB-888
is in IND-enabling trials with the ultimate goal of submitting an IND to the FDA in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging
    our Trident Artificial Intelligence Platform.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAI
is a computational intelligence platform that identifies synthetic lethal sensitivities associated with degree of cell plasticity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
    and commercializing Quatramer in collaboration with leading pharmaceutical companies.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our internal development programs, we actively seek opportunities to collaborate with recognized biopharmaceutical companies
to develop Quatramer incorporating therapeutic payloads from their proprietary product portfolios.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging
    our novel platform to develop a pipeline of high value Quatramer leads.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tunability of our technology allows us to efficiently expand our pipeline of Quatramer, both on our own and in collaboration with others,
through various combinations of targeted DNA encoded for anti-tumor cytokines and therapeutic payloads, which enables us to move into
other areas of oncology, including immuno-oncology whereby we could increase the effectiveness of ICIs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commercializing
    proprietary Quatramer based products, including HSB-1216, directly in the United States and with collaborators outside the United
    States.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own HSB-1216 and our other proprietary pipeline and expect to maintain similar rights with respect to other proprietary Quatramer we
develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing
    to extend and protect our product technology and Quatramer through our intellectual property portfolio.</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our novel platform through U.S. and international patents as well as know-how and trade secrets relating to the design
and manufacturing of our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, we closed the initial public offering of our common stock pursuant to which we issued and sold an aggregate of 3,750,000
shares of our common stock for a purchase price of $4.00 per share. We received net proceeds of approximately $13.0 million, after deducting
underwriting discounts and commissions and offering expenses borne by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trends
and Uncertainties&#8212;COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global COVID-19 pandemic continues to evolve. The extent of the impact of the COVID-19 on our business, operations, pre-clinical and
clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread
of the outbreak, COVID-19 variants, and the future impact of COVID-19 on our clinical trial enrollment, clinical trial sites, CROs, third-party
manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific
and management personnel. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to
change. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and
with many of our employees and consultants working remotely. We will continue to actively monitor the evolving situation related to COVID-19
and may take further actions that alter our operations, including those that may be required by federal, state or local authorities,
or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the
extent to which the COVID-19 pandemic may affect our business, operations and clinical development timelines and plans, including the
resulting impact on our expenditures and capital needs, remains uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not recognize revenues for years ended December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include personnel costs associated with research and development activities, including third-party contractors
to perform research, conduct clinical trials, stock based compensation and manufacture drug supplies and materials. Research and development
expenses are charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
accrue costs incurred by external service providers, including contract research organizations and clinical investigators, based on estimates
of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment
in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing
of amounts invoiced by service providers, we may also record payments made to those providers as prepaid expenses that will be recognized
as expense in future periods as the related services are rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred research and development expenses related to the development of HSB-1216. We expect that our research and development expenses
will increase as we plan for and commence our clinical trials of HSB-1216 and HSB-888.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot determine with certainty the duration and costs of future clinical trials of our product candidates, HSB-1216 and HSB-888, or
any other product candidates we may develop or if, when or to what extent we will generate revenue from the commercialization and sale
of any of our product candidates for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any
of our product candidates. The duration, costs and timing of clinical trials and development of our current and future product candidates
will depend on a variety of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress, expense and results of clinical trials of our current product candidates, as well as of any future clinical
    trials of our future product candidates and other research and development activities that we may conduct;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties
    in clinical trial design and patient enrollment rates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition,
    manufacturing capability and commercial viability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulations and regulatory guidance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and receipt of any marketing approvals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change
in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority
were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development
of a product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment
or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation and consulting related expenses, <span style="background-color: white">including
stock based compensation</span>. General and administrative expenses also include professional fees and other corporate expenses, including
legal fees relating to corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel
expenses and other operating costs that are not specifically attributable to research activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our
continued research activities and development of our product candidates. We also incur expenses associated with being a public company,
including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, director and officer insurance expenses,
corporate governance expenses, investor relations activities and other administrative and professional services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acquired
In-process Research and Development Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs incurred in obtaining technology licenses and asset purchases are charged to research and development expense if
the technology licensed has not reached technological feasibility which includes manufacturing, clinical, intellectual property and/or
regulatory success which has no alternative future use. The <span style="background-color: white">licenses purchased</span> by
us require substantial completion of research and development and regulatory and marketing approval efforts in order to reach technological
feasibility. As such, for the years ended December 31, 2021 and 2020, the purchase price of licenses and assets acquired was classified
as acquired in-process research and development expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Redemption Value</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for derivative instruments in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 815, <i>Derivative and Hedging,
</i>which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded
in other financial instruments or contracts, and requires recognition of all derivatives on the balance sheet at fair value. Our derivative
financial instrument consists of an embedded feature contained in our convertible debt that we call the &#8220;redemption liability.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2015-03, <i>Interest
&#8212; Imputation of Interest</i>, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
redemption liability includes a provision that provides the noteholder with certain conversion and put rights at various conversion or
redemption values as well as certain call options for us. The fair value of the redemption liability is calculated under Level 3 of the
fair value hierarchy, determined based upon a Probability-Weighted Expected Returns Method (&#8220;PWERM&#8221;). This PWERM was determined
to be the most appropriate method of estimating the value of possible redemption or conversion outcomes over time, since we have not
entered into a priced equity round through December 31, 2021. The significant assumptions utilized in these calculations are the possible
exit scenarios (either a conversion of the principal and accrued interest of the Notes in the event of a Next Equity Financing, a repayment
of the Notes and accrued interest in the event of a Corporate Transaction (as defined in the Notes) or a repayment of the Notes and accrued
interest at maturity), the pre-money valuation of our common stock, the probabilities of such exit events occurring and discounts/premiums
available to the noteholders at such measurement dates. At December 31, 2020, we assumed a 40% probability of a Next Equity
Financing event occurring at IPO pricing and a 5% probability of a Corporate Transaction. The calculation of the redemption
liability at December 31, 2021 is based upon the actual incremental value derived by the noteholders at the IPO date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred
Offering Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering consisted of legal, accounting, printing, and filing fees that the Company capitalized which will be offset against the proceeds
from the our initial public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Years Ended December 31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth key components of our results of operations for the years ended December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    Statements of Operations Data:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 55%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,842,803</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">847,272</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">995,531</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Acquired
    in-process research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">289,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(289,200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365,214</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">671,879</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">693,335</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,208,017</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,808,351</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,399,666</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    (expenses) income:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(831,277</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(246,534</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(584,743</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in redemption value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,832,651</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(362,486</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,195,137</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    other (expenses) income, net</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,001,374</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(609,020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,610,394</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    (loss) income</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,206,643</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,417,371</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">210,728</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by $995,531, or 117.5%, to $1,842,803 for the year ended December 31, 2021 from $847,272 for the year
ended December 31, 2020. The increase was primarily the result of an increase in expenses for pre-clinical activities of $512,279; stock
based compensation expense of $406,024 related to research and development team members; and consulting expenses of $78,357. These
increases were offset by decreases of $1,129 in various other expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acquired
In-Process Research and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
in-process research and development expense was $0 for the year ended December 31, 2021 and $289,200 for the year ended December 31,
2020, a decrease of $289,200. The in-process research and development expenses represent expenses incurred with the acquisition
of Farrington that closed during the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $693,335, or 103.2%, to $1,365,214 for the year ended December 31, 2021 from $671,879
for the year ended December 31, 2020. The increase in general and administrative expenses was primarily due to an increase of $598,665
in stock based compensation expense; $164,862 in accounting expenses; $8,665 in insurance expenses; and $3,080 in legal
expenses. These increases were offset by a decreases of $34,786 in consulting expenses and $47,151 in various other expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense increased by $584,743, or 237.2%, to $831,277 for the year ended December 31, 2021 from $246,534 for the year ended December
31, 2020. The increase in interest expense was primarily related to the issuance of convertible promissory notes. See Note 4 of
our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Redemption Value</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in redemption value decreased by $2,195,137, or 605.6%, to $1,832,651 for the year ended December 31, 2021 from $362,486 for the
year ended December 31, 2020 as the redemption liability was re-evaluated in light of the actual fair value increment provided to the
debt holders upon completion of our initial public offering in January 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that we are a going concern, which contemplates, among
other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December
31, 2021, we incurred operating losses in the amount of approximately $3.2 million and have an accumulated deficit of approximately
$6.9 million at December 31, 2021. We have financed our working capital requirements through December 31, 2021 primarily through
the issuance of convertible promissory notes payable issued to related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, we closed our initial public offering (&#8220;IPO&#8221;) of 3,750,000 shares of our common stock at a public
offering price of $4.00 per share. The gross proceeds from the IPO were $15.0 million, prior to deducting underwriting discounts, commissions,
and other offering expenses. The net proceeds from the IPO were approximately $13.0 million. We granted the underwriters a 45-day
option to purchase up to an additional 562,500 shares of common stock at the public offering price less discounts and commissions, to
cover over-allotments; however, this option expired unexercised. Additionally, and as a result of the completion of the IPO, all
of our related party convertible debt and accrued interest was converted into an aggregate of 1,225,384 shares of our
common stock pursuant to the terms of the convertible note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our cash on hand after the IPO is sufficient to meet our operating obligations and capital requirements for at least twelve
months from the issuance of the financial statements included in this Annual Report on Form 10-K. Thereafter, we may need
to raise further capital through the sale of additional equity or debt securities or other debt instruments to support our future
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flow Activities for the Years Ended December 31, 2021and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of our cash flows for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 68%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,086,244</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,078,432</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">898,748</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,232,003</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net
    (decrease) increase in cash</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(187,496</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">153,571</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities for the year ended December 31, 2021 was $1,086,244 which consisted of net loss of $2,206,643, partially
offset by $73,184 in non-cash charges and other adjustments to reconcile net loss to net cash used in operating activities and $1,047,215
in net increase in operating accounts. The non-cash charges consist of stock compensation expenses of $1,239,269, amortization of debt
discount of $666,566 offset by decrease in fair value of redemption liability of $1,832,651. The net increase in operating activities
was primarily due to an increase of $850,293 in accounts payable and accrued expenses, an increase in accrued interest of $164,646 and
a decrease of $32,276 in prepaid expenses and other current assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2021 was $898,748. The net increase in financing activities was from
net cash proceeds of $1,078,015 from the issuance of convertible promissory notes offset by deferred offering costs of $179,267.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Promissory Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
in May 2017, we issued convertible promissory notes (the &#8220;Notes&#8221;) to certain investors to help finance our operations. The
principal amount of such notes ranged from $1,000 to $300,000. Interest on the unpaid principal balance accrued at a rate
of 5% per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares
of our common stock or preferred stock (&#8220;Equity Securities&#8221;), the principal and accrued interest was due and payable
by us on demand by the holders at any time after the earlier of (i) the maturity date of each Note and (ii) the closing of the Next Equity
Financing. &#8220;Next Equity Financing&#8221; means the next sale or series of related sales of our Equity Securities pursuant to which
we receive gross proceeds of not less than $5,000,000 for Notes issued in 2017 and through November 2020 and $7,500,000 for Notes issued
after November 2020 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation
of Notes).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, the maturity date was two years from the date of issuance, except for the Notes issued in December 2020 and thereafter, in the
aggregate principal amount of approximately $2,135,000, which had a maturity date of three years from the date of issuance. For
Notes issued in 2017 through September 2018, the default interest rate of 20% was added to the Notes for the period after the
maturity date (&#8220;default period&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed below, the</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Notes automatically converted
into the type of Equity Securities issued in the Next Equity Financing upon closing of the IPO. The number of shares of such
Equity Securities to be issued was equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest
due on the Note on the date of conversion by the lesser of (i) 80% of the price paid per share of Equity Securities by the investors
in the Next Equity Financing, or (ii) an equity valuation of $25 million ($50 million for notes issued after December 2020). In connection
with the closing of our IPO, in January 2022, notes in the aggregate amount of approximately $3,920,640, including interest
accrued thereon, were converted into an aggregate of 1,225,384 shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, we issued a related party note holder notes (&#8220;Exchange Notes&#8221;) in exchange for seven Notes which were
in default (&#8220;Original Notes&#8221;) at such time by more than 90 days. The Original Notes had a principal of approximately $265,000
and accrued interest of $37,000 at December 31, 2019. As of September 27, 2020, the aggregate outstanding principal of the Original Notes
was approximately $265,000 and accrued interest (which included the default interest rate of 20% as described above) was approximately
$71,000. The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of
37.5% to determine the new principal, which amounted to an aggregate of $537,968. The Company accounted for this transaction as a debt
extinguishment, and the incremental amount of the principal of the notes payable of $201,737 was recorded to accumulated deficit (analogous
to a &#8220;deemed dividend&#8221;), since the notes were with related parties, and included in the calculation of loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, we issued certain related party note holders Exchange Notes in exchange for five Notes payable which were in default.
As of such date, the aggregate outstanding principal and interest was approximately $26,000, which included the 20% default interest
rate. The new Exchange Notes in the aggregate principal amount of approximately $26,000 had substantially the same terms as the
original Notes. There were no accounting entries required upon the re-issuance of such Exchange Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2020, all Notes which matured, and were not repaid or converted, were rolled over on substantially the same terms as the Original
Notes (&#8220;Rolled Over&#8221;). Approximately $805,000 of such Original Notes were Rolled Over through December 31, 2021, of which
approximately $166,000 occurred prior to December 31, 2020 and $639,000 occurred between January 1, 2021 and December 31, 2021. Since
the terms of the new notes are not substantially different from the Original Notes, this was not accounted for as a debt modification
or debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S.
GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on
assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable
estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.
Estimates are used in the following areas, among others: research and development expense recognition, valuation of common shares and
stock options, allowances of deferred tax assets, valuation of debt related instruments, accrued expenses and liabilities, and cash flow
assumptions regarding going concern considerations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Accounting Policies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Research
and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. We accrue for costs incurred by external service providers, including contract research organizations and clinical investigators,
based on our estimates of service performed and costs incurred. These estimates include the level of services performed by third
parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services
completed. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquired
in-process research and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process research
and development assets. In accordance with Financial Accounting Standards Board&#8217;s ASC 730-10-25-1, Research and Development, the
up-front acquisition or licensing payments are expensed as acquired in-process research and development provided that the drug has not
achieved regulatory approval for marketing, and, absent obtaining such approval, have no alternative future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
based compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation represents the cost related to stock based awards granted to our employees, directors and consultants and our
affiliates. We measure stock based compensation costs at the grant date, based on the estimated fair value of the award and recognize
the cost over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize compensation costs resulting from the issuance of stock based awards to employees, non-employees and directors as an expense
in our consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock
based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model. The
fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. As of December
31, 2021, we were a private company and lacked company-specific historical and implied volatility information. Therefore,
we estimated our expected stock volatility based on the historical data regarding the volatility of a publicly traded set of peer
companies. The expected term of stock options granted to non-employees was between five and seven years. The risk-free interest
rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods
approximately equal to the expected term of the award. The fair value of common stock was determined with the assistance of an
independent third-party valuation expert when issuing stock options and computing its estimated stock based compensation expense and
value of shares issued in acquiring product candidates. The assumptions underlying these valuations represented management&#8217;s best
estimates, which involved inherent uncertainties and the application of significant levels of management judgment. In order to determine
the fair value, we considered, among other things, contemporaneous valuations of our common stock, our business, financial condition
and results of operations, including related industry trends affecting our operations; the likelihood of achieving various liquidity
events; the lack of marketability of our common stock; the market performance of comparable publicly traded companies; and U.S. and global
economic and capital market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
value measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
apply ASC 820, Fair Value Measurement (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the
definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received
for an asset or paid to transfer a liability in our principal or most advantageous market in an orderly transaction between market participants
on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable
inputs and minimize the use of unobservable inputs when measuring fair value. The calculation of the redemption liability at
December 31, 2021 is based upon the actual incremental value derived by the noteholders at the IPO date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt
discount and derivative instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption value relating to the convertible debt instruments is treated as a debt discount and amortized over
the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full, any unamortized
financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is recorded as a component
of interest expense. In accordance with ASU 2015-03, <i>Interest &#8212; Imputation of Interest</i>, the unamortized debt discount is
presented in the accompanying balance sheet as a direct deduction from the carrying amount of the related debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for derivative instruments in accordance with ASC 815, Derivative and Hedging, which establishes accounting and reporting standards
for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts and requires
recognition of all derivatives on the balance sheet at fair value. Our derivative financial instrument consists of an embedded feature
contained in our convertible debt that is bifurcated and accounted for separately. See Note 4 of our audited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued and Adopted Accounting Standards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JOBS
Act</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Emerging growth companies can take advantage of the extended
transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other
words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We have chosen to take advantage of the extended transition periods available to emerging growth companies
under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies
provided under the JOBS Act. As a result, our consolidated financial statements may not be comparable to those of companies that comply
with public company effective dates for complying with new or revised accounting standards. For as long as we continue to be an emerging
growth company, we also intend to take advantage of certain other exemptions from various reporting requirements that are applicable
to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic
reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation
and any golden parachute payments not previously approved, exemption from the requirement of auditor attestation in the assessment of
our internal control over financial reporting and exemption from any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information
about the audit and the financial statements (auditor discussion and analysis). We will remain an emerging growth company until the earliest
of (i) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, (ii) the end of the fiscal year in
which we have total annual gross revenues of $1.07 billion or more during such fiscal year, (iii) the date on which we issue more than
$1 billion in non-convertible debt in a three-year period or (iv) the end of the fiscal year following the fifth anniversary of the date
of the completion of our IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_012"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we are not required to provide the information required by this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_013"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HILLSTREAM
                                            BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDITED
    FINANCIAL STATEMENTS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span id="xdx_904_edei--AuditorFirmId_c20210101__20211231_zvh1kDQxaV97"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorFirmId">199</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003">Consolidated Statements of Operations for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span><span style="font-family: Times New Roman, Times, Serif">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004">Consolidated Statements of Changes in Stockholders&#8217; Deficit for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span><span style="font-family: Times New Roman, Times, Serif">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005">Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span><span style="font-family: Times New Roman, Times, Serif">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="f_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Hillstream BioPharma, Inc.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Consolidated Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Hillstream BioPharma, Inc. (the &#8220;Company&#8221;) as of December 31,
2021 and 2020, and the related consolidated statements of operations, changes in stockholders&#8217; deficit, and cash flows for each
of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2021 and 2020, and the results of their operations and their cash flows for each of the two years in the period ended December 31,
2021, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
<span id="xdx_90D_edei--AuditorName_c20210101__20211231_zmPLcEPRuHTf"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorName">Mayer Hoffman McCann P.C</ix:nonNumeric></span></i></span><i><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90E_edei--AuditorLocation_c20210101__20211231_zAc8nijymlhc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorLocation">Los
Angeles, California</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
1, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="f_002"></span><b>HILLSTREAM
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_111_zKhBbrcpzAZe" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20211231_zTXJ7npRLC74" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20201231_zoSPaliHe6jd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zoRQo3LSmGh3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zgr3NB7RZpZh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    assets:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--Cash_i02I_maACzVxx_z8Z7eB1AzVzc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,356</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,852</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzVxx_zbHjejYKgNMi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,670</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,946</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredOfferingCosts_i02I_maACzVxx_zAPyOwedaje9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred
    offering costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,651</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0061">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_i02TI_mtACzVxx_maAzW5Y_zMo2Q7n6mZR4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,677</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,798</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtAzW5Y_zHaH7MDEwUX7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,677</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,798</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zKvUEEYrocHi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Liabilities
    and Stockholders&#8217; Deficit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zNFALcOx1GJ3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    liabilities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_maLCznda_zrFX3rp1IHOi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,463,059</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">514,828</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPayableCurrent_i02I_maLCznda_z72zh5EPTpd2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,621</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,066</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DueToRelatedPartiesCurrent_i02I_maLCznda_zooYSpQFsKdg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Due
    to founder</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCznda_zx1tSFkW6Aol" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,223</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,777</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--RedemptionLiability_i02I_maLCznda_zyxF5YTkWan5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Redemption
    liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:RedemptionLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">980,233</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:RedemptionLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,325,288</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maLCznda_zv6mW2LOudvh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Short-term
    portion of related-party convertible notes, net</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392,544</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">563,425</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_mtLCznda_maLzv7k_zDgA6eLAyVZ1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,533,680</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,725,384</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ConvertibleLongTermNotesPayable_i01I_maLzv7k_zPHSHxds07Ie" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Related-party
    convertible notes, net, less short-term portion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772,899</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,286,942</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_mtLzv7k_maLASEzFux_zeg1luoYCKaf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,306,579</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,012,326</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzFux_zzAbJHmigZ14" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments
    and contingencies (See Note 10)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0102">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0103">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquityAbstract_iB_zqzD4837Pqrd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;
    deficit:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PreferredStockValue_i01I_maSEzC5Z_zzlrD7tG9D97" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Preferred
    stock, $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pdd"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif">par
    value, <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20201231_pdd"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif">shares
    authorized; <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20201231_zMi3lmMvggr1"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif">shares
    issued and outstanding as of December 31, 2021 and 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0108">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0109">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i01I_maSEzC5Z_zbasg1ZEaDAl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common
    stock, $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif">par
    value, <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif">shares
    authorized; <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,357,314</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif">shares
    issued and outstanding as of December 31, 2021 and 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AdditionalPaidInCapital_i01I_maSEzC5Z_zXnavZHkQki5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,225,712</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">986,443</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzC5Z_zDYMsGnIbAYg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,911,250</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,704,607</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i01TI_mtSEzC5Z_maLASEzFux_zGsTJWXU5kGe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stockholders&#8217; deficit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,684,902</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,717,528</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzFux_zwPXpPnVqHwj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; deficit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,677</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,798</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_003"></span>HILLSTREAM
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zJt8ukpqf9f2" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49E_20210101__20211231_zKA4EE8OAM6a" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_495_20200101__20201231_zT2SLVQZdadg" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zOiqaSqPfvr4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_maCAEzuSd_zJkDwtS2NPd8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,842,803</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,272</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--AcquiredInprocessResearchAndDevelopment1_i01_maCAEzuSd_zEpqub8PUBk4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Acquired
    in-process research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0138">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:AcquiredInprocessResearchAndDevelopment1" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,200</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maCAEzuSd_zCTRt0ouxTuh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,365,214</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,879</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_mtCAEzuSd_msOILzHq7_zn1cUMA3jY7h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,208,017</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,808,351</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_maNILzybU_mtOILzHq7_zoA92twG0oR2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,208,017</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,808,351</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zpSywehZfPOl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    income (expenses):</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_i01N_di_msNIEz6QJ_zrSt6OqZCXFc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest
    expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,277</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">246,534</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_ecustom--GainLossInRedemptionValue_i01_maNIEz6QJ_z3VNcrFSoKvk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in redemption value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:GainLossInRedemptionValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,651</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:GainLossInRedemptionValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">362,486</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEz6QJ_maNILzybU_zKCKlwn40jY7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    other income (expenses), net</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,001,374</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">609,020</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iT_mtNILzybU_zcYTcQ0n3WA9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,206,643</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,417,371</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zkeT54Jr7eG" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Net loss per share:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pid_zvVdj6n3dGJk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Basic
    and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.35</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.38</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zsavWq22vDm8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Weighted average
    number of common shares outstanding:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_pid_zA5xi4aOEkGg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Basic
    and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,357,314</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,347,144</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="f_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HILLSTREAM
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_zgAgFOMByPr7" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_znjOxtD5bnwf" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zkjhjhlzDiVb" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zqWnpyZp0sU9" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4B5_z0EwXzRMnWYi" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-in</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Par
    Value</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_437_c20200101__20201231_eus-gaap--StockholdersEquity_iS_ztUPNIW705u4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 32%; font-weight: bold; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR8lw3tpn5H2" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,281,557</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">628</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,671</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,085,499</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,622,200</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zGWtCR26bjji" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of shares for the acquisition of Farrington Therapeutics LLC</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPsOAVR1z148" title="Issuance of shares for the acquisition of Farrington Therapeutics LLC, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,757</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,192</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0186">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,200</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zAsUxmOY6BHb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0191">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,580</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0193">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,580</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--DeemedDividendUponDebtExchange_z98bsaJ5lZJ4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deemed
    dividend upon debt exchange</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0196">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0197">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:DeemedDividendUponDebtExchange" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">201,737</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:DeemedDividendUponDebtExchange" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">201,737</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zWuLZBRwtNTk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0201">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0202">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,417,371</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,417,371</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_432_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zvoFehiIlgY6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAY82cu6IY09" title="Beginning balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,357,314</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">986,443</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,704,607</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,717,528</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zNPNfaY9okR9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0213">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,239,269</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0215">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,239,269</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zB9AZwC0mZWb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0219">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,206,643</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,206,643</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43C_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zsc4sxv0nlt6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYxqypR32mHk" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,357,314</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,225,712</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,911,250</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,684,902</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="f_005"></span><b>HILLSTREAM
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENT OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_z4AXBeOHNRpg" summary="xdx: Statement - Consolidated Statement of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_496_20210101__20211231_zo32upxpoUSb" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_491_20200101__20201231_zvWz9nShnROi" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the years ended</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zLic2buSrkB7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    flows from operating activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_maNCPBUzVSj_zbeYluj8bqE4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,206,643</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,417,371</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zDUFWVr0F6y9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used in operating activities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentInProcess_i02_maNCPBUzVSj_zEOjwMjYypJ5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">In-process
    research and development expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0239">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,200</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzVSj_zkROZVTDGKGi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization
    of debt discount</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">666,566</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,356</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_maNCPBUzVSj_zUvb0WX6Hsj1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock
    based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,239,269</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,580</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--GainLossInRedemptionValue_i02N_di_msNCPBUzVSj_zsoG2wJVt8Hf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value of redemption liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:GainLossInRedemptionValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,651</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:GainLossInRedemptionValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">362,486</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z0sBSz5elko8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes
    in operating accounts:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzVSj_zec4NWAgaOJ1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes
    in prepaid expenses and other current assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,276</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,346</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUzVSj_z8WNc4trk9T1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes
    in accounts payable and accrued expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">850,293</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,570</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccruedInterestReceivableNet_i03N_di_msNCPBUzVSj_ztp1rv72ipG6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes
    in accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">164,646</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,093</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzVSj_maCCERCzo3z_z8hHIuRBqKBk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,086,244</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,078,432</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zHSpn0Rv9tQ2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    flows from financing activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzdMR_zNCJakHSDlR6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from related-party convertible notes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,078,015</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,232,003</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--RepaymentsOfDeferredOfferingCosts_i01N_di_msNCPBUzdMR_zIHJZ2EBk353" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred
    offering costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:RepaymentsOfDeferredOfferingCosts" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,267</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzdMR_maCCERCzo3z_zEoC9fDz39t" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">898,748</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,232,003</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzo3z_zd4ChFPsObwh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    (decrease) increase in cash</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">187,496</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,571</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zffZ3NipJsd3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    - beginning of year</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,852</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,281</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zvD9PsvX75W9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    - end of year</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,356</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,852</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zS3YEmsi2bNi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental
    disclosure of non-cash investing and financing activities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssued1_i01_zba9j3yQnsLh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issued upon acquisition</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,200</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--DeemedDividend_i01_z0syFik2ym69" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deemed
    dividend</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:DeemedDividend" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,737</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--AccruedInterestRolloverToNewNotesPayable_i01_zuhAlChmMSm5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest roll-over to new notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:AccruedInterestRolloverToNewNotesPayable" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,091</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:AccruedInterestRolloverToNewNotesPayable" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,456</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--DueToFounderConvertedToNotePayable_i01_zMS9MAOv4Pk6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due
    to founder converted to note payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:DueToFounderConvertedToNotePayable" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,068</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--UnpaidDeferredOfferingCosts_i01_z6CW9wrxFSSk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unpaid
    deferred offering costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:UnpaidDeferredOfferingCosts" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,384</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_802_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zEGU3gAJK5s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b><span id="f_006"></span>Note
1 - Description of Business and Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82A_zvJ8MCpmCayb" style="display: none">DESCRIPTION
OF BUSINESS AND LIQUIDITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma, Inc. (&#8220;HBI&#8221;) was incorporated on March 28, 2017, as a Delaware C-corporation. At December 31, 2021, Hillstream
BioPharma, Inc. had two wholly-owned subsidiaries: HB Pharma Corp. (&#8220;HB&#8221;) and Farrington Therapeutics LLC (&#8220;Farrington&#8221;
and together with HBI and HB, the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death (&#8220;IMCD&#8221;) for treatment resistant cancers. The Company&#8217;s most advanced
product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to reduce
tumor burden in a clinical pilot study in Germany in treatment resistant cancers, including triple negative breast cancer and epithelial
carcinomas. The Company&#8217;s goal is to file an investigational new drug application (&#8220;IND&#8221;) with the U.S. Food
and Drug Administration (&#8220;FDA&#8221;) in 2023 and start a clinical study with HSB-1216 in 2023; however, no assurance can
be provided that the Company&#8217;s IND will be accepted by the FDA in 2023, if at all. If the IND is accepted by the FDA, the HSB-1216
clinical study will focus on expanding upon the clinical pilot study conducted in Germany. If the Company is able to start the clinical
study with HSB-1216 in 2023, the Company anticipates that initial data from such trial will be released either at the end of 2023 or
early 2024. The Company uses Quatramer&#8482;, the proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor
microenvironment with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence, the
Company&#8217;s artificial intelligence precision medicine platform, is used to identify biomarkers in its clinical programs to target
specific patient segments. The discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target
discovery for drug development. Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular
iron or the Labile Iron Pool (&#8220;LIP&#8221;). Cancer cells increase the LIP leading to unregulated cell growth and metabolism. Decreasing
the LIP, induces iron-led reactive oxygen species production and lipid peroxidation, two key hallmarks of ferroptosis/IMCD. HSB-1216
binds iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD, leading to regulated cell death.
Areas of interest for the development of HSB-1216 are as a treatment of solid tumors, including triple negative breast cancer,
uveal melanoma, glioblastoma multiforme, head and neck squamous cell carcinoma and other treatment resistant cancers with high unmet
need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December
31, 2021, the Company incurred operating losses in the amount of approximately $<span id="xdx_903_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20210101__20211231_zHE3QPfeJhJ4"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">3.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and had an accumulated deficit
of approximately $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20211231_zAfcas2gEaWc"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">6.9</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million at December 31, 2021. The Company financed its working
capital requirements through December 31, 2021 primarily through the issuance of convertible promissory notes payable issued to
related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, the Company closed its initial public offering (&#8220;IPO&#8221;) of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpMtUEkKb1zh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock at
a public offering price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVc9VEbAwPY2"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The gross proceeds to the Company
from the IPO were $<span id="xdx_90C_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5aCE4PKBKWc"><ix:nonFraction name="HILS:GrossProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, prior to deducting underwriting discounts,
commissions, and other offering expenses. The net proceeds to the Company from the IPO were approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zax5aKIRq9ji"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company granted the underwriters
a 45-day option to purchase up to an additional <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8MHlNI5u2Ki"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">562,500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at the public offering
price less discounts and commissions, to cover over-allotments; however, this option expired unexercised. Additionally, and as
a result of the completion of the IPO, all of the related party convertible debt and accrued interest was converted into an aggregate
of <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzkBBQU2tMU2"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,225,384</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
pursuant to the terms of the convertible notes. The shares of the Company&#8217;s common stock began trading on The Nasdaq
Capital Market on January 12, 2022 under the ticker symbol &#8220;HILS&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes its cash on hand after the completion of the IPO is sufficient to meet its operating obligations and capital
requirements for at least twelve months from the issuance of these financial statements. Thereafter, the Company may need to raise further
capital through the sale of additional equity or debt securities or other debt instruments to support its future operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
risks and uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the Company&#8217;s products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all. The Company is subject to risks common to biopharmaceutical companies including,
but not limited to, the development of new technological innovations, dependence on key personnel, protection of proprietary technology,
compliance with government regulations, product liability, uncertainty of market acceptance of products and the need to obtain additional
financing. The Company is dependent on third party suppliers. The Company&#8217;s products require approval or clearance from the FDA
prior to commencing commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions in which
the Company may license or sell its products. There can be no assurance that the Company&#8217;s products will receive all of the required
approvals or clearances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) was reported globally. The World Health Organization declared COVID-19
to constitute a &#8220;Public Health Emergency of International Concern&#8221; on January 30, 2020 and a global pandemic on March 11,
2020. In March 2020, individual states mandated &#8220;stay at home orders&#8221;, restricted access to hospitals, prohibited elective
surgeries and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on the Company&#8217;s
operational and financial performance will depend on future developments, including access to products, potential disruptions
in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity of the COVID-19
outbreak. As of December 31, 2021, the Company&#8217;s operations have not been materially affected by COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1LUHJ2g9Q65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_821_zpdq6neefWQj" style="display: none">BASIS
OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaxim83qcPgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86A_zYYLtqYOC5ba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (&#8220;US GAAP&#8221;). The Company operates in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="HILS:ReverseStockSplitPolicyTextBlock"><p id="xdx_846_ecustom--ReverseStockSplitPolicyTextBlock_zdbQhsP0ve13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86F_z5QFZvzSTBmh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
stock split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 16, 2021, the Company effectuated a reverse split of shares of its common stock at a ratio of <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20210915__20210916_zJAmx8oAjv6h"><ix:nonNumeric contextRef="From2021-09-152021-09-16" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-26.4</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">pursuant to an amendment
to the Company&#8217;s Certificate of Incorporation, as amended, filed with the Delaware Secretary of State and approved by the
Company&#8217;s board of directors and stockholders. The par value of the Company&#8217;s common stock was not adjusted as a result
of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have
been retroactively adjusted to reflect this reverse split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhqrq9UiGnlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86A_zITKkpzU2uZ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of consolidation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_845_eus-gaap--UseOfEstimates_z2G4rkEXcLD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86B_zACQJuQS3ejk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases
its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often
may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls
within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense
recognition, valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments,
accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPeS4dNFE2uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86E_z2bSal0T2Qsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_z70A0iT8PGI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86F_zub6YjCkQKRh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrolment in clinical trials, administrative costs incurred by third parties, and other indicators of the services
completed. Substantially all of the prepaid expenses at December 31, 2021 relate to a manufacturing services agreement. Substantially
all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical ingredient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InProcessResearchAndDevelopmentPolicy"><p id="xdx_849_eus-gaap--InProcessResearchAndDevelopmentPolicy_zfBmMRtzJU86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_868_zEnb1ySasfnd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquired
in-process research and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards
Codification (&#8220;ASC&#8221;) 730-10-25-1, <i>Research and Development,</i> the up-front acquisition or licensing payments are
expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and,
absent obtaining such approval, has no alternative future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zicSb1T6sC35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_867_zVPVwjd2G2C5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
based compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as
an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock-based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date of grant
using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line
basis over the requisite service period of the awards, which is generally the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. At December
31, 2021, the Company was a private company and lacked company-specific historical and implied volatility information.
Therefore, it estimated its expected stock volatility based on the historical data regarding the volatility of a publicly traded
set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate
was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately
equal to the expected term of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="HILS:CommonStockValuationsPolicyTextBlock"><p id="xdx_842_ecustom--CommonStockValuationsPolicyTextBlock_z4EclXTDGCn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86F_zyIZ2zQWvntb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
stock valuations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock-based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&#8217;s common stock, the Company&#8217;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&#8217;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="HILS:DebtDiscountAndDerivativeInstrumentsPolicyTextBlock"><p id="xdx_84A_ecustom--DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_zW47rGNvvRvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_869_zGTrVFJYXOgk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt
discount and derivative instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2015-03, <i>Interest
&#8212; Imputation of Interest</i>, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative instruments in accordance with ASC 815, <i>Derivative and Hedging</i>, which establishes accounting and
reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts
and requires recognition of all derivatives on the balance sheet at fair value. The Company&#8217;s derivative financial instrument consists
of an embedded feature contained in the Company&#8217;s convertible debt that is bifurcated and accounted for separately. See Note 4
for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkhgGoSNxgXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_863_zH0qyYncS6Xl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
value measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies ASC 820, <i>Fair Value Measurement </i>(&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data
and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&#8217;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term
maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value. See Note 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input
that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable
    inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms,
    as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no
    market data exists for the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_844_eus-gaap--DeferredChargesPolicyTextBlock_zVNOQhg82IL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_865_zkAnzY8Z7pva" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
Offering Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs consisted of legal, accounting, printing, and filing fees that the Company capitalized which will be offset against the
proceeds from the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_ziGgCs4wbED4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_867_zUI0tZjl0Ku7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance has been recognized for all periods since it is &#8220;more
likely than not&#8221; that some portion or all of the deferred tax assets will not be realized in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. At December 31, 2021 and 2020, the Company had no unrecognized uncertain income tax positions,
and therefore no amounts have been recognized in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zkqfmNdYCvR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_866_zEPkQOkIFLN1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
loss per share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports loss per share in accordance with ASC 260-10, <i>Earnings Per Share</i>, which provides for calculation of basic and
diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to
common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of earnings (loss) per share for the years ended December 31, 2021 and 2020 included
options to purchase <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zRF9Ba03TFdb"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">903,468</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zM288QWeU1M6"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,731</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, respectively. The number
of shares issuable upon the conversion of convertible debt and accrued interest (which was <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH1qaVehsYQh"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,225,384</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at the IPO date of January 14, 2022) is
not included in the denominator since their inclusion would be anti-dilutive. All common share amounts and per share amounts have been
adjusted to reflect a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20210101__20211231_zoB5kqzxwndd"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-26.4</ix:nonNumeric></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse stock split of the Company&#8217;s common stock effectuated
on September 16, 2021. Management concluded that the deemed dividend (see Note 4) is analogous to a return on equity classified
preference shares, therefore the deemed dividend is added to the net loss for purposes of the basic and diluted loss per share calculation.
Accordingly, the numerator of the loss per share calculation (basic and diluted) is $<span id="xdx_90A_ecustom--BacisAndDilutedLoss_c20200101__20201231_zbqgZvCLl9Nb"><ix:nonFraction name="HILS:BacisAndDilutedLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,619,108</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyKFsLikxSNc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_869_zRakjnhEqyf9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
accounting pronouncements not yet adopted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all recent accounting pronouncements and believes that none of them will have a material effect on the Company&#8217;s
financial position, results of operations or cash flows except as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU No. 2016-02, &#8220;<i>Leases (Topic 842)</i>&#8221; which replaces the existing guidance in ASC 840
- <i>Leases</i>. This ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases
or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding
lease liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset and for operating
leases, the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December
15, 2021 and for interim periods within those fiscal years. The Company will evaluate the impact of adoption of this ASU when it enters
into a lease arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
with Conversion and Other Options and Derivatives and Hedging</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB recently issued ASU 2020-06, <i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity</i>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&#8217;s own stock and classified in stockholders&#8217; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, <i>Earnings Per Share</i>, to require entities to calculate diluted
earnings per share (&#8220;EPS&#8221;) for convertible instruments by using the if-converted method. In addition, entities must
presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments
in ASU 2020-06 are effective for public entities that meet the definition of an SEC filer, excluding smaller reporting companies as defined
by the Securities and Exchange Commission (&#8220;SEC&#8221;), for fiscal years beginning after December 15, 2021. For all other
entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact this standard will have on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Earnings
Per Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share</i> (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50),
<i>Compensation-Stock Compensation</i> (Topic 718), and <i>Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</i> (Subtopic
815-40). The new ASU addresses issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written
call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods
within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this standard will have
on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants,
and the SEC did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated
financial statement presentation or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Codification
Improvements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the FASB issued ASU 2020-10, <i>Codification Improvements</i>. The guidance contains improvements to the Codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may
affect the application of the guidance in cases in which the original guidance may have been unclear. This is effective for the Company
for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022.
Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated
financial statements.</span></p>

</ix:nonNumeric><p id="xdx_857_zlwPG8Ljltr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_806_eus-gaap--BusinessCombinationDisclosureTextBlock_zSgZywnvnSD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
3 - Acquisition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82F_zeSUe7Cgl4H8" style="display: none">ACQUISITION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Farrington</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2020, the Company acquired <span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPercent_c20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zJPlY9Bk1Ml6"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">100</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the member interests of Farrington, an early-stage biotech company which owned a next generation anthracycline, HSB-888, for pediatric
osteosarcoma. Pursuant to an Exchange Agreement, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zbDM9mDh0p3i"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-11-112020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,757</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock to the seller as consideration
for the purchase. The transaction did not meet the definition of a business combination for financial reporting purposes, since there
were no business inputs, employees acquired, processes or outputs at the time of the transaction. The fair value of the common stock
issued was estimated to be approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zB791mlu5Nx5"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-11-112020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,200</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
for which the single asset was recognized as a component of acquired in-process research and development expense in the accompanying
consolidated statements of operations in the year ended December 31, 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zumNHdMuS9N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
4 - Convertible Notes - Related Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_826_zNgpaS2ON2Hi" style="display: none">CONVERTIBLE
NOTES - RELATED PARTIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
in May 2017, the Company entered into Subordinated Convertible Promissory Note Agreements (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued Subordinated
Convertible Promissory Notes (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally all
to the Chief Executive Officer and founder of the Company, a member of the Company&#8217;s board of directors and third parties
that are family members of the founder and Chief Executive Officer. See Note 9. Interest on the unpaid principal balance accrues
at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170531__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zLropNQfLpwk"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of
the Company&#8217;s common stock or preferred stock (collectively, the &#8220;Equity Securities&#8221;), the principal and accrued interest
shall be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in
each Agreement) and (ii) the closing of the Next Equity Financing. &#8220;Next Equity Financing&#8221; means the next sale, or series
of related sales, by the Company of its Equity Securities pursuant to which the Company receives gross proceeds of not less than $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20170501__20170531__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zNkSPDb9IFMk"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2017-05-012017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for Notes issued in 2017 and through November
2020 and $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zLaab7jIVNr"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-12-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for Notes issued after November 2020 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of the Notes).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, the stated maturity date was <span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dt_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z7NCGaRLzSR4"><ix:nonNumeric contextRef="From2020-12-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">two
years</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance, except for the
Notes entered into in December 2020 and thereafter (in the aggregate principal amount of approximately $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z0UoWoLLU6U"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="-2" unitRef="USD">2,135,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
which have a stated maturity date of <span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dt_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zYpUPkOymGE5"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">three
years</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. For Notes entered into in 2017 and through
September 2018, the default interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20180930__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zIpxiKJNHlt"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2018-09-30_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">20</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
was added to the Notes for the period after the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the Note on the date of conversion by the lesser of <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zPOgadkdTc3c"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" name="us-gaap:DebtInstrumentDescription">(i)
80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing, or (ii) an equity valuation of $</ix:nonNumeric></span></span><span id="xdx_902_ecustom--EquityValuation_iI_pn5n6_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zeyosqxahYW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="HILS:EquityValuation" contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
($</span><span id="xdx_902_eus-gaap--NotesIssued1_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z95xpPSaqbR6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">50</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
for Notes issued after December 2020). No Next Equity Financing occurred through December 31, 2021; however on January 14, 2022,
all outstanding Notes and accrued interest were converted into an aggregate of</span> <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z11WHJpLbiyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,225,384</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of the Company&#8217;s common stock as the IPO qualified as a Next Equity Financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
embedded features contained in the Notes in the aggregate are embedded derivative instruments, which were recorded as a debt discount
and derivative liability at the issuance date at their estimated fair value for all Notes of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmbeddedDerivativeFinancialInstrumentsMember_z6nbJV5mmbq9"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,421,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Accretion of debt discount for the Notes was recorded as interest expense was approximately $<span id="xdx_903_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z4dAd4PICqQi"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">667,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90E_eus-gaap--InterestExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z2MtfWj2qgKc"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively. Accrued interest expense associated with the Notes at December 31, 2021 and December 31, 2020 amounted to approximately
$<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zl4OWRkgkv4"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zPWDaLIQNP02"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. Interest expense, including accretion of the debt discount, amounted to approximately $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z2Sa7i29FlD2"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zrmZVskUqdZ3"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">246,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock"><p id="xdx_89B_eus-gaap--ConvertibleDebtTableTextBlock_zurV691P91ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, all convertible debt instruments which had matured had been rolled over into new notes as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zXcf6N7RCUMb" style="display: none">SCHEDULE
OF CONVERTIBLE DEBT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_z286mMqTQbj4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_zmIoqgHKUgN6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December
    31,</b></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_maCDzeeB_zAobAk9K9ev8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Principal
    amount outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,734,446</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,598,340</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msCDzeeB_z49Nrl1plWXk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    debt discount, net of accretion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,569,003</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">747,973</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iTI_mtCDzeeB_zGsjpo7otGx1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Carrying value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,165,443</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,850,367</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleDebtCurrent_iI_maCDzsmY_zicQ6vqPjBic" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    portion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392,544</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">563,425</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebtNoncurrent_iI_maCDzsmY_z5eyShgNnHy" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long
    term portion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772,899</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,286,942</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iTI_mtCDzsmY_z16a0vJ40mx7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Total carrying value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,165,443</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,850,367</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zY5ZG7HoiNdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, the Company agreed to issue a related party Note holder notes (&#8220;Exchange Notes&#8221;) in exchange for seven
Notes payable which were in default (&#8220;Original Notes&#8221;) at such time by more than 90 days. The Original Notes had a principal
amount of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20191231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zhjmMXyNbpq7"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and accrued interest of $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20191231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zlQMeQZTlPk5"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2019-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2019. As of September 27, 2020,
the aggregate outstanding principal was approximately $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z6hWQLp8UqB3"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and accrued interest, which included the default
interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z9KJBOGxNsS9"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">20</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
as described above, was approximately $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zAYIBY4qCiFh"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zYIHavmEi658"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">37.5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
to determine the new principal amount which amounted to an aggregate of $<span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20200904__20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zMRj7YoMyZQ3"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-09-042020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,968</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company accounted for this transaction as a debt extinguishment, and the incremental amount of the principal of the Exchange Notes
payable of $<span id="xdx_90C_eus-gaap--NotesPayable_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z9jJbVyvv0v9"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,737</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was recorded to accumulated deficit (analogous
to a &#8220;deemed dividend&#8221;) in the year ended December 31, 2020, since the Exchange Notes are with related parties, and included
in the calculation of loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, the Company issued certain related party Noteholders notes (&#8220;September Exchange Notes&#8221;) in exchange for
five Notes payable, which were in default. As of such date, the aggregate outstanding principal and interest was approximately $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--SeptemberExchangeNotesMember_zB017qMiFkZh"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_SeptemberExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which included the default interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zThhoTkCjgP2"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_ExchangeNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">20</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
as described above. The September Exchange Notes in the aggregate principal amount of approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--SeptemberExchangeNotesMember_zgcp0yQLNkS9"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_SeptemberExchangeNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were issued with substantially the same terms
as the Original Notes. There were no accounting entries required upon the re-issuance of such Exchange Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Roll-over
notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2020, all Notes which matured, and were not repaid or converted, were rolled over on substantially the same terms as the Original
Notes (&#8220;Rolled Over&#8221;). Approximately $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20201001__20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zz5VS2jxjbW8"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-10-012021-12-31_custom_RolledOverMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of such Original Notes were Rolled Over through
December 31, 2021, of which approximately $<span id="xdx_901_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zVtI115C22s1"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-01-012020-12-31_custom_RolledOverMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurred prior to December 31, 2020 and $<span id="xdx_909_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zadilj4MmWP6"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-01-012021-12-31_custom_RolledOverMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">639,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurred between January 1, 2021 and December
31, 2021. Since the terms of the new notes are not substantially different from the Original Notes, this was not accounted for as a debt
modification or debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="HILS:RedemptionLiabilityDisclosureTextBlock"><p id="xdx_803_ecustom--RedemptionLiabilityDisclosureTextBlock_zWhbbhB3R6A9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
5 - Redemption Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_821_z8O0uIksMSol" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">REDEMPTION
LIABILITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, determined based upon a Probability-Weighted
Expected Returns Method (&#8220;PWERM&#8221;). This PWERM was determined to be the most appropriate method of estimating the value of
possible redemption or conversion outcomes over time, since the Company has not entered into a priced equity round through December 31,
2021. The significant assumptions utilized in these calculations are the possible exit scenarios (either a conversion of the principal
and accrued interest of the Notes in the event of a Next Equity Financing, a repayment of the Notes and accrued interest in the event
of a Corporate Transaction (as defined in the Notes) or a repayment of the Notes and accrued interest at maturity), the pre-money valuation
of the Company&#8217;s common stock, the probabilities of such exit events occurring and discounts/premiums available to the noteholders
at such measurement dates. At December 31, 2020, the Company assumed a 40% probability of a Next Equity Financing event occurring
at IPO pricing. At December 31, 2020, the Company assumed a 5% probability of a Corporate Transaction. The calculation of the redemption
liability at December 31, 2021 is based upon the actual incremental value derived by the Holders at the IPO date. The calculation
of the redemption liability also used the following assumptions during the years:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_z9vTxxSBrpqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zYZ7RQcr9tm2" style="display: none">SCHEDULE
OF ASSUMPTIONS OF REDEMPTION LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Assumed
    ranges pre-money valuation at time of Next Equity Financing</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">$
                                            <span id="xdx_901_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MinimumMember_zGiZMlrcLBH2"><ix:nonFraction name="HILS:EquityFinancingRangeValuationAssumedPercentage" contextRef="AsOf2020-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">&#8211; <span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MaximumMember_zKQzlP9cQSAg"><ix:nonFraction name="HILS:EquityFinancingRangeValuationAssumedPercentage" contextRef="AsOf2020-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">50</ix:nonFraction>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">million</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Discount
    rate</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MinimumMember_zVID6tuR15sb" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:EquityFinancingRangeValuationAssumedDiscountRate" contextRef="AsOf2020-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">8.86</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif">-
                                            <span id="xdx_90E_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MaximumMember_zhHKYvah5rMa"><ix:nonFraction name="HILS:EquityFinancingRangeValuationAssumedDiscountRate" contextRef="AsOf2020-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">11.13</ix:nonFraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    coupon interest rate on Notes</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_ecustom--EquityFinancingRangeValuationAssumedExpectedInterestRate_iI_pid_dp_uPercent_c20201231_zxjHsFFGEzO4" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:EquityFinancingRangeValuationAssumedExpectedInterestRate" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">5.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    term to exit event</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MinimumMember_z8p08iPrfyr8" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2020-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="HILS:EquityFinancingRangeValuationAssumedExpectedTerm">2.0</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">-
                                            <span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MaximumMember_zdEpX4f7qS3"><ix:nonNumeric contextRef="AsOf2020-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="HILS:EquityFinancingRangeValuationAssumedExpectedTerm">3.0</ix:nonNumeric>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zdukVwrdvcMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"><p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z6Kzb1otI7M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is re-measured at each period and is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z6mCpzfiEuL4" style="display: none">SCHEDULE
OF FAIR VALUE OF THE REDEMPTION LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zcA0ZS3BuXZ5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20200101__20201231_zKzqTdnCm9wh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zXp6PWXGhkGf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning
    balance</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,325,288</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,183</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_z08lIbYHdYuk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Initial
    embedded redemption value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,487,596</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">836,619</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_iI_zTkkZScxcJXg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,832,651</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,486</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zYiHXKB9CmVk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">980,233</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,325,288</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_ziWFSZ2MzLv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of a gain of $<span id="xdx_906_ecustom--GainOnRedemptionValue_c20210101__20211231_zl8dCMdyTdba"><ix:nonFraction name="HILS:GainOnRedemptionValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,651</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and loss of $<span id="xdx_901_ecustom--LossOnRedemptionValue_iN_di_c20200101__20201231_zhFiCOFzcWr3"><ix:nonFraction name="HILS:LossOnRedemptionValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">362,486</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively, is recorded as a component of other income (expenses), net in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zZtEEkgXngrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
6 - Stock Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_826_zv3Zw03Oiih6" style="display: none">STOCK
BASED COMPENSATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&#8217;s 2017 Stock Incentive Plan (the &#8220;2017 Stock Incentive Plan&#8221;) the Company may grant incentive stock options,
non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares and performance
units to employees, directors and consultants of the Company and its affiliates. Up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zdEM1dYGNhme"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">94,696</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock may
be issued pursuant to the 2017 Stock Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zvaRrnXhdGQc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,801</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_znoEYg8NibZf"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_custom_TwentySeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share under the 2017 Stock Incentive Plan,
and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zHE8y5SE6v5e"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-12-31_custom_TwentySeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,895</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remains available for issuance. At each of December
31, 2021 and December 31, 2020, there were options outstanding to acquire <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_znjshPQAssE1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_TwentySeventeenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,801</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. As of December 31, 2021,
all such options were fully vested, and the weighted average remaining contractual life for such options was approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_z2jdOJIDXOH5"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.2</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company authorized a new plan (the &#8220;2019 Stock Incentive Plan&#8221;). The Company initially reserved <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20190731__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zqYMa2qnZeQc"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2019-07-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,090</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock for issuance pursuant
to the 2019 Stock Incentive Plan in the form of incentive stock options, non-statutory stock options, rights to purchase common stock,
stock appreciation rights, restricted stock, restricted stock, performance shares and performance units to employees, directors and consultants
of the Company and its affiliates. On August 30, 2019, the Company approved an increase in the number of shares authorized for issuance
under the 2019 Stock Incentive Plan by <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20190830__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zLvd9NLF5x3"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-08-30_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,575,757</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. In January 2021, the Company approved
an increase in the number of shares reserved for issuance under the 2019 Stock Incentive Plan by <span id="xdx_90A_ecustom--IncreaseInSharesReservedForIssuance_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zArxo3wKzs51"><ix:nonFraction name="HILS:IncreaseInSharesReservedForIssuance" contextRef="From2021-01-012021-01-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">574,494</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. On May 31, 2021, the Company approved
an increase in the number of shares reserved for issuance under the 2019 Stock Incentive Plan by <span id="xdx_903_ecustom--IncreaseInSharesReservedForIssuance_c20210530__20210531__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zQGR911sCzjl"><ix:nonFraction name="HILS:IncreaseInSharesReservedForIssuance" contextRef="From2021-05-302021-05-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">467,171</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. At December 31, 2021, a total of <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zGmEZCrWtzPj"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,901,512</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares are authorized for issuance under the
2019 Stock Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zmm3APy8aVTe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,420,514</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock under the 2019 Stock Incentive
Plan, and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_z3bIFo3nFVKj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,480,998</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remain available for issuance at December 31,
2021. The shares issued in 2021 and 2020 and the shares exercised under the 2019 Stock Incentive Plan are included in the table below.
At December 31, 2021, there are stock options outstanding to acquire <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zlHstcuMKTj9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">810,667</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock with a weighted average
exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zwQqbZqgzGe6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.25</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and a weighted average contractual term of
<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_z59Ng475YWv2"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_TwentyNineteenStockIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.0</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRhHmeJC28O6" style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock-based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plans:</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B8_zbPkbuGy2Qz4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares
    Underlying Options</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Contractual Terms</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zt0KoJSNCQgc" title="Shares underlying option, Beginning outstanding" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,368</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td title="Weigthed average exercise price, Beginning outstanding" style="font-family: Times New Roman, Times, Serif; text-align: right"><p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zimBABLIc9fk" title="Weigthed average exercise price, Beginning outstanding" style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.22</ix:nonFraction></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zwoz5GUagsU6" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31" format="ixt-sec:duryear" name="HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">9.4</ix:nonNumeric>
                                            </span><span style="font-family: Times New Roman, Times, Serif">years</span></p></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zv2M8zFnOhf5" title="Shares underlying options, granted" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,363</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zQjRr0BLErx1" title="Weigthed average exercise price, granted" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231_zYuJ5qaWucg1" title="Shares underlying options, exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zrL51YMdtIXg" title="Weigthed average exercise price, exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zOren017Gxkj" title="Shares underlying options, Forfeited" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zst98Ghis4ua" title="Weigthed average exercise price, forfeited" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zBY93IYXwno5" title="Shares underlying option, Beginning outstanding" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,731</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z8HbLzbL0Djc" title="Weigthed average exercise price, Beginning outstanding" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.09</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zdkrYd6IC2x7" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">8.8</ix:nonNumeric>
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zJOEI931jEkh" title="Shares underlying options, granted" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">227,737</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zQ275cLdXXA5" title="Weigthed average exercise price, granted" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.76</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zG4ZYX03eV6f" title="Shares underlying options, exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zpBJOxGQSkE" title="Weigthed average exercise price, exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zsxrfJHqrUva" title="Shares underlying options, Forfeited" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zdrVuE6N0udh" title="Weigthed average exercise price, forfeited" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211231_zV5uAkbonhTi" title="Shares underlyling options, Ending outstanding" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">903,468</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zGYvvYlF9OAe" title="Weigthed average exercise price, Ending outstanding" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.27</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zKV1bmLvYbZ6" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.9</ix:nonNumeric>
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercisable options
    at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zY35yC0Ic5qj" title="Shares underlyling options, exercisable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">580,642</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_z9ev5DhHfNVe" title="Weigthed average exercise price, exercisable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.98</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zUBC61X72ZW9" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.0</ix:nonNumeric>
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested
    and expected to vest at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20210101__20211231_z0eq8bXZ0b19" title="Shares underlying options, Vested and expected to vest" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">658,206</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zNXu29RX17Od" title="Weighted average exercise price, Vested and expected to vest" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.72</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zDVeHkpfePx8" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">8.5</ix:nonNumeric>
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zDLxtQVcLJLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWRnD8SbEGJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the exercise price range as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BB_zHWGln1bDQO7" style="display: none">SCHEDULE
OF EXERCISE PRICE RANGE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    Options</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    Options</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 30%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zxnKEf4W7fJe" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zcK5fXh2slzf" title="Outstanding options" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">275,564</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z2DK62VPO32f" title="Exercisable options" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,261</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztGMpnIuSQ6i" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zv0bXkbDTp8f" title="Outstanding options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,212</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zNBZ8OLR2pc7" title="Exercisable options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,133</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zKhCjvufukN4" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.64</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpq3FaRZpHx7" title="Outstanding options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,004</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z4yFGvoQuKLk" title="Exercisable options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,564</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvqXSGzY4c44" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.82</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbFL9eEbb0Ol" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,857</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbq950e6zzWd" title="Exercisable options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,857</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFhXEtA9oKgi" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.28</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7Jq2SSi5t0f" title="Outstanding options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,294</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zjPM2tl2Ywug" title="Exercisable options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,044</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zwHn54hmVib9" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.03</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zOFCsqeJJu48" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,940</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zMU4sQD5X3i" title="Exercisable options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,940</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zCtH7Cbtci8l" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.82</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNsPRtWpxEue" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">208,797</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zpBIwQtFmK0h" title="Exercisable options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">204,180</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zkaZYIilIGE8" style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="AsOf2021-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z4xYzaiKcd1c" title="Outstanding options" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,800</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zl6yRB7oGYbk" title="Exercisable options" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,663</ix:nonFraction></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zmvecubytDKf" title="Outstanding Options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">903,468</ix:nonFraction></b></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231_zy5cKzru8eoh" title="Exercisable Options" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">580,642</ix:nonFraction></b></span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zE3dgHWJ6r7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 2.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair
value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between
immediate vesting and 4 years). The determination of fair value using the Black-Scholes model is affected by the Company&#8217;s share
price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest
rate and forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z0IraCnnogNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options granted during the years ended December 31, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following
weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zUrldP9f5w04" style="display: none">SCHEDULE
OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zOKtmoStbdRj" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20200101__20201231_zu3Jp9fIRkIe" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_z1LGsY4hik89" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">111.3</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">83.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zD54fN8bZZdk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">0.6</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">0.7</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zqIk53Io5Ged" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">-</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">-</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    life of options in years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z0K5NqXvCBO8" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zT5IwxgHC6Zh" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iE_zY76PXAn9MV2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Estimated
    fair value of common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.03</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.455</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z8ZcjmwcuoUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of stock options granted during the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z863K5uimEQ5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.48</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231_z5tJTbyNRXa9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. The weighted average fair value of stock options vested in the years ended December 2021 and 2020 was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20211231_zYajcUjINj7j"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.47</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20200101__20201231_zNfHwqwRTDG5"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31" format="ixt:numunitdecimalin" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction>,
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation expense was approximately $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_z09NnwKYnhSb"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,239,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXzBl3lXIWQ4"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">531,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in research and development expense
and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zu8KO2uGElcb"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">708,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in general and administrative expenses)
and approximately $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_zWFeytRFQp55"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUdAJ4QTcDd7"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in research and development expense
and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zX0yeBUIu1C6"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in general and administrative expenses)
for the years ended December 2021 and 2020, respectively, and is included in the accompanying consolidated statements of operations.
At December 31, 2021, the total unrecognized compensation expense related to non-vested options was approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20211231_zcI5PYj9Mhf2"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and is expected to be recognized over the remaining
weighted average service period of approximately <span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNvR1C7XBFc2"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2">0.5</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the above table are stock options granted in 2019 to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrYdSyJe9qNk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">231,058</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMuxpAkd4WQl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.079</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and stock options granted in 2020 to
purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6SAsQBwQvv7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,204</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuczbZ8UKc2g"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.28</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, which vest upon a specified performance
condition. Since the occurrence of this condition was not considered probable as of December 31, 2021 and 2020, the Company has not recognized
any expense for such grants through December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20210301__20210331_zdi24GgJnzld"><ix:nonNumeric contextRef="From2021-03-012021-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">the
Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price of such stock options
from $0.18 or $2.598 to $0.314 or $3.817 per share, respectively.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in the stock option exercise price was accounted for as a modification of the stock grant in 2021; however, the impact
on the Company&#8217;s consolidated statements of operations was immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFfSOxakTXpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
7 &#8211; Stockholders&#8217; deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_827_zJbmClDOHzQb" style="display: none">STOCKHOLDERS&#8217;
DEFICIT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an amendment to the Company&#8217;s Certificate of Incorporation filed in April 2019, the Company increased the number of authorized
shares of common stock to <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20211231_zXTAJTxg2D7e"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">250</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million shares. See Note 2 for a discussion of the reverse
stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHkITzQWMfHi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,757</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for the Farrington acquisition
transaction described in Note 3.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zcaNUQypWNXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
8 &#8211; income taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_82A_zHboNnM8Ggl4" style="display: none">INCOME
TAXES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have any significant current income taxes due because of the losses generated in each period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets relate primarily to its net operating
loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance
to fully offset the gross deferred tax asset because it is not more likely than not that the Company will realize future benefits associated
with these deferred tax assets at December 31, 2021 and 2020. The valuation allowance increased by approximately $<span id="xdx_904_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zlryWvRdoHPl"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">652,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zD3x2MKiIE3g"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">589,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOQumCcKequj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&#8217;s deferred tax assets at December 31, 2021 and 2020 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zEwTtXBHJNEb" style="display: none">SCHEDULE
OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20211231_z0Jryg3Jzkqi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zPSrRuCLFgei" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax assets:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_maDTAGzm4g_z88JdmmLa9T9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    net operating loss carryforward</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">702,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzm4g_zlAyQ15FI4Aa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    net operating loss carryforward</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">238,000</ix:nonFraction></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_iI_maDTAGzm4g_z9ioebGue6Ze" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Capitalized
    costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--AcquiredInprocessResearchAndDevelopment_iI_maDTAGzm4g_zn7zQQnHKLK" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Acquired
    In-process research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:AcquiredInprocessResearchAndDevelopment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:AcquiredInprocessResearchAndDevelopment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzm4g_zBZzUlOeN0S8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development credit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzm4g_z7ncOSJFlzEj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther_iI_maDTAGzm4g_zEUB5dvgWEc2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses and other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">)</span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzj39_mtDTAGzm4g_zBO8AR2aqLM4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,175,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzj39_zy2amT6qXc5e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,175,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzj39_msDTLzhRs_zv8TypsLERne" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax asset, net of valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zb5KwMmE47Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
income tax benefit for the years ended December 31, 2021 and 2020 differ from the amounts computed by applying the U.S. Federal income
tax rate of <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPercent_c20200101__20201231_zI3ak3ijABJ"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">21</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">%
to loss before income tax benefit as a result of non-deductible expenses, tax credits generated and increases in the Company&#8217;s
valuation allowance.</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zOm1cbaALyFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxF3hxINXQBg" style="display: none">SCHEDULE
OF EFFECTIVE INCOME TAX EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z1i9eA68bINg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20200101__20201231_zdkQ9I67Bpde" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzMie_zxOQ71uemCD5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax benefit at the federal statutory rate</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">463,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">508,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_ecustom--IncomeTaxReconciliationPermanentDifferencesAndOther_maITEBzMie_zjHsSBSgbnJ3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Permanent
    differences and other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HILS:IncomeTaxReconciliationPermanentDifferencesAndOther" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">61,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HILS:IncomeTaxReconciliationPermanentDifferencesAndOther" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzMie_zwve8BbcKm94" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    income taxes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">118,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">167,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzMie_zoopKL53uTtg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development credit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzMie_zqwZAnzJwZdd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0640">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzMie_zFnRmSIrvHkd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">652,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">589,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzMie_zZUCrr7C3JVe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective
    income tax expense</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zUEuN488LgB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely
than not that some portion or all of the deferred tax assets will not be realized. After consideration of the available evidence, both
positive and negative, the Company determined that valuation allowances of $<span id="xdx_902_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pp0p0_c20211231_zWPKO4NOy45a"><ix:nonFraction name="us-gaap:OperatingLossCarryforwardsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,827,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif">million and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pp0p0_c20201231_zv8ugyTBC9O8"><ix:nonFraction name="us-gaap:OperatingLossCarryforwardsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,175,000</ix:nonFraction>
</span>at December 31, 2021 and 2020, respectively, were necessary to reduce the deferred tax assets to the amount that
will more likely than not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company had available net operating loss carryforwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zleqs09q4Rxa"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for federal income tax purposes,
all of which was generated after 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act. At December 31, 2021,
the Company had approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmMxYoSLSnh1"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction>
thousand </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of federal research and development
(&#8220;R&amp;D&#8221;) tax credit carryforwards. If not utilized, the federal R&amp;D credits will begin to expire in 2038. The Company
also had $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ztQS9YL1xywd"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of state net operating losses
that will begin to expire in 2037.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available
to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of
significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the
NOL carryforwards that the Company may utilize in any one year may be limited. Although the Company has not undertaken a formal analysis,
it is likely that such an ownership change occurred during 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;). The CARES
Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund
a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19
pandemic, some of the more significant provisions which are expected to impact the Company&#8217;s financial statements include removal
of certain limitations on utilization of NOLs, increasing the loss carryback period for certain losses to five years, and increasing
the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company
has concluded that the CARES Act did not have a material impact on its financial position, results of operations, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended many of the benefits of the CARES Act
that were scheduled to expire. The Company evaluated the impact of the Consolidated Appropriations Act on its consolidated financial
statements and related disclosures and concluded that the impact is immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zitDLyq6PAhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
9 - Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_821_zdrTY9GucNo6" style="display: none">RELATED
PARTY TRANSACTIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 4, the Company entered into the Notes with the Holders commencing in May 2017. The Holders of substantially all of
the Notes are the Company&#8217;s founder and Chief Executive Officer, a member of the Company&#8217;s board of directors
and third parties that are family members of the founder and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above Notes, the Company has amounts due to the founder and Chief Executive Officer that totaled $<span id="xdx_90E_eus-gaap--DueToRelatedPartiesCurrent_iI_c20201231__srt--TitleOfIndividualAxis__custom--FounderAndChiefExecutiveOfficerMember_zfHIvR5ccsSf"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2020-12-31_custom_FounderAndChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2021 and December 31, 2020 for
accrued compensation. See Note 10. There are no established terms for repayment of such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, expenses paid on behalf of the Company by the Chief Executive Officer of $<span id="xdx_90F_ecustom--DueToFounderConvertedToNotePayable_c20200101__20201231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zlmeP3Xz3OGi"><ix:nonFraction name="HILS:DueToFounderConvertedToNotePayable" contextRef="From2020-01-012020-12-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,068</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were converted into a convertible promissory
note and is included in convertible notes-related parties on the accompanying balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhbCufOFXMcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
10 - Commitments And Contingencies</b></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82A_zYb2cd1SA5ih" style="display: none">COMMITMENTS
AND CONTINGENCIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Small
molecule analogues</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2019, <span id="xdx_90D_ecustom--AssetAcquisitionDescription_c20191229__20191230__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z1Vh1b6oFsde"><ix:nonNumeric contextRef="From2019-12-292019-12-30_custom_AssetPurchaseAgreementMember" name="HILS:AssetAcquisitionDescription">the
Company acquired a series of small molecule analogues pursuant to an asset purchase agreement (&#8220;APA&#8221;). Pursuant to the APA,
the Company is required to make a payment of $50,000 upon raising of at least $2 million in funding, and up to $1.75 million based
upon successfully meeting clinical and sales milestones.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, such fund-raising requirement was not met and <span id="xdx_900_eus-gaap--PaymentsToAcquireProductiveAssets_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zySSmG4KCFHi"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2021-01-012021-12-31_custom_AssetPurchaseAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments were made pursuant to the APA. The Company
included, in accounts payable at December 31, 2021 and December 31, 2020, the $<span id="xdx_907_ecustom--MilestonePayment_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zx6vF2uKJ0ui"><ix:nonFraction name="HILS:MilestonePayment" contextRef="From2021-01-012021-12-31_custom_AssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required initial payment. Milestone based payments,
if any, will be expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, the Company entered into a three-year employment agreement with its Chief Executive Officer which provides a specified
base salary and bonus. The employment agreement also provides the Chief Executive Officer with certain benefits while employed and if
employment ceases. The Company accrued $<span id="xdx_909_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20190131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zT2VTMXmlbyf"><ix:nonFraction name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextRef="AsOf2019-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in 2019 related to the Chief Executive Officer&#8217;s
base salary as per the employment agreement, which is included in due to founder, which remains outstanding as of December 31, 2021.
<span id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_do_c20190131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zovAXAt473k2"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2019-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No
</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">bonus was approved by the board of directors
of the Company for any period through December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, the Company amended the employment agreement pursuant to which, in lieu of a cash base salary, the Chief Executive Officer
will be compensated with stock options to purchase <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20200101__20200131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zAH7FHnvkFRc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2020-01-012020-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,575</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock per month (at an exercise
price based upon the most recent 409A valuation) effective January 1, 2020 until the Company receives a minimum of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200101__20200131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zco2AaCZxc45"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-01-012020-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of gross proceeds from the sale of the Company&#8217;s
securities, after which time, cash compensation, pursuant to the employment agreement, shall be paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company amended the employment agreement with its Chief Executive Officer to provide a revised base salary pre-funding
(as defined in the employment agreement). In lieu of cash base salary, the Chief Executive Officer will be compensated with stock options
to purchase <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zn3xPOMTOj4b"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,939</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock per
month (an exercise price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zQj1hTgXH8t1"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.82</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share) effective January 1, 2021 until
funding meets or exceeds $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zO84LhYvY4Kh"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
after which time, cash compensation, pursuant to his employment agreement, shall be paid. The amended employment agreement also provides
for a future base salary for the Chief Executive Officer after the Company receives funding greater than $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember__srt--RangeAxis__srt--MinimumMember_zHw7NMfA4gdd"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or completes an initial public offering or similar
transaction as set forth in the employment agreement. In addition, if the Chief Executive Officer acts as the &#8220;finder&#8221; of
an investor who purchases more than $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zR6IIfuiZTi5"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Company&#8217;s equity, he will receive
a grant of stock options to acquire <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zXE4uegW6xjk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">757,575</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the Company at an exercise
price equal to the most recent fair value of the Company&#8217;s common stock. This grant has not been earned as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2021, the Company entered into an Amended and Restated Employment Agreement, as amended on September 24, 2021 (the &#8220;Amended
and Restated Employment Agreement&#8221;) with the Company&#8217;s President and Chief Executive Officer. The term of the Amended and
Restated Employment Agreement will commence upon the closing of the Company&#8217;s initial public offering of its securities and continues
for a period of five years and automatically renews for successive one-year periods at the end of each term unless either party provides
written notice of their intent not to review at least 60 days prior to the expiration of the then effective term. Pursuant to the Amended
and Restated Employment Agreement, the Chief Executive Officer will receive an annual base salary of $<span id="xdx_90A_eus-gaap--ProfessionalFees_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zoU5l0YEY2hg"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which may be increased from time to time, and shall be eligible to receive an annual cash bonus equal to <span id="xdx_902_ecustom--CashBonusReceived_pid_dp_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zMO7eE8ttlra"><ix:nonFraction name="HILS:CashBonusReceived" contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">55</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of his then base salary based upon the achievement of Company and individual performance targets established by the Company&#8217;s board
of directors. In addition, in the first year in which the Company&#8217;s market capitalization (as defined in the Amended and Restated
Employment Agreement) equals or exceeds <span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zclUTdxdNscg"><ix:nonNumeric contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember" name="us-gaap:OtherCommitmentsDescription">(i)
$250 million, the Chief Executive Officer shall receive a cash payment of $150,000; (ii) $500 million, the Chief Executive Officer shall
receive a cash payment of $350,000; and (iii) $1 billion, the Chief Executive Officer shall receive a cash payment of $750,000. Furthermore,
on or as soon as reasonably practicable following the date of the consummation the Company&#8217;s initial public offering of its securities,
the Chief Executive Officer shall be granted</ix:nonNumeric> </span></span><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_znE1KMfugung" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">757,575</ix:nonFraction>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock at the public
offering price per share of common stock sold in the Company&#8217;s initial public offering of its securities which shall vest over
a 48-month period commencing 12 months after the date of grant. This shall be in addition to any additional equity-based compensation
awards the Company may grant the Chief Executive Officer from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zxnshU3mULmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
11 - Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_828_z3UA3i93gtGl" style="display: none">SUBSEQUENT
EVENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IPO</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, the Company closed its IPO pursuant to which it issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zm5VGJCTRnkj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock at
a public offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEMn6XuFoNv6"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The gross proceeds to the Company
from the IPO were $<span id="xdx_903_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuNRpsy91LU2"><ix:nonFraction name="HILS:GrossProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
prior to deducting underwriting discounts, commissions, and other offering expenses. The net proceeds to the Company from the IPO
were $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zYEca8EBd0U5"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company granted the underwriters
a 45-day option to purchase up to an additional <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5YMQKOYR378"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">562,500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at the public offering
price less discounts and commissions, to cover over-allotments; however, this option expired unexercised. Additionally, and as
a result of the completion of the IPO, all of the Company&#8217;s convertible debt and accrued interest was converted into an
aggregate of <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2rY5psnE233"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,225,384</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
pursuant to the terms of the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
    payable</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2022 and January 6, 2022, the Company issued unsecured promissory notes in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_z7TQBvdWmQwe"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,887</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(including an original issuance discount of an
aggregate of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zQBo5FjC6Fd"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,887</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
to three related-party investors. The notes accrue interest at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPercent_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zoY7yiwUhzK1"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">12</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum and mature upon the earlier of (i) June 30, 2022, and (ii) the closing of a Subsequent Equity Financing. &#8220;Subsequent
Equity Financing&#8221; means the next sale (or series of related sales) by the Company of its Equity Securities following the date of
the notes pursuant to which the Company receives gross proceeds of not less than $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220103__20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNotesPayableMember_zogLiozg9fhh"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-032022-01-06_us-gaap_SubsequentEventMember_custom_PromissoryNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The notes were repaid in full on January 21, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Stock option grant</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, the Company granted its Chief Executive Officer a stock option to purchase up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zPkInq2ODlz6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">757,575</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
at an exercise price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_znQ75AquruYl"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share in accordance with his employment
agreement. See Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2022, the Company granted options to purchase up to an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220320__20220321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardMember_zeLNYsvtKHgl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-03-202022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">247,500</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
at an exercise price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardMember_zzz4w6DxM0k"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to the independent members of
the Company&#8217;s board of directors and members of the Company&#8217;s Scientific Advisory Board.</span></p>

</ix:nonNumeric><p id="xdx_813_zmqe8yOF4yf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_014"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="c_015"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive officer and principal financial officer evaluated the effectiveness of our &#8220;disclosure controls and procedures&#8221;
as of December 31, 2021, the end of the period covered by this Annual Report on Form 10-K. The term &#8220;disclosure controls and procedures&#8221;
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed
to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports
that it files under the Exchange Act is accumulated and communicated to a company&#8217;s management, including its principal executive
officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating
the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated,
cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our
disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that,
as of such date, our disclosure controls and procedures were not effective due to a material weakness with respect to the lack
of <span style="background-color: white">control(s)</span> to review the completeness and accuracy of contracts with a financial reporting
implication and the timely communication of the terms and conditions to the financial reporting function.&#160; Effective internal control
contemplates an appropriate level of review to ensure timely preparation and completeness and accuracy of the financial statements and
disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined
in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation
of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with
U.S. GAAP. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined
to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, under the supervision and with the participation of our management, including our principal executive officer and
principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on
the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework - 2013. Based on this assessment,
our management concluded that, as of December 31, 2021, our internal control over financial reporting was not effective due to
a material weakness in our internal controls with respect to the lack of <span style="background-color: white">control(s)</span> to
review the completeness and accuracy of contracts with a financial reporting implication and the timely communication of the terms and
conditions to the financial reporting function.&#160; Effective internal control contemplates an appropriate level of review to ensure
timely preparation and completeness and accuracy of the financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first half of 2021, vendor invoices were controlled by our Chief Executive Officer who was responsible for the approval and payment
of invoices. Beginning the second half of 2021, invoices were reviewed by our Chief Financial Officer prior to payment. Our Chief Executive
Officer controls the release of our payments based on knowledge of the vendor&#8217;s progress and a cash management review with our
Chief Financial Officer. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the material weakness, we performed additional analysis and other post-closing procedures to ensure the reliability of financial
reporting and that our financial statements were prepared in accordance with U.S. GAAP. Accordingly, we believe that the financial statements
included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the
periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Remediation
Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
intend to remediate the material weakness by hiring qualified personnel to address adequate controls over the review of the completeness
and accuracy of contracts.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 119; Options: NewSection; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding
internal control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s registered
public accounting firm pursuant to the exemption provided to issuers that are not &#8220;large accelerated filers&#8221; nor &#8220;accelerated
filers&#8221; under the Dodd-Frank Wall Street Reform and Consumer Protection Act as well as issuers that are &#8220;emerging growth
companies&#8221; under the JOBS Act.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_016"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="c_017"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="c_018"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="c_019"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name, age and positions of our executive officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Hess</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard
    Mazur</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynne
    A. Bui, MD</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
    Appajosyula</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business background and certain other information about our directors and executive officers is set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Randy
Milby</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
Milby has served as our Chief Executive Officer and Chairman of our board of directors since inception in 2017. Mr. Milby is an experienced
biopharmaceutical executive and served as the Chief Executive Officer and member of the board of directors at CorMedix Inc., a biopharmaceutical
company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious
diseases, from May 2012 to December 2012 and from January 2013 until September 2016, respectively. Mr. Milby has served in various other
positions including, but not limited to, Global Business Director &#8211; BioMedical and Global Business Director &#8211; Applied BioSciences
of DuPont de Nemours, Inc.; Global Marketing Director of DuPont Crop Protection; Securities Analyst, Investment Research, Biotechnology
of Goldman Sachs; and Senior Director of DuPont Merck Pharmaceuticals. Mr. Milby received his BS in pharmacy from The University of Kansas
and his MBA in finance/marketing from Washington University in St. Louis &#8211; Olin Business School. We believe Mr. Milby is qualified
to serve as a member of our board of directors because of his extensive experience in the biotechnology industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Thomas
Hess</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
Hess has served as our Chief Financial Officer since June 2021. In addition, since June 2021, Mr. Hess has served as a consulting
Chief Financial Officer through Danforth Advisors and TH Advisors for various biotechnology companies. From August 2014 until June 2021,
Mr. Hess served as Chief Financial Officer and Senior Vice President of Finance of Genomind, Inc, a pharmacogenetics company focused
on mental health. From September 2011 until its sale in April 2014, Mr. Hess served as Chief Financial Officer and Executive Vice President
of Finance of The Keane Organization, a comprehensive provider of unclaimed property services. Mr. Hess also previously served in various
other capacities including, but not limited to, Chief Financial Officer and Senior Vice President of Yaupon Therapeutics, Inc.; Chief
Financial Officer and Vice President, Finance of Adolor Corporation; Corporate Controller of Vicuron Pharmaceuticals, Inc.; and Senior
Manager &#8211; Accounting and Audit of KPMG. Mr. Hess received his B.S. in accounting from The Pennsylvania State University and his
MBA from Katz Graduate School of Business, University of Pittsburgh. He is a Certified Public Accountant in the state of Pennsylvania
and serves on the Board of Directors of Life Sciences Pennsylvania as the audit committee chair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 120; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leonard
Mazur</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard
Mazur has served as a member of our board of directors since July 2021. In addition, since September 2014, Mr. Mazur has served as Executive
Chairman of the board of directors and Secretary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) (&#8220;Citius&#8221;). Mr. Mazur also
serves as the Secretary of Citius&#8217; majority-owned subsidiary, NoveCite, Inc. Mr. Mazur is the co-founder and Vice Chairman of Akrimax
Pharmaceuticals, LLC (&#8220;Akrimax&#8221;), a privately held pharmaceutical company specializing in producing cardiovascular and general
pharmaceutical products. Akrimax was founded in September 2008 and has successfully launched prescription drugs while acquiring drugs
from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur co-founded and served as the Chief Operating Officer of
Triax Pharmaceuticals LLC (&#8220;Triax&#8221;), a specialty pharmaceutical company producing prescription dermatological drugs. Prior
to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. (&#8220;Genesis&#8221;),
a dermatological products company that marketed its products through dermatologists&#8217; offices as well as co-promoting products for
major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur
has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation as Executive
Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales and Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories,
Inc. Mr. Mazur is a member of the Board of Trustees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previously
the chairman of the board of directors of LMB, Citius&#8217; wholly-owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from
Temple University and has served in the U.S. Marine Corps Reserves. We believe Mr. Mazur is qualified to serve as a member of our board
of directors because of his extensive experience in the biotechnology industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lynne
A. Bui, MD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynne
Bui has served as a member of our board of directors since July 2021. In addition, since June 2017, she has served as President, Chief
Executive Officer and a member of the board of directors of Khloris Biosciences, Inc., a biotechnology company dedicated to revolutionizing
medical treatment and prevention of cancer and other diseases. Dr. Bui is a board-certified hematologist oncologist, seasoned entrepreneur,
angel investor and drug developer, having unparalleled experience in basic, translational and clinical research spanning over 15 years
with direct patient care and leading clinical development programs from preclinical IND enabling studies to Phase 1 to 3 registration
studies for multiple approved drugs, including cabozantinib, carfilzomib and enzalutamide. In addition, she has held senior level positions
at Exelixis, Inc., Onyx Pharmaceuticals (acquired by Amgen Inc.) and Intellikine, Inc. (acquired by Millennium/Takeda in 2012) and has
served as Chief Medical Officer and clinical development lead for multiple biotechnology and pharmaceutical companies. She has experience
with small molecules, antibodies, dendritic cell vaccines, gene therapies, embryonic stem cells, and cell therapies. As a clinician,
Dr. Bui has previously been clinical attending at Stanford Hospital and UCLA Medical Center, and is the Founder and Chairman of Global
Cancer Research Institute (&#8220;GCRI&#8221;), a community-based hematology/oncology clinical practice and clinical trial site. She
is also the Founder and Chairman of GCRI Foundation, a non-profit organization dedicated to funding clinical research in cancer; and
a former Fellow of the Leukemia &amp; Lymphoma Society, Lymphoma Research Foundation and Howard Hughes Medical Institute. Dr. Bui received
her B.A. in molecular and cell biology, with an emphasis in neurobiology from University of California, Berkeley and her M.D. from the
David Geffen UCLA School of Medicine. We believe Dr. Bui is qualified to serve as a member of our board of directors because of her extensive
clinical and industry experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sireesh
Appajosyula</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
Appajosyula has served as a member of our board of directors since July 2021. Since April 2020, he has served as SVP, Corporate Development
and Operations of 9 Meters Biopharma, Inc. (Nasdaq: NMTR) (&#8220;9 Meters&#8221;), a company focused on rare and unmet needs in gastrointestinal
patient populations developing compounds with unique gastrointestinal biology, and since 2018 he has served as Managing Member of Highpoint
Pharmaceuticals, LLC, a pharmaceutical research and development company. In addition, since 2015, Mr. Appajosyula has served as Managing
Partner of Channel BioConsulting, LLC, a company that assists in enhancing search and evaluation efforts for complementary assets to
be added to existing portfolios of biopharmaceutical companies. Prior to joining 9 Meters, Mr. Appajosyula spent approximately 8 years
at Salix Pharmaceuticals, Inc. (&#8220;Salix&#8221;) (Nasdaq: SLXP) in various roles in medical affairs, product commercialization and
business development until its acquisition by Bausch Health (Nasdaq: BHC). Prior to Salix, he was involved in various roles at Amgen
Inc., Critical Therapeutics, Inc. and Sanofi (formerly Aventis). Mr. Appajosyula received his Bachelor of Science and Doctor of Pharmacy
from Rutgers University. We believe Mr. Appajosyula is qualified to serve as a member of our board of directors because of his extensive
experience in the biotechnology industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers or directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arrangements
between Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth in this Annual Report on Form 10-K, to our knowledge, there is no arrangement or understanding between any of our officers
or directors and any other person pursuant to which such officer or director was selected to serve as an officer or director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any of our directors or officers being involved in any legal proceedings in the past ten years relating to any matters
in bankruptcy, insolvency, criminal proceedings (other than traffic and other minor offenses), or being subject to any of the items set
forth under Item 401(f) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors directs the management of our business and affairs, as provided by Delaware law, and conducts its business through
meetings of the board of directors and its standing committees. We have a standing audit committee, compensation committee and nominating
and corporate governance committee. In addition, from time to time, special committees may be established under the direction of the
board of directors when necessary to address specific issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    and retaining the independent auditors to conduct the annual audit of our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the proposed scope and results of the audit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and pre-approving audit and non-audit fees and services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    accounting and financial controls with the independent auditors and our financial and accounting staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving transactions between us and our directors, officers and affiliates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for complaints received by us regarding accounting matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    internal audit functions, if any; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the audit committee that the rules of the SEC require to be included in our annual meeting proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee consists of Lynne Bui and Leonard Mazur with Leonard Mazur serving as chair. As permitted under the applicable rules
and regulations of the SEC and Nasdaq, we intend to phase in compliance with the audit committee composition requirements prior to the
end of the one-year transition period. Our board of directors has affirmatively determined that Lynne Bui and Leonard Mazur each meet
the definition of &#8220;independent director&#8221; under Nasdaq rules, and that they meet the independence standards under Rule 10A-3.
Each member of our audit committee meets the financial literacy requirements of Nasdaq. In addition, our board of directors has determined
that Leonard Mazur qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation
S-K. Our board of directors has adopted a written charter for the audit committee which is available on our website at <i>www.hillstreambio.com</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending the compensation arrangements for management, including the compensation for our chief executive officer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and reviewing general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our stock incentive plans; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the report of the compensation committee that the rules of the SEC require to be included in our annual meeting proxy statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee consists of Lynne Bui and Leonard Mazur with Lynne Bui serving as chair. Our board has determined that Lynne Bui
and Leonard Mazur are each independent directors under Nasdaq rules. Our board of directors has adopted a written charter for the compensation
committee which is available on our website at <i>www.hillstreambio.com</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and governance committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nominating
    members of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    a set of corporate governance principles applicable to our Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our board of directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee consists of Lynne Bui and Sireesh Appajosyula with Sireesh Appajosyula serving as chair.
Our board has determined that Lynne Bui and Sireesh Appajosyula are each independent directors under Nasdaq rules. Our board of directors
has adopted a written charter for the nominating and governance committee which is available on our website at <i>www.hillstreambio.com</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are supported by members of our Scientific Advisory Board who provide advice and guidance in their respective fields of expertise from
pre-clinical to clinical development. Our Scientific Advisory Board is currently composed of the following members who receive compensation
in a combination of cash and options to purchase shares of our common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
Kufe, MD &#8211; Chair of the Scientific Advisory Board; Dana-Farber Cancer Institute/Harvard University</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwok-Kin
Wong, MD, PhD &#8211; New York University School of Medicine</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Richardson, MD &#8211; Dana-Farber Cancer Institute/Harvard University</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surender
Kharbanda, PhD - Dana-Farber Cancer Institute</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
Paul Eder, MD &#8211; Yale University/Yale Cancer Center</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Weaver, PhD &#8211; FemtoDx</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
Stone, MD &#8211; Dana-Farber Cancer Institute</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
Rayner, PhD &#8211; University of South Alabama</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
Dixon, PhD &#8211; Stanford University</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harpal
Singh, PhD &#8211; Indian Institute of Technology Delhi</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.
A copy of the code is filed as an exhibit to this Annual Report on Form 10-K and is posted on our website, <i>www.hillstreambio.com</i>.
We intend to post on our website all disclosures that are required by law or Nasdaq rules concerning any amendments to, or waivers from,
any provision of the code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Nominating Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_020"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the compensation awarded to, earned by or paid to our principal executive officer, who we also refer to as our
&#8220;named executive officer&#8221;, for the year ended December 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name
    and Principal Position</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(2)</sup></b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Randy
    Milby, President and</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">973,401</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">973,401</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Chief
    Executive Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193,627</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">193,627</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    fiscal year 2021, in lieu of base salary, Mr. Milby was compensated with stock options to purchase 18,939 shares of common stock
    per month through May 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the aggregate grant date fair value of stock options granted during the fiscal year calculated in accordance with FASB ASC Topic
    718. For a discussion of the assumptions made by us in determining the grant date fair value of our equity awards see Note 6 to our
    audited consolidated financial statements for the year ended December 31, 2021 included elsewhere in this Annual Report on Form 10-K.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    fiscal year 2020, in lieu of base salary, Mr. Milby was compensated with stock options to purchase 7,575 shares of common stock per
    month.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreement with Randy Milby</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2019, we entered into an employment agreement with Randy Milby, to serve as our President and Chief Executive Officer. Pursuant
to the employment agreement, Mr. Milby received an annual base salary of $200,000; provided, however, instead of base salary, Mr. Milby
was to receive 75,757 shares of our common stock per year until funding met or exceeded $2,000,000 after which cash compensation would
be paid. Mr. Milby was also eligible to receive an annual target bonus of up to 100% of the base salary, subject to achievements to be
mutually agreed upon by our board of directors and Mr. Milby. Mr. Milby was also entitled to receive an annual grant of stock or stock
options as determined by our board of directors, in its sole discretion, among other bonus payments based upon our capitalization. In
January 2020, we amended the employment agreement pursuant to which Mr. Milby was to receive stock options to purchase 7,575 shares of
common stock per month (at an exercise price based upon the most recent 409A valuation) effective January 1, 2020 until funding met or
exceeded $3,000,000, after which time, cash compensation of $200,000 per year would be paid. In addition, if Mr. Milby raised more than
$3,000,000, he would receive a grant of options to purchase up to 757,575 shares of our common stock at an exercise price of $4.88.
Effective January 1, 2021, we further amended the employment agreement such that in lieu of base salary, Mr. Milby would receive
stock options to purchase 18,939 shares of our common stock per month at an exercise price of $7.822 per share effective January 1, 2021
until funding meets or exceeds $5,000,000, after which time, cash compensation of $300,000 per year would be paid. The amendment also
provided for a base salary of $435,000 after we received funding greater than $5,000,000, or we completed an initial public offering
or similar transaction as set forth in the employment agreement. In addition, if Mr. Milby raised more than $5,000,000, he would receive
a grant of stock options to acquire 757,575 shares of our common stock with an exercise price based upon the most recent 409A valuation.
Subsequently, on January 20, 2021, we entered into a further amendment to the employment agreement pursuant to which Mr. Milby would
receive a base salary of $200,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2021, we entered into an Amended and Restated Employment Agreement, as amended on September 24, 2021 (the &#8220;Amended and
Restated Employment Agreement&#8221;), with Randy Milby pursuant to which Mr. Milby will continue to serve as our President and Chief
Executive Officer. The term of the Amended and Restated Employment Agreement commenced upon the closing of our initial public offering
and continues for a period of five years and automatically renews for successive one year periods at the end of each term unless either
party provides written notice of their intent not to review at least 60 days prior to the expiration of the then effective term. Pursuant
to the Amended and Restated Employment Agreement, Mr. Milby will receive an annual base salary of $485,000, which may be increased from
time to time, and shall be eligible to receive an annual cash bonus equal to 55% of his then base salary based upon the achievement of
Company and individual performance targets established by our board. In addition, in the first year in which our market capitalization
(as defined in the Amended and Restated Employment Agreement) equals or exceeds (i) $250 million, Mr. Milby shall receive a cash payment
of $150,000; (ii) $500 million, Mr. Milby shall receive a cash payment of $350,000; and (iii) $1 billion, Mr. Milby shall receive a cash
payment of $750,000. Furthermore, on January 14, 2022, Mr. Milby was granted an option to purchase 757,575 shares of our common stock
at an exercise price of $4.00 per share which shall vest over a 48 month period commencing 12 months after the date of grant. This shall
be in addition to any additional equity-based compensation awards we may grant Mr. Milby from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amended and Restated Employment Agreement, Mr. Milby&#8217;s employment may be terminated (i) by us for Cause (as defined in the
Amended and Restated Employment Agreement); (ii) upon Mr. Milby&#8217;s death; (iii) upon Mr. Milby&#8217;s Disability (as defined in
the Amended and Restated Employment Agreement); (iv) or by Mr. Milby for Good Reason (as defined in the Amended and Restated Employment
Agreement). In the event Mr. Milby&#8217;s employment is terminated, we shall pay Mr. Milby his then base salary through the last day
of his employment, the reimbursement of expenses incurred on or prior to the termination date and any earned but unpaid bonus (collectively,
the &#8220;Accrued Compensation&#8221;). In the event Mr. Milby&#8217;s employment is terminated as a result of his death or Disability,
we shall pay Mr. Milby (i) the Accrued Compensation, (ii) his then base salary through the date which is 90 days after his death or Disability
and (iii) such other or additional benefits as may be provided under our employee benefit plans, programs and arrangements (collectively,
the &#8220;Plans&#8221;). In addition, all shares of our capital stock that are subject to vesting and all stock options that are scheduled
to vest on or before the next succeeding anniversary of the effective date of the Amended and Restated Employment Agreement shall be
accelerated and deemed to have vested as of the termination date. All shares and options that have not vested as of the date of termination
shall be forfeited. Any stock options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60
months after the termination date and (ii) the expiration date of the option (all payments to be paid upon Mr. Milby&#8217;s death or
Disability are hereinafter referred to as the &#8220;Death and Disability Severance&#8221;). Any payments that shall be made to Mr. Milby
as a result of his Disability shall be contingent upon Mr. Milby executing a general release within 21 days of separation from service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event Mr. Milby&#8217;s employment is terminated for Cause, Mr. Milby shall receive (i) the Accrued Compensation and (ii) such other
and additional benefits, if any, as may be required pursuant to the Plans, and all shares that have not vested as of the termination
date shall be forfeited while all stock options that are vested as of the termination date shall remain exercisable for 90 days after
such termination (all payments to be paid upon termination of Mr. Milby&#8217;s termination for Cause are hereinafter referred to as
the &#8220;Cause Severance&#8221;). If Mr. Milby&#8217;s employment is terminated other than for death, Disability or Cause, including
if Mr. Milby&#8217;s employment is terminated for Good Reason, then, subject to the execution of a separation agreement within 60 days
from the separation of service, we shall pay Mr. Milby, (i) the Accrued Compensation, (ii) his then base salary and provide him with
health benefits for a period of 12 months following the effective date of his separation from service and (iii) provide such other or
additional benefits, if any, as may be provided under the Plans. Furthermore, all shares and stock options that have not vested as of
the termination date shall be forfeited, and any stock options that have vested as of the termination date shall remain exercisable until
the earlier of (i) 60 months following such termination and (ii) the termination date of such option (all payments to be paid upon Mr.
Milby&#8217;s termination other than for death, Disability or Cause, including Good Reason, are hereinafter referred to as the &#8220;Other
Severance&#8221; and together with the Death and Disability Severance and the Cause Severance, &#8220;Severance&#8221;). In the event
Mr. Milby&#8217;s employment is terminated either (i) by us without Cause at any time within 12 months prior to the consummation of a
Change of Control (as defined in the Amended and Restated Employment Agreement), (ii) by Mr. Milby for Good Reason at any time within
12 months after the consummation of a Change of Control or (iii) by us without Cause at any time upon or within 12 months after the consummation
of a Change of Control, then Mr. Milby shall (A) be entitled to the acceleration and vesting in full of any then outstanding and unvested
equity award, with options continuing to be exercisable for 60 months following termination (or, if earlier, their expiration date) and
(B) all Severance; provided, however, that such Severance amount shall equal two times the sum of Mr. Milby&#8217;s then base salary
and target bonus and the Severance period shall be 24 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at December 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning outstanding equity awards held by our named executive officer as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">OPTION
    AWARDS</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Date</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number
                                            of Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Underlying
                                            Unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Options
                                            (#) Exercisable</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number
                                            of Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Underlying
                                            Unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Options
                                            (#) Unexercisable</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Equity
                                            Incentive</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Plan
                                            Awards:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number
                                            of Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Underlying
                                            Unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Unearned
                                            Options (#)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Price
                                            ($)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Date</b></span></p></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 14%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Randy
    Milby</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/20/2018</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,045</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,894</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.200</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/20/2023</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/20/2018</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,635</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,349</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/20/2023</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/31/2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,633</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,245</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0792</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/31/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/30/2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">189,393</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0792</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/30/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/17/2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,272</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">621</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.6400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/17/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/19/2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,272</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">621</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.6400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/19/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/5/2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">621</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">325</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.6400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/05/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/13/2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,721</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,854</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.6400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/13/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/31/2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,970</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,908</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(9)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.6400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/31/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1/31/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1/31/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/29/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/28/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3/31/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3/31/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/30/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/30/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/31/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/31/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/30/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/30/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/31/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/31/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/31/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/31/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/30/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3142</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/30/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/31/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.8174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/31/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/12/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.8174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/12/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/12/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,878</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.8174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/12/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/30/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.8174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/30/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/31/2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.8174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/31/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">01/31/2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,939</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.8223</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">01/31/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">02/01/2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,454</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.8223</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">02/01/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">02/28/2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,939</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.8223</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">02/28/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">03/31/2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,939</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.8223</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">03/31/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">04/02/2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,878</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.8223</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">04/02/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">04/30/2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,939</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.8223</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">04/30/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">05/31/2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,939</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.8223</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">05/31/2031</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,787
    of the options vested on the date of grant (June 20, 2018), with the balance of the 15,152 options vesting over a period of 48 months
    thereafter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 126; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,787
    of the options vested on date of grant (September 20, 2018), with the remaining 7,197 of the options vesting in equal installments
    over a period of 48 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options vested on the one year anniversary of the vesting starting date (July 31, 2019), with the remaining 28,409 of the
    options vesting in equal installments over a period of 48 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    of the options shall vest on the completion of our IPO or a public listing via reverse merger with a public company. Our
    IPO closed on January 14, 2022, at which time 100% of the options vested.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options vested on the one year anniversary of the vesting starting date (September 17, 2019), with the remaining 1,420 of
    the options vesting in equal installments over a period of 48 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options vested on the one year anniversary of the vesting starting date (September 19, 2019), with the remaining 1,420 of
    the options vesting over a period of 48 equal monthly installments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options vested on the one year anniversary of the vesting starting date (November 5, 2019), with the remaining 710 of the
    options vesting in equal installments over a period of 48 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,787
    of the options vested on the one year anniversary of the vesting starting date (December 13, 2019), with the remaining 3,788 of the
    options vesting in equal installments over a period of 48 months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
    of the options vested on the one year anniversary of the vesting starting date (December 31, 2019), with the remaining 28,409 of
    the options vesting in equal installments over a period of 48 months.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Director Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not compensate our non-employee directors for their service during the fiscal year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017
Stock Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors and our stockholders approved the 2017 Stock Incentive Plan (&#8220;2017 Plan&#8221;) on March 30, 2017, under which
we may grant equity incentive awards in order to attract, motivate and retain the talent who are expected to make important contributions
to the Company. The material terms of the 2017 Plan are summarized below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration
of the 2017 Plan: </i></b>The 2017 Plan is administered by our board of directors. Our board of directors may delegate any or all of
its powers under the 2017 Plan to one or more committees or subcommittees of the board (a &#8220;Committee&#8221;). All references in
the 2017 Plan to the &#8220;Board&#8221; shall mean our board of directors or a Committee of our board of directors to the extent that
the board&#8217;s powers or authority under the 2017 Plan have been delegated to such Committee. The Board shall have authority to grant
awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the 2017 Plan as it shall deem
advisable. The Board may correct any defect, supply any omission or reconcile any inconsistency in the 2017 Plan or any award in the
manner and to the extent it shall deem expedient to carry the 2017 Plan into effect and it shall be the sole and final judge of such
expediency. All decisions by the Board shall be made in the Board&#8217;s sole discretion and shall be final and binding on all persons
having or claiming any interest in the 2017 Plan or in any award thereunder. No director or person acting pursuant to the authority delegated
by the Board shall be liable for any action or determination relating to or under the 2017 Plan made in good faith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eligibility
Participants: </i></b>The 2017 Plan authorizes the grant of stock options, restricted stock, restricted stock units and/or other stock
based awards to employees, officers, directors, individual consultants and advisors of the Company. The Board determines, in its sole
discretion, who will receive awards under the 2017 Plan. Notwithstanding anything in the 2017 Plan or any award documentation to the
contrary, for so long as the Company has elected Subchapter S status under Section 1362 of the Internal Revenue Code of 1986, as amended,
no award shall be granted or exercised, as the case may be, if the result of such grant or exercise would result in the termination of
such Subchapter S status, unless such grant or exercise, as the case may be, is consented to by all stockholders of the Company. Any
such purported grant or exercise of an award that does not comply with the foregoing shall be void and have no legal force or effect
and shall not be recognized on the books of the Company as effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Available Under the 2017 Plan: </i></b>The maximum number of shares of common stock that may be issued to participants under the 2017
Plan is 94,696, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an
award under the 2017 Plan for which the award is canceled, forfeited or expires again become available for grants under the 2017 Plan.
Shares subject to an award that is settled in cash will not again be made available for grants under the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General:
</i>The Board has the authority to grant options to purchase shares of the Company&#8217;s common stock and determine the number of shares
of the Company&#8217;s common stock to be covered by each option, the exercise price of each option and the conditions and limitations
applicable to the exercise of each option, including conditions relating to applicable federal or state securities laws, as it considers
necessary or advisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
of Options:</i> An option may be exercised only in accordance with the terms and conditions of the option agreement as established by
the Board at the time of the grant. The option must be exercised by notice to the Company, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the Board, by actual or constructive delivery of shares of common stock to the holder
of the option based upon the fair market value of the shares on the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expiration
or Termination</i>: Options, if not previously exercised, will expire on the expiration date established by the Board at the time of
grant; provided that such term cannot exceed ten years and that such term of an incentive stock option granted to a holder of more than
10% of our voting stock cannot exceed five years. Options will terminate before the expiration date to the extent the vested portion
of the option is not exercised within 3 months of the termination date if the holder&#8217;s service with us terminates before the expiration
date. The option may remain exercisable for specified periods after certain terminations of service, including terminations as a result
of death, disability or retirement, with the precise period during which the option may be exercised to be established by the Board and
reflected in the agreement evidencing the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Shares and Restricted Stock Units</i>: </b>Eligible participants may be awarded grants of restricted stock units, which represent the
right to receive shares of the common stock to be delivered when the common stock vests. The holders of restricted stock units will have
none of the rights of a stockholder of the Company until such time or times as shares of the common stock have been issued to participant
in settlement of the award. The Board shall determine the participants to whom and the time or times at which grants of restricted stock
units shall be awarded, the number of units to be awarded to any participant, the conditions for vesting, the time or times within which
such awards may be subject to forfeiture and restrictions on transfer and other terms and conditions of the awards. Each restricted stock
unit shall at all times be equal in value to the fair market value of one share of the common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Stock Based Awards</i>:</b> The Board may grant or sell other awards that may be denominated or payable in, valued in whole or in part
by reference to, or otherwise based on or related to, common stock or factors that may influence the value of such shares. In addition,
the Board may grant unrestricted shares to eligible participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Material Provisions</i>:</b> Awards will be evidenced by a written agreement, in such form as may be approved by the Board. In the event
of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate
adjustment will be made by the Board to the number of shares covered by outstanding awards or to the exercise price of such awards. The
Board is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of
a change of control of our Company, including acceleration of vesting. Except as otherwise determined by the Board at the date of grant,
awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are
permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. The Board also has the authority,
at any time, to discontinue the granting of awards. The Board also has the authority to alter or amend the 2017 Plan or any outstanding
award or may terminate the 2017 Plan as to further grants, provided that no amendment will, without the approval of our stockholders,
increase the number of shares available under the 2017 Plan or change the persons eligible for awards under the 2017 Plan. No amendment
that would adversely affect any outstanding award made under the 2017 Plan can be made without the consent of the holder of such award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2019
Stock Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors and our stockholders approved the 2019 Stock Incentive Plan (&#8220;2019 Plan&#8221;) on July 24, 2019, under which
we may grant equity incentive awards in order to attract, motivate and retain the talent who are expected to make important contributions
to the Company. The material terms of the 2019 Plan are summarized below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration
of the 2019 Plan: </i></b>The 2019 Plan is administered by our board of directors. Our board of directors may delegate any or all of
its powers under the 2019 Plan to one or more committees or subcommittees of the board (a &#8220;Committee&#8221;). All references in
the 2019 Plan to the &#8220;Board&#8221; shall mean our board of directors or a Committee of our board of directors to the extent that
the board&#8217;s powers or authority under the 2019 Plan have been delegated to such Committee. The Board shall have authority to grant
awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the 2019 Plan as it shall deem
advisable. The Board may correct any defect, supply any omission or reconcile any inconsistency in the 2019 Plan or any award in the
manner and to the extent it shall deem expedient to carry the 2019 Plan into effect and it shall be the sole and final judge of such
expediency. All decisions by the Board shall be made in the Board&#8217;s sole discretion and shall be final and binding on all persons
having or claiming any interest in the 2019 Plan or in any Award. No director or person acting pursuant to the authority delegated by
the Board shall be liable for any action or determination relating to or under the 2019 Plan made in good faith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eligibility
Participants:</i></b> The 2019 Plan authorizes the grant of stock options, restricted stock, restricted stock units and/or other stock
based awards to employees, officers, directors, individual consultants and advisors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board determines, in its sole discretion, who will receive awards under the 2019 Plan. Notwithstanding anything in the 2019 Plan or any
award documentation to the contrary, for so long as the Company has elected Subchapter S status under Section 1362 of the Internal Revenue
Code of 1986, as amended, no award shall be granted or exercised, as the case may be, if the result of such grant or exercise would result
in the termination of such Subchapter S status, unless such grant or exercise, as the case may be, is consented to by all stockholders
of the Company. Any such purported grant or exercise of an award that does not comply with the foregoing shall be void and have no legal
force or effect and shall not be recognized on the books of the Company as effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Available Under the 2019 Plan: </i></b>The maximum number of shares of common stock that may be delivered to participants under the 2019
Plan is 3,901,512, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to
an award under the 2019 Plan for which the award is canceled, forfeited or expires again become available for grants under the 2019 Plan.
Shares subject to an award that is settled in cash will not again be made available for grants under the 2019 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General:
</i>The Board has the authority to grant options to purchase shares of the Company&#8217;s common stock and determine the number of shares
of the Company&#8217;s common stock to be covered by each option, the exercise price of each option and the conditions and limitations
applicable to the exercise of each option, including conditions relating to applicable federal or state securities laws, as it considers
necessary or advisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
of Options:</i> An option may be exercised only in accordance with the terms and conditions of the option agreement as established by
the Board at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price. Payments
may be made in cash or, at the option of the Board, by actual or constructive delivery of shares of common stock to the holder of the
option based upon the fair market value of the shares on the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expiration
or Termination</i>: Options, if not previously exercised, will expire on the expiration date established by the Board at the time of
grant; provided that such term cannot exceed ten years and that such term of an incentive stock option granted to a holder of more than
10% of our voting stock cannot exceed five years. Options will terminate before the expiration date to the extent the vested portion
of the option is not exercised within 3 months of the termination date if the holder&#8217;s service with us terminates before the expiration
date. The option may remain exercisable for specified periods after certain terminations of service, including terminations as a result
of death, disability or retirement, with the precise period during which the option may be exercised to be established by the Board and
reflected in the agreement evidencing the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Shares and Restricted Stock Units</i>: </b>Eligible participants may be awarded grants of restricted stock units, which represent the
right to receive shares of the Company&#8217;s common stock to be delivered when the common stock vests. The holders of restricted stock
units will have none of the rights of a stockholder of the Company until such time or times as shares of the common stock have been issued
to participant in settlement of the award. The Board shall determine the participants to whom and the time or times at which grants of
restricted stock units shall be awarded, the number of units to be awarded to any participant, the conditions for vesting, the time or
times within which such awards may be subject to forfeiture and restrictions on transfer and other terms and conditions of the awards.
Each restricted stock unit shall at all times be equal in value to the fair market value of one share of the common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Stock Based Awards</i>:</b> The Board may grant or sell other awards that may be denominated or payable in, valued in whole or in part
by reference to, or otherwise based on or related to, common stock or factors that may influence the value of such shares. In addition,
the Board may grant unrestricted shares to eligible participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Material Provisions</i>:</b> Awards will be evidenced by a written agreement, in such form as may be approved by the Board. In the event
of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate
adjustment will be made by the Board to the number of shares covered by outstanding awards or to the exercise price of such awards. The
Board is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of
a change of control of our Company, including acceleration of vesting. Except as otherwise determined by the Board at the date of grant,
awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are
permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. The Board also has the authority,
at any time, to discontinue the granting of awards. The Board also has the authority to alter or amend the 2019 Plan or any outstanding
award or may terminate the 2019 Plan as to further grants, provided that no amendment will, without the approval of our stockholders,
increase the number of shares available under the 2019 Plan or change the persons eligible for awards under the 2019 Plan. No amendment
that would adversely affect any outstanding award made under the 2019 Plan can be made without the consent of the holder of such award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 129; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_021"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock as of March 21, 2022 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our current directors and named executive officers as a group; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    stockholder known by us to own beneficially more than 5% of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
Shares of common stock that may be acquired by an individual or group within 60 days of March 21, 2022, pursuant to the exercise of options
or warrants, vesting of common stock or conversion of convertible debt, are deemed to be outstanding for the purpose of computing the
percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership
of any other person shown in the table. Percentage of ownership is based on 11,364,444 shares of common stock issued and outstanding
as of March 21, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
noted otherwise, the address of all listed stockholders is c/o Hillstream BioPharma, Inc., 1200 Route 22 East, Suite 200, Bridgewater,
NJ 08807.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated by the footnotes below, we believe, based on information furnished to us, that each of the stockholders listed has sole
voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community
property laws where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Beneficial Owner</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of Common Stock Beneficially Owned</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 59%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and Named Executive Officers:</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,292,965</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard
    Mazur</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132,065</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynne
    Bui</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,924</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
    Appajosyula</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,378,279</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Named Executive Officers and Directors as a Group (4 persons)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,830,233</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5%
    or Greater Stockholders:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highpoint
    Pharmaceuticals LLC (5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">972,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.55</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kufe
    LLC (6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">842,317</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    Kufe</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">843,263</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)(7)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surender
    Kharbanda</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">722,602</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.36</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Varinder
    Kaur</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">653,059</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bearing
    Circle Capital LLC (9)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636,008</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandeep
    Laumas</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">668,174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)(10)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.88</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents less than 1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 2,694,013 shares of common stock and (ii) 598,952 shares of common stock issuable upon exercise of options.
    Excludes 780,382 shares of common stock issuable upon exercise of options which are subject to vesting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 123,733 shares of common stock and (ii) 8,332 shares of common stock issuable upon exercise of options. Excludes
    options to purchase up to 41,668 shares of common stock issuable upon exercise of options which are subject to vesting.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    26,924 shares of common stock issuable upon exercise of options. Excludes options to purchase up to 42,015 shares of
    common stock issuable upon exercise of options which are subject to vesting. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 46,210 shares of common stock issuable upon exercise of options, (ii) 284,090 shares of common stock, (iii) 972,222 shares
    of common stock held by Highpoint Pharmaceuticals LLC and (iv) 75,757 shares of common stock held by Mercer Lake Group LLC. Excludes
    options to purchase up to 41,668 shares of common stock issuable upon exercise of options which are subject to vesting.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
    Appajosyula is the Managing Member of each of Highpoint Pharmaceuticals LLC and Mercer Lake Group LLC and in such capacity has the
    right to vote and dispose of the securities held by such entities. The address of Highpoint Pharmaceuticals LLC is 16192 Coastal
    Highway Lewes, DE 19958. The address of Mercer Lake Group LLC is 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    Kufe is the Managing Director of Kufe LLC and in such capacity has the right to vote and dispose of the securities held by such entity.
    The address of Kufe LLC is 179 Grove Street, Wellesley, MA 02482.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 842,317 shares of common stock held by Kufe LLC and (ii) 1,778 shares of common stock issuable upon exercise
    of options held by Donald Kufe. Excludes options to purchase up to 4,168 shares of common stock issuable upon exercise
    of options which are subject to vesting.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 721,240 shares of common stock and (ii) 1,362 shares of common stock issuable upon exercise of options.
    Excludes options to purchase up to 2,084 shares of common stock issuable upon exercise of options which are subject
    to vesting.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandeep
    Laumas is the Managing Member of Bearing Circle Capital LLC and in such capacity has the right to vote and dispose of the securities
    held by such entity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    (i) 32,166 shares of common stock and (ii) 636,008 shares of common stock held by Bearing Circle Capital LLC. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about our equity compensation plans as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Plan
    Category</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of securities to be issued upon exercise of outstanding options, warrants and rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average exercise price of outstanding options, warrants and rights</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans approved by security holder</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">903,468</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,480,998</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans not approved by security holder</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">903,468</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,480,998</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 131; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_022"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following includes a summary of transactions during our fiscal years ended December 31, 2021 and December 31, 2020 to which we have been
a party, including transactions in which the amount involved in the transaction exceeds the lesser of $120,000 or 1% of the average of
our total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or, to our
knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons
had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and
other arrangements, which are described elsewhere in this Annual Report on Form 10-K. We are not otherwise a party to a related party
transaction, and no transaction is currently proposed, in which the amount of the transaction exceeds the lesser of $120,000 or 1% of
the average of our total assets at year-end for the last two completed fiscal years and in which a related person had or will have a
direct or indirect material interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Promissory Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
in May 2017, we entered into Subordinated Convertible Promissory Note Agreements with our Chief Executive Officer with respect to the
issuance of convertible promissory notes in the aggregate principal amount of $2,804,318 and $2,031,236 as of December 31, 2021 and
2020, respectively. The convertible promissory notes accrued interest at a rate of 5% per annum. Unless earlier converted into shares
of Equity Securities (as defined herein), the principal and accrued interest shall be due and payable by the Company on demand by the
holder thereof at any time after the earlier of (i) the Maturity Date (as defined in each note) and (ii) the closing of the Next Equity
Financing (as defined herein). &#8220;Equity Securities&#8221; means, subject to certain exceptions, the Company&#8217;s common stock,
preferred stock and common stock and preferred stock equivalents. &#8220;Next Equity Financing&#8221; means the next sale (or series
of related sales) by the Company of its Equity Securities from which the Company receives gross proceeds of not less than $5,000,000
for notes issued from 2017 through November 2020 and $7,500,000 for notes issued in December 2020 (including the aggregate amount of
debt securities converted into Equity Securities upon conversion or cancellation of promissory notes). The principal amount of the notes
together with interest accrued thereon will automatically be converted into the type of Equity Securities issued in the Next Equity Financing
upon closing thereof. The number of Equity Securities to be issued upon such conversion shall be equal to the quotient obtained by dividing
the outstanding principal amount together with interest accrued thereon by the lesser of (i) 80% of the price paid per Equity Security
in the Next Equity Financing or (ii) an equity valuation of $25 million for notes issued from 2017 through November 2020 and $50 million
for notes issued in December 2020. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, we agreed to provide our Chief Executive Officer Exchange Notes in exchange for Original Notes which were in default
at such time by more than 90 days. The Original Notes had a principal of approximately $265,000 and accrued interest of $37,000 at December
31, 2019. As of September 27, 2020, the aggregate outstanding principal was approximately $265,000 and accrued interest (which included
the default interest rate of 20% as described above) was approximately $71,000. The Exchange Notes took the then principal and accrued
interest of the Original Notes and added an original issue discount of 37.5% to determine the new principal (which amounted to an aggregate
of $537,968) of the Exchange Notes outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2020, all notes held by our Chief Executive Officer which matured, and were not repaid or converted, were rolled over on substantially
the same terms as the original notes with a new two year term. Effective December 1, 2020, all notes held by our Chief Executive Officer
which matured, and were not repaid or converted, were rolled over on substantially the same terms as the original notes with a new three
year term. The principal amount of the notes together with interest accrued thereon will automatically be converted into the type of
Equity Securities issued in the Next Equity Financing upon closing thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
IPO qualified as a Next Equity Financing and, on January 14, 2022, the notes were converted into an aggregate of 921,288 shares of our
common stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2020, we issued Leonard Mazur, a member of our board of directors, a subordinated convertible promissory note in
the principal amount of $300,000. The note accrues interest at 5% per annum and, unless earlier converted, matures upon the earlier of
December 31, 2023 and the closing of the Next Equity Financing. The principal amount of the note together with any accrued interest thereon
will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon the closing thereof. The number
of Equity Securities to be issued upon such conversion shall be equal to the quotient obtained by dividing the outstanding principal
amount together with interest accrued thereon by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing
or (ii) an equity valuation of $50 million. Our IPO qualified as a Next Equity Financing and, on January 14, 2022, the note
was converted into an aggregate of 98,733 shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 132; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payments
to the Chief Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, we owed our Chief Executive Officer $200,000 and $200,000, respectively. The expenses were
comprised of expenses paid by the Chief Executive Officer on behalf of our Company of $55,068 (which was converted into a convertible
promissory note in 2020) and $200,000 for accrued compensation at December 31, 2019. At December 31, 2021 and 2020, the balance
comprised $200,000 and $200,000, respectively, for accrued compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Person Transaction Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval
or ratification of related person transactions. For purposes of our policy only, a related person transaction is a transaction, arrangement
or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or
will be participants in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end.
Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related
person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of
their immediate family members and any entity owned or controlled by such persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person
transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to
consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee
approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification.
The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related
persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to
or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information
that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable
us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our
code of business conduct and ethics, our employees and directors will have an affirmative responsibility to disclose any transaction
or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions,
our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances
including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risks, costs and benefits to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact on a director&#8217;s independence in the event that the related person is a director, immediate family member of a director
    or an entity with which a director is affiliated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of other sources for comparable services or products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms available to or from, as the case may be, unrelated third parties or to or from employees generally.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other
independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not
inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our board of
directors, determines in the good faith exercise of its discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Independence
                                            of the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors undertook a review of the independence of our directors and considered whether any director has a relationship with
us that could compromise that director&#8217;s ability to exercise independent judgment in carrying out that director&#8217;s responsibilities.
Our board of directors has affirmatively determined that Leonard Mazur, Lynne Bui and Sireesh Appajosyula are each an &#8220;independent
director,&#8221; as defined under Nasdaq rules.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_023"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of Mayer Hoffman McCann P.C. (&#8220;MHM&#8221;) personnel, who work under the control of MHM shareholders, are employees of wholly-owned
subsidiaries of CBIZ, Inc., which provides personnel and various services to MHM in an alternative practice structure.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The following table sets forth the aggregate fees billed by as described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font-family: Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">343,323</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">120,238</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    related fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other fees</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">343,323</span></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">120,238</span></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Fees:</b> Audit fees consist of fees billed for the professional services rendered to the Company for the audit of the Company&#8217;s
annual consolidated financial statements for the years ended December 31, 2021 and 2020, reviews of the quarterly financial statements
during the periods, the issuance of consent and comfort letters in connection with registration statement filings, and all other services
that are normally provided by the accounting firm in connection with statutory and regulatory filings and engagements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit-Related
Fees:</b> Fees not included in audit fees that are billed by the auditor for assurance and related services that are reasonably related
to the performance of the audit of the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
Fees:</b> Fees for professional services rendered for tax compliance, tax advice and tax planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
Other Fees:</b> All other fees billed by the auditor for products and services not included in the foregoing categories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval
Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
February 2022, our board of directors approved </span><span style="font-family: Times New Roman, Times, Serif">all audit and permitted
non-audit services provided by our independent registered public accounting firm. In the fiscal years ended December 31, 2021 and
2020, all of the services performed by our independent registered public accounting firm were pre-approved by our board of directors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_024"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_025"></span>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
The following documents are filed as part of this report:</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_013">Index to Consolidated Financial Statements:</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Financial Statements:</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of the Independent Registered Public Accounting Firm</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003">Consolidated Statements of Operations for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004">Consolidated Statements of Changes in Stockholders&#8217; Deficit for the Years ended December 31, 2021 and 2020</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005">Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_006">Notes to the Consolidated Financial Statements</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements required by this Item are included beginning at page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedules:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in
the consolidated financial statements or the notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 134; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are included as exhibits to this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Document</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Incorporation (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form S-1 filed with the
    SEC on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-2.htm" style="-sec-extract: exhibit">Amendment
    to Certificate of Incorporation dated August 7, 2019 (Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Registration
    Statement on Form S-1 filed with the SEC on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-3.htm" style="-sec-extract: exhibit">Amendment
    to Certificate of Incorporation dated September 16, 2021 (Incorporated by reference to Exhibit 3.3 to the Company&#8217;s Registration
    Statement on Form S-1 filed with the SEC on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221025555/ex3-5.htm" style="-sec-extract: exhibit">Amendment
    to Certificate of Incorporation dated October 11, 2021 (Incorporated by reference to Exhibit 3.5 to the Company&#8217;s Registration
    Statement on Form S-1/A filed with the SEC on October 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex3-4.htm" style="-sec-extract: exhibit">Bylaws
    (Incorporated by reference to Exhibit 3.4 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on September
    27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex4-1.htm" style="-sec-extract: exhibit">Specimen
    Stock Certificate Evidencing the Shares of Common Stock (Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration
    Statement on Form S-1 filed with the SEC on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221031127/ex4-2.htm" style="-sec-extract: exhibit">Form
    of Underwriter Warrant (Incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1/A filed
    with the SEC on December 10, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-3.htm">Description
    of the Registrant&#8217;s Securities</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-1.htm" style="-sec-extract: exhibit">Amended
    and Restated Employment Agreement by and between the Company and Randy Milby dated June 1, 2021 (Incorporated by reference to Exhibit
    10.1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-7.htm" style="-sec-extract: exhibit">First
    Amendment to Amended and Restated Employment Agreement by and between the Company and Randy Milby dated June 1, 2021 (Incorporated
    by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1861657/000149315221023881/ex10-2.htm" style="-sec-extract: exhibit">Hillstream
    BioPharma, Inc. 2017 Stock Incentive Plan (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement
    on Form S-1 filed with the SEC on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex14-1.htm">Code
    of Business Conduct and Ethics</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">Subsidiaries</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent
    of Mayer Hoffman McCann P.C.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">24.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_007">Power of Attorney (included on signature page hereto)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350,
    as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>

  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File &#8211; the</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> cover
    page of the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 is formatted in Inline
    XBRL</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Management contract or compensatory plan or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_026"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="c_027"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report
on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on this 1st day of April, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HILLSTREAM
    BIOPHARMA, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Randy Milby</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span id="f_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Randy Milby as his or her
attorney-in-fact, with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments
to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorney-in-fact full power and authority to do and perform each and every act
and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on
behalf of the registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Randy Milby</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Thomas Hess</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Hess</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lynne Bui</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynne
    Bui</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Leonard Mazur</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard
    Mazur</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Sireesh Appajosyula</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sireesh
    Appajosyula</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 11, 2022, Hillstream BioPharma, Inc. (the &ldquo;Company&rdquo;) had one class of security registered under Section
12 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), its common stock, par value $0.0001 per share
(the &ldquo;Common Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of the Company&rsquo;s Common Stock is a summary and does not purport to be complete. It is subject to and qualified
in its entirety by reference to the Company&rsquo;s Certificate of Incorporation, as amended (the &ldquo;Certificate of Incorporation&rdquo;)
and the Company&rsquo;s Bylaws, each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this
Exhibit 4.3 is a part. The Company encourages you to read its Certificate of Incorporation, Bylaws, and the applicable provisions of
the Delaware General Corporation Law for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized
Capital Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s authorized capital shares consist of 250,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000
shares of preferred stock, $0.0001 par value per share (&ldquo;Preferred Stock&rdquo;). As of December 31, 2021, there were 6,357,314
shares of Common Stock issued and outstanding and no shares of Preferred Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of the Company&rsquo;s Common Stock are entitled to one vote for each share held on all matters submitted to a vote of the Company&rsquo;s
stockholders. Holders of the Company&rsquo;s Common Stock have no cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to preferences that may be applicable to any outstanding shares of the Company&rsquo;s Preferred Stock, holders of the Company&rsquo;s
Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Company&rsquo;s board of directors
out of the Company&rsquo;s assets which are legally available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Company&rsquo;s liquidation, dissolution or winding-up, holders of the Company&rsquo;s Common Stock are entitled to share in all
assets remaining after payment of all liabilities and the liquidation preferences of any of the Company&rsquo;s outstanding shares of
Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of the Company&rsquo;s Common Stock have no preemptive or conversion rights or other subscription rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicable
Anti-Takeover Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a summary of the provisions of the Company&rsquo;s Certificate of Incorporation and Bylaws and the Delaware General Corporation
Law that could have the effect of delaying or preventing a change in control of the Company. The following description is only a summary,
and it is qualified by reference to the Certificate of Incorporation, Bylaws and relevant provisions of the Delaware General Corporation
Law (the &ldquo;DGCL&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly traded Delaware corporation
from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction
in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business
combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder
is a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more of the corporation&rsquo;s
voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Bylaws authorize the Company&rsquo;s board of directors to fill vacant directorships. In addition, the number of directors
constituting the Company&rsquo;s board of directors may be set by resolution of the incumbent directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
Meeting of Stockholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Bylaws provide that special meetings of the Company&rsquo;s stockholders may be called by the board of directors, the
Chief Executive Officer, or the President (in the absence of a Chief Executive Officer), the chairman of the board of directors or stockholders
entitled to cast at least one-fifth of the votes which all stockholders are entitled to cast at the particular meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements for Stockholder Proposals and Director Nominations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Bylaws provide that stockholders seeking to bring business before the Company&rsquo;s annual meeting of stockholders,
or to nominate candidates for election as directors at the Company&rsquo;s annual meeting of stockholders, must provide timely notice
of their intent in writing. To be timely, a stockholder&rsquo;s notice must be delivered to the Company&rsquo;s Secretary at the Company&rsquo;s
principal executive offices not later than the close of business on the 60<SUP>th </SUP>day nor earlier than the close of business on
the 90<SUP>th</SUP> day prior to the first anniversary of the preceding year&rsquo;s annual meeting; provided, however, that in the event
the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, or if no annual meeting
was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on
the 90<SUP>th</SUP> day prior to such annual meeting and not later than the close of business on the later of the 60<SUP>th</SUP> day
prior to such annual meeting or the 10<SUP>th</SUP> day following the day on which a public announcement of the date of such meeting
is first made by the Company. These provisions may preclude the Company&rsquo;s stockholders from bringing matters before the Company&rsquo;s
annual meeting of stockholders or from making nominations for directors at the Company&rsquo;s annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
but Unissued Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s authorized but unissued shares of Common Stock and Preferred Stock are available for future issuance without stockholder
approval and may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate
acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could
render more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or
otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
Forum</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Certificate of Incorporation provides that unless the Company consent in writing to the selection of an alternative forum,
the State of Delaware is the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of the Company,
(ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the
Company or the Company&rsquo;s stockholders, (iii) any action arising pursuant to any provision of the DGCL or the Company&rsquo;s Certificate
of Incorporation or Bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Exchange Act
of 1934, as amended, or the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in
shares of the Company&rsquo;s capital stock are deemed to have notice of and consented to this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s transfer agent and registrar is Philadelphia Stock Transfer, Inc. whose address is 2320 Haverford Road, Suite 230, Ardmore,
PA 19003.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;HILS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>3
<FILENAME>ex14-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
14.1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HILLSTREAM
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CODE
OF BUSINESS CONDUCT AND ETHICS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Effective
September 23, 2021)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma, Inc. (the &ldquo;Company&rdquo;) has adopted the following Code of Business Conduct and Ethics (this &ldquo;Code&rdquo;) for
directors, executive officers and employees of the Company. This Code is intended to focus the directors, executive officers and employees
on areas of ethical risk, provide guidance to directors, executive officers and employees to help them recognize and deal with ethical
issues, provide mechanisms to report unethical conduct, and help foster a culture of honesty and accountability. Each director, executive
officer and employee must comply with the letter and spirit of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
code or policy can anticipate every situation that may arise. Accordingly, this Code is intended to serve as a source of guiding principles
for directors, executive officers and employees. Directors, executive officers and employees are encouraged to bring questions about
particular circumstances that may implicate one or more of the provisions of this Code to the attention of the Chairman of the Audit
Committee, who may consult with inside or outside legal counsel as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Maintain
                                            Fiduciary Duties.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and executive officers must be loyal to the Company and must act at all times in the best interest of the Company and its stockholders
and subordinate self-interest to the corporate and stockholder good. Directors and executive officers should never use their position
to make a personal profit. Directors and executive officers must perform their duties in good faith, with sound business judgment and
with the care of a prudent person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conflict
                                            of Interest.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an employee of the Company, you are expected to act at all times in the Company&rsquo;s best interests and to exercise sound judgment
unclouded by personal interests or divided loyalties. Both in performing your duties at the Company and in your outside activities, you
should avoid the appearance as well as the reality of a conflict of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
conflict of interest exists if your circumstances would lead a reasonable person to question whether your motivations are aligned with
the Company&rsquo;s best interests. If, for example, you are involved in an outside activity or have a financial or other personal interest
that might interfere with your objectivity in performing your Company duties and responsibilities, you may have, or appear to have, a
conflict of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it is impractical to describe all situations that may create a conflict of interest, the following provides policy guidance about some
of the most common conflict of interest situations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
                                            of Company Information for Private Gain</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Friends
                                            and Family Stock</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
                                            Activities &ndash; Non-Profit and Civic Organizations</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
                                            Outside Company &ndash; Moonlighting</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
                                            on a Board of Directors of a for Profit Company</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scientific
                                            Advisory Boards</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Family
                                            and Romantic Relationships</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Family
                                            Members or Relatives as Suppliers and other Business Partners</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kickbacks
                                            and Rebates by Suppliers</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gifts
                                            from Vendors, Suppliers or Customers</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Honorariums</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
note that the above is not an exhaustive list of examples. There are many other situations that may also create a potential for a conflict
of interest or the appearance of a conflict of interest. It is up to you to be aware of the potential for a conflict of interest in your
own particular situation and to resolve the issue in accordance with this policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Service
on a Board of Directors of a For Profit Company:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
owe a duty of loyalty to the company on whose board they serve. You should carefully consider all potential conflict of interest issues
before agreeing to serve on the board of a for profit company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
your position on the board of directors of another company becomes potentially relevant to a Company decision or action, you must promptly
disclose your relationship with the other company to the Company employees responsible for the decision or action and you must not participate
in that decision or action on behalf of either the Company or the other company. For example, if a Company business unit is considering
a transaction with the company on whose board you serve, you must disclose your relationship with the other company, to the decision
makers in your business unit and you must refrain from any discussions about or involvement in the transaction on behalf of either the
Company or the other company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
employee considering service on another company&rsquo;s board should understand that such service can lead to personal liability, particularly
with financially troubled companies. As your board service is outside the scope of your employment, the Company will not defend or indemnify
you if you are sued in your capacity as a board member of another company. <B><U>The Company&rsquo;s approval of your request to serve
on an outside board does not constitute any endorsement or ratification of any action you take as a board member of another company.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may at times ask an employee to serve on the board of directors of a for- profit organization pursuant to a Company investment
in, or strategic partnership with, that organization. The Company may also request that an employee serve on the board of a non-profit
organization, such as a standards body. Service on such boards as a representative of the Company is outside the scope of this policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Scientific
Advisory Boards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
accepting appointment to or service on a scientific advisory board for a company other than the Company, you should consider whether
the entity is offering you this opportunity in order to leverage your relationship with the Company to gain a special advantage for itself
with the Company, whether serving on this board will interfere with your ability to exercise your independent judgment in the best interest
of the Company, and whether the products and technologies you work on at the Company are so similar to those of the company on whose
board you wish to serve that it would be difficult to serve as a scientific advisor without using or disclosing Company confidential
information and trade secrets. If, after considering these questions, you still wish to serve on the scientific advisory board, you must
obtain prior written approval from your manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any decision is to be made or action taken by the Company concerning a company for which you serve as a member of a scientific advisory
board, you must disclose to the Company employees responsible for the decision or action your, relationship to the entity and not participate
in that decision or action on behalf of either party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
who are asked by the Company to serve on a scientific advisory board of another company as part of the Company&rsquo;s job duties are
not required to obtain approval under this policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Outside
Activities &ndash; Non-Profit Organizations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may encourage its employees to be active in their communities and to volunteer their time to bona fide charitable, educational,
civic, and trade organizations, provided of course that such activities do not detract from their job performance. Participation in these
types of activities does not generally require prior approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
taking on outside obligations, however, you should guard against possible conflicts of interest or the appearance of such conflicts.
If participation in an outside activity has the potential to cloud your judgment, prevent you from acting in the Company&rsquo;s best
interests, or create an appearance that you will not act objectively, you must refrain from participation in the activity unless you
obtain prior written approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
must also honor your non-disclosure obligation in all your outside activities. If an outside organization&rsquo;s interests are so closely
related to your work at the Company that you might inadvertently use or disclose Company confidential information in the course of that
outside work, you must not participate in the organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
who are asked by the Company to serve on the board of non-profit organizations, such as public standards bodies, as part of their Company
job, are not required to obtain conflict of interest approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Corporate
                                            Opportunities.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
executive officers and employees owe a duty to the Company to advance its legitimate interests when the opportunity to do so arises.
Directors, executive officers and employees are prohibited from: (a) taking for themselves personally opportunities that are discovered
through the use of corporate property, information or the director&rsquo;s or executive officer&rsquo;s position; (b) using the Company&rsquo;s
property, information, or position for personal gain; or (c) competing with the Company, directly or indirectly, for business opportunities;
provided, however, if the Company&rsquo;s disinterested directors determine that the Company will not pursue an opportunity that relates
to the Company&rsquo;s business, a director, executive officer or employee may do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality.</U></FONT></TD>
    </TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
executive officers and employees must maintain the confidentiality of information entrusted to them by the Company or its customers,
and any other confidential information about the Company that comes to them, from whatever source, in their capacity as a director, executive
officer or employee, except when disclosure is authorized or required by laws or regulations. Confidential information includes all non-public
information that might be of use to competitors, or harmful to the Company or its customers, if disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Protection
                                            and Proper Use of Company Assets.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
executive officers and employees must protect the Company&rsquo;s assets and ensure their efficient use. Theft, loss, misuse, carelessness
and waste of assets have a direct impact on the Company&rsquo;s profitability. Directors, executive officers and employees must not use
Company time, employees, supplies, equipment, tools, buildings or other assets for personal benefit without prior authorization from
the Chairman of the Nominating and Corporate Governance Committee or as part of a compensation or expense reimbursement program available
to all directors or executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fair
                                            Dealing.</U></FONT></TD>
    <TD STYLE="width: 0">&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
executive officers and employees shall deal fairly and directors and executive officers shall oversee fair dealing by employees and officers
with the Company&rsquo;s directors, officers, employees, customers, suppliers and competitors. None should take unfair advantage of anyone
through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair dealing practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
                                            with Laws, Rules and Regulations.</U></FONT></TD>
    <TD STYLE="width: 0">&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and executive officers shall comply, and oversee compliance by employees, officers and other directors, with all laws, rules and regulations
applicable to the Company, including insider-trading laws. Transactions in Company securities are governed by Company Policy entitled
&ldquo;Insider Trading Policy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accuracy
                                            of Records.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
integrity, reliability and accuracy in all material respects of the Company&rsquo;s books, records and financial statements is fundamental
to the Company&rsquo;s continued and future business success. No director, executive officer or employee may cause the Company to enter
into a transaction with the intent to document or record it in a deceptive or unlawful manner. In addition, no director, executive officer
or employee may create any false or artificial documentation or book entry for any transaction entered into by the Company. Similarly,
executive officers and employees who have responsibility for accounting and financial reporting matters have a responsibility to accurately
record all funds, assets and transactions on the Company&rsquo;s books and records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Quality
                                            of Public Disclosures.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is committed to providing its stockholders with information about its financial condition and results of operations as required
by the securities laws of the United States. It is the Company&rsquo;s policy that the reports and documents it files with or submits
to the Securities and Exchange Commission, and its earnings releases and similar public communications made by the Company, include fair,
timely and understandable disclosure. Executive officers and employees who are responsible for these filings and disclosures, including
the Company&rsquo;s principal executive, financial and accounting officers, must use reasonable judgment and perform their responsibilities
honestly, ethically and objectively in order to ensure that this disclosure policy is fulfilled. The Company&rsquo;s senior management
are primarily responsible for monitoring the Company&rsquo;s public disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waivers
                                            and Amendments of the Code of Business Conduct and Ethics.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
waiver of any provisions of the Code for the benefit of a director or an executive officer (which includes, without limitation, for purposes
of this Code, the Company&rsquo;s principal executive, financial and accounting officers) shall be effective unless (i) approved by the
Board of Directors or, if permitted, a committee thereof, and (ii) if applicable, such a waiver is promptly disclosed to the Company&rsquo;s
stockholders in accordance with applicable United States securities laws and/or the rules and regulations of the exchange or system on
which the Company&rsquo;s shares are traded or quoted, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
waivers of this Code for the other employees may be made by the Board of Directors, or, if permitted, a committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
amendments to this Code must be approved by the Board of Directors or a committee thereof and, if applicable, must be promptly disclosed
to the Company&rsquo;s stockholders in accordance with applicable United States securities laws and/or the rules and regulations of the
exchange or system on which the Company&rsquo;s shares are traded or quoted, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Encouraging
                                            the Reporting of any Illegal or Unethical Behavior.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and executive officers should promote ethical behavior and take steps to ensure the Company (a) encourages employees to talk to supervisors,
managers and other appropriate personnel when in doubt about the best course of action in a particular situation; (b) encourages employees
to report violations of laws, rules or regulations to appropriate personnel; and (c) informs employees that the Company will not permit
retaliation for reports made in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
executive officer or employee who in good faith reports a suspected violation under this Code by the Company, or its agents acting on
behalf of the Company, or who in good faith raises issues or concerns regarding the Company&rsquo;s business or operations, may not be
fired, demoted, reprimanded or otherwise harmed for, or because of, the reporting of the suspected violation, issues or concerns, regardless
of whether the suspected violation involves the executive officer or employee, the executive officer&rsquo;s or employee&rsquo;s supervisor
or senior management of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any executive officer or employee who in good faith reports a suspected violation under this Code which the executive officer
or employee reasonably believes constitutes a violation of a federal statute by the Company, or its agents acting on behalf of the Company,
to a federal regulatory or law enforcement agency, may not be reprimanded, discharged, demoted, suspended, threatened, harassed or in
any manner discriminated against in the terms and conditions of the executive officer&rsquo;s or employee&rsquo;s employment for, or
because of, the reporting of the suspected violation, regardless of whether the suspected violation involves the executive officer or
employee, the executive officer&rsquo;s or employee&rsquo;s supervisor or senior management of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
report any violations under this Code or concerns regarding the Company&rsquo;s business or operations, please email Lynne Bui at lbui@hillstreambio.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Communication
                                            of Code.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
directors, executive officers and employees will be supplied with a copy of this Code upon beginning service at the Company. Updates
of this Code will be provided from time to time. A copy of this Code is also available to all directors, executive officers and employees
by requesting one from the human resources department.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Failure
                                            to Comply; Compliance Procedures.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
failure by any director or executive officer to comply with the laws or regulations governing the Company&rsquo;s business, this Code
or any other Company policy or requirement may result in disciplinary action, and, if warranted, legal proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and executive officers should communicate any suspected violations of this Code promptly to the Chairman of the Audit Committee. The
Chairman of our Audit Committee is currently Lynne Bui and she can be reached at lbui@hillstreambio.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
will be investigated by the Board or by a person or persons designated by the Board and appropriate action will be taken in the event
of any violations of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
acknowledge that I have reviewed and understand Hillstream BioPharma, Inc.&rsquo;s Code of Business Conduct and Ethics (the &ldquo;Code&rdquo;)
and agree to abide by the provisions of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    (Printed or typed)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>List
of Subsidiaries of Hillstream BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State/Country
    of Organization or Incorporation</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HB
    Pharma Corp.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Farrington
    Therapeutics LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in Registration Statement No. 333-262909 on Form S-8 and Registration Statement No. 333-259821
on Form S-1 of our report dated April 1, 2022, relating to the consolidated financial statements of Hillstream BioPharma, Inc.
as of and for the years ended December 31, 2021 and 2020, included in this Annual Report on Form 10-K for the year ended December 31,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Mayer Hoffman McCann P.C.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
1,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
of Chief Executive Officer of Hillstream BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Randy Milby, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Hillstream BioPharma, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in
    all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated
    financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures, and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 1, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Randy Milby</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
of Chief Financial Officer of Hillstream BioPharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Thomas Hess, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Hillstream BioPharma, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in
    all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated
    financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures, and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 1, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas Hess</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Hess</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statement
of Chief Executive Officer and Chief Financial Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 1350 of Title 18 of the United States Code</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned,
Randy Milby and Thomas Hess, the Chief Executive Officer and Chief Financial Officer, respectively, of Hillstream BioPharma, Inc. (the
&ldquo;Company&rdquo;), hereby certify that based on the undersigned&rsquo;s knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&rsquo;s Annual Report on Form 10-K for the period ended December 31, 2021 (the &ldquo;Report&rdquo;) fully complies with
    the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 1, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Randy Milby</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randy
    Milby</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 1, 2022</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas Hess</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Hess</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #^ G # 2(  A$! Q$!_\0
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M_P "7_QH^K/N'M4?2=%?-G_"3:Y_T&=1_P# E_\ &C_A)M<_Z#.H_P#@2_\
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MXWG\2:3!8S6D<(BD63>KDY(7;T[>M<Q6D7)KWB':^A;3_D#3?]?,?_H+U?\
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M * E]_WZJS=^$?$,D5F%T6])2 *V(^AWL<?J*^@J*7UB78?LD?.G_"&^(_\
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MT_X0WQ'_ - 2^_[]4?\ "&^(_P#H"7W_ 'ZKZ+HI_6)=@]DCYT_X0WQ'_P!
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M\'CUM3UO1;.S@>W%TVZ<2E#E2DF%7G)Y3.X<4 =OFBN);QJVGWEZ]^S2XO\
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M_P#\16A10!G^9J__ #ZV/_@2_P#\11YFK_\ /K8_^!+_ /Q%:%% &?YFK_\
M/K8_^!+_ /Q%'F:O_P ^MC_X$O\ _$5H44 9_F:O_P ^MC_X$O\ _$4>9J__
M #ZV/_@2_P#\16A10!G^9J__ #ZV/_@2_P#\11YFK_\ /K8_^!+_ /Q%:%%
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MMZGD\$C'% ':U#=0?:+:6+Y/G0K\Z[EY'<=Q[5**6@#@'^&<[B'.M.?+A:(
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M#2HK-^VZE_T"O_)A:/MNI?\ 0*_\F%H TJ*S?MNI?] K_P F%H^VZE_T"O\
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M565[ :M%06=PMW:QSJ" XS@]JGJ0"BN \=^.+WPOJTEM FY&TQYXL0%\3!P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DC^7$S\?*">:@L;Y+V#S -
MK X9>N#_ %!Z@U9/2LF:TDAU*/[#+Y9E#&12NY54=\>N<8^IIK4"W>3MYT%O
M$Q#RDEBN,J@ZG^0_&E>PBE1DF,L@88(:0_TJJ1)I]V+BZ<S1R*(S+M \OGC@
M?PDGK6I2>FP&5'?Q:6OV:];R_* $;D9$B]L8[CN/\:;)K,5[$\%DLKRN-JDH
M0O/&<^PYJPB+>:F\K;7CMQY:#J-QP6/U' _.K^!3T 9#&L,21H,*@"@>PJ2B
MBD!AZOX3L-;NI[B[,^^:S:Q;8^!Y;,&/;KD=:JR^ ])GU":\F^U22RVS6PWS
MDK&C)L8HO0$@4_Q9XBN=#LV>RA2>X4 B-L_-DGCCV5S_ ,!]ZQ/^%@71MI)S
M%!$8X%F%LR,99O,!,> #P N"QP>XXQ0!LZ1X!T+1X&C6U^UEG5]]Z?.8%1A<
M$],#IBI],\(:?I>JW>I1&YENKI61GGF,FQ2<E4ST&>:Q'\7ZHR0O&+())]FB
M_P!6S/YLBAGVKN&X*&7@<\^U3:KXWGL]?M[&WM-ULZ?O9Y493&X^=@1VQ&K'
MZE: +%S\.M$N]'L--E6Y\FQ#+$ZS%7VL<LK$=0>XKIX(8[:".&% D<:A$4=
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MST5CZ>A[5Z:"#R#FO*/!7@EM59-0U.,BR!S'$>LQ]3_L_P Z]610@ 4  #
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M).J>*=0U#4HRMBMU(8XCQYWS?^@_SKT6C%9SIJ=K]"X5)0O;J-1 BA5 "@8
M X IU%+6A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R:0Q1,X1I"!D(F
M,GV&:I?VG-_T"K[_ ,A__%U?QFC% %#^TYO^@5??^0__ (NC^TYO^@5??^0_
M_BZOT4 4/[3F_P"@5??^0_\ XNC^TYO^@5??^0__ (NK]% %#^TYO^@5??\
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MHH H?VG-_P! J^_\A_\ Q=']IS?] J^_\A__ !=7Z* *']IS?] J^_\ (?\
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MN$A,XCCX R64D@KWX]: /2J6LCPMJC:QX=LKR4YF>/;+E=IWJ2K<=N0>*UZ
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M% &;NUG_ )Y:?_W\?_XFC=K/_/+3_P#OX_\ \36E10!F[M9_YY:?_P!_'_\
MB:-VL_\ /+3_ /OX_P#\36E10!F[M9_YY:?_ -_'_P#B:-VL_P#/+3_^_C__
M !-:5% &;NUG_GEI_P#W\?\ ^)HW:S_SRT__ +^/_P#$UI44 9N[6?\ GEI_
M_?Q__B:-VL_\\M/_ ._C_P#Q-:5% &;NUG_GEI__ '\?_P")HW:S_P \M/\
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M /?Q_P#XFC=K/_/+3_\ OX__ ,36E10!F[M9_P">6G_]_'_^)HW:S_SRT_\
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89_YY:?\ ]_'_ /B:T$+$?,,&G44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'G G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBH;B806TLS D1H6('? S0!+4<L
MJ01-+(P1%&68G@"N;M-;OFNT:X$)MG90P7CR]W3D]?>I-8UK3+NQEM8[U3(<
M$%59ER#G!('M2B^97BBW3<9)2-6RU:SOW9+>7<RC)4@@X]>:OUQ&BW]HVII-
M.\5L5+8W9!<MQCTP/\*[<'(R*%S6]Y6"I&,96B+1113("BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:RAE*L 0
M1@@]Z=4-S*8+6:55W,B%@OK@4 <YJ_AZ"*S,MM#-+B16>$.3E >0!]*U=+O[
M&Z5H;6,PM%C,+Q["!VXKG/[6U"%#<#4(VW;0RR@;5+>@'I6WI^FK+<27EU=Q
MWLKJ$#1@!5 [<'WH@XN.AK4C*+]YW%U/4]/WR64\$ERVWYXXH2^,],^AJ;08
MIX=&MXKD,L@!PK=0N> ?PQ5"]MVTRZN)[34[>V\Q0SPS ') P,<YZ"L$7+WC
M)<3/,E_)EUV@Y_V0H]*)RY8JP0I\^EST*BHXM_DIYF-^T;L>O>I*#(**** "
MBBB@ HHHH **** "BBB@ HHK-UN[EL=,:>%T1A)&NYEW!0S@$X[\&@#2HK&&
MK1V=K')=3FX24MLFCBVJ2.B8SU/./6HVUQX+F_-S:RK!;)&V1M)!8=,9Y//Z
M4 ;M%9DVJ?9UCDGM)XT8@,S;?DRV!GGGMTSC-(VLPHEQ,T,PMH"P,V!M)4X(
M SGKQTH U**PI-9:5[>.%3$_VF..5&VM\C!L8()';]*73]9WV.ZY#-,EN]PY
M50 5#,,#WXH W**Q;;5)I;F]Q$\L:"$Q1H &&Y,G)) _6I(=;BN)+>.*">22
M96;  ^0*VUMQSC@_GVH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBH;EI%M)FA7=*$)0>IQQ0!EW
MMKI6EP2WCV49)^7:!G<6., '@9JMI6GW*7TUTMLNG12(JB%2&R1U) X%8(D@
MG*_:KZ39(Z"4/(><]3[8_I6_HDDD\EW#'>RW%I%(ODSL<EN/F7/<"B$DXMI&
MM2#@[-W*QT^YM+RY>728M2,LF]9V=0V,="#TQ5Y/$-FMNKS0R1S*S1M"%W,A
M'7\*KV=O<ZSYEQ+J%U#$LACBCA;;PO&6/<FFWGAZ2$1MIN&(4K()6Y?)SNSW
M-.H_=TW%"*YK2T-VTO(;^W6:!]R'CW!]"*3_ $R//^JE&/=#_45#I-D]G;OY
MI3S)'WL$^ZO &!^5:%2KVU(DDF[%<W83/F12QX[E<C\QFI8YHI1F.17_ -TY
MJ2LO[3))>2M#:1,D#;))F?#9QD[1CG&>Y%,1J45D0:L=L#W4*0I/$9HV23=P
M "0>!S@^^::^ME--^T&T?S=[*(=W("M@DGMC^?% &S1110 4444 %%%% !5/
M4;/[?:&#S6B.]'5U )!5@PX/N*N53.IV()!NH@1P?FH J3Z,U[$L=[=R3;-Q
M4A0F&/W6X[KSCZT2Z-YYN"]U)BXC19!M'++C#>W3I5O^U;#_ )^XO^^J/[5L
M/^?N+_OJG9BT*E[HJ7MT\S3NH<("NT'&TY&TGI[XZT'1U:.X@:XE-I,6;R<#
MY68Y)!QGKR!5K^U;#_GZB_[ZH_M6P_Y^HO\ OJBS"Z*ZZ2Y6'SKII&BG68$1
MJ@X!&, >]0?\(^JQ+'%=RQ_N6@DPJG>C$GN.#DGFM#^U;#_G[B_[ZH_M6P_Y
M^XO^^J+,-"B^@QX.VX<%FB/S*&7Y%V@$'J#U^N*GL=(CLIDD21VV(Z $#^)]
MYZ>]3_VK8?\ /W%_WU1_:MA_S]Q?]]468:%RBJ7]JV'_ #]1?]]4?VK8?\_4
M7_?5*S"Z+M%4O[5L/^?J+_OJC^U;#_GZB_[ZHLPNB[15+^U;#_GZB_[ZH_M6
MP_Y^HO\ OJBS"Z+M%4O[5L/^?J+_ +ZH_M6P_P"?J+_OJBS"Z+M%4O[5L/\
MGZB_[ZH_M6P_Y^HO^^J+,+HNT52_M6P_Y^HO^^J/[5L/^?J+_OJBS"Z+M%4O
M[5L/^?J+_OJC^U;#_GZB_P"^J+,+HNT52_M6P_Y^HO\ OJC^U;#_ )^HO^^J
M+,+HNT52_M6P_P"?J+_OJC^U;#_GZB_[ZHLPNB[15+^U;#_GZB_[ZH_M6P_Y
M^HO^^J+,+HNT52_M6P_Y^HO^^J/[5L/^?J+_ +ZHLPNB[15+^U;#_GZB_P"^
MJ/[5L/\ GZB_[ZHLPNB[15,:I8G_ )>HO^^J/[3L?^?N'_OL46871<HJG_:=
MC_S]P_\ ?8H_M.Q_Y^X?^^Q3LPNBY15/^T['_G[A_P"^Q1_:=C_S]P_]]BBS
M"Z+E%4_[3L?^?N'_ +[%']IV/_/W#_WV*+,+HN453_M.Q_Y^X?\ OL4?VG8_
M\_</_?8HLPNBY15/^T['_G[A_P"^Q1_:=C_S]P_]]BBS"Z+E%4_[3L?^?N'_
M +[%']IV/_/W#_WV*+,+HN453_M.Q_Y^X?\ OL4?VG8_\_</_?8HLPNBY159
M+^TD.$N82?9Q5FD,**** "BBB@ HHHH ***:2%!+$ #N: '455;4;-#AKJ$'
M_?%-_M.Q_P"?N'_OL468KHD-I;L7+01$O]XE!\WU]:D2)(HPD:*JCH%& *K_
M -IV/_/W#_WV*/[3L?\ G[A_[[%.S'<H^&O^0:?^NTG_ *$:VJYWP]J5H-/E
M$EW$#]HEQE@.-QK6_M.Q_P"?N'_OL4Y)W'.:<FRY15/^T['_ )^X?^^Q1_:=
MC_S]P_\ ?8I69-T7*SS8#[5),EQ,BRD-+$I&UR!C/(R. .AYQ4G]IV/_ #]P
M_P#?8H_M.Q_Y^X?^^Q19A=%>/1;8(D<[O<I'&(D6;&%7CH !SP.?:HV\.:8]
MN\)MQARQW?Q#)S@'TJY_:=C_ ,_</_?8H_M.Q_Y^X?\ OL468:%I5"J%48 &
M *=5/^T['_G[A_[[%']IV/\ S]P_]]BBS"Z+E%4_[3L?^?N'_OL4?VG8_P#/
MW#_WV*+,+HN45##=07&[R9DDV]=ISBIJ0P-<T\^C>8^Y(]VXY^0]:Z6H#:6Q
M.3;Q9_W!51E8F4;G/^?HG]R/_O@T>?HG]R/_ +X-=!]DM_\ GWB_[X%'V2W_
M .?>+_O@57.3R'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB
M_P"^!1SAR'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^
M!1SAR'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SA
MR'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^
M?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]
MR/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\
M[X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'
MGZ)_<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'GZ)_
M<C_[X-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'GZ)_<C_[
MX-=!]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'GZ)_<C_[X-=!
M]DM_^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_
M^?>+_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+
M_O@4?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4
M?9+?_GWB_P"^!1SAR'/^?HG]R/\ [X-'GZ)_<C_[X-=!]DM_^?>+_O@4?9+?
M_GWB_P"^!1SAR'/^?HG]R/\ [X-)Y^B?W(_^^#71"V@7I!&/H@I?(A_YY)_W
MR*.<.0YSS]$_N1_]\&CS]$_N1_\ ?!KH_(A_YY)_WR*/(A_YY)_WR*.<.0YS
MS]$_N1_]\&CS]$_N1_\ ?!KH_(A_YY)_WR*/(A_YY)_WR*.<.0YSS]$_N1_]
M\&CS]$_N1_\ ?!KH_(A_YY)_WR*/(A_YY)_WR*.<.0YSS]$_N1_]\&CS]$_N
M1_\ ?!KH_(A_YY)_WR*/(A_YY)_WR*.<.0YSS]$_N1_]\&CS]$_N1_\ ?!KH
M_(A_YY)_WR*/(A_YY)_WR*.<.0YSS]$_N1_]\&CS]$_N1_\ ?!KH_(A_YY)_
MWR*/(A_YY)_WR*.<.0YSS]$_N1_]\&CS]$_N1_\ ?!KH_(A_YY)_WR*/(A_Y
MY)_WR*.<.0YT?V).=H$:D_5:D$=WI@\VSE::W'+0N<\>QK9FL;6=2LD$9!_V
M<'\ZQUC?2;]+<N6M)_\ 5EOX#Z4U)2T$XM:FS9W<5[;K-$?E/4'J#Z&K-8%I
M_H.N&%>(;I=P'8,*WZSDK,TB[H****0PHHHH IZA?QZ?!O8;G8X1!U8UD-:S
M7@\_4YR%ZB('"J/>I ?MVMS3-S';?NT';/<_SIEM;_VS=223$_8X6VH@XWGU
M-:))*[,VVW9$._1(_EQ&<>Q-'GZ)_<C_ .^#70I:6T:A4@B4#T44[R(?^>2?
M]\BCG#D.<\_1/[D?_?!I1/HF1\D?_?!KHO(A_P">2?\ ?(IDB6\,;2/'&%12
MQ.T< 4<X<AQNA3:0+"3S%3=]HDZJ>F[BM+S]$_N1_P#?!JYX;MD&BQ2/$F9F
M>7!4=&8D?I6OY$/_ #R3_OD4Y3]YC<-3G//T3^Y'_P!\&CS]$_N1_P#?!KH_
M(A_YY)_WR*/(A_YY)_WR*7.+D.<\_1/[D?\ WP://T3^Y'_WP:Z/R(?^>2?]
M\BCR(?\ GDG_ 'R*.<.0YSS]$_N1_P#?!H\_1/[D?_?!KH_(A_YY)_WR*/(A
M_P">2?\ ?(HYPY#G//T3^Y'_ -\&CS]$_N1_]\&NC\B'_GDG_?(H\B'_ )Y)
M_P!\BCG#D.<\_1/[D?\ WP://T3^Y'_WP:Z/R(?^>2?]\BCR(?\ GDG_ 'R*
M.<.0S](>R<2_8PHQC=@$>N*U.U-2-$SL15SUP,4^H;N[EI65@HHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L7Q 08K51_K#.-M;)( )/ %<_&YU/4VO#_P >\'RQ9[GN?\^U5!:DR>@^
M[YU?3@/O;R?PK>K!TY3?:M)>_P#+&$>7&?4]S_GUK>HF]106@4445)84444
M<]IP.^_CZ/YS?K5KP\RG3-@^\CL&'O5>]4Z=JPN?^7>Y^5S_ '6]?\^]-=SI
M6I"Y&?LTYVR@?PGU_P ^]:O6)DM)'0U7GO;:U'[^XBBXS\[@5E2WESJUP]KI
MTOE6T9Q-=+R2?[J>_O5N#0M.M\G[,DLA^])-\[-]2:SLEN:E]&5T#*0RL,@C
MH163K$5U?21Z=%&R6\HW3S]@@/W1[FM< *    . !3J2=G<!B(L<:H@ 50
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M3S% WH>C#G]#@UHT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8E]CW:H+VRBTI;2XMU*I$VR3G)8'N??K6L79ZF4XV5WN6/#["VA?3"H4VO"
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M.O=32WE%M#%)<W3#<(H\<#U8GA1]:$K@:-%06S3O K7$2Q2'JB/N _' J>@
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MMK;A3V9J*<;:&=6?-JR/48RMC:V2_>=U3'TKHE4*H Z 8K"M1]OULRCF&U&
M>Q8UOU<WJ1!:!1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 57CM8X[R:Z4MYDRJK GC"YQC\S5BB@#/M=.6T<"*XF\D
M$[8"1L7//'&?ISQ5F&Y@G+K%(K-&Q5U[J?<=JGJG=:?%<,)0&CG7[LT9PX]L
M]Q['B@!\_P TL2=N6/X=/YTMJ,Q>8>LAW?AV_2L^2XN+295O0&C*E5N(UX[?
M?'\/U''?CMHVCK):1,I!4H,$'.:?074P;K6=+NY/)OH$$ +".:0!AN'&,=0:
MI:39P7'FV,=XZ.(E9GMK@F.=#D9(ZJWJ!BG36AN9;B>PTS$BS,(KB.8!UE4X
MW%3P%)SG'4=JLZI/9)I\UHVVUNF4/*R0MM5NOS%1P&P1GK3A%I6>[-9-?9V$
MNM3N=.O/L\?D0Q0"-8X"IQ*I')#=L8QTZCWK8M;M-4T[S41HVR1M;JK _P"-
M8ND1Z3J$;P&P:.1XU=E9RP ]$;/&">@QUKHX((;.W$4**D2#A1VI234K$\T)
M1TW(H'S.K#I+'N_$?_K_ $JY5&#.ZV''"$GVZ5>H9""BBJ&I07L\.VSG6/U&
M,$_CVI#+H96R 0<'!P>E.K TBSOXHIHVE:W(DS@QAMW'7-:R0W 'S718_P"X
M!0!9HIB*P^\^[\,4^@ HHHH I:G8B^M3'G$B_,C>AK*B9=2MGM+H%+F/AAW!
M'<5T59NHZ8+LB>!O*ND^ZX[^QJHRMH1*-]2K::F]FXM-1.".$F[,/>MH$, 0
M00>A%<\;M&_T35(!')ZL/E;W![4Y+.ZM/FT^[Q&>1')\R_A5.%]A*=MSH:*P
MUU34HN)M/\S_ &HFIW]N3'@:;<9]/\BIY65S(UI8TFC,<B*R,,%6&0:BCBM;
M"$B-(H(QR< **S&U#59^(;-(!_>D;-0O8M(?.U.[,@'.W.U!34'U!SZ(?<WT
MNJ,UM996#I).1U'H*9._V:./3K%<SOP,?PCN31]KDN/]&TJ'('!EQA5K2T_3
M8[!"Q/F3O]^0]3_]:J;440DY,FL+)+&T2%.2.6;^\?6K5%%9&H4444 %%%%
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MW<H.,_C5RL[1(9+?0-.@F0I+':Q(ZGJI"@$5HT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5:^M5O;.2!OXA\I]#V-6:*
M*>FV8LK*.'C<!ER.['K5RBF"1&!(=3CK@]* 'T444 %%%% "=ZR/$$F+&.+M
M+,JGZ#YC_*M?O6)XC&;>U_Z[8_\ '&JH?$A2V(88IQX0G-N"+J:WED3UWL"1
M_2O'M.FM(M'97 \UY$53L4LJ;3GJ#QG'3G->Y:4P;2+,@Y'DI_*N9U;X=:9J
M5Z]W!//922L6D2(*49CU.".">^*[,-7C3;4^IR5J4IV<3B]-AMD\<:.FCEV
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M<#D<"NDT>Q72O&^F1VLEUY5_I$LUT);AY!+*KQ;7.XGYL.W(QU]J .^HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 2EI,U3O=4L--C\R_O;:V3&=TTJH#
M^9H!*^Q<HKGCXY\*@X_X2'3/_ E?\:3_ (3KPI_T,.F?^!"_XTKHKV<^S^XZ
M*BN=_P"$Z\*?]##IG_@0O^-'_"=>%/\ H8=,_P# A?\ &BZ#V<^S^XZ*BN=_
MX3KPI_T,.F?^!"_XT?\ "=>%/^AATS_P(7_&BZ#V<^S^XZ*BN=_X3KPI_P!#
M#IG_ ($+_C1_PG7A3_H8=,_\"%_QHN@]G/L_N.BHKG?^$Z\*?]##IG_@0O\
MC1_PG7A3_H8=,_\  A?\:+H/9S[/[CHJ*YW_ (3KPI_T,.F?^!"_XT^+QKX7
MFD$::_II8\ ?:5&?UHN@]G/L_N.@HJ*&>*XB66"5)8VY5T8$'\14M,D****
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MY5L=1SR#6)]F]J:I7#ZV9'V8>E'V8>E=KHG@37->5)K.T"VS=+B9MJ'Z=S^
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MO6;X=U&;P_K]IJ<)(\I\2*/XHSPP_+]0*:IZ:&%6I&HM=SZ:HIB.LD:NARK
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MHKS#N(K@2F!A"P63^$GI4E5CMNB\3+(JQN"6(P&(.<#U%6J&(****!A1110
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M ***:65>K ?4T .HIH8,,@@CVIU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %075M#>VDUI<1
MB2&9&CD1NC*1@C\C4]% &*/"VBM:VL%UIMK?&WA6&.6\A2:3:HP,LPR:O?V=
M9$EC9P$F83Y,2_ZP  /T^\  ,]>*N44 9^I:7;:LMJEUO9+>X2Y5%; 9TY7<
M.X!P<>H%:%%% !1110 4444 %%%% $;Q1RX\Q%;!R-PS@TGD1>?YWEKYN,;\
M<XJI:ZQIM[?75E:WUO-<VAQ<1)("T1_VAVZ5?S1J%A:*** "JLUJKMYD9:*7
M^^G7\1T/XU:HH YJ\UJYL[^.&1HW$1_>&/\ C!]NQ%=#%*D\2RQL&1AD$4A@
MB8DM$A)ZDJ*>J*B[54*/0# H =5>6XVG8F"V,DL<!?K4Y/&:S%>/S,SX^Z'P
M1D$MW_#@4XJY,G8)"Q1WFG5(U.UFD?:OY#'ZFE2$2MM"1[<;@ZH"&'&,9KAO
MB/;2I<6;R122::L3Y1<D++V+?AC!]C6M\/XI[32+IG$Z6/G9M5G4AMN!N('H
M3T_&NATK4E43^1@IWJ<C1TLEJ(H2XVL5&<; N?RZ4>8T8WHSB//WF.Y?\0*N
M*RRQAARK>HIL@C*B)B%#<* <'\*POW->7L)'/N;RY%V/V'8_0U8K+)1I6CC#
MC;DMN/0CHPYSG^=:,3%XD<C!8 TI*Q47<<>M5K^Y^R64T_\ <7=5DUA>)KJ2
MWTXQB'?',#&S[L;">G%2W97-:<>::B;:MN0'U&:J:I=2V.F37$$(FE0#9&6V
MAB2 !GMUJ#1+V6_L!-+$L2YVH <Y XS^=:$L,<\9210R'&0>G!S0G=7)G%QD
MXLP?^$E6:]6.WB)M]JYE;DF0NJF,#U&X9.>#QV-.B\46QM8Y[F">'=&CR' 9
M8RREE4X/)('8=QG%:5RFG1RP_:?LZ2,_[K>0I9MP;CU.0#5*.#P_B%D^PXVL
M(_G!!49SCGD $_3-,0KZZ(+HK<VL\,'E1N7902A8N/FP3Q\HZ9]Z8WBBS3(:
MWNA(J&1DV#*H%#;CSTP?KUXIZ2Z'$@"FU^S[0WG&12GRM@ DGJ"QJO/+X9TZ
M(B1[)58O"<NIY*Y9"2>/E4#!]J 'KXEC>_2..WE>WD&V)U49D?>5XYZ<'DXJ
M.;Q-%%:KC#W$D4CQ';A&*[C@C.X<*?:K4"Z$LQF M(IU"S.&90T>XY!//'+?
MF?>I8M+TBXC6XAMK>2-U^5TP5(((X[="1GWH U:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD+!>I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+&.A..3S6M''N@G3Q.ZV?='C5\+.G*QKT9KE[KQ/;09\R[BC]MP!_P :S/\
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MJ_XFU=M1OVA1CY$+$?[S=S_05AUY6&HN5ZU764OP78^BPF'5.%VM63_;;O\
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M$=ZU* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $JG?PB6 ^W\JNTA4$$'O6&(HJM2E3?4:=G<\6\5Z>;/53,
M!A)^?HPZ_P!#^-8->J^)]"_M*!H0=K*=R/C.#_ABO-[_ $F\TU\7$1V9XD7E
M3^->/A*ZY?93=I1TMZ'T>%KQG!)O4WEO(+3P5IAGTZ&\#7$H"R,RA>O(Q6II
MUQ_Q3NFMIMC=RD2NTT=E.(]C[L@.",D8Z9[5P)=BH4LQ4<A<\#\*<DLD6?+D
M=,\':Q&?RKTE.PIX526_6_4[34M3N[/PO=2V8:PEEU1U=$8$I\N2 1QU':IK
M[46CU;PU9W$Y&GM:0O,F?E8]BWJ,A:X/>VS9N;9G.W/&?7%#.SXWNS8&!N.<
M#TJO:,2P<?S_ !5OP.ZN!JHL?$;:X7-F5/V;SB"IDW'9Y?X8Z5KW!U4>*VDN
MFE&@K:YEWD>41LYSZG->7M+)(JJ\KNJ_=#,2!]*NZMJ]QJUX\\V(]ZJ#$C';
M\HP#@T>T(>$DWT^[;9:>>FYUZSW-QI7AN>>66330Q^V,S97 <!-_T.*;.-5\
MOQ"=;+G3VC86XD(*%]W[OR__ *U<)YK;/+\QMF<[-W&?I0TSNJH\K,J_=5G)
M ^@HYR_JFNZ^[SO]_3T/1+L7-VL%U<"\T^2.YMT>TD<-#*=PQY>/3KQ2VYN9
M=2U.T6"\BAEU!B+ZS8 HV ,..ZBO/#+*P4-+(0GW06/R_3TH$THWXED&_P"]
MAS\WU]:/:D_4W:U_ZO\ UN:5CIHO_$36DDXDA65WGG'0QJ26;\0/UJOJU^=4
MU2XN\;4=L1K_ '4'"C\@*K13S0+(L4KQB1-CA3C<OH?:HZSOI8[%#WN9]K?Y
MG4^"+;S+^><CA5" _4Y/\J]8MEV6ZCVS7GG@2-/L#,/O-*V[\@!^E>D#@ 5R
MX%<^*J3?2R/"S"=ZK0ZD/0TM(>AKV3SWL<OX&.=&N3ZWLW\ZZCO7+> _^0#,
M?6[E/ZUU/>F]S'#_ ,*/H<'%<WOA#Q'KIFTC4;[3]3N%O+>:P@\XK)Y:H\;@
M'*\H"">,'J,5BS>&-7N_"(TAK![;5-<U:7499P=RZ7E]^[>I'[P*%4 'DD]@
M:Z0?$;2F N?L6I#2#+Y*ZLT %J6W; <[MVW=QNVX]Z[/-(W/*-974-*^'NCZ
MQ:Z0MCJ_AR80+:$823=^X8(?XE?>K ]\#O5V#19_!.J^'[M;"[U"SMM)>PE^
MQQ>;)'.761I-@Y(<ALD=#C/!KM=0T+3M5O+*[O86EDLG\RW!E8('XPQ0':Q&
M 02#CM3-;\.:9KPA_M"!V>'/E2Q3/%(F<9 9"#@X&1GG% 'E5I8:A?Z=INM6
ML6J006>MZFT\5@J-<P"61E#!2&5MO*D#)PQQ6S::#,;G0KJUL]9D5_$#WES+
MJ<2++C[.4\PJH&Q20H&0#GGO7>Z9%:Z7(FAV&FRVMG;PJT;I&!#R2-H.<EN,
MGCOG-:X(/2@#E?#EE=6OBOQ9<3021P7-Y"\#L,"0"WC4D>O((_"NJI,@]#2T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>'9M+MK>WN+;5;2*Q\E0IVLX5D&.JE"V1W SVKJ7T'39M6N=2DM@9[JV^R7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+1>1;QD^ZY_G4ZQHGW$5?H,4^B@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%96H:C+8WL65W0,OS#'?/8T :M%,CD26-9(V#*PR"*Q=:ULV1%O;
M-<-U.,[/P[F@#=HKD?[/U]HC<M<NK8W;3*0?RZ"FVVMZA>&.S+A92<!Q\I;Z
M^E '845SDD.JV2^<)F=1RP#%L?4&M73M02]B/ 65?O+_ %'M0!>HJK?7T6GV
MK3S'@<!1U8^@KF8WUG7':6*0PP@X&&*K]..30!V%%<:=2U71IVM[B02@CC<=
MV/<'^AJ_#!JEY"MTER<,,K^\QG\N* .CHK#L-5E2;[+>Y#9P'/!!]#_C6Y0
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MSS2MJ=WEG8DQ[NY[M_A26^B:C<222WTX#D< G<<_AT%3K;ZS$GD(QV8P"&&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<3Y1CV# 5>> ,9H ]\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB4G'?8]*I:Q/#VN#7+.25H?*DB;:Z@Y'3((K:K"2<79FR::NA:***0PHHHH
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MZ7$,OJ-HH'K,O^->+O"7.7RQ]6.:C-L/[H_*BP7/9O\ A)-%SC^UK+_O\O\
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MP>U-,'M6J8/:F&#VHL!E&#VIA@]JU3![4PP>U%AF48/:F&#VK5,'M3#![4K
M91@]J;Y)5@RY##D$=16J8/:F&#VHL!=T[7WCQ%?99>@E Y'U']:Z..1)8U>-
M@R,,@@\&N,,'M6OH#2))+#UCQNQZ&I<2DS?HHI"0!DG J"A:*IG5-/!(-];
MCL9E_P :/[5T[_G_ +7_ +_+_C0!<KAO$W@*RU;6=#O+32],"VU\;B^WP*#,
MA4@@X7YCD@X-=;_:NG?\_P#:_P#?Y?\ &C^U=._Y_P"U_P"_R_XT /L[&TT^
MW%O9VL-M""2(X4"*">O XJS5/^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\
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M67H%T;SP_83D_,855OJ.#_*M'.3BBXA^:,U1EU&-9F@@BEN)U.TI&O"GT)/
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MCA409+&BWM=;FN;N*2:.S4QD1E &(.>"#6E:V4%MYOE!F6X^9BYW,&'^%6P
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MZNLTNHO%&(<+D':&SSC].?7BMW:2YT8JZ?*SIX+D.JACDG@,. QZG'L/6K(
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MQG<NT #IC!Z^^:WK.RMK"W$%K"L48.=JCOZU8I:B4Y2W92BEL%%%%24%%%%
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M<'Y5^4Y_6G[-]S7VE'^7\33_ .%YVW_0OW?_ '_3_"C_ (7G;?\ 0OW?_?\
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M=I_A)X'H!4?]KRVR;;JTN[=QP<1[U)XZ$9XR?TKH:*I3[ZD\O8K65Y!?P>;
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M/DEFR"7+=1GD;L8QDMTG7KR"P\02W[2W']EY=1-$(9G41[CE1P%)!VGTZ]*
M*>OZ-J4_B>YO+2QG::9+-;6[CF"I"4D<R%QN!QM/H<YQ5GP7#<M<:E/)<&>U
MM9#86+^:7#Q(S-OST)RX0G_IE5'4?&FJ16D30Z>EO<Q7%O)+#Y@F\VV>-Y&
M( P^(V]>0.3FM/1->GU'Q==V=OY/]CQVH:V*+_K'#X=@?[N3M'^Z: .MHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/2 9F
MN+ME):>9F]\*=J]AV'ZU7\1Z@UA8SR^5-)';PF>1$X9@.,!NP]?:I]! 2U:
MJ T;O&PZ<AC4.MK>1)<-8/'#<S6[11R'[J/V))X%546MD33MNSEK/XA2[5BC
MTS2P,D8CU%"./P]ZV--UIK^1[F.VA@:(;W$,PD5AG!R!CGT-<Z?"?B88"76K
M+ZG[1#Z?3UK8T33-8TQ;R"_O+N=+E56**Y,;L#GEAMYP!_2N=4:BE=ST['9.
MI0<&HPU.SD^> G:W3<-V,G\*I:&P2.ZM0<BWF*KSG"D!@.I]<?A5U%$5OA=G
M"[05JCH^7N=0FR2&F" G_94 ]_6NE? SC?Q(V:***@H**** "O'/B/X7UFS\
M02^)-#$[+<1>7<_9P3)&=NTD8YP5 Y'(_&O8Z3%9U*:J1LS2E5=*7,CYC&NZ
M]($66\NR8T,8+*=P7Y<C.,_P+UYX%7DUW6WG:9KJ?S&&"0@'<GT]68_C7T;@
M>@HVCT%<CP<G]L[UF$5_R[1\_P!OKFM1QPQK<S;(5VHIC! &,8.1SP .?0>E
M7DUG4MML(C)'Y".H."V\NVYB<Y')QQTXKW+:/04FP>@_*H>!E_.4LRC_ ,^T
M>*QZCJ+1F-IIBK+M(*]1@CT]S73Z#9:IJ]S$]V9?LJ2>8S2KC<V<X'&>OX5Z
M&% [#\J7'Y40P%I)RFVNPJN9\\6HP2?<<.!1117I'EA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%)%'+M\
MQ%?8P9=PS@CN/>I:* ,JYT#3+K4%U":T#7*E#NW, Q0DH64'#%2<C(..U0IX
M7T5#,5T],S$,X+,1P_F8 )P%W\E1@'N*VZ* ,N31-.ETV33&M1]D=S)Y08@!
MM^_((.5^;D8QCM1;Z%IMKJ+ZA%:*+IBQ+[B0"V-Q )PI; R0!GO6I10!B_\
M"+:.;NZN3:MYEV6:X4SR%)2R[6W)NVGCCI4MMH.FVMG=6<5M^YN5*SAW9VD&
MW;@LQ)(V\=>*U:* ,T:'IHN$G%J@EC,95LGC8K*G?L'8?C2:?H6F:3Y(L+**
MW$4/D1A,@+'NW;1^))K3HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*.PZ_G6A1)JUD"75BT445)04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I*"<#)K$U+Q'9V.GRW$,L=RR,$V1R _,?7T'!IJ+;L
MA-I;FW44T\,";YI4C7IN=@!^M<'?>*-2U/2V>RBDM_*?]^T)W$*1\O.,CH<U
M!+I>LZUHMM=3OYGENR*LQPQ4D?-^>1SSBM51?VG8S=3LCM[[6M/TX1_:KI$\
MP97&6R/7CM[U7O/$^E63QK+<Y,BAP8U+ *>A.*YBX\)R/I-C+]J_?*A1U(RH
M&20!Z8Z59U#PC:D6?E7,B@1!'. =V,<^QYIJG3TNQ.<^QOW/B;2;6=(9;M=S
M@-E02 #T)(Z5;?5M/2Z6V:\A$[8PA<9.>E<OJ/A"WEU2!8IWBB955EQD\#'!
M^@JO=^$7GU]A%.JVY8,=P.Y0 "0/7M1[.FUN'//L=[FBO.4TW7$\3O+&99"D
MI<S;_E90>GY<8JQI?C.^DU39>B,6IW%P$P8@!G_ZW-2Z+Z.XU574[ZCM61I/
MB.PUB5XK=G$B#=LD7!(]16Q6;33LS1-/5!1112&%%%% !1110 4444 %%%%
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M>?XSZGVJR\BQKENG0 =Z8;B,*"K!\_="<YJ .SR;@N^0<  _*GX^M $EQ'N
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MN!5:UTFZ:P%O:*GV#RA#+>A5<_:2 ZJ#G<N?RY '-1_:-1^];U7EW*59=O\
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MP9V/V=%2I--/OWZKT^3,/6O"LFA:GI,D-_YMM<ZA#$IE7;)$V[<#D8!'RD=
M>1UKU4#!KAOB7=V'_"-&QED9M2FD1K&"(_O6E#?*0/3W_K78:>+D:;:B\96N
M1$HF91@%\#=^N:Z80C!M11S5JLZL8RF[M71;HHHK0P"BBF1R)*@>-U=#T93D
M&@!]%%% "56O[DVEA<7*H7,4;.%'? S5FL?Q+?7%AH<]Q:C]X"%W8SM!."<4
MXJ[2$W97.0T"^AU'79;C4+*&61UWAT7&T_3.#]>M=BZ6IPPDV'LLZG'X$\C\
M#7.^$;YS9W EM(F0N/WHC"[O4$@8./ZUTL1CD/[A'1O^F,BD?B,X_2NBII(Q
MAL7(BL< 8YP>>&+_ )'TJ1)8Y/N.I^AH?S-HV%<]]U0O#))]Y8"?7:<US,W)
M9(4DY(^8=&'!%<IJ:R+J$PESD'Y21U':MG4)+BULG>,LO09#9 S]>16':R,;
MV$L/-)< J_S9R?>@#9T.W1K02R1(6#'8Y7G%;-8&J>([;3Y#;Q*)9EX(!PJ>
MQ_PK*/B^[)XCA ],$_UKDJ8RE3=F[^B-H4*DE=':45Q7_"87?]R#\C_C1_PE
M]Y_SS@_[Y/\ C6?]H4?/[BOJE3R^\[6BN*_X3"[_ +D'Y'_&C_A+[O\ N0?]
M\G_&C^T*/G]P?5*GE]YV9 8$$9!Z@US6N0"&ZCV1*D13C:N 3GG^E45\87(/
MS1PD>@!']:U(-?M]2M)HP@6X5"PC?!!QW'KBM:6+I5'RIZ^:(G0G!78:#"TG
MG;MPAXX'&36_\L:=E4?@!7%Q3RPR!XG96!XP>M=4L$KX9P ?]LEB/PZ5U&1,
MLK2L-B_)W=N,_2F7:!HLL%*KR=[E5_'UI_D;O]9([^V<#\A4C+\FT9&!QBFG
M9B>QG>9=R*!" J]BJ;1^;?X5Q5]I;:;XFAN+R^AC2283^9N)8#.>1C\,]*[<
MPW4F3OD1?5Y.?R4?UKC_ !=I<,5Q%=27ZAW&QD*EC@=QR?7O6]-J]K[F4UI<
M] 5@RAE(((R".]*:I:2T#:3:?99/-@$2JC^H Q_2KQKG:LS9!1110 45&DB2
M%@CJVTE6P<X/H:DH **** ,G6;'2KNR:35;>&2WMP9=\@_U8 Y((Y''I7BFM
M+IP^RW,EG!;+)<22Q1.A)AA*XVX!!+'Y.,_>->Z7]E!J-C-972;X)D*.N2,C
MZCI7FVK^%_"/VB>*_P!>9M0MRODR3%6-N.I4J!M8G/.1NZ=.M95%*Z<78\_&
M49S<7%I);]_)' VA-E9000VL=MIXDFBN6EW>9(QPZ#8"0K8R%(// (R :LR7
MWB'Q7X2%V-4N[Z2U@%U=0ED\I50G.1M!W_*>GH>U/E1!X;G:TABO=UV]S%%
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M?$?C+^U+?5K?3M5,21&3*JLSCY=OINP!E2!D8XX%:/B3Q=XP^S:GX?OECNX
M%MKJ^L[<9B=S@(3N"Y_+K75-X(\'Z3IESX@^W2SV+_Z22;A1%*02RC*@$\\
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MZ6/4G@E26-]LB$,I'8BLW5H!IUXL*.Y5XED&\8(SG@\#T]!5%9G=@B99V.%
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MPRKM8 D@$/VR#@5OGQW;S^*=(U/P_H=Q!=1Q-936L4@(N(@IV)L49^5N<XR
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M;+')(.T<6YOSR<?G7'^'-/:RUJ:WO;B*W94VF+S%)<]?I^==@6MT3:C/*O\
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ME!C?ICY>O.<]NG2B25W;IT>X:]3JZ***D84444 %%%% !1110 4444 %%%%
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MI7V.Z665P^SYE"CKCK^(ZUNLJ31X.&5A0 B.LJ97D'J#49A:/F%MOJA^Z?\
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M&23^)J33[&'3;&*UASY<8P">I]2:MUG.HY:+8N$.746BBBLS0**** "BBB@
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M #G_ #WK+A^%R11O$VK&:)E V36Y<*?49?(KT:D_&BFY0=TW<PGAH3^/7U.
MMOAE!93PW%KK-Y%=11F)9E5<HA_A4]0,=,DD9XKHM \+V'AY':W\R:Y<8DN)
MFW.W.2/89YXZGDY-;U!JG)O<TA2A#X586BBBD:!1110 4444 %%%% !1110
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MP)5">2!UP* ):*BDFBBVB21$WMM7<P&X^@]ZAEO[*WD\N:\MXY/[KR@'\B:
M+=%-5@RAE(*D9!'0TQI8TE6,NHD8$JA/) ZX% $M%-) !). .I-4[35]-U"6
M2*RU"TN9(_OI#,KE?J >* +U%%0R3Q1.BR2HC.<(&8 L?0>M $U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1)-'(SJDB,R'#A6!*GT
M/I0!+147GQ><81(GFA=Q3<-P'KCTJK+J^FV]VMG/J-I'=/\ =@>=5=OHI.:
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M-LJJP9I(\,2Q.WA<<9]J )?C!X8M+SPAK6M75U>RRV]NOV>W-PP@B8,!N"#
M+')Y.:T?B3<3P_#/R;>5XC=O;6KO&<,$D=5;'U!(_&M/XA:1>ZQ\/=6TO383
M<7<T 2*/< 6(93U) Z"D\9^'[O7_  +)IMHR)?QB*: .?E,D;*P4^QQC\: .
M=\4^']*\*:IX/U'0M/M]/G_M:&PD-O&$\V&56#*^/O= ><\UZ?7FL_\ ;_C7
M6] BN_#MUI%EIEZM]>274J'?*BG8D>TG<,G[W' KTJ@ HHHH **** "BBB@
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M;!J=/^$,U?3FFCU"TGM;=YRSI=<(;DLKYYXW%V ^O%6C#X8GUMX/M-NVH0+
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M@]D\DNY&,9E$3&+S F\Q[\8W[><?AUXJWI&K6^MZ;%?6BSB"49C,T31EE[,
MW.#V- 'FMY:^(KF+Q ES->-,UM?H]HMM.RRH0PA"L3Y7 V;=@W'D'G-:-W;3
M:;+K8@M-4#7.H6LDLB-<%1"84!?Y/F8!U92J$'IG"BO2J* . 5M9/PRD"?V@
M=02X*1[D=9_+%SA>#EO]7CJ2<=2:72[758]?MKR5]3)EU>]BF6660Q"W D,7
MR'Y0N53! []>:[ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZR?NT#N0Q;:"=PZ-R.2,#&?2J=CHUK9V$MFP-T+AVDG>XPS3NW4OQ@] ,8P
M  ,"BB@!\>BVL5_;W4<:K]FA,,$* +'$&.6*@#J< ?0>YSI444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) E # 2(  A$! Q$!_\0
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M>HW]OI>FW.H7<ACMK:)II7 )VJHR3@<G@5 -4\VXTY;>UN9[>]1I!<QJ/+B
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M11^ H MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/!.@W-Q(TD\VGV\DCL<EF,:DD_4UNU7MK:&RM8K:WB2*"% D<:#"HH&  .P
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MN_.EN)K?+['Y#^O Z?04U:3=WN*2E&*LKVU&:E<?VS<+I5JY6*0-YLFWLI'
M_6KVAJMO!-8J /L\A4#;@E>Q/KGGFH=!\AVN9XE2,,^Q8U&-H4?UX-3P3)%J
M&HSL<1KM!9NN0O0>W]<TY/1P6R_,FFO>563U=_N%B!37YPO(D@5GR.A!P,>H
MZTNL0EK3[0F?-MCYJ87.2!TQZ<TFFH\]Q-?S1/&9/EB5SRL?';MD\U<NFVV<
MS,Q4"-B6'4<=JB]I(U4;P=^MV.1UN;97!!5TZCD<U3T0EM+C7 VH65#_ '@#
MP<=JABN'M=!@14/GO%MC1!DDXX/]:O6%L+6SCBYW?>?)S\QY/ZTFK)KS'%\T
MD_+7YERBBJSW=O'=QVKSQ+<2J6CB+@,X'4@=3C(J#<LT444 %%%% !1110 4
M444 %%%% !1110 W^=>4_&J]TX:;86#Q![YI#+&^<&)!PWUSTQ[>U>JCKQTK
MQ'XOPO;>,--OY(O,MF@4 'HQ1R67\B/SK;#PC.HE)71A7JSI0YH.S[KI<X[1
MC9Z!XC@;Q'HTTMMM#^0X*G!Y#[3]X>W_ .JOH[1]5T_6-/CNM,FBEM2,*8_X
M<?PD=B/2LW4-)T+QUH4+S1I/!*F^"=.'CSZ'L?4>W(KR"]L]?^$_B)+BVF,U
MA,V%;HDZC^!QV8#O^7<5SUJU3G;GJOR/7PF$PM>BH4?=J)=7?F\[]SZ$%%9N
MB:M;ZYH]MJ5L28IT#@'JI[@^X.1^%:/J*I.^J."47%N+W0ZBBB@04444 %%%
M% !1110 4444 %%%5;N\M[./=-*BD@[59@"Y'89ZFA*X$\CI&A9V55'4L<"N
M;O\ Q9%%?3Z?:P2278!2-L#:9,<#UK":YO\ QKNMML5O]G)D4<X;MM/O_P#7
MK;L-'M;:"WG6-?MMN KRL.3VS_3Z ULJ:C\6YBYM_"8IAU[Q#IDJW4OE^1)G
M;(NPOP<\#TQ_.KR^%H!+874]Q+*RA1-GHQ7 Z]<?X5T0.;GS0O$BX9>X[,/P
MX/YT]+5S$$<X7.3SST(/]#3=2VV@N2_F8\?AW2X)[]1!E9$/#,2%'!X].HIL
MGA_3&TVV@^S@;96.0Q#'G!Y_*M]K8')=\%@5)QURH']*4VL;,?F)PQ./0G!_
MI^M3[3S*Y/(P)/#>FR:RT^QHUC3.Q&PN0 ,_Y]*QE\.WNFZ=<7%C>.)I&$85
M?D)0')Y]?\#ZUVS6A)?YP0_#?3=D_IQ4+0L/+\P8CCY/_H1/\A^)JE4?<3@<
MK_PD.KZ"+2ROK<3R$;F9VRQ4G@ CN/QKJK+6=/U":2*UNDDD3[RC(_$9Z_A4
M9*[Y+F55W_=12,X.,G\AU_&N9O?#\NDVWGZ3).+V4XV*1E4/8>^<?K0U&?DP
M3E'S1W=%<MHOB0+)!I>IF0:AG8S%1C=V!([XQ755E*+B[,UC)-:!1114C"BB
MB@ HHHH **** "BBB@ HHHH 2F.ZQ(SNP55&23T I]9OB D:#>X_YXM3BN:2
MCW!%FSO;:_A\ZVE66/.-R^M13:G9P7Z6<DX6=\;4P>_3GH.E9/@X+_9UQ@C?
MYYW#T^48K-U K_PG*&4[5$L6"?\ =X_6NA8=.I*'1)E<NK1U<6I6DU[)9QSH
MUQ&,L@/(J:XGCM;>2>4X2-2S'V%<?IY\KQS*'X+22J/Q (_05T.OSQP:'=;V
M \R-HT'JQ& !4SHJ,XQ76WX@UJ3:9JEOJENTT&\!6VLKC!!_R:O5S/@U&%A<
MN?NM-P?7"@&NFJ*T%"HXQV0FK,,5BW4<+ZVB7$0,<L.T;URK,"2 /0@9_.MJ
MJ=]:?:X1AF26,[D93C#8_E4Q=F95(\T=.A5_LEX"#9WDL6"<(QWH >P%&W6(
M4&)+>?:<98%2X]3C@&G6^JQD^3=D6]P,#:[#YL]Q4\NI6D"DM.I(.W:IW'/I
M@53<KVM<S2IVNG;Y_H<M%!<M83M(EO#-;,3O&?,SDX^GUYS[5=M-"O<"XGGC
MFD8;C'<)NR?<_3';BG2Q375T-2:TD:U)^:#/S.!]UMIQ^5;=O?VMQ'OCG3&W
M<06 *CW':M9U)):?UY'-2HQ;]Y[;>?F55DU@':;>V(ZA@Y  _NX[GWZ54NY]
M4G$=LR11-.?NH2611UR>AJ_=:M;V_P L;":8@;(U.=Q/3FBRLG69KNZVFY8G
M;@DA%..!^59IV]YI&\H\SY4V^X6.DP6>QR \RC D(Q@=, =N !6E116;DY.[
M.B,(Q5DA:Y#QIX*A\4)!=VUP]AK=G\UE?PG#(>NUO52?\]CU]%(HX+PCXXN+
MC46\->*818>(X!@=H[M?[\9Z<^GY>@[VN9\7>#M/\7Z>L%UNANX3OM;R+B2!
M^Q!]/;_]=<]X:\9:AH^JQ^$_&NV+4>EGJ/2*]7MSV?\ G]>H!Z/1110 4444
M %%%% !1110 4444 )VK!\4>&;+Q3I#V-W\I!W13*/FB?L1_4=ZWJ*:;B[HF
M45)6>QX!:W_B;X5:N;:XB\[3Y&)V$GRIA_>0_P +?Y(KI/'/C#0?$GPXE>WF
M!N9)D5().)$<')./3:&Y''-=#X_\6>'M*TZ73M2@CU*XD7(LL_DS'^#Z]?2O
M!7TZ\>P.J?8Y4L&E\I9L'9NZ[0>_UIUZ\:RY(Q]]Z:;?,[,NP4\/)8FK+EI1
MUUW]%W/=?@_%,G@.)I 0CW$K19_NYQ_,&N^ P*P?!]]8ZCX5TZXTZ$06WDA!
M"/\ EF5X*_@0>>];]1&+@N5]#&O65>K*K':3N+1113,PHHHH **** "BBB@
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M\_U"[N;6_NH['[28IC^_;R6;[.W +IQSD=AWKJIJ,8IGE5_:5*K@G:VR[_\
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M+KOB1I9(YCYJ6[L=TV>=\AZX/IWKI_BM=6&F^!3IP6-'G=$MHD &T*P)('8
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M,:]95ZLJL=I.XM%%%,S"BBB@ HHHH **** "BBB@ ICHLB,CJ&5A@@]Q3Z*
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MC4&]S*T718=*LX(W6.6XC4CSM@SR>@/7%:W:BEK)MMW9HDDK(****0PHHHH
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M@A"VP7#6T@AS_O[<?CTK>U_Q9H?AG38-1U:]$-I<.(XI%1I Y(+#&T'L"<T
M;M%<;I?Q2\&ZQ?QV-IK4?VB4[8TFBDBW'T!=0,^U=E0 45FZKKFEZ%:FYU6_
MM[*$?Q3R!<^PSU/L*?I.JV>M:7;ZEI\OG6MPN^.3:5W#.,X//:@"_16#J?B[
M0=&O;>QOM6MHKRXE6**W#;I&9B /E&2.3U/%;U !16-JGB?1]&U+3M.U"\6*
M\U"3R[:+:6+G('8<#) R<5LT %%%% !1110 4444 %%%% !1110 4444 <E?
M:QXAN/%=[H^C1:8$M+6&=GO#)EC(7&!MZ8V?K3-,\=Z?-HEI=Z@KV]W/+-!]
ME@1[AF>%BLA0(I+(",[L=",\TRY\(1:KXYU'4=1MY&LWL;>&!H[EXR65I"X(
M1@3PR]:;=:)<:!XAT_5-!T=;JR@T]]/-E Z1-$"X=73<0I!((;D'H>: );WQ
ME;1ZAH\]M<PR:-=V=W=S7"JS$+"$.1CGC+9&,\8K4N_%6B6*A[G4(T3[(;T'
M:2/(!4;^!TRP_P @US&D>%=1L]1T>\OX(!$IU*XO8Q("D!N75Q&,XW #()Z<
M'UK"T?PS?:EX+\1I;O'>/C^R=+<, KVMO(=IW'CDE@3G!VB@#MF^('AU7DC^
MU7/G1KO,(LIO,,?_ #T";,E.#\P&/>K5YXPT.SM[2=[WS$NX?M$/V>)YF:(
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M8SNSQCZTYG5<;F R<#)ZFO ],O+C0_A$^GWLS/IVKZ7+-8RN?]5< $R09]&
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M?UK1HH S],TJTTB&6"R1HXI)Y)RA8D!W8LV,]!DDX''-:%%% !1110 4444
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F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &1 EH# 2(  A$! Q$!_\0
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M4Y!!Z'CG\*Z&&YCF+*I^9<;E/49K*<.56L=%.ISN]RQ11169L%%%% !1110
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MBOJ&V,_+N41-LRQ*\\@8JXWC-KZ#14T+3A>WNJVWVM(YY?*2"$8RTC 'N=H
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MCF=CC=@X8 J0<8R#5B[\'7U[X7OK2T\/Z+HL]Q=VLB06C@DI'(K,9'"@$]<
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M!3N;NPZ'WX-<;X(UX:]X>GT.9LWMI&)80W61%X_,#C\JZ+4Y%@:61%#)$H"
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MS%S^1T=%<Y'XBNK54&JZ>\0\LR/-#\RJ,\<>_P!:V[6]M[V%9;:99%*AN#R
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M?8C-(9-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME*L5!5<_*!51X?/ E3 )Z@U'!.XD"LQ(/'-/WHC$1R[!W+=_I6=[LW244->
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M-LRI+.Q3GC&)$(SP2N*<?"5RSWTPL+="\=JL<'G%@8T<M)#N(R%(P/0].@H
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MZL_[[?\ H1KK/ :L[$U%%% ALGW#4%3R?<-052 ****8!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 6:***@ HHHH ****
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M8V]M8P@O?K:W.Z8D!6A,JLAVC/ [CMWSF@^."FF6M_/I?EQS1?:-@NE:00Y
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M=+./]'="'D<&.>1"/,.7 (8':QY*],\XHU @LO$/VS79=.^QM"%!9&ED"NX
M!W",@$J<]03TYQ5*XN=6A\17\*ZLQMK:Q%ZL1MX^26D&PG&<#8/>MF+1;"'4
M?MT=N1<99E)D8JI; 8JI.%)P,D#FIGL+62XFN'A!EF@%O(V3\T>2=OYL?SH
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MI6$=I)8-9[)KB*W87$;D@R.%R,,.F>E1GQ-;06[-<K(SPS36\IC3"EXHS(Y
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M@_U;?[[?^A&I:B@_U;?[[?\ H1H EHHHH ;)]PU!4\GW#4%4@"BBBF 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %FBBBH
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M 4444 %%%% !4-QUB_ZZ"IJAN.L7_704 34444 %%%% !1110 4444 %%%%
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M'_LV?PQ2&]U(082V9I"?E8Q$ KSR1G@].*;+=ZG#*L1179B=I$1^;&[CKQG
M.>V:!$@756"JQX.X')7TXZ4OEZL6!$@ &2?NX+9XQQ]W'XU;L);B59?M"%2K
MD+\NW(JY0,R;BWOIYRF_$'F*2,@94,IP._3=G/7BI)8M0,KM%-CD[4.W;C*X
MSQGINK2HH QXX=69?WMQM; ^Z%]\]CWVTEO!J<0?+'DN^"R\L2Q '' Y%;-%
M &+Y>M>62)%W] #MZ?-S]?N]ZU+82BW03G,N/F.!_2IJ* "BBB@ J*#_ %;?
M[[?^A&I:B@_U;?[[?^A&@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *AN.L7_ %T%34R2-9%VN,@'/!Q0 ^BH?LT?
MJ_\ W\;_ !H^S1^K_P#?QO\ &@":BH?LT?J__?QO\:/LT?J__?QO\: )J*A^
MS1^K_P#?QO\ &C[-'ZO_ -_&_P : )J*A^S1^K_]_&_QH^S1^K_]_&_QH FH
MJ'[-'ZO_ -_&_P :/LT?J_\ W\;_ !H FHJ'[-'ZO_W\;_&C[-'ZO_W\;_&@
M":BH?LT?J_\ W\;_ !H^S1^K_P#?QO\ &@":BH?LT?J__?QO\:/LT?J__?QO
M\: )J*A^S1^K_P#?QO\ &C[-'ZO_ -_&_P : )J*A^S1^K_]_&_QH^S1^K_]
M_&_QH FHJ'[-'ZO_ -_&_P :/LT?J_\ W\;_ !H FHJ'[-'ZO_W\;_&C[-'Z
MO_W\;_&@":BH?LT?J_\ W\;_ !H^S1^K_P#?QO\ &@":HH/]6W^^W_H1I/LT
M?J__ '\;_&GHBQH%48'US0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  F$# 2(  A$! Q$!_\0
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M<\$'KQR1S6^WB+3%$K-,ZB(D$F)P&(?80O'S?,0..Y%$^O00SV\8BE;SVC
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M&1<L>H[U\YM_K-9_WC_Z6)7T4APZD],BO"F\,^(/,UC_ (D=_P#,3L_=??\
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M%<G\/[ZP&E_97F":M.[230R JS$<#;GJ H'3/>MCQ-J4VEV^G3PN55M0ACF
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M9A\V\8 !_P" XI1?[GGZK3[_ /('O8UM=Y\/:E_UZR?^@FI-(YT2P_Z]H_\
MT$4S7/\ D7]2_P"O63_T$T[1O^0'I_\ U[1_^@BLO^77S_0?4NT445D,****
M "BBB@ HHHH EF&="O!_N?\ H5<KLK<U#5DL[.:T-O)(TB*^Y2   WN:YO\
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MZ%>S:A;7<\QR/MDJQ>T8/R_IS^- SJ="U^\LM0M;"]N?M%I.3%$[H%DB8*6
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M4_WKDMDTC]0PN-7U&-*2]Z4)._WE_P -.?#GQ"T^-F/^AZFUDQ]5+-#_ .S
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ML^A:9#YL9BD\NT1=Z'JIP.0?2@#CO#B07?C8P/Y<L3Z1,CKD$$&6,$&NFM/
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MK3_ORO\ A0?[/TB-2L<%LLL@0!$"[V/08 Y/6L;0-$U'3[2[2>=UEDC5%?S
MX\P YD "CJ2.N2<<U6L?#=VMS:27,$2)!-&Y03-)EU1PT@)'5BR<?[.357?1
M&;BKM.=TOQ_$[.BBBK.8**** "BBB@!N?6O$?&7_ "6"+_MA_P"@U[=CIS7E
MOB3P?KFH?$B+5K6S5[$>5F4S*,;5P>"<_I65:+:5NZ/0RRK"E4DYNUXR7S94
M^!Y_=ZS_ +MM_*2O7J\X^%GAC6/#4>I?VM:B SB(1@2J^=N_/W2<?>%>C#I3
MHQ<8),G,ZL*N*G.#NGU^2 BOF27_ %GB?ZG_ -+(J^FN]>&R?#SQ.9->(T],
M7))A_?Q_/_I*2>O'RJ3SBLZ\92M9=_R.C*:]*DY^T=KV_"2;_ [_ .%1/_"O
M+#_KK/\ ^CGKM,<5R_P_TF]T3P?::?J$0ANHWE9D#AL!I&8<CCH174#I6L$U
M!)]C@Q<HSKSE%W3;_,YOQ\?^*!UL=_LCU\]ZA_R+-H/^FUW_ .@6]?1OBS3[
MG5/">J6-HGF7,]NR1J6"Y)[9/ KQR[^''BN;0K:V33$,RRW#,IN(_E#K"%.<
MXZHU85X2D]%T_5'K93B:5*FU.27O7^7*U^9[Y#_J(O\ ='\JDID2E8D4]0H!
MI]=1X;W"C%%% A,#TJ">VBN%"2(& 97 /JI!!_,"IZ* 3:>@8'I1@>@I:* $
MP/04M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! EH# 2(  A$! Q$!_\0
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M "_XU\I;$_NK^5&Q/[B_E1]07\P?7G_*?5O]LZ7_ -!*S_[_ "_XT?VSI?\
MT$K/_O\ +_C7REL3^XOY4;$_N+^5'U!?S!]>?\I]6?VSI?\ T$;3_O\ K_C3
MX-0LKN0I;WD$L@&=L<H8X]< U\H;$_N+^5>A?!M5'C*XPH'^A/T'^TM9U,'R
M0<K[%T\6YS4;;GO-%%%<)W!1110 4444 %%%% !1110 4444 %%%% !1110
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M)K&-I;A=P^55QD^_4=*LGPQJP=4%NC2&2.)XUF4O$S\(' .5R>.:Z?JE'O\
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M1O;]1?6ZMK_H>W_\+A\+_P#3_P#^ _\ ]>C_ (7#X7_Z?_\ P'_^O7@X!.<
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MQ\Z_D8LCHW"C<' #YP.20!DGGWI(=5U.>VATV*>66'<J1PJ 6/S9" @;L9[
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MN;FR%TV8Y,KDD;54*2W3L.Q)P*/:1[AR2[$WA_5Q9Z7-;S7HCA2^M;AH&/\
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MB*N*P9016IQBT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTU&JBZZ'7T4Q75B0K D=<'I3ZR- HHHH **** "BBB@ HHHH **** "BBB@
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M->PDXWW8Z.2P2X:/:5V.S[F<[5.!DC)X_P!9CCOFK"Z=8NBND:O&5&W#DKC
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M4,RH,LP ]2: '44QG12%9E!;H">M*651EF [\F@!U%1B6,D ,I+ D 'J!4E
M!1110 4444 %%%% #3G!QC/;-<-H+ZT^OW,UQ"7(!65G4?*<\!3_ $]*[6X4
MO;2JLGEED(#_ -WCK7"^$[.1+J[9=2APN%*I(3O.?O=N/?WK:E;ED95-T=8#
MND&^$1.3C(+(3^(&#6@ZN0-C[?7(SFJ,3,)4W3HY)Z"8_P L5<E9DY$B*O\
MM5G(N(QK=GY+(3ZE*P=:\^.9%=F\K;E<,2,]ZW1-*?ND,/41G_&N=U:>=[QH
MY&8*N-JXP/KBI*-;00_V$EU &[Y3CDBL?5_B/X7T2\:SNM2!N$.'2&-I-A]"
M5! /M3_$6IW5EX O+U&9+@0[%D Y7<P7=^1S7E6C>"K#4[72;EKI$6Z^T&9&
MG59&V9QY:D9/3GK5*#:N5!PO[YZ)_P +?\'_ //[<?\ @))_A1_PM_P?_P _
MMQ_X"2?X5P6G^#=#OTT\1R7<C2O EQ)&Z?(S_>5HR-T?^RW(-4=<\)64 MIM
M*+/%)#)(XDN(W"['*G#C 8^H'(H]G*]C3FH>9Z7_ ,+?\'_\_MQ_X"2?X4?\
M+?\ !_\ S^W'_@))_A7F#>'M%CBT6=7O[B/4(Y<Q(BB1Y%;:JJ.< GN<\=JD
MG\-:$)]<C@NYY'T^V\] I5D!&T,K./O89B.!SBG[.0<U#S/9-!\;:!XDE:'3
M;]9)U&3$Z&-\>H# 9'TJ/7!(-0RRX0J-I Z^M>1:CX?B\-6]CJFGW>Z[M6B>
MXD609BD=-Z+LQP",\Y.?05[!JUS-/:6;X*12QB0C_:(SBDXM*[,Y.#?N%W38
M9Y+%#,3WV[\DX[<5H>0I^^S/[$\?D*R=%FN7MG!+M&K84D;OJ.M:69&^\)<>
MB@#^M2232 "%@. !V.,?C6:520?/<D#T!9OU/^%:28$)X91S]X\UG-)'GF(R
M^XD9OYC%7$B9R-B-+L/&:I'+</\ .50X 57;C![D<UZ&*\]N+RWC\:P[-,16
M$B)@DAB3CY@.F1_2O0JNONGY$TNHM%%%8FI!<A#:RB10R;3N!Z$8K@K2TBL+
M7RP=P^\S-CFNYO[<W-C+$N-S#C/3-<5>0M-;NB?>]/7VK"L=V$M9@DUM<-M!
M1R/4=O:N;U:YGL9VBE.U6)\O:.6'M6K96DRW2NR%0G//>EDL+74-9\^0.6M
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MD:Z JI8,5!(Z$CI3J ,+[$;.YMMK1>;+<[]D2;%50A#8&3V S[XK=INU=P;
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M1QM(H>3.Q<\MCDXH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<**L5E.7-)LTBN56%HHHJ2@HHJO=7<%I&))WV(3C."?Y4 5;G1+"[D$DD #
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M;W**/E^;^54Y;_)P&)]EK,O;^&TMVGO;B."%1DM(VT5PVH?%&PBE:/3;*6[
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MI1P,D(>-RIQG -3V]TUPN''S+Q2<;#4KZ$NX X/%!7S 4SR>*4@$8(R*KVY
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M+_9$X@C#PF4A8G=#)G<ZR9/4]=N: .AC=9!N0@C)&1[<412QSQ"2)@R'H16
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MQ&9GVN(OX&0=R?YU%KEN7+TV.!NK<(, $-7JGPKL8H/"TEVC;I;J=M_^SMX
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MYAO6TZVO)(HU_P!(,!.,>AP>>_'-%]=A\K4=):E[0M#M]<U^UTPS"-)2VZ0
M'H"?E]SBJWC#P]'X<\0MIL-R9XRB2*S##*&[''?C^56_#GAW5/$IN'TEHHS;
M8/F2.4^8] N.<\=>U8D%AJ>I:RUHL<USJ)<JREMQ!!P2S>@]34O;8J/Q7OL=
M/\.O"EGK4]QJ.H!I8[24)'$?N.V,Y/J!QQ7L<4?F/CL.M8WAK0X_#VAP6",'
MD&7F<?QN>I'MV'TKI;. DX8=>3["MX1Y4<M6?/*_0M6L7.\C '2K=(!@8%+5
M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBH9W,<#L"FX#Y=YP,]LGZT 345SL6JW%NK&ZD
MD+J?WL1C56C(4L0,<%3\H'?GK4[ZQ<HTL;6<8EC+9_?_ "@! Q).WME1T[T
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M> /3.:<-98SQ(;4@.HSEOF1]A?:>,#@>N>>E &Q16"==<1H/L1-PS-^Z#,2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #9 BH# 2(  A$! Q$!_\0
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M1+R*!&_YFZFDV @YJV(-ZD@@?6JX7$^UAQ4FZML0KD94MQ2R [<#E:=)'M?
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M6L^0H3C'-13WY:/D9Q5=KAF02(NY>XIPBXHF4D6A$P!.,BIXD5BI8X%4XY)
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M/[PY:I"H,N<4K1@_-G\*&BW,K2(.@J)T[BK;)U-0E.#2$5'7.*IS*5) %7I
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #6 8T# 2(  A$! Q$!_\0
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M,DYZ<>M:L]M!<Q^7/"DJ9!VR*&&1T.#3(].LXKI[N.SMTN7^_*L0#M]6QDT
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M+_<'\J ):*** "J>HV4>HZ=<V4OW)XFC/XC&:N4AZ4 9/AV\DOM#MY9P/M*
MPSCTD0E6_4$_C6O7/Z<?L'BG4K#I'=*M]"/?[D@_,*?^!5T% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!4ORHT^Y+2-&OE-N=025&#R,5P_A[3
M]0GU."[9Y=D,:+ON89D8198E4+GY]V1G=T%=IJ2W+VK);Q1S;@0\4CE-ZD8(
M##H:R] TK^SIG:+2(=.C8!6'GF5FQT]@* .B[5QNFW&I-XWNQ*;AK+,J*IR/
M+QLQN'0J>=A'/)S79#I1B@#E_&%QJ2Z!JD<&GQ2VYM6S,USM(XY^7:>GUKH(
M2X@@VJ""HW'.,#'ZUG^*_P#D5-5_Z]G_ )5J6_\ Q[1?[@_E0 *7WL"@"C&T
MYZ^O':F;I_*5O*7><;EW]/7G%6** (\OYN-HV8^]GOZ8IA,OEL?+&X$[5W=?
M3GM4]% '.^(BUI/IFKA1MM+C9.2>D4GR-]<$J?PK=!?+Y08'W3N^]Q^E0:C9
M1ZCIUS92_<GB:-OQ&,U4\.7LE]H=N]Q_Q\Q@PSCTD0[6_49_&@#0!EVJ1&NX
MXW#=]WUYQS3@6\PC: F!AL]_3%2T8H @W3>5GRQYF?N[O?UQZ4XE_,4!05P<
MMGH>W%2T4 09DQ)^[&03M&[[W^%*3)A,(,G[WS?=X_6IJ* (AO\ ,8%0%XP<
M]?7BF%I?*#>6N_(RN_ISZXJQ10!%EO, V_)C[V>_IBFEI=K'RUWC.U=WWO3G
M'%3T4 1$ON3"@@_>.>G'ZT ON?*  ?=.>O'Z5+BB@"ONFV*?*&XD;EW?=]><
M<T_+^805^3&0V>_IBI:* (-TOED^6N\$X7=UY]<>E.)?>H"@J<Y.>GIQ4M&*
M (LOA_D''W?F^]Q^E)F3"9C&3C<-WW?\:FHQ0!$-^\@J H P<]?7BF[IO*W>
M6-^?N;O?UQZ5/BB@"++^8 %^3!);/0^F*:3+M8^6-PSM&[[WISCBI\44 1$O
ME,(""?F^;IQ^M("Y9@5 48VG/7_"IJ* ( 9?+4^6-YQN7?T]><<T[<_F8VC9
MC[V><^F*EHH KDS>6Q\I=XSM7?U].<<4]MX90$!4YW'/3\.]2T4 1 O\_P G
M3[OS?>X_2FYDVQGRQDD;AN^[Z_6IZ* (@7\P@J-F!AL]3Z8INZ;RMVP>9G[N
M[CKZX]*GHH BRWF !1L(.6ST/IBFYDVN=@R"=HW?>]/I4]% $1,GR80<_>^;
M[O'ZT*7\P@H HQM;/7UX[5+1B@" -*8E/EC><;EW=/7G%3BC%% &+KLAAAMK
M@1O-Y4ZN+=) C2G! "Y(#'N%[XJ#1KR34=4O+O['<6:[$0PW! D8\G>4!.T8
MX'<_A5C6Q)Y=N]LT(O%ES DRDJS8.0<#(XS\W:L[PMJ<VN27&HS^0DC*(XD@
M5]K1@GYP[ ;P3G! QQ[T =4.E%':DS0!C^*_^14U7_KV?^5:=O\ \>L7^X/Y
M5F^*O^14U7_KV?\ E6E;_P#'K%_N#^5 $U%%% !1110 5@:?FP\4:E8GB*[1
M;V$=MWW)!^80_P# JWZP/$7^B2:?JXX%G<!)3_TRD^1OR)4_\!H WZ*04M !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &'XD^RG3BM]827ED<F98@S.
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MCR?TK7\MBCKYK;F)VMQE?I]*L44 1%6+(0Y '48ZT@1@SDN2&Z#CY>.U344
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M  .D_P :/^$<B_Z"6K?^!TG^-;1Z5F6NKVMVUV 7B-JP27SEV $@$<GCD$4
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6X4-SEN22">XZ<9[FBB@#=HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %K ;(# 2(  A$! Q$!_\0
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M+7S$39YT97=@]LU[K4RO?4:MT"N(?6K[5?B7<>&X[A[2QL;!;J0Q@"2=W8
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M)=H8*X(#+D$=NA!KCM)^)%W>_P#"+SSV]I%:ZO++;7/W@]M<)GY#DXY(P,T
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MR_Q>_P"24Z__ -<4_P#1BUU&A_\ (OZ;_P!>L7_H H T**** "BBB@ HHHH
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MX&?RH FHHHH **** "O&O%EYX6TGQ5K%Q=^!Y=:-NL;W][*PE$3RC]TBH^<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+W_)*=?_ .N*?^C%KJ-#_P"1?TW_ *]8O_0!0!H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8VI6ZR:II
MQ,DZ[Y&5A'.Z!@$8C(! ZT ;-%%% !4-Q$D]O)'(NY&4@CUJ:F/]QOH: ,[0
MH4@T.R"*1O@1VR226*C)R:U*HZ-_R [#_KVC_P#015Z@ K \:WMQIW@?7+VT
ME:*XM[*62)UZJP0D&K'B#Q'I7AC37O\ 5KV.V@7.-QRSGT5>K'V%>=7*^+?B
MI:20P>;X:\,2@@/-'NN;M2.ZY&U#]>?4T >":A\0?%FK6TUM?:W=30SQ^5*A
MP R9S@X'2OK+P"=WP]\/' !.G0'@ #[@]*\B_P"&=+;^T_L?_"33?ZGS=WV,
M?WL8^_7MV@:7_8GA[3M*$IE%G;1VXD*[2^U0,X[=* -2BBB@ HHHH **** "
MBBB@ KSGQA::_J,[VM_X*T_Q)I22^9;"*^\B1.,?.K\$\GH:]&K@-=^)-KX=
MU'7+2\2V#:<+0P(UT$>X$QPY /9.O&>/2@"MX*TW6=,OMEGX*T[PWIDK;KG=
M>^?-+@';M"\#D]STS7I%<QX=\5Q>(==URRM7MYK/3F@6*Y@E#B7?'N;D<<'C
MBNGH **** "BBB@#A_B]_P DIU__ *XI_P"C%KJ-#_Y%_3?^O6+_ - %<O\
M%[_DE.O_ /7%/_1BUU&A_P#(OZ;_ ->L7_H H T**** "BBB@ HHHH ****
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MO>*.Y92N/EY0[>E>J5P?BWQ5X@T#4L0Q^'8M/=1Y4VI:E]G=SCD8([&@"O\
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M/4_NFR3[DY)]S7+_  [M9_$>M:C\0-0C93?9M]+B?K#:J>OL6(S^?K7=7_\
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M*?\ HQ:ZC0_^1?TW_KUB_P#0!0!H4444 %%%% !1110 4444 %%%% !1110
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MTW_KUB_] % &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!15:ZOK2S"FZN88 QPIE<+GZ9J6-UD0.C!D894@Y!% $E%%<UXI\;:+X1M0^
MIW.9Y!^YM(1OFE/8*O\ 4X% '-_%[QSJW@72-/N])6V:2XN#&XGC+# 7/&"*
M\;T3Q_K/C'Q_X6@U9+1[>'4@ZQ)&50O(_+$9Y(SQZ5W/BOPK\0/BM9V]Q<6N
MGZ+812%[:RNG;SB#QO<A3@X[<?2L;P;\$_$FF^*--UB:\TQK>RO@\BK(Y<B-
M\' V8[<<T ?1M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T4&J]
MU?6UDBO<S)$K' +'&33[>XANH5F@D5XV&593D$4N97L.SM>VA/1113$%%%%
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M.?X ?N#Z<^]=7;6T%I;I;VT,<,,8VHD:A54>@ Z58H *S]'_ ./:X_Z^Y_\
MT8U7SG''6L_3;.XLDD2>XCF#R-(-D13!9B3_ !'/6@#1HHHH **** "BBB@
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M[PY\4/&?ABZCO3IMI&[(4TBW(+288'YY6.!CKP><4 <[_P -*ZG_ -"Y:?\
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M3B'7GS+1=A:***Z3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2$J#WXS@9-=>&!&0:\\L?"=U+J3PS%5CB(WE6Z@\C%=./#-J/NSW"G_9D_\
MK5AAZN(DGSQ-\33PT9+V<OU-[</44;AZU@GPPG\.HWZ?26D'AIU^[J^H?C+F
MNCGJ?R_B<W)3_F_ ;XDGTX6\*7GELXEC95(R0N]2Q^F ?K6I;W=I]E1X9$$
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M!!^A% '&_%[_ ))3K_\ UQ3_ -&+74:'_P B_IO_ %ZQ?^@"N7^+W_)*=?\
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MD!<%1RPZ$CT%1?#:W6*VUV>SM9+72;G5));")H3$/*V("RH0"JE@V!@5W=%
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M7@$#UKUZB@#S:.T^+LD:N-5\+ , <&&7_"G_ &+XN_\ 07\+?]^9?\*]&HH
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $X G # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEN[B^:0ZO-<(&*;N<H3NZ=JZ[6+?2KCQ1<:5I_ABWU.YL+.-)7NKGRHH8PO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"CSN?F.1CCM@5R=IX+O[%1=6=[IUK<07JW=K8H[O:Q_(4=<GYANW$\#CC H
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MN"P4J0#[?(N?H*L66BV.G7<UQ:0+$\L4<)"C "1YVJ!V W&@"_1110 4444
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M_$$5K4 <_P#\)8?^@!KO_@(/_BJ/^$L/_0 UW_P$'_Q5:VH7;V5MYT=N\_S
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M:XN4WP0X5N9%[@YQVYQS0!VD<B31K)$ZNC#*LIR"/4&N6\)_\C1XN_Z_X_\
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M (5SX=_Y])/^_P"_^- 'C7)HP?2O:$^'OAY#Q9M^,K'^M+_P@'A_!_T-N?\
MIJW^- 'BA%%>SGX=>'3_ ,N;_P#?Y_\ &D/PX\.G_ETD_P"_[_XT >,45[/_
M ,*X\.?\^DG_ '_?_&C_ (5QX<_Y\Y/^_P"_^- 'C1D(0CGI7T!HG_(!T_\
MZ]H__016)_PK?PX?^7.3_O\ O_C72V\"6MM%!$,1Q($49S@ 8% $E%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F_C?23XE\4M9:?
MI-A-=V=JDEQ/=74L)>-F;" 1D$_=/)X&:Z/P-#I=QH<&L:;IR64E["BR(K;M
MOEY0*#Z#!QCKUI-?T/PKXCE2;5A:3S1*55Q<[&Q_=)5AD>QI_P /]0;5/ VE
M73PP0%XB!% FU$ 8J !DXX H Z.BBB@ KE?B!J5CI6CV]U=:=_:%S'.#:1%&
M95EP1O;&> ">WTKJJ* .$\-:5J!\+62^&]=AACW2O.\VG,1)(SY.U6*E5!)
M&*G\!Q7<.M>*8]0N4N;E;V/?*D7EACY2_P .3CC'>NTKE/"?_(T>+O\ K_C_
M /1*4 =71110 4444 %4[W5M/TYU6^OK6V9QE1-,J$CVR:N5YMXVTZTU;XJ^
M%K/4+=+BVE@GWQOT;"DC]0* .KU+Q+HDFEW:1ZQIS.T+A56Y0DG:>!S4MMXF
MT-;6)6UG3@0@!!NDXX^M96H?#SPK!IUS+%H=HLD<3,K '@@$@]:?;_#KPI);
MQ.VA6A9D!)P>N/K2ZFGV/F=#9:I8ZEO^P7MM=;,;_)E5]N>F<'CI5JO/O &G
MVNE^./&5G8P)!;Q26P2-.BC8Q_F37H-,S.'^%/\ R M5_P"PO<_S%=Q7#_"G
M_D!:K_V%[G^8KN* .9^(_P#R3W6_^O8_S%7/!O\ R)6A_P#7A#_Z *I_$?\
MY)[K?_7L?YBKG@W_ )$K0_\ KPA_] % '.?%_P#Y%>P_["<'_LU=[7!?%_\
MY%>P_P"PG!_[-7>T %<-K/\ R63P[_UXW'\C7<UPVL_\ED\._P#7C<?R- '<
MTA&001D&EHH K65A:Z=$8K*WBMXV8L5C4*"3WXI+W3X+]8_.#AXFW1R1N4=#
MC!P1SR"15JBC8#(/AC30A6-)H\C:3'.ZEAM"X)!Y! &<]^>M:D4:0Q)%&H5$
M4*JCH .@I]% !1110 4444 %%%% !1110 4444 9FN3:G!:Q/I,"S2B3YT)
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MGK0!6_&DH!/(8$,.H-2)$TC849- $><4?C5B>R>"6.%V'GR9*Q Y;'7)]*K
MY% "GI7I-E_QXV__ %S7^5>;=C7I-E_QXV__ %S7^5 $]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445R7C#5]4@U?3=*T
MBZ2SDN8;BXDG:(2$"-00H!XY)Y]J .MHKF[+4]4UWP%::A826MKJ%U;I(9)@
M3'%G&]L>PR0#[9KFD\1>)[GPW-+ICS:B3JBV]O?06:[I(,?/($.%(# @'(!]
M: /2:Y3PG_R-'B[_ *_X_P#T2E5]-\=V%EH%E-JEY>74TYD4N+!E8,K8965
M0I'3KSUIO@'48-5UCQ1>6OF>3+>QE?,C*-_JE'(/(Z4 =5JNFPZQI5UI]R76
M&ZB:)RAPP##!Q[UR$7PHT^&)(HM=\1)&@"JBWV H'0 ;:[JB@#@(OAO:2WEQ
M;G7/$"B';AUOL,VX9Y..<8XJ=?A5IGVFVFGU?7+G[/,LR)/=AUW*<C@K74VI
M U?4"3@8C_D:O#D54]_N_(!:***D#D_&_B:31]'D2&TE9YV,'F2(0@!!R<]_
M:H?!VNZAKAAN9MR6R*8&BCB.PL ,-N[=^/>NKN[.WO[=H+N&.:%NJ.N0:6VM
M8+.W6"UA2&)!A41< ?A6?++GO?0['7H?5O9\GOWO>Y-1116AQA1110 4444
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M)VHU!)?+1#.69CM+;?N?G79VK;[2%L8W(IQ^% $M%%% !1110 4444 %%%%
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MM.GUR&V@N-*B2.WO["Y8O<H!@I(&7E3U.>_3&:V+_P &V%]K@U('RC,ABO8
MH,=XF. ZGN#T;K6['&D,21Q(J1H JJHP !T H ?114<XD:"00L%E*D(Q' ..
M#0!D^(O$<&@6?GR1R2QJX6X:'#&V0_\ +1EZ[1QG'K7EX-_X<56M]5TN#5IX
M3);O9P&ZN=69FRI9F&%5CV'3'H*T-*UC3O#_ (<NX([-4\;%3;S07,322W<K
M-US_ !(W7KC\!7H'ASPY!X>AGCM6D6&:3S4MF;<EL2/F6/N%)R<4 :EHTSV<
M+72JDYC4R*O0-CD#\:FHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+!IL/D0R2M,8PQ*AFZX!Z#V'%0^']"BT&Q>(2O<7,[F:YN9/OS2'JQ]/0 =
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M<G?CZJ: -+0]$&B0S(+F6X,LF\M(3G^>,^_&:U*Y&+7-;O+:^NEAAMHH[3=
M7CD(>3>PW8VAMN .,9&<XJ.#Q-J7RS7$,\*AX 8)+-BWE-MW2EEXSDL,#ICI
M0!V5%8?AW5;B^B;[>76Y9V!A^S,@AQ_#N/!X(Y[\X]MR@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $  & ,"EHHH
M0@'J,TM%% !1110 4444 %%%% !1110 4F,]:**  C(P>E  4    = *** %
MHHHH 88D,@D*+O P&QR!Z9I]%% !1110 4444 %%%% !1110 4444 %%%% !
*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10-k_013.jpg
<TEXT>
begin 644 form10-k_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I D0# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7\4&QXU4#8H)V @<9"[<^^:Z>B@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?.OQ5TF"]^*2SWL\\5ILMQ,(?O-&,[L<_>]*]1M? ["UAET_QGXFBB*#R
MP;M)5VXXX=#VKDO'EK;CQLUS-$)SLB/ERD[, 'C QP<@GZ#WKL[7Q_I,$4,6
MK6]UH[,JA6O+=HX6X_AD&5QZ9(K##2G7J3A!7Y>B6O\ P2YXS!58QIT$U./Q
M7VOY"GPWXO@/^B>.I)%'1+W3(9/S*;#2;_B-9,2T7AS5(AV1IK60_GO6NKMK
MJ"\@2>VGCGA<962-@RL/8CBK%;M-.S(.+_X3;5+$8UOP;K-J.\MELO8P/7Y#
MNQ_P&M71O&?AWQ!)Y6FZO;RW ZV[DQS#ZQMAOTK?K'UGPSH?B*$1ZOI=M=X'
MRM)&-Z_[K#D?@: -BBO-?$'@'7?["N].\.>([G[/,F%L]1E:01D'*F*8?O$P
M0."6'8\51^%-PGART;0O$EU>V_B2YE+F/4'.)5'"B%R2KC') .<D\<4 >L44
M44 %%%% !1110 4444 %%%% $3.J(6=@J@<D\ 5%;75O>0B6VGCGB/&^-PP_
M,5S'B+P=<:Q:WB0ZWJ$;7 )6%W!A'?:0%SM_'\ZQO"?P]U#2[*47>LW-M)(^
M?+L9!MX[DLO)K)SJ*=E'3U.Z&'PTJ#J2K6DFM+,])%85QXIL+;6%TZ2.[!,R
M6YN?(;R5F< K&7]3D>V2!G/%;,,?E1)&79]JA=SG)..Y]ZX_7['6=4U>U1-,
M*M:7D4]GJ"7(\I(LKYGF1$Y9\;U'RG[P(*G.-3A9N:SXETG0;-+J^NT59)!%
M&J'<TC[MN% ZX)Y].]/\0:]8^&M);4M3D:.U1T1W5=VW<P4$CTYYK+\2:7-J
MGA.YM;#3A%=-(-D1**<><K,<@X&X+NZ\]^:N>*-.N-3L+*&WA$I34;6:12P
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M>:BD\:6\=XJFU<6CVS2I,S88R N!'M_VO+;!S2O3[(/?.D\A?^>MS_X%2_\
MQ5,EA AD(EN@0A(_TJ7T_P!ZLK1-=GU2>))[9(#+:?: JL6*LLK1LI/?H"/J
M:V9O^/>7_<;^54HP:ND)N2>Y4TU#+I5G(\UTSO!&S$W4O)*C)^]3(-0TZYN/
ML\5_,TWF-%L-S,"77[RC+<D=Q4VE?\@>P_Z]H_\ T$5A-X6N9VD$E\D2F_GO
MHW@!WJSH549/IG/OQTJ7%)*T1W[LZ3R!_P ]+K_P*E_^*H\@?\]+K_P*E_\
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MPRJ95"KN))48/S8Z^PXJQX^%VWA^&*QOI[&XGO[6%;B$_-'NF49]QSR.XXH
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M,6<"-RTCX.1AU&"!L*GWXCN?%M_;Z)$T<D\ERETB7-UY FBQNCW*C1#:<A\
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MWP-KJ)S?W!^6QE/60^BT =;165_PD%M_SZ:G_P""^;_XFC_A(+;_ )]-3_\
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M&6.!FI*@EB@G39,D<BY!VN 1GUYJ;<OJ/SH 6BDW+ZC\Z-R^H_.@#R7XC_\
M(T#_ *]T_F:*/B,P_P"$H'/_ "[I_,T4 >MUGZO%Y^C7\7DK-OMY%\IY3$'R
MI&TN/N@],]NM:%<QXRU9M.L;&Q2TM;EM5NQ8E;LXA",K,Y?U&U6&.Y- '%^"
M;2WT7QE9Z>=!ATYYK69H'AU^6\4!-N5\L\#[PY/H<5ZW7DG@"^MD\2V<EKX>
MT6PLM:MKF6Q:S@*7,<44@ \T]"'!##&*];H \Z\0^$-4U+QI'J%G8V<)>6VD
M&K)=2)/ D9^=#'RK;AD#&!\QSFH/"7@G6M.NHX]2>.U@L=)ETFVGM)\R2AY=
M_FC*_(0%7 .>:],HH X'P7I;:-XV\56;:A?:@1#8MY]]*))3D2\9 ' [<5WU
M<EHG_)2/%G_7M8?^@RUUM !1110 4444 %%%% &1X@T.W\0:3+8W#-&6P\<R
M</%(IRKJ>Q!YJCX4UNXU&WGT_5%6/6=/?RKM!P'_ +LJ_P"RXY'XCM725R?B
MO3[FTN;?Q/I,1DO[!2MQ"G6[MNKQ_P"\/O+[C'>NBC)3C[&3WV?9_P"3V];,
M3TU-/6-.EN!%?6)"7]N<Q^DB]T;V/Z&K>F7\6IV*7$8*G[KHWWHV'53[@TNF
MZG:ZMIT%_92B6VG0/&X[@_YZ5E:@C:)J)U:$,;27"WL:C.WTD ]N_M7#4BZ4
MF[>J[>?^9A/]W+VBV>_^?^96\5:07!U:TMEGG2)HKJV*Y%W;G[T9'<XR5]^.
M]>:^'O&6KZ?K-AH%A?\ VK24NDA@,L :7R"W"DYZA3MS[5[BK+( RD,I&00<
M@UYCXN\/2Z+J:ZKI")%*]PL]O)C CN.<QN?^>4H)4]E8@\5-2,KIP=E?4]W
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M.3P<F@"_XD\/Z+%H;M'I-DK>? ,B!1UF0'M6O_PC>A_] >P_\!U_PJ+Q0,:
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MHH Y+1/^2D>+/^O:P_\ 09:ZVN2T3_DI'BS_ *]K#_T&6NMH **** "BBB@
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M3/YUV-<'=Z3=:Y\*H-.LEB:XE6 @2X*X696;(/48!X[].] &^=-U%5W'Q-=
M8SDP0=/^^*=_96J9 _X26[R>@^SP?_$5PU_\.=055L;.6*6U_P!$S-,B%05N
M)Y9 (3\NQ1(N$Z8X[4RR\)^*;2ZT"_%O;Q_V)#!;K"UP9))$Y%P5/W0&## (
MS^[4#% ';1VEY)-+"GBJX:6)@LB"&WRA(R 1LX)!S4W]EZF,_P#%37?'7_1X
M./\ QRN*E\,ZM?V^E:K'IH.JSWDM]*+LH8H1(Z862-ANRL2(H*X92ON:JW'A
M#Q9)_;4[06DC:PHFFACG(9)8YU>(,S'!_=Y3*X'R"@#T Z5J@Z^);L?]N\'_
M ,12'2]3! /B6[!/0?9X.?\ QRLCQ79:EJ^EZ/-;Z(TMY;WT%TT37**80CAF
M&<X)(!''K5#Q%X=U35-0TV6VL&\VWU(3_:+BXC<+&)5;&<>8JD X5".N&R*
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M<8)W;E(?^,<;MGR=-O>@#6_LG5?^ADO/_ >#_P"(K'\/Z9J;V]]MU^[3%_<
M@6\/)\P\\I78UB^&_P#CWU#_ +"-S_Z,- "_V3JO_0R7G_@/!_\ $4?V3JO_
M $,EY_X#P?\ Q%;-9?B$WHT&\.G[_M6SY?*&7QD;MO\ M;<X]\4 1?V3JO\
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MO_H!Q_\ @:O_ ,36S7-:?KUW=:V+9XH1:RO=)'M)\Q# ZH2W8AB2>,8XZYH
MN?;];_Z <?\ X&K_ /$T?;];_P"@''_X&K_\36%%XIUBX@22*UMV\V"*\!BC
M:0PP/YG#+N&YAL7H1U/''.I;Z_+-K]E:IY,EG>VAN(9A&Z;L!2,$\-D,3C@@
M#O0!9^WZW_T X_\ P-7_ .)J*YO]:-K,#H<8&QL_Z:OI_NUO5!=_\><__7-O
MY4 <[H-]K*^'-,":-&RBUB ;[8!D;!S]VM#[?K?_ $ X_P#P-7_XFIO#O_(L
MZ5_UYP_^@"C6KZ6PT_S(%5I9)HH(]^=JM(ZH"<=ANSCOTH A^WZW_P! ./\
M\#5_^)H^WZW_ - ./_P-7_XFJ*Z[?2Z?9)%':K?7%Y-:%WW&$&+S,L!G.#Y1
MP,\9ZG',-KXCO;V\T^)4MX$U"P-S$TL;XC<*AV[L@2?>;@8( S0!J?;];_Z
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M!J__ !-;-% 'C?CJ>]E\0!KFR2"3R%&WSU;C)YSMHJS\1_\ D:!_U[I_,T4
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M^%;=% &)_P )?H/_ $$$_P"^&_PH_P"$OT'_ *""?]\-_A6W10!B?\)?H/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M('2<M%J2:6Q"#F5@N#U^[\X_PJ3Q#IMQJ&CQ"V(>]M)X;J$,=HD>-@VT^FX
MCVS6?-X,2XU4W8U*[BMGOXM1:S"IM,Z!1DMC=@A1QGKS0!B6?C?59O"FK7$L
M5M_:\4VRS0*0CJ[$1,1G)QM?//\  :W]#U^ZNY])CO%BQJ>EI>Q,G&) $\Q<
M9Z?O%(_&H8/ EE%+:2"[N"UM!-#VP_F%R&(QU3S) /\ >-6-/T"2UU?2\DFR
MT?3?LEN[$;I7;8&8@=,+&OXL?2@#IJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>form10-k_014.jpg
<TEXT>
begin 644 form10-k_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $J G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M #Z*:&4YPP..O-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+?6+=I8 R[3@JW6M&LFFG9FB=]4+1112&%%%% !1110 4444 %%%% !1110
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M;$K#YV'85QAN2Q))))[FN#$XJ4'RTUJ=-&@I>],[5O%J;OEMR1[FD_X2T?\
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ML>&+-[72$,L2)(Y+'9W':MOM4<$*6\*0QC"(,"I:SD[NYHE96"BBBD,****
M$/%5)K](VP,5-=/L@8UY5XW\7I:0R:?8SDWK'$A7^ ?7UI-I*Y4(.3LCKM9\
M8Z?I8_TFZ1#V1>6/X5BI\2-$,3R&[=2O\#(03]*\>E^:02%F=SU9CG-(8Q*2
M< XZUE[1G4J$.I[+:_$O19]WF7#0%>TBD9^E;%AXITW5&Q97<<K?W0W/Y5\_
MR)\Z,R@@&I][03)/:NT4J\AE.,4*HP="+V/IJSN?.&#UJW7 > O$<FLZ,LTW
M^OC;RY".Y'>N[BD$B9[]ZU3NKG+*+B[,DHHHIDA1110 4444 %%%% !1110
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M[FM.XMXKJ$Q3(KH>H85Q-Q]I\+7K32'SX925B7LM;1?.K=3*2Y7?H=I%(LN
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MZ2BBBJ-PHHJ![JW23RWFC5P-VTL,X]: )Z*I6>JV&H/(MI=Q3&,X8(V<5=H
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M@&KM% !1110 5 W_ !]K_N&IZ@;_ (^U_P!PT 3T444 %%%% !1110 4444
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MT=%4M/U&+4(<KE9%X=#P5-7:S:MHRD[BT444#"H&_P"/M?\ <-3U W_'VO\
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M@RAAT(S69JL FM95/\2'I4FBS&?2+=FSD+@Y]JTEK%,B.CL:-%%%9EA4#?\
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MJ-K=VB7&GR6,S&ZU%9DO%7**"0>3U!XQ3EAUX3Q0"RNF\C[26D+X1]P^3!H
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M95C,:_4]344'@>:VTN.R%[#*H:0LLL *G<<Y [$>U'_" QQ-:2QW$<TT-O\
M9W-U$) XSD'GH10!=N?%NFWGAF:\M+](I7MRZ#.70G@<?6L_P1>RV\ITS4X;
MR'49(A/_ *1-YBR#N5]/I6U=>%K*[T-M/:.))&C"^?%$%((.01CWI-/T&XBU
MA-3U"\%Q/%!Y$01-H [D^YH Z"BBB@ HHHH **** "BBB@ HHHH *0]#2T4
M<_I/[N6X0GE)VR.*T[N+S;>5%3)(ZDUESYL=<8-Q%=#*^S"MA6$L>2>G45I/
M74B/8BTJ99;) "-R?*0*O5D/:SV]QYUJ1E^L?;% U2X  -FVXY Q699IS2+%
M"[L< #-9>E(3'),8P1(V012,EWJ)3SOW,)Y '7/O6A'&L2X"[ OITH K:BP6
MW8],(33/#Z%-&@![@G]:I:O,UPR6D?,DYVX]%[FMV")8+=(E^ZB@"M):12(6
MLKDM%%%9EA4#?\?:_P"X:GJ!O^/M?]PT 3T444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *BDE,9 $;MG^Z*EHH @^T,>D$F?<8HAC8,TDA^=
MO3L*GHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>form10-k_015.jpg
<TEXT>
begin 644 form10-k_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "3 G # 2(  A$! Q$!_\0
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MMKP=L\G[=LN_,QCS/+\KY<]]N=V.V<T =]1110 4444 %%%% !1110 4444
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M4Q'61%=&#*P!!'<5Q.L^-WTOQWIVAK=:(MK<*3.\]T5EA*XRI'0$AAMSUP:
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M9J>H:7>_9+JTA,ZN8ED#;1G:0W'/K6OI:7":7:B[NC<S^4IDG*!-YQUVC@4
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MYYIB!"%M_.W/./K7<UP_PR>:31]:>XA$$[:W>&2(/O"-OY&[O]:[B@ HHHH
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M\EWI*=K.T)52O(S@9R<5ZM6%X0NXKWPAI4\*RJHM4C(EC*-E1M.01GJ#6[0
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M2HU>_!@@3/&Z-2-\F.HX ]ZX@?"S2H_BW:"XBUR^M/*-Q<7-S$7CEN<AAND
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M>,;[Q%J1E;<977RHDQSA H"DG'Y5Z!\)=(^']YX/L;F6TTR?5 6%Q]MV/()
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M*L4LRJ8W<94,K!AG';*@&J_AW0;BQTK48-4:"6?4;J:YN(X"WEKYG&Q2<$C
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M8['5C(P#6"B*2./3YS<AW7#'*QB/@,W4!AWQ0!Z%_P *L\'?] N7_P #)_\
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M]_9/_BJKQ_"'P2D\TIT</YI4B-YG*QX&/E&>,]3UYKNZ* .*/PI\"J"3H$
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MY>_9K>VB&YY9 %51[FK]8OBBVU&Z\/W$6D6]E/?DJ8!>C,2L&!#D8.2N,CW
MH H6E_X/@O$FM;O3EN-;<2(1(";A@ @('X8[<^]=%]DM_P#GWB_[X%>6P_#_
M %M3&BP6L:WGD?;99+HR21/%<F=I =@W&3)X&T ^U>LT 4;/2=/L;9;:ULK>
M&!<[8TC  R<GCZDUGZK=>'$G71M3FLDEU!#&EM(0K2JWRD#OST_E6]7$>+_#
MVKZYJ=DMG#9+;++!*]R9"LB&.3<0ZX(E7'W1D8;F@#:T6Y\/7<+V.D2V4Z6
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MYTBLJB,HD8"A0%!9CVSUQZ8%=30 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>form10-k_016.jpg
<TEXT>
begin 644 form10-k_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "3 G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*%2DHNVO^1Z=K/B*71K/2;=+);M[V,KAY=@&U 3G@YSFJO@_6)EGM]$ET^&
M+ \@DCFW;BI4'(VC^]^E4_%_^N\*?27_ -%"E\-_\C?;?]><W_H4=>5*"Y6_
M7\SM=::Q*A?33\CT*BBBN4],**** "BBB@#DKOX>Z!>:A<WSI>)/=2>;-Y5[
M*@9L 9P&QV%7M"\*Z3X=FNIM.282W002O-.\I8+G;RQ/3)KCM4^(U_8Z[J-@
M)-*A2UF\I!<;][# .3AO>MOP5XMNO$MSJ,=Q]C=;41%)+7=AMV[.<D],5W5,
M)B8TN>7PV77OL<T<;3G4]DF[^C_,WKSP]I^H7<US<1NTDUJ;5P&P-A.<X_O>
M]0OX8L9;=XI7G??MW-N"D[=V.@ 'WSV]*H:AXAN-,U:;SWA6Q1BBD8921%OP
M[ ED?([J1C'<UFR^/)P'D6V0B+S4:/<5W.F[N1D X';(KA.DWI?"6GS1)"\E
MR88GWPQEP5B;.<J,>O/.?3IQ6O:6XM;9($9F5!P6QD_D /RKFY?%TEN)!)9Q
M[K9MDZB;DDR,@\L8^897)Z8%0CQI/#L>\L(XX>LCQSEMB[(I&;[HX"RC_ODT
M =G17*R^*)T261K6-%BE2)D,W[PL0I/RX^[\V,^V>].C\174^D22F**VN!<6
M\!8/YB()1&0W09P)/ID>E '445R%SXAO%TBTN4>WCE>.X=W9<J_E9P%&>-^,
M]>E7X-7O%N-9-Q%%Y=G"DT,:9W8*,Q#$]\CM0!T%%<=)XP==5V+'";18V4D-
MN)E(C,8!'8F3;CU(K?T.[GOM#L[FYV>?)$&D\L87=WQ[4 7I)$AC:21U1%&6
M9C@ >I-06^HV5TYCMKRWFD R5CE5CCUP#4LT$5S \,\22Q2*5='4,K ]00>H
MKS;X>74-QXEOPB6$;*LRB.VBM(RJK*% VQ_O0, ?>X_2@#L_%:WS>%=4.G7$
M\%XEL[Q20(&?<%)PH(/)QCUYXKG+?^W;_7K^RF:[$$MJZ@,S1QA3%!Y9#@?*
MQ<S@D9/'(X%=_10!Y_XO?6[71-/L9+"VFLTN=/$]\+K:P<7$><1;>1D#G<.O
M3BCQ_P",%T[[7X;CTJ^O+J\TYW#V^W:@?<@SD@]16SXZ(/AA"#D&_L<$?]?4
M5<=XV_Y*<G_8&7_T<U:T(*=1)CBKLZ[PEXN3Q*;N#^S+RPELUC++=;<L&W8(
MVD_W37+W?BFPU+7;34E\/SRBU>1&=C'N<J<*1ENQ!//K5WX>_P#(P:]_U[VO
M\Y:Y+3,_97Y_Y>)O_1C5ZF"PU-SJ7Z66_>]SR,XQ=3"PBZ=M7U/49/%-G#X6
MAU^:*=+:5$81JH9QN( & ?4UB:%XRL&U2XMFM=0C:^O<Q-);%5&451DYXY4U
M1U'_ )([IGTM?_1BU7!SJNEC_J(0_P S7#*C%.:71M?<74Q,XU()=4OQ/4J*
M**Y#TPHHHH ***Q;;7H[K6[G25LKY);<;GE>("/!SM(;/?!QQVH2N!RWQ'_Y
M#'A__MY_]!6LCPO_ ,C_ *7_ ->\_P#):U_B/_R&/#__ &\?^@K61X8_Y'_2
M_P#KWN/Y+7T-#_</E+\V?,XC_D;P^7Y,[CQ#.ZBT^SZF]JQN4B<1,G*L0#G<
M#R*W(71XP4E$H'!8$')_"O(KO2["]\2:])=6D4KB^90S#G&U>*ZWX;11P:3J
M<42!(TU*4*HZ ;4KQ)T[03N>Q1Q//6<+?TCMJ***Q.X**** "BB@]* *QO+4
M'!N(@?\ ?%2QR1RKNC=77IE3D5Y9'\/M<A#J+30I@9'8/+N+$%B>?E]Z[#P7
MH-WX?TNYM[P6RR37+SA;8G8H(48&0/2M)0BEH[G+2JU93M*%EW-J/4[.:Z>V
MBNH7G3.Z-6!(P<'\CU]*E6Z@:Z>W653,@!9 >5!Z9].AKDKC0]62YN6M(TBB
M<R%H6N#)&Y9P=T8(!C8\DC.TDXYZUFV_A+7_ +0'EF54;:L@6Y;)029 R /X
M3C]*S.H]'J&6&*= LL:R*&# ,,X(.0?P-<5<>&M;*7$4,V"3(()OM3_NXB)
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M\4ZK+HGA75-4MT1YK2V>9%D!*DJ,C..U>6IXQ\865S/K4D>ALMRD"RHJ2Y"
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M@:>+*8VJ,9#>AYQCV/I6S7/Z;X8BTV]BN1=2.8^%5E& /+"D#T&=S?5C704
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M +LO_HH4OAO_ )&^V_Z\YO\ T*.O*?P/Y_F=4O\ >U\OR/0J***XSV HHHH
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M*, CJ>.G8<TQ/$ES'>OJQT6W&^)02)QN Y.<[<Y(/Z59\%_\@GQ'_P!?LO\
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M.D%Q"%,R;;B)HV.(EY /4>]3:+.+7Q-'.T<L@CL9V*1(7=OFCX"CDFI?%_\
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M/AO5;K58)6N#'(J",K-$A56+(&9<$GE2<5N@ =!2UH<@4444 %%%% !1110
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M***+A8Y?QEHVE02>&Q%I=D@?6H(VVVZ#*[7XZ=*ZC_A']%W?\@BP_P# 9/\
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M_P# 9/\ "I+;3K&PR;.RMK<N/F,,2IGZX%%% %VBBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>form10-k_017.jpg
<TEXT>
begin 644 form10-k_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (H EH# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <?H,*QWNJ*UK'$WVDY/GY/?MG_.:Z>/+6
MZ;>/Q/\ 2N9MD6P\4ZA"T-K"LX$R,[%F;UP/KGBNDMSYD3*#G!XR,9_"M:FN
MIE#30JZO$/[/?=.000<>OM7'>,M(OM<\'6B:<#/]FGWS1-W&#T'?&:[N6*W\
MMHW02$\%?\]*R-/NGTZ=H+S]U&PRJD=#GK]*S3L[FIXWI?A^:&_#:A8QO $8
M8*%L-C@D<=ZVY-)T1MGEZ(Z*HY!!R_RXQG/J<Y]J]JHJW4OT%KW/GS5?#TDU
MZK:;8JL10 KL*_-D]!SVQ^M=_P"&]+N]%\&0V>H@Q327#S1Q#D*IQP?3N?QK
MT)W6-&=SA5&2?05STTLNJ7ZM$IEM8R,J1@#USWI2G=6L"3ZLU+.&,6<0$Y<;
M1R?\*GF&+?"G=Z84']*11 P&T;.PP,?_ %J+CA%0#=GW S4QW!['.:I<'_A(
M='B%Y(A\T_+Y/!_'WZ5UE<HKO<^,X81-<H+:$NT<JY4Y]#^(Y]JZNKJ=$3#J
M+1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ<B^4"6;"_YYH 4;2-Y!4CKSU_QK-O;E8DDDD",$4MY;G:6'L?6K,LQ<K&@
M!Y4'HWM7,R9\2WWV& ;],A?_ $@M\KQOSPI[C_Z]:QCU9G*71%_PK;R&"YU"
M7[0C7;Y$4QSL )QC/)ZUTE,CB6&-(T&%50H'L*?6<I<SN7%65A:***0PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0N,;:BT445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT@N>C45SUAXTT._(47?D2'^"X&S]>GZUO(ZR('1@RGD$'(- Q]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !36940NQ 51DD]A2D@ DG '>N:\1ZU']A>RMLO)<L(-XZ '[WUXS18#4TD
M$VAO)#A[IC,<]E/W1^"@?K276NZ?:Y!F\QQ_#&-W_P!:N9NKJYNOEDD/ECI&
MO"@?2JAB]JKE)YC7NO%D[9%K;*@_O2')_(5BW>IZA>9$UW(5/\*G:/R%*8O:
MFF*JLA7*!B]J:8O:KYBIIBH H&+VIIB]JOF*FF+VH H&*FF*KYB]J:8J *!B
MIIBJ^8J:8J0% Q4TQ>U7S%33%[4 4#%[4TQ5?,5-,7M18"@8J:8O:KYB]J:8
MO:@"@8J:8O:KYBIIBI#*!B]J:8O:KYB]J:8O:@"@8O:K>GZGJ.E/NL;N6$=T
M!RI^JGBG&*FF*@#M-(^(2,5BU:#RST\^$97\5ZC\,UVMK=V][ LUM,DT3=&0
MY%>*&*I[*\O-,G\ZRN'A?OM/#?4=#2L.Y[717#Z5X]4[8]4@V'IYT(R/Q7J/
MPS77VE[;7T(FM9TFC/=#G_\ 52&6:*** "BBB@ HHHH **** "BBB@ HHHH
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M:FF+VJ^8O:FF*E8"@8J:8JOF*FF+VHL!0,5-,57S%33%0,H&*FF*KYBIABH
MHF*FF*KQB]J:8O:D!1,5-,57S%33%0!0,5-,57S%33%[4 4#%33%5\Q4TQ4
M4#%33%5\Q>U-,7M0!0,5-,57S%[4TQ>U("@8J:8JOF+VIIBH&4#%5S3M3O=*
M?-O)^[SS$W*G_#\*4Q4TQ46"YVFE^(+34L1D^5<?\\V/7Z'O6Q7F)BK<TOQ%
M/:[8KO=-#T#_ ,2_XU+B-,[*BHH+B*YB$L,BNAZ$5+4E!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !44LR1#YCSV IMS-Y,?'WCP*SBQ)R223W-5&-Q-V)99FE;)X'84S--S1
MFM"!V:,TF:,T .S13<T9IB&7)Q:3G_IFW\C69X3_ .13TS_KB/YFM*XYM9AZ
MQL/T-9/A!PWA/3O:,K^3&EU'T-S-+FFYHS3$.HI,T9H 6BDHH 6CCTI,T9H
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M,EXR/,*C' ^A_I5U?$"Q7<-I=VTD4S*GF'LK$9Z>G-= 5W30I_#&0OX@9/\
M(5";>VFN);N6&-W"84E><'@#/^>M/F%8KVM]:WH)MITDQU /(_"K%8D_AF"/
M3=MI(\=Q+("&9B1@9XX[?_6I_P!FUNROK>T@=+N+RQO>3L>^3U^E5="U-BC-
M8]MX@@D60W$,MMY;;79AE02<8S6I%-%.@>&19%/0J<T 29I<TW-&: '44F:*
M %HI** %HX]*3-+F@!-HHV"EHH MV@Q"1_M59JO:?ZMOK5BL9;FBV"BBBD,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 055U XM?JPJT*I:D<0J/5OZ4UN#,VBDHJR!<TN:;FES0 N:,TF:* %S2Y
MI "QPH)/H*M16$K\N=@_6BXRM[5A>.--FE\+R70&UK6195SUZX/\Z[6&VBA^
MZO/J>M>?^-_%&H63SZ.VG(D$Z%1/(Q;S%/4KC !_E4N0TCM-'GBNM'M+Y,?O
MH5=F/J1S^M4?&#NN@.$Z-(H;Z9_QQ7D6GW%[?7>G:8UU,UOYZ(D.\[0"W/'Y
MU[%XHN6M=$E=$1BS*GSJ& R?0T1^) ]C+\-6L]KI@FVSIYS;]R ,".@RO6NB
M64R(7D>-@A!4@%2#[@UF:)K$M_IL9\I!(GR,54XR/0 <5J*TC1,7+@]<L @_
MK52O?4E>0TSN4)7')*@ =#Q_]>G^86N?+SQN/3TVC_&L#Q'>O9VL#*?-21BC
M@$KVXP?7K6'I&K3Z9J*P2P/(=WELK,=XR?YT^2ZN+FU.V5G;?N8EXP#^*DY_
M,?SI%X%N1T; _(\?S-<Z=5U9_$;0PVI1&8IAHSTZ;B?P!]*A.D>(;BQB1Y=L
MD,[%0TF#CCYLCMG-*W<=SJ0N9IXN^PX_$Y_K5>:\MUTT7#SQA-[ L6&,G/%9
M?_",W\FK3W$M[^ZE1@74G<<KC&/2F0^##]A:":]PYD#J43Y1@8Z'OS1[O<->
MQL2:C9QZK#$;B,/*H91GKD''YU1_M[3A:W9$^?)9< *<GG QZTY/"-DMQ;2F
M65O)50RG&'(Z$^E31^%-,C6==DC";CYG^YSGY?2E>(694E\26""P8-(P<#<0
MOW0"!S^(--_X2>R6?4$*2$(K;3CA\'''XFM,>'=+$<"&U#"#[A).>N>?7FIQ
MH^GB6:46D6^<$2''W@>M'-$+,YY_%=H+2U/DRDESO''R@']>M6&\360O;U62
M0*D9"MC[QX& *V?[%TXPPPFSB,<)W(".AI7T?3Y'G=K2,M.,2''+"CFB%F9,
M&NV,YL(?,*O,22&'W>>A/X$5H6]];75Q<RPS1N(<Y*MTXQ_0U&WAO3'GBE\@
MKY2;%56(&.>OOS66_@T16=Q';7C^9(5QO&%V@YP<=?\ ZU%XL+,VE;;:)(.=
MS#'T X_E^M2J"LR0JQX"[B/;)/Y\?G7-/H6MVIL(;:YWQ1')*OM5#NR>#U&*
MC_MG6+%KZYO+4E<B--R[50D]CW&!_*G:^P7MN=2LK2(2RJ1PO(ZEC_@:7,3
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M]15OM64MRUL+1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.9\-ZI.^O3VGEQI!(7;RT0*$(^E=K7':#J<=YXEN2ME'$TJL0Z@[A@]^W/\
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M0-Z(V=I]*I]Q%ZP&96/HM:-4;"-E#NP(SP,U>-92W+6P4444AA1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXMN['O[UTU% 'BUA9VUSX[\)W>B:'XB6UMIIOME[J2SG#-$0 ?,)P<]6  Y
MR:VM U:[\#66I:'=Z%JEW=K>3S6+6EJTD5VLC%U^<#"$9PV[&/>O3Z* //9;
M#5=0^(.AW=Y8/;AM$GBN6BR\<,K,OR;\8SU^N*Y=+W4=*^%=_P"")?#NKS:Q
M!:SVJ?9[1FAE4EL2K(/EQ@YQUSQC->U44 97AV*2'PSI44J,DB6<*NC#!4A
M""/6M6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6JR-%I
M5U*OWHHS(/\ @//]*NU%-&)H)(F&0ZE2/J* %BD6:))4.4=0RGU!YJ2N?\%W
M9N_"MGN.9( ;=_JAV_R KH* "BBB@ HHHH **** "BBB@!*Q?$=I-<Z>)K9I
M1<6["5!#]Y\=5S6W24XNSN)JZL8NF7\=S;QSQ!!D?/&AW;#W#-ZUJL3L_=]&
M_BKF;VTFT&]-U:0F73Y6R]M&,"-N\A]N*V+*^BGB26"0312'"L/XR.I'H!6D
MHW]Y$1=M&-O=+ANML:823.7<+U^M5?+U6W$_E3;XUPJYP3CV%;4;1O\ .C<D
M=#1Y1$+)QS61H5;.:^\Q$NTC*NN0RG!!]"*74(IG@\VVP;F!M\:DX#^JGZC(
M_(U<$8PN[DKTI] %+3[^#4K-;B!CM.0RL,,C#JK#L0>U7:YW5=*O;:[?5M#*
MK=D#S[5^([H#U]&]&_.I-&\4V&KN;9MUI?H<26D_RNI]O7\* -E(421Y%4!I
M""Y'? Q4M<KHGC.TU;7KS3<*FQR+9\\3*.OXYR?I754 %%%% !1110 4444
M%%%% !1110 4444 %%-)"@DD #J35">]N7REA;><_3?(VR-?QQD_@#0!H$@
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MXYR>!5OP/XFO/%%AJ,][8QV4]GJ$UD84D\S&S&<MW.2>G'% '5T444 %%%%
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M)JD-C!<QS1QW$<1!D"@??(]#4NFZ1KNN^+K/Q'XALH=.ATZ*2.QL$F$SAY
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .;\;6T=QX1U#SM9N-(B2(R/=P-@J .
MA]0>F 03ZUX7\/O"6KVOQ#\.W&HZ=/!;S[KR*61>' 0D9/9NAP>>:]CO[?\
MX33Q"+%^?#^DS!KGTN[I>1'[HG5O5L#L:[7% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%-+*I 9@,],FG4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%9.KS7#(MA8/LNKC($N,^0G\4GU'8=R1VS6M4*0JLDDG\;XRWL.@^G^)H @T
MZPM]+L(;*U3;!$NU0>3[DGN2<DGN35VBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO5TE<%\9_P#DD^M?]L?_ $<E $5[XN\6^'+'^U?$&@:<=)C*_:);"\9Y(5)
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MQIMG)%Y@G_M!)CGC V!0><U8\4>(;C0(+#[%IIU&\OKM;6&W$XBR2K,26((
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M?KJ6;%-QQYXASGS,=MO7FNFU#P"NI^-=,>]M3/I%EHQM%N%F,<B3!UVE=I#
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M;&SE2:"!255'0Y5N#R<\\]>];=% !1110 4444 %,DC25"DB*Z'JK#(-/HH
MC,:&19"JEU! 8CD ]>?PIIMX6613$A67/F#:,/QCGUJ:B@"O%:V\(7RH(H]B
M;%V(!M7T&.WM3)YK33K9I9I8;6 '+.[!%!)[D\<FK=>=_$R5[JZ\.:-#ICZF
M;B^-U-9(4'G10+N(.\A<;F3.>N,4 =A:_P!C:F\MU:&QNW<;))8MDA(]"1_6
MIO*T_41%<&*WNA&28I2JOM(.#M/8Y':O*;.]M='U?Q5XCBT2#P_/HVD^2=+5
M%!F=_G21S'\A!*A1@D_>SCBNCTVYUBXD3PUHGV#2?[,M(6U&X2T#(MQ(N_RX
MH@0!U+$DG[P'7F@#O?+C\WS=B^81MW8YQZ9]*HJNDVNI);*EG%>W&Z=8PJK)
M)MX9\=3C<!GWKB=/\9:YJMAINEVR6@URZNKJW>\,9,"16[[7G"9R<G: N<;C
MUP*QI]?O/#WB3Q'K>L7$&IW&E06^DV+QQ&$2RS'S6#*"V",IDKV7IGB@#UIK
M:!H7A,,9B?.]"@VMGKD=Z6WMX+6%8;>&.&)?NI&H51] *\QT_P"(=U:7MY->
M:E!J^G0Z=+>3M;V$EM]GD0J!&I?[P;=@9YR*OS:GXTL-0\.K=WNG>9K-XL<M
M@EJ<VL84R/M?=\Q"J5)(ZG(H Z.Q\*VMMKNL:I<>5='49HI5CEA!\@I&$X)S
MG.,YXK=,49E64HID4$!R.0#VS7GMAXD\07NF:CXE?4=)@T:*>YCLH;A#'YJJ
MYC1I)<G W G"J2>G>JNG>/+VTUB^74-3BU'3K;2GU&X=-.DM&A96 54#G+AN
M<?3K0!Z/=S6=C#)?W;PP1P1DO/*0H1.IRQZ"L[7]&77;&W,-P8+NVF6YL[I5
MW>7(.AQ_$I!*D=PQK@?$J>*=5TG1[35KNR2'Q!?003:9%;D-;Q9\U@)-WS$*
MA#9&.3C%2^*_'.J:=)J%QI^K:>193K##8PVDEP)R6"[99AA8V))&T=.Y)XH
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M3[*UM";?;M\DH-F/3;TJQ10!A:WH":OI$>D*XM=/:11<PQ1@>;$.3&,?=#'
M)],COFMI55%"J J@8  P *?10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<A\1[:6?
MPC)=0QO*^GW,%\8T&2ZQ2*[ >^T-^5=?10!YQJNJ7"?$[2;[2+%M6$NA3,$A
MF1"T;2Q$,I8A3VXR.#FH(O"OB".VC\0"SA_MA=;DU4Z=YXQY;Q^28M_W=X0
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MZN&0KYCGU&[C QP!T%:NGZ$ECX@U?5S</+-J'DKM91B)(U("K[9+'ZFMFB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
MIUO1]-D^(VLWFO\ A6]U:TEM;9;22*P:X4,H?> 1TZK3--T36DT_PRKZ?<Q6
ML'B)[BVM9/F>RLC'((U?KC&?4XR!VKUFB@#RO7-+O=-\>ZMJ4TOB6.RU&* P
MRZ(@DPT:E3'(NUB/4'@?,:8UC>Z#;>'[&"S\16N@I92;OL<:S7JSM)N6.5D!
M*K@G[N!G&3Q7J]% 'BUKX4U;5/"^DZ=-!JVGE_$5U--*?^/B*%TF^=FY'.X
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M74[O3D@5A3:1JL^E^*-.CTR[:ZB\0?VK'&\96.[A$J.%1S\I)"GCU'->MT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLRN'_> *"=Q!+'W-)I/@-)A?0S^$M(T-9[&:T>XM;@S2LTB[24X 5<$]>>E
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>form10-k_018.jpg
<TEXT>
begin 644 form10-k_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "" '$# 2(  A$! Q$!_\0
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MC7\>T@_991U_V#0!YC1110!WGA26U>QMX)BRR#=M([_,:[,SV]O:O'$JJ2,
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>form10-k_019.jpg
<TEXT>
begin 644 form10-k_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ E(# 2(  A$! Q$!_\0
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M@BN::<XZT1SN6 !J):E1/K;POJW]N>&['4>-\L?SX_O X;]0:C_X2:Q7Q?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#ZUW%S<16EM+<S-MBB0NY] !DUY$]]-?7-]K)P;FXD^S6RYSL8X&/^ @ ?\
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MBM9=7O[>XCE9Y&D6(R8P2?E&%R . <=N*Z-_!^@O+;RMIRYMTCC0"1PI6/\
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MMGC(IVBF_0^D+S5].TY"U]?VML%Y/FRJN/S-<K?_ !2\,6MO)):7C7[(=O\
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MJN?8"O2M"^*]M<E8]7M&MV)QY]L3-%CU; ^7]?K71.A*.VIO2Q]*>C?*_/\
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MJO<S.HM6\O>,$D,GSOR<XQU&*])JI9:C9:E"9;*\M[F(-M+P2AU!],@]:MT
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M5JA3?03Q%1.[?5?B+=7TZWEE+/8N@65D+1R*X.Y2 .QZ@4CZ@$U=)/L=X!+
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M*0?0,/E/X&NLKG::=F>A&49*\7="T444B@HHHH **** "BBB@ HHHH ****
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M!@P;@CD$\YJ(>!+E=+U.W%E$_G:$;2W%Q*DC),7F<KN"@  NO(  [=*]+HH
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M-!>?9+BYL(HFFDC;S(T4X"H_/S-VP<^_2F6L5V+NXMWO#"I_?HD"C #$Y +
MG@_SIQ@CLI[22)=J;S%(2<D[^A)[G<!S[U%?WPCN8);9?-:)S'(^<1JK8&"W
MJ#M.!FAT4O,%4YOAZ_F$&GG;=:<;Z[6-?NKN5@8VZ=1V.1^%0S17US:JTT=O
M>2V4A#*1L<XZ@=0<K@CISBIKE+M+FWNI;H1?-Y+B",8"L>.6SG#8_.ED@N;6
M_CD34)?](_=N7C0C>/N\ #J,C\J7LO(I5.M_ZZG,:CI-O=21K8F199HR]J9'
M,<JD_,4W='4]1SQSSVKE[I]2LGS=P"50PR^,.A'56 YW>Q_E7H\MO<;)]-FB
MAN89098BI\MEYYV@Y&0>>HZUD7T-M)!))=1.)5VQW-O< @<<ATD&>0.1DGCC
MM5*,H['?1Q*VDKK\?\SF+;5H;AE#2DN'+*LB'*\=F&,?B*N)<I)"H8AU*GB7
M# _]M,?UIU[X>19%=HHD+N6CD[3+CJK#Y<CN#C/M5*.S>.-2C,5<, P!"D^F
M6. ?9L_6MHSEU-I*C)7@S3\UMFUB0FT82?+Q?\!;)S^M=-HOCC7= *1PW<BP
M;P!#=#S8V'HOW=@_$5R<2[0P)$1V#>$3>R_[T?0#W%6!$8,NA\M&?[T;!U;_
M 'ANROZ5K926J,%.5.5X.S/;]#^*FE:CB#4XFT^8_P 8;S8C[[U^[^./K7=V
M]Q#=P)/;S1S1.,J\;!E(]B*^58_EP2!&.3NC_>1'W;[W\JU=+UW5=!_?V-W-
M:H5!+Q M QS_ ,\\*OX_K6,L.GK%G?2S%K2HOFO\CZ;HKR_0OBU'+LAUJU"G
M(7[1:G>"?5D!)7\":]$L-2LM4MQ/97,4\6<;HV!P?0^AKFE"4=T>E2KTZBO!
MW+M%%%2:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445!<75O:1^9<3Q0I_>D<*/S- $NZEKFKGQWX:MF=/[5BFD3JEN#*1_P!\
M@X_&N=NOC!HR3M#;6=Q(ZMM_>LL>?H.2?RJU3F]D8RQ%*.\D>C49KQ:^^+FM
M.#&EG;Z<SY"-(N_\=S%1^!%<[?\ C'Q+?0,;O4[L1,N3+:NRI^ 4+_,UHL/-
M[Z'-/,:,=KL^@KJ_M+%-]W=0P+ZR2!1^M<WJ/Q(\+Z<RH=0\]VX401E@?^!<
M+^M>#2-+=Y9B+X!E/!PZ^Y*YY_X$.M1JP9RB3!V+$,LZ@L?9?O']:T6&75G+
M/,Y?87WGJ^H_&*.-F%AH\SH%W>?*^4'U"9_G7':W\0=<\1V]Q:2/:+92 'R[
M<?,!U&X_-Z#N*Y78L76*6!U0YV'S$3\/FY_[YIQC-P&<>1<X"G=G:1[LP)Q[
M?,/I711A&E-32U3N<\L;5E\3T_K^MRHT^0>:A,_O4]Y87#-YD,$B[CA5)!+^
MZXZC\*R6$VXJ48'TQ7V%/&PJ1O$TA&,E>+N6Q<MG@UT&C3(B LQ23=GS7'[N
M$8^\3TW=<9Z=:Q[#1[F9#<S(8[=.2SG;N]AGO7965K]OL)I(K:0:=:C,D6P[
MR1WD'7_@/?J:\?-,73Y.24DKV_KYLY<742CR07,^MM;?\'^F)LMY+7S)DQIT
M?,<;#)F8_P 9[DD]/4G/I2V<K6;R/?LQ<I^Y);<0@_Y9Y[MG'UX]*@C!M)UG
MNB4LP3Y,;'(@;MGZ]O0\=ZFE@FO0+DAE>,^9;1'C:1_$WN1QCL#ZUY/LK^O]
M?TCQW.VDG[K_ *MZ]V.DB=(VU"0#[4A$I&>%0=4'MM)_&I;9A>.;UAF-UVQ*
M>T9[_5NOTQ42RKJ978#]E7!?/_+1O[GT'?U/%-CN#;1-:1@-.CF.)3_=/S*3
M[ ']*T4$FI&;YW%Q^U^2[?ULA(6:X5=/8'9:MB4D?? .47\L$_2IA<+97=T[
M@E9(UE51U9@=N![GY:9;PBTO3$&9A,F\LW5G4X8_B"/RJ"<^?>VMUP8()3&I
M_O,PP6^@.!]<T_96CR];_P!?@5=RJ/M;_@_BT3)$UM/;32D&6:1DF8=RXX'T
M!  INK%KB/RD4,D!6:7(SG!R%_$9)]OK3]5D,6GR,HS("#&N,[G!R!^GY9J:
MVB06P#-YGF_/(_\ ?+=35NDG+EZ$*;255[W_ *^Y.Q+<>6]G-O8"-HSECTP1
MUJM8-)=Q07=R/G";8XR/N8X;/^T<<^G2H+,O=Q1Q29\JU8QOG_EHZG _ 8!^
MOTJQ$9UU!["T@,]S<L)+>,=,GAB3V4$9/UK*HXPC[6>B7]7'&G+6C#63_P"&
M_*S8^SG\D?841YKE)#'%#&,NZGE?H,'&3QQ79Z#H\?AO39+W69(O-+,Z1KR(
M0>=H/\1Y/-1V]GIG@/3VU/4'>XU&<!69%+/*W7:B^@_05Y_XKUR]\0/$?M*>
M:V6CMK>3B*+^(NW?/"X[DU\?5KULXFX4&XT([RV<O)>1])0PU/!)2J*]26R>
MJ7FQUA:1ZCJ-S=0HR07+LEE$S%A:VX/S.,]R>!Z?A6M:7$UO,VC6FS; /DN'
MYV)_=Q_$X)_4$U5MIKFSECT]HXH9[A5W31Y*P+C"QX/0X!"^IR:N7WV?2[2W
MN%Q&EJ_ ZEE/##U)YS]17>Z71]/F<M6LW*W?;_,6"QM[?6)0T:RO<1"3S)0&
M8LIP>3[%>GI0EC;37]]#-$-V\2*ZG:P5UYP1SU!_.HK^_DW6UU#8SE(91EY"
M(]RM\O //<'\*<VH(FLVYFBEMC-$T.90 I8'<H# X_O52A+JC%N3U3UMW[%.
M*^EM].LTO6&ZWG58I^@8*Q0JWHV#^./6H=4A^Q37EM;Q^667[5;,K8Q(<B1/
M8,%X]ZT7MUFCU:Q=059BX!'3>N0?P8&J,4OV];*&\.Z62$Q._0NI 9''N"I!
M]_K6L*5FG'_AF-55)MR7KYK<=IFK0Q3PW]O$'@LSB*W/!:;& ".ORY_$\]JW
MYO'6KAF/^CHL(Q((H\[Y#T1<FN"NX(]/9+R25!)$XM+N0%E\J3'R2@#U3 /_
M .NK\2W"/&UO/N" R11W"@X4]9'(QC/.*WJX#"8N2JUZ:E)*VNMOEL.,ZU!*
M%&;47\OQ_K>Y/K>H37DX:\=)+W'[Z55"Y[A.,9 ]\UF-(Z7 \\2 \,0V0Q!Y
M[^U17$I:5R3DDDYJ SL[;I&9FQC+')XZ5\]5G=VBK16R6R7H?O.3Y70P.&C"
M*O*WO2ZM]7<VDNU8&+#M:E\^4[9R,YP?7W]:LV[_ &J1M.W;K2'#[B>9%_A3
MZ*>OX"L&&Y S6NEV+73X+QAN:)S&$!P75NWYX/X5ZF5UI2FZ<M5:_P!Q\3QY
ME-"%".+HQM*]G;K>]GZJV_F7+^X>WOK?R& GE!B8D9"*3PY^C<#U)I]Q"+:R
M#1 EX'$V2<EB#EB?<C--:S=[:;>0US,,LP[,.5 ]@>E-2X_M155<BWP/.(XW
M-WC'T/7\J^A]EKYL_)U*Z7+M'?\ K[TAUXQU:UEB@8K:NORN.#*>HQZ+G'/>
MK$:QWFF*JJ%CEBQM P%R/Z'^50V+".R*.P46Q:,DG  7H?RQ56SW733PL62U
M#^8D>,&16Y!/^SG/'YTO96LD)MOFZ*+_ *^>Q.M\-0TWR4B:61T,<C_=16'!
M.[OR,\9I%%]J.G@2W21/T*I'R'4^I)[BGP[;>YFB^5$($R]@HZ-].0#^-00W
M<AO9$M4!CG&])),A=PX;:.I['M4NBEOJ7[23OR*RW)'6[N[&.XBNI/M$?SJO
MEIPPX9>GU'Y4R0W<2+J4-RDR,@$@>#&4_O'!ZK_+-"6\D=ZR2W<VV;,BB,[%
MWC[PXYZ8/7UJ%X+&TNG@N6_=R LF^5NO\2XS^/XFE[*Q4:BO9:]=NG5$4EDU
MO)M>TVQ3R;HI+2?9L?KWP.3R.O<53EMI&D;SD<7.P[XW@*K.OJ2G ^N/KQ5I
M([ ,UHT-Q+&W,)C#\KUV]AE>WMCTH\MI,6\J7_VE07AF$A!(Z;@"V,]B/\:E
M4SH51K?^O/?[S)>.%8B^\!% 78C8FB/_  )02/8G\ZEQY $HEC@#L,3PRJ=_
M'\8WX_'^5:"Q7+2$$7<%^L?+-,I5U_'J/U%0%CYTGE2?9K@,&D22[0!QZ\+^
MH_&FHV-?:<VG]?\ #>?WHHO\DB^8\<<C;CF.16B;W;+''^>: JH2X40,4_UT
M:[H^OH$_SZU8@DR=EM)Y398M;-([[_IL'3W''M2&,YVJIAE*9^S3J=F,]07?
M^7XBG8OFZ?U_7WH9)^Z+-.K1!F7]\F<2?[P9A@?A5C3[V]T^=+BRDDCD#$B:
MR8@#_>5%^;\S4"NB3,(9!;3$C(!4H_L!&O\ (@TDB")U,T;6SES@GE'/J=[?
MS44-)[CC)Q=UH_Z_K2YZ7H/Q;N(XXX]8@2ZBQS=6Y5)/QBR<GZ8^E>E:3KVF
M:Y!YFGW<<IQEH_NNO^\IY'XBOFO:^/-96'[LYN;;) 'T4*/U(IT,TD$@F@?S
M'&TI+:L$F'O\NYOR(^E83P\7\.AZ%',:D=)^\OQ_R^^Q]39S17BFA?%/5K+$
M5^(]0A5MK%\0RQCZL?F_%1]:]*T3QCHNO*JVEWY<[=(+A3'(?H#][ZC-<LZ4
MX;H]6EBJ=7X7KVZG14445F= 4444 %%%% !1110 4444 %%%% !1110 5%(X
MCB9RK-M!.%&2<>@[FI:* /.]0^+&FVA>.#3[R69?^64VV!L^FUOF'XBN<OOB
M[J\ZM'96EK:2X#!;A6+ ?5BH_0UZ?J_AS2=<B9=0LHY7*[1*HVR*/9Q@C\Z\
MWU_X1W$<<CZ1,EW%QBUN-L;_ (2 <GZX^M=%-TOM(\_$1Q:U@[KR2O\ \$Y>
M_P#'?B/4 %EU6XME#XS&N%?(Z H ,?\  JP9YIIYU>[,OG ,!,DF\*/]H#>W
MOS4U_I]YIMTT%]%)#*6 \J]0#([[&8L6^H!JJ!Y6Q1YEJI+8BDR4<^HR57\O
MRKKC&*UBCQJDZK=IMW\[_P!?FA)5$B!YT6= @_?J0)#] [$_D/PIWSR*RH5N
M8E(S')E3']?N+GZBFA=FZ0*T#>7\T]ODI^2*!^9/UISJ)'R\:3?,NR2$KY@]
MSC>WY'OTJS/^OZ_X%@@;:0EM*4)9@8G!R_L"@SC_ ($:C_=Q.,_Z)-L/*[60
M<_\  SG\JD),B[7=+I Q#"? =?8;SU_X"*(B0BQ0NZ@H<6TVX@^^?E'\Q3%_
M7]?\%?,;.N3ON8<YV[98S\[>^&);'T4U)AW'+QW4:N0?, &SV!? S_P&FIM2
M1O+=K20[0QC(*,?0",8]N2#4CA8ID:XB$4F_Y)HBJ$>[8W/2_K^O^")]OZ_K
MT?R(XU79&J/)!A3LBF&4^N7PO_?(-2RQY4R7=L60 9N(<X_[[;!4#_9%."OY
M/F,GVN J<S+& 2/]YSS^ 'TI83D^=9RI<8  A;=<.OT8C"GV/%.W]?U^A+;W
M_K[^GS)8(Y&5I;6;SXV;Y\L50CN#*?F/T%/B$&HA89+<22J"5A V1QC^\&'+
M_49_"D: 22M,@$$R,#(]Y(,'ZQCCZ']:>)(=20Q3M<7$R<A(5VJG;<IX!'N3
M^%:)=#%M[K[^J^[0<)WMIQYS&_9<*LO1(3TPQZ?\"Y-=?X9U\:-.+34;@2)<
MN,!5_P!6W3@#G;ZDUR\+7+@V=R8K153.% /FIW(_A'N.:CLYK>SF>SMD:X9^
M8W4[BP'56<\?+_*N?&8*EC*$J%7:7WI]&O0*%:="HJM/XE]S7Y)=TCK_ !7X
M62.1KM27L9!_JQ]V)C_%[^Q[5R]O/)J$30!R!$=DLRGF0_['L1R3^5==X:UM
MRPT765A>WN@4@S\R@XYC8GKD<C\1Z4^Z\%7,>K336CH+3R#A2?F8CE%_F,^E
M>%@LS> G+ YF[./PR?VH[+YK0[\3@5B8K$8573Z?ROK\F<>DD>G/-#M(CX>&
M-1R<\%0/][^=)%%)!J<=Q,1YES&8V Z1X^8*#],Y/<T30O#);WUPP:6-]K ?
M=C1N"!^..:=K$YAMB(5\RZC(FC0=MO4MZ#&1[U]:HZ-]CR5#6RU<M'_7W-L9
MJDOSPQQLRNC@RNO_ "SC;Y2?J<\?3-6KFW']GR01*%V)\@'8KR/U%-2T1K*6
M(.7:X4EY3U9B.O\ +'IBJZ7!U*.*!>$V W)!Z'^Y]3W]OK5<MGKNRE#1*/3?
M^OP1+9L+YUOV7Y"N(5/H>K?CT^@]ZBBEDCMEL8F_TE7:('^XJG[_ .1&/>I;
M26.TLYTD.U+5V7Z+U7]"!4NA:7>WNM2A8?WET@D=L?+"%XVD_0@^YS65>I3H
MT_:59<L5JV^B*A1=27)%7MLN_P#2=V.TW3Y#J?\ 9]E"665!(@[ CAB3^1S7
M8F/3_ ^G37TX%SJ,JX '#/Z1IZ+G\S5F[N+/PCIC);1BXOF7<%)P7/N>P]!7
M W6IOJLYU:XD:9 <0+CF1SQP.WH!]37RCC7SZIUAA4].CG;\HGKQ4,N][XJK
MWZJ/_!96U'Q ;R\>_O+@?;G!58C_ ,NJ?W0O=O\ T(^U9&BW%MY[ZA)&$FF8
M"")P?G;/R[GQCC)9CGJ1Z4FI.US<BP\Q!))N:XFSPBCAVSZ*/E7\:W;6!+.W
MB@AMPTKQ>7;V[](H?[S_ %ZGU/%>M.E"G%4:2M&/1'+*5HNI.[E+SZ?Y%N:%
M(K8V',]Y<_.[=/F_YZ$]@"!CZ "G6$"W-LTETS2W3!H9G?\ A/0A1T4=^/6H
M+,Q:0TEK<2Y+#?%*PRTHZ%<=25/0>A%(LUX-2=8XXX([E?,7S@6;<N > >,C
M'?M6:IG*Y.S2>F]^_P#78GC5[O0GA;F41M$?7>O _4 TV]=+G3K2Y=59#)&[
M C((;Y3_ .A5#"+VWOYT2[1MX6?#P#:2?E/0Y'0?G4"S[=*N[&Y41F-I$CD'
MW"?O*/\ 9ZC&?SJU"2UL+1O1]?S+$<ITS6D25W>WN(@BL_/E%6X!/<'=@$]*
MJW"&'2Q*L>^?3[DF,;L='P0?8J?Y5:O"EPMA.RAHY24(/<.G3\Q56 $#4]-E
MD+R-'YL3,.64KCD]R"O/X5HJ26JV)52]NZM^#L_SU*VJ(DQN[NWC\Q)(4F:,
MC.]!D,,>H*_S%9PL;RR=(K.Y1[1CY\4<J;M\9 (P>I*<<<\8(K8A9H=0LY]P
M\BZC(Y/20@-@?[V"?KGUJF$2%+>"YRT,5R\<;YP4R<;<]L94@_45JJ5F;4ZS
M7NK5??W7WIHS9U9=LC2Q2EAEVCR!D^Q (S5,N,UU$:RP1SZ=<1O.BKNCEC4$
MA&)QE?4'T]JI06-G=Q I:W!G4E)%7Y%5AZENGK^->3B,HJ.=Z?7H^G^9^E91
MQQ2CAU3Q::E&RNE=-='O=/N9$0R2Q.%')/H*ZJPLE>T#3\B2,K&O]Q&')^I[
M_E46D6*(@GEC03*Q0QKRL9!P?J??WXJ:*X^R6IM@/,GCD,,4><;NZ_08(R?:
MO2R[+?JWOU-6_P #YSBKB7^U>6AADU"+OKNWM\DA([F6>VAMXVQ<%=LC_P#/
M(*=I;ZDCC_ZU2V$:VXGM$!"0R?("<_*PW#]<TRPA-O=W<3L'DEVSL^,;B1@_
M@"/UJ*[)?5X[>*3:)HBL[#J .0 ?4C/X9KUE%I)O?8^/=).]./K^O^:0D82\
MU:4')M74.H[2NAVD_P"Z./J1[59NY4M;R&ZD;;&ZF-V/K]Y?ZC\:2Z"6WV69
M0J1PN$/8*C#;^0XJ"Y62]B:Z7(2#]Y;K_>*\[S]<$#V.:'"UTM]Q\BDU_+:W
MZ??L%Q"T[P7MT@6*-P!"W9&XRWOG!QT%3:I*MO D_)DB?=&BC+/C[R@?3-2W
M4\4EF %\S[2NV.,'!;(_0 <Y[5%I<1,"S3MYMWS'*Q_A(X*@=A_.IY-;+J1R
MZ*3V6EOZ^:;&3V]SJ$ D,@B  DA2-OF)[;G]QQ@>O6HW^Q_94^SKMG;#QA%W
M.&'KWZY!S[T6DLDSR6=O($@B8[9^I9"> GT.1N]J=NBTJZ,,">8)\-L##*R'
MC+$] WJ>^?6HY5N5R->[VU27;S#-WJ<'*QVK(_)8[WC<>W0?KD&JOF0W@:">
MZN);N(\I;]$;LR[1C'U/M4]W;.DBW5Q('D<A6M8LA9!Z#NS#U/':B1EN((YQ
M,EC&A(B*#,F?[I X^J\TG'O_ %^@XQ2VVZ6Z/MU;^14:W21/)N;.&VGV[EEG
ME)W?[2]?;(S^E,9E.U+@_*KCRYK6W"*6_P!]ONG].:DD:)5,5[ EJ[CB:X+2
M._NG<'V."/2DG,\?RW*/=1-@*+E_G(_ZY+][]#637]?YFZ3Z_P!>CU^XBN&=
M66.^/G?,=LAG9VC]"4C^Z?<<5"8]EOET6:V*\2>7'&Y_%B2?J.:EC;RODL[@
MHH8[H)#Y8^@1,N/QJ!C'#*"RM8W+)U 5%'/ON8G\CS4/^OZ_S-4K:+^OET^0
M\%YHV$3_ &R$8S%(78H/J=J_G4<+(DGE6DWEOO.8G'+>P" D?@QI9\_?NX./
MEVSH?G/_ 'V2V/H"*<2\T>&9+N$.?F;(\OZ;BJY_ 4=0Z>7]?+\F1$)"RAO]
M$F*D['"E,YZG<6Y_ &G2@HC/,DD8(7-Q'N(8_0[1CZ@BDA;Y!%;.Q4J<V\N<
MG\4 X_$BF@I&Y*-]EF"J"#M*?0;0QSVZ@T%=?Z_X?\T2!6<!O*2<*_RO;?*4
M^NP=?^!?A3(F+8>*5+C&>&PLH/L?F8?B!]:69524/<Q-$S29#H<[_=@Y)_-:
M7#O&DDBBXC ;$\6X%?H,H,_2@//^OZ^:.KT/XA:YHA2 S_:(U4$6M^Q# >TK
M'=^AKTO1?B1H>J;8[F1M/N"0,7 Q&Q/99/NG]#[5X/&#)$4CVW46P'RL8DSZ
MDHO\R/K3MX\]EBF42;AF.X .!Z*26;\JPG0A+5:';1QU6EHWS+S_ ,]_O/J<
M$, 000>010>?2OG31/%NL^'YHTM;J>&-G.+:XS)%)]"Y&W/^R!7KGA7QA=:\
MRP7NB75M,5)\^-&:W./]L@8/MS]:Y)TI0W/6P^+A6TU3_KJ=C11161UA1110
M 4444 %%%% !1110 4444 %%%% %*^TZSU.V-O>VT4\1_AD4''T]#7GVL_"6
MW8O+H5W]G.#_ *-/\RL?^NF"ZC\Z]-HJHSE%WBS*K1IU5::N?-.K^&]3T!L7
M]H]HH7"NP$EMG/9V)Y]L#Z5FR!HU9Y4D@!*YGC#%7^H.U<?45]1R11SQ-%*B
MR1L,,K#((]Q7$:Y\+M)OF:?2V.F71.28U#(WM@_=_P" XKIAB>DD>96RQ[TW
M\G_G_F>*8<LK>4LN&.V2UX*#U/EC_P!F-,R)(MV8[J,J<E]BR'_OHL?T!KHM
M>\%:SH+E[JT<P;RWVBTS+$?=]QPOXK^-<^-S*)<%L(<W-IN( ^BA?YD5TQDI
M*Z?]?UW/,J4ITW:2L_Z_K1_(?\[AD1FGPH_T:X#':/JY4?H11!*L<ACM9S;L
M7^:)F #_ .Z(P3^1J)MLD9WK'<1X4J\>P2D^O&XCUX_*I29)<C<UW$LGW3O#
M1?GL!(_ _6K,[:6?]?UYV8Y(P)E_<-:71!(C,&Y7]\R-S]0,T]Y!+*5DF-O=
M[1EFNU5''IA!\P]NM5$:(P,J^7<0\AA(L0D7V&XDG^?O4BW$;6QC#&6WV@E/
M-594]\!/_K_6FF-Q=[_U_7D_O+*/;O* 7LK6XC;*NB-*6^A/WAZCM4XG:]XE
MO+B.[BR5\FW.!VR.,E3562[41@37LDT.\;&2Y4/&?]KY!^?YU,))9&C6XFNV
MN@S&WFAFC<'\!W]5[XK1,APZ_P!?\-W70E5;>\3'V.Z:]A(.YU+[&['YC]T_
MJ*M&:YO[8+#9B&6)^"\H7RY![ 'C^8-4VN)%_>-<74-]$F'CFA!!4]L@8YQD
M$]_QJ3[0 PO(-6#))@3#RT!5>S;?4'@^WTK6-OZL9N#_ ,MW_2?0T; +>O!/
MJ;,T"N&:WM_D(=3T+'G@^F*]0TOQ!IFJV\;VUP%+<>5+\K@],8/>O)GMYXKP
M%KV?RIS@E%5?W@'';N!^E)#906^HLK*TAE'FQ/*Q8AA][&>AZ'\Z\3.N'*6;
M.,IR<91T3O=?<=^!S"6$O%)-/6UOU-77H)$U6_TZ&+"[F5I91A%#<C ZL<'Z
M5GZ:BBT#2$M,V5G=^K,O!S_A[TMU>SP7,YG>27>%:(N2<<8(SZ# /XUBRO+(
MKS'>4WX8@?+N/Z9XKHK9BL!"%*7OS22?1:*U_G:Y[N2\*5LWC*MS>SIMZ/=O
MR2TT6WR-2&XE6%;"#FYC)0N1D1H#PQ]3C&!WJ33XA;O<VBDG:_F L<E@_.3[
MY!K-@NEC2,1EUD!.YMW!';C\ZFFEDGNK<*3&LH,,[J><=5 ]"<$9]ZUP&;4\
M3)0:M+IV96><(5\MI.K"7/#J[6:\VNQJ:/I-QX@U\FV1OL*@;YB/D,BG /O@
M$X]2/:NRUG6K7PC9#3],A$]^R^8XSDJO=V]_0=_I7,1>([OPYI,ZV@3R\#RX
MR.AX^Z/4CBLU9?*AEO[F0R33$22.#DL3]U1Z]@*Y<7D^)S#&M8N25"%FHI_$
M^\O)/2QXE+$TZ%%2I1]]Z7?3T]>Y-?7,NH2*@E:1[D;Y)<\B/U^IZ#\?2LN9
M(A(\\+M!&I*1>6V%R!\\F/8<#U--5I].0P%3ONCG?&"Q@'<8Z[5!X([FLM[R
M#5KKRH)52QA81*"^WS O8G^%,\D]\ "O8JN%.FHVM;1+;T2\CCC3DVY/;OO_
M $^A-H^E0!S=_95DDE<_9X';<"!TW?[*]2>['V%; WZ.S?92LY/_ !]$CY8O
M1N.@&?N>G/%1PV$7E^;:2+;  EKU!MW#T0=-GU_#GFK%E=O-#]F@MTC*#YW?
M.Q@>-ZCJP/J:\]4^YSUJ[FW+==4_Z_KJ6;BU\B+[=O,MS"?,\UN-R]U'8 C/
M'TJ.^U.Q\J*XCN5D:%UD 3+$J>&Z>Q/Y5%;6D,,QM[IC,8P&A,Q^79Z =.#Q
M]"*ELW@7SK#?&50_*H8<HV>/PY%6J?R.5S2UU=OEHQ\MY:RWMI)!<(^XM"0.
M#AAD<'GJOZT!0NIW$3*"DT:2;2,@]5/\A526#[3H\L4BAI8,K\PY)0Y'/N /
MSI)I6LY[2Z+R2VS!DY&YT5AN!S_$!M^M:1@XZBY5).,=]5^J(%E>RTA8IF+Q
M0S 1N>J%7^Z?8CI^7I5RXA9M45XR!-Y.^,GNRMT/L0Q!^M'EK/'J$ (9)1O4
MCD$.G7\P:KV=R[/IPF8F91M)/\:.G#?7*X/N*TC!+T?_  QKJWSK?6_S5_S6
MHP!+K0[<N&14G"D'ADPY7\QG]*DC4WAU*PN5!EVJS ?WL8##ZE014%QFWGU.
M,G]U.VX9_@DV@K^!P?Q%6KN62*_L[V!-QDB82(!S(O# ?4<D5I&'?I^6J-%%
MZI==5^#_ ,R."\E$NGRW."91L\T#"ON'0^C!A_A6K:1 Z\MO(2L=UM;([$$*
M<?@1^59>([K1;N&+:Z*7*<9!&=Z_SI7@MX6L;V'?&B3QN521@NUB >,^XIU(
MS]E)P>MM/N?ZEPIP<U?36UOQ-_Q)8V_AW5$MK?SIGO(S,L;$<L/E/..!C;DF
ML.WB:'5VDG97EN(>H'"[3]U?;!_'%=K\1$"7&C78[2O"3[.!_4"N,OY$MTAN
MW.%AE&XX_A;Y3_,5YO#>)GBLLA7K2O+6[?DVCNS"A&EB73IJR?\ D@OIS:75
MK-&H>24M J9QN)&1^ (YIL\(M;5)MY9XIEFD<]6R<,?R/Y"J]Q'*]O+?3+BX
M7$B)_P \U4@[?J<<U<OY5^QLB .]P-D:^I(Z_0#FO?Y-V^IR<EN5?>-U%&OA
M+8QG"!<RL.YZJOYX)]OK4\=W']@2ZDX0H&8 =_3'UXQ5?2P!IL!!)<C+L>2S
M]&)_$5!8_O[N>/<#;VLQ,:C^)FYS] <@>^:.5JSZL3IJW+TB2Z1&RI)YP/GQ
MMY84G/EIU51^!Y]2*8Q,^J26RNRVDI_>$<>9(H^9 ?3&,_0CUHNY'CU&**!P
MCW2;)&_N <AOJ?F _P#K5)>)Y5I%;6JA9\C[,#T5ASN/L._KGWJ'#1Q[?B'+
M[U^_X>?R8M\TBO$EB@^T0J2=H&$C[C'J>P]11FW>W^SVJB=[A=SN_/!_B<^O
MH/RQ38+A5M42U&ZZE)+[^JL.&9_IZ?0"H'#VC31V<N(U&^[D8A3N/4J>@<_D
M..]9M=?Z_KN)0Z=5_6OSV'+.UC-)"S"6485KZ3E4]G]#[#CUQ4;HH<75K</'
M(YP;MEWM.?1$[_7C'O3'OXE B-O+$D9!CMWC;'/1Y2,YR>B]2:SIKFV#;DCF
M\QBP9D5HRWJ#@C:/11^)KGG)(UC2=[V_K^NFQ=>XEBCD6:VR-O[YXG#N?9V;
M[O\ NKDU6\Z"!F2"Y>U=MI*$,JD?0_.<_51519BJ#RFO?E3Y N"1D]A_>^F/
MJ:0W#C<K7 50R_+-%E03[@8)]R.*P<S3V5OZ_34MEG;&ZVCD56.'A;:%'J0"
M.?JYJ.";Y/+@G)0H<PS*06^I7''U8U&D>75OLW1F(DMI,@<=2!G^E7+/3]1U
M5 ;.UEU%2I',)\PG/J V/QQ4N5M6-0<M(J_]?UV*XVPB1D,EF?EW-$<QGV&T
M8_-A3B&9U+0*Y#$K);$;A[MC<WMUKK+/X;^*+R-9([9;0%0!'>.&5,=N2[#Z
MUTMI\&SNS=:MY7S;F6V0D-]0QV_^.UDZT%U-X8.O/6UO73_@_F>6[O-C&6CO
M%P<F0J),^@W$GVZ TX.Y4Q(Y?"#_ $>ZS@#ZL5'Z&O<[/X8>&[=UEE@FN95'
M!>38/R3;^M=%9Z#I.G8^QZ;:PD?Q+$-WY]:R>)71'3#+)OXFE^/]?@?/>F>'
M]7O2YT[3;Y/G&_;&QC?Z;0H ^C"M^Q^%WB*[;S)[:"QD&</YJC.>Y #'/U_.
MO>!28&:R>(F]CIAEM)?$VSRNV^#BS1J=5U;S9,89H(B&/T9F./RKH[7X9^&X
M(U2>WFNPN"!/*<9'?"X'Z5V6*0YJ'5F]V=,<+1AM%%"ST32]..;/3K6 _P!Z
M.)0?SK0HI:S-[)!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!*X_7OAWH>N,]P(?L=X00)X%&,^I0C:?RS[UV&.*3\::;3NB)PC-6DKH\$
M\0_#W7-%$DR1O=0' ^TV88O@?WHP0 /^^A7(M'OD^>)9623 :W #K_OX#']3
M7U2:Y[7O!6A^(FWWEKLN.HGA.Q_Q[-^(-=,,2]IZGG5<M3UINWE_P3YU$CN%
M<N9@H8><K%'C]MN5S_GBG+/&Z[S([L(_]?&Q$PY[J'Y'^<5W6O?"K5K%_/T\
MC4(D!(>/$4Z^VU<!OS_"N#N;>ZBF>WGCE:=%PROF.X'X<_TKIC5C+X6>;4H3
MINTE;\OO![LQNS1S2J-R[Y(0Q9O^NB%^/K5872+^[<0K&[,"K;9 Q]8VQ\I]
MLBG2+N<CY7<,N5.(I%_X$0-U5I%9RJEBJL[?)L$9;CTZ/]:IR80432M[XJJM
M;R3)(B82<N4!YY1U?*C\_I5T74>]VFCMKA9'"S0S((WC<CJ<Y!SQG''0UQ\U
MI<!@L+'_ %9!608;&>F">1^.*9#K%[I\IBNK51]U7#1Y5E]&'?Z]1ZT1Q'+\
M1M]54]8.[_$[6."QC22SN$ELYE^:&1RR\9^4Y!QD'C\!5@P+>Z>MQ').\L)W
M%1.Q&Y>&7@]QG\Q6'8ZS'*L>R^^>-R85F)*L,<QL3ROISD=/2M0/9&>.ZFM3
M;Q7"@%P<*KCI\R\#/0YQR!7?3G&2TL<DZ4XO6]_Z_,34!!"(C;KB-TW@Y)SG
MZUFM,_*;CL)R5SP3ZUHS6.Z)X(79_*^>'+;LQGL/H<UC2/AL,,$5\=FU"I#%
M2<EI+5'[-PKC:-3+:<(/6*L^][_J65G 85=B?SHY0'"[4+AB< %>0?S%8X)8
M@"M&UN--MT(NKF-I%8'R1\Q!'J!4991E4Q4+:6=V_)&W$>+ITLNJ<_VDTEW;
M-BT=K\QWSJ50C]Q&?X?5C[G]!5:VFB%T\<LBI:6Q9X6<X5_4Y]$R169/K,@A
MG@M()HXY91LEF4J &^\ .O///O42V\]Z(FN)+>XCCR%BY15[ *O))[=/QK[:
MIBH*RCJU]S_K<_%7",;\SLNG];>19%[<:K)+]FBD1)EP'8$,T8Z*HZ@'J6.!
MSBK=L5MXC$UH/+4@#808 ?61\?,1Z8P*KB*TBQ%/']BE9  ),HOMA5R7/^\?
MPJY))-;)OO$:>W& LDW[M%'O&.H]\?A7"Y2F^:3.:K/F=DM.B_R>S)=@1U>V
M7[;(K%GA0;8A[KG@'\\T^X,ES"ET;V*"1 ?+"-M/NC,>?;IP:A0N45K.6>ZM
MR26BMEV(!_L,?Y9_*F!HX2;NTBLHB00Z2S!F<_T;ZFBW]?U_F<W*[^?]:.^W
MW?,?(=.N($N(D:2X5MP\Q7<DC[R$D'KT_(TLUQI+B"Y580JG:Z-'M^4\'J.H
M./R--^WR$F]MKR)MP DB2!^<=\9^\/U_*D345B=F6>SN+:X;#H&*%&/!X.>#
MW]#]::L-4Y/OIYOYK;[BV+4VM]_H<HB2=-RH?GC=EZY^H(Y'I4*7#'3Y+>0;
M;NR<,4SG*J005/<;34*H($$2[[>_@/FPQ.WR3*.!P."<9'&#5A3%?WABD5H7
MGA\Q".H8#&Y3W!4C/TP:UBNW]?TP4.KUMUZZ?FFB7]WINL1[<_9KI, ?PQ,#
MG\CN_ U6G3R=*2=59I;"<[0#@L ^"OX@_P J6*=;FTM8YT_>VTOV>93Z$%-P
M]CQ^-.A23R-5LI7#2@>8ASRRE>&/OE<?45JDGML_^'_-&JARN[\K^>MK_<RP
MZ0WEU,F=T-W;*P(]B1GZC(JK:W/FZ=9EO]=:3K#+GKW3/T/6BV9HM3M-JGR+
MB)W1AT5B Q7\QD?C5>\C>*VO985R\,K;E'\29#C\1G(_&MN5[]5?]&:QI[0]
M+?BBV@:QU6Y$40>"95FDC7[V>5)7\AQ26[)=Z#)#&X=D1XQ@\Y4G'';H*GF=
M3?6DR,&25'4,#D'@,/Y&C3-'AU;7;BR;R$ED99$>0=25Z9'.>#3J\E*G*I)V
MBKW\E:]]"Z=/G:7VM/O6AV/CN59_!-C=NV&8(ZX!)+%-PQCW%<)/&^I6SSRC
M ,9:"+/W#C(8^K?RKUJY\/-=^&;32'N K0*BF0+D':,=*\R2*&V:2U@F::.V
MD:$2,,%MIQG%?+<%8O#5L//#0E=QE)[.UF]'?;Y'KYI1E":JVWM^6H1R)/:)
M*Y 22/<Q/8$<U1TMFN;>.YD.2J^3&/[JJ<9^IQG\JBA)F1K'!$-O(RRG^]SE
M5_(C-6+9UAFO$<A55A+D]@1S^H-?;)7<9/\ IGF>SY8O^M!!,T37%C$VV:20
MLA_N(PRS?@<_B12N\6FSPR8VPF,Q$#U'*CZGD?C4-NTG]HI=R9'VI3&JG^$#
MYE'U(W'\:6\#WDS)$2!:D.#_ 'I1R!^ _G4\ONNV_3\P=/7E[[D[P$6,\L[!
M)W_>L_\ <(Y4?0=/S]:6UN5>U;4IQB1QM\L=4P>(Q[YZ^],,RZ@\:I_Q[JJR
MRYZ$GE5_#J?PK/FU6UM]4>8.LJ(W,$9W,SXP7 'ITY]S65248I2OIM_P?D)4
MW)6MK_6A>>.Z@E#0.GV^YYF5ON*H[^VWH#W-5)]1\JV4QVCB)%WQ([*0QSS(
MYSSST'<\UE7?B.?R"8M/D#SMF:2?Y5V#H@ YQV]^:[[P=\*;[Q-9?VIXON)[
M>"X >&PM_P!V=N."Y[#' 7TKS,1C*<%[M_Z]?Q.NA@IU'[UOZ]/P/+[[Q)/-
M.T5G@G?DONR23U+-TW'IQT' J[H_ASQ!JTL31Z=>7#[FRRPEU'IDYP!7TGI'
MP_\ "VBH@L]%M-RXP\J>8V?7+9P:Z555%"J %'0 8 KRI8B4G=GIQP<$K+3\
M_O/ ]+^#FOW17[:EE:Q;-IRQW]<X 7( _$&NTTSX.Z9;$M?:E=W7  C7"HN/
M3.X_K7I5&*AUIOJ7'"4ENK^ISVG>"/#>EY-MI%MO)R7E7S&)]<MGFM]$6- J
M*%4= !@"G4M9MM[FZBDK(****104444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E9>M>']+U^V-O
MJ5G%<)V)&&7Z,.16J*2@32>C/)==^$+8:31KM9(\Y%M=\8_W77'Z_G7G.J:%
MJ.CW*P7]M+ S.V$N4W"0?[#@,,?C7U!UJ"YMH;N%H+B&.:)QADD4,I'N#6\*
M\EOJ<-7 4YZPT?X?<?*3QH@V-^Y.TYC8AXQ]2"2/TIL]LJQ$3HRQD+B0#>A^
MBM@@>^*]UUKX6:9>(6TJ9]/?&!%S) ?^ 9&/P/X5YKKG@K6O#SR2RVDL<60/
MM5G\\;?5% V_CCZUT0JPGH>?5PU:CK:Z[K^K_F<<^DPS*6$"RIYART#$@#'\
M6<C\ :BBTI'0+ Y?()V([(^0>,(":UF17E!:$2.'RKV[#=CU8#<WZTK'S8E,
MACN4 8%V(5Q[ ,?PX45KR(Y_;S2W_K^O0RH[%K:4B*\EAEV* DCF,\]?F!&?
MRZU;\EX#BY>8 O@/.-^1[,<$#ZYJV,F-HD;S$V@_9I]PP/<_*#^.:(BL);R6
M-NQ< \[D8XZ H./^^JF=&$U::NC:EF&(H2YJ4W%^6G]?B0K$_DA@H*$',UN<
M@?GC]":;%9QR(?)CANOE&49-KGW8J/YFIRJ+,K2)]GGRV)(2"/JWWVS]13I]
MSQ![J-;B,)Q,H^<_3>W_ *"/PHA1ITU:"L3B<=B,3).M4<GYO^E^01"-)62&
M:2"4L 5)W!O8!,_^ABI2PB=1<0"%\G#Q/M ]R$R_YFD!>6-@C"\A!7,<A8^6
M/<G:OYBD@?:WE6D[Q?,<P,3AOH$'3_@1'-:G$]?Z_I_?H2!W@MON^=;,O+ )
M$S?BV6;]#1!E2\NGE7Z93RRQ3Z/)]TX]L5!NC@DR?] N"AR5V*HY_P"!$_C@
M\TZX''FWD/3;BX5"2?Q<Y _ BBXK?C^/Z/Y$NZ*:8K%)MFWG=%+(TGF'O\J#
M!^H-(93',I8&QNRI"E42-"/JQ.[UP<&C=+*@# 7L(?AD+-Y?X+M0D?6H8B/+
MV6\BRQ%2#$^U9#[?*K-[8;\Z/Z_K_@ H_P!?U^J)7O)U+OYTD,H"@W*NTB-[
M$!,?G^=0SW4R,SRLT#2,,G&])>.X8\?7'YTI&&V!A'(%'^CW0^4#V,C9_('Z
M4@'EL702VNZ3DC+)(?8@*H_,4-LJ,4NG]?UZF9)>SVD<1%N712S*"^],>G'R
M[?;@^]2VOB2.6V\AE:T$6)K=F.?*8'YE#'[RD$^_.*L^0H.#'Y388EK=@Z?5
ME 8_G^=0R641C,CQHRE!B:$!6//9"1_(U"YXO1G4ITFK2C_7Y&NQ-\EZT#(M
MU$%N %.5=3R0/4$KD>A/UJU-();ZUU*U!<26Y90!_K$!!*_DWYBN9_LNVDD=
ME2.0!ADQDQLH_P!K@ _I420VT>#'>$>6S#:7*NOT";@/K71'$-;K\2?9P>S?
MW=SHG'GZ'8R0R8:&=?+<=L$J/PY%6K:07<]U\NTRQJ60_P +8*L/S%<\-,O$
MM8HA->6\3C*QRR$1%LYR7SZ\T]M-OXKV39<W$<AV^?.DQDC4>AP,Y_SQ71#$
MM--P?]*P<M/;F[_F7H7:SL[%R#]E$B$G_GB?NG_@)S^!K59FAU:&5&*EXCM8
M=BI!!_6L"3P\A,<<=VUXDA.R*&=ER.Y;.1C\J630;*VCC-P-0\\ K''G=&3Z
M#&>!ZGM5?6';E<-/7Y/IU[ Y4KW3=]>G_#'L<GBN%_"$U\9HTNE'DL"P&)#P
M#_7\*\E?5(+>ZN+6*ZA#R.'$A<$*".<>IR.E,BTJQMX3Y<ME<S3,H$+1#:7&
M<<9& ,GYCS5L:/\ 8RBK!I\]Q*_R$PD!?4@9X4#\_P :\K*,NAECJ>PCI.7-
MZ+M\M3HKXZ-;EY];*W:[[E2WO[*SO);=&=O,59$549BQZ,?T'-5[K4UGOPD<
M$OEJF+@.RH" <J,D^O7VK9-@T*K90PVGGR@L\YCW,H[MSZG@#_"GK9RR8L$D
MABMX0N\QPXYZA.2<^I_"O8E7KR7*K)>GX:LYGB8M\UOQ_'_(R'U"_NU5H[(0
MJDJ^5(0TF]NVT  '\Z8L>J0>7:W%VEO-)N<K'@E03]X@ DDGMD?I6D\]G(\D
M]W=S72QDK#&K$\]"<)TR>!FB**YC@6UCACM'N2S3R9!=5_BQV  PHR:S<JLW
M=R?R_P" /VS?2W]>?;TW,8Z7$EL9Y-\]LYPAG8J;B0GD[%YQGW%+);VD!:+R
MWCPR;U&%,C]EQT1!UYR?UK0DE$'FW=HP"1 0PW,IW;F/!V#OS@>G!ZUI>$/"
M\OC'Q ;+R3%IED^^[E_B9C]X$_\ /1NG^R,]ZYZJA3CS,WHQJ596-[X6^!8]
M7G7Q)JL32V<<C-91S#B9\\S%3V&,+GTS7N-100Q6T$<$*+'%&H1%48"@< "I
MJ\6<W-W9[M.FH1Y4%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4451U/5+/2+47-](Z1%@N5B9^?HH)[4 7J*R='\
M0:7XAA:;2[DSQ  [_*= 0>A!8#(X[5K4 %%%5[BY@M(Q)/*D2,ZH&8X!9B !
M]22!0!8HJ*.6.7=Y<BOL8JVTYP1U!]ZEH ***JSWMM!=6UK+*JSW)80H>KE1
MDX^@YH M445075;![EK<74?G+/\ 9RA.#YFS?M^NWGZ4 7Z*Y\^+=):(RHUQ
M(C71M(C';R-Y\@SGR\#YP-K98<#:>>*Z"@ HHHH **J-?6B-$IN(@TLAAC&X
M'<X!)4>XVGCVJP[+&A=V"JHR23@ 4 /I",C%5EO;62X6W2>-IFB$P16R2A.
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MX.3[] *6VL+.;S;T1A(VXC*.5"H._![G)_*I+B:*>Q$%LZL)B(5 _A'?([8
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M6DMTCR*X\KKE1\LR'G"N!C)YYKT*B@#A+CPAJ6R=X#92S/J4]Y&6EE@=%D
MVRQ_,C#G(P00<5U6B6=UI^BV=I>7"W-S#$J2S*@0.W<@#I6C10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9.K>'-&UZ(IJ
MFF6]UQC<Z?,/HPY'X&FZ1X9T30(@FE:7;6O^TB?.?JQY/XFMBBGS.U@"BBBD
M 4444 %<G>^%+JZU#5G75S!8:J4^U0);CS"HC$959"W (']W//%=910!S%UX
M0M[FSUJU6=XH]3:)EV(/W!C1%7'/(_=@_I67J'AJ_M([C5S>W-[JC74-RC6=
MJ@\LI&8_]6S_ #*58Y&[//!KNZ* .1\)Z+*-,FN=8M!]LN+R>X1IHU$L:NW'
M3.PD=@3CUS3;3P=>:?;V)L=;$-U:VGV'SS:A@\ .4!4MPZ_WL\Y.17844 <5
M+\/-.DLI;03'R3%:)"LL8D"-;EBK,#P^=QR"!W_"YI?A"+3KO3KE9+9'M#.S
M):V:P1N9%5?N@\8"CKDGUKJ:* .&B^'PCU$W1U(.=MRH8VJ^:XF!!\R3.7*Y
MXZ<#'O5Z?P5#<6GV=[Q]O]C'220G../GZ]>.GZUU=% ')ZWI6KW#^&TM;E?M
M%K<LTUVMN"BCR)%W%"W0D@8![]:I7/P[MK@6\YGMYKY/.\^:\LEG24ROYC$(
M2 I#=,'@<'-=S10!S47A5;:'5H[6[,/VY8E7RX4Q%Y<:H!M/RD';R, 8)%5M
M.\%+8O:NUXI,%\;T1P0>5"I\EHMJ)N.P?-N/)R:ZZB@#BX? BA=36XU'>+^S
MDM&,-LL);=_RTDVG$D@[-@=3ZTEQX!ANM2COYYK&:X>&**Z:?3DE\SR^ T>X
MGRR1P?O#@<5VM% ',/X7/]E7EA%>JOVB]DO&\VW66,[V+&-T;AEY]0> >*T/
M#VC_ -A:3'8?:&GVN[[MNU5W,3M1<G:HS@+DX K7HH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>form10-k_020.jpg
<TEXT>
begin 644 form10-k_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S EX# 2(  A$! Q$!_\0
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M(^]?G/7U-)''(%?]VW0=CZTY4?>ORMU]*XZG+S'53V.0DO;L2O\ Z5/]X_\
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M""#G/)!K<N)/*@=_0<?6M())<QK!)*Y)N&<9&?2EZ5S&A$W&HR3+(Y7DG/\
MGW%=/50ES*YIL[,**PW\3627<ML<B2/!.XX&#T/ZU3U#Q )HUAM"CS2':D8?
M.X^IQT4=30Y)(AU(FO\ VYIQN6MQ<H9%;:0#GGTK1KC[70HKAB^T&X('F76,
M$GKGVZFNO484#T%$97"$F]QU%%%46(<8JI+J-G!,(9;F%)#_  /( ?RJIXAO
MI;'2G:WQ]HD98H<_WV.!45CX<TZVM-DUO'<R.,RRS*'>1NY)-0Y.]HF<I2;M
M$?XBNH[?P]>NT@4&%E!SCDC Q7(>'_"ES>J+B]#6]L1E4Z2./_91^M=='X;T
MB&99ELU+(<IO9F53[ G J'5_$MII:M'&RS7 XV+T4_[1_IUKGK4H2?/5V1RU
MZ5.4E.O:RZ%N&UTO0+-Y%2*UB4?/(W4_4GDUR>L>.9+G_1=$AE:25MB/M^9R
M?[H[?4UAS7USXAU (Y>ZG)_<VXX4>X'3'N:U+Z2T\ 6,=]<0B^U>YRL8SA8Q
MCG![#ISU/M6<:KJ*T%RQ1G&NZJM!<L%U_P CJ/#.A'1[+S;DJ^H3_-<2=3G^
MZ#Z#]34/BS4(=%2SUF5U!MI&383@R*XP0/?@'\*X&W\?Z[JQ+I*;;#;=D<2X
MS]3DU'JVH7^LQQKJ,@E\I2$PH'7N0.">E34QE.FN1)HBKCZ5*/(DT^A-J>KZ
MW?S+?3?:X(V >(1AU15Z@@]_K6?]HUES.-/N)2;QMTR0K\TA^JC/KQ7L.BB)
MM#L3"<Q^0FWZ;17'>(=/DM=:_P")%')'<K$US,L> H'3*^A//L?2E*C.-JD9
M7ONO\B9X>I"U6,G*^Z]>QYS/9S)$_GHPD4E65EP5QVQVKLV\.:-X:\+6\DMO
M%/JFH* )9QG82,G;Z;1^9Q6#:FXO[\Q*3<&Z;)>7Y<EN[$]*[/X@Z!>W6C6$
MU@C2M8J5>-1DE2!R![;:FA>2FTO0G#\TXU&EZ')V%G]F2VU"[L;:Y#^8(//3
M<"%.W)'3(--ET]X;==0O'VSWV'6VB01J(<XW$#&">P'8'-7-(FU;Q%H]M96^
MG/FQCD0R'Y5<DYZGH>,8JP=#\2:@]K-?Z9((X%2%EB=-[*O&<$_Y-3&G*THI
M-K2WKU(A2FE.*3<=+>O6WHS1T:/6] %G'!>1W<5ZIDBMYF.%Q_"&/0G(]LUW
MFFWR:E8172*RA^J-U4@X(/T(-<K.FIS7MDRVB6DB*8K."1P[*,?-(^.  ,<<
M\XKJM-L5TZQBM58OM!+.W5F)R2?J2:[:*DI-/;_@+_@GHX=34FGM_P !?J7J
M***Z3K"BBB@#A-9L#/+J>ZQU"34V=Q:3Q"0 *57: ZG"C/7]:L-<S^&8I+F+
M3+N.+.Z> R>='(Q.-ZR9)5O7< #[=:[.JUY:17UG-:S@F*52K8.#CV- &)<^
M);BTO+>RGTW%U=$BW5+@%6(^]DXXP.>AJGY&IZA)K$40M[:64#S(I09/O1A0
M58$=0.XX/K7/ZK;(=6,ESJVHW$UI>+'%;HA=TBRN]LQKN&X,<GT'%;&E2H-1
MN;S1C<&SDA0-)*9-KR*S#'[ST& <4 26>B:()8(5TV%4\U< IM)4HPPX'!(=
M2.?:M/6-3O83)9Z7:R3W2JC%QL"Q*Q]&89. V!TZ9KS?Q=XZN[3Q D6F0&VN
M+9P]R9%RLK<8"C^Z1U/?MW-<U=?%CQ)J6O7,VGPVFG1@+'+D"<MC.W&0,'D_
MY%9NM%-IO8[X97BIQA*,;J>WR_(]<@\3PZ?9SWVI:B)K(6T=PCF$(X+%@$VJ
M>2<<#ZUR,?CBQ\2?;Y;@7%G>QQK]CA$CML7)#R I@# 89)Z8]*\]ET;3IO!L
MWB&77M3?4[*2-)K1MGEL[$@;% Y!!^HYS5WP/9C5]82RGM"\LB"22,, &0=8
MPW8,2-Y[*"!G=4N;<XVM9FL<)26&JNHI*I!I;:+U9ZC=1Z?=R6VB_P#"07,M
M@T>2\3I)AQ(NWS&5<8;)^]U-=9H6B)H5K+;17,]PCRF7]]M^4G&0, <<9^I-
M9D'AZ^2U-FTEBD$D_G2&&!E8?O-^T<XX/ /IVKJ<_E6G+'FYK:GD\L>;GMKL
M.HHHJB@HHHH **** "BBB@ HHHH 2J=QI\%S*LKAMZKM!5RO'X5<'UHJ*E.-
M1<LE=#BW%W3*']DV_P#?G_[_ +_XTG]D6W]Z;_O\W^-:%%9?5:/\I7M)]S/_
M +)MO[T__?YO\:/[)MO[T_\ W^;_ !KAO$%TJ>(=8"WNHIK")!_9<$$LNUGV
M]-@^1E+?>R.F<XJ])XCU6RU"& 6P>)YYD$2(S22$3.O&X], '(SC.2,8H^JT
M?Y4'M)]SJ_[)MO[T_P#W^;_&C^R+7^]-_P!_6_QKBHO&>MMIS2S6\44C,BJ4
MB+[)"KEHV^8 $%5')SSC&2*<?&>NA'==/265K)9X[:.)LAC&K'=D@@ EN@(.
M ,@YH^JT?Y4'M)_S'9_V1:^LW_?UO\:/[(M?6;_OZW^-<S)JE_J/@N_GN)7M
MRLP1+FT1GW1@J2QV<A>64E#D $CD50T_6KNTL83:B5X-TJBYEDEGC1-\ ,B%
M\,R*'?ALG*G!Q1]4H_RH/:S_ )CM?[(MO[TW_?YO\:/[(MO[TW_?YO\ &N5M
M?$VLW"&=#:S00R*K%+9P9P;IX<CYOEPBAN_/M5,>*-8O[R.-',$,=S YD6W(
MW!C*IC8;C@95!S@@GD"CZI0_E0>UGW.V_LBV_O3?]_F_QI?[)M_[TW_?]_\
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M2V, GZ=JO=!10>E*UA62U1PNL^,&:UE@MD,3AF1VSS@''R_XUP-W=2_9FNI
MZP;BH;&=S=2!ZGUK:O\ 1KV?Q+<Z7!'OD,C."3@!#SN)[#D5I>.=.BM+?24\
MH101QL@CCY56X)QGK]:\F:G*,JE3II^)X=15)QE4JZ\NGXG.Z'X@O#!*=''V
M9(V599!$"[%L[0S'/H< 8%.UF>^UM8AJ$YF:$$(2H!&>O3Z5EV^]YC9V%LS2
M3N (T_C8=#CUZ\UU=UHFHZ+8I=:DBS )F1XN?+/HW^-<]15^7GIM\O8Y:L<3
MR>TI-\O8@\ Z;;6=Y=ZA>2JL%D 5)_O,"/Y _G1J%[IEYK$OV17C@9=P#@#Y
MN^!Z53TBPO-:U!H;?*1R$,P_A '\3?3)Q]:ZN^TO04M_[#M[<W&H8+HZ'Y@_
MNPZ?3IBNKV3Q%#EDK?YG9[&6*P_+)6??S+G@;4A<V<]A\Q%LV5?'&UN<9]0<
M_A6MJFB6&N.DC3R1SP$H);:7:R_[)_PKG;,WWAS1;ZPN8S$GDNUK< 8&\@Y4
MD=^XS7,:^;'^U1;64BQ620Q^9);-S(2,[CZG-==-^SIJ#UL=])NE2C"6MCTF
MV\-V-I8W,$>YWG0J\TYWN>..3Z=:LZ==F53;3H8[N%0'0G.1T#*>X./\:YS1
M/$%X?A]-J$Y4W=LDB*\IX<KT)]?ZXJ*RUFXL-3L6URXC*SV^^&[V; =P4F-@
M.!@]#6O-&-C;FC&S1W7%%>::CXIU"ZU*:[LKFY@L8W6.,B(%2.[%3ZGIG%+H
MWB;5-7UPZ%>W(C616=+BW3:TB@=.?N\9[9%0L1!RY49K%4W+E6IV%H3>ZY->
M+_Q[P(;>,_WVSER/88 _ UM5%;V\5K D,*!8T4*JCL*EK:*L=$59:BT44510
M4444 %%%% &+>:9=?VO_ &A8?9A*\(AE$RD;@#D'*\^HYJ;2=+6QL8XIEBDF
M!9WD"8^9F+'&><<UJ5EZU>36=I$;=T1YIXX?,=<A QQG&1F@#G?%'AG3O%FO
M65K=*Z&W1GEDA(5V4XQ&3Z=_Y5P]IX"T7P/K=[K]U9->:(T#1RP& W#6DH89
M..24(R0>2 >?6NF,*:=JXM_(2[NHY(;K[>(EC(!=BZR29QD@<9ZYQ71?V[81
MZGPTLGVB+,T,<+2,A' 9@H/!'&>AP*5EN:.K4Y5&[LMM=K[V/([C4_AY=Z/?
MK:V$#:K>SR'3Q#:GS"SL/*"D<*>>AQCH:Z'P=X+?0/&ELGB!8FG>%I=.:)R4
M,B</G@?,%8$#TW>E>=PV%Q<^(G_LNPFMY+S49$LW,!ME>16SE0?N[?3MBO<=
M2M[Z\\,6_P"^6;Q'I6RZ3*>6994'S #NKJ67(X^:LHVG*[CL>A5E4PV'4*=5
M2517DNWJ=I167HVN:=KMDMU87,4R%5+JK M&6 .UAV//2M2MCRPHHHH ***8
MS*BEF8!0,DDX % #J*Y.X^)/@ZU0-)X@LF4OY?[MBYS]%!X]^E=/!/%<P1S0
MNLD4BAT=3D,#R"#3<)15VK!<FHHHI %%5-1OHM,TVYOI\^5;QM(P'4@#.![U
ME)XIM89I;?4H9=/N$57\N3#[E(8Y!3/0(V?3% '045C7GB32;%&:XO%4)R^U
M&8J-H;) !P,,O)XY%6;[5(K&[L+9XIG>]E,491,JI"EB6/884T 7MP]1^=&0
M>A%<3J'_ "$;G_KJW\ZO:/\ ZF;_ 'A_*M94N6/-<B,^:7*=1D>M&Y?[P_.L
M&]_X\+C_ *YFN2_$USN5CIC2OU/2C(@ZL!^- =&^ZP/T->!^+\_VXG)_X]H^
M_L:W/AE_Q_ZGR?\ 4)W_ -JE&=Y<I<\/RT^>Y[%FJEW;VU];M;W"K)$<$@GN
M#D'V((!S6;7G3??;D]37;2P_/?4X)UN7H>KVT%K96Z00!(XER54'U.2?<YR<
MU8$L9. ZD^QKYV\;$^;IG)_U#]_]LU7\$D_\),G)_P!1+W]J4Z'*F[[%PGS-
M>9]);USU'YTNX>H_.O-#T/)J[)_K#6-&/M6UL:UE[-)G>-(BCYF ^II!/$Q
M$BDGL"*\$^*!/V;2N3_K)>_LM<UX%)_X3W0^3_Q]KW^M8U:GLZG(=-'"^TH^
MUOW_  /J6BBBM#D"BBB@ HHHH **** "BBB@!*P-0U>474EM#$Y*?W< MT]>
M@Y_0UK3WUM;SQ032JDDN=BG^+%1V6V=7N#\RR/NC)!^[@ $9]>OXU,DVK(+)
MIW.>72[^ZU&VG-O$D2Y#LYRPX."#^)X]ZZQ$"(%'0# I])1&*1*BD(RAE*L
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MIIU\SM;LVH*P@DEQN\IR.K$9(_,'GGT(:Q\0[+C4K*WC4=9;2Q-TGY)*'_\
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M1!T51@422QQ@&1U4'^\<4X$,H*D$'H10 ZBBB@ HHHH **** "BBB@ HHHH
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M6K=/N/3E"$6N72W3H=A13$;<@;!7(S@]13ZZ#K"BBB@ HHHH **** "BBB@
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MW):O;SSA)%%JH)'UQ4.ABDKWC^):G2??\#W&.1)4#HRLIZ%3D&GU7M%"Q,
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M=:C= K:K"EM'&P8*L?F #.T<8D[Y/')H UY_$^D10B3[6) T7G)Y:EMXV%P
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>form10-k_021.jpg
<TEXT>
begin 644 form10-k_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] ET# 2(  A$! Q$!_\0
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M *]6%&T8HQ2TU%+83DWN1F($YXI/)'M^O^-2T4Q$7DCV_7_&CR1[?K_C4M%
M$7DCV_7_ !H\D>WZ_P"-2T4 1>2/;]?\:/)'M^O^-2T4 1>2/;]?\:/)'M^O
M^-2U%+*D$+RR,%C12S,>P')- !Y ]OU_QH\@>WZ_XTJ2+)&LB$,C %2.A!J"
M^NTL;*:ZDY6)"V!U/H![GI1;H!-Y(]OU_P :/)'M^O\ C7+> M<O-8TJ=-1S
M]KAF;)/="QQ^1#+_ ,!KK<TY1<).+%%\RNB/R1[?K_C1Y(]OU_QIJ7,4DTL"
M2 R1XWJ/X<]*GI#(O)'M^O\ C1Y(]OU_QJ6B@"+R1[?K_C1Y(]OU_P :EHH
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M0@9ENI#QO?'(7/0?@.YKB=+T37K7XR>%[K7KQI]<OM]Y=1 \6\>& 3VX!X'
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M#IWAV]G5=TJM$(T_O.T,04?B2*O7>GMIWAZV:',EQIQ%QD=9",^9_P!] O\
MB:J7Q/S)6R\BW8_\C'JW^Y!_)JUS6)ILJ3:_J<L;!D>&W96'0@AL&M>2/>2=
M[C(Q\IQ6;W+6Q)4-Q;PW4+0W$*31/PR2*&4_4&G>5SG>_7.,U)4E'*Q:YX0O
M;:Y\B?3[F& (9(XH1(0 VQ3M )(!X! P*U+[3++[.Y6QMLNHC?\ =+\R 8"G
MCD=.*\OTWP'XGMM.FC\DQSBT-L"]VIS_ *2LH$1491=H;=D\G'I5Z_\ !GB>
MX.IB,;;B6*]5[K[8?]-\V0- -O\ !Y:C'MCC.30!UWV*!5 ^R0@ *H'E#  .
M5'3L>1Z4&Q@=D#6<+,K^8N8@=K'^(<<'WZUR$W@/6=/U26ZTN%"JWEPT*R73
M[/(>WPJ$9S@R\D#GO5;1? .NR75DFK0>78)J374D"7&T*GD 8 4]/,&< ^YH
M [[P]'I.IZ9+-9V]I-8W!*L5@ 60JS Y&.<,#UK9?3K*0*'M+=MK^8NZ)3A_
M[PXZ^]>1VW@#Q79V,EN&21'G29@)Q_JA+(6MPIPI!W))DXR05)X%;*>!=1?<
M;N6_F$6C"UMF6_V3)*7EW=/ER$=5!.1VSWH ]%^R6ZR"001!PY<,$&=Q&"<^
MI'&:LU@>$;/4+#PW:VNI10Q7,9<;(>@7<=N>2-V,9QQG..*WZ "BBB@!*\+^
M+%RQ\>)'.?+BATY#$6. P9W+D?DH_"O=:X+XCZ;9:V=$TB[M89%N[IM\KH"Z
M1HA=E1NJEB%!([9K6A6]C44[7L8UZ7MH.%[7/&9E@BM=%"RQ//-827,RJX)4
MO.S*"!T.S;P:KS3K'!*R,K.B,VT')X'I7K.K>"="U#2'LX=-M;.1$/V>>WB"
M/"X'!!')YZ@]:\I<6<7@[PSJ<L5O!/<R:A]HF"A3)B1, GJ0,G%>GA<=9>S:
MU;>OK=W/-Q> O/VB>B2T]+*QF6<"):J>&>0;I'/5R>I-=!X,Q#)J5G&H$*ND
MR@=%+ @C_P =!KD([F>%'CM%,MN&(AW1MD+C(YQR,Y'X5V?@ZZT\6/D?: -3
MF/F7$4F5?=T 4'J /3-?'UZ<XRGS.^O1WZ[GW>=8W#U\KITZ=)Q:MO%I+3:]
MCIZX7QM9'^U+80*$.H)Y4C <;D(.X^IVD_E74Z_-);^'M0FA=DD2W9D93@@X
M[5E:S'/JV@Z/?6H0W FA=0YV@[QM()[<D"C!J/MH.7PMV?YGQ]"K5HOVE%VE
M9K[TT<Y_8Z0VX%M/.DRKA&:0L#CL5Z8^E) J:G#:Q2KA+B:*-U],N 1_.K%A
MJ2:M=VMC8([7EU(D4*RKM4,QP"S>G/;-4'MS!I_V20@O',(G9"1DB3!(/7FO
M;SF.&4J<J*5[ZV_K<^CX5Q..]EB:>);Y>5M)]_*_0L3^9I3@R#,NFW6UP#U,
M;[6_0&O8?AQ%9ZGK3:O)J6G/<Q0M%:V-O=++)$K$%WDQ_$< 8' &>>:\[O?!
MLCWLT=I<10Z=*Y+H02\8/W@O8YYY/3/>NCN=.L[L)YL"[D_U<B_+(A]58<@_
M0UXL*U.G+FM?5V\KG+FV8T,5*E4A=R44I>J_,]XI:X3X?:[>WL=_I.I7+74]
M@8WBN&'SR0N#MW>K JPSWX[UW5>I&2E%274XDTU="T4458SQ+XO6T=QXL E^
MSKOT21(&GL7N"TOF?*L17[DA[-SCTI'O]8LKW6;I4U#3([F72$U&=(S+-:0&
MV/F$$J<D-A2V#C).*]NHH \8&OZW_9]BM_K.KVWAV2_ND768[7%S)"JJ8-W[
MLX#,7&[:-VT=,UG:YK'B:]\-QVNO7FJV8N-"G:!;>SYOIR[J$E 0[<Q;"5^7
M&XG(Q7O%% &7X;4KX7TE2I4BRA!![?(*U*** $(!Z@&DV+_='Y4ZB@!NQ?[H
M_*C8O]T?E3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*C8
MO]T?E3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*C8O]T?
ME3J* &[%_NC\J-B_W1^5.HH ;L7^Z/RHV+_='Y4ZB@!NU?[H_*OF[PGX'76O
MB;KGA_7[N5;+3[M[[^SP"!=%FPKD^FTK[X; [U])U76V@2Z>X6&-9Y%"O(%
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MR SD^B]D7T5<"@#@-?\ B9<O92:?;VD5G)-&4?4!,TD2 \$Q_*,GTSC%<'8
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MM ;C/KZUZA%_JD_W13/L=M_S[Q?]\"I@,#%1*7,5&-A:***DH**** "BBB@
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MQ#IOAOR-1NVTRXEAU:V@>.Z#E\^5.3]Z0Y.T]?EZ"O8/*DYZ<_[0H,<AZ_\
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M>9-LSA]X9\+D'/\ =V\ #I77T44 %%%% !1110 4444 %%%% !1110 4444
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M+MYDL)&:-@!.XSCCM6]-IR.2HFEJ2/TJN]69 1D$8JL]=D3ED0/6;J7W(O\
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MOC,?E0#"(>H'^->V_"?_ )$2W_Z[2_\ H5>#WB-!=/!)@2IPR^GXU[O\)_\
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MC:T[Q/I.HZ);ZM]KCMK:=&8?:G6)DVMM<,">"K<&KK:E8)>1V;7]JMU*H:.
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M_AW0)[?4',B6]S)DV#9("@A"&3: <#'S&M/K%:TD[/FWON4I8>,7%-Z^2/6
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M] ,5'=74-G:375Q((X(4:21ST50,D_E6"OCWPQ(R*NKPDNT2*-K<M("4'3N
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M>TDCM!NN'5_EC7.,D^F1C(XJ73M?T?5YYX-.U.UNI;?_ %J12!B@Z9^GN.*
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M?=^XOW>3\OM]:Z&O1>A 4444 %1R2B,\U)5:ZZ_E_6@ ^TK[_E_]>C[2OO\
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M:Z#!IMC?M=R-!?,\=N(X'9W=?O)L R&R",$9S0!U'VE??\O_ *]'VE??\O\
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MY+.'5D:6::)L. JY**>QSD?E6X/"&EOJ5]?7UO%?2W3ALW$2MY8 P%7-4O\
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M9C2-DY4\$1J<]01P:ZS8O]T?E1L7^Z/RH Y6;PG:3::VGK)=0V[7'GX0+D'
M& 2I*X &",,/6KVF:;-9"[>4[Y;FZDG;:#@!L!1^"JOXYK<V+_='Y4;%_NC\
MJ */EO\ W&_*CRW_ +C?E5[8O]T?E1L7^Z/RH H^6_\ <;\JNQ B, \&EV+_
- '1^5+TH 6BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>form10-k_022.jpg
<TEXT>
begin 644 form10-k_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B E,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR",DD'/''8U$E8J+N%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M.&\6_$"'P_=MI]G&L]\J[GW?=3C.#CJ<<UF>'OBDE[?PVFII$@F(42Q@@*Q/
M&02>/>O./BM97FE>-;R:='\B[/FP28X88&1GV/'Y5R_AZTO]>UVUT^Q5WEED
M X_A'=CZ #FF[6T!'UW135&U0,DX&,FG4@"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P# &+_"C^Q_$/\ T-,G_@#%_A0!T-%<]_8_B'_H:9/_  !B_P */['\0_\
M0TR?^ ,7^% '0T5SW]C^(?\ H:9/_ &+_"C^Q_$/_0TR?^ ,7^% '0T5B6>F
M:U#=QR7/B%[F%?O0FTC3=^(Y%;= $%S<16L)EFD6.,$ LQP 2<#]2*FKE?B*
MQ7P'JA4D,%3!'8[UJ[X3U@:[X9LKXG,C1[91GD2+PV?Q&?QJN3W.?SL3S>]R
MF]1114E"5X;\3;Z35?$;A.;*P#6RGL9=N]_RX'X5[!KVJ1Z+H=[J4G2WB+ >
MK=A^)P*\F\1Z3)IWA708KCF[N1=W=R3U,C1[C^7 _"NG"Z2YGZ&%;56.V^&N
MHRW'AS^S;KBZT]A$P)ZHPW(?R./PKM:\ZL6_L/7O#FI#Y;;5["*SG]!*J QG
M\>E>BUE67O<RZFE-Z6["T445F607%S!:6[SW$JQ1)]YV. .U35YU\4M9-O!I
MND1,=]U<I)+CM&K#&?JV/RKT4=*IQM%/N2I7DUV%HJI?0W-Q:/%:79M)CC;,
M(P^WGG@\>U9/]C^(?^AID_\  &+_  J2CH:*Y[^Q_$/_ $-,G_@#%_A1_8_B
M'_H:9/\ P!B_PH Z&BN>_L?Q#_T-,G_@#%_A1_8_B'_H:9/_  !B_P * .AH
MKGO['\0_]#3)_P" ,7^%<]XP\*>+]5T5+?3?%#_:OM$;JYB2#8 <EMR#=QZ#
MK0!Z#7D_B;_D8;S_ *Z&O0_#]EJ5AH\%MJVI_P!I7J##W/DB+=^ _GWKS[Q*
M/^*@O/\ KH:[<!\;]#BQOP+U,>BG8HQ7JW/-L-H R<4[%7]%L_MNL6L!&59P
M6^@Y/Z U,I<J;948MNR/2-#M/L6E6D!&&5-S#W;)-:M58GW7+^@_^O5JO E)
MR;;/;C'E22%HHHI%!1110 4444 %%%% !1110 4444 075S%9VLMQ,P6*-2S
M'VKCO#UM)KVMS:]=K^ZC;;;H>@(Z?D/U-.\37<NL:K!X?LFXW!IV'0=^?8#G
MZXKK;.TBL;2*U@7;'$NU171_"I_WI?@O^"<W\6IY1_/_ (!%J=_!I>FW%]<M
MMB@0NWO[#W/2O*H+TW,MQJ$X8S[O/E1A@^8XPBX]EQC_ 'JVO&^NP76L)HB3
M+Y-J!/=*&Y9L9"8]AC\67TK!VF/4+7>!NSNN3GC>^2@_ _TKY?-:KJ2]DMEJ
M=L*JI[]1Z1,-,DTD,/.<NC,.RD;BW_CP4?\ UJF>Z6*'3+@)EG(C6->"=R=!
M[ @?2HK64?VC-=.P6.>'<I/9$/7\0V:K0@M83W+@AX93Y:G_ )9H'#@?4@Y/
MY=J\GV#;U]7\T/Z[;7Y+Y$LT+/;7QN6\QHI1,$!/EKG:W []^3^E+=V5NK:A
MY<0C81I,C1_*1C/I_NBIKF2&*ZN(Y9%1;BW^7/5B"1P._45!'?P2/;/)YJK/
M:E&8Q-C/!]/<T*,WK%.PG6ZREKZA<S3VS7;$&XC BN0PP'7!Y..C<+VY^M-6
M>2PU3^UM,DWM%<;BJ\AUD _J,$=_J!3[62.\2U"2*_FVK0OM.<$8Z_K5=H7G
M2-X7\J6XM<' R'=".H]>>O7BMZ4'&2E'1HB>*:TEJCUO1-8M=?TB#4;4GRY!
MRAZHPZJ?<&M*O&=#\03:%K;7HW1V=VJRW5H>0P(P9(CW93R1W!/&0*]@M[F&
M\MX[BWE62&0;D=#D,*^GP]7VL+O1]2(S4MB>BBBN@H**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D_B.<>!-1 /7RQ_X^M4
M_#Q_L3QGJ.BD;;:_C6_M03P&P!(H_'FK7Q)_Y$>]'J\0_P#(BU#XWB>QL]-\
M10*3-I,RO(!U:%L+(/RK>#O!1[W_ . 8R^*_8[2BHH94GA26)@T<BAE8=P>0
M:>Q"@DD #DDU@;'&^+/^)SXAT7PVO,32?;;P#_GE']T'ZM_*LSXFKON])CQ_
MR[WK?E#6GX,']K:EK'B>0'%Y-]GM<]H(^ 1]3D_A5#XA#?K6E)_TYWY_\@UT
MPTJ*/;\S&6L6^Y=NM*?6OAA9PP'%U'90SV[#J)$4%<?EC\:W_#FKIKGA^RU%
M>#-$"Z_W7'##\"#47A%MW@_1S_TYQ_\ H(K&\,?\23Q5K/AYN()&^WV8_P!A
M_OJ/HW\ZB7O*2[._^92T:?<[2BBN=\:ZM)I/AFY>W&;RXQ;6RCJ9'X'Y<G\*
MRC%MI(MNRN<#KC'6;?6O$+?-"U];V5H?^F<<@W$?5J]?'2O/_%.E1Z'\-;33
MH^EO+;*Q_O-Y@W'\3DUZ!T%:U9)Q5MM?T(@K-W'4445B:!1110 4444 %%%%
M &3XAGEM]!NIH)&CE4#:Z]1\P%>3:I+.VI3E[B9VW'YF;)->R7]G%J%E+:3%
MA'( "4.#USQ^5>6:UI,4&K7$:RS,%<C+,,G]*[L$U=W5SEQ5[+4PO,E_YZO^
M='F2_P#/5_SJ]_9\?]^3\Q_A1_9\?]^3\Q_A7H7C_*<7S*/F2_\ /5_SK6T-
MKA)9;A+F>,HN R-@Y-5_[/C_ +\GYC_"NOT[PO;)HD4LEQ=+)-ERJN,8Z#M]
M#6->I"$-5N:T(.4]&9PU#4%29UU*\!"$C]YZ X[5Z-9.SV-N['+-$I)/<X%<
MM9^%K*<LC7-Y@C!Q(O(Y_P!FNMBB6&%(D^ZBA1GT%>74E"5N56/0C&2^)DM%
M%%9E!1110 4444 %%%% !1110 G>N?UCQ-:6%C=>3,CW43>6(SU#^I'IWK?/
M2O+'TN]UKQ!>M9Q97[0^96X1?F[G^E=&'IPFVYO1'/7J2BDH+5G6>#](>TM6
MO[K)NKKYB6ZA3S^9ZG\*U->U>/1-'N+]UWN@Q%'G'F2'A5_$XJW8QSPV<:74
MXFF48:0)MR?I7DWB[64\3:WY229TNR+*A!RLKX^>0^H4<+[G/>N>O4;;DQ2G
M&A2N9T5N)4D>ZDW22L;JXG[DY)#?BV2/90*?*\EUHQ5ABZNMS2#^Z5ZC\,!1
M]:AME*7"6FT+'<?O]G_/-5Z1_3H<>S5+:SHEU>W#_P"KP)(_=1P2/JPS^(KR
M?JSD[RU:/(GBV[VZZ_,GO)4N)[%5'[HLK28Z;6&%7\3C\J=-*4FN[5%#2W"!
MD!Z#(*EC[# ^M9\;>1HD\DO$D3,S<YY4Y4#\-H%68MPU".X<_O+A6!QT &&5
M1]!G]:/J>EGLM_O,_K=M5Z+\R2T 62QN2S/)*A5Y&.23M!Q[#*GBEC_=QVV.
M##<M%^!W ?S%5&N_+@\N&,R-;7/+9PBC=TS]&Z#--GFO$6]XMQL=)\?-['K_
M ,!--8>;^%: ZT?M/4G>"(F-F0;H;MDW#A@&SCD<_P 0IB_:+<H8[C<(+HJ%
MF7=@-[C!_B'K4=Q<SK]M5K=3PDP,<G3'?! _NTL]P9'O$2WF_>1K(GW>HXSU
M]A6RPTG\43/V[7PRT!W81".YLDEBAF:-PK@@H_3@X]5[]JOZ!XINO"L[I+]I
MN+ OMF@E7#1'M(K=#D=02.>_6L\S37,S 0QQQW</5WW=/8=\-Z]JA>29@KO+
M-/.%,<\$("Y4=<^GKR>0:UA0<'=:#IXV4)73/4W^(7A9(#+_ &M$Q"Y,2*S2
M+[%0,@^QK#N_B]I"2K#I]C>7DS_<& @)],\D?B*\HU&WM+ET9+F,G^!QEG49
MZ YW$=N1_P#7N:1IVG1,=B":X?ES)G?(3P ,^N.W0!CW%=$IJ,-M?P/1>/D]
M=EZ:_B=O>>.O$5X$:**&PAV[V$#"20*.I+,N-H]0,GG&:RM0U/Q+>JKIXCO!
M&ZXBD")'$['D*<;3@]F[^E54;[(Z!CYUL\@55S]Z4=\_\\QT [8S4IB07$ME
M(@N7D!89.$A8\D#/3LPP,]:\V4ZZES*0GC>9:L9I/Q)\0Z#*(-47[5 &*_O6
MW#(Y(64=_8YXKTO0_'^B:XJQBX%K<MP(K@A<G_9;H?Y^U>6WED+J+-U'8AF(
MAE 4Q[7'W7!^I';HU<M>VMQIUR4FC;RFR/, QM8=0W9AR"#U(/.*]/#UHU?=
MJ:2[K9DK%3AK!\R[/?Y,^IAQVI<U\[Z#XYUS066*&Z,\ Q_H\X+ #CH"<C_@
M)Q[5Z9H7Q2T75%5+_.GS]"7.Z+/^]@8_X$!6TZ$H^9VTL=2J:7L_,[VBHXI(
MYHUDB=71AE64Y!'L:DK([ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
M'XD?\B9<CUEA'_D1:Z6YM8KRPEM9UW1S1F-QZ@C!KF?B1_R*$@];B ?^1%KK
MATK1Z4X^K_0A?$SDO 5U(NDW&C739NM)G:U;)Y*#E&_%?Y5-XZU&6S\.26UI
M_P ?M^ZV=N!UW/P3^ S5._\ ^)#\1+&^Z6FL1?9)O03+RA_$9%#?\3[XD*OW
MK/0X<GT-Q(./R6KLG+GZ;_U\R;^[R]=CI=(TZ+2=)M+"$ 1V\2QCCK@<G\3S
M7'>.!O\ $^F)_P!0Z_/_ )"KOZX+Q=\WC/3E]-+O3_XYBII.\[OS'->[8WO!
M1SX)T8_].D?\JS/&ZMIEUI7B6('.GSB.XQW@D^5OR.#6AX%.? VC'_IU2M?4
MK"'4]-N;"<9BN(FC;Z$8H;M4=^["UX(L(RR*KJ001D$=Q7'WO_$]^(MG9?>M
M-&B^U2^AF?A!^ YI_A#6?(\)3QZD^+C1C);W))YQ'T/XKBI/ 5K+_8\VKW:X
MN]7F:[DSU"G[B_@O\Z:7)S/MI]__   OS60WXD?\B@Y]+F _^1%KK?2N2^)'
M_(G2_P#7Q!_Z,6NM]*E_PUZO]!KXG\AU%%%9EA1110 4444 %%%% "5YMKZY
MUNY_WS7I->=ZZN=9N/\ ?-=6$=ILYL2KQ1C[:-M3;*-E>AS''RC;:W:>YCB3
M[SL%'U-=Y>%8BENGW(E" ?05SWAJU$FJ"9A\D*ES_G\?TK4FF,DS,>I->=C)
MW:B=^#IZ.1I:6V;@_2M>L32&S<D>U;E<J.B:U"BBBF2%%%% !1110 4444 )
M1[TUF5 69@H'4DX%<)X\\;6VEZ.8=+OH'O97"9BD#&->I/'0]OQK6A1G7J1I
M0W9G4J*G%R9W/FQ[]F]=WIGFB...%-L:*J^BC KYF.OR+.9A,YD/)=C\V>Y!
MK8F^(/B^_2&SLM16"V5,27"1KYQYYRS9 XQR!G\:]+&Y/5PL.?FNCCIXZ+3<
MU9([[X@^,HX _A[3KM$NY1MNI@X'D(>J@]F([_PC)ZXK@(K**WA7[,BQ!$$C
M=@8ARJM_O=?;BH+)(H-Z21/O8DMO.YIF/.TMW8GEL\X 'K5R%/+N#:NRF/\
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M ")=R?26$_\ D1:ZQ?N#Z5#_ (:]64OB8ZBJMZUXMHYL8H)+CC:L[E$//.2
M3T]JR_/\6?\ 0.T;_P #I?\ XU699O45@^?XL_Z!VC?^!TO_ ,:H\_Q9_P!
M[1O_  .E_P#C5 &]16#Y_BS_ *!VC?\ @=+_ /&J//\ %G_0.T;_ ,#I?_C5
M &]16#Y_BS_H':-_X'2__&JYKQEJ'Q"M=+MGT/3K!KPW2+MMYFFW+ALA@Z*
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MFV\$K6\5A:#S+UI=D6X@98'(8YZ#&/Y5B1W820E&.#CENN:T[>X"2>?@O+<
M!?=E[>PQ@_A77@<T6-E*E&/+*SMU7]7L>KGO"<LII1K\_/%M)Z6=_P#(] SI
MW@BQ!.VXU-E^9CU0$\D^BYY/KC\N&U6]EO+F6_N9R))%^9FZ"+L".V3^0!J.
M:Y9GN4O9S*5_?7,TAY=#T'/Y?0>]9!8WDJ%IBEL#N4.IPS=N>N% P!U/6HPN
M71P?-6K/GK2W;_)=DO(\#$5O:)1BN6$=E^OFV6M+MR3-<&ZE\^5LGU Y 4+Q
MSCKZ<]SQJR2Q[(Y;@(C0':;9.0%[\#ENQ';BJI<*RH[^3.H^1D&6/^R.<(/5
M2<GKFG"[5&\Q3:PY/ES(\H8D]B?7KUR>#5\G<\RI.4G<M2W2JDZ".50")HR8
MSCKD_J#^=,E($LEQ R[EECE5P<A@>#G'4=?I4*W)C*;Y+>01-Y+;) "R-T/)
MQZ=_6H1*C0AH9(]YC>)XRP7<R],^C8Y!K6--&2C)O1$[J\H7RT*RH\L>P^XS
MM/U']#49<2,DK?/;S"$R+Z9!0G^A_"D:[MQ.MZMQ'Y;-$[_..01MS]1_(^U1
MY@C,UN9HBDL<R!2X^\K9Q^(Y_.MHP7]?@;0IOJOZZ_<R543'D7JJ8RC0K*PS
MRI.W)[''YUT5II<,GA4:Y;OND4>688PH4G<!R?8Y_.N:6\BB9DDN$.)$EC<N
M/F4C!!/KC/UKKM/N[=/ FMP?:(%:&5I5!D4<85_7U!K@S>O4PU.E.E*WOP3V
MV;LT=^#PRJ2E&HOLMKM<YE8Q';7HE<;P22W8 _,H'MDFGB7!AOYFV;^"#_ C
M#@?GC/O5874,^H+)YL8A*90%Q\Q4\,?SXJ)YXY()+=9HPMNQ/WQ\S [E'T''
MZ5[W*GM_74YU1;W+L+".XN)IUQYB!PO<+TV_4_+^)IB;Q9[F&Z\5O+C3/0KR
MJCVQR3]:BDO()KN";SHO*C;&2XY+#K^''Z^E(MW$ER;@21%K@;(E+CY2.A/U
M')^@%)Q7]?G]X>R>]OZ[?YEAG*XN(7WS%=T\F/NH>P'J.P]CFF,_E O$&:&0
M;V3=AI!_ST)[#VZG]*K-<P6Q9/.22#?DY8?-+U)/^R.I]ZS;_6;.T5G2[().
MX[,'<W/.#T/H.WU/'/4<8*[81P\I.R1?DGC3*"1&7D>3(-H7U"@_=^A!/TJJ
M\^<A0P4]58>8OY@D_GFL:#4KC5)Q' &8G[D?RECR>U==IO@+7;XH\B6=JC<[
M[F=%]/X1\PKAE7CW.J."GLE=F)O+@*!E1CY?OJ.G;[PI"VX;B=P'\1)8#_@0
M^8?C7I&G_"RR^1M4\1V[8',<# _D['(Z5U%CX%\%6.UW:*[D7I)<W08_H0*P
MEB8+S.B&6U9;V1X@I9W^0,SL<+MZGKP&'!^AK9L?"7B#4 #:Z/=%&;!9X_+'
MXAOE(]Q7O=G'H.GKMLUTZW'I$47^56_[2L/^?VV_[^K_ (UF\4^B.F&5Q7QR
M^X\:L_A-K]PH%U+:6J C"LYD].@'3\#726GP>L4(:^U2ZF(Z>4H0C_@7)/XU
MZ#_:5A_S^6W_ ']7_&E_M*P_Y_;;_OZO^-9.O4?4ZH8&A'[-_4P++X>^&+')
M73(YF/4SDOG\#Q^E=.JK&@55"J!@ #@"JW]I6/\ S^VW_?U?\:7^T[#_ )_;
M;_OZO^-9.3>YU1A&"M%6+=%5/[3L/^?VV_[^K_C1_:=A_P _MM_W]7_&D46Z
M*J?VG8?\_MM_W]7_ !H_M.P_Y_;;_OZO^- %NBJT=]:2N$CN8'<]%60$FK-
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M5;U% &#_ &#J7_0U:K_WZMO_ (U1_8.I?]#5JO\ WZMO_C5;U% &#_8.I?\
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MZMO_ (U6CIMF;"T$!<.=Q.0,5<[5F:+8PO[!U+_H:M5_[]6W_P :H_L'4O\
MH:M5_P"_5M_\:K>HH&8/]@ZE_P!#5JO_ 'ZMO_C5']@ZE_T-6J_]^K;_ .-5
MO44 8/\ 8.I?]#5JO_?JV_\ C5<YXR\#Z[K^BQ6EEXJO5F%S'+OG6)!&%SE@
M8XU;<.W(KT&B@#*T/3KO2](@L[W5)]2N$7#74ZJK-^ '\\GU)K/\7:G_ &1X
M8U&\! <1&.,]]S':/RR#71GFN2\=^&+_ ,3Z7#8V5U# HF\R4R _-Q@#CZG]
M*BI?E=MS?#*#K0]H[1OJ> ^;SUH\WWKOO^%+ZS_T$[+_ +Y;_"C_ (4OK/\
MT$[+_OEO\*\[V-7L?9?VC@O^?B_'_(X'S?>CS?>N^_X4OK7_ $$[+_OE_P#"
MC_A3&L_]!.R_[Y?_  H]A5[!_:."_P"?B_'_ "(?A0^[QEC_ *=W_I7N@KS/
MP5\.]1\,>(/[0N;VWFC$3)LC#9R<>HKTP<"NVA&486DCYG-JU*KB.:E*ZLA:
M***W/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH QO$6A6?B71YM-O%(23E' YC8=&'^>1D5\Z>(_#VJ>%;J2SU2!Y%8_N[
MQ$)1UZ9SVX[=?YU]1TR2-)8V21%9&&"",@BNS"8ZIAFTM4^@G%,^7_#?AG4?
M&&H"UT^.;[*!M>[E5O)B7N<G[Q[ #T[#FOHOP]X?L/#6DQV%@F$7EW;[TC8Y
M9CZ\?A6LB+&@1%"JHP !@ 4ZEBL;4Q+][1=@22%HHHKD&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :
M>*Y;Q497U'2($BN)DDDDW0P3F(OA,CG<O3KUKJCQ4+PQO*CLBLZYV,1DKGK@
M]J4E=6+I3Y)7M??\CBOM5_H<D;W,S1@07,D<4\K2!%+PA0Q&2Q!)QU^]C/>E
M7Q9JTD4L:16[3179A=A%@E/*#Y$9DR2"<$!B0.<=J[*6U@N,B:&-\J4(90<J
M>HY[' X]J@.D::8/LYL+4PY!\LQ+MR.!QC'%1RRZ,Z%7IO64;LY6/7+J;46F
M%RD]K,]H88PK+M#J22.<\^A'IFIX/$%W<V,,LTUE(T[VLB0PLX:)9)0N&YYQ
MZ\9(((Q74&RM?,$IMH3(  &V#( Y S[=J:FGV<9?R[2%/,<2/MC W.#D,>.3
MGO3Y9=R75IM?"<GIWB#4K:QMH[AX;J>Z=XX)"I&9!*5(;D\!3N[<*:[<&LXZ
M/:M?0W2KL\IFD$2JJH9&&"YP,EL$C.>YK1P.:J*:W,ZLXR:<5;N.HHHIF044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>form10-k_023.jpg
<TEXT>
begin 644 form10-k_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "_ ET# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "5AW%^EEXG(N9FCADM%" YVE][9]LXQ1JFMOIMVD(ACVE-XDGE,:N<D;
M%;!&[C^(CJ/P?+XFTN"2>)[@AH Q?"$\K]X#'4CT%4HOL0Y+N8,>KZS=*S3-
M]E5)XC($0EHAYH4H>.F.O/;/0TMMJFK6.FQI-)*P:&-UD-N28B78$,2?0#D_
MER*WT\06#RQ0AIO-E=D$9A8,I4@'(QQ]Y?SS4(\1P><T91MJ[3Y@5BK9=UP.
M,Y^0U=W_ "DV\R+PW=WM]))<7J2)(]O#E"I50P:0' /0\#-='6'=^([:V)$:
MO<8VY6-22<M&..,' D4GZU?M=1M[R39"S%@F\@J1M&XKSZ'*L,>U1)/>Q<6M
MKEVBBBI*"BBB@ HHHH ;G->'ZC\2?$$7B"XNXIPEE;SNHLC&NUD1B""<;MQ
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MS^Z>FC2-):%+>*YVX#!"DPW99U?/UW*N/88J]I>G?89+N5RAFNIS*VS. .@
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M /?!KWL*U[&.J/.KQYJC=B]N3^^O_?0HW)_?7_OH51\EO^>3_P#?!I1"Q/\
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ML5D$A8*%P,LWRG@<_D<6;CQ#I-G9VUW+>H+>Z_U#("_F<%C@ $G@$_@:PO\
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M2E([C_T6U>M#&3>%J1E]E73^:/&I8"$LQHI:*;L_G>X7(MKJ^M)BJ2>9 QY
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MN5<9W#BKM%',RO81.D@D66(.@P#VJ7I533O^/1:MU:.6:M)I"T444$A1110
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M/05Z?J.CZ=)*KO86S2.268Q#+'CK7GGQ$-E975E8VEM#$5C,KF., G<<*#]
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M9\1ZWH5S++Y(MY465,!P8YX]K=,9^4=L=:\WV#]K;Y?.US[59K#ZC[17WO\
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M-;RM?,6P^$9HRA(P,YRJ]\]A^/6MDU:C&2O8YI5ZM.?*VG;[AL:+'&J(H 4
M #L*DHHK0Y0HHHH *X3XAVMP)_#FK+8SWUEIFH">ZMX(_,?:4*B0)U;:3GCF
MN[HH \KUG6AJ&A:QJ&F>&M3M(;F\MHWOHUDMI;I.C2N$7S?+3H<#)!XQS6%H
M-IX@U"YT73;V?6TL1K5_%(RO<0G[-Y*M&"S'>$))P6.><9S7N-% 'AZ2:O\
MV+H4?B"7Q)_9$2WT4CV7G?:#,LI$'F%?F(V?=)X)QFDUF3Q6VOQ!+C6K7_1K
M+^RFFCGDDSQYOFK#^Z9\Y#^9CCI7N-% '!>!].O6USQ'JFHSZFT@U6YM[:*X
MGD\E8,J040\8SG#>G K"O?"VL>(O'_C6U@U)M,TV\M[.*=FL!+]I4Q,"$=B
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MM FDSFO^$:E_YZI^9_PH_P"$:E_YZI^9_P *Z6BG<7*CFO\ A&I?^>J?F?\
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7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>hils-20211231.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaOKbP9z5Z8KekhvWB5bVnKTyMqqpIuvC8rcNEWIYQN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:HILS="http://hillstreambio.com/20211231" elementFormDefault="qualified" targetNamespace="http://hillstreambio.com/20211231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://hillstreambio.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit" id="StatementsOfChangesInStockholdersDeficit">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StatementOfCashFlows" id="StatementOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statement of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity" id="DescriptionOfBusinessAndLiquidity">
	  <link:definition>00000007 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/Acquisition" id="Acquisition">
	  <link:definition>00000009 - Disclosure - ACQUISITION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedParties" id="ConvertibleNotes-RelatedParties">
	  <link:definition>00000010 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/RedemptionLiability" id="RedemptionLiability">
	  <link:definition>00000011 - Disclosure - REDEMPTION LIABILITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StockBasedCompensation" id="StockBasedCompensation">
	  <link:definition>00000012 - Disclosure - STOCK BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StockholdersDeficit" id="StockholdersDeficit">
	  <link:definition>00000013 - Disclosure - STOCKHOLDERS&#8217; DEFICIT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000014 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000015 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000017 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000018 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables" id="ConvertibleNotes-RelatedPartiesTables">
	  <link:definition>00000019 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/RedemptionLiabilityTables" id="RedemptionLiabilityTables">
	  <link:definition>00000020 - Disclosure - REDEMPTION LIABILITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
	  <link:definition>00000021 - Disclosure - STOCK BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000022 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative" id="DescriptionOfBusinessAndLiquidityDetailsNarrative">
	  <link:definition>00000023 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/AcquisitionDetailsNarrative" id="AcquisitionDetailsNarrative">
	  <link:definition>00000025 - Disclosure - ACQUISITION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails" id="ScheduleOfConvertibleDebtDetails">
	  <link:definition>00000026 - Disclosure - SCHEDULE OF CONVERTIBLE DEBT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative" id="ConvertibleNotes-RelatedPartiesDetailsNarrative">
	  <link:definition>00000027 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails" id="ScheduleOfAssumptionsOfRedemptionLiabilityDetails">
	  <link:definition>00000028 - Disclosure - SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails" id="ScheduleOfFairValueOfRedemptionLiabilityDetails">
	  <link:definition>00000029 - Disclosure - SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative" id="RedemptionLiabilityDetailsNarrative">
	  <link:definition>00000030 - Disclosure - REDEMPTION LIABILITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
	  <link:definition>00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails" id="ScheduleOfExercisePriceRangeDetails">
	  <link:definition>00000032 - Disclosure - SCHEDULE OF EXERCISE PRICE RANGE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" id="ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails">
	  <link:definition>00000033 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative" id="StockBasedCompensationDetailsNarrative">
	  <link:definition>00000034 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative" id="StockholdersDeficitDetailsNarrative">
	  <link:definition>00000035 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" id="ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails">
	  <link:definition>00000036 - Disclosure - SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails" id="ScheduleOfEffectiveIncomeTaxExpenseDetails">
	  <link:definition>00000037 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000038 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://hillstreambio.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hils-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hils-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hils-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hils-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="HILS_FarringtonMember" name="FarringtonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ConvertiblePromissoryNoteAgreementsMember" name="ConvertiblePromissoryNoteAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_OriginalNotesMember" name="OriginalNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExchangeNotesMember" name="ExchangeNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_FiveNotesPayableMember" name="FiveNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_SeptemberExchangeNotesMember" name="SeptemberExchangeNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_RolledOverMember" name="RolledOverMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_RolledOverInToNewNotesMember" name="RolledOverInToNewNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_TwentySeventeenStockIncentivePlanMember" name="TwentySeventeenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_TwentyNineteenStockIncentivePlanMember" name="TwentyNineteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_FounderAndChiefExecutiveOfficerMember" name="FounderAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_EmployeeAgreementMember" name="EmployeeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_RestatedEmploymentAgreementMember" name="RestatedEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_UnsecuredPromissoryNotesMember" name="UnsecuredPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_PromissoryNotesPayableMember" name="PromissoryNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember" name="BoardOfDirectorsAndScientificAdvisoryBoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_RedemptionLiability" name="RedemptionLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_AcquiredInprocessResearchAndDevelopment1" name="AcquiredInprocessResearchAndDevelopment1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_GainLossInRedemptionValue" name="GainLossInRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DeemedDividendUponDebtExchange" name="DeemedDividendUponDebtExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_RepaymentsOfDeferredOfferingCosts" name="RepaymentsOfDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_AccruedInterestRolloverToNewNotesPayable" name="AccruedInterestRolloverToNewNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DueToFounderConvertedToNotePayable" name="DueToFounderConvertedToNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_UnpaidDeferredOfferingCosts" name="UnpaidDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DisclosureRedemptionLiabilityAbstract" name="DisclosureRedemptionLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_RedemptionLiabilityDisclosureTextBlock" name="RedemptionLiabilityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_CommonStockValuationsPolicyTextBlock" name="CommonStockValuationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock" name="DebtDiscountAndDerivativeInstrumentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_GrossProceedsFromIssuanceInitialPublicOffering" name="GrossProceedsFromIssuanceInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_BacisAndDilutedLoss" name="BacisAndDilutedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_EquityValuation" name="EquityValuation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_EquityFinancingRangeValuationAssumedPercentage" name="EquityFinancingRangeValuationAssumedPercentage" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_EquityFinancingRangeValuationAssumedDiscountRate" name="EquityFinancingRangeValuationAssumedDiscountRate" nillable="true" xbrli:periodType="instant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate" name="EquityFinancingRangeValuationAssumedExpectedInterestRate" nillable="true" xbrli:periodType="instant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_EquityFinancingRangeValuationAssumedExpectedTerm" name="EquityFinancingRangeValuationAssumedExpectedTerm" nillable="true" xbrli:periodType="instant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_GainOnRedemptionValue" name="GainOnRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_LossOnRedemptionValue" name="LossOnRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_IncreaseInSharesReservedForIssuance" name="IncreaseInSharesReservedForIssuance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" name="DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_AcquiredInprocessResearchAndDevelopment" name="AcquiredInprocessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" name="DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther" name="IncomeTaxReconciliationPermanentDifferencesAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_AssetAcquisitionDescription" name="AssetAcquisitionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_CashBonusReceived" name="CashBonusReceived" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_IncomeTaxReconciliationTaxAssetsDeferredTrueUp" name="IncomeTaxReconciliationTaxAssetsDeferredTrueUp" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_OperatingLossCarryforwardsExpirationDate1" name="OperatingLossCarryforwardsExpirationDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HILS_AcquiredInprocessResearchAndDevelopmentExpense" name="AcquiredInprocessResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>33
<FILENAME>hils-20211231_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://hillstreambio.com/role/Cover" xlink:href="hils-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BalanceSheets" xlink:href="hils-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BalanceSheetsParenthetical" xlink:href="hils-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementsOfOperations" xlink:href="hils-20211231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="hils-20211231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementOfCashFlows" xlink:href="hils-20211231.xsd#StatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity" xlink:href="hils-20211231.xsd#DescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/Acquisition" xlink:href="hils-20211231.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedParties" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiability" xlink:href="hils-20211231.xsd#RedemptionLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensation" xlink:href="hils-20211231.xsd#StockBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockholdersDeficit" xlink:href="hils-20211231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxes" xlink:href="hils-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RelatedPartyTransactions" xlink:href="hils-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/CommitmentsAndContingencies" xlink:href="hils-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/SubsequentEvents" xlink:href="hils-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedPartiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiabilityTables" xlink:href="hils-20211231.xsd#RedemptionLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensationTables" xlink:href="hils-20211231.xsd#StockBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxesTables" xlink:href="hils-20211231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="hils-20211231.xsd#DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/AcquisitionDetailsNarrative" xlink:href="hils-20211231.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails" xlink:href="hils-20211231.xsd#ScheduleOfConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:href="hils-20211231.xsd#ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:href="hils-20211231.xsd#ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative" xlink:href="hils-20211231.xsd#RedemptionLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="hils-20211231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails" xlink:href="hils-20211231.xsd#ScheduleOfExercisePriceRangeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:href="hils-20211231.xsd#ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative" xlink:href="hils-20211231.xsd#StockBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative" xlink:href="hils-20211231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:href="hils-20211231.xsd#ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:href="hils-20211231.xsd#ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxesDetailsNarrative" xlink:href="hils-20211231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="hils-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hils-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/SubsequentEventsDetailsNarrative" xlink:href="hils-20211231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RedemptionLiability" xlink:label="loc_HILSRedemptionLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_HILSRedemptionLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AcquiredInprocessResearchAndDevelopment1" xlink:label="loc_HILSAcquiredInprocessResearchAndDevelopment1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_HILSAcquiredInprocessResearchAndDevelopment1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GainLossInRedemptionValue" xlink:label="loc_HILSGainLossInRedemptionValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_HILSGainLossInRedemptionValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statement of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GainLossInRedemptionValue" xlink:label="loc_HILSGainLossInRedemptionValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HILSGainLossInRedemptionValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RepaymentsOfDeferredOfferingCosts" xlink:label="loc_HILSRepaymentsOfDeferredOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_HILSRepaymentsOfDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/Acquisition" xlink:title="00000009 - Disclosure - ACQUISITION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedParties" xlink:title="00000010 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiability" xlink:title="00000011 - Disclosure - REDEMPTION LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensation" xlink:title="00000012 - Disclosure - STOCK BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockholdersDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RelatedPartyTransactions" xlink:title="00000015 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables" xlink:title="00000019 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiabilityTables" xlink:title="00000020 - Disclosure - REDEMPTION LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensationTables" xlink:title="00000021 - Disclosure - STOCK BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000023 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/AcquisitionDetailsNarrative" xlink:title="00000025 - Disclosure - ACQUISITION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF CONVERTIBLE DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapConvertibleDebt" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapConvertibleDebt" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:title="00000027 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative" xlink:title="00000030 - Disclosure - REDEMPTION LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF EXERCISE PRICE RANGE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative" xlink:title="00000034 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000035 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" xlink:label="loc_HILSDeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_HILSDeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AcquiredInprocessResearchAndDevelopment" xlink:label="loc_HILSAcquiredInprocessResearchAndDevelopment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_HILSAcquiredInprocessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" xlink:label="loc_HILSDeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_HILSDeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_IncomeTaxReconciliationPermanentDifferencesAndOther" xlink:label="loc_HILSIncomeTaxReconciliationPermanentDifferencesAndOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_HILSIncomeTaxReconciliationPermanentDifferencesAndOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000038 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>34
<FILENAME>hils-20211231_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://hillstreambio.com/role/Cover" xlink:href="hils-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BalanceSheets" xlink:href="hils-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BalanceSheetsParenthetical" xlink:href="hils-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementsOfOperations" xlink:href="hils-20211231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="hils-20211231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementOfCashFlows" xlink:href="hils-20211231.xsd#StatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity" xlink:href="hils-20211231.xsd#DescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/Acquisition" xlink:href="hils-20211231.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedParties" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiability" xlink:href="hils-20211231.xsd#RedemptionLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensation" xlink:href="hils-20211231.xsd#StockBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockholdersDeficit" xlink:href="hils-20211231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxes" xlink:href="hils-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RelatedPartyTransactions" xlink:href="hils-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/CommitmentsAndContingencies" xlink:href="hils-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/SubsequentEvents" xlink:href="hils-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedPartiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiabilityTables" xlink:href="hils-20211231.xsd#RedemptionLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensationTables" xlink:href="hils-20211231.xsd#StockBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxesTables" xlink:href="hils-20211231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="hils-20211231.xsd#DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/AcquisitionDetailsNarrative" xlink:href="hils-20211231.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails" xlink:href="hils-20211231.xsd#ScheduleOfConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:href="hils-20211231.xsd#ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:href="hils-20211231.xsd#ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative" xlink:href="hils-20211231.xsd#RedemptionLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="hils-20211231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails" xlink:href="hils-20211231.xsd#ScheduleOfExercisePriceRangeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:href="hils-20211231.xsd#ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative" xlink:href="hils-20211231.xsd#StockBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative" xlink:href="hils-20211231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:href="hils-20211231.xsd#ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:href="hils-20211231.xsd#ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxesDetailsNarrative" xlink:href="hils-20211231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="hils-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hils-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/SubsequentEventsDetailsNarrative" xlink:href="hils-20211231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeemedDividendUponDebtExchange" xlink:label="loc_HILSDeemedDividendUponDebtExchange_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSDeemedDividendUponDebtExchange_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statement of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/Acquisition" xlink:title="00000009 - Disclosure - ACQUISITION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedParties" xlink:title="00000010 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiability" xlink:title="00000011 - Disclosure - REDEMPTION LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensation" xlink:title="00000012 - Disclosure - STOCK BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockholdersDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RelatedPartyTransactions" xlink:title="00000015 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables" xlink:title="00000019 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiabilityTables" xlink:title="00000020 - Disclosure - REDEMPTION LIABILITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensationTables" xlink:title="00000021 - Disclosure - STOCK BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000023 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_BacisAndDilutedLoss" xlink:label="loc_HILSBacisAndDilutedLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HILSBacisAndDilutedLoss_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/AcquisitionDetailsNarrative" xlink:title="00000025 - Disclosure - ACQUISITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FarringtonMember" xlink:label="loc_HILSFarringtonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_HILSFarringtonMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExchangeAgreementMember" xlink:label="loc_HILSExchangeAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSExchangeAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF CONVERTIBLE DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RolledOverInToNewNotesMember" xlink:label="loc_HILSRolledOverInToNewNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSRolledOverInToNewNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtCurrent_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtNoncurrent_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:title="00000027 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ConvertiblePromissoryNoteAgreementsMember" xlink:label="loc_HILSConvertiblePromissoryNoteAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSConvertiblePromissoryNoteAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaapEmbeddedDerivativeFinancialInstrumentsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapEmbeddedDerivativeFinancialInstrumentsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_OriginalNotesMember" xlink:label="loc_HILSOriginalNotesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSOriginalNotesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FiveNotesPayableMember" xlink:label="loc_HILSFiveNotesPayableMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSFiveNotesPayableMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RolledOverMember" xlink:label="loc_HILSRolledOverMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSRolledOverMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExchangeNotesMember" xlink:label="loc_HILSExchangeNotesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_HILSExchangeNotesMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SeptemberExchangeNotesMember" xlink:label="loc_HILSSeptemberExchangeNotesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_HILSSeptemberExchangeNotesMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityValuation" xlink:label="loc_HILSEquityValuation_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_HILSEquityValuation_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesIssued1_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_200" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedPercentage" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedPercentage_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedDiscountRate" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedDiscountRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedDiscountRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedExpectedInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedExpectedInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedExpectedTerm" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedExpectedTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedExpectedTerm_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative" xlink:title="00000030 - Disclosure - REDEMPTION LIABILITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF EXERCISE PRICE RANGE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceOneMember" xlink:label="loc_HILSExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceTwoMember" xlink:label="loc_HILSExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceThreeMember" xlink:label="loc_HILSExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceFourMember" xlink:label="loc_HILSExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceFiveMember" xlink:label="loc_HILSExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceSixMember" xlink:label="loc_HILSExercisePriceSixMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceSixMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceSevenMember" xlink:label="loc_HILSExercisePriceSevenMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceSevenMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceEightMember" xlink:label="loc_HILSExercisePriceEightMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceEightMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="loc_HILSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_HILSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative" xlink:title="00000034 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_TwentySeventeenStockIncentivePlanMember" xlink:label="loc_HILSTwentySeventeenStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HILSTwentySeventeenStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_TwentyNineteenStockIncentivePlanMember" xlink:label="loc_HILSTwentyNineteenStockIncentivePlanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HILSTwentyNineteenStockIncentivePlanMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_IncreaseInSharesReservedForIssuance" xlink:label="loc_HILSIncreaseInSharesReservedForIssuance_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_HILSIncreaseInSharesReservedForIssuance_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_HILSSharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_HILSSharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_200" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_200" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000035 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000038 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaapOperatingLossCarryforwardsValuationAllowance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsValuationAllowance_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FounderAndChiefExecutiveOfficerMember" xlink:label="loc_HILSFounderAndChiefExecutiveOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HILSFounderAndChiefExecutiveOfficerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DueToFounderConvertedToNotePayable" xlink:label="loc_HILSDueToFounderConvertedToNotePayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_HILSDueToFounderConvertedToNotePayable_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AssetPurchaseAgreementMember" xlink:label="loc_HILSAssetPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSAssetPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EmployeeAgreementMember" xlink:label="loc_HILSEmployeeAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSEmployeeAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RestatedEmploymentAgreementMember" xlink:label="loc_HILSRestatedEmploymentAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSRestatedEmploymentAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_70" xlink:type="arc" order="74" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AssetAcquisitionDescription" xlink:label="loc_HILSAssetAcquisitionDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HILSAssetAcquisitionDescription_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_MilestonePayment" xlink:label="loc_HILSMilestonePayment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HILSMilestonePayment_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedSalariesCurrentAndNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccruedSalariesCurrentAndNoncurrent_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProfessionalFees_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_CashBonusReceived" xlink:label="loc_HILSCashBonusReceived_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HILSCashBonusReceived_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_100" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_UnsecuredPromissoryNotesMember" xlink:label="loc_HILSUnsecuredPromissoryNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSUnsecuredPromissoryNotesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_PromissoryNotesPayableMember" xlink:label="loc_HILSPromissoryNotesPayableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_HILSPromissoryNotesPayableMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember" xlink:label="loc_HILSBoardOfDirectorsAndScientificAdvisoryBoardMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HILSBoardOfDirectorsAndScientificAdvisoryBoardMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EmployeeAgreementMember" xlink:label="loc_HILSEmployeeAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSEmployeeAgreementMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" xlink:type="arc" order="10" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>35
<FILENAME>hils-20211231_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FarringtonMember" xlink:label="HILS_FarringtonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FarringtonMember" xlink:to="HILS_FarringtonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_FarringtonMember_lbl" xml:lang="en-US">Farrington [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExchangeAgreementMember" xlink:label="HILS_ExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExchangeAgreementMember" xlink:to="HILS_ExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ConvertiblePromissoryNoteAgreementsMember" xlink:label="HILS_ConvertiblePromissoryNoteAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ConvertiblePromissoryNoteAgreementsMember" xlink:to="HILS_ConvertiblePromissoryNoteAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ConvertiblePromissoryNoteAgreementsMember_lbl" xml:lang="en-US">Convertible Promissory Note Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_OriginalNotesMember" xlink:label="HILS_OriginalNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_OriginalNotesMember" xlink:to="HILS_OriginalNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_OriginalNotesMember_lbl" xml:lang="en-US">Original Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExchangeNotesMember" xlink:label="HILS_ExchangeNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExchangeNotesMember" xlink:to="HILS_ExchangeNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExchangeNotesMember_lbl" xml:lang="en-US">Exchange Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FiveNotesPayableMember" xlink:label="HILS_FiveNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FiveNotesPayableMember" xlink:to="HILS_FiveNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_FiveNotesPayableMember_lbl" xml:lang="en-US">Five Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SeptemberExchangeNotesMember" xlink:label="HILS_SeptemberExchangeNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_SeptemberExchangeNotesMember" xlink:to="HILS_SeptemberExchangeNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_SeptemberExchangeNotesMember_lbl" xml:lang="en-US">September Exchange Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RolledOverMember" xlink:label="HILS_RolledOverMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RolledOverMember" xlink:to="HILS_RolledOverMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_RolledOverMember_lbl" xml:lang="en-US">Rolled Over [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RolledOverInToNewNotesMember" xlink:label="HILS_RolledOverInToNewNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RolledOverInToNewNotesMember" xlink:to="HILS_RolledOverInToNewNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_RolledOverInToNewNotesMember_lbl" xml:lang="en-US">Rolled Over in toNew Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_TwentySeventeenStockIncentivePlanMember" xlink:label="HILS_TwentySeventeenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_TwentySeventeenStockIncentivePlanMember" xlink:to="HILS_TwentySeventeenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_TwentySeventeenStockIncentivePlanMember_lbl" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_TwentyNineteenStockIncentivePlanMember" xlink:label="HILS_TwentyNineteenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_TwentyNineteenStockIncentivePlanMember" xlink:to="HILS_TwentyNineteenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_TwentyNineteenStockIncentivePlanMember_lbl" xml:lang="en-US">2019 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceOneMember" xlink:label="HILS_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceOneMember" xlink:to="HILS_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceTwoMember" xlink:label="HILS_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceTwoMember" xlink:to="HILS_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceThreeMember" xlink:label="HILS_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceThreeMember" xlink:to="HILS_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceFourMember" xlink:label="HILS_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceFourMember" xlink:to="HILS_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceFiveMember" xlink:label="HILS_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceFiveMember" xlink:to="HILS_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceSixMember" xlink:label="HILS_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceSixMember" xlink:to="HILS_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceSevenMember" xlink:label="HILS_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceSevenMember" xlink:to="HILS_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceEightMember" xlink:label="HILS_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceEightMember" xlink:to="HILS_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eigjht [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FounderAndChiefExecutiveOfficerMember" xlink:label="HILS_FounderAndChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FounderAndChiefExecutiveOfficerMember" xlink:to="HILS_FounderAndChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_FounderAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Founder and Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AssetPurchaseAgreementMember" xlink:label="HILS_AssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AssetPurchaseAgreementMember" xlink:to="HILS_AssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EmployeeAgreementMember" xlink:label="HILS_EmployeeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EmployeeAgreementMember" xlink:to="HILS_EmployeeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_EmployeeAgreementMember_lbl" xml:lang="en-US">Employee Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RestatedEmploymentAgreementMember" xlink:label="HILS_RestatedEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RestatedEmploymentAgreementMember" xlink:to="HILS_RestatedEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_RestatedEmploymentAgreementMember_lbl" xml:lang="en-US">Restated Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_UnsecuredPromissoryNotesMember" xlink:label="HILS_UnsecuredPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_UnsecuredPromissoryNotesMember" xlink:to="HILS_UnsecuredPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_UnsecuredPromissoryNotesMember_lbl" xml:lang="en-US">Unsecured Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_PromissoryNotesPayableMember" xlink:label="HILS_PromissoryNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_PromissoryNotesPayableMember" xlink:to="HILS_PromissoryNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_PromissoryNotesPayableMember_lbl" xml:lang="en-US">Promissory Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember" xlink:label="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember" xlink:to="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember_lbl" xml:lang="en-US">Board of Directors and Scientific Advisory Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to founder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RedemptionLiability" xlink:label="HILS_RedemptionLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RedemptionLiability" xlink:to="HILS_RedemptionLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_RedemptionLiability_lbl" xml:lang="en-US">Redemption liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Short-term portion of related-party convertible notes, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Related-party convertible notes, net, less short-term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (See Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 250,000,000 shares authorized; 6,357,314 shares issued and outstanding as of December 31, 2021 and 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AcquiredInprocessResearchAndDevelopment1" xlink:label="HILS_AcquiredInprocessResearchAndDevelopment1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AcquiredInprocessResearchAndDevelopment1" xlink:to="HILS_AcquiredInprocessResearchAndDevelopment1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_AcquiredInprocessResearchAndDevelopment1_lbl" xml:lang="en-US">Acquired in-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GainLossInRedemptionValue" xlink:label="HILS_GainLossInRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_GainLossInRedemptionValue" xlink:to="HILS_GainLossInRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_GainLossInRedemptionValue_lbl" xml:lang="en-US">Change in redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net loss per share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of shares for the acquisition of Farrington Therapeutics LLC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of shares for the acquisition of Farrington Therapeutics LLC, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeemedDividendUponDebtExchange" xlink:label="HILS_DeemedDividendUponDebtExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeemedDividendUponDebtExchange" xlink:to="HILS_DeemedDividendUponDebtExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_DeemedDividendUponDebtExchange_lbl" xml:lang="en-US">Deemed dividend upon debt exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">In-process research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_GainLossInRedemptionValue" xlink:to="HILS_GainLossInRedemptionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HILS_GainLossInRedemptionValue_2_lbl" xml:lang="en-US">Change in fair value of redemption liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating accounts:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Changes in prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Changes in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Changes in accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from related-party convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RepaymentsOfDeferredOfferingCosts" xlink:label="HILS_RepaymentsOfDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RepaymentsOfDeferredOfferingCosts" xlink:to="HILS_RepaymentsOfDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HILS_RepaymentsOfDeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash - beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash - end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Shares issued upon acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeemedDividend" xlink:label="HILS_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeemedDividend" xlink:to="HILS_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AccruedInterestRolloverToNewNotesPayable" xlink:label="HILS_AccruedInterestRolloverToNewNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AccruedInterestRolloverToNewNotesPayable" xlink:to="HILS_AccruedInterestRolloverToNewNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_AccruedInterestRolloverToNewNotesPayable_lbl" xml:lang="en-US">Accrued interest roll-over to new notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DueToFounderConvertedToNotePayable" xlink:label="HILS_DueToFounderConvertedToNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DueToFounderConvertedToNotePayable" xlink:to="HILS_DueToFounderConvertedToNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_DueToFounderConvertedToNotePayable_lbl" xml:lang="en-US">Due to founder converted to note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_UnpaidDeferredOfferingCosts" xlink:label="HILS_UnpaidDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_UnpaidDeferredOfferingCosts" xlink:to="HILS_UnpaidDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_UnpaidDeferredOfferingCosts_lbl" xml:lang="en-US">Unpaid deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS AND LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">ACQUISITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES - RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DisclosureRedemptionLiabilityAbstract" xlink:label="HILS_DisclosureRedemptionLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DisclosureRedemptionLiabilityAbstract" xlink:to="HILS_DisclosureRedemptionLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_DisclosureRedemptionLiabilityAbstract_lbl" xml:lang="en-US">Redemption Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RedemptionLiabilityDisclosureTextBlock" xlink:label="HILS_RedemptionLiabilityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RedemptionLiabilityDisclosureTextBlock" xlink:to="HILS_RedemptionLiabilityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_RedemptionLiabilityDisclosureTextBlock_lbl" xml:lang="en-US">REDEMPTION LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ReverseStockSplitPolicyTextBlock" xlink:label="HILS_ReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ReverseStockSplitPolicyTextBlock" xlink:to="HILS_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US">Acquired in-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_CommonStockValuationsPolicyTextBlock" xlink:label="HILS_CommonStockValuationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_CommonStockValuationsPolicyTextBlock" xlink:to="HILS_CommonStockValuationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_CommonStockValuationsPolicyTextBlock_lbl" xml:lang="en-US">Common stock valuations</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock" xlink:label="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock" xlink:to="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_lbl" xml:lang="en-US">Debt discount and derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting pronouncements not yet adopted:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CONVERTIBLE DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EXERCISE PRICE RANGE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="HILS_GrossProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="HILS_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_GrossProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds from issuance initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_BacisAndDilutedLoss" xlink:label="HILS_BacisAndDilutedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_BacisAndDilutedLoss" xlink:to="HILS_BacisAndDilutedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_BacisAndDilutedLoss_lbl" xml:lang="en-US">[custom:BacisAndDilutedLoss]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Less: debt discount, net of accretion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Total carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Long term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt Instrument, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityValuation" xlink:label="HILS_EquityValuation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityValuation" xlink:to="HILS_EquityValuation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_EquityValuation_lbl" xml:lang="en-US">[custom:EquityValuation-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Notes Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_2_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedPercentage" xlink:label="HILS_EquityFinancingRangeValuationAssumedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedPercentage" xlink:to="HILS_EquityFinancingRangeValuationAssumedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_EquityFinancingRangeValuationAssumedPercentage_lbl" xml:lang="en-US">[custom:EquityFinancingRangeValuationAssumedPercentage-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedDiscountRate" xlink:label="HILS_EquityFinancingRangeValuationAssumedDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedDiscountRate" xlink:to="HILS_EquityFinancingRangeValuationAssumedDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_EquityFinancingRangeValuationAssumedDiscountRate_lbl" xml:lang="en-US">[custom:EquityFinancingRangeValuationAssumedDiscountRate-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate" xlink:label="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate" xlink:to="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate_lbl" xml:lang="en-US">[custom:EquityFinancingRangeValuationAssumedExpectedInterestRate-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedExpectedTerm" xlink:label="HILS_EquityFinancingRangeValuationAssumedExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedExpectedTerm" xlink:to="HILS_EquityFinancingRangeValuationAssumedExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_EquityFinancingRangeValuationAssumedExpectedTerm_lbl" xml:lang="en-US">[custom:EquityFinancingRangeValuationAssumedExpectedTerm-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DisclosureRedemptionLiabilityAbstract" xlink:to="HILS_DisclosureRedemptionLiabilityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HILS_DisclosureRedemptionLiabilityAbstract_2_lbl" xml:lang="en-US">Schedule Of Fair Value Of Redemption Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" xlink:label="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" xlink:to="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_lbl" xml:lang="en-US">Initial embedded redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:label="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:to="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GainOnRedemptionValue" xlink:label="HILS_GainOnRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_GainOnRedemptionValue" xlink:to="HILS_GainOnRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_GainOnRedemptionValue_lbl" xml:lang="en-US">Gain on redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_LossOnRedemptionValue" xlink:label="HILS_LossOnRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_LossOnRedemptionValue" xlink:to="HILS_LossOnRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HILS_LossOnRedemptionValue_lbl" xml:lang="en-US">Loss on redemption value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Shares underlying option, Beginning outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weigthed average exercise price, Beginning outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares underlying options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weigthed average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares underlying options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weigthed average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares underlying options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weigthed average exercise price, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Shares underlyling options, Ending outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weigthed average exercise price, Ending outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares underlyling options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weigthed average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Shares underlying options, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xml:lang="en-US">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Outstanding Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Exercisable Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Estimated fair value of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_IncreaseInSharesReservedForIssuance" xlink:label="HILS_IncreaseInSharesReservedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_IncreaseInSharesReservedForIssuance" xlink:to="HILS_IncreaseInSharesReservedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_IncreaseInSharesReservedForIssuance_lbl" xml:lang="en-US">[custom:IncreaseInSharesReservedForIssuance]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average contractual term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" xlink:label="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" xlink:to="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_lbl" xml:lang="en-US">Capitalized costs</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AcquiredInprocessResearchAndDevelopment" xlink:label="HILS_AcquiredInprocessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AcquiredInprocessResearchAndDevelopment" xlink:to="HILS_AcquiredInprocessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_AcquiredInprocessResearchAndDevelopment_lbl" xml:lang="en-US">Acquired In-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" xlink:label="HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" xlink:to="HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther_lbl" xml:lang="en-US">Accrued expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset, net of valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax benefit at the federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_IncomeTaxReconciliationPermanentDifferencesAndOther" xlink:label="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther" xlink:to="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther_lbl" xml:lang="en-US">Permanent differences and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Effective income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Due to Related Parties, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AssetAcquisitionDescription" xlink:label="HILS_AssetAcquisitionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AssetAcquisitionDescription" xlink:to="HILS_AssetAcquisitionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_AssetAcquisitionDescription_lbl" xml:lang="en-US">[custom:AssetAcquisitionDescription]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_MilestonePayment" xlink:label="HILS_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_MilestonePayment" xlink:to="HILS_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_MilestonePayment_lbl" xml:lang="en-US">[custom:MilestonePayment]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_CashBonusReceived" xlink:label="HILS_CashBonusReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_CashBonusReceived" xlink:to="HILS_CashBonusReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_CashBonusReceived_lbl" xml:lang="en-US">[custom:CashBonusReceived]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Other Commitments, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ConvertiblePromissoryNoteAgreementsMember" xlink:to="HILS_ConvertiblePromissoryNoteAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ConvertiblePromissoryNoteAgreementsMember_doc" xml:lang="en-US">Convertible Promissory Note Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RedemptionLiability" xlink:to="HILS_RedemptionLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_RedemptionLiability_doc" xml:lang="en-US">Redemption liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityValuation" xlink:to="HILS_EquityValuation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_EquityValuation_doc" xml:lang="en-US">Equity Valuation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_OriginalNotesMember" xlink:to="HILS_OriginalNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_OriginalNotesMember_doc" xml:lang="en-US">Original Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExchangeNotesMember" xlink:to="HILS_ExchangeNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExchangeNotesMember_doc" xml:lang="en-US">Exchange Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_SeptemberExchangeNotesMember" xlink:to="HILS_SeptemberExchangeNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_SeptemberExchangeNotesMember_doc" xml:lang="en-US">September Exchange Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FiveNotesPayableMember" xlink:to="HILS_FiveNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_FiveNotesPayableMember_doc" xml:lang="en-US">Five Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RolledOverMember" xlink:to="HILS_RolledOverMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_RolledOverMember_doc" xml:lang="en-US">Rolled Over [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RolledOverInToNewNotesMember" xlink:to="HILS_RolledOverInToNewNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_RolledOverInToNewNotesMember_doc" xml:lang="en-US">Rolled Over in toNew Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AssetAcquisitionDescription" xlink:to="HILS_AssetAcquisitionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_AssetAcquisitionDescription_doc" xml:lang="en-US">Asset acquisition description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_GainLossInRedemptionValue" xlink:to="HILS_GainLossInRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_GainLossInRedemptionValue_doc" xml:lang="en-US">Change in redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RepaymentsOfDeferredOfferingCosts" xlink:to="HILS_RepaymentsOfDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_RepaymentsOfDeferredOfferingCosts_doc" xml:lang="en-US">Repayments of deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeemedDividend" xlink:to="HILS_DeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_DeemedDividend_doc" xml:lang="en-US">Deemed dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AccruedInterestRolloverToNewNotesPayable" xlink:to="HILS_AccruedInterestRolloverToNewNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_AccruedInterestRolloverToNewNotesPayable_doc" xml:lang="en-US">Accrued interest rollover to new notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DueToFounderConvertedToNotePayable" xlink:to="HILS_DueToFounderConvertedToNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_DueToFounderConvertedToNotePayable_doc" xml:lang="en-US">Due to founder converted to note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_UnpaidDeferredOfferingCosts" xlink:to="HILS_UnpaidDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_UnpaidDeferredOfferingCosts_doc" xml:lang="en-US">Unpaid deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeemedDividendUponDebtExchange" xlink:to="HILS_DeemedDividendUponDebtExchange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_DeemedDividendUponDebtExchange_doc" xml:lang="en-US">Deemed dividend upon debt exchange.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ReverseStockSplitPolicyTextBlock" xlink:to="HILS_ReverseStockSplitPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ReverseStockSplitPolicyTextBlock_doc" xml:lang="en-US">Reverse stock split [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_CommonStockValuationsPolicyTextBlock" xlink:to="HILS_CommonStockValuationsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_CommonStockValuationsPolicyTextBlock_doc" xml:lang="en-US">Common stock valuations [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FarringtonMember" xlink:to="HILS_FarringtonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_FarringtonMember_doc" xml:lang="en-US">Farrington [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AcquiredInprocessResearchAndDevelopment" xlink:to="HILS_AcquiredInprocessResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_AcquiredInprocessResearchAndDevelopment_doc" xml:lang="en-US">Acquired in process research and development.</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchAndDevelopmentCosts" xlink:label="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchAndDevelopmentCosts" xlink:to="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchAndDevelopmentCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchAndDevelopmentCosts_doc" xml:lang="en-US">Deferred tax assets operating loss carryforwards capitalized research and development costs.</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_IncomeTaxReconciliationTaxAssetsDeferredTrueUp" xlink:label="HILS_IncomeTaxReconciliationTaxAssetsDeferredTrueUp" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_IncomeTaxReconciliationTaxAssetsDeferredTrueUp" xlink:to="HILS_IncomeTaxReconciliationTaxAssetsDeferredTrueUp_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_IncomeTaxReconciliationTaxAssetsDeferredTrueUp_doc" xml:lang="en-US">Income tax reconciliation tax assets deferred true up.</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_OperatingLossCarryforwardsExpirationDate1" xlink:label="HILS_OperatingLossCarryforwardsExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_OperatingLossCarryforwardsExpirationDate1" xlink:to="HILS_OperatingLossCarryforwardsExpirationDate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_OperatingLossCarryforwardsExpirationDate1_doc" xml:lang="en-US">Operating loss carryforwards expiration date1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:to="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliations recurring basis liability change in fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AssetPurchaseAgreementMember" xlink:to="HILS_AssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_AssetPurchaseAgreementMember_doc" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EmployeeAgreementMember" xlink:to="HILS_EmployeeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_EmployeeAgreementMember_doc" xml:lang="en-US">Employee Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RedemptionLiabilityDisclosureTextBlock" xlink:to="HILS_RedemptionLiabilityDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_RedemptionLiabilityDisclosureTextBlock_doc" xml:lang="en-US">Redemption liability disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_PromissoryNotesPayableMember" xlink:to="HILS_PromissoryNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_PromissoryNotesPayableMember_doc" xml:lang="en-US">Promissory Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RestatedEmploymentAgreementMember" xlink:to="HILS_RestatedEmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_RestatedEmploymentAgreementMember_doc" xml:lang="en-US">Restated Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_CashBonusReceived" xlink:to="HILS_CashBonusReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_CashBonusReceived_doc" xml:lang="en-US">Cash bonus received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_TwentySeventeenStockIncentivePlanMember" xlink:to="HILS_TwentySeventeenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_TwentySeventeenStockIncentivePlanMember_doc" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_TwentyNineteenStockIncentivePlanMember" xlink:to="HILS_TwentyNineteenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_TwentyNineteenStockIncentivePlanMember_doc" xml:lang="en-US">2019 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_GrossProceedsFromIssuanceInitialPublicOffering" xlink:to="HILS_GrossProceedsFromIssuanceInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_GrossProceedsFromIssuanceInitialPublicOffering_doc" xml:lang="en-US">Gross proceeds from issuance initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock" xlink:to="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_doc" xml:lang="en-US">Debt discount and derivative instruments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExchangeAgreementMember" xlink:to="HILS_ExchangeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExchangeAgreementMember_doc" xml:lang="en-US">Exchange Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FounderAndChiefExecutiveOfficerMember" xlink:to="HILS_FounderAndChiefExecutiveOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_FounderAndChiefExecutiveOfficerMember_doc" xml:lang="en-US">Founder and Chief Executive Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" xlink:to="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliations recurring basis liability initial embedded redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedPercentage" xlink:to="HILS_EquityFinancingRangeValuationAssumedPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_EquityFinancingRangeValuationAssumedPercentage_doc" xml:lang="en-US">Assumed ranges pre-money valuation at time of next equity financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedDiscountRate" xlink:to="HILS_EquityFinancingRangeValuationAssumedDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_EquityFinancingRangeValuationAssumedDiscountRate_doc" xml:lang="en-US">Discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate" xlink:to="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate_doc" xml:lang="en-US">Expected coupon interest rate on notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_EquityFinancingRangeValuationAssumedExpectedTerm" xlink:to="HILS_EquityFinancingRangeValuationAssumedExpectedTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_EquityFinancingRangeValuationAssumedExpectedTerm_doc" xml:lang="en-US">Expected term to exit event.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_IncreaseInSharesReservedForIssuance" xlink:to="HILS_IncreaseInSharesReservedForIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_IncreaseInSharesReservedForIssuance_doc" xml:lang="en-US">The increase in shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted average contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_doc" xml:lang="en-US">The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceOneMember" xlink:to="HILS_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceTwoMember" xlink:to="HILS_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceThreeMember" xlink:to="HILS_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceFourMember" xlink:to="HILS_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceFiveMember" xlink:to="HILS_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceSixMember" xlink:to="HILS_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceSevenMember" xlink:to="HILS_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_ExercisePriceEightMember" xlink:to="HILS_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eigjht [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_MilestonePayment" xlink:to="HILS_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_MilestonePayment_doc" xml:lang="en-US">Milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_UnsecuredPromissoryNotesMember" xlink:to="HILS_UnsecuredPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_UnsecuredPromissoryNotesMember_doc" xml:lang="en-US">Unsecured Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AcquiredInprocessResearchAndDevelopmentExpense" xlink:label="HILS_AcquiredInprocessResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AcquiredInprocessResearchAndDevelopmentExpense" xlink:to="HILS_AcquiredInprocessResearchAndDevelopmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_AcquiredInprocessResearchAndDevelopmentExpense_doc" xml:lang="en-US">Acquired in-process research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_GainOnRedemptionValue" xlink:to="HILS_GainOnRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_GainOnRedemptionValue_doc" xml:lang="en-US">Gain on redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_LossOnRedemptionValue" xlink:to="HILS_LossOnRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_LossOnRedemptionValue_doc" xml:lang="en-US">Loss on redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_AcquiredInprocessResearchAndDevelopment1" xlink:to="HILS_AcquiredInprocessResearchAndDevelopment1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_AcquiredInprocessResearchAndDevelopment1_doc" xml:lang="en-US">Acquired in-process research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember" xlink:to="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember_doc" xml:lang="en-US">Board of Directors and Scientific Advisory Board [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_BacisAndDilutedLoss" xlink:to="HILS_BacisAndDilutedLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_BacisAndDilutedLoss_doc" xml:lang="en-US">Loss for basic and diluted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" xlink:to="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_doc" xml:lang="en-US">Capitalized costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther" xlink:to="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HILS_IncomeTaxReconciliationPermanentDifferencesAndOther_doc" xml:lang="en-US">Permanent differences and other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_RepaymentsOfDeferredOfferingCosts" xlink:to="HILS_RepaymentsOfDeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_RepaymentsOfDeferredOfferingCosts_3_lbl" xml:lang="en-US">RepaymentsOfDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_2_lbl" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HILS_LossOnRedemptionValue" xlink:to="HILS_LossOnRedemptionValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HILS_LossOnRedemptionValue_3_lbl" xml:lang="en-US">Loss on redemption value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>36
<FILENAME>hils-20211231_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://hillstreambio.com/role/Cover" xlink:href="hils-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BalanceSheets" xlink:href="hils-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BalanceSheetsParenthetical" xlink:href="hils-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementsOfOperations" xlink:href="hils-20211231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="hils-20211231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StatementOfCashFlows" xlink:href="hils-20211231.xsd#StatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity" xlink:href="hils-20211231.xsd#DescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/Acquisition" xlink:href="hils-20211231.xsd#Acquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedParties" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiability" xlink:href="hils-20211231.xsd#RedemptionLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensation" xlink:href="hils-20211231.xsd#StockBasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockholdersDeficit" xlink:href="hils-20211231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxes" xlink:href="hils-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RelatedPartyTransactions" xlink:href="hils-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/CommitmentsAndContingencies" xlink:href="hils-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/SubsequentEvents" xlink:href="hils-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedPartiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiabilityTables" xlink:href="hils-20211231.xsd#RedemptionLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensationTables" xlink:href="hils-20211231.xsd#StockBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxesTables" xlink:href="hils-20211231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="hils-20211231.xsd#DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hils-20211231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/AcquisitionDetailsNarrative" xlink:href="hils-20211231.xsd#AcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails" xlink:href="hils-20211231.xsd#ScheduleOfConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:href="hils-20211231.xsd#ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:href="hils-20211231.xsd#ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:href="hils-20211231.xsd#ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative" xlink:href="hils-20211231.xsd#RedemptionLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="hils-20211231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails" xlink:href="hils-20211231.xsd#ScheduleOfExercisePriceRangeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:href="hils-20211231.xsd#ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative" xlink:href="hils-20211231.xsd#StockBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative" xlink:href="hils-20211231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:href="hils-20211231.xsd#ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:href="hils-20211231.xsd#ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/IncomeTaxesDetailsNarrative" xlink:href="hils-20211231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="hils-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hils-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://hillstreambio.com/role/SubsequentEventsDetailsNarrative" xlink:href="hils-20211231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RedemptionLiability" xlink:label="loc_HILSRedemptionLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_HILSRedemptionLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AcquiredInprocessResearchAndDevelopment1" xlink:label="loc_HILSAcquiredInprocessResearchAndDevelopment1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_HILSAcquiredInprocessResearchAndDevelopment1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GainLossInRedemptionValue" xlink:label="loc_HILSGainLossInRedemptionValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_HILSGainLossInRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeemedDividendUponDebtExchange" xlink:label="loc_HILSDeemedDividendUponDebtExchange" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSDeemedDividendUponDebtExchange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statement of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaapResearchAndDevelopmentInProcess" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GainLossInRedemptionValue" xlink:label="loc_HILSGainLossInRedemptionValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HILSGainLossInRedemptionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RepaymentsOfDeferredOfferingCosts" xlink:label="loc_HILSRepaymentsOfDeferredOfferingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_HILSRepaymentsOfDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeemedDividend" xlink:label="loc_HILSDeemedDividend" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_HILSDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AccruedInterestRolloverToNewNotesPayable" xlink:label="loc_HILSAccruedInterestRolloverToNewNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_HILSAccruedInterestRolloverToNewNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DueToFounderConvertedToNotePayable" xlink:label="loc_HILSDueToFounderConvertedToNotePayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_HILSDueToFounderConvertedToNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_UnpaidDeferredOfferingCosts" xlink:label="loc_HILSUnpaidDeferredOfferingCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_HILSUnpaidDeferredOfferingCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/Acquisition" xlink:title="00000009 - Disclosure - ACQUISITION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedParties" xlink:title="00000010 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiability" xlink:title="00000011 - Disclosure - REDEMPTION LIABILITY">
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DisclosureRedemptionLiabilityAbstract" xlink:label="loc_HILSDisclosureRedemptionLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RedemptionLiabilityDisclosureTextBlock" xlink:label="loc_HILSRedemptionLiabilityDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_HILSRedemptionLiabilityDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensation" xlink:title="00000012 - Disclosure - STOCK BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockholdersDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; DEFICIT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RelatedPartyTransactions" xlink:title="00000015 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ReverseStockSplitPolicyTextBlock" xlink:label="loc_HILSReverseStockSplitPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HILSReverseStockSplitPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_CommonStockValuationsPolicyTextBlock" xlink:label="loc_HILSCommonStockValuationsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HILSCommonStockValuationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock" xlink:label="loc_HILSDebtDiscountAndDerivativeInstrumentsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HILSDebtDiscountAndDerivativeInstrumentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables" xlink:title="00000019 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiabilityTables" xlink:title="00000020 - Disclosure - REDEMPTION LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DisclosureRedemptionLiabilityAbstract" xlink:label="loc_HILSDisclosureRedemptionLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensationTables" xlink:title="00000021 - Disclosure - STOCK BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxesTables" xlink:title="00000022 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000023 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_BacisAndDilutedLoss" xlink:label="loc_HILSBacisAndDilutedLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HILSBacisAndDilutedLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/AcquisitionDetailsNarrative" xlink:title="00000025 - Disclosure - ACQUISITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FarringtonMember" xlink:label="loc_HILSFarringtonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_HILSFarringtonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExchangeAgreementMember" xlink:label="loc_HILSExchangeAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF CONVERTIBLE DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RolledOverInToNewNotesMember" xlink:label="loc_HILSRolledOverInToNewNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSRolledOverInToNewNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative" xlink:title="00000027 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ConvertiblePromissoryNoteAgreementsMember" xlink:label="loc_HILSConvertiblePromissoryNoteAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSConvertiblePromissoryNoteAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaapEmbeddedDerivativeFinancialInstrumentsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapEmbeddedDerivativeFinancialInstrumentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_OriginalNotesMember" xlink:label="loc_HILSOriginalNotesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSOriginalNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FiveNotesPayableMember" xlink:label="loc_HILSFiveNotesPayableMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSFiveNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RolledOverMember" xlink:label="loc_HILSRolledOverMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSRolledOverMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExchangeNotesMember" xlink:label="loc_HILSExchangeNotesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_HILSExchangeNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SeptemberExchangeNotesMember" xlink:label="loc_HILSSeptemberExchangeNotesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_HILSSeptemberExchangeNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityValuation" xlink:label="loc_HILSEquityValuation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_HILSEquityValuation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DisclosureRedemptionLiabilityAbstract" xlink:label="loc_HILSDisclosureRedemptionLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedPercentage" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedDiscountRate" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedDiscountRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedExpectedInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedExpectedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EquityFinancingRangeValuationAssumedExpectedTerm" xlink:label="loc_HILSEquityFinancingRangeValuationAssumedExpectedTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HILSEquityFinancingRangeValuationAssumedExpectedTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DisclosureRedemptionLiabilityAbstract" xlink:label="loc_HILSDisclosureRedemptionLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" xlink:label="loc_HILSFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_HILSFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:label="loc_HILSFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_HILSFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative" xlink:title="00000030 - Disclosure - REDEMPTION LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DisclosureRedemptionLiabilityAbstract" xlink:label="loc_HILSDisclosureRedemptionLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GainOnRedemptionValue" xlink:label="loc_HILSGainOnRedemptionValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_HILSGainOnRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_LossOnRedemptionValue" xlink:label="loc_HILSLossOnRedemptionValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HILSDisclosureRedemptionLiabilityAbstract" xlink:to="loc_HILSLossOnRedemptionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_HILSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_HILSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF EXERCISE PRICE RANGE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceOneMember" xlink:label="loc_HILSExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceTwoMember" xlink:label="loc_HILSExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceThreeMember" xlink:label="loc_HILSExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceFourMember" xlink:label="loc_HILSExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceFiveMember" xlink:label="loc_HILSExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceSixMember" xlink:label="loc_HILSExercisePriceSixMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceSevenMember" xlink:label="loc_HILSExercisePriceSevenMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ExercisePriceEightMember" xlink:label="loc_HILSExercisePriceEightMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HILSExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="loc_HILSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_HILSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative" xlink:title="00000034 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_TwentySeventeenStockIncentivePlanMember" xlink:label="loc_HILSTwentySeventeenStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HILSTwentySeventeenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_TwentyNineteenStockIncentivePlanMember" xlink:label="loc_HILSTwentyNineteenStockIncentivePlanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HILSTwentyNineteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_IncreaseInSharesReservedForIssuance" xlink:label="loc_HILSIncreaseInSharesReservedForIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_HILSIncreaseInSharesReservedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_HILSSharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_HILSSharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000035 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" xlink:label="loc_HILSDeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HILSDeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AcquiredInprocessResearchAndDevelopment" xlink:label="loc_HILSAcquiredInprocessResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HILSAcquiredInprocessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" xlink:label="loc_HILSDeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HILSDeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_IncomeTaxReconciliationPermanentDifferencesAndOther" xlink:label="loc_HILSIncomeTaxReconciliationPermanentDifferencesAndOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HILSIncomeTaxReconciliationPermanentDifferencesAndOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000038 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaapOperatingLossCarryforwardsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_FounderAndChiefExecutiveOfficerMember" xlink:label="loc_HILSFounderAndChiefExecutiveOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HILSFounderAndChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_DueToFounderConvertedToNotePayable" xlink:label="loc_HILSDueToFounderConvertedToNotePayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_HILSDueToFounderConvertedToNotePayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AssetPurchaseAgreementMember" xlink:label="loc_HILSAssetPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EmployeeAgreementMember" xlink:label="loc_HILSEmployeeAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSEmployeeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_RestatedEmploymentAgreementMember" xlink:label="loc_HILSRestatedEmploymentAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSRestatedEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_AssetAcquisitionDescription" xlink:label="loc_HILSAssetAcquisitionDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HILSAssetAcquisitionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_MilestonePayment" xlink:label="loc_HILSMilestonePayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HILSMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedSalariesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccruedSalariesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_CashBonusReceived" xlink:label="loc_HILSCashBonusReceived" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HILSCashBonusReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://hillstreambio.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_UnsecuredPromissoryNotesMember" xlink:label="loc_HILSUnsecuredPromissoryNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_HILSUnsecuredPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_PromissoryNotesPayableMember" xlink:label="loc_HILSPromissoryNotesPayableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_HILSPromissoryNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember" xlink:label="loc_HILSBoardOfDirectorsAndScientificAdvisoryBoardMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HILSBoardOfDirectorsAndScientificAdvisoryBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_EmployeeAgreementMember" xlink:label="loc_HILSEmployeeAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HILSEmployeeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hils-20211231.xsd#HILS_GrossProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HILSGrossProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905408307240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HILLSTREAM
BIOPHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001861657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-2642541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200
    Route 22 East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">955-3140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HILS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,364,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Mayer Hoffman McCann P.C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los
Angeles, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905406577752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 4,356<span></span>
</td>
<td class="nump">$ 191,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">70,670<span></span>
</td>
<td class="nump">102,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">546,651<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">621,677<span></span>
</td>
<td class="nump">294,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">621,677<span></span>
</td>
<td class="nump">294,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,463,059<span></span>
</td>
<td class="nump">514,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">179,621<span></span>
</td>
<td class="nump">73,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to founder</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">318,223<span></span>
</td>
<td class="nump">48,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_RedemptionLiability', window );">Redemption liability</a></td>
<td class="nump">980,233<span></span>
</td>
<td class="nump">1,325,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Short-term portion of related-party convertible notes, net</a></td>
<td class="nump">1,392,544<span></span>
</td>
<td class="nump">563,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,533,680<span></span>
</td>
<td class="nump">2,725,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Related-party convertible notes, net, less short-term portion</a></td>
<td class="nump">772,899<span></span>
</td>
<td class="nump">1,286,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,306,579<span></span>
</td>
<td class="nump">4,012,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 250,000,000 shares authorized; 6,357,314 shares issued and outstanding as of December 31, 2021 and 2020</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,225,712<span></span>
</td>
<td class="nump">986,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,911,250)<span></span>
</td>
<td class="num">(4,704,607)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(4,684,902)<span></span>
</td>
<td class="num">(3,717,528)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 621,677<span></span>
</td>
<td class="nump">$ 294,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_RedemptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_RedemptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905409299304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">6,357,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905406578984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,842,803<span></span>
</td>
<td class="nump">$ 847,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_AcquiredInprocessResearchAndDevelopment1', window );">Acquired in-process research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">289,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,365,214<span></span>
</td>
<td class="nump">671,879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,208,017<span></span>
</td>
<td class="nump">1,808,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,208,017)<span></span>
</td>
<td class="num">(1,808,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(831,277)<span></span>
</td>
<td class="num">(246,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_GainLossInRedemptionValue', window );">Change in redemption value</a></td>
<td class="nump">1,832,651<span></span>
</td>
<td class="num">(362,486)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="nump">1,001,374<span></span>
</td>
<td class="num">(609,020)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,206,643)<span></span>
</td>
<td class="num">$ (2,417,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">6,357,314<span></span>
</td>
<td class="nump">6,347,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_AcquiredInprocessResearchAndDevelopment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_AcquiredInprocessResearchAndDevelopment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_GainLossInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_GainLossInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905407387352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 628<span></span>
</td>
<td class="nump">$ 462,671<span></span>
</td>
<td class="num">$ (2,085,499)<span></span>
</td>
<td class="num">$ (1,622,200)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">6,281,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of shares for the acquisition of Farrington Therapeutics LLC</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">289,192<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">289,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares for the acquisition of Farrington Therapeutics LLC, shares</a></td>
<td class="nump">75,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">234,580<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">234,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DeemedDividendUponDebtExchange', window );">Deemed dividend upon debt exchange</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(201,737)<span></span>
</td>
<td class="num">(201,737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,417,371)<span></span>
</td>
<td class="num">(2,417,371)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">986,443<span></span>
</td>
<td class="num">(4,704,607)<span></span>
</td>
<td class="num">(3,717,528)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">6,357,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,239,269<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,239,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,206,643)<span></span>
</td>
<td class="num">(2,206,643)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">$ 2,225,712<span></span>
</td>
<td class="num">$ (6,911,250)<span></span>
</td>
<td class="num">$ (4,684,902)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">6,357,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DeemedDividendUponDebtExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend upon debt exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DeemedDividendUponDebtExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905403942680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,206,643)<span></span>
</td>
<td class="num">$ (2,417,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">289,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">666,566<span></span>
</td>
<td class="nump">145,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,239,269<span></span>
</td>
<td class="nump">234,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_GainLossInRedemptionValue', window );">Change in fair value of redemption liability</a></td>
<td class="num">(1,832,651)<span></span>
</td>
<td class="nump">362,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating accounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Changes in prepaid expenses and other current assets</a></td>
<td class="nump">32,276<span></span>
</td>
<td class="num">(100,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Changes in accounts payable and accrued expenses</a></td>
<td class="nump">850,293<span></span>
</td>
<td class="nump">306,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Changes in accrued interest</a></td>
<td class="nump">164,646<span></span>
</td>
<td class="nump">101,093<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,086,244)<span></span>
</td>
<td class="num">(1,078,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from related-party convertible notes</a></td>
<td class="nump">1,078,015<span></span>
</td>
<td class="nump">1,232,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_RepaymentsOfDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="num">(179,267)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">898,748<span></span>
</td>
<td class="nump">1,232,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash</a></td>
<td class="num">(187,496)<span></span>
</td>
<td class="nump">153,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash - beginning of year</a></td>
<td class="nump">191,852<span></span>
</td>
<td class="nump">38,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash - end of year</a></td>
<td class="nump">4,356<span></span>
</td>
<td class="nump">191,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued upon acquisition</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">289,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">201,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_AccruedInterestRolloverToNewNotesPayable', window );">Accrued interest roll-over to new notes payable</a></td>
<td class="nump">58,091<span></span>
</td>
<td class="nump">89,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DueToFounderConvertedToNotePayable', window );">Due to founder converted to note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">55,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_UnpaidDeferredOfferingCosts', window );">Unpaid deferred offering costs</a></td>
<td class="nump">$ 367,384<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_AccruedInterestRolloverToNewNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest rollover to new notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_AccruedInterestRolloverToNewNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DueToFounderConvertedToNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to founder converted to note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DueToFounderConvertedToNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_GainLossInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_GainLossInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_RepaymentsOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_RepaymentsOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_UnpaidDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_UnpaidDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405595192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS AND LIQUIDITY</a></td>
<td class="text"><p id="xdx_802_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zEGU3gAJK5s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b><span id="f_006"/>Note
1 - Description of Business and Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82A_zvJ8MCpmCayb" style="display: none">DESCRIPTION
OF BUSINESS AND LIQUIDITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillstream
BioPharma, Inc. (&#8220;HBI&#8221;) was incorporated on March 28, 2017, as a Delaware C-corporation. At December 31, 2021, Hillstream
BioPharma, Inc. had two wholly-owned subsidiaries: HB Pharma Corp. (&#8220;HB&#8221;) and Farrington Therapeutics LLC (&#8220;Farrington&#8221;
and together with HBI and HB, the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death (&#8220;IMCD&#8221;) for treatment resistant cancers. The Company&#8217;s most advanced
product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to reduce
tumor burden in a clinical pilot study in Germany in treatment resistant cancers, including triple negative breast cancer and epithelial
carcinomas. The Company&#8217;s goal is to file an investigational new drug application (&#8220;IND&#8221;) with the U.S. Food
and Drug Administration (&#8220;FDA&#8221;) in 2023 and start a clinical study with HSB-1216 in 2023; however, no assurance can
be provided that the Company&#8217;s IND will be accepted by the FDA in 2023, if at all. If the IND is accepted by the FDA, the HSB-1216
clinical study will focus on expanding upon the clinical pilot study conducted in Germany. If the Company is able to start the clinical
study with HSB-1216 in 2023, the Company anticipates that initial data from such trial will be released either at the end of 2023 or
early 2024. The Company uses Quatramer&#8482;, the proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor
microenvironment with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence, the
Company&#8217;s artificial intelligence precision medicine platform, is used to identify biomarkers in its clinical programs to target
specific patient segments. The discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target
discovery for drug development. Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular
iron or the Labile Iron Pool (&#8220;LIP&#8221;). Cancer cells increase the LIP leading to unregulated cell growth and metabolism. Decreasing
the LIP, induces iron-led reactive oxygen species production and lipid peroxidation, two key hallmarks of ferroptosis/IMCD. HSB-1216
binds iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD, leading to regulated cell death.
Areas of interest for the development of HSB-1216 are as a treatment of solid tumors, including triple negative breast cancer,
uveal melanoma, glioblastoma multiforme, head and neck squamous cell carcinoma and other treatment resistant cancers with high unmet
need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December
31, 2021, the Company incurred operating losses in the amount of approximately $<span id="xdx_903_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20210101__20211231_zHE3QPfeJhJ4">3.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and had an accumulated deficit
of approximately $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20211231_zAfcas2gEaWc">6.9</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million at December 31, 2021. The Company financed its working
capital requirements through December 31, 2021 primarily through the issuance of convertible promissory notes payable issued to
related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, the Company closed its initial public offering (&#8220;IPO&#8221;) of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpMtUEkKb1zh">3,750,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock at
a public offering price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVc9VEbAwPY2">4.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The gross proceeds to the Company
from the IPO were $<span id="xdx_90C_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5aCE4PKBKWc">15.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, prior to deducting underwriting discounts,
commissions, and other offering expenses. The net proceeds to the Company from the IPO were approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zax5aKIRq9ji">13.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company granted the underwriters
a 45-day option to purchase up to an additional <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8MHlNI5u2Ki">562,500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at the public offering
price less discounts and commissions, to cover over-allotments; however, this option expired unexercised. Additionally, and as
a result of the completion of the IPO, all of the related party convertible debt and accrued interest was converted into an aggregate
of <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzkBBQU2tMU2">1,225,384
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
pursuant to the terms of the convertible notes. The shares of the Company&#8217;s common stock began trading on The Nasdaq
Capital Market on January 12, 2022 under the ticker symbol &#8220;HILS&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes its cash on hand after the completion of the IPO is sufficient to meet its operating obligations and capital
requirements for at least twelve months from the issuance of these financial statements. Thereafter, the Company may need to raise further
capital through the sale of additional equity or debt securities or other debt instruments to support its future operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
risks and uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the Company&#8217;s products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all. The Company is subject to risks common to biopharmaceutical companies including,
but not limited to, the development of new technological innovations, dependence on key personnel, protection of proprietary technology,
compliance with government regulations, product liability, uncertainty of market acceptance of products and the need to obtain additional
financing. The Company is dependent on third party suppliers. The Company&#8217;s products require approval or clearance from the FDA
prior to commencing commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions in which
the Company may license or sell its products. There can be no assurance that the Company&#8217;s products will receive all of the required
approvals or clearances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) was reported globally. The World Health Organization declared COVID-19
to constitute a &#8220;Public Health Emergency of International Concern&#8221; on January 30, 2020 and a global pandemic on March 11,
2020. In March 2020, individual states mandated &#8220;stay at home orders&#8221;, restricted access to hospitals, prohibited elective
surgeries and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on the Company&#8217;s
operational and financial performance will depend on future developments, including access to products, potential disruptions
in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity of the COVID-19
outbreak. As of December 31, 2021, the Company&#8217;s operations have not been materially affected by COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405752040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1LUHJ2g9Q65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
2 - Basis of Presentation and Summary of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_821_zpdq6neefWQj" style="display: none">BASIS
OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaxim83qcPgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86A_zYYLtqYOC5ba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (&#8220;US GAAP&#8221;). The Company operates in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--ReverseStockSplitPolicyTextBlock_zdbQhsP0ve13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86F_z5QFZvzSTBmh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
stock split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 16, 2021, the Company effectuated a reverse split of shares of its common stock at a ratio of <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20210915__20210916_zJAmx8oAjv6h">1-for-26.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">pursuant to an amendment
to the Company&#8217;s Certificate of Incorporation, as amended, filed with the Delaware Secretary of State and approved by the
Company&#8217;s board of directors and stockholders. The par value of the Company&#8217;s common stock was not adjusted as a result
of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have
been retroactively adjusted to reflect this reverse split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhqrq9UiGnlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86A_zITKkpzU2uZ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of consolidation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--UseOfEstimates_z2G4rkEXcLD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86B_zACQJuQS3ejk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases
its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often
may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls
within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense
recognition, valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments,
accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPeS4dNFE2uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86E_z2bSal0T2Qsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_z70A0iT8PGI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86F_zub6YjCkQKRh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrolment in clinical trials, administrative costs incurred by third parties, and other indicators of the services
completed. Substantially all of the prepaid expenses at December 31, 2021 relate to a manufacturing services agreement. Substantially
all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical ingredient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--InProcessResearchAndDevelopmentPolicy_zfBmMRtzJU86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_868_zEnb1ySasfnd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquired
in-process research and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards
Codification (&#8220;ASC&#8221;) 730-10-25-1, <i>Research and Development,</i> the up-front acquisition or licensing payments are
expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and,
absent obtaining such approval, has no alternative future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zicSb1T6sC35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_867_zVPVwjd2G2C5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
based compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as
an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock-based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date of grant
using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line
basis over the requisite service period of the awards, which is generally the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. At December
31, 2021, the Company was a private company and lacked company-specific historical and implied volatility information.
Therefore, it estimated its expected stock volatility based on the historical data regarding the volatility of a publicly traded
set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate
was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately
equal to the expected term of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_ecustom--CommonStockValuationsPolicyTextBlock_z4EclXTDGCn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86F_zyIZ2zQWvntb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
stock valuations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock-based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&#8217;s common stock, the Company&#8217;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&#8217;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84A_ecustom--DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_zW47rGNvvRvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_869_zGTrVFJYXOgk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt
discount and derivative instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2015-03, <i>Interest
&#8212; Imputation of Interest</i>, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative instruments in accordance with ASC 815, <i>Derivative and Hedging</i>, which establishes accounting and
reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts
and requires recognition of all derivatives on the balance sheet at fair value. The Company&#8217;s derivative financial instrument consists
of an embedded feature contained in the Company&#8217;s convertible debt that is bifurcated and accounted for separately. See Note 4
for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkhgGoSNxgXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_863_zH0qyYncS6Xl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
value measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies ASC 820, <i>Fair Value Measurement </i>(&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data
and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&#8217;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term
maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value. See Note 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input
that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable
    inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms,
    as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no
    market data exists for the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--DeferredChargesPolicyTextBlock_zVNOQhg82IL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_865_zkAnzY8Z7pva" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
Offering Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs consisted of legal, accounting, printing, and filing fees that the Company capitalized which will be offset against the
proceeds from the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_ziGgCs4wbED4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_867_zUI0tZjl0Ku7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance has been recognized for all periods since it is &#8220;more
likely than not&#8221; that some portion or all of the deferred tax assets will not be realized in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. At December 31, 2021 and 2020, the Company had no unrecognized uncertain income tax positions,
and therefore no amounts have been recognized in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zkqfmNdYCvR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_866_zEPkQOkIFLN1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
loss per share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports loss per share in accordance with ASC 260-10, <i>Earnings Per Share</i>, which provides for calculation of basic and
diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to
common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of earnings (loss) per share for the years ended December 31, 2021 and 2020 included
options to purchase <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zRF9Ba03TFdb">903,468
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zM288QWeU1M6">675,731
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, respectively. The number
of shares issuable upon the conversion of convertible debt and accrued interest (which was <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH1qaVehsYQh">1,225,384
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at the IPO date of January 14, 2022) is
not included in the denominator since their inclusion would be anti-dilutive. All common share amounts and per share amounts have been
adjusted to reflect a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20210101__20211231_zoB5kqzxwndd">1-for-26.4</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse stock split of the Company&#8217;s common stock effectuated
on September 16, 2021. Management concluded that the deemed dividend (see Note 4) is analogous to a return on equity classified
preference shares, therefore the deemed dividend is added to the net loss for purposes of the basic and diluted loss per share calculation.
Accordingly, the numerator of the loss per share calculation (basic and diluted) is $<span id="xdx_90A_ecustom--BacisAndDilutedLoss_c20200101__20201231_zbqgZvCLl9Nb">2,619,108
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyKFsLikxSNc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_869_zRakjnhEqyf9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
accounting pronouncements not yet adopted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all recent accounting pronouncements and believes that none of them will have a material effect on the Company&#8217;s
financial position, results of operations or cash flows except as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU No. 2016-02, &#8220;<i>Leases (Topic 842)</i>&#8221; which replaces the existing guidance in ASC 840
- <i>Leases</i>. This ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases
or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding
lease liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset and for operating
leases, the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December
15, 2021 and for interim periods within those fiscal years. The Company will evaluate the impact of adoption of this ASU when it enters
into a lease arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
with Conversion and Other Options and Derivatives and Hedging</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB recently issued ASU 2020-06, <i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity</i>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&#8217;s own stock and classified in stockholders&#8217; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, <i>Earnings Per Share</i>, to require entities to calculate diluted
earnings per share (&#8220;EPS&#8221;) for convertible instruments by using the if-converted method. In addition, entities must
presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments
in ASU 2020-06 are effective for public entities that meet the definition of an SEC filer, excluding smaller reporting companies as defined
by the Securities and Exchange Commission (&#8220;SEC&#8221;), for fiscal years beginning after December 15, 2021. For all other
entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact this standard will have on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Earnings
Per Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share</i> (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50),
<i>Compensation-Stock Compensation</i> (Topic 718), and <i>Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</i> (Subtopic
815-40). The new ASU addresses issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written
call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods
within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this standard will have
on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants,
and the SEC did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated
financial statement presentation or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Codification
Improvements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the FASB issued ASU 2020-10, <i>Codification Improvements</i>. The guidance contains improvements to the Codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may
affect the application of the guidance in cases in which the original guidance may have been unclear. This is effective for the Company
for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022.
Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated
financial statements.</span></p>

<p id="xdx_857_zlwPG8Ljltr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405657064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION</a></td>
<td class="text"><p id="xdx_806_eus-gaap--BusinessCombinationDisclosureTextBlock_zSgZywnvnSD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
3 - Acquisition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82F_zeSUe7Cgl4H8" style="display: none">ACQUISITION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Farrington</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2020, the Company acquired <span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPercent_c20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zJPlY9Bk1Ml6">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the member interests of Farrington, an early-stage biotech company which owned a next generation anthracycline, HSB-888, for pediatric
osteosarcoma. Pursuant to an Exchange Agreement, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zbDM9mDh0p3i">75,757
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock to the seller as consideration
for the purchase. The transaction did not meet the definition of a business combination for financial reporting purposes, since there
were no business inputs, employees acquired, processes or outputs at the time of the transaction. The fair value of the common stock
issued was estimated to be approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zB791mlu5Nx5">289,200</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
for which the single asset was recognized as a component of acquired in-process research and development expense in the accompanying
consolidated statements of operations in the year ended December 31, 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405763256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES - RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES - RELATED PARTIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zumNHdMuS9N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
4 - Convertible Notes - Related Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_826_zNgpaS2ON2Hi" style="display: none">CONVERTIBLE
NOTES - RELATED PARTIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
in May 2017, the Company entered into Subordinated Convertible Promissory Note Agreements (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued Subordinated
Convertible Promissory Notes (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally all
to the Chief Executive Officer and founder of the Company, a member of the Company&#8217;s board of directors and third parties
that are family members of the founder and Chief Executive Officer. See Note 9. Interest on the unpaid principal balance accrues
at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170531__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zLropNQfLpwk">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of
the Company&#8217;s common stock or preferred stock (collectively, the &#8220;Equity Securities&#8221;), the principal and accrued interest
shall be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in
each Agreement) and (ii) the closing of the Next Equity Financing. &#8220;Next Equity Financing&#8221; means the next sale, or series
of related sales, by the Company of its Equity Securities pursuant to which the Company receives gross proceeds of not less than $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20170501__20170531__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zNkSPDb9IFMk">5,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for Notes issued in 2017 and through November
2020 and $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zLaab7jIVNr">7,500,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for Notes issued after November 2020 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of the Notes).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, the stated maturity date was <span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dt_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z7NCGaRLzSR4">two
years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance, except for the
Notes entered into in December 2020 and thereafter (in the aggregate principal amount of approximately $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z0UoWoLLU6U">2,135,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
which have a stated maturity date of <span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dt_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zYpUPkOymGE5">three
years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. For Notes entered into in 2017 and through
September 2018, the default interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20180930__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zIpxiKJNHlt">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
was added to the Notes for the period after the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the Note on the date of conversion by the lesser of <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zPOgadkdTc3c">(i)
80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing, or (ii) an equity valuation of $</span></span><span id="xdx_902_ecustom--EquityValuation_iI_pn5n6_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zeyosqxahYW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
($</span><span id="xdx_902_eus-gaap--NotesIssued1_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z95xpPSaqbR6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
for Notes issued after December 2020). No Next Equity Financing occurred through December 31, 2021; however on January 14, 2022,
all outstanding Notes and accrued interest were converted into an aggregate of</span> <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z11WHJpLbiyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,225,384
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of the Company&#8217;s common stock as the IPO qualified as a Next Equity Financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
embedded features contained in the Notes in the aggregate are embedded derivative instruments, which were recorded as a debt discount
and derivative liability at the issuance date at their estimated fair value for all Notes of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmbeddedDerivativeFinancialInstrumentsMember_z6nbJV5mmbq9">2,421,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Accretion of debt discount for the Notes was recorded as interest expense was approximately $<span id="xdx_903_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z4dAd4PICqQi">667,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90E_eus-gaap--InterestExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z2MtfWj2qgKc">145,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively. Accrued interest expense associated with the Notes at December 31, 2021 and December 31, 2020 amounted to approximately
$<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zl4OWRkgkv4">180,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zPWDaLIQNP02">73,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. Interest expense, including accretion of the debt discount, amounted to approximately $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z2Sa7i29FlD2">831,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zrmZVskUqdZ3">246,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ConvertibleDebtTableTextBlock_zurV691P91ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, all convertible debt instruments which had matured had been rolled over into new notes as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zXcf6N7RCUMb" style="display: none">SCHEDULE
OF CONVERTIBLE DEBT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_z286mMqTQbj4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_zmIoqgHKUgN6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December
    31,</b></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_maCDzeeB_zAobAk9K9ev8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Principal
    amount outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,734,446</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,598,340</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msCDzeeB_z49Nrl1plWXk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    debt discount, net of accretion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,569,003</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(747,973</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iTI_mtCDzeeB_zGsjpo7otGx1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Carrying value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,165,443</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,850,367</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleDebtCurrent_iI_maCDzsmY_zicQ6vqPjBic" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    portion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,392,544</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">563,425</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebtNoncurrent_iI_maCDzsmY_z5eyShgNnHy" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long
    term portion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">772,899</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,286,942</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iTI_mtCDzsmY_z16a0vJ40mx7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Total carrying value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,165,443</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,850,367</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A9_zY5ZG7HoiNdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, the Company agreed to issue a related party Note holder notes (&#8220;Exchange Notes&#8221;) in exchange for seven
Notes payable which were in default (&#8220;Original Notes&#8221;) at such time by more than 90 days. The Original Notes had a principal
amount of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20191231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zhjmMXyNbpq7">265,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and accrued interest of $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20191231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zlQMeQZTlPk5">37,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2019. As of September 27, 2020,
the aggregate outstanding principal was approximately $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z6hWQLp8UqB3">265,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and accrued interest, which included the default
interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z9KJBOGxNsS9">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
as described above, was approximately $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zAYIBY4qCiFh">71,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zYIHavmEi658">37.5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
to determine the new principal amount which amounted to an aggregate of $<span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20200904__20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zMRj7YoMyZQ3">537,968</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company accounted for this transaction as a debt extinguishment, and the incremental amount of the principal of the Exchange Notes
payable of $<span id="xdx_90C_eus-gaap--NotesPayable_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z9jJbVyvv0v9">201,737
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was recorded to accumulated deficit (analogous
to a &#8220;deemed dividend&#8221;) in the year ended December 31, 2020, since the Exchange Notes are with related parties, and included
in the calculation of loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2020, the Company issued certain related party Noteholders notes (&#8220;September Exchange Notes&#8221;) in exchange for
five Notes payable, which were in default. As of such date, the aggregate outstanding principal and interest was approximately $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--SeptemberExchangeNotesMember_zB017qMiFkZh">26,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which included the default interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zThhoTkCjgP2">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
as described above. The September Exchange Notes in the aggregate principal amount of approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--SeptemberExchangeNotesMember_zgcp0yQLNkS9">26,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were issued with substantially the same terms
as the Original Notes. There were no accounting entries required upon the re-issuance of such Exchange Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Roll-over
notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2020, all Notes which matured, and were not repaid or converted, were rolled over on substantially the same terms as the Original
Notes (&#8220;Rolled Over&#8221;). Approximately $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20201001__20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zz5VS2jxjbW8">805,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of such Original Notes were Rolled Over through
December 31, 2021, of which approximately $<span id="xdx_901_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zVtI115C22s1">166,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurred prior to December 31, 2020 and $<span id="xdx_909_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zadilj4MmWP6">639,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurred between January 1, 2021 and December
31, 2021. Since the terms of the new notes are not substantially different from the Original Notes, this was not accounted for as a debt
modification or debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405701080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEMPTION LIABILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DisclosureRedemptionLiabilityAbstract', window );"><strong>Redemption Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_RedemptionLiabilityDisclosureTextBlock', window );">REDEMPTION LIABILITY</a></td>
<td class="text"><p id="xdx_803_ecustom--RedemptionLiabilityDisclosureTextBlock_zWhbbhB3R6A9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
5 - Redemption Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_821_z8O0uIksMSol" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">REDEMPTION
LIABILITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, determined based upon a Probability-Weighted
Expected Returns Method (&#8220;PWERM&#8221;). This PWERM was determined to be the most appropriate method of estimating the value of
possible redemption or conversion outcomes over time, since the Company has not entered into a priced equity round through December 31,
2021. The significant assumptions utilized in these calculations are the possible exit scenarios (either a conversion of the principal
and accrued interest of the Notes in the event of a Next Equity Financing, a repayment of the Notes and accrued interest in the event
of a Corporate Transaction (as defined in the Notes) or a repayment of the Notes and accrued interest at maturity), the pre-money valuation
of the Company&#8217;s common stock, the probabilities of such exit events occurring and discounts/premiums available to the noteholders
at such measurement dates. At December 31, 2020, the Company assumed a 40% probability of a Next Equity Financing event occurring
at IPO pricing. At December 31, 2020, the Company assumed a 5% probability of a Corporate Transaction. The calculation of the redemption
liability at December 31, 2021 is based upon the actual incremental value derived by the Holders at the IPO date. The calculation
of the redemption liability also used the following assumptions during the years:</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_z9vTxxSBrpqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zYZ7RQcr9tm2" style="display: none">SCHEDULE
OF ASSUMPTIONS OF REDEMPTION LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Assumed
    ranges pre-money valuation at time of Next Equity Financing</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">$
                                            <span id="xdx_901_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MinimumMember_zGiZMlrcLBH2">5
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">&#8211; <span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MaximumMember_zKQzlP9cQSAg">50
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">million</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Discount
    rate</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MinimumMember_zVID6tuR15sb" style="font-family: Times New Roman, Times, Serif">8.86</span><span style="font-family: Times New Roman, Times, Serif">-
                                            <span id="xdx_90E_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MaximumMember_zhHKYvah5rMa">11.13</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    coupon interest rate on Notes</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_ecustom--EquityFinancingRangeValuationAssumedExpectedInterestRate_iI_pid_dp_uPercent_c20201231_zxjHsFFGEzO4" style="font-family: Times New Roman, Times, Serif">5.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    term to exit event</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MinimumMember_z8p08iPrfyr8" style="font-family: Times New Roman, Times, Serif">2.0</span><span style="font-family: Times New Roman, Times, Serif">-
                                            <span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MaximumMember_zdEpX4f7qS3">3.0
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_zdukVwrdvcMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z6Kzb1otI7M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is re-measured at each period and is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z6mCpzfiEuL4" style="display: none">SCHEDULE
OF FAIR VALUE OF THE REDEMPTION LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zcA0ZS3BuXZ5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20200101__20201231_zKzqTdnCm9wh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zXp6PWXGhkGf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning
    balance</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,288</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,183</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_z08lIbYHdYuk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Initial
    embedded redemption value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,487,596</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">836,619</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_iI_zTkkZScxcJXg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,832,651</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">362,486</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zYiHXKB9CmVk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">980,233</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,288</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_ziWFSZ2MzLv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of a gain of $<span id="xdx_906_ecustom--GainOnRedemptionValue_c20210101__20211231_zl8dCMdyTdba">1,832,651</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and loss of $<span id="xdx_901_ecustom--LossOnRedemptionValue_iN_di_c20200101__20201231_zhFiCOFzcWr3">362,486
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively, is recorded as a component of other income (expenses), net in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DisclosureRedemptionLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DisclosureRedemptionLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_RedemptionLiabilityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption liability disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_RedemptionLiabilityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405615256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zZtEEkgXngrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
6 - Stock Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_826_zv3Zw03Oiih6" style="display: none">STOCK
BASED COMPENSATION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Company&#8217;s 2017 Stock Incentive Plan (the &#8220;2017 Stock Incentive Plan&#8221;) the Company may grant incentive stock options,
non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares and performance
units to employees, directors and consultants of the Company and its affiliates. Up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zdEM1dYGNhme">94,696
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock may
be issued pursuant to the 2017 Stock Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zvaRrnXhdGQc">92,801
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_znoEYg8NibZf">13.20
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share under the 2017 Stock Incentive Plan,
and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zHE8y5SE6v5e">1,895
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remains available for issuance. At each of December
31, 2021 and December 31, 2020, there were options outstanding to acquire <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_znjshPQAssE1">92,801
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. As of December 31, 2021,
all such options were fully vested, and the weighted average remaining contractual life for such options was approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_z2jdOJIDXOH5">6.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company authorized a new plan (the &#8220;2019 Stock Incentive Plan&#8221;). The Company initially reserved <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20190731__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zqYMa2qnZeQc">284,090
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock for issuance pursuant
to the 2019 Stock Incentive Plan in the form of incentive stock options, non-statutory stock options, rights to purchase common stock,
stock appreciation rights, restricted stock, restricted stock, performance shares and performance units to employees, directors and consultants
of the Company and its affiliates. On August 30, 2019, the Company approved an increase in the number of shares authorized for issuance
under the 2019 Stock Incentive Plan by <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20190830__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zLvd9NLF5x3">2,575,757
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. In January 2021, the Company approved
an increase in the number of shares reserved for issuance under the 2019 Stock Incentive Plan by <span id="xdx_90A_ecustom--IncreaseInSharesReservedForIssuance_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zArxo3wKzs51">574,494
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. On May 31, 2021, the Company approved
an increase in the number of shares reserved for issuance under the 2019 Stock Incentive Plan by <span id="xdx_903_ecustom--IncreaseInSharesReservedForIssuance_c20210530__20210531__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zQGR911sCzjl">467,171
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. At December 31, 2021, a total of <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zGmEZCrWtzPj">3,901,512
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares are authorized for issuance under the
2019 Stock Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has granted options to acquire <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zmm3APy8aVTe">2,420,514
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock under the 2019 Stock Incentive
Plan, and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_z3bIFo3nFVKj">1,480,998
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remain available for issuance at December 31,
2021. The shares issued in 2021 and 2020 and the shares exercised under the 2019 Stock Incentive Plan are included in the table below.
At December 31, 2021, there are stock options outstanding to acquire <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zlHstcuMKTj9">810,667
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock with a weighted average
exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zwQqbZqgzGe6">3.25
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and a weighted average contractual term of
<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_z59Ng475YWv2">8.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRhHmeJC28O6" style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock-based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plans:</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B8_zbPkbuGy2Qz4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"/><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares
    Underlying Options</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Contractual Terms</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zt0KoJSNCQgc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying option, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">475,368</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Beginning outstanding"><p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zimBABLIc9fk" style="margin: 0; font-family: Times New Roman, Times, Serif" title="Weigthed average exercise price, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">3.22</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zwoz5GUagsU6" style="font-family: Times New Roman, Times, Serif">9.4
                                            </span><span style="font-family: Times New Roman, Times, Serif">years</span></p></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zv2M8zFnOhf5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"><span style="font-family: Times New Roman, Times, Serif">200,363</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zQjRr0BLErx1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.80</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231_zYuJ5qaWucg1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zrL51YMdtIXg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zOren017Gxkj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zst98Ghis4ua" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weigthed average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zBY93IYXwno5" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Shares underlying option, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">675,731</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"/><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z8HbLzbL0Djc" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weigthed average exercise price, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">3.09</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zdkrYd6IC2x7" style="font-family: Times New Roman, Times, Serif">8.8
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zJOEI931jEkh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"><span style="font-family: Times New Roman, Times, Serif">227,737</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zQ275cLdXXA5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">7.76</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zG4ZYX03eV6f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zpBJOxGQSkE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zsxrfJHqrUva" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zdrVuE6N0udh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211231_zV5uAkbonhTi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, Ending outstanding"><span style="font-family: Times New Roman, Times, Serif">903,468</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zGYvvYlF9OAe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Ending outstanding"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zKV1bmLvYbZ6" style="font-family: Times New Roman, Times, Serif">7.9
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercisable options
    at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zY35yC0Ic5qj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, exercisable"><span style="font-family: Times New Roman, Times, Serif">580,642</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_z9ev5DhHfNVe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif">5.98</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zUBC61X72ZW9" style="font-family: Times New Roman, Times, Serif">8.0
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested
    and expected to vest at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20210101__20211231_z0eq8bXZ0b19" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">658,206</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zNXu29RX17Od" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">5.72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zDVeHkpfePx8" style="font-family: Times New Roman, Times, Serif">8.5
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  </table>

<p id="xdx_8AE_zDLxtQVcLJLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWRnD8SbEGJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the exercise price range as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BB_zHWGln1bDQO7" style="display: none">SCHEDULE
OF EXERCISE PRICE RANGE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    Options</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    Options</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 30%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zxnKEf4W7fJe" style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zcK5fXh2slzf" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">275,564</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z2DK62VPO32f" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">33,261</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztGMpnIuSQ6i" style="font-family: Times New Roman, Times, Serif">0.31</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zv0bXkbDTp8f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">78,212</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zNBZ8OLR2pc7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">78,133</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zKhCjvufukN4" style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpq3FaRZpHx7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">107,004</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z4yFGvoQuKLk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">65,564</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvqXSGzY4c44" style="font-family: Times New Roman, Times, Serif">3.82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbFL9eEbb0Ol" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73,857</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbq950e6zzWd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">73,857</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFhXEtA9oKgi" style="font-family: Times New Roman, Times, Serif">5.28</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7Jq2SSi5t0f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">48,294</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zjPM2tl2Ywug" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">19,044</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zwHn54hmVib9" style="font-family: Times New Roman, Times, Serif">7.03</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zOFCsqeJJu48" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,940</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zMU4sQD5X3i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">18,940</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zCtH7Cbtci8l" style="font-family: Times New Roman, Times, Serif">7.82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNsPRtWpxEue" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">208,797</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zpBIwQtFmK0h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">204,180</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zkaZYIilIGE8" style="font-family: Times New Roman, Times, Serif">13.20</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z4xYzaiKcd1c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">92,800</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zl6yRB7oGYbk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">87,663</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zmvecubytDKf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding Options"><span style="font-family: Times New Roman, Times, Serif"><b>903,468</b></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231_zy5cKzru8eoh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable Options"><span style="font-family: Times New Roman, Times, Serif"><b>580,642</b></span></td></tr>
  </table>


<p id="xdx_8A9_zE3dgHWJ6r7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 2.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair
value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between
immediate vesting and 4 years). The determination of fair value using the Black-Scholes model is affected by the Company&#8217;s share
price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest
rate and forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z0IraCnnogNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options granted during the years ended December 31, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following
weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zUrldP9f5w04" style="display: none">SCHEDULE
OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zOKtmoStbdRj" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20200101__20201231_zu3Jp9fIRkIe" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_z1LGsY4hik89" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">111.3</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">83.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zD54fN8bZZdk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.6</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.7</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zqIk53Io5Ged" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">-</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">-</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    life of options in years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z0K5NqXvCBO8" style="font-family: Times New Roman, Times, Serif">5.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zT5IwxgHC6Zh" style="font-family: Times New Roman, Times, Serif">5.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iE_zY76PXAn9MV2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Estimated
    fair value of common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.03</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.455</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_z8ZcjmwcuoUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of stock options granted during the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z863K5uimEQ5">5.48
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231_z5tJTbyNRXa9">1.53</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. The weighted average fair value of stock options vested in the years ended December 2021 and 2020 was approximately $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20211231_zYajcUjINj7j">5.47
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20200101__20201231_zNfHwqwRTDG5">1.37,
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation expense was approximately $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_z09NnwKYnhSb">1,239,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXzBl3lXIWQ4">531,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in research and development expense
and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zu8KO2uGElcb">708,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in general and administrative expenses)
and approximately $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_zWFeytRFQp55">234,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUdAJ4QTcDd7">124,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in research and development expense
and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zX0yeBUIu1C6">110,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">included in general and administrative expenses)
for the years ended December 2021 and 2020, respectively, and is included in the accompanying consolidated statements of operations.
At December 31, 2021, the total unrecognized compensation expense related to non-vested options was approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20211231_zcI5PYj9Mhf2">75,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and is expected to be recognized over the remaining
weighted average service period of approximately <span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNvR1C7XBFc2">0.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the above table are stock options granted in 2019 to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrYdSyJe9qNk">231,058
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMuxpAkd4WQl">0.079
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and stock options granted in 2020 to
purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6SAsQBwQvv7">14,204
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuczbZ8UKc2g">5.28
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, which vest upon a specified performance
condition. Since the occurrence of this condition was not considered probable as of December 31, 2021 and 2020, the Company has not recognized
any expense for such grants through December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20210301__20210331_zdi24GgJnzld">the
Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price of such stock options
from $0.18 or $2.598 to $0.314 or $3.817 per share, respectively.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in the stock option exercise price was accounted for as a modification of the stock grant in 2021; however, the impact
on the Company&#8217;s consolidated statements of operations was immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405601768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFfSOxakTXpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
7 &#8211; Stockholders&#8217; deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_827_zJbmClDOHzQb" style="display: none">STOCKHOLDERS&#8217;
DEFICIT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an amendment to the Company&#8217;s Certificate of Incorporation filed in April 2019, the Company increased the number of authorized
shares of common stock to <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20211231_zXTAJTxg2D7e">250</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million shares. See Note 2 for a discussion of the reverse
stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHkITzQWMfHi">75,757
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for the Farrington acquisition
transaction described in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405586328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zcaNUQypWNXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
8 &#8211; income taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_82A_zHboNnM8Ggl4" style="display: none">INCOME
TAXES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have any significant current income taxes due because of the losses generated in each period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets relate primarily to its net operating
loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance
to fully offset the gross deferred tax asset because it is not more likely than not that the Company will realize future benefits associated
with these deferred tax assets at December 31, 2021 and 2020. The valuation allowance increased by approximately $<span id="xdx_904_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zlryWvRdoHPl">652,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zD3x2MKiIE3g">589,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOQumCcKequj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&#8217;s deferred tax assets at December 31, 2021 and 2020 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zEwTtXBHJNEb" style="display: none">SCHEDULE
OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20211231_z0Jryg3Jzkqi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zPSrRuCLFgei" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax assets:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_maDTAGzm4g_z88JdmmLa9T9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    net operating loss carryforward</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">702,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">424,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzm4g_zlAyQ15FI4Aa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    net operating loss carryforward</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">238,000</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">182,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_iI_maDTAGzm4g_z9ioebGue6Ze" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Capitalized
    costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">199,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--AcquiredInprocessResearchAndDevelopment_iI_maDTAGzm4g_zn7zQQnHKLK" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Acquired
    In-process research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">178,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzm4g_zBZzUlOeN0S8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development credit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzm4g_z7ncOSJFlzEj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">336,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther_iI_maDTAGzm4g_zEUB5dvgWEc2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses and other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(66,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">)</span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">82,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzj39_mtDTAGzm4g_zBO8AR2aqLM4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,827,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,175,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzj39_zy2amT6qXc5e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,827,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,175,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzj39_msDTLzhRs_zv8TypsLERne" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax asset, net of valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zb5KwMmE47Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
income tax benefit for the years ended December 31, 2021 and 2020 differ from the amounts computed by applying the U.S. Federal income
tax rate of <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPercent_c20200101__20201231_zI3ak3ijABJ">21</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">%
to loss before income tax benefit as a result of non-deductible expenses, tax credits generated and increases in the Company&#8217;s
valuation allowance.</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zOm1cbaALyFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxF3hxINXQBg" style="display: none">SCHEDULE
OF EFFECTIVE INCOME TAX EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z1i9eA68bINg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20200101__20201231_zdkQ9I67Bpde" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzMie_zxOQ71uemCD5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax benefit at the federal statutory rate</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(463,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(508,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_ecustom--IncomeTaxReconciliationPermanentDifferencesAndOther_maITEBzMie_zjHsSBSgbnJ3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Permanent
    differences and other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(61,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzMie_zwve8BbcKm94" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    income taxes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(167,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzMie_zoopKL53uTtg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development credit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(31,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzMie_zqwZAnzJwZdd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0640">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzMie_zFnRmSIrvHkd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">652,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">589,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzMie_zZUCrr7C3JVe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective
    income tax expense</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_zUEuN488LgB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely
than not that some portion or all of the deferred tax assets will not be realized. After consideration of the available evidence, both
positive and negative, the Company determined that valuation allowances of $<span id="xdx_902_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pp0p0_c20211231_zWPKO4NOy45a">1,827,000
</span></span><span style="font-family: Times New Roman, Times, Serif">million and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pp0p0_c20201231_zv8ugyTBC9O8">1,175,000
</span>at December 31, 2021 and 2020, respectively, were necessary to reduce the deferred tax assets to the amount that
will more likely than not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company had available net operating loss carryforwards of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zleqs09q4Rxa">3.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for federal income tax purposes,
all of which was generated after 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act. At December 31, 2021,
the Company had approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmMxYoSLSnh1">46
thousand </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of federal research and development
(&#8220;R&amp;D&#8221;) tax credit carryforwards. If not utilized, the federal R&amp;D credits will begin to expire in 2038. The Company
also had $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ztQS9YL1xywd">3.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of state net operating losses
that will begin to expire in 2037.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available
to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of
significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the
NOL carryforwards that the Company may utilize in any one year may be limited. Although the Company has not undertaken a formal analysis,
it is likely that such an ownership change occurred during 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;). The CARES
Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund
a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19
pandemic, some of the more significant provisions which are expected to impact the Company&#8217;s financial statements include removal
of certain limitations on utilization of NOLs, increasing the loss carryback period for certain losses to five years, and increasing
the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company
has concluded that the CARES Act did not have a material impact on its financial position, results of operations, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended many of the benefits of the CARES Act
that were scheduled to expire. The Company evaluated the impact of the Consolidated Appropriations Act on its consolidated financial
statements and related disclosures and concluded that the impact is immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905406540808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zitDLyq6PAhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
9 - Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_821_zdrTY9GucNo6" style="display: none">RELATED
PARTY TRANSACTIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 4, the Company entered into the Notes with the Holders commencing in May 2017. The Holders of substantially all of
the Notes are the Company&#8217;s founder and Chief Executive Officer, a member of the Company&#8217;s board of directors
and third parties that are family members of the founder and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above Notes, the Company has amounts due to the founder and Chief Executive Officer that totaled $<span id="xdx_90E_eus-gaap--DueToRelatedPartiesCurrent_iI_c20201231__srt--TitleOfIndividualAxis__custom--FounderAndChiefExecutiveOfficerMember_zfHIvR5ccsSf">200,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2021 and December 31, 2020 for
accrued compensation. See Note 10. There are no established terms for repayment of such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, expenses paid on behalf of the Company by the Chief Executive Officer of $<span id="xdx_90F_ecustom--DueToFounderConvertedToNotePayable_c20200101__20201231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zlmeP3Xz3OGi">55,068
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were converted into a convertible promissory
note and is included in convertible notes-related parties on the accompanying balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405739928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhbCufOFXMcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
10 - Commitments And Contingencies</b></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82A_zYb2cd1SA5ih" style="display: none">COMMITMENTS
AND CONTINGENCIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Small
molecule analogues</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2019, <span id="xdx_90D_ecustom--AssetAcquisitionDescription_c20191229__20191230__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z1Vh1b6oFsde">the
Company acquired a series of small molecule analogues pursuant to an asset purchase agreement (&#8220;APA&#8221;). Pursuant to the APA,
the Company is required to make a payment of $50,000 upon raising of at least $2 million in funding, and up to $1.75 million based
upon successfully meeting clinical and sales milestones.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, such fund-raising requirement was not met and <span id="xdx_900_eus-gaap--PaymentsToAcquireProductiveAssets_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zySSmG4KCFHi">no
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments were made pursuant to the APA. The Company
included, in accounts payable at December 31, 2021 and December 31, 2020, the $<span id="xdx_907_ecustom--MilestonePayment_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zx6vF2uKJ0ui">50,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required initial payment. Milestone based payments,
if any, will be expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, the Company entered into a three-year employment agreement with its Chief Executive Officer which provides a specified
base salary and bonus. The employment agreement also provides the Chief Executive Officer with certain benefits while employed and if
employment ceases. The Company accrued $<span id="xdx_909_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20190131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zT2VTMXmlbyf">200,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in 2019 related to the Chief Executive Officer&#8217;s
base salary as per the employment agreement, which is included in due to founder, which remains outstanding as of December 31, 2021.
<span id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_do_c20190131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zovAXAt473k2">No
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">bonus was approved by the board of directors
of the Company for any period through December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, the Company amended the employment agreement pursuant to which, in lieu of a cash base salary, the Chief Executive Officer
will be compensated with stock options to purchase <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20200101__20200131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zAH7FHnvkFRc">7,575
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock per month (at an exercise
price based upon the most recent 409A valuation) effective January 1, 2020 until the Company receives a minimum of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200101__20200131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zco2AaCZxc45">3,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of gross proceeds from the sale of the Company&#8217;s
securities, after which time, cash compensation, pursuant to the employment agreement, shall be paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company amended the employment agreement with its Chief Executive Officer to provide a revised base salary pre-funding
(as defined in the employment agreement). In lieu of cash base salary, the Chief Executive Officer will be compensated with stock options
to purchase <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zn3xPOMTOj4b">18,939
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock per
month (an exercise price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zQj1hTgXH8t1">7.82
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share) effective January 1, 2021 until
funding meets or exceeds $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zO84LhYvY4Kh">5,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
after which time, cash compensation, pursuant to his employment agreement, shall be paid. The amended employment agreement also provides
for a future base salary for the Chief Executive Officer after the Company receives funding greater than $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember__srt--RangeAxis__srt--MinimumMember_zHw7NMfA4gdd">5,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or completes an initial public offering or similar
transaction as set forth in the employment agreement. In addition, if the Chief Executive Officer acts as the &#8220;finder&#8221; of
an investor who purchases more than $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zR6IIfuiZTi5">5,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Company&#8217;s equity, he will receive
a grant of stock options to acquire <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zXE4uegW6xjk">757,575
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the Company at an exercise
price equal to the most recent fair value of the Company&#8217;s common stock. This grant has not been earned as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2021, the Company entered into an Amended and Restated Employment Agreement, as amended on September 24, 2021 (the &#8220;Amended
and Restated Employment Agreement&#8221;) with the Company&#8217;s President and Chief Executive Officer. The term of the Amended and
Restated Employment Agreement will commence upon the closing of the Company&#8217;s initial public offering of its securities and continues
for a period of five years and automatically renews for successive one-year periods at the end of each term unless either party provides
written notice of their intent not to review at least 60 days prior to the expiration of the then effective term. Pursuant to the Amended
and Restated Employment Agreement, the Chief Executive Officer will receive an annual base salary of $<span id="xdx_90A_eus-gaap--ProfessionalFees_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zoU5l0YEY2hg">485,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which may be increased from time to time, and shall be eligible to receive an annual cash bonus equal to <span id="xdx_902_ecustom--CashBonusReceived_pid_dp_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zMO7eE8ttlra">55</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of his then base salary based upon the achievement of Company and individual performance targets established by the Company&#8217;s board
of directors. In addition, in the first year in which the Company&#8217;s market capitalization (as defined in the Amended and Restated
Employment Agreement) equals or exceeds <span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zclUTdxdNscg">(i)
$250 million, the Chief Executive Officer shall receive a cash payment of $150,000; (ii) $500 million, the Chief Executive Officer shall
receive a cash payment of $350,000; and (iii) $1 billion, the Chief Executive Officer shall receive a cash payment of $750,000. Furthermore,
on or as soon as reasonably practicable following the date of the consummation the Company&#8217;s initial public offering of its securities,
the Chief Executive Officer shall be granted </span></span><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_znE1KMfugung" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">757,575
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock at the public
offering price per share of common stock sold in the Company&#8217;s initial public offering of its securities which shall vest over
a 48-month period commencing 12 months after the date of grant. This shall be in addition to any additional equity-based compensation
awards the Company may grant the Chief Executive Officer from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405710552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zxnshU3mULmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Note
11 - Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_828_z3UA3i93gtGl" style="display: none">SUBSEQUENT
EVENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IPO</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, the Company closed its IPO pursuant to which it issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zm5VGJCTRnkj">3,750,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock at
a public offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEMn6XuFoNv6">4.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The gross proceeds to the Company
from the IPO were $<span id="xdx_903_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuNRpsy91LU2">15,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
prior to deducting underwriting discounts, commissions, and other offering expenses. The net proceeds to the Company from the IPO
were $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zYEca8EBd0U5">13.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company granted the underwriters
a 45-day option to purchase up to an additional <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5YMQKOYR378">562,500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at the public offering
price less discounts and commissions, to cover over-allotments; however, this option expired unexercised. Additionally, and as
a result of the completion of the IPO, all of the Company&#8217;s convertible debt and accrued interest was converted into an
aggregate of <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2rY5psnE233">1,225,384
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
pursuant to the terms of the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
    payable</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2022 and January 6, 2022, the Company issued unsecured promissory notes in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_z7TQBvdWmQwe">138,887
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(including an original issuance discount of an
aggregate of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zQBo5FjC6Fd">13,887</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
to three related-party investors. The notes accrue interest at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPercent_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zoY7yiwUhzK1">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum and mature upon the earlier of (i) June 30, 2022, and (ii) the closing of a Subsequent Equity Financing. &#8220;Subsequent
Equity Financing&#8221; means the next sale (or series of related sales) by the Company of its Equity Securities following the date of
the notes pursuant to which the Company receives gross proceeds of not less than $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220103__20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNotesPayableMember_zogLiozg9fhh">5,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The notes were repaid in full on January 21, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Stock option grant</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 14, 2022, the Company granted its Chief Executive Officer a stock option to purchase up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zPkInq2ODlz6">757,575
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
at an exercise price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_znQ75AquruYl">4.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share in accordance with his employment
agreement. See Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2022, the Company granted options to purchase up to an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220320__20220321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardMember_zeLNYsvtKHgl">247,500
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
at an exercise price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardMember_zzz4w6DxM0k">1.33
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to the independent members of
the Company&#8217;s board of directors and members of the Company&#8217;s Scientific Advisory Board.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905408399464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaxim83qcPgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86A_zYYLtqYOC5ba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (&#8220;US GAAP&#8221;). The Company operates in one segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ReverseStockSplitPolicyTextBlock', window );">Reverse stock split</a></td>
<td class="text"><p id="xdx_846_ecustom--ReverseStockSplitPolicyTextBlock_zdbQhsP0ve13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86F_z5QFZvzSTBmh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
stock split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 16, 2021, the Company effectuated a reverse split of shares of its common stock at a ratio of <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20210915__20210916_zJAmx8oAjv6h">1-for-26.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">pursuant to an amendment
to the Company&#8217;s Certificate of Incorporation, as amended, filed with the Delaware Secretary of State and approved by the
Company&#8217;s board of directors and stockholders. The par value of the Company&#8217;s common stock was not adjusted as a result
of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have
been retroactively adjusted to reflect this reverse split for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhqrq9UiGnlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86A_zITKkpzU2uZ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of consolidation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_845_eus-gaap--UseOfEstimates_z2G4rkEXcLD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86B_zACQJuQS3ejk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases
its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often
may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls
within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense
recognition, valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments,
accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPeS4dNFE2uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86E_z2bSal0T2Qsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_z70A0iT8PGI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_86F_zub6YjCkQKRh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrolment in clinical trials, administrative costs incurred by third parties, and other indicators of the services
completed. Substantially all of the prepaid expenses at December 31, 2021 relate to a manufacturing services agreement. Substantially
all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical ingredient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired in-process research and development</a></td>
<td class="text"><p id="xdx_849_eus-gaap--InProcessResearchAndDevelopmentPolicy_zfBmMRtzJU86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_868_zEnb1ySasfnd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquired
in-process research and development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards
Codification (&#8220;ASC&#8221;) 730-10-25-1, <i>Research and Development,</i> the up-front acquisition or licensing payments are
expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and,
absent obtaining such approval, has no alternative future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock based compensation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zicSb1T6sC35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_867_zVPVwjd2G2C5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
based compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as
an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock-based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date of grant
using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line
basis over the requisite service period of the awards, which is generally the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. At December
31, 2021, the Company was a private company and lacked company-specific historical and implied volatility information.
Therefore, it estimated its expected stock volatility based on the historical data regarding the volatility of a publicly traded
set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate
was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately
equal to the expected term of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_CommonStockValuationsPolicyTextBlock', window );">Common stock valuations</a></td>
<td class="text"><p id="xdx_842_ecustom--CommonStockValuationsPolicyTextBlock_z4EclXTDGCn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86F_zyIZ2zQWvntb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
stock valuations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock-based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&#8217;s common stock, the Company&#8217;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&#8217;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock', window );">Debt discount and derivative instruments</a></td>
<td class="text"><p id="xdx_84A_ecustom--DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_zW47rGNvvRvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_869_zGTrVFJYXOgk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt
discount and derivative instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2015-03, <i>Interest
&#8212; Imputation of Interest</i>, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative instruments in accordance with ASC 815, <i>Derivative and Hedging</i>, which establishes accounting and
reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts
and requires recognition of all derivatives on the balance sheet at fair value. The Company&#8217;s derivative financial instrument consists
of an embedded feature contained in the Company&#8217;s convertible debt that is bifurcated and accounted for separately. See Note 4
for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkhgGoSNxgXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_863_zH0qyYncS6Xl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
value measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies ASC 820, <i>Fair Value Measurement </i>(&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data
and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&#8217;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term
maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value. See Note 5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input
that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable
    inputs, such as quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms,
    as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no
    market data exists for the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_844_eus-gaap--DeferredChargesPolicyTextBlock_zVNOQhg82IL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_865_zkAnzY8Z7pva" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
Offering Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs consisted of legal, accounting, printing, and filing fees that the Company capitalized which will be offset against the
proceeds from the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_ziGgCs4wbED4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_867_zUI0tZjl0Ku7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance has been recognized for all periods since it is &#8220;more
likely than not&#8221; that some portion or all of the deferred tax assets will not be realized in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. At December 31, 2021 and 2020, the Company had no unrecognized uncertain income tax positions,
and therefore no amounts have been recognized in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zkqfmNdYCvR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_866_zEPkQOkIFLN1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
loss per share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports loss per share in accordance with ASC 260-10, <i>Earnings Per Share</i>, which provides for calculation of basic and
diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to
common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities not included in the computation of earnings (loss) per share for the years ended December 31, 2021 and 2020 included
options to purchase <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zRF9Ba03TFdb">903,468
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zM288QWeU1M6">675,731
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, respectively. The number
of shares issuable upon the conversion of convertible debt and accrued interest (which was <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH1qaVehsYQh">1,225,384
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares at the IPO date of January 14, 2022) is
not included in the denominator since their inclusion would be anti-dilutive. All common share amounts and per share amounts have been
adjusted to reflect a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20210101__20211231_zoB5kqzxwndd">1-for-26.4</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reverse stock split of the Company&#8217;s common stock effectuated
on September 16, 2021. Management concluded that the deemed dividend (see Note 4) is analogous to a return on equity classified
preference shares, therefore the deemed dividend is added to the net loss for purposes of the basic and diluted loss per share calculation.
Accordingly, the numerator of the loss per share calculation (basic and diluted) is $<span id="xdx_90A_ecustom--BacisAndDilutedLoss_c20200101__20201231_zbqgZvCLl9Nb">2,619,108
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements not yet adopted:</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyKFsLikxSNc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_869_zRakjnhEqyf9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
accounting pronouncements not yet adopted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all recent accounting pronouncements and believes that none of them will have a material effect on the Company&#8217;s
financial position, results of operations or cash flows except as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU No. 2016-02, &#8220;<i>Leases (Topic 842)</i>&#8221; which replaces the existing guidance in ASC 840
- <i>Leases</i>. This ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases
or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding
lease liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset and for operating
leases, the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December
15, 2021 and for interim periods within those fiscal years. The Company will evaluate the impact of adoption of this ASU when it enters
into a lease arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
with Conversion and Other Options and Derivatives and Hedging</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB recently issued ASU 2020-06, <i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity</i>, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&#8217;s own stock and classified in stockholders&#8217; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, <i>Earnings Per Share</i>, to require entities to calculate diluted
earnings per share (&#8220;EPS&#8221;) for convertible instruments by using the if-converted method. In addition, entities must
presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments
in ASU 2020-06 are effective for public entities that meet the definition of an SEC filer, excluding smaller reporting companies as defined
by the Securities and Exchange Commission (&#8220;SEC&#8221;), for fiscal years beginning after December 15, 2021. For all other
entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact this standard will have on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Earnings
Per Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <i>Earnings Per Share</i> (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50),
<i>Compensation-Stock Compensation</i> (Topic 718), and <i>Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</i> (Subtopic
815-40). The new ASU addresses issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written
call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods
within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this standard will have
on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants,
and the SEC did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated
financial statement presentation or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Codification
Improvements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the FASB issued ASU 2020-10, <i>Codification Improvements</i>. The guidance contains improvements to the Codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may
affect the application of the guidance in cases in which the original guidance may have been unclear. This is effective for the Company
for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022.
Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated
financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_CommonStockValuationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock valuations [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_CommonStockValuationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt discount and derivative instruments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405587768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES - RELATED PARTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">SCHEDULE OF CONVERTIBLE DEBT</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ConvertibleDebtTableTextBlock_zurV691P91ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, all convertible debt instruments which had matured had been rolled over into new notes as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zXcf6N7RCUMb" style="display: none">SCHEDULE
OF CONVERTIBLE DEBT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_z286mMqTQbj4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_zmIoqgHKUgN6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December
    31,</b></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_maCDzeeB_zAobAk9K9ev8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Principal
    amount outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,734,446</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,598,340</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msCDzeeB_z49Nrl1plWXk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:
    debt discount, net of accretion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,569,003</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(747,973</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iTI_mtCDzeeB_zGsjpo7otGx1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Carrying value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,165,443</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,850,367</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleDebtCurrent_iI_maCDzsmY_zicQ6vqPjBic" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    portion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,392,544</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">563,425</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebtNoncurrent_iI_maCDzsmY_z5eyShgNnHy" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long
    term portion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">772,899</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,286,942</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ConvertibleDebt_iTI_mtCDzsmY_z16a0vJ40mx7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Total carrying value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,165,443</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,850,367</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905406630488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEMPTION LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DisclosureRedemptionLiabilityAbstract', window );"><strong>Redemption Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_z9vTxxSBrpqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zYZ7RQcr9tm2" style="display: none">SCHEDULE
OF ASSUMPTIONS OF REDEMPTION LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Assumed
    ranges pre-money valuation at time of Next Equity Financing</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">$
                                            <span id="xdx_901_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MinimumMember_zGiZMlrcLBH2">5
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">&#8211; <span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MaximumMember_zKQzlP9cQSAg">50
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">million</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Discount
    rate</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MinimumMember_zVID6tuR15sb" style="font-family: Times New Roman, Times, Serif">8.86</span><span style="font-family: Times New Roman, Times, Serif">-
                                            <span id="xdx_90E_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MaximumMember_zhHKYvah5rMa">11.13</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    coupon interest rate on Notes</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_ecustom--EquityFinancingRangeValuationAssumedExpectedInterestRate_iI_pid_dp_uPercent_c20201231_zxjHsFFGEzO4" style="font-family: Times New Roman, Times, Serif">5.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    term to exit event</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MinimumMember_z8p08iPrfyr8" style="font-family: Times New Roman, Times, Serif">2.0</span><span style="font-family: Times New Roman, Times, Serif">-
                                            <span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MaximumMember_zdEpX4f7qS3">3.0
                                            </span></span><span style="font-family: Times New Roman, Times, Serif">years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z6Kzb1otI7M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the redemption liability is re-measured at each period and is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z6mCpzfiEuL4" style="display: none">SCHEDULE
OF FAIR VALUE OF THE REDEMPTION LIABILITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zcA0ZS3BuXZ5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20200101__20201231_zKzqTdnCm9wh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zXp6PWXGhkGf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Beginning
    balance</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,288</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,183</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_z08lIbYHdYuk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Initial
    embedded redemption value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,487,596</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">836,619</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_iI_zTkkZScxcJXg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,832,651</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">362,486</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zYiHXKB9CmVk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">980,233</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,288</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DisclosureRedemptionLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DisclosureRedemptionLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905404722472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRhHmeJC28O6" style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes stock-based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plans:</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B8_zbPkbuGy2Qz4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"/><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares
    Underlying Options</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Contractual Terms</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zt0KoJSNCQgc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying option, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">475,368</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Beginning outstanding"><p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zimBABLIc9fk" style="margin: 0; font-family: Times New Roman, Times, Serif" title="Weigthed average exercise price, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">3.22</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zwoz5GUagsU6" style="font-family: Times New Roman, Times, Serif">9.4
                                            </span><span style="font-family: Times New Roman, Times, Serif">years</span></p></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zv2M8zFnOhf5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"><span style="font-family: Times New Roman, Times, Serif">200,363</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zQjRr0BLErx1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.80</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231_zYuJ5qaWucg1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zrL51YMdtIXg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zOren017Gxkj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zst98Ghis4ua" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weigthed average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zBY93IYXwno5" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Shares underlying option, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">675,731</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"/><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z8HbLzbL0Djc" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weigthed average exercise price, Beginning outstanding"><span style="font-family: Times New Roman, Times, Serif">3.09</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zdkrYd6IC2x7" style="font-family: Times New Roman, Times, Serif">8.8
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zJOEI931jEkh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"><span style="font-family: Times New Roman, Times, Serif">227,737</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zQ275cLdXXA5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">7.76</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zG4ZYX03eV6f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zpBJOxGQSkE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited/cancelled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zsxrfJHqrUva" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zdrVuE6N0udh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211231_zV5uAkbonhTi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, Ending outstanding"><span style="font-family: Times New Roman, Times, Serif">903,468</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zGYvvYlF9OAe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Ending outstanding"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zKV1bmLvYbZ6" style="font-family: Times New Roman, Times, Serif">7.9
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercisable options
    at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zY35yC0Ic5qj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, exercisable"><span style="font-family: Times New Roman, Times, Serif">580,642</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_z9ev5DhHfNVe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif">5.98</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zUBC61X72ZW9" style="font-family: Times New Roman, Times, Serif">8.0
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested
    and expected to vest at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20210101__20211231_z0eq8bXZ0b19" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">658,206</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zNXu29RX17Od" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">5.72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zDVeHkpfePx8" style="font-family: Times New Roman, Times, Serif">8.5
    </span><span style="font-family: Times New Roman, Times, Serif">years</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF EXERCISE PRICE RANGE</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWRnD8SbEGJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the exercise price range as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b><span id="xdx_8BB_zHWGln1bDQO7" style="display: none">SCHEDULE
OF EXERCISE PRICE RANGE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    Options</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable
    Options</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 30%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zxnKEf4W7fJe" style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zcK5fXh2slzf" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">275,564</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z2DK62VPO32f" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">33,261</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztGMpnIuSQ6i" style="font-family: Times New Roman, Times, Serif">0.31</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zv0bXkbDTp8f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">78,212</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zNBZ8OLR2pc7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">78,133</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zKhCjvufukN4" style="font-family: Times New Roman, Times, Serif">2.64</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpq3FaRZpHx7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">107,004</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z4yFGvoQuKLk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">65,564</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvqXSGzY4c44" style="font-family: Times New Roman, Times, Serif">3.82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbFL9eEbb0Ol" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73,857</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbq950e6zzWd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">73,857</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFhXEtA9oKgi" style="font-family: Times New Roman, Times, Serif">5.28</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7Jq2SSi5t0f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">48,294</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zjPM2tl2Ywug" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">19,044</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zwHn54hmVib9" style="font-family: Times New Roman, Times, Serif">7.03</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zOFCsqeJJu48" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,940</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zMU4sQD5X3i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">18,940</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zCtH7Cbtci8l" style="font-family: Times New Roman, Times, Serif">7.82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNsPRtWpxEue" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">208,797</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zpBIwQtFmK0h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">204,180</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zkaZYIilIGE8" style="font-family: Times New Roman, Times, Serif">13.20</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z4xYzaiKcd1c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"><span style="font-family: Times New Roman, Times, Serif">92,800</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zl6yRB7oGYbk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"><span style="font-family: Times New Roman, Times, Serif">87,663</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zmvecubytDKf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding Options"><span style="font-family: Times New Roman, Times, Serif"><b>903,468</b></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231_zy5cKzru8eoh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable Options"><span style="font-family: Times New Roman, Times, Serif"><b>580,642</b></span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z0IraCnnogNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options granted during the years ended December 31, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following
weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zUrldP9f5w04" style="display: none">SCHEDULE
OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zOKtmoStbdRj" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20200101__20201231_zu3Jp9fIRkIe" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_z1LGsY4hik89" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">111.3</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">83.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zD54fN8bZZdk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.6</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.7</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zqIk53Io5Ged" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">-</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">-</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    life of options in years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z0K5NqXvCBO8" style="font-family: Times New Roman, Times, Serif">5.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zT5IwxgHC6Zh" style="font-family: Times New Roman, Times, Serif">5.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iE_zY76PXAn9MV2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Estimated
    fair value of common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.03</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.455</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905405713768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOQumCcKequj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&#8217;s deferred tax assets at December 31, 2021 and 2020 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zEwTtXBHJNEb" style="display: none">SCHEDULE
OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20211231_z0Jryg3Jzkqi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zPSrRuCLFgei" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax assets:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_maDTAGzm4g_z88JdmmLa9T9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    net operating loss carryforward</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">702,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">424,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzm4g_zlAyQ15FI4Aa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    net operating loss carryforward</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">238,000</span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">182,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_iI_maDTAGzm4g_z9ioebGue6Ze" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Capitalized
    costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">394,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">199,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--AcquiredInprocessResearchAndDevelopment_iI_maDTAGzm4g_zn7zQQnHKLK" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Acquired
    In-process research and development</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">178,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzm4g_zBZzUlOeN0S8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development credit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzm4g_z7ncOSJFlzEj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">336,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther_iI_maDTAGzm4g_zEUB5dvgWEc2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses and other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(66,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><p style="margin: 0; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">)</span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">82,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzj39_mtDTAGzm4g_zBO8AR2aqLM4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,827,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,175,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzj39_zy2amT6qXc5e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,827,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,175,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzj39_msDTLzhRs_zv8TypsLERne" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax asset, net of valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zOm1cbaALyFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxF3hxINXQBg" style="display: none">SCHEDULE
OF EFFECTIVE INCOME TAX EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20210101__20211231_z1i9eA68bINg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20200101__20201231_zdkQ9I67Bpde" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzMie_zxOQ71uemCD5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax benefit at the federal statutory rate</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(463,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(508,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_ecustom--IncomeTaxReconciliationPermanentDifferencesAndOther_maITEBzMie_zjHsSBSgbnJ3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Permanent
    differences and other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(61,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzMie_zwve8BbcKm94" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    income taxes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(167,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzMie_zoopKL53uTtg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development credit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(31,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzMie_zqwZAnzJwZdd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0640">&#160;</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzMie_zFnRmSIrvHkd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">652,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">589,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzMie_zZUCrr7C3JVe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective
    income tax expense</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905407279480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,208,017<span></span>
</td>
<td class="nump">$ 1,808,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,911,250<span></span>
</td>
<td class="nump">$ 4,704,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,468<span></span>
</td>
<td class="nump">675,731<span></span>
</td>
<td class="nump">475,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_GrossProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from issuance initial public offering</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_GrossProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_GrossProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905407404776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Sep. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-26.4<span></span>
</td>
<td class="text">1-for-26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,468<span></span>
</td>
<td class="nump">675,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_BacisAndDilutedLoss', window );">[custom:BacisAndDilutedLoss]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,619,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_BacisAndDilutedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss for basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_BacisAndDilutedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905404766968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=HILS_FarringtonMember', window );">Farrington [Member] | Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">75,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="nump">$ 289,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=HILS_FarringtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=HILS_FarringtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HILS_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HILS_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905406516456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CONVERTIBLE DEBT (Details) - Rolled Over in toNew Notes [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount outstanding</a></td>
<td class="nump">$ 3,734,446<span></span>
</td>
<td class="nump">$ 2,598,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount, net of accretion</a></td>
<td class="num">(1,569,003)<span></span>
</td>
<td class="num">(747,973)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total carrying value</a></td>
<td class="nump">2,165,443<span></span>
</td>
<td class="nump">1,850,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current portion</a></td>
<td class="nump">1,392,544<span></span>
</td>
<td class="nump">563,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Long term portion</a></td>
<td class="nump">$ 772,899<span></span>
</td>
<td class="nump">$ 1,286,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=HILS_RolledOverInToNewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=HILS_RolledOverInToNewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905402635752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 831,277<span></span>
</td>
<td class="nump">$ 246,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,621<span></span>
</td>
<td class="nump">73,066<span></span>
</td>
<td class="nump">$ 179,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=HILS_OriginalNotesMember', window );">Original Notes [Member] | Exchange Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=HILS_FiveNotesPayableMember', window );">Five Notes Payable [Member] | Exchange Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=HILS_FiveNotesPayableMember', window );">Five Notes Payable [Member] | September Exchange Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=HILS_RolledOverMember', window );">Rolled Over [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 639,000<span></span>
</td>
<td class="nump">166,000<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HILS_ConvertiblePromissoryNoteAgreementsMember', window );">Convertible Promissory Note Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing, or (ii) an equity valuation of $<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityValuation', window );">[custom:EquityValuation-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,000<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831,000<span></span>
</td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="nump">831,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HILS_ConvertiblePromissoryNoteAgreementsMember', window );">Convertible Promissory Note Agreements [Member] | Embedded Derivative Financial Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_EquityValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Valuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_EquityValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=HILS_OriginalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=HILS_OriginalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=HILS_ExchangeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=HILS_ExchangeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=HILS_FiveNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=HILS_FiveNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=HILS_SeptemberExchangeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=HILS_SeptemberExchangeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=HILS_RolledOverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=HILS_RolledOverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HILS_ConvertiblePromissoryNoteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HILS_ConvertiblePromissoryNoteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905403918264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate', window );">[custom:EquityFinancingRangeValuationAssumedExpectedInterestRate-0]</a></td>
<td class="nump">0.050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityFinancingRangeValuationAssumedPercentage', window );">[custom:EquityFinancingRangeValuationAssumedPercentage-0]</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityFinancingRangeValuationAssumedDiscountRate', window );">[custom:EquityFinancingRangeValuationAssumedDiscountRate-0]</a></td>
<td class="nump">0.0886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityFinancingRangeValuationAssumedExpectedTerm', window );">[custom:EquityFinancingRangeValuationAssumedExpectedTerm-0]</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityFinancingRangeValuationAssumedPercentage', window );">[custom:EquityFinancingRangeValuationAssumedPercentage-0]</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityFinancingRangeValuationAssumedDiscountRate', window );">[custom:EquityFinancingRangeValuationAssumedDiscountRate-0]</a></td>
<td class="nump">0.1113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_EquityFinancingRangeValuationAssumedExpectedTerm', window );">[custom:EquityFinancingRangeValuationAssumedExpectedTerm-0]</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_EquityFinancingRangeValuationAssumedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_EquityFinancingRangeValuationAssumedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected coupon interest rate on notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_EquityFinancingRangeValuationAssumedExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term to exit event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_EquityFinancingRangeValuationAssumedExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_EquityFinancingRangeValuationAssumedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed ranges pre-money valuation at time of next equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_EquityFinancingRangeValuationAssumedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905403879624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DisclosureRedemptionLiabilityAbstract', window );"><strong>Redemption Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,325,288<span></span>
</td>
<td class="nump">$ 126,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue', window );">Initial embedded redemption value</a></td>
<td class="nump">1,487,596<span></span>
</td>
<td class="nump">836,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue', window );">Change in fair value</a></td>
<td class="num">(1,832,651)<span></span>
</td>
<td class="nump">362,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 980,233<span></span>
</td>
<td class="nump">$ 1,325,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DisclosureRedemptionLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DisclosureRedemptionLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliations recurring basis liability change in fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliations recurring basis liability initial embedded redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905410259336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEMPTION LIABILITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DisclosureRedemptionLiabilityAbstract', window );"><strong>Redemption Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_GainOnRedemptionValue', window );">Gain on redemption value</a></td>
<td class="nump">$ 1,832,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_LossOnRedemptionValue', window );">Loss on redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DisclosureRedemptionLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DisclosureRedemptionLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_GainOnRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_GainOnRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_LossOnRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_LossOnRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905407252488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares underlying option, Beginning outstanding</a></td>
<td class="nump">675,731<span></span>
</td>
<td class="nump">475,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weigthed average exercise price, Beginning outstanding</a></td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 3.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1]</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares underlying options, granted</a></td>
<td class="nump">227,737<span></span>
</td>
<td class="nump">200,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weigthed average exercise price, granted</a></td>
<td class="nump">$ 7.76<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares underlying options, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weigthed average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares underlying options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weigthed average exercise price, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares underlyling options, Ending outstanding</a></td>
<td class="nump">903,468<span></span>
</td>
<td class="nump">675,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weigthed average exercise price, Ending outstanding</a></td>
<td class="nump">$ 4.27<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares underlyling options, exercisable</a></td>
<td class="nump">580,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weigthed average exercise price, exercisable</a></td>
<td class="nump">$ 5.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares underlying options, Vested and expected to vest</a></td>
<td class="nump">658,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905402464504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF EXERCISE PRICE RANGE (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">903,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">580,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">275,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">33,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">78,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">78,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 2.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">107,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">65,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 3.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">73,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">73,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">48,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">19,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 7.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">18,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">18,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 7.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">208,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">204,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceEightMember', window );">Exercise Price Eigjht [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0] | $ / shares</a></td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Options</a></td>
<td class="nump">92,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Options</a></td>
<td class="nump">87,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HILS_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905407444392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">111.30%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Estimated fair value of common stock</a></td>
<td class="nump">$ 7.03<span></span>
</td>
<td class="nump">$ 2.455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905402089336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,737<span></span>
</td>
<td class="nump">200,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,468<span></span>
</td>
<td class="nump">675,731<span></span>
</td>
<td class="nump">475,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.27<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 3.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.48<span></span>
</td>
<td class="nump">1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.47<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,239,000<span></span>
</td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.76<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price of such stock options
from $0.18 or $2.598 to $0.314 or $3.817 per share, respectively.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,204<span></span>
</td>
<td class="nump">231,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 0.079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531,000<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,000<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=HILS_TwentySeventeenStockIncentivePlanMember', window );">2017 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=HILS_TwentyNineteenStockIncentivePlanMember', window );">2019 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,420,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_IncreaseInSharesReservedForIssuance', window );">[custom:IncreaseInSharesReservedForIssuance]</a></td>
<td class="nump">467,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_IncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_IncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=HILS_TwentySeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=HILS_TwentySeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=HILS_TwentyNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=HILS_TwentyNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905408279704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">75,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905408342600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY&#8217;S DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforward</a></td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="nump">$ 424,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">238,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts', window );">Capitalized costs</a></td>
<td class="nump">394,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_AcquiredInprocessResearchAndDevelopment', window );">Acquired In-process research and development</a></td>
<td class="nump">178,000<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">336,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther', window );">Accrued expenses and other</a></td>
<td class="num">(66,000)<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">1,827,000<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,827,000)<span></span>
</td>
<td class="num">(1,175,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset, net of valuation allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_AcquiredInprocessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_AcquiredInprocessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905408341528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at the federal statutory rate</a></td>
<td class="num">$ (463,000)<span></span>
</td>
<td class="num">$ (508,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_IncomeTaxReconciliationPermanentDifferencesAndOther', window );">Permanent differences and other</a></td>
<td class="num">(61,000)<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">(118,000)<span></span>
</td>
<td class="num">(167,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="num">(31,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation allowance</a></td>
<td class="nump">652,000<span></span>
</td>
<td class="nump">589,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_IncomeTaxReconciliationPermanentDifferencesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Permanent differences and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_IncomeTaxReconciliationPermanentDifferencesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905407408696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 652,000<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating Loss Carryforwards, Valuation Allowance</a></td>
<td class="nump">1,827,000<span></span>
</td>
<td class="nump">$ 1,175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905402614440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to Related Parties, Current</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DueToFounderConvertedToNotePayable', window );">Due to founder converted to note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">55,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HILS_FounderAndChiefExecutiveOfficerMember', window );">Founder and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to Related Parties, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_DueToFounderConvertedToNotePayable', window );">Due to founder converted to note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_DueToFounderConvertedToNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to founder converted to note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_DueToFounderConvertedToNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HILS_FounderAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HILS_FounderAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905403186072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,737<span></span>
</td>
<td class="nump">200,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HILS_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_AssetAcquisitionDescription', window );">[custom:AssetAcquisitionDescription]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
Company acquired a series of small molecule analogues pursuant to an asset purchase agreement (&#8220;APA&#8221;). Pursuant to the APA,
the Company is required to make a payment of $50,000 upon raising of at least $2 million in funding, and up to $1.75 million based
upon successfully meeting clinical and sales milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to Acquire Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_MilestonePayment', window );">[custom:MilestonePayment]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HILS_EmployeeAgreementMember', window );">Employee Agreement [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued Salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued Employee Benefits, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HILS_EmployeeAgreementMember', window );">Employee Agreement [Member] | Chief Executive Officer [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HILS_EmployeeAgreementMember', window );">Employee Agreement [Member] | Chief Executive Officer [Member] | Minimum [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HILS_RestatedEmploymentAgreementMember', window );">Restated Employment Agreement [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Fees</a></td>
<td class="nump">$ 485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_CashBonusReceived', window );">[custom:CashBonusReceived]</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Other Commitments, Description</a></td>
<td class="text">(i)
$250 million, the Chief Executive Officer shall receive a cash payment of $150,000; (ii) $500 million, the Chief Executive Officer shall
receive a cash payment of $350,000; and (iii) $1 billion, the Chief Executive Officer shall receive a cash payment of $750,000. Furthermore,
on or as soon as reasonably practicable following the date of the consummation the Company&#8217;s initial public offering of its securities,
the Chief Executive Officer shall be granted<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</a></td>
<td class="nump">757,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_AssetAcquisitionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_AssetAcquisitionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_CashBonusReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash bonus received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_CashBonusReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HILS_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HILS_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HILS_EmployeeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HILS_EmployeeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HILS_RestatedEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HILS_RestatedEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139905402769192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2022</div></th>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Jan. 06, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,468<span></span>
</td>
<td class="nump">675,731<span></span>
</td>
<td class="nump">475,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,737<span></span>
</td>
<td class="nump">200,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Employee Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Board of Directors and Scientific Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">247,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Promissory Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Unsecured Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HILS_GrossProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,225,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HILS_GrossProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HILS_GrossProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HILS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HILS_EmployeeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HILS_EmployeeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=HILS_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=HILS_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=HILS_UnsecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=HILS_UnsecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:HILS="http://hillstreambio.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hils-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-14</instant>
        </period>
    </context>
    <context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="From2021-09-152021-09-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <startDate>2021-09-15</startDate>
            <endDate>2021-09-16</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">HILS:FarringtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="From2020-11-112020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">HILS:FarringtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-11</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="AsOf2017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="From2017-05-012017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-30_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:ConvertiblePromissoryNoteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="From2020-09-042020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-04</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:OriginalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_SeptemberExchangeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:FiveNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:SeptemberExchangeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_ExchangeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:FiveNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">HILS:ExchangeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="From2020-10-012021-12-31_custom_RolledOverMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RolledOverMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_RolledOverMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_RolledOverInToNewNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverInToNewNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_RolledOverInToNewNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:RolledOverInToNewNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentySeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwentySeventeenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentySeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TwentySeventeenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentySeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-07-31_custom_TwentyNineteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="AsOf2019-08-30_custom_TwentyNineteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_TwentyNineteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="From2021-05-302021-05-31_custom_TwentyNineteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-30</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwentyNineteenStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HILS:TwentyNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-03-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HILS:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_FounderAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HILS:FounderAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-292019-12-30_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-29</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:RestatedEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-30</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">HILS:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-06</instant>
        </period>
    </context>
    <context id="From2022-01-032022-01-06_us-gaap_SubsequentEventMember_custom_PromissoryNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">HILS:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-06</endDate>
        </period>
    </context>
    <context id="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HILS:EmployeeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-14</instant>
        </period>
    </context>
    <context id="From2022-03-202022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HILS:BoardOfDirectorsAndScientificAdvisoryBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-20</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HILS:BoardOfDirectorsAndScientificAdvisoryBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-12-31">0001861657</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-12-31">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0061"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0103"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0108"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <HILS:AcquiredInprocessResearchAndDevelopment1
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0138"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0191"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0193"
      unitRef="USD"
      xsi:nil="true"/>
    <HILS:DeemedDividendUponDebtExchange
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <HILS:DeemedDividendUponDebtExchange
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <HILS:RepaymentsOfDeferredOfferingCosts
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <HILS:DeemedDividend
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <HILS:DueToFounderConvertedToNotePayable
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <HILS:UnpaidDeferredOfferingCosts
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0468"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0470"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0472"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0474"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0485"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0487"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0489"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0491"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0559"
      unitRef="Percent"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0560"
      unitRef="Percent"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2021-01-01to2021-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-12-31">001-41210</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-12-31">HILLSTREAM BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-12-31">84-2642541</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-12-31">1200     Route 22 East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-12-31">Suite     2000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-12-31">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-12-31">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-12-31">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-12-31">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-12-31">955-3140</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-12-31">Common     stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-01to2021-12-31">HILS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-01to2021-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-01-01to2021-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-01-01to2021-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-12-31">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-01-01to2021-12-31">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2021-01-01to2021-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-03-21" decimals="INF" unitRef="Shares">11364444</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2021-01-01to2021-12-31">None.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2021-01-01to2021-12-31">199</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2021-01-01to2021-12-31">Mayer Hoffman McCann P.C</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2021-01-01to2021-12-31">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4356</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">191852</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">70670</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">102946</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DeferredOfferingCosts contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">546651</us-gaap:DeferredOfferingCosts>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">621677</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">294798</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">621677</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">294798</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1463059</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">514828</us-gaap:AccountsPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">179621</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">73066</us-gaap:InterestPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">200000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">200000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">318223</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">48777</us-gaap:AccruedLiabilitiesCurrent>
    <HILS:RedemptionLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">980233</HILS:RedemptionLiability>
    <HILS:RedemptionLiability contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1325288</HILS:RedemptionLiability>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1392544</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">563425</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4533680</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2725384</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">772899</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1286942</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5306579</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4012326</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">6357314</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">636</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">636</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2225712</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">986443</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-6911250</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-4704607</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-4684902</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-3717528</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">621677</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">294798</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1842803</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">847272</us-gaap:ResearchAndDevelopmentExpense>
    <HILS:AcquiredInprocessResearchAndDevelopment1
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">289200</HILS:AcquiredInprocessResearchAndDevelopment1>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1365214</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">671879</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">3208017</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1808351</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-3208017</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-1808351</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">831277</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">246534</us-gaap:InterestExpense>
    <HILS:GainLossInRedemptionValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1832651</HILS:GainLossInRedemptionValue>
    <HILS:GainLossInRedemptionValue
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-362486</HILS:GainLossInRedemptionValue>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1001374</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-609020</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-2206643</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-2417371</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">6357314</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">6347144</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6281557</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">628</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">462671</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2085499</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-1622200</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75757</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">289192</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">289200</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">234580</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">234580</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <HILS:DeemedDividendUponDebtExchange
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-201737</HILS:DeemedDividendUponDebtExchange>
    <HILS:DeemedDividendUponDebtExchange
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-201737</HILS:DeemedDividendUponDebtExchange>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2417371</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-2417371</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6357314</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">986443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4704607</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-3717528</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1239269</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1239269</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2206643</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-2206643</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6357314</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2225712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6911250</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-4684902</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-2206643</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-2417371</us-gaap:NetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">289200</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">666566</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">145356</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1239269</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">234580</us-gaap:ShareBasedCompensation>
    <HILS:GainLossInRedemptionValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1832651</HILS:GainLossInRedemptionValue>
    <HILS:GainLossInRedemptionValue
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-362486</HILS:GainLossInRedemptionValue>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-32276</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">100346</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">850293</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">306570</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-164646</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-101093</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-1086244</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-1078432</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1078015</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1232003</us-gaap:ProceedsFromConvertibleDebt>
    <HILS:RepaymentsOfDeferredOfferingCosts
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">179267</HILS:RepaymentsOfDeferredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">898748</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">1232003</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-187496</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">153571</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">191852</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">38281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4356</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">191852</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockIssued1
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">289200</us-gaap:StockIssued1>
    <HILS:DeemedDividend
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">201737</HILS:DeemedDividend>
    <HILS:AccruedInterestRolloverToNewNotesPayable
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">58091</HILS:AccruedInterestRolloverToNewNotesPayable>
    <HILS:AccruedInterestRolloverToNewNotesPayable
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">89456</HILS:AccruedInterestRolloverToNewNotesPayable>
    <HILS:DueToFounderConvertedToNotePayable
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">55068</HILS:DueToFounderConvertedToNotePayable>
    <HILS:UnpaidDeferredOfferingCosts
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">367384</HILS:UnpaidDeferredOfferingCosts>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_802_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zEGU3gAJK5s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span id="f_006"/&gt;Note
1 - Description of Business and Liquidity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_82A_zvJ8MCpmCayb" style="display: none"&gt;DESCRIPTION
OF BUSINESS AND LIQUIDITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hillstream
BioPharma, Inc. (&#x201c;HBI&#x201d;) was incorporated on March 28, 2017, as a Delaware C-corporation. At December 31, 2021, Hillstream
BioPharma, Inc. had two wholly-owned subsidiaries: HB Pharma Corp. (&#x201c;HB&#x201d;) and Farrington Therapeutics LLC (&#x201c;Farrington&#x201d;
and together with HBI and HB, the &#x201c;Company&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a pre-clinical biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death (&#x201c;IMCD&#x201d;) for treatment resistant cancers. The Company&#x2019;s most advanced
product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to reduce
tumor burden in a clinical pilot study in Germany in treatment resistant cancers, including triple negative breast cancer and epithelial
carcinomas. The Company&#x2019;s goal is to file an investigational new drug application (&#x201c;IND&#x201d;) with the U.S. Food
and Drug Administration (&#x201c;FDA&#x201d;) in 2023 and start a clinical study with HSB-1216 in 2023; however, no assurance can
be provided that the Company&#x2019;s IND will be accepted by the FDA in 2023, if at all. If the IND is accepted by the FDA, the HSB-1216
clinical study will focus on expanding upon the clinical pilot study conducted in Germany. If the Company is able to start the clinical
study with HSB-1216 in 2023, the Company anticipates that initial data from such trial will be released either at the end of 2023 or
early 2024. The Company uses Quatramer&#x2122;, the proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor
microenvironment with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence, the
Company&#x2019;s artificial intelligence precision medicine platform, is used to identify biomarkers in its clinical programs to target
specific patient segments. The discovery of regulated cell death processes, such as apoptosis and autophagy, has enabled novel target
discovery for drug development. Ferroptosis, a form of IMCD, is an emerging regulated cell death process which decreases intracellular
iron or the Labile Iron Pool (&#x201c;LIP&#x201d;). Cancer cells increase the LIP leading to unregulated cell growth and metabolism. Decreasing
the LIP, induces iron-led reactive oxygen species production and lipid peroxidation, two key hallmarks of ferroptosis/IMCD. HSB-1216
binds iron in the cytoplasm of cancer cells and decreases the LIP, thereby inducing ferroptosis/IMCD, leading to regulated cell death.
Areas of interest for the development of HSB-1216 are as a treatment of solid tumors, including triple negative breast cancer,
uveal melanoma, glioblastoma multiforme, head and neck squamous cell carcinoma and other treatment resistant cancers with high unmet
need.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity
&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the year ended December
31, 2021, the Company incurred operating losses in the amount of approximately $&lt;span id="xdx_903_eus-gaap--OperatingIncomeLoss_iN_pn5n6_di_c20210101__20211231_zHE3QPfeJhJ4"&gt;3.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and had an accumulated deficit
of approximately $&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20211231_zAfcas2gEaWc"&gt;6.9&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million at December 31, 2021. The Company financed its working
capital requirements through December 31, 2021 primarily through the issuance of convertible promissory notes payable issued to
related parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 14, 2022, the Company closed its initial public offering (&#x201c;IPO&#x201d;) of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpMtUEkKb1zh"&gt;3,750,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock at
a public offering price of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVc9VEbAwPY2"&gt;4.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The gross proceeds to the Company
from the IPO were $&lt;span id="xdx_90C_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5aCE4PKBKWc"&gt;15.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, prior to deducting underwriting discounts,
commissions, and other offering expenses. The net proceeds to the Company from the IPO were approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zax5aKIRq9ji"&gt;13.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. The Company granted the underwriters
a 45-day option to purchase up to an additional &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z8MHlNI5u2Ki"&gt;562,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock at the public offering
price less discounts and commissions, to cover over-allotments; however, this option expired unexercised. Additionally, and as
a result of the completion of the IPO, all of the related party convertible debt and accrued interest was converted into an aggregate
of &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzkBBQU2tMU2"&gt;1,225,384
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
pursuant to the terms of the convertible notes. The shares of the Company&#x2019;s common stock began trading on The Nasdaq
Capital Market on January 12, 2022 under the ticker symbol &#x201c;HILS&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company believes its cash on hand after the completion of the IPO is sufficient to meet its operating obligations and capital
requirements for at least twelve months from the issuance of these financial statements. Thereafter, the Company may need to raise further
capital through the sale of additional equity or debt securities or other debt instruments to support its future operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
risks and uncertainties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
can be no assurance that the Company&#x2019;s products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all. The Company is subject to risks common to biopharmaceutical companies including,
but not limited to, the development of new technological innovations, dependence on key personnel, protection of proprietary technology,
compliance with government regulations, product liability, uncertainty of market acceptance of products and the need to obtain additional
financing. The Company is dependent on third party suppliers. The Company&#x2019;s products require approval or clearance from the FDA
prior to commencing commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions in which
the Company may license or sell its products. There can be no assurance that the Company&#x2019;s products will receive all of the required
approvals or clearances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;COVID-19&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, a novel strain of coronavirus (&#x201c;COVID-19&#x201d;) was reported globally. The World Health Organization declared COVID-19
to constitute a &#x201c;Public Health Emergency of International Concern&#x201d; on January 30, 2020 and a global pandemic on March 11,
2020. In March 2020, individual states mandated &#x201c;stay at home orders&#x201d;, restricted access to hospitals, prohibited elective
surgeries and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on the Company&#x2019;s
operational and financial performance will depend on future developments, including access to products, potential disruptions
in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity of the COVID-19
outbreak. As of December 31, 2021, the Company&#x2019;s operations have not been materially affected by COVID-19.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-5"
      unitRef="USD">-3200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">-6900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">3750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:SharesIssuedPricePerShare>
    <HILS:GrossProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">15000000.0</HILS:GrossProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">13000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">562500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1225384</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1LUHJ2g9Q65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
2 - Basis of Presentation and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_821_zpdq6neefWQj" style="display: none"&gt;BASIS
OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaxim83qcPgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_86A_zYYLtqYOC5ba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (&#x201c;US GAAP&#x201d;). The Company operates in one segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--ReverseStockSplitPolicyTextBlock_zdbQhsP0ve13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_z5QFZvzSTBmh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reverse
stock split&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 16, 2021, the Company effectuated a reverse split of shares of its common stock at a ratio of &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20210915__20210916_zJAmx8oAjv6h"&gt;1-for-26.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;pursuant to an amendment
to the Company&#x2019;s Certificate of Incorporation, as amended, filed with the Delaware Secretary of State and approved by the
Company&#x2019;s board of directors and stockholders. The par value of the Company&#x2019;s common stock was not adjusted as a result
of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have
been retroactively adjusted to reflect this reverse split for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhqrq9UiGnlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86A_zITKkpzU2uZ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles
of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_z2G4rkEXcLD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zACQJuQS3ejk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases
its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often
may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls
within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense
recognition, valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments,
accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPeS4dNFE2uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_86E_z2bSal0T2Qsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_z70A0iT8PGI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_86F_zub6YjCkQKRh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrolment in clinical trials, administrative costs incurred by third parties, and other indicators of the services
completed. Substantially all of the prepaid expenses at December 31, 2021 relate to a manufacturing services agreement. Substantially
all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical ingredient.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--InProcessResearchAndDevelopmentPolicy_zfBmMRtzJU86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_868_zEnb1ySasfnd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquired
in-process research and development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards
Codification (&#x201c;ASC&#x201d;) 730-10-25-1, &lt;i&gt;Research and Development,&lt;/i&gt; the up-front acquisition or licensing payments are
expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and,
absent obtaining such approval, has no alternative future use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zicSb1T6sC35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_867_zVPVwjd2G2C5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
based compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as
an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock-based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date of grant
using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line
basis over the requisite service period of the awards, which is generally the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. At December
31, 2021, the Company was a private company and lacked company-specific historical and implied volatility information.
Therefore, it estimated its expected stock volatility based on the historical data regarding the volatility of a publicly traded
set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate
was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately
equal to the expected term of the award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--CommonStockValuationsPolicyTextBlock_z4EclXTDGCn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_zyIZ2zQWvntb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
stock valuations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock-based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&#x2019;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&#x2019;s common stock, the Company&#x2019;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&#x2019;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_zW47rGNvvRvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_869_zGTrVFJYXOgk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Debt
discount and derivative instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2015-03, &lt;i&gt;Interest
&#x2014; Imputation of Interest&lt;/i&gt;, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for derivative instruments in accordance with ASC 815, &lt;i&gt;Derivative and Hedging&lt;/i&gt;, which establishes accounting and
reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts
and requires recognition of all derivatives on the balance sheet at fair value. The Company&#x2019;s derivative financial instrument consists
of an embedded feature contained in the Company&#x2019;s convertible debt that is bifurcated and accounted for separately. See Note 4
for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkhgGoSNxgXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_863_zH0qyYncS6Xl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
value measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies ASC 820, &lt;i&gt;Fair Value Measurement &lt;/i&gt;(&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data
and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the Company&#x2019;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term
maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value. See Note 5.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input
that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.6in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
    and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable
    inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms,
    as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no
    market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--DeferredChargesPolicyTextBlock_zVNOQhg82IL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zkAnzY8Z7pva" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Deferred
Offering Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs consisted of legal, accounting, printing, and filing fees that the Company capitalized which will be offset against the
proceeds from the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_ziGgCs4wbED4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_867_zUI0tZjl0Ku7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance has been recognized for all periods since it is &#x201c;more
likely than not&#x201d; that some portion or all of the deferred tax assets will not be realized in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. At December 31, 2021 and 2020, the Company had no unrecognized uncertain income tax positions,
and therefore no amounts have been recognized in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zkqfmNdYCvR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_866_zEPkQOkIFLN1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
loss per share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reports loss per share in accordance with ASC 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which provides for calculation of basic and
diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to
common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities not included in the computation of earnings (loss) per share for the years ended December 31, 2021 and 2020 included
options to purchase &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zRF9Ba03TFdb"&gt;903,468
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zM288QWeU1M6"&gt;675,731
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, respectively. The number
of shares issuable upon the conversion of convertible debt and accrued interest (which was &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH1qaVehsYQh"&gt;1,225,384
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares at the IPO date of January 14, 2022) is
not included in the denominator since their inclusion would be anti-dilutive. All common share amounts and per share amounts have been
adjusted to reflect a &lt;span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20210101__20211231_zoB5kqzxwndd"&gt;1-for-26.4&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reverse stock split of the Company&#x2019;s common stock effectuated
on September 16, 2021. Management concluded that the deemed dividend (see Note 4) is analogous to a return on equity classified
preference shares, therefore the deemed dividend is added to the net loss for purposes of the basic and diluted loss per share calculation.
Accordingly, the numerator of the loss per share calculation (basic and diluted) is $&lt;span id="xdx_90A_ecustom--BacisAndDilutedLoss_c20200101__20201231_zbqgZvCLl9Nb"&gt;2,619,108
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyKFsLikxSNc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_869_zRakjnhEqyf9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;New
accounting pronouncements not yet adopted:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated all recent accounting pronouncements and believes that none of them will have a material effect on the Company&#x2019;s
financial position, results of operations or cash flows except as discussed below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the FASB issued ASU No. 2016-02, &#x201c;&lt;i&gt;Leases (Topic 842)&lt;/i&gt;&#x201d; which replaces the existing guidance in ASC 840
- &lt;i&gt;Leases&lt;/i&gt;. This ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases
or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding
lease liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset and for operating
leases, the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December
15, 2021 and for interim periods within those fiscal years. The Company will evaluate the impact of adoption of this ASU when it enters
into a lease arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Debt
with Conversion and Other Options and Derivatives and Hedging&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB recently issued ASU 2020-06, &lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity&lt;/i&gt;, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&#x2019;s own stock and classified in stockholders&#x2019; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, to require entities to calculate diluted
earnings per share (&#x201c;EPS&#x201d;) for convertible instruments by using the if-converted method. In addition, entities must
presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments
in ASU 2020-06 are effective for public entities that meet the definition of an SEC filer, excluding smaller reporting companies as defined
by the Securities and Exchange Commission (&#x201c;SEC&#x201d;), for fiscal years beginning after December 15, 2021. For all other
entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact this standard will have on its financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
Per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share&lt;/i&gt; (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50),
&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt; (Topic 718), and &lt;i&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity&lt;/i&gt; (Subtopic
815-40). The new ASU addresses issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written
call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods
within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this standard will have
on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recent
accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants,
and the SEC did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated
financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Codification
Improvements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the FASB issued ASU 2020-10, &lt;i&gt;Codification Improvements&lt;/i&gt;. The guidance contains improvements to the Codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may
affect the application of the guidance in cases in which the original guidance may have been unclear. This is effective for the Company
for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022.
Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_857_zlwPG8Ljltr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaxim83qcPgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_86A_zYYLtqYOC5ba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (&#x201c;US GAAP&#x201d;). The Company operates in one segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <HILS:ReverseStockSplitPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_846_ecustom--ReverseStockSplitPolicyTextBlock_zdbQhsP0ve13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_z5QFZvzSTBmh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reverse
stock split&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 16, 2021, the Company effectuated a reverse split of shares of its common stock at a ratio of &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20210915__20210916_zJAmx8oAjv6h"&gt;1-for-26.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;pursuant to an amendment
to the Company&#x2019;s Certificate of Incorporation, as amended, filed with the Delaware Secretary of State and approved by the
Company&#x2019;s board of directors and stockholders. The par value of the Company&#x2019;s common stock was not adjusted as a result
of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have
been retroactively adjusted to reflect this reverse split for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HILS:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2021-09-152021-09-16">1-for-26.4</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zhqrq9UiGnlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86A_zITKkpzU2uZ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles
of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Hillstream BioPharma, Inc. and its wholly-owned subsidiaries, HB Pharma Corp.,
Nanoproteagen and Farrington. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_z2G4rkEXcLD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zACQJuQS3ejk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and related disclosures in the financial statements and accompanying notes. Management bases
its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often
may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls
within that range of reasonable estimates. Estimates are used in the following areas, among others: research and development expense
recognition, valuation of common shares and stock options, allowances of deferred tax assets, valuation of debt related instruments,
accrued expenses and liabilities, and cash flow assumptions regarding going concern considerations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPeS4dNFE2uc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_86E_z2bSal0T2Qsc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally
insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit
risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_z70A0iT8PGI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_86F_zub6YjCkQKRh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and
development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies
and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical
investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed
by third parties, patient enrolment in clinical trials, administrative costs incurred by third parties, and other indicators of the services
completed. Substantially all of the prepaid expenses at December 31, 2021 relate to a manufacturing services agreement. Substantially
all of the prepaid expenses at December 31, 2020 relate to the purchase of an active pharmaceutical ingredient.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_849_eus-gaap--InProcessResearchAndDevelopmentPolicy_zfBmMRtzJU86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_868_zEnb1ySasfnd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquired
in-process research and development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has acquired, and may in the future acquire, rights to develop and commercialize new product candidates and/or other in-process
research and development assets. In accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards
Codification (&#x201c;ASC&#x201d;) 730-10-25-1, &lt;i&gt;Research and Development,&lt;/i&gt; the up-front acquisition or licensing payments are
expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing, and,
absent obtaining such approval, has no alternative future use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zicSb1T6sC35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_867_zVPVwjd2G2C5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
based compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as
an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each
stock-based award. The fair value of each option grant to employees, non-employees and directors is estimated as of the date of grant
using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on a straight-line
basis over the requisite service period of the awards, which is generally the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. At December
31, 2021, the Company was a private company and lacked company-specific historical and implied volatility information.
Therefore, it estimated its expected stock volatility based on the historical data regarding the volatility of a publicly traded
set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate
was determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately
equal to the expected term of the award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <HILS:CommonStockValuationsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_842_ecustom--CommonStockValuationsPolicyTextBlock_z4EclXTDGCn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_zyIZ2zQWvntb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
stock valuations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was required to periodically estimate the fair value of common stock with the assistance of an independent third-party valuation
expert when issuing stock options and computing its estimated stock-based compensation expense and value of shares issued in acquiring
product candidates. The assumptions underlying these valuations represented management&#x2019;s best estimates, which involved inherent
uncertainties and the application of significant levels of management judgment. In order to determine the fair value, the Company considered,
among other things, contemporaneous valuations of the Company&#x2019;s common stock, the Company&#x2019;s business, financial condition
and results of operations, including related industry trends affecting its operations; the likelihood of achieving various liquidity
events; the lack of marketability of the Company&#x2019;s common stock; the market performance of comparable publicly traded companies;
and U.S. and global economic and capital market conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HILS:CommonStockValuationsPolicyTextBlock>
    <HILS:DebtDiscountAndDerivativeInstrumentsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84A_ecustom--DebtDiscountAndDerivativeInstrumentsPolicyTextBlock_zW47rGNvvRvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_869_zGTrVFJYXOgk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Debt
discount and derivative instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
initial fair value of the redemption feature relating to the convertible debt instruments is treated as a debt discount and amortized
over the term of the related debt using the straight-line method, which approximates the interest method. If a loan is paid in full,
any unamortized financing costs will be removed from the related accounts and charged to operations. Amortization of debt discount is
recorded as a component of interest expense. In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2015-03, &lt;i&gt;Interest
&#x2014; Imputation of Interest&lt;/i&gt;, the unamortized debt discount is presented in the accompanying balance sheet as a direct deduction
from the carrying amount of the related debt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for derivative instruments in accordance with ASC 815, &lt;i&gt;Derivative and Hedging&lt;/i&gt;, which establishes accounting and
reporting standards for derivative instruments, including certain derivative instruments embedded in other financial instruments or contracts
and requires recognition of all derivatives on the balance sheet at fair value. The Company&#x2019;s derivative financial instrument consists
of an embedded feature contained in the Company&#x2019;s convertible debt that is bifurcated and accounted for separately. See Note 4
for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HILS:DebtDiscountAndDerivativeInstrumentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zkhgGoSNxgXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_863_zH0qyYncS6Xl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
value measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies ASC 820, &lt;i&gt;Fair Value Measurement &lt;/i&gt;(&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data
and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the Company&#x2019;s prepaid expenses, accounts payable and accrued expenses approximate fair value because of the short-term
maturity of these financial instruments. The redemption feature of the debt instruments is recorded at fair value. See Note 5.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input
that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.6in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
    and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable
    inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms,
    as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no
    market data exists for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_844_eus-gaap--DeferredChargesPolicyTextBlock_zVNOQhg82IL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zkAnzY8Z7pva" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Deferred
Offering Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs consisted of legal, accounting, printing, and filing fees that the Company capitalized which will be offset against the
proceeds from the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.55in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_ziGgCs4wbED4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_867_zUI0tZjl0Ku7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset-and-liability method in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;).
Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance has been recognized for all periods since it is &#x201c;more
likely than not&#x201d; that some portion or all of the deferred tax assets will not be realized in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and
clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement.
The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical
merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold
are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the
taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that
the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties
related to tax positions in income tax expense. At December 31, 2021 and 2020, the Company had no unrecognized uncertain income tax positions,
and therefore no amounts have been recognized in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zkqfmNdYCvR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_866_zEPkQOkIFLN1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
loss per share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reports loss per share in accordance with ASC 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which provides for calculation of basic and
diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to
common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential
dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives
effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities not included in the computation of earnings (loss) per share for the years ended December 31, 2021 and 2020 included
options to purchase &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zRF9Ba03TFdb"&gt;903,468
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zM288QWeU1M6"&gt;675,731
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, respectively. The number
of shares issuable upon the conversion of convertible debt and accrued interest (which was &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH1qaVehsYQh"&gt;1,225,384
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares at the IPO date of January 14, 2022) is
not included in the denominator since their inclusion would be anti-dilutive. All common share amounts and per share amounts have been
adjusted to reflect a &lt;span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20210101__20211231_zoB5kqzxwndd"&gt;1-for-26.4&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reverse stock split of the Company&#x2019;s common stock effectuated
on September 16, 2021. Management concluded that the deemed dividend (see Note 4) is analogous to a return on equity classified
preference shares, therefore the deemed dividend is added to the net loss for purposes of the basic and diluted loss per share calculation.
Accordingly, the numerator of the loss per share calculation (basic and diluted) is $&lt;span id="xdx_90A_ecustom--BacisAndDilutedLoss_c20200101__20201231_zbqgZvCLl9Nb"&gt;2,619,108
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">903468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">675731</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1225384</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2021-01-01to2021-12-31">1-for-26.4</us-gaap:StockholdersEquityReverseStockSplit>
    <HILS:BacisAndDilutedLoss
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">2619108</HILS:BacisAndDilutedLoss>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyKFsLikxSNc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_869_zRakjnhEqyf9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;New
accounting pronouncements not yet adopted:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated all recent accounting pronouncements and believes that none of them will have a material effect on the Company&#x2019;s
financial position, results of operations or cash flows except as discussed below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the FASB issued ASU No. 2016-02, &#x201c;&lt;i&gt;Leases (Topic 842)&lt;/i&gt;&#x201d; which replaces the existing guidance in ASC 840
- &lt;i&gt;Leases&lt;/i&gt;. This ASU requires a dual approach for lessee accounting under which a lessee would account for leases as finance leases
or operating leases. Both finance leases and operating leases will result in the lessee recognizing a right-of-use asset and a corresponding
lease liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset and for operating
leases, the lessee would recognize a straight-line total lease expense. This ASU is effective for fiscal years beginning after December
15, 2021 and for interim periods within those fiscal years. The Company will evaluate the impact of adoption of this ASU when it enters
into a lease arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Debt
with Conversion and Other Options and Derivatives and Hedging&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
FASB recently issued ASU 2020-06, &lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging
&#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity&lt;/i&gt;, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.
The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the
existing guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately
from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded
conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments
revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer&#x2019;s own stock and classified in stockholders&#x2019; equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification
(and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract.
The amendments in ASU 2020-06 further revise the guidance in ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, to require entities to calculate diluted
earnings per share (&#x201c;EPS&#x201d;) for convertible instruments by using the if-converted method. In addition, entities must
presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments
in ASU 2020-06 are effective for public entities that meet the definition of an SEC filer, excluding smaller reporting companies as defined
by the Securities and Exchange Commission (&#x201c;SEC&#x201d;), for fiscal years beginning after December 15, 2021. For all other
entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact this standard will have on its financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
Per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share&lt;/i&gt; (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50),
&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt; (Topic 718), and &lt;i&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity&lt;/i&gt; (Subtopic
815-40). The new ASU addresses issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written
call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods
within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this standard will have
on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recent
accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants,
and the SEC did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated
financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Codification
Improvements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the FASB issued ASU 2020-10, &lt;i&gt;Codification Improvements&lt;/i&gt;. The guidance contains improvements to the Codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may
affect the application of the guidance in cases in which the original guidance may have been unclear. This is effective for the Company
for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022.
Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_806_eus-gaap--BusinessCombinationDisclosureTextBlock_zSgZywnvnSD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
3 - Acquisition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_82F_zeSUe7Cgl4H8" style="display: none"&gt;ACQUISITION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Farrington&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2020, the Company acquired &lt;span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPercent_c20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zJPlY9Bk1Ml6"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the member interests of Farrington, an early-stage biotech company which owned a next generation anthracycline, HSB-888, for pediatric
osteosarcoma. Pursuant to an Exchange Agreement, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zbDM9mDh0p3i"&gt;75,757
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of its common stock to the seller as consideration
for the purchase. The transaction did not meet the definition of a business combination for financial reporting purposes, since there
were no business inputs, employees acquired, processes or outputs at the time of the transaction. The fair value of the common stock
issued was estimated to be approximately $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--FarringtonMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zB791mlu5Nx5"&gt;289,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
for which the single asset was recognized as a component of acquired in-process research and development expense in the accompanying
consolidated statements of operations in the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember"
      decimals="INF"
      unitRef="Percent">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-11-112020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember"
      decimals="INF"
      unitRef="Shares">75757</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-11-112020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember"
      decimals="0"
      unitRef="USD">289200</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zumNHdMuS9N5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
4 - Convertible Notes - Related Parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_826_zNgpaS2ON2Hi" style="display: none"&gt;CONVERTIBLE
NOTES - RELATED PARTIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
in May 2017, the Company entered into Subordinated Convertible Promissory Note Agreements (the &#x201c;Agreements&#x201d;) with certain
lenders (together, the &#x201c;Holders&#x201d; or individually, the &#x201c;Holder&#x201d;), pursuant to which the Company issued Subordinated
Convertible Promissory Notes (individually the &#x201c;Note&#x201d; or together the &#x201c;Notes&#x201d;) to the Holders, principally all
to the Chief Executive Officer and founder of the Company, a member of the Company&#x2019;s board of directors and third parties
that are family members of the founder and Chief Executive Officer. See Note 9. Interest on the unpaid principal balance accrues
at a rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170531__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zLropNQfLpwk"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
per annum, computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier converted into shares of
the Company&#x2019;s common stock or preferred stock (collectively, the &#x201c;Equity Securities&#x201d;), the principal and accrued interest
shall be due and payable by the Company on demand by the Holders at any time after the earlier of (i) the Maturity Date (as defined in
each Agreement) and (ii) the closing of the Next Equity Financing. &#x201c;Next Equity Financing&#x201d; means the next sale, or series
of related sales, by the Company of its Equity Securities pursuant to which the Company receives gross proceeds of not less than $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20170501__20170531__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zNkSPDb9IFMk"&gt;5,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for Notes issued in 2017 and through November
2020 and $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zLaab7jIVNr"&gt;7,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for Notes issued after November 2020 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of the Notes).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
general, the stated maturity date was &lt;span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dt_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z7NCGaRLzSR4"&gt;two
years&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the date of issuance, except for the
Notes entered into in December 2020 and thereafter (in the aggregate principal amount of approximately $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z0UoWoLLU6U"&gt;2,135,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
which have a stated maturity date of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentTerm_dt_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zYpUPkOymGE5"&gt;three
years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. For Notes entered into in 2017 and through
September 2018, the default interest rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20180930__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zIpxiKJNHlt"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
was added to the Notes for the period after the maturity date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notes will automatically convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares
of such Equity Securities to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued
interest due on the Note on the date of conversion by the lesser of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zPOgadkdTc3c"&gt;(i)
80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing, or (ii) an equity valuation of $&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_902_ecustom--EquityValuation_iI_pn5n6_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zeyosqxahYW1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
($&lt;/span&gt;&lt;span id="xdx_902_eus-gaap--NotesIssued1_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z95xpPSaqbR6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
for Notes issued after December 2020). No Next Equity Financing occurred through December 31, 2021; however on January 14, 2022,
all outstanding Notes and accrued interest were converted into an aggregate of&lt;/span&gt; &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z11WHJpLbiyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,225,384
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of the Company&#x2019;s common stock as the IPO qualified as a Next Equity Financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
embedded features contained in the Notes in the aggregate are embedded derivative instruments, which were recorded as a debt discount
and derivative liability at the issuance date at their estimated fair value for all Notes of approximately $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--EmbeddedDerivativeFinancialInstrumentsMember_z6nbJV5mmbq9"&gt;2,421,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Accretion of debt discount for the Notes was recorded as interest expense was approximately $&lt;span id="xdx_903_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z4dAd4PICqQi"&gt;667,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90E_eus-gaap--InterestExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z2MtfWj2qgKc"&gt;145,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2021 and 2020,
respectively. Accrued interest expense associated with the Notes at December 31, 2021 and December 31, 2020 amounted to approximately
$&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zl4OWRkgkv4"&gt;180,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zPWDaLIQNP02"&gt;73,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively. Interest expense, including accretion of the debt discount, amounted to approximately $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_z2Sa7i29FlD2"&gt;831,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--TypeOfArrangementAxis__custom--ConvertiblePromissoryNoteAgreementsMember_zrmZVskUqdZ3"&gt;246,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2021 and 2020,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ConvertibleDebtTableTextBlock_zurV691P91ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021 and 2020, all convertible debt instruments which had matured had been rolled over into new notes as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zXcf6N7RCUMb" style="display: none"&gt;SCHEDULE
OF CONVERTIBLE DEBT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_z286mMqTQbj4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_zmIoqgHKUgN6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_maCDzeeB_zAobAk9K9ev8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Principal
    amount outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,734,446&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,598,340&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msCDzeeB_z49Nrl1plWXk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,569,003&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(747,973&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebt_iTI_mtCDzeeB_zGsjpo7otGx1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,165,443&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,850,367&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConvertibleDebtCurrent_iI_maCDzsmY_zicQ6vqPjBic" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,392,544&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;563,425&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebtNoncurrent_iI_maCDzsmY_z5eyShgNnHy" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Long
    term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;772,899&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,286,942&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConvertibleDebt_iTI_mtCDzsmY_z16a0vJ40mx7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,165,443&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,850,367&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zY5ZG7HoiNdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exchange
notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 27, 2020, the Company agreed to issue a related party Note holder notes (&#x201c;Exchange Notes&#x201d;) in exchange for seven
Notes payable which were in default (&#x201c;Original Notes&#x201d;) at such time by more than 90 days. The Original Notes had a principal
amount of approximately $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20191231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zhjmMXyNbpq7"&gt;265,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and accrued interest of $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_c20191231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zlQMeQZTlPk5"&gt;37,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at December 31, 2019. As of September 27, 2020,
the aggregate outstanding principal was approximately $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z6hWQLp8UqB3"&gt;265,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and accrued interest, which included the default
interest rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z9KJBOGxNsS9"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
as described above, was approximately $&lt;span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zAYIBY4qCiFh"&gt;71,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Exchange Notes took the then principal and accrued interest of the Original Notes and added an original issue discount of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zYIHavmEi658"&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
to determine the new principal amount which amounted to an aggregate of $&lt;span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20200904__20200927__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zMRj7YoMyZQ3"&gt;537,968&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Company accounted for this transaction as a debt extinguishment, and the incremental amount of the principal of the Exchange Notes
payable of $&lt;span id="xdx_90C_eus-gaap--NotesPayable_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--OriginalNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_z9jJbVyvv0v9"&gt;201,737
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;was recorded to accumulated deficit (analogous
to a &#x201c;deemed dividend&#x201d;) in the year ended December 31, 2020, since the Exchange Notes are with related parties, and included
in the calculation of loss per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 27, 2020, the Company issued certain related party Noteholders notes (&#x201c;September Exchange Notes&#x201d;) in exchange for
five Notes payable, which were in default. As of such date, the aggregate outstanding principal and interest was approximately $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--SeptemberExchangeNotesMember_zB017qMiFkZh"&gt;26,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which included the default interest rate of &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--ExchangeNotesMember_zThhoTkCjgP2"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
as described above. The September Exchange Notes in the aggregate principal amount of approximately $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20200927__us-gaap--DebtInstrumentAxis__custom--FiveNotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--SeptemberExchangeNotesMember_zgcp0yQLNkS9"&gt;26,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were issued with substantially the same terms
as the Original Notes. There were no accounting entries required upon the re-issuance of such Exchange Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Roll-over
notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
October 1, 2020, all Notes which matured, and were not repaid or converted, were rolled over on substantially the same terms as the Original
Notes (&#x201c;Rolled Over&#x201d;). Approximately $&lt;span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20201001__20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zz5VS2jxjbW8"&gt;805,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of such Original Notes were Rolled Over through
December 31, 2021, of which approximately $&lt;span id="xdx_901_eus-gaap--DebtConversionOriginalDebtAmount1_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zVtI115C22s1"&gt;166,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;occurred prior to December 31, 2020 and $&lt;span id="xdx_909_eus-gaap--DebtConversionOriginalDebtAmount1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverMember_zadilj4MmWP6"&gt;639,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;occurred between January 1, 2021 and December
31, 2021. Since the terms of the new notes are not substantially different from the Original Notes, this was not accounted for as a debt
modification or debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="INF"
      unitRef="Percent">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2017-05-012017-05-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-12-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">7500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DebtInstrumentTerm contextRef="From2020-12-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">21350</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2018-09-30_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="INF"
      unitRef="Percent">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentDescription contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember">(i)
80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing, or (ii) an equity valuation of $</us-gaap:DebtInstrumentDescription>
    <HILS:EquityValuation
      contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="-5"
      unitRef="USD">25000000</HILS:EquityValuation>
    <us-gaap:NotesIssued1
      contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="-5"
      unitRef="USD">50000000</us-gaap:NotesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1225384</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"
      decimals="0"
      unitRef="USD">2421000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">667000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">145000</us-gaap:InterestExpense>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">180000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">73000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">831000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2020-12-31_custom_ConvertiblePromissoryNoteAgreementsMember"
      decimals="0"
      unitRef="USD">246000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89B_eus-gaap--ConvertibleDebtTableTextBlock_zurV691P91ug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021 and 2020, all convertible debt instruments which had matured had been rolled over into new notes as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zXcf6N7RCUMb" style="display: none"&gt;SCHEDULE
OF CONVERTIBLE DEBT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_z286mMqTQbj4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20201231__us-gaap--DebtInstrumentAxis__custom--RolledOverInToNewNotesMember_zmIoqgHKUgN6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentFaceAmount_iI_maCDzeeB_zAobAk9K9ev8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Principal
    amount outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,734,446&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,598,340&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msCDzeeB_z49Nrl1plWXk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,569,003&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(747,973&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebt_iTI_mtCDzeeB_zGsjpo7otGx1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,165,443&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,850,367&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConvertibleDebtCurrent_iI_maCDzsmY_zicQ6vqPjBic" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,392,544&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;563,425&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebtNoncurrent_iI_maCDzsmY_z5eyShgNnHy" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Long
    term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;772,899&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,286,942&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConvertibleDebt_iTI_mtCDzsmY_z16a0vJ40mx7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,165,443&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,850,367&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">3734446</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">2598340</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">1569003</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">747973</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">2165443</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">1850367</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">1392544</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">563425</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">772899</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">1286942</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2021-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">2165443</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2020-12-31_custom_RolledOverInToNewNotesMember"
      decimals="0"
      unitRef="USD">1850367</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="0"
      unitRef="USD">265000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2019-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="0"
      unitRef="USD">37000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="0"
      unitRef="USD">265000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="INF"
      unitRef="Percent">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="0"
      unitRef="USD">71000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="INF"
      unitRef="Percent">0.375</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2020-09-042020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="0"
      unitRef="USD">537968</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:NotesPayable
      contextRef="AsOf2020-12-31_custom_OriginalNotesMember_custom_ExchangeNotesMember"
      decimals="0"
      unitRef="USD">201737</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_SeptemberExchangeNotesMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_ExchangeNotesMember"
      decimals="INF"
      unitRef="Percent">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-09-27_custom_FiveNotesPayableMember_custom_SeptemberExchangeNotesMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2020-10-012021-12-31_custom_RolledOverMember"
      decimals="0"
      unitRef="USD">805000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2020-01-012020-12-31_custom_RolledOverMember"
      decimals="0"
      unitRef="USD">166000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2021-01-012021-12-31_custom_RolledOverMember"
      decimals="0"
      unitRef="USD">639000</us-gaap:DebtConversionOriginalDebtAmount1>
    <HILS:RedemptionLiabilityDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_803_ecustom--RedemptionLiabilityDisclosureTextBlock_zWhbbhB3R6A9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
5 - Redemption Liability&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_821_z8O0uIksMSol" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;REDEMPTION
LIABILITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the redemption liability is calculated under Level 3 of the fair value hierarchy, determined based upon a Probability-Weighted
Expected Returns Method (&#x201c;PWERM&#x201d;). This PWERM was determined to be the most appropriate method of estimating the value of
possible redemption or conversion outcomes over time, since the Company has not entered into a priced equity round through December 31,
2021. The significant assumptions utilized in these calculations are the possible exit scenarios (either a conversion of the principal
and accrued interest of the Notes in the event of a Next Equity Financing, a repayment of the Notes and accrued interest in the event
of a Corporate Transaction (as defined in the Notes) or a repayment of the Notes and accrued interest at maturity), the pre-money valuation
of the Company&#x2019;s common stock, the probabilities of such exit events occurring and discounts/premiums available to the noteholders
at such measurement dates. At December 31, 2020, the Company assumed a 40% probability of a Next Equity Financing event occurring
at IPO pricing. At December 31, 2020, the Company assumed a 5% probability of a Corporate Transaction. The calculation of the redemption
liability at December 31, 2021 is based upon the actual incremental value derived by the Holders at the IPO date. The calculation
of the redemption liability also used the following assumptions during the years:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_z9vTxxSBrpqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zYZ7RQcr9tm2" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF REDEMPTION LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assumed
    ranges pre-money valuation at time of Next Equity Financing&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$
                                            &lt;span id="xdx_901_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MinimumMember_zGiZMlrcLBH2"&gt;5
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2013; &lt;span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MaximumMember_zKQzlP9cQSAg"&gt;50
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Discount
    rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MinimumMember_zVID6tuR15sb" style="font-family: Times New Roman, Times, Serif"&gt;8.86&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-
                                            &lt;span id="xdx_90E_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MaximumMember_zhHKYvah5rMa"&gt;11.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    coupon interest rate on Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--EquityFinancingRangeValuationAssumedExpectedInterestRate_iI_pid_dp_uPercent_c20201231_zxjHsFFGEzO4" style="font-family: Times New Roman, Times, Serif"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    term to exit event&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MinimumMember_z8p08iPrfyr8" style="font-family: Times New Roman, Times, Serif"&gt;2.0&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-
                                            &lt;span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MaximumMember_zdEpX4f7qS3"&gt;3.0
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zdukVwrdvcMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z6Kzb1otI7M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the redemption liability is re-measured at each period and is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z6mCpzfiEuL4" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF THE REDEMPTION LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zcA0ZS3BuXZ5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20200101__20201231_zKzqTdnCm9wh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zXp6PWXGhkGf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning
    balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,183&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_z08lIbYHdYuk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Initial
    embedded redemption value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,487,596&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;836,619&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_iI_zTkkZScxcJXg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,832,651&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;362,486&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zYiHXKB9CmVk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;980,233&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_ziWFSZ2MzLv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in fair value of a gain of $&lt;span id="xdx_906_ecustom--GainOnRedemptionValue_c20210101__20211231_zl8dCMdyTdba"&gt;1,832,651&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and loss of $&lt;span id="xdx_901_ecustom--LossOnRedemptionValue_iN_di_c20200101__20201231_zhFiCOFzcWr3"&gt;362,486
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2021 and 2020,
respectively, is recorded as a component of other income (expenses), net in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HILS:RedemptionLiabilityDisclosureTextBlock>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_z9vTxxSBrpqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zYZ7RQcr9tm2" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF REDEMPTION LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assumed
    ranges pre-money valuation at time of Next Equity Financing&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$
                                            &lt;span id="xdx_901_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MinimumMember_zGiZMlrcLBH2"&gt;5
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2013; &lt;span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedPercentage_iI_pn6n6_c20201231__srt--RangeAxis__srt--MaximumMember_zKQzlP9cQSAg"&gt;50
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;million&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Discount
    rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MinimumMember_zVID6tuR15sb" style="font-family: Times New Roman, Times, Serif"&gt;8.86&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-
                                            &lt;span id="xdx_90E_ecustom--EquityFinancingRangeValuationAssumedDiscountRate_iI_pid_dp_uPercent_c20201231__srt--RangeAxis__srt--MaximumMember_zhHKYvah5rMa"&gt;11.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    coupon interest rate on Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--EquityFinancingRangeValuationAssumedExpectedInterestRate_iI_pid_dp_uPercent_c20201231_zxjHsFFGEzO4" style="font-family: Times New Roman, Times, Serif"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    term to exit event&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MinimumMember_z8p08iPrfyr8" style="font-family: Times New Roman, Times, Serif"&gt;2.0&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-
                                            &lt;span id="xdx_907_ecustom--EquityFinancingRangeValuationAssumedExpectedTerm_iI_dtY_c20201231__srt--RangeAxis__srt--MaximumMember_zdEpX4f7qS3"&gt;3.0
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <HILS:EquityFinancingRangeValuationAssumedPercentage
      contextRef="AsOf2020-12-31_srt_MinimumMember"
      decimals="-6"
      unitRef="USD">5000000</HILS:EquityFinancingRangeValuationAssumedPercentage>
    <HILS:EquityFinancingRangeValuationAssumedPercentage
      contextRef="AsOf2020-12-31_srt_MaximumMember"
      decimals="-6"
      unitRef="USD">50000000</HILS:EquityFinancingRangeValuationAssumedPercentage>
    <HILS:EquityFinancingRangeValuationAssumedDiscountRate
      contextRef="AsOf2020-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Percent">0.0886</HILS:EquityFinancingRangeValuationAssumedDiscountRate>
    <HILS:EquityFinancingRangeValuationAssumedDiscountRate
      contextRef="AsOf2020-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Percent">0.1113</HILS:EquityFinancingRangeValuationAssumedDiscountRate>
    <HILS:EquityFinancingRangeValuationAssumedExpectedInterestRate
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="Percent">0.050</HILS:EquityFinancingRangeValuationAssumedExpectedInterestRate>
    <HILS:EquityFinancingRangeValuationAssumedExpectedTerm contextRef="AsOf2020-12-31_srt_MinimumMember">P2Y</HILS:EquityFinancingRangeValuationAssumedExpectedTerm>
    <HILS:EquityFinancingRangeValuationAssumedExpectedTerm contextRef="AsOf2020-12-31_srt_MaximumMember">P3Y</HILS:EquityFinancingRangeValuationAssumedExpectedTerm>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z6Kzb1otI7M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the redemption liability is re-measured at each period and is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z6mCpzfiEuL4" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF THE REDEMPTION LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zcA0ZS3BuXZ5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20200101__20201231_zKzqTdnCm9wh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zXp6PWXGhkGf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning
    balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;126,183&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue_z08lIbYHdYuk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Initial
    embedded redemption value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,487,596&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;836,619&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue_iI_zTkkZScxcJXg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,832,651&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;362,486&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zYiHXKB9CmVk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;980,233&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1325288</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">126183</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1487596</HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue>
    <HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">836619</HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue>
    <HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-1832651</HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue>
    <HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">362486</HILS:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">980233</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1325288</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <HILS:GainOnRedemptionValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1832651</HILS:GainOnRedemptionValue>
    <HILS:LossOnRedemptionValue
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-362486</HILS:LossOnRedemptionValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zZtEEkgXngrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
6 - Stock Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_826_zv3Zw03Oiih6" style="display: none"&gt;STOCK
BASED COMPENSATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the Company&#x2019;s 2017 Stock Incentive Plan (the &#x201c;2017 Stock Incentive Plan&#x201d;) the Company may grant incentive stock options,
non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares and performance
units to employees, directors and consultants of the Company and its affiliates. Up to &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zdEM1dYGNhme"&gt;94,696
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock may
be issued pursuant to the 2017 Stock Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has granted options to acquire &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zvaRrnXhdGQc"&gt;92,801
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock at $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_znoEYg8NibZf"&gt;13.20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share under the 2017 Stock Incentive Plan,
and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_zHE8y5SE6v5e"&gt;1,895
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remains available for issuance. At each of December
31, 2021 and December 31, 2020, there were options outstanding to acquire &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_znjshPQAssE1"&gt;92,801
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. As of December 31, 2021,
all such options were fully vested, and the weighted average remaining contractual life for such options was approximately &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockIncentivePlanMember_z2jdOJIDXOH5"&gt;6.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2019, the Company authorized a new plan (the &#x201c;2019 Stock Incentive Plan&#x201d;). The Company initially reserved &lt;span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20190731__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zqYMa2qnZeQc"&gt;284,090
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of its common stock for issuance pursuant
to the 2019 Stock Incentive Plan in the form of incentive stock options, non-statutory stock options, rights to purchase common stock,
stock appreciation rights, restricted stock, restricted stock, performance shares and performance units to employees, directors and consultants
of the Company and its affiliates. On August 30, 2019, the Company approved an increase in the number of shares authorized for issuance
under the 2019 Stock Incentive Plan by &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20190830__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zLvd9NLF5x3"&gt;2,575,757
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares. In January 2021, the Company approved
an increase in the number of shares reserved for issuance under the 2019 Stock Incentive Plan by &lt;span id="xdx_90A_ecustom--IncreaseInSharesReservedForIssuance_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zArxo3wKzs51"&gt;574,494
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares. On May 31, 2021, the Company approved
an increase in the number of shares reserved for issuance under the 2019 Stock Incentive Plan by &lt;span id="xdx_903_ecustom--IncreaseInSharesReservedForIssuance_c20210530__20210531__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zQGR911sCzjl"&gt;467,171
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares. At December 31, 2021, a total of &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zGmEZCrWtzPj"&gt;3,901,512
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares are authorized for issuance under the
2019 Stock Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has granted options to acquire &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zmm3APy8aVTe"&gt;2,420,514
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock under the 2019 Stock Incentive
Plan, and &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_z3bIFo3nFVKj"&gt;1,480,998
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remain available for issuance at December 31,
2021. The shares issued in 2021 and 2020 and the shares exercised under the 2019 Stock Incentive Plan are included in the table below.
At December 31, 2021, there are stock options outstanding to acquire &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zlHstcuMKTj9"&gt;810,667
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock with a weighted average
exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_zwQqbZqgzGe6"&gt;3.25
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and a weighted average contractual term of
&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwentyNineteenStockIncentivePlanMember_z59Ng475YWv2"&gt;8.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRhHmeJC28O6" style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock-based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plans:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B8_zbPkbuGy2Qz4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"/&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    Underlying Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Contractual Terms&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zt0KoJSNCQgc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying option, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;475,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Beginning outstanding"&gt;&lt;p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zimBABLIc9fk" style="margin: 0; font-family: Times New Roman, Times, Serif" title="Weigthed average exercise price, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0; font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zwoz5GUagsU6" style="font-family: Times New Roman, Times, Serif"&gt;9.4
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zv2M8zFnOhf5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zQjRr0BLErx1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231_zYuJ5qaWucg1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0468"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zrL51YMdtIXg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0470"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zOren017Gxkj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0472"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zst98Ghis4ua" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weigthed average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0474"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zBY93IYXwno5" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Shares underlying option, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;675,731&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"/&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z8HbLzbL0Djc" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weigthed average exercise price, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zdkrYd6IC2x7" style="font-family: Times New Roman, Times, Serif"&gt;8.8
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zJOEI931jEkh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;227,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zQ275cLdXXA5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.76&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zG4ZYX03eV6f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zpBJOxGQSkE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0487"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zsxrfJHqrUva" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0489"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zdrVuE6N0udh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0491"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211231_zV5uAkbonhTi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, Ending outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;903,468&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zGYvvYlF9OAe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Ending outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zKV1bmLvYbZ6" style="font-family: Times New Roman, Times, Serif"&gt;7.9
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable options
    at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zY35yC0Ic5qj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;580,642&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_z9ev5DhHfNVe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zUBC61X72ZW9" style="font-family: Times New Roman, Times, Serif"&gt;8.0
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested
    and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20210101__20211231_z0eq8bXZ0b19" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;658,206&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zNXu29RX17Od" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zDVeHkpfePx8" style="font-family: Times New Roman, Times, Serif"&gt;8.5
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zDLxtQVcLJLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWRnD8SbEGJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the exercise price range as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8BB_zHWGln1bDQO7" style="display: none"&gt;SCHEDULE
OF EXERCISE PRICE RANGE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 30%; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zxnKEf4W7fJe" style="font-family: Times New Roman, Times, Serif"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zcK5fXh2slzf" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;275,564&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z2DK62VPO32f" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33,261&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztGMpnIuSQ6i" style="font-family: Times New Roman, Times, Serif"&gt;0.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zv0bXkbDTp8f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;78,212&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zNBZ8OLR2pc7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;78,133&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zKhCjvufukN4" style="font-family: Times New Roman, Times, Serif"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpq3FaRZpHx7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107,004&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z4yFGvoQuKLk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,564&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvqXSGzY4c44" style="font-family: Times New Roman, Times, Serif"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbFL9eEbb0Ol" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73,857&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbq950e6zzWd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73,857&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFhXEtA9oKgi" style="font-family: Times New Roman, Times, Serif"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7Jq2SSi5t0f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,294&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zjPM2tl2Ywug" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,044&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zwHn54hmVib9" style="font-family: Times New Roman, Times, Serif"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zOFCsqeJJu48" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,940&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zMU4sQD5X3i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,940&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zCtH7Cbtci8l" style="font-family: Times New Roman, Times, Serif"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNsPRtWpxEue" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;208,797&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zpBIwQtFmK0h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;204,180&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zkaZYIilIGE8" style="font-family: Times New Roman, Times, Serif"&gt;13.20&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z4xYzaiKcd1c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92,800&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zl6yRB7oGYbk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;87,663&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zmvecubytDKf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding Options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;903,468&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231_zy5cKzru8eoh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable Options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;580,642&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zE3dgHWJ6r7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 2.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair
value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between
immediate vesting and 4 years). The determination of fair value using the Black-Scholes model is affected by the Company&#x2019;s share
price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest
rate and forfeitures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z0IraCnnogNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
options granted during the years ended December 31, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following
weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zUrldP9f5w04" style="display: none"&gt;SCHEDULE
OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zOKtmoStbdRj" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200101__20201231_zu3Jp9fIRkIe" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_z1LGsY4hik89" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;111.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zD54fN8bZZdk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zqIk53Io5Ged" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"/&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z0K5NqXvCBO8" style="font-family: Times New Roman, Times, Serif"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zT5IwxgHC6Zh" style="font-family: Times New Roman, Times, Serif"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iE_zY76PXAn9MV2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated
    fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.455&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z8ZcjmwcuoUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of stock options granted during the years ended December 31, 2021 and 2020 was approximately $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z863K5uimEQ5"&gt;5.48
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231_z5tJTbyNRXa9"&gt;1.53&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively. The weighted average fair value of stock options vested in the years ended December 2021 and 2020 was approximately $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20211231_zYajcUjINj7j"&gt;5.47
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20200101__20201231_zNfHwqwRTDG5"&gt;1.37,
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
based compensation expense was approximately $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_z09NnwKYnhSb"&gt;1,239,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;($&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXzBl3lXIWQ4"&gt;531,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;included in research and development expense
and $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zu8KO2uGElcb"&gt;708,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;included in general and administrative expenses)
and approximately $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_zWFeytRFQp55"&gt;234,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;($&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUdAJ4QTcDd7"&gt;124,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;included in research and development expense
and $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zX0yeBUIu1C6"&gt;110,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;included in general and administrative expenses)
for the years ended December 2021 and 2020, respectively, and is included in the accompanying consolidated statements of operations.
At December 31, 2021, the total unrecognized compensation expense related to non-vested options was approximately $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20211231_zcI5PYj9Mhf2"&gt;75,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and is expected to be recognized over the remaining
weighted average service period of approximately &lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zNvR1C7XBFc2"&gt;0.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Included
in the above table are stock options granted in 2019 to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrYdSyJe9qNk"&gt;231,058
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
at an exercise price of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMuxpAkd4WQl"&gt;0.079
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share and stock options granted in 2020 to
purchase &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6SAsQBwQvv7"&gt;14,204
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock at an exercise price of
$&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuczbZ8UKc2g"&gt;5.28
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, which vest upon a specified performance
condition. Since the occurrence of this condition was not considered probable as of December 31, 2021 and 2020, the Company has not recognized
any expense for such grants through December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2021, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20210301__20210331_zdi24GgJnzld"&gt;the
Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price of such stock options
from $0.18 or $2.598 to $0.314 or $3.817 per share, respectively.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
increase in the stock option exercise price was accounted for as a modification of the stock grant in 2021; however, the impact
on the Company&#x2019;s consolidated statements of operations was immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">94696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">92801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_custom_TwentySeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">13.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_custom_TwentySeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_TwentySeventeenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">92801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_TwentySeventeenStockIncentivePlanMember">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2019-07-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">284090</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2019-08-30_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2575757</us-gaap:CommonStockSharesAuthorized>
    <HILS:IncreaseInSharesReservedForIssuance
      contextRef="From2021-01-012021-01-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">574494</HILS:IncreaseInSharesReservedForIssuance>
    <HILS:IncreaseInSharesReservedForIssuance
      contextRef="From2021-05-302021-05-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">467171</HILS:IncreaseInSharesReservedForIssuance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">3901512</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2420514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1480998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">810667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_TwentyNineteenStockIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_TwentyNineteenStockIncentivePlanMember">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRhHmeJC28O6" style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes stock-based activities under the 2017 Stock Incentive Plan and 2019 Stock Incentive Plans:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B8_zbPkbuGy2Qz4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family: Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"/&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    Underlying Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Contractual Terms&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zt0KoJSNCQgc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying option, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;475,368&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Beginning outstanding"&gt;&lt;p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zimBABLIc9fk" style="margin: 0; font-family: Times New Roman, Times, Serif" title="Weigthed average exercise price, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0; font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zwoz5GUagsU6" style="font-family: Times New Roman, Times, Serif"&gt;9.4
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zv2M8zFnOhf5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200,363&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zQjRr0BLErx1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231_zYuJ5qaWucg1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0468"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_zrL51YMdtIXg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0470"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zOren017Gxkj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0472"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zst98Ghis4ua" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Weigthed average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0474"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zBY93IYXwno5" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Shares underlying option, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;675,731&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"/&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z8HbLzbL0Djc" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weigthed average exercise price, Beginning outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zdkrYd6IC2x7" style="font-family: Times New Roman, Times, Serif"&gt;8.8
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zJOEI931jEkh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;227,737&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zQ275cLdXXA5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.76&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231_zG4ZYX03eV6f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zpBJOxGQSkE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0487"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zsxrfJHqrUva" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0489"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zdrVuE6N0udh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0491"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211231_zV5uAkbonhTi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, Ending outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;903,468&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zGYvvYlF9OAe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, Ending outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zKV1bmLvYbZ6" style="font-family: Times New Roman, Times, Serif"&gt;7.9
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable options
    at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zY35yC0Ic5qj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlyling options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;580,642&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_z9ev5DhHfNVe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weigthed average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zUBC61X72ZW9" style="font-family: Times New Roman, Times, Serif"&gt;8.0
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested
    and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20210101__20211231_z0eq8bXZ0b19" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares underlying options, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;658,206&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zNXu29RX17Od" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zDVeHkpfePx8" style="font-family: Times New Roman, Times, Serif"&gt;8.5
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">475368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">3.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-12-31">P9Y4M24D</HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Shares">200363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">2.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">675731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-12-31">P8Y9M18D</HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">227737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">7.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">903468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-12-31">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">580642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-12-31">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">658206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-12-31">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWRnD8SbEGJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the exercise price range as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;span id="xdx_8BB_zHWGln1bDQO7" style="display: none"&gt;SCHEDULE
OF EXERCISE PRICE RANGE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable
    Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 30%; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zxnKEf4W7fJe" style="font-family: Times New Roman, Times, Serif"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zcK5fXh2slzf" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;275,564&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z2DK62VPO32f" style="font-family: Times New Roman, Times, Serif; width: 32%; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33,261&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztGMpnIuSQ6i" style="font-family: Times New Roman, Times, Serif"&gt;0.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zv0bXkbDTp8f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;78,212&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zNBZ8OLR2pc7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;78,133&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zKhCjvufukN4" style="font-family: Times New Roman, Times, Serif"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zpq3FaRZpHx7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107,004&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z4yFGvoQuKLk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,564&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvqXSGzY4c44" style="font-family: Times New Roman, Times, Serif"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbFL9eEbb0Ol" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73,857&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbq950e6zzWd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73,857&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFhXEtA9oKgi" style="font-family: Times New Roman, Times, Serif"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7Jq2SSi5t0f" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,294&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zjPM2tl2Ywug" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,044&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zwHn54hmVib9" style="font-family: Times New Roman, Times, Serif"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zOFCsqeJJu48" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,940&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zMU4sQD5X3i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,940&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zCtH7Cbtci8l" style="font-family: Times New Roman, Times, Serif"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNsPRtWpxEue" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;208,797&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zpBIwQtFmK0h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;204,180&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zkaZYIilIGE8" style="font-family: Times New Roman, Times, Serif"&gt;13.20&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z4xYzaiKcd1c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92,800&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zl6yRB7oGYbk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;87,663&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zmvecubytDKf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding Options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;903,468&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20211231_zy5cKzru8eoh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable Options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;580,642&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">0.08</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">275564</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">33261</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">0.31</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">78212</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">78133</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">2.64</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">107004</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">65564</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="USDPShares">3.82</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">73857</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">73857</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="USDPShares">5.28</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">48294</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">19044</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="USDPShares">7.03</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">18940</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">18940</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="USDPShares">7.82</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">208797</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">204180</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="AsOf2021-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="USDPShares">13.20</HILS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">92800</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">87663</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">903468</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">580642</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z0IraCnnogNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
options granted during the years ended December 31, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following
weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zUrldP9f5w04" style="display: none"&gt;SCHEDULE
OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zOKtmoStbdRj" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200101__20201231_zu3Jp9fIRkIe" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_z1LGsY4hik89" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;111.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zD54fN8bZZdk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zqIk53Io5Ged" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"/&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z0K5NqXvCBO8" style="font-family: Times New Roman, Times, Serif"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_zT5IwxgHC6Zh" style="font-family: Times New Roman, Times, Serif"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iE_zY76PXAn9MV2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated
    fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.455&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Percent">1.113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Percent">0.830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Percent">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Percent">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-12-31">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">7.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">2.455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.47</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">1.37</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">1239000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">531000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">708000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">124000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">75000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-12-31">P0Y6M</HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">231058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.079</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">14204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="From2021-03-012021-03-31">the
Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price of such stock options
from $0.18 or $2.598 to $0.314 or $3.817 per share, respectively.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zFfSOxakTXpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
7 &#x2013; Stockholders&#x2019; deficit&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_827_zJbmClDOHzQb" style="display: none"&gt;STOCKHOLDERS&#x2019;
DEFICIT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to an amendment to the Company&#x2019;s Certificate of Incorporation filed in April 2019, the Company increased the number of authorized
shares of common stock to &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20211231_zXTAJTxg2D7e"&gt;250&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million shares. See Note 2 for a discussion of the reverse
stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2020, the Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHkITzQWMfHi"&gt;75,757
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for the Farrington acquisition
transaction described in Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="-6" unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75757</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zcaNUQypWNXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
8 &#x2013; income taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_82A_zHboNnM8Ggl4" style="display: none"&gt;INCOME
TAXES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not have any significant current income taxes due because of the losses generated in each period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred tax assets relate primarily to its net operating
loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance
to fully offset the gross deferred tax asset because it is not more likely than not that the Company will realize future benefits associated
with these deferred tax assets at December 31, 2021 and 2020. The valuation allowance increased by approximately $&lt;span id="xdx_904_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zlryWvRdoHPl"&gt;652,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zD3x2MKiIE3g"&gt;589,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2021 and 2020,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOQumCcKequj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
components of the Company&#x2019;s deferred tax assets at December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zEwTtXBHJNEb" style="display: none"&gt;SCHEDULE
OF SIGNIFICANT COMPONENTS OF COMPANY&#x2019;S DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z0Jryg3Jzkqi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zPSrRuCLFgei" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_maDTAGzm4g_z88JdmmLa9T9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal
    net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;702,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;424,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzm4g_zlAyQ15FI4Aa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;238,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;182,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_iI_maDTAGzm4g_z9ioebGue6Ze" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capitalized
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;199,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AcquiredInprocessResearchAndDevelopment_iI_maDTAGzm4g_zn7zQQnHKLK" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired
    In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;178,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzm4g_zBZzUlOeN0S8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzm4g_z7ncOSJFlzEj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;336,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther_iI_maDTAGzm4g_zEUB5dvgWEc2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(66,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="margin: 0; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;82,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzj39_mtDTAGzm4g_zBO8AR2aqLM4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,827,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,175,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzj39_zy2amT6qXc5e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,827,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,175,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzj39_msDTLzhRs_zv8TypsLERne" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax asset, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0622"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zb5KwMmE47Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
income tax benefit for the years ended December 31, 2021 and 2020 differ from the amounts computed by applying the U.S. Federal income
tax rate of &lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPercent_c20200101__20201231_zI3ak3ijABJ"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;%
to loss before income tax benefit as a result of non-deductible expenses, tax credits generated and increases in the Company&#x2019;s
valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zOm1cbaALyFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zxF3hxINXQBg" style="display: none"&gt;SCHEDULE
OF EFFECTIVE INCOME TAX EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_z1i9eA68bINg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200101__20201231_zdkQ9I67Bpde" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzMie_zxOQ71uemCD5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax benefit at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(463,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(508,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--IncomeTaxReconciliationPermanentDifferencesAndOther_maITEBzMie_zjHsSBSgbnJ3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent
    differences and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(61,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzMie_zwve8BbcKm94" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(118,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(167,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzMie_zoopKL53uTtg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(31,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzMie_zqwZAnzJwZdd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzMie_zFnRmSIrvHkd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;652,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;589,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzMie_zZUCrr7C3JVe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effective
    income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zUEuN488LgB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely
than not that some portion or all of the deferred tax assets will not be realized. After consideration of the available evidence, both
positive and negative, the Company determined that valuation allowances of $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pp0p0_c20211231_zWPKO4NOy45a"&gt;1,827,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;million and $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pp0p0_c20201231_zv8ugyTBC9O8"&gt;1,175,000
&lt;/span&gt;at December 31, 2021 and 2020, respectively, were necessary to reduce the deferred tax assets to the amount that
will more likely than not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, the Company had available net operating loss carryforwards of approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zleqs09q4Rxa"&gt;3.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million for federal income tax purposes,
all of which was generated after 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act. At December 31, 2021,
the Company had approximately $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zmMxYoSLSnh1"&gt;46
thousand &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of federal research and development
(&#x201c;R&amp;amp;D&#x201d;) tax credit carryforwards. If not utilized, the federal R&amp;amp;D credits will begin to expire in 2038. The Company
also had $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ztQS9YL1xywd"&gt;3.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of state net operating losses
that will begin to expire in 2037.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sections
382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available
to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of
significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the
NOL carryforwards that the Company may utilize in any one year may be limited. Although the Company has not undertaken a formal analysis,
it is likely that such an ownership change occurred during 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;). The CARES
Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund
a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19
pandemic, some of the more significant provisions which are expected to impact the Company&#x2019;s financial statements include removal
of certain limitations on utilization of NOLs, increasing the loss carryback period for certain losses to five years, and increasing
the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company
has concluded that the CARES Act did not have a material impact on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended many of the benefits of the CARES Act
that were scheduled to expire. The Company evaluated the impact of the Consolidated Appropriations Act on its consolidated financial
statements and related disclosures and concluded that the impact is immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">652000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">589000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOQumCcKequj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
components of the Company&#x2019;s deferred tax assets at December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zEwTtXBHJNEb" style="display: none"&gt;SCHEDULE
OF SIGNIFICANT COMPONENTS OF COMPANY&#x2019;S DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_z0Jryg3Jzkqi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zPSrRuCLFgei" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_maDTAGzm4g_z88JdmmLa9T9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal
    net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;702,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;424,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzm4g_zlAyQ15FI4Aa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;238,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;182,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts_iI_maDTAGzm4g_z9ioebGue6Ze" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capitalized
    costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;394,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;199,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AcquiredInprocessResearchAndDevelopment_iI_maDTAGzm4g_zn7zQQnHKLK" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired
    In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;178,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzm4g_zBZzUlOeN0S8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzm4g_z7ncOSJFlzEj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;336,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther_iI_maDTAGzm4g_zEUB5dvgWEc2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(66,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="margin: 0; font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;82,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzj39_mtDTAGzm4g_zBO8AR2aqLM4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,827,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,175,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzj39_zy2amT6qXc5e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,827,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,175,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzj39_msDTLzhRs_zv8TypsLERne" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax asset, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0622"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">702000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">424000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">238000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">182000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <HILS:DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">394000</HILS:DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts>
    <HILS:DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">199000</HILS:DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts>
    <HILS:AcquiredInprocessResearchAndDevelopment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">178000</HILS:AcquiredInprocessResearchAndDevelopment>
    <HILS:AcquiredInprocessResearchAndDevelopment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">205000</HILS:AcquiredInprocessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">45000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">66000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">336000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <HILS:DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-66000</HILS:DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther>
    <HILS:DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">82000</HILS:DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1827000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1175000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1827000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1175000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Percent">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zOm1cbaALyFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zxF3hxINXQBg" style="display: none"&gt;SCHEDULE
OF EFFECTIVE INCOME TAX EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_z1i9eA68bINg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200101__20201231_zdkQ9I67Bpde" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzMie_zxOQ71uemCD5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax benefit at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(463,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(508,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--IncomeTaxReconciliationPermanentDifferencesAndOther_maITEBzMie_zjHsSBSgbnJ3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent
    differences and other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(61,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzMie_zwve8BbcKm94" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(118,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(167,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzMie_zoopKL53uTtg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(31,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzMie_zqwZAnzJwZdd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzMie_zFnRmSIrvHkd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;652,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;589,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzMie_zZUCrr7C3JVe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effective
    income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-463000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-508000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <HILS:IncomeTaxReconciliationPermanentDifferencesAndOther
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-61000</HILS:IncomeTaxReconciliationPermanentDifferencesAndOther>
    <HILS:IncomeTaxReconciliationPermanentDifferencesAndOther
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">117000</HILS:IncomeTaxReconciliationPermanentDifferencesAndOther>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">-118000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">-167000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">40000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">31000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">30000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-01to2021-12-31"
      decimals="0"
      unitRef="USD">652000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">589000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1827000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1175000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      unitRef="USD">3300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">46000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      unitRef="USD">3300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zitDLyq6PAhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
9 - Related Party Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_821_zdrTY9GucNo6" style="display: none"&gt;RELATED
PARTY TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
described in Note 4, the Company entered into the Notes with the Holders commencing in May 2017. The Holders of substantially all of
the Notes are the Company&#x2019;s founder and Chief Executive Officer, a member of the Company&#x2019;s board of directors
and third parties that are family members of the founder and Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the above Notes, the Company has amounts due to the founder and Chief Executive Officer that totaled $&lt;span id="xdx_90E_eus-gaap--DueToRelatedPartiesCurrent_iI_c20201231__srt--TitleOfIndividualAxis__custom--FounderAndChiefExecutiveOfficerMember_zfHIvR5ccsSf"&gt;200,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at December 31, 2021 and December 31, 2020 for
accrued compensation. See Note 10. There are no established terms for repayment of such amounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2020, expenses paid on behalf of the Company by the Chief Executive Officer of $&lt;span id="xdx_90F_ecustom--DueToFounderConvertedToNotePayable_c20200101__20201231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zlmeP3Xz3OGi"&gt;55,068
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were converted into a convertible promissory
note and is included in convertible notes-related parties on the accompanying balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2020-12-31_custom_FounderAndChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:DueToRelatedPartiesCurrent>
    <HILS:DueToFounderConvertedToNotePayable
      contextRef="From2020-01-012020-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">55068</HILS:DueToFounderConvertedToNotePayable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhbCufOFXMcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
10 - Commitments And Contingencies&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_82A_zYb2cd1SA5ih" style="display: none"&gt;COMMITMENTS
AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Small
molecule analogues&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 30, 2019, &lt;span id="xdx_90D_ecustom--AssetAcquisitionDescription_c20191229__20191230__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z1Vh1b6oFsde"&gt;the
Company acquired a series of small molecule analogues pursuant to an asset purchase agreement (&#x201c;APA&#x201d;). Pursuant to the APA,
the Company is required to make a payment of $50,000 upon raising of at least $2 million in funding, and up to $1.75 million based
upon successfully meeting clinical and sales milestones.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, such fund-raising requirement was not met and &lt;span id="xdx_900_eus-gaap--PaymentsToAcquireProductiveAssets_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zySSmG4KCFHi"&gt;no
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;payments were made pursuant to the APA. The Company
included, in accounts payable at December 31, 2021 and December 31, 2020, the $&lt;span id="xdx_907_ecustom--MilestonePayment_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zx6vF2uKJ0ui"&gt;50,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;required initial payment. Milestone based payments,
if any, will be expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employment
agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2019, the Company entered into a three-year employment agreement with its Chief Executive Officer which provides a specified
base salary and bonus. The employment agreement also provides the Chief Executive Officer with certain benefits while employed and if
employment ceases. The Company accrued $&lt;span id="xdx_909_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20190131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zT2VTMXmlbyf"&gt;200,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in 2019 related to the Chief Executive Officer&#x2019;s
base salary as per the employment agreement, which is included in due to founder, which remains outstanding as of December 31, 2021.
&lt;span id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_do_c20190131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zovAXAt473k2"&gt;No
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;bonus was approved by the board of directors
of the Company for any period through December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2020, the Company amended the employment agreement pursuant to which, in lieu of a cash base salary, the Chief Executive Officer
will be compensated with stock options to purchase &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20200101__20200131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zAH7FHnvkFRc"&gt;7,575
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock per month (at an exercise
price based upon the most recent 409A valuation) effective January 1, 2020 until the Company receives a minimum of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200101__20200131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zco2AaCZxc45"&gt;3,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of gross proceeds from the sale of the Company&#x2019;s
securities, after which time, cash compensation, pursuant to the employment agreement, shall be paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
January 1, 2021, the Company amended the employment agreement with its Chief Executive Officer to provide a revised base salary pre-funding
(as defined in the employment agreement). In lieu of cash base salary, the Chief Executive Officer will be compensated with stock options
to purchase &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zn3xPOMTOj4b"&gt;18,939
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock per
month (an exercise price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zQj1hTgXH8t1"&gt;7.82
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share) effective January 1, 2021 until
funding meets or exceeds $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zO84LhYvY4Kh"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
after which time, cash compensation, pursuant to his employment agreement, shall be paid. The amended employment agreement also provides
for a future base salary for the Chief Executive Officer after the Company receives funding greater than $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember__srt--RangeAxis__srt--MinimumMember_zHw7NMfA4gdd"&gt;5,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;or completes an initial public offering or similar
transaction as set forth in the employment agreement. In addition, if the Chief Executive Officer acts as the &#x201c;finder&#x201d; of
an investor who purchases more than $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zR6IIfuiZTi5"&gt;5,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the Company&#x2019;s equity, he will receive
a grant of stock options to acquire &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210101__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zXE4uegW6xjk"&gt;757,575
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock of the Company at an exercise
price equal to the most recent fair value of the Company&#x2019;s common stock. This grant has not been earned as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 1, 2021, the Company entered into an Amended and Restated Employment Agreement, as amended on September 24, 2021 (the &#x201c;Amended
and Restated Employment Agreement&#x201d;) with the Company&#x2019;s President and Chief Executive Officer. The term of the Amended and
Restated Employment Agreement will commence upon the closing of the Company&#x2019;s initial public offering of its securities and continues
for a period of five years and automatically renews for successive one-year periods at the end of each term unless either party provides
written notice of their intent not to review at least 60 days prior to the expiration of the then effective term. Pursuant to the Amended
and Restated Employment Agreement, the Chief Executive Officer will receive an annual base salary of $&lt;span id="xdx_90A_eus-gaap--ProfessionalFees_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zoU5l0YEY2hg"&gt;485,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which may be increased from time to time, and shall be eligible to receive an annual cash bonus equal to &lt;span id="xdx_902_ecustom--CashBonusReceived_pid_dp_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zMO7eE8ttlra"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of his then base salary based upon the achievement of Company and individual performance targets established by the Company&#x2019;s board
of directors. In addition, in the first year in which the Company&#x2019;s market capitalization (as defined in the Amended and Restated
Employment Agreement) equals or exceeds &lt;span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_zclUTdxdNscg"&gt;(i)
$250 million, the Chief Executive Officer shall receive a cash payment of $150,000; (ii) $500 million, the Chief Executive Officer shall
receive a cash payment of $350,000; and (iii) $1 billion, the Chief Executive Officer shall receive a cash payment of $750,000. Furthermore,
on or as soon as reasonably practicable following the date of the consummation the Company&#x2019;s initial public offering of its securities,
the Chief Executive Officer shall be granted &lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210530__20210601__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--RestatedEmploymentAgreementMember_znE1KMfugung" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;757,575
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock at the public
offering price per share of common stock sold in the Company&#x2019;s initial public offering of its securities which shall vest over
a 48-month period commencing 12 months after the date of grant. This shall be in addition to any additional equity-based compensation
awards the Company may grant the Chief Executive Officer from time to time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <HILS:AssetAcquisitionDescription contextRef="From2019-12-292019-12-30_custom_AssetPurchaseAgreementMember">the
Company acquired a series of small molecule analogues pursuant to an asset purchase agreement (&#x201c;APA&#x201d;). Pursuant to the APA,
the Company is required to make a payment of $50,000 upon raising of at least $2 million in funding, and up to $1.75 million based
upon successfully meeting clinical and sales milestones.</HILS:AssetAcquisitionDescription>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2021-01-012021-12-31_custom_AssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <HILS:MilestonePayment
      contextRef="From2021-01-012021-12-31_custom_AssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">50000</HILS:MilestonePayment>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="AsOf2019-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2019-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2020-01-012020-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="INF"
      unitRef="Shares">7575</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-01-012020-01-31_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="INF"
      unitRef="Shares">18939</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="INF"
      unitRef="USDPShares">7.82</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember_srt_MinimumMember_us-gaap_InvestorMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-01-01_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="INF"
      unitRef="Shares">757575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ProfessionalFees
      contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember"
      decimals="0"
      unitRef="USD">485000</us-gaap:ProfessionalFees>
    <HILS:CashBonusReceived
      contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember"
      decimals="INF"
      unitRef="Percent">0.55</HILS:CashBonusReceived>
    <us-gaap:OtherCommitmentsDescription contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember">(i)
$250 million, the Chief Executive Officer shall receive a cash payment of $150,000; (ii) $500 million, the Chief Executive Officer shall
receive a cash payment of $350,000; and (iii) $1 billion, the Chief Executive Officer shall receive a cash payment of $750,000. Furthermore,
on or as soon as reasonably practicable following the date of the consummation the Company&#x2019;s initial public offering of its securities,
the Chief Executive Officer shall be granted</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-05-302021-06-01_srt_ChiefExecutiveOfficerMember_custom_RestatedEmploymentAgreementMember"
      decimals="INF"
      unitRef="Shares">757575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zxnshU3mULmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font: small-caps 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
11 - Subsequent Events&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_828_z3UA3i93gtGl" style="display: none"&gt;SUBSEQUENT
EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IPO&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 14, 2022, the Company closed its IPO pursuant to which it issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zm5VGJCTRnkj"&gt;3,750,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock at
a public offering price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEMn6XuFoNv6"&gt;4.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The gross proceeds to the Company
from the IPO were $&lt;span id="xdx_903_ecustom--GrossProceedsFromIssuanceInitialPublicOffering_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zuNRpsy91LU2"&gt;15,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
prior to deducting underwriting discounts, commissions, and other offering expenses. The net proceeds to the Company from the IPO
were $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zYEca8EBd0U5"&gt;13.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. The Company granted the underwriters
a 45-day option to purchase up to an additional &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5YMQKOYR378"&gt;562,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock at the public offering
price less discounts and commissions, to cover over-allotments; however, this option expired unexercised. Additionally, and as
a result of the completion of the IPO, all of the Company&#x2019;s convertible debt and accrued interest was converted into an
aggregate of &lt;span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2rY5psnE233"&gt;1,225,384
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
pursuant to the terms of the convertible notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
    payable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 4, 2022 and January 6, 2022, the Company issued unsecured promissory notes in the aggregate principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_z7TQBvdWmQwe"&gt;138,887
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(including an original issuance discount of an
aggregate of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zQBo5FjC6Fd"&gt;13,887&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
to three related-party investors. The notes accrue interest at a rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPercent_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNotesMember_zoY7yiwUhzK1"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
per annum and mature upon the earlier of (i) June 30, 2022, and (ii) the closing of a Subsequent Equity Financing. &#x201c;Subsequent
Equity Financing&#x201d; means the next sale (or series of related sales) by the Company of its Equity Securities following the date of
the notes pursuant to which the Company receives gross proceeds of not less than $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220103__20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNotesPayableMember_zogLiozg9fhh"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The notes were repaid in full on January 21, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.
Stock option grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 14, 2022, the Company granted its Chief Executive Officer a stock option to purchase up to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220113__20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_zPkInq2ODlz6"&gt;757,575
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
at an exercise price of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--TypeOfArrangementAxis__custom--EmployeeAgreementMember_znQ75AquruYl"&gt;4.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share in accordance with his employment
agreement. See Note 10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 21, 2022, the Company granted options to purchase up to an aggregate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220320__20220321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardMember_zeLNYsvtKHgl"&gt;247,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
at an exercise price of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsAndScientificAdvisoryBoardMember_zzz4w6DxM0k"&gt;1.33
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share to the independent members of
the Company&#x2019;s board of directors and members of the Company&#x2019;s Scientific Advisory Board.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">3750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:SharesIssuedPricePerShare>
    <HILS:GrossProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">15000000</HILS:GrossProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="-5"
      unitRef="USD">13000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">562500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">1225384</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember"
      decimals="0"
      unitRef="USD">138887</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember"
      decimals="0"
      unitRef="USD">13887</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNotesMember"
      decimals="INF"
      unitRef="Percent">0.12</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-032022-01-06_us-gaap_SubsequentEventMember_custom_PromissoryNotesPayableMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-132022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="INF"
      unitRef="Shares">757575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-03-202022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember"
      decimals="INF"
      unitRef="Shares">247500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-03-21_us-gaap_SubsequentEventMember_custom_BoardOfDirectorsAndScientificAdvisoryBoardMember"
      decimals="INF"
      unitRef="USDPShares">1.33</us-gaap:SharesIssuedPricePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MI2M1HI15 AJ2$Z@M_X20(,+D'*QMF,2A[],!O/V@0,8'!1AFFJ)I)>"P\IQ
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M<%"O%=1DX[+["2F'Q7JTF""^T-R=$J2BKM7(=L2])<_#!WRD7NV(!M#YW@)
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M84;?2Z@QX>_K[*Q%2B!HP.VL;PP%Q^G'OG)T//^.XG%=N8P +$<AR7>O-:(
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M;]<[L+>EKSC[<X,PLS"0<( #S4!>>(_O"?G:,W0B[IY=W=F9E. .N40XOYM
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M:7?UT1]IS3^<(V@R 0>6',)[FO[J*\0:W@+>C^A 4P]&=+C0S:E]]1;3I>0
M71K^T()MZ_Y",(]2^\LMR<5&+N0[-<('+M.F(B#V9/" 'SCR-+@D,YCGT"]J
MCJ.?-=$6\N,M9D:HT_W"J7O:_3[LS/TLJG_=_;CLDZ8IP?7,$D.GD^=/C]P]
MI/ !424_DEI435-MY,^UT9FI^0*^7U9(EOX#%^A^-??V_P%02P,$%     @
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MT+]<6\,&MI>C=&BJ%Z4A.^<&_)Q7&>484($RRBT^RJ2LRQ'I.P[0I1-\#\Z
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M.5%JW]^[MAR_?6DQUY1>7(3A<NV(S24BZ0O[J5Q6L_DN>;I!O*70;MR]N2"
MPJNDIMFZW:)MJ9'8'2L.2@!]NU)7BUT/(,@;A-@TEPM^8IEVP(')B6/V8.8
M!SS!)MNC->BC82IM&7"G<K#M>YUCPE"80OJH2  4#1>T,J*F"WPA4[^[( U^
MX'.Y@@29*WLEH,FH9#([$!:O2$P$"!I5> J]'733^UX]=5OO]Q8BG]%;3&0
M4JA7?<UJ\Z)TJ-X/OFQ7;UG!&V9X'9^**1R%#J774;>B]8]2+NEMX426I5S0
MU[D(P9UQ SR?2EG6/Y!!\_KXXC]02P,$%     @ 6$^!5"0F;7;Q @  -@8
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M_K0 O\?&V/J%-FC^:>+BOU!+ P04    " !83X%47,4!6ZD#   :"   &0
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M/M0?O\WB:'IB*=%%@6$"+Y-O)%P@@+K,50+[E32J7%-E5"+9_1F-0^!5$AK
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M0/I..RO:Q2;0-DN6OFG8Z-MZ(MZWVJ8M:QL%4W)=\P"Y2RP=81_Z8.BWTKY
M=%>R3#?,7$9"S,V.N8/$"POK2 WYJ\MIR"6-O88 [S)MDX (AK!61HBWYL%Y
M-'*56JD2.*F2W[U]'1#,U+)JS$L7%)1J-J$1P%F)'..9>F283K:IM!NQHCT[
MQE&J-65+"&!M/+9+5>EBA\Z4\S\[&#PNF^!Q.1@\KHF!OH QN*H_8( 4!XF
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M=O.%*OOP'JX+O=FN]B\5\TTVVYYWNF$YSGWJ/XWJ&?W%4GOR %05K#-4?66
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M4?LKE5\W3T(C6%7[,3Q7EH:Z7Q;TBJ)V #I?*FKXK> ,[-_EP7]02P,$%
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MC6XKF9=)&M,DUY4)(8ER3B4E J9/49+')(8U9RGX+-WE$A?]BZUABGE&LXV
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M 'P_%]BMJHEIG?6?LO<?4$L#!!0    ( %A/@52PY6*";P8  .0=   9
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MX_0?/V4+L0%P.S4 F %@4P#* *@IH),!.ML 5 /H9H#N%J!VTEX&\)JZY&<
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M+*)",/Z<, LXO^.$Z$W:B&-@P7-P+ZTK+$@,[K]Y'>VPT:W2?OK"N0.WLU[
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MPFS0ZRO.U7M@FE'U7R+X#5!+ P04    " !83X%4DS>6%;T"   ,!P  &0
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M,26L;W+A7=HP%YFG<>H)-7BR$7Q+8KYF,(U]XE<-F )VCAT=L8^1UN(-6;3
ML:\ 6<BN 31Y_7)+ \?)0^DH>TY3*&5@/DE-^7"'#T+K'$:4XGA%U///T9QQ
M*G3[2^.LG3MK*V=MG3,&6Q%*&AZ"> 7)1NZ+*QB351#':F3+&<>Q+Y[KTI4Z
MZ"@'<K?OAJ[7\1P1R5TYB.?3VE['<;OYM K^3HZ_H\7_0^POOA:1PCM"Q7D!
MY)G01< (;&BP(&^@D?KIEO Y+:MW0J)N$D+U%-R<@JNE\#/=GM<J%2KMDR02
MQRO#,A&ES(\/Q91,&*,]IOY,98S-"GX_U*E#_%$:E'LB#V(Q/A$;1RIGB\-'
M0B/[5UT@]&B[<""8,NA!E.Y"NPL^/M1MY(G>4B^SU#Y:0NT:2Y60>GE(O7>I
MFEW!2H23GQX;*7'O3*$(>9[CG6B@9IIE.:Y3KX)N#KE[F9 UP+MGJO1:GGL"
M^WP2:C5LOEZ.N??>,!_1U^+56I4-QS7;X 49&**C8(3NB#&$.GU=;J="V[:*
M8F==EBPM?;WQ-_#_ $/5 )2JO?W>S(NN:$F"!J7JS;Z%^N6&JM1101U=EONE
M-@!:X^_ 7705MO.&E(65G$U5U7BI0F8.RB=?SW+:I1*>Y>9\WDE'4*50]"JV
MOEEY,?2OY-$^.PK;+71ZS-?,JC0$50Y%OV+K&Y9R=U>N\Y46;WZ VBY05OLK
MF!W35JKX5W"L^9 5?<BK/I3*/LBZ7QL4/6PO*]:V]?IJ;1<=D*UO!73:S'*,
MYR&IQ>V>B:W3M=QV0U-F%RV$K>\A7GO&-P+SSO33:?4:*JY=M FVOD_X2/U,
M"P:7ZT</.VL;=6HIN@[[W6W'$V&2@M@3(CT;\8DO7G@".S%<"[IW?E)UNLAR
MZ[.$B@8!O=P@J& VB>>-0#-W53%Y#1I'11E'KRCC'R2F$J-IB9$<_MB3Z@5.
MQP\4-SNHZB1GEBXZ(D)7ZOZ'P2+9QCR]-\A'\SNFD;I9.1D?V]>3]*:H,)->
M7'W#5'QX,@C)4IBT6IX0&4WO@M(7GFS4=<H\X>+K3SVN"1:2EA/$[\LDX<<7
MZ2"_D1O^#U!+ P04    " !83X%44^6G1F8$   _&@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6S-F>]OXC88Q_\5"^W%)O6(?T%"!4@MI;M*=RN"
MZS:INA<&7,B:Q,PVI3?MCY\=(.86C$"*='D#<9+G^7YM/_D0[.Y&R%>UY%R#
M]S3)5*^QU'IU'01JMN0I4TVQXIFY\B)DRK1IRD6@5I*S>1Z4)@&&L!VD+,X:
M_6Y^;B3[7;'629SQD01JG:9,?KOEB=CT&JBQ/S&.%TMM3P3][HHM^(3KI]5(
MFE909)G'*<]4+#(@^4NO<8.N;RFU ?D=O\=\HPZ.@>W*5(A7VWB8]QK0.N()
MGVF;@IFO-S[@26(S&1]_[Y(V"DT;>'B\SWZ?=]YT9LH4'XCDCWBNE[U&U !S
M_L+6B1Z+S4>^ZU#+YIN)1.6?8+.[%S; ;*VT2'?!QD$:9]MO]KX;B(, X@O
MNP"<^]X*Y2[OF&;]KA0;(.W=)IL]R+N:1QMS<69G9:*EN1J;.-V?##X.[YX^
M#<'C/1C^.1P/'B9#,!H_#(9@?//;KT/P\QW7+$[4+]U &ST;%<QVN6^WN;$G
M]QV?-0%!5P!#C'X" 5!+)KG:?GZ?+C"V"^^X\([S_,3GW2;Z8.=D#D;LFZD5
M#6ZD9-F"V^,K\+BR,W\%AN]<SF+%P4C&,P[&]@[P_,FD P^:I^KK"3.D,$-R
M,]1CYG&ME6;9/,X6.UUU;,2V25IY$OO$O/4[D-!VU W>CHC30IR>%-]UD$T3
M?DJ<EL1;$6Q3?%R\58BWSA'?C^ZC&=7GSSR=<GEJ7-M%]O:/G^2P,!.>[.KS
M]HF\SDW=6D\#D1I *F8]Y&?5S5HOA8S_X?.G;,[E1(O9Z];C*&&9VMO,77Z
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M.6?[.SSJZ6B^F*7"_,+^&.M8$&^%9-D1K"K(:%[^D[=C'TX ;O<,P#L"O,^
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MM3YQ[L% \Y%6/?'XY>*,,P##^G$49YS!$GZ^1OC//!,QRJQ?'@X,J->D=P:
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MO.^<.)#AG%2%NN/K2VSR"0U?R@MI?V%=QX:?'4@KJ3AKP-H!HV7]),]-';8
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MG8_T/HBJ_U<3Q;>VA:ZYT@W9#G-]9T)A#/3SC'/U.C$!ZEO8[!=02P,$%
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MAHGI3%':#>;[6@C],+$&JEYW^@M02P,$%     @ 6$^!5+%%/^<= P  O D
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M7J&R"V@^DZ2UZ5@';<$V^@902P,$%     @ 6$^!5%VI$,)@!@  ]!<  !D
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M&+972.]-O R8"V0^%>D*!S,H+* N#((*RBO="TL-7%*TTNA.O;),R_$0ER]
M/V'JF/'H73)YI#T38$$J$:>)>U>D;9JTO6JS1_/@=E+?AT^)6+%(PO;K Z$%
MNVT-B>2*.7E1?&,N+)=<07F;QS4E'A7Z /SN<Z[V+_H.-+OHO_X'4$L#!!0
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M4$L! A0#%     @ 6$^!5-CV&4E[ @  V@8  !@              ("!"10
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %A/@536SXS-
M 00   L-   8              " @;H6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !83X%4V*YDO$0$  !F$0  &
M@('Q&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 6$^!
M5' &TK/$!0  /A4  !@              ("!:Q\  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( %A/@50?5EMHN@T  (8@   8
M      " @64E  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !83X%4&@ /F7T4  !!-P  &               @(%5,P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 6$^!5'4J^Q74 P  W@<  !@
M             ("!"$@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( %A/@50:D3YU&PL   L>   9              " @1),  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 6$^!5**$B _Q!0
MD0T  !D              ("!9%<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !83X%4(@6QWKL*  !*'@  &0              @(&,
M70  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %A/@50D
M)FUV\0(  #8&   9              " @7YH  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ 6$^!5/^[7;\F"@  IA@  !D
M     ("!IFL  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %A/@52=\O5E)@,  %4&   9              "
M@;B>  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 6$^!
M5 YZ9-QP P  HP<  !D              ("!%:(  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !83X%41U&/IQ@%  "M"P  &0
M        @(&\I0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( %A/@50DB[TG(P0  )X)   9              " @0NK  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 6$^!5-R@K H6!   F X
M !D              ("!9:\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !83X%4WFS%^G #  !9"P  &0              @(&RLP
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %A/@533C_9*
ME (  !8'   9              " @5FW  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ 6$^!5#W>:6_8 @  -0<  !D
M ("!)+H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !8
M3X%4L.5B@F\&  #D'0  &0              @($SO0  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %A/@50KW#'8H@(  %<(   9
M          " @=G#  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ 6$^!5),WEA6] @  # <  !D              ("!LL8  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !83X%4;I'TG$("  !@
M!0  &0              @(&FR0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( %A/@52W611>L@0  )T3   9              " @1_,
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 6$^!5%/E
MIT9F!   /QH  !D              ("!"-$  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " !83X%4[5_"%#T#  #J"   &0
M    @(&EU0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M %A/@53=$Q:>1P<  !LF   9              " @1G9  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ 6$^!5.TJ <*< @  DP8  !D
M             ("!E^   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !83X%4K4_D>(D#   6"P  &0              @(%JXP  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %A/@51.8,^P0P,
M )$)   9              " @2KG  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ 6$^!5'L0]D%H P  ]PH  !D              ("!
MI.H  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !83X%4
ML44_YQT#  "\"0  &0              @(%#[@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %A/@51=J1#"8 8  /07   9
M      " @9?Q  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ 6$^!5"G2<09[!0  OQ@  !D              ("!+O@  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !83X%4:DY,RS4#  #Z$P
M#0              @ '@_0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %A/
M@527BKL<P    !,"   +              "  4 ! 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( %A/@51^OL>Z' 0  ,(;   /              "  2D" 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !83X%4*5V(H),!  #B&   &@
M            @ %R!@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !83X%4B(RI-Z4!   O&0  $P              @ $]" $ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     ,0 Q $X-   3"@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>93</ContextCount>
  <ElementCount>229</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/Acquisition</Role>
      <ShortName>ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://hillstreambio.com/role/ConvertibleNotes-RelatedParties</Role>
      <ShortName>CONVERTIBLE NOTES - RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - REDEMPTION LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/RedemptionLiability</Role>
      <ShortName>REDEMPTION LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - STOCK BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StockBasedCompensation</Role>
      <ShortName>STOCK BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - STOCKHOLDERS??? DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StockholdersDeficit</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables</Role>
      <ShortName>CONVERTIBLE NOTES - RELATED PARTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/ConvertibleNotes-RelatedParties</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - REDEMPTION LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/RedemptionLiabilityTables</Role>
      <ShortName>REDEMPTION LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/RedemptionLiability</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - STOCK BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StockBasedCompensationTables</Role>
      <ShortName>STOCK BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/StockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/IncomeTaxes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - ACQUISITION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/AcquisitionDetailsNarrative</Role>
      <ShortName>ACQUISITION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/Acquisition</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SCHEDULE OF CONVERTIBLE DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails</Role>
      <ShortName>SCHEDULE OF CONVERTIBLE DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative</Role>
      <ShortName>CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - REDEMPTION LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative</Role>
      <ShortName>REDEMPTION LIABILITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/RedemptionLiabilityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SCHEDULE OF EXERCISE PRICE RANGE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails</Role>
      <ShortName>SCHEDULE OF EXERCISE PRICE RANGE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative</Role>
      <ShortName>STOCK BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/StockholdersDeficit</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY???S DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY???S DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails</Role>
      <ShortName>SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/IncomeTaxesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://hillstreambio.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://hillstreambio.com/role/SubsequentEvents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex14-1.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex4-3.htm</File>
    <File>hils-20211231.xsd</File>
    <File>hils-20211231_cal.xml</File>
    <File>hils-20211231_def.xml</File>
    <File>hils-20211231_lab.xml</File>
    <File>hils-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
    <File>form10-k_013.jpg</File>
    <File>form10-k_014.jpg</File>
    <File>form10-k_015.jpg</File>
    <File>form10-k_016.jpg</File>
    <File>form10-k_017.jpg</File>
    <File>form10-k_018.jpg</File>
    <File>form10-k_019.jpg</File>
    <File>form10-k_020.jpg</File>
    <File>form10-k_021.jpg</File>
    <File>form10-k_022.jpg</File>
    <File>form10-k_023.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="367">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 93,
   "dts": {
    "calculationLink": {
     "local": [
      "hils-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hils-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hils-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hils-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hils-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 377,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 31,
    "http://hillstreambio.com/20211231": 7,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 42
   },
   "keyCustom": 35,
   "keyStandard": 194,
   "memberCustom": 26,
   "memberStandard": 15,
   "nsprefix": "HILS",
   "nsuri": "http://hillstreambio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://hillstreambio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES",
     "role": "http://hillstreambio.com/role/ConvertibleNotes-RelatedParties",
     "shortName": "CONVERTIBLE NOTES - RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HILS:RedemptionLiabilityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - REDEMPTION LIABILITY",
     "role": "http://hillstreambio.com/role/RedemptionLiability",
     "shortName": "REDEMPTION LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HILS:RedemptionLiabilityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - STOCK BASED COMPENSATION",
     "role": "http://hillstreambio.com/role/StockBasedCompensation",
     "shortName": "STOCK BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - STOCKHOLDERS\u2019 DEFICIT",
     "role": "http://hillstreambio.com/role/StockholdersDeficit",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - INCOME TAXES",
     "role": "http://hillstreambio.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://hillstreambio.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://hillstreambio.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://hillstreambio.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Tables)",
     "role": "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables",
     "shortName": "CONVERTIBLE NOTES - RELATED PARTIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://hillstreambio.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - REDEMPTION LIABILITY (Tables)",
     "role": "http://hillstreambio.com/role/RedemptionLiabilityTables",
     "shortName": "REDEMPTION LIABILITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - STOCK BASED COMPENSATION (Tables)",
     "role": "http://hillstreambio.com/role/StockBasedCompensationTables",
     "shortName": "STOCK BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://hillstreambio.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)",
     "role": "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
     "shortName": "DESCRIPTION OF BUSINESS AND LIQUIDITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HILS:ReverseStockSplitPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-09-152021-09-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HILS:ReverseStockSplitPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-09-152021-09-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - ACQUISITION (Details Narrative)",
     "role": "http://hillstreambio.com/role/AcquisitionDetailsNarrative",
     "shortName": "ACQUISITION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-11-12_custom_FarringtonMember_custom_ExchangeAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_custom_RolledOverInToNewNotesMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - SCHEDULE OF CONVERTIBLE DEBT (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails",
     "shortName": "SCHEDULE OF CONVERTIBLE DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_custom_RolledOverInToNewNotesMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)",
     "role": "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
     "shortName": "CONVERTIBLE NOTES - RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-09-27_custom_OriginalNotesMember_custom_ExchangeNotesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "HILS:EquityFinancingRangeValuationAssumedExpectedInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails",
     "shortName": "SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "HILS:EquityFinancingRangeValuationAssumedExpectedInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails",
     "shortName": "SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://hillstreambio.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "HILS:GainOnRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - REDEMPTION LIABILITY (Details Narrative)",
     "role": "http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative",
     "shortName": "REDEMPTION LIABILITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HILS:RedemptionLiabilityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "HILS:GainOnRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "HILS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - SCHEDULE OF EXERCISE PRICE RANGE (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails",
     "shortName": "SCHEDULE OF EXERCISE PRICE RANGE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails",
     "shortName": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - STOCK BASED COMPENSATION (Details Narrative)",
     "role": "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative",
     "shortName": "STOCK BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "role": "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY\u2019S DEFERRED TAX ASSETS (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails",
     "shortName": "SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY\u2019S DEFERRED TAX ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)",
     "role": "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails",
     "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - INCOME TAXES (Details Narrative)",
     "role": "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_FounderAndChiefExecutiveOfficerMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "role": "http://hillstreambio.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-12-292019-12-30_custom_AssetPurchaseAgreementMember",
      "decimals": null,
      "lang": "en-US",
      "name": "HILS:AssetAcquisitionDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-01-14_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember_custom_EmployeeAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit",
     "role": "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit",
     "shortName": "Consolidated Statements of Changes in Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statement of Cash Flows",
     "role": "http://hillstreambio.com/role/StatementOfCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS AND LIQUIDITY",
     "role": "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity",
     "shortName": "DESCRIPTION OF BUSINESS AND LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - ACQUISITION",
     "role": "http://hillstreambio.com/role/Acquisition",
     "shortName": "ACQUISITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "HILS_AccruedInterestRolloverToNewNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest rollover to new notes payable.",
        "label": "Accrued interest roll-over to new notes payable"
       }
      }
     },
     "localname": "AccruedInterestRolloverToNewNotesPayable",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_AcquiredInprocessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in process research and development.",
        "label": "Acquired In-process research and development"
       }
      }
     },
     "localname": "AcquiredInprocessResearchAndDevelopment",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_AcquiredInprocessResearchAndDevelopment1": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in-process research and development.",
        "label": "Acquired in-process research and development"
       }
      }
     },
     "localname": "AcquiredInprocessResearchAndDevelopment1",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_AssetAcquisitionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition description.",
        "label": "[custom:AssetAcquisitionDescription]"
       }
      }
     },
     "localname": "AssetAcquisitionDescription",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HILS_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement [Member]",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_BacisAndDilutedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss for basic and diluted.",
        "label": "[custom:BacisAndDilutedLoss]"
       }
      }
     },
     "localname": "BacisAndDilutedLoss",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_BoardOfDirectorsAndScientificAdvisoryBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board of Directors and Scientific Advisory Board [Member]",
        "label": "Board of Directors and Scientific Advisory Board [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsAndScientificAdvisoryBoardMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_CashBonusReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash bonus received",
        "label": "[custom:CashBonusReceived]"
       }
      }
     },
     "localname": "CashBonusReceived",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HILS_CommonStockValuationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock valuations [Policy Text Block]",
        "label": "Common stock valuations"
       }
      }
     },
     "localname": "CommonStockValuationsPolicyTextBlock",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HILS_ConvertiblePromissoryNoteAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note Agreements [Member]",
        "label": "Convertible Promissory Note Agreements [Member]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNoteAgreementsMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_DebtDiscountAndDerivativeInstrumentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt discount and derivative instruments [Policy Text Block]",
        "label": "Debt discount and derivative instruments"
       }
      }
     },
     "localname": "DebtDiscountAndDerivativeInstrumentsPolicyTextBlock",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HILS_DeemedDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend.",
        "label": "Deemed dividend"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_DeemedDividendUponDebtExchange": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend upon debt exchange.",
        "label": "Deemed dividend upon debt exchange"
       }
      }
     },
     "localname": "DeemedDividendUponDebtExchange",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized costs.",
        "label": "Capitalized costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_DisclosureRedemptionLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption Liability",
        "verboseLabel": "Schedule Of Fair Value Of Redemption Liability"
       }
      }
     },
     "localname": "DisclosureRedemptionLiabilityAbstract",
     "nsuri": "http://hillstreambio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "HILS_DueToFounderConvertedToNotePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to founder converted to note payable.",
        "label": "Due to founder converted to note payable"
       }
      }
     },
     "localname": "DueToFounderConvertedToNotePayable",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_EmployeeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Agreement [Member]",
        "label": "Employee Agreement [Member]"
       }
      }
     },
     "localname": "EmployeeAgreementMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_EquityFinancingRangeValuationAssumedDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate.",
        "label": "[custom:EquityFinancingRangeValuationAssumedDiscountRate-0]"
       }
      }
     },
     "localname": "EquityFinancingRangeValuationAssumedDiscountRate",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "HILS_EquityFinancingRangeValuationAssumedExpectedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected coupon interest rate on notes.",
        "label": "[custom:EquityFinancingRangeValuationAssumedExpectedInterestRate-0]"
       }
      }
     },
     "localname": "EquityFinancingRangeValuationAssumedExpectedInterestRate",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "HILS_EquityFinancingRangeValuationAssumedExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term to exit event.",
        "label": "[custom:EquityFinancingRangeValuationAssumedExpectedTerm-0]"
       }
      }
     },
     "localname": "EquityFinancingRangeValuationAssumedExpectedTerm",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "HILS_EquityFinancingRangeValuationAssumedPercentage": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed ranges pre-money valuation at time of next equity financing.",
        "label": "[custom:EquityFinancingRangeValuationAssumedPercentage-0]"
       }
      }
     },
     "localname": "EquityFinancingRangeValuationAssumedPercentage",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_EquityValuation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Valuation.",
        "label": "[custom:EquityValuation-0]"
       }
      }
     },
     "localname": "EquityValuation",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement [Member]",
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExchangeNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Notes [Member]",
        "label": "Exchange Notes [Member]"
       }
      }
     },
     "localname": "ExchangeNotesMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eigjht [Member]",
        "label": "Exercise Price Eigjht [Member]"
       }
      }
     },
     "localname": "ExercisePriceEightMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member]",
        "label": "Exercise Price Five [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member]",
        "label": "Exercise Price Four [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One [Member]",
        "label": "Exercise Price One [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven [Member]",
        "label": "Exercise Price Seven [Member]"
       }
      }
     },
     "localname": "ExercisePriceSevenMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six [Member]",
        "label": "Exercise Price Six [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three [Member]",
        "label": "Exercise Price Three [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two [Member]",
        "label": "Exercise Price Two [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis liability change in fair value.",
        "label": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis liability initial embedded redemption value.",
        "label": "Initial embedded redemption value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_FarringtonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Farrington [Member]",
        "label": "Farrington [Member]"
       }
      }
     },
     "localname": "FarringtonMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_FiveNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Notes Payable [Member]",
        "label": "Five Notes Payable [Member]"
       }
      }
     },
     "localname": "FiveNotesPayableMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_FounderAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder and Chief Executive Officer [Member]",
        "label": "Founder and Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "FounderAndChiefExecutiveOfficerMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_GainLossInRedemptionValue": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in redemption value.",
        "label": "Change in redemption value",
        "negatedLabel": "Change in fair value of redemption liability"
       }
      }
     },
     "localname": "GainLossInRedemptionValue",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows",
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_GainOnRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on redemption value.",
        "label": "Gain on redemption value"
       }
      }
     },
     "localname": "GainOnRedemptionValue",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_GrossProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance initial public offering.",
        "label": "Gross proceeds from issuance initial public offering"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_IncomeTaxReconciliationPermanentDifferencesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Permanent differences and other.",
        "label": "Permanent differences and other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentDifferencesAndOther",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_IncreaseInSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in shares reserved for issuance.",
        "label": "[custom:IncreaseInSharesReservedForIssuance]"
       }
      }
     },
     "localname": "IncreaseInSharesReservedForIssuance",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HILS_LossOnRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss on redemption value.",
        "label": "Loss on redemption value",
        "negatedLabel": "Loss on redemption value"
       }
      }
     },
     "localname": "LossOnRedemptionValue",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/RedemptionLiabilityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "[custom:MilestonePayment]"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_OriginalNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original Notes [Member]",
        "label": "Original Notes [Member]"
       }
      }
     },
     "localname": "OriginalNotesMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_PromissoryNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes Payable [Member]",
        "label": "Promissory Notes Payable [Member]"
       }
      }
     },
     "localname": "PromissoryNotesPayableMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_RedemptionLiability": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption liability.",
        "label": "Redemption liability"
       }
      }
     },
     "localname": "RedemptionLiability",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_RedemptionLiabilityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption liability disclosure [Text Block]",
        "label": "REDEMPTION LIABILITY"
       }
      }
     },
     "localname": "RedemptionLiabilityDisclosureTextBlock",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/RedemptionLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HILS_RepaymentsOfDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of deferred offering costs.",
        "label": "RepaymentsOfDeferredOfferingCosts",
        "negatedLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "RepaymentsOfDeferredOfferingCosts",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_RestatedEmploymentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restated Employment Agreement [Member]",
        "label": "Restated Employment Agreement [Member]"
       }
      }
     },
     "localname": "RestatedEmploymentAgreementMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split [Policy Text Block]",
        "label": "Reverse stock split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HILS_RolledOverInToNewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rolled Over in toNew Notes [Member]",
        "label": "Rolled Over in toNew Notes [Member]"
       }
      }
     },
     "localname": "RolledOverInToNewNotesMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_RolledOverMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rolled Over [Member]",
        "label": "Rolled Over [Member]"
       }
      }
     },
     "localname": "RolledOverMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_SeptemberExchangeNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September Exchange Notes [Member]",
        "label": "September Exchange Notes [Member]"
       }
      }
     },
     "localname": "SeptemberExchangeNotesMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "[custom:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice-0]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average contractual term.",
        "label": "Weighted average contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "HILS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average contractual term.",
        "label": "[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "HILS_TwentyNineteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Stock Incentive Plan [Member]",
        "label": "2019 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwentyNineteenStockIncentivePlanMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_TwentySeventeenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Stock Incentive Plan [Member]",
        "label": "2017 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwentySeventeenStockIncentivePlanMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HILS_UnpaidDeferredOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid deferred offering costs.",
        "label": "Unpaid deferred offering costs"
       }
      }
     },
     "localname": "UnpaidDeferredOfferingCosts",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HILS_UnsecuredPromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured Promissory Notes [Member]",
        "label": "Unsecured Promissory Notes [Member]"
       }
      }
     },
     "localname": "UnsecuredPromissoryNotesMember",
     "nsuri": "http://hillstreambio.com/20211231",
     "presentation": [
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r384",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r384",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r384",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r384",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r384",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://hillstreambio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r144",
      "r176",
      "r199",
      "r201",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r358",
      "r359",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r144",
      "r176",
      "r199",
      "r201",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r358",
      "r359",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r144",
      "r176",
      "r195",
      "r199",
      "r201",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r358",
      "r359",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r144",
      "r176",
      "r195",
      "r199",
      "r201",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r358",
      "r359",
      "r370",
      "r371"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r108",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r315"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrentAndNoncurrent": {
     "auth_ref": [
      "r344",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.",
        "label": "Accrued Salaries"
       }
      }
     },
     "localname": "AccruedSalariesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r40",
      "r41",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r233",
      "r315"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r230",
      "r231",
      "r232",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r203",
      "r227",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r48",
      "r55",
      "r164",
      "r300"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative",
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r67",
      "r100",
      "r102",
      "r106",
      "r110",
      "r128",
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r275",
      "r278",
      "r290",
      "r313",
      "r315",
      "r340",
      "r350"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r35",
      "r67",
      "r110",
      "r128",
      "r129",
      "r130",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r275",
      "r278",
      "r290",
      "r313",
      "r315"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r204",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r198",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r198",
      "r200",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "ACQUISITION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/Acquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r72",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "DESCRIPTION OF BUSINESS AND LIQUIDITY"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r21",
      "r315",
      "r365",
      "r366"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r52",
      "r57",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash - end of year",
        "periodStartLabel": "Cash - beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r52",
      "r291"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r118",
      "r345",
      "r354"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (See Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r125",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheetsParenthetical",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative",
      "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r315"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value, 250,000,000 shares authorized; 6,357,314 shares issued and outstanding as of December 31, 2021 and 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r11",
      "r342",
      "r351"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Total carrying value"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Current portion"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Long term portion"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "SCHEDULE OF CONVERTIBLE DEBT"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Related-party convertible notes, net, less short-term portion"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Short-term portion of related-party convertible notes, net"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r59",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r158",
      "r165",
      "r166",
      "r167",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "CONVERTIBLE NOTES - RELATED PARTIES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r66",
      "r71",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r303",
      "r341",
      "r342",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r9",
      "r11",
      "r189",
      "r341",
      "r342",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r141",
      "r169",
      "r170",
      "r301",
      "r303",
      "r304"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal amount outstanding",
        "verboseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r156",
      "r169",
      "r170",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r29",
      "r168",
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r29",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r30",
      "r66",
      "r71",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r154",
      "r300",
      "r304"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: debt discount, net of accretion"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r34",
      "r112"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax asset, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Federal net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r252",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development credit",
        "verboseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r36",
      "r280",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r24",
      "r70",
      "r131",
      "r133",
      "r134",
      "r138",
      "r139",
      "r140",
      "r308"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to founder",
        "verboseLabel": "Due to Related Parties, Current"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets",
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r68",
      "r242",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument embedded in host contract.",
        "label": "Embedded Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r40",
      "r41",
      "r42",
      "r73",
      "r74",
      "r75",
      "r77",
      "r82",
      "r84",
      "r89",
      "r111",
      "r188",
      "r190",
      "r230",
      "r231",
      "r232",
      "r257",
      "r258",
      "r284",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r360",
      "r361",
      "r362",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "SCHEDULE OF FAIR VALUE OF THE REDEMPTION LIABILITY"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/RedemptionLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfFairValueOfRedemptionLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r22",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "verboseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r243",
      "r245",
      "r251",
      "r259",
      "r262",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r69",
      "r83",
      "r84",
      "r99",
      "r241",
      "r260",
      "r263",
      "r357"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Effective income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r239",
      "r240",
      "r245",
      "r246",
      "r250",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income tax benefit at the federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfEffectiveIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Changes in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Changes in accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating accounts:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Changes in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r43",
      "r98",
      "r299",
      "r302",
      "r347"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued interest",
        "verboseLabel": "Interest Payable, Current"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r67",
      "r103",
      "r110",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r276",
      "r278",
      "r279",
      "r290",
      "r313",
      "r314"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r67",
      "r110",
      "r290",
      "r315",
      "r343",
      "r353"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r67",
      "r110",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r276",
      "r278",
      "r279",
      "r290",
      "r313",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r53",
      "r56"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r37",
      "r38",
      "r42",
      "r44",
      "r56",
      "r67",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r83",
      "r84",
      "r85",
      "r100",
      "r101",
      "r104",
      "r105",
      "r107",
      "r110",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r285",
      "r290",
      "r346",
      "r356"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New accounting pronouncements not yet adopted:"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expenses), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r11",
      "r342",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r100",
      "r101",
      "r104",
      "r105",
      "r107"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedLabel": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Other Commitments, Description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r49",
      "r270",
      "r271",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r204",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r315"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r19",
      "r20"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from related-party convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r197",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r197",
      "r307",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r197",
      "r307",
      "r310",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r305",
      "r306",
      "r308",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r237",
      "r326",
      "r372"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "In-process research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r190",
      "r233",
      "r315",
      "r352",
      "r363",
      "r364"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r77",
      "r82",
      "r84",
      "r111",
      "r230",
      "r231",
      "r232",
      "r257",
      "r258",
      "r284",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "SCHEDULE OF ASSUMPTIONS OF REDEMPTION LIABILITY"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/RedemptionLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF SIGNIFICANT COMPONENTS OF COMPANY\u2019S DEFERRED TAX ASSETS"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r204",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "SCHEDULE OF EXERCISE PRICE RANGE"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r208",
      "r216",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL WEIGHTED AVERAGE ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://hillstreambio.com/role/StatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "periodEndLabel": "Estimated fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Shares underlyling options, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weigthed average exercise price, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Shares underlying options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Shares underlying options, granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r210",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares underlyling options, Ending outstanding",
        "periodStartLabel": "Shares underlying option, Beginning outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weigthed average exercise price, Ending outstanding",
        "periodStartLabel": "Weigthed average exercise price, Beginning outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Shares underlying options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r202",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weigthed average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weigthed average exercise price, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weigthed average exercise price, granted",
        "verboseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r204",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Exercisable Options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Outstanding Options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfExercisePriceRangeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r222",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfBlack-scholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r40",
      "r41",
      "r42",
      "r73",
      "r74",
      "r75",
      "r77",
      "r82",
      "r84",
      "r89",
      "r111",
      "r188",
      "r190",
      "r230",
      "r231",
      "r232",
      "r257",
      "r258",
      "r284",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r360",
      "r361",
      "r362",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r89",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfAssumptionsOfRedemptionLiabilityDetails",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Shares issued upon acquisition"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r12",
      "r13",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Issuance of shares for the acquisition of Farrington Therapeutics LLC, shares",
        "verboseLabel": "Stock Issued During Period, Shares, Acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://hillstreambio.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r12",
      "r13",
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/StockBasedCompensationDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r188",
      "r190",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Shares underlying options, exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r33",
      "r188",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Issuance of shares for the acquisition of Farrington Therapeutics LLC",
        "verboseLabel": "Stock Issued During Period, Value, Acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r67",
      "r109",
      "r110",
      "r290",
      "r315"
     ],
     "calculation": {
      "http://hillstreambio.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets",
      "http://hillstreambio.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r298",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r298",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r298",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r298",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://hillstreambio.com/role/DescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/AcquisitionDetailsNarrative",
      "http://hillstreambio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://hillstreambio.com/role/ConvertibleNotes-RelatedPartiesDetailsNarrative",
      "http://hillstreambio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://hillstreambio.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r373": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r376": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r377": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r380": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r381": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r382": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r384": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r385": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r386": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r387": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r388": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r389": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r390": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r391": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r392": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001493152-22-008703-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-008703-xbrl.zip
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M^TR>S]^Y'@G< 0%'+]C4CT8<-)$WC2;>9-C/%(-RZCI V@\GF6!3*M0AUZ0
M]JN\RA@#>" E4]0& >@ _PIO1Q)T@?VS:GVDPM1]*P=:#Y@6>4/:!VP4[K2U
M2G#A6*,+"OV T5"&/2YAI4,/J[8V8*%P/4P%XT$_'=<R$ONZNG8K*IJDP"]C
M+ '#M;LR^06]O;FV*!AW@7NJ@76X[4)!J1;WL/D43+]7Y6"NM)U4KBUYB^"W
M<EN,(;;2Q<9>V&ERKGGG O/0.F'2!#,N8^[V0ND<[AG,,\",KHXY$8?N;E5/
M3.3F,D8'-<J5[Y A1P6%5U7<#00!9:%3I^/# M]9DQ;GXBYE\RKQ!&]EB,T
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MNR -U+.OY>?8\F";GW]? %!+ P04    " !83X%41Q>B__4"  # #0  "@
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M1#"H_B+[;9F,;6A[<^8;V@O^R#2CT&6\%P2T?"">0L&][(N!2D5(S/<3J!V
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M4+'+.6*7SZ.>5CSAN7G"G&O<?S/H]'4 T5PQE44'J(HK/3M76@P0>DC \.N
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M!BP!E,1]F2<U?HY]443I%*$\=YY#!5H/ ZV?9203$<*)[@5]%2F=)I08]_J
MZUXG48'70YN%591K$2C7W$8630>MBG(M#N6:5_!"<Q:#UUBO^L/^((R'4I(,
M>SK 4W\9(+5W+9)@O&3%U/T^)^#8^WD0X(SFE3XQ7:H 9PX 9VXI#@IQ:[EQ
M>PUF6_!2[&L_8O1=>V(SW>&-3'REY5FB?'D:O1#AX*(G$OE):!E@]1]X2K(!
M_:KWLK07)^HO&7R- IDXR(EF&/UI6#H2)^C)9,1,.J^7:LV[!\Q<7L<5S#P
M9O+S>LTPTTMD16D>!#7%B;UBN#F*LQ>2+?-$8%,<V&N&&E#X*ZAY"-3D!_:*
MH>9"W51 \P"@R<_K-<,,!JY64/,0J"E.[!7#S:'J]EY(5ZDG@AOGQ%X)W%@C
MZD'<ESI5_GZ<16DR?!E0P\Z<2W%C0"0=EBVI$S?]RBZ>7%U[48">KO"?6:)T
MH/R78T._"P3NV/X+!X:1#"'0ZY""PG'L]Y3L &GT,_1KGG8Z0!P77$?&Y-)+
ME6)7W>,H4%<JR$3HED:ZS^:?$1Z>(B%UW,F&J<:O"QCPT1Q!P$(XV=@#W-K)
M?<%Y8M&>UC(]RQ*_!\+;"VMU>EM!\]OV_<P.?KJI'W'P-QX3A*;'=E<@-%\@
M-(=AD4528_,>3"M7EDT@Q0N!J<?D:;."Z2E'_GQBE869)Q.K*@BM(/2A!/<'
MQ;XG2?5T$X<;%6!7@/T$DD3IHT<*9ZO N0+G>X!SR6!7@LNGJ-3PMR'T994&
M?+$P>]\#F*?:B'-.Z)\,H7)/RW%T)>'3RG+ZVO'L(=N<TDQ!?QJZ3\H^K3*@
M57A_9Y&:S0?@_3D<+9X[PQ@!7B7T/15BWWGXSPWL/U1#9_.QM1EJZ-S8O*-[
MN 'PKQ& 7I8 92DU8GTA9<+GH9/XU%+EMQ_],ZHV!H >5;7A.=8>"JXC1U7J
M:U0!Z]\'UHM>G*27,NDCU!8K('B][>R?E1(;6'H8)1X!\D<1.VB.9@[DS?4[
M@/QUVI_F ?X701R:$QO8..HU?P3UFNN/+P15"%<AW.(CW*AD5F#.8TEF:W7T
M*)I_->\GF7V*11*<=@Y4(OTT3O1>%%SXBD'7WPNN% H.]%*%/(^(/ 2X#[V+
MYV8A"&\/9B$(FH_-0BKPK\#_L0FZ"\=_GZ!GD6(@_GIQ, 9C?2ETELA=.(#U
M5G/K/;QC![./RE/@:%/&YVRLJ5.8\Z*7?G@.6-_9E'GHVB?0"/SV).O+1,#-
MC\/5 \Y@=(V31G4F/9 1J,?17=/>?2ZC\TX:V#XOG<(]#O1,)E@M^(Y;&\ _
M[WEG']^IF_>PE3B#@37^1+_TI @(@3Z^@R7"?_%_/@X\G0Y#(& =@-SW7K,Q
M2+U+0&OMG<AK[SSNBZC&/]2\"X#XS@>O+Y*NBMY[^&K^OQ\\A/NZ"%47'N&&
MD)Y^U ,1N3/4.Z*OPN'[V^=8V?WO_VIN-CY\?(??[WY\-]A]BL7::?Y7O>X=
M*1D&[[WS+)3U,]&57KV^^Q'.[>&;^>!=JR#MX7(;_U@I#=*.$[B2>AH/WGN?
M0N%_]]9A>3H.5?#!,P_;<0J\S#YOKFX4;YA3N.L09G<-"#?F_SIG]*YT2/,+
M57Q@=:W^DKRD9P*S6:Q^&U?_L;W[]>3X\O!@>>GB<N_R\.+CN_;N F_FXG#_
MZ_GQY?'AQ?+2WLF!=_B?_5_V3GX^]/9/OWPYOK@X/CU9T!VVS Y_$[JGHFX:
M1[7EI8/5_56OU=A8WUG07;T,%#HZ/?\"*Z8AD1_?!#??=AKKWV0@5;U^$/OD
M(T)A^IN/WL(&_,^W;_BO9FNM^>VO<_5I2Y]N;?SK]#N,!XPVBB.22Y3O&7'P
M7'9&PUW2N,C(6/$B@3H$3/C>G6]EM]FH_XN8=S%F 2@5S-QG]:'LI';MQ?5N
MCUSO7A2!OG(N!W&23K[FF_6OYZ=77_ZZW.NNS.00?A!4.G'2%^E/*^HF?=^.
MXU"";I)D<A(,N9O"0]_96M_\, I.* _R/<SL>@&I]DY.ONY]]LX/ST[/+[VS
MK^<77_=.+KW+4P^(_"40<J^YYIV>>\V--\%;[_1H>>GRET.O8  %[=_;OX3G
M7G-G;;T"^>=:_5&<+"^E/>EUE/9%Z VE2#P9!3+P1C%K;02SSDA-/F1CT&34
M:FZ>GOQV=OKYH!/.!"T"+!T.W_4",<25RF@2=I06-DXA+ /8SQ(8(#VBC?\.
MH]VZE?#K\;]_^?<__Q0;8N9;*6]CVKI6=@^DS^893#V9R#MJ'LXWE;$L)HP^
M/U,9DQDP6E!AL.!MC.5_?MO[_=.QW-<;X;PQEHX(]43.,KHSPUW6GXB[7)[O
MG5P<$QNY'X=97@(64G&8.5Y]SF'2'+0\MK!Z'0!:[YOY?UX:Y__^MJB;7>RK
MVH_[&',$-[2\U%&A]**,V,TH.3PTY/"0#/%'\.9)QNZ9260P.52;\7_^.)4;
MG1FH4:-SHB.F65]OPKP5VYO1ZHN;;I1N^EQVJ1]+E&*GO"G:U.^_=YJ];N.O
MJ][?9GI6D9\1T)273^ZKSQ>7YX=[7Y:7/AV?GOVR=_YEK^8=G^ROCH/2XK*/
M-X<WPD^7E_ XO+CC)?DQ>$)[>B!]]%D&GHH\OR<2F/WMHFYU,LJD&#D)LX4A
M_.ZKJ/O32F.%_AZ((+!_/WB'CO$_M^G[<1B*@88%V7^Q]^=CFCQ\@BN9I IT
M 'M>:3RPOJ2/:3#B:K#>A/94;\+]M[2^\X_'OBG$ZA%:LUFB-5A<+@$)E(M1
M8F:"J22X'P=32$]_;;/1'U[M7&W_N+W.D97K6OKO*2=BD,17B#UE/>T>ZT25
M+137 CU\=]OZTF#\=A]\=ZU'O[H1))NTZJ>'R6E@="ENCDU8!G<;NTU2.3Z^
M:G8'/Y]%Z=:,%+:9\:XI^UC9W5ZOMS;76QOK$[3^,FS!_TD>FQC=?[Q'YGF$
MB;R\./'^<(I/ @O\V$Z\=V;Q)?S%=^.D*R+U%_W]=D:X^>P(.2]+/5X]7[U8
MY>69@,^D=!LE&/=.XM7)$/R.>/IN)9I4HLF]-)>]($BDUN8_GU4DFY-9P$;O
M^TG[D]_8_G=KWEC A#VL[#9;C0:?^WF<I=)KM;Q#H=/;>$%[AE!=&[,-;-UQ
M[JW)YQ[U!_)_3O:_^'IV1H()DZ_L7F3*,@8XNCMM!NW'/J_-2>>U#_\\32[C
MZVB*H))].=[HM7[35QNS/JUBZI7=3XD*NO(:.&GRU.=D:,G(8>U-.BQB]:?)
M&0CI*O*GZ :'?QS\H@_BK\EA=]8G-C+_RN[)/^]Q6I6T/Q,R/Y'<G,6@MH7_
MHP;3=<7-RZW^]ZLOAUN_SIVH/VD3*[N-[>W&5B7B.R*^.2<CY'>\00+HIP8B
M]*1-98*?,9=)5W+\K \?X)(7YP-TOGTI0CH@L;V$Y['W%H3MDXU20(J02#&=
ME W^T_GYGV=;.\$?8GY(F;ML )>=QO;;21[D<:ETG-E3^XBS7AS=ZF6Z&?[G
ME]]VAHUH[X]G=;871S"Z[I7=G8T->&=]NM#97CR3^YO"J_+?_[7=:FY] (J<
MRE .<.?&@UCS@#2'&2JTG@"H&*$:"[;EQ7;R7F 9%)4J"??$KB"9R, ;9(G.
MT">4QO I6\J:K3?MM\A:T7V_YZ?O%W7/M]+U%V2#@8E ]NXFV&X%)XN3]]YU
M3Z7R:8PS:^M/X3>B9,1<ZI/"[WE^*+2N?"GWWE?C2>XI$8@]O*&+8;\=AV]0
M$J]NZ9XZ\.-O#&X)0R'*R"1O_![69_"  P#Q@%\*-O'H"N<D"O9?^_N'AT='
MCZ2+%@+GCA$X#8<<-EMMHC53PIJ^_\]_MHZ/UK[\O#DG N?HNCF@"X.Y\-@T
M]FZL>?^[L8J9Z]Y )-Z5"+/IGNEYUC^?2%4>CP V1(W)V91(\?YVXS2X^L]7
MV9P3P"@MFM/VJUM_W*5>]N1D$_;F")$Y--1V>D3=1>*?_<]A_U_JS^;,PEJ0
MQH]'M$Q:TPIP"!V(/V\W:7LSU$^03O'9?1')=YEZGS_O/X^!Z8],IZHSK'3'
M'],=NR7=T4-A(X[DZB+'4C[E]3T"]&$!%Y\"8]I#S^])D%%A(=\]Q=?D1(8J
M[0GO&G3@^O<HOH;9I=!P>0$\T!D:=(3V ME1$0>.8J$ ;[VQ82^\ !2\^U4;
MXO$[_&WR2<8(8[/DR?D-IOX7SGQA)CZF>2=3R#^W=_[=.S[1C?_Y<0HYZH69
ML@ @A_&3D<(\L7-!P>TU84L4I_#+GYE"@@ATD/(G$LJATI,)Y!I&F^5_4;IL
M02Y7O=MP9;V$*[_&81:E(J&LB$1/QI'?!XWF+\=_^9M_;<T,1T8FGH0;19K8
MK+/%*N282^2X[DD X6040]XTWWH]X!F(%H$GPC#'#1=IVM*\ &.6\:2$'PYW
ML:+J\A(@#3['9#\O@,=1E]X=)-*7Y'AHMCQ*N-7>&Q@0)&)/9W[/TUB$&19L
M<M+2GDA'%W\M]#ANT\=F$V^!'T:!]Z;U=GD)=]D&P1I>:/\!>\ /Z%WX"I=A
M!L)D2TVKH%4*G7H[#2\00WT[ZI<#'DRN,.=JHHJ7BC2;0@%^^6?_RZ=_7PQZ
MVVLSHP"3YZ\(044(IA$"1 _ C+Y*4T F&0*&)'&$5L!PZ,DKF0R]8Y3:L1?+
ME?0.1"J\(^:E)3I1C.$R5Y1#EY>,('HNNUDHB(A<U"^]-WC06Q^\UEIK-1=5
M@7,# 1E@TM.,J<;RTBC9X"7GQ$#JM[E@?+LP[!P(GH=!NLE8OO-+_X_&U4'3
M#W^\Y,)XCLND^5=V?\>J>D\K"R\OG<1>GI*^H"CSNC">5,D05BH]X?N \0FV
MF2$,0#TRFO@KR--1?>(#W0=2 ;,DEN<L+_EQ'_8VK*&@ .,!;\5CZ7K=)+Y.
M>YYYO H;DJRT*I,(XF'(0JOQ8=KJZ''S@WWMSA?,VM X8A9G)\_?1#G!O#UE
MG?9-JU8W6^UZRXH^5MYAM7I1(>@U)D,\W*^Y\8]'OXC/"/B\U#'@GJV7=OT?
MLP6@,@>8S1*;CW_@,W5A6$#9?/QU[Q70P0M^%!!Y@N,?@YOYC9D>V7\A'1Z,
MU=](]N%FNG$RG"P4GGV__&OMG_MK@\Z\%")B+Q2MGR#)-^N?E&)=VB#JEB7)
MH 2.C^#4G#GX;3Z&!W.^2=5,?5!6QL*UC,E9,UWNM"PM6L*G3*M(ZBG&EO7L
MC].CM>'V+Y_]>4&Y:44E)^QI:DW)A22<+Q@9'BTBXO4<X:'1PG@Q957L\0^V
M(#$;)1)C5_4SK6>?ES.9U/S\VQ_GUP>__[X6?%\,4C-Q;P\D.57HQY-;?3K+
M2].-*YCAP58A[RYG*5J R>X+BB9Z3=/8R[2DMV '7'MV0JW .*&YPB'AZK6"
MN6%>+X(-Q&@-NE*:--=(1+X2(>JS6(@'EXIM7@*1!-K#2CXJF!:RLO9&O)UH
M:+DC:_OPIBB;R<5G)V/JO[M7P^WKP_5?_SV3 D53BWE.6]748IY/6BFO0JT9
MN%",']4(P!BJC89%D:;4Q1NA&0!;I1H&B@3WVK/I69[0&F0\_,D"N^QT))GW
M(TJHA5_Q4X5F_PA0"6$SB4,O!J'-P;!"^,X :8M8AO7&NI,W="&2MH!QZZ<W
MH1PB.GEOFAO>U]4+[)*PU=K$)*.W2#6*;6)4V?+2(&N'@!D.(G=4TF=?RP F
M%^A7 =RGD*2 EBRR0*5F8>-8:RM8'_N=9 _?C).]XL2.0M&=$NJ](S[]MK<C
MAGNM1\7;Z>NJ,'<^E_\CKA#=DV%H^:;WQ@FD@S%NM_B_O3TV8+NLI>(\MTJ.
M-\._3HYD*^I<KS\!/W+74T4(S#^2S&:>1S\<BK1W<(R$1(G")6(/^?J 5\7
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M&];&Q:WEI4&,(2;:#,1JF<-7G< -[2?X:6RJUPNM"BLX#HSB#/X0(;VM4T@
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MM*5".)Q=&-F#DW:IB3*%KMFT>M*#*4JN,(&5XN&0T!85!+@S!0[KF OS#^4
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M22E..:G)L*',+*%/&]-\V-"/)(;!^[$'D%/4K@:<*Q)^$5[H$A"K,7L ..1
M2PWG]>:B".I]DQO.]LA_I:OUL]A4\<&4O0XTW(UP";8(:1E.[4?56)Z\SZVS
MA1.#S@PIUK,^2(%/(1V4=1H*N")[\T((L."E" 6S5E? ^'_Z; Q+KB1?N!;P
M8)W-6BAX2R.SS<YC@Z+:=,=&;H!FY!96"!.]/TIELXXGTSIVQD4IHE$4?F#Y
M(F9 F%;96M*8DK]"#'U3VUODT3(F]A8NROQ"[&GU-[2;D16D1.X*:B]C+Q!?
M07J 9"A9]3.IF>T4S&F64#B\K2R3/2KQ$8+RCR?WS[*B945FV#-POSO_X3RT
M#J1#05;UND92YUM0?/&71\F;M"@G_E\*>IUIKD>,GF["4<+[T "<;< #QCT_
M-P HXJ?SPS&H$1BTY @)63H[M(IJ2)M60*9<KT..=[$0G@7=4HTXU>S3:0UC
M=P4M\1ZA=<4E,+M?(V]L/R*E76?2,0M9K+'Z%/':+D&D9T['Z/!@0=Y>A8:-
MK(RL7=86Q;/D]'T>CFQ3?HL1.-TQ/?4K.-'3 2=ZO3C1TP$G.EAANWB6H;X/
M#UZQV55K4UHT\_I HJIV757.R@_!, :TD%043<UAKKJM2!DRNLJMI2?MV_?_
M,TJ^?_/\[2AQS?3HOJ4M:@3#5QJ.X6^>_\][DO+O?WY+XI*_.NK*ZXBYS4>>
M2,!/ 0[HR%X>2D>?CB+\ER_ES/0C(P6J5R*427MD)>P4 ,\.#]Y%-<HCM71L
MI2377E8;5DR:>6^RV89U)>FU/+GW8/3P_GB2U?:I2^Z]><5_?7.*J-&;5V].
MN0$=\S T0@$9P3Z$VI;FB-0VZF%WO>1LQ*]IJOY[Y(,W9_JF,^W;8('5A\]X
MRO;/1\_(6"DQ $513+)_M_2&MLXW9C5)5T8NY:FC *U_CIKMD8T%GC[K<5QR
M(J.<;KBV^GSBF&X_Z9I-W44./3]7ZYS!5K,H^NK)E)1UF^VSI<NJV'HR1[@V
MFL/ ZJL_CJTIFIE"90 "!$QB#J?86S.].+D2MD;A\A$YT'0W];]?M.36RG]B
M<.?YVFE0/3;1 EEY62Q*/L:=G@("T5@#HT<W9P48E=BL4LTCJ '&]TU+CLIH
MP'=7@VC\/?.]#YG)53B_::I"AC[JO[W;\R9TO,F,Y8&?*:;IJO1@*JOSYX@;
MHRUB+LK5VH*OM%W*C";= #NP5<\ CP7[:R RQ6_YQ E3 $?O%/3%>W+'K*7]
M&?ZY4M63&U#JT? 9A_[%Z;1 YUQ7W>*(,/N\/RP""?)]S)!QX>QK1&T/^QJ^
M'1(!W.L,RJK.<"K2PM%E\3%0E3([Q@;X:%3:);04\B-U!16RR'IB-JO$4H>C
MP%/0E/!D$]JV^3DH,),C46$J(W/^:-B2W/.=7()$NLSHME^*2Z#YB'"KO](I
MO_[B[CT_Y#'=P$.A&P"(9)R\MF+ KQ?J&3;G<X@#'GR2..#IDX@XX-'I@STG
M#MCW#?3 NY.3!V1<O?_I.WH;V;5@E;[/B)JH).0=\+7O!5^KU5-[#[#;\PW$
MAHF'@1:J@;B);+N3IX\?PL L"_OW$Z8+2(ITI=!X$)L;AHP[O[/#Z<$7G+QG
M0,;8@XP5-*"<^HP,_^!K^@5WHO4-&:#Z,9/04?*#1?W8''=1Z8=%YNY-R03-
M<WACY!-\2!= O=.)<T8@.RU3\F%*I(?!+4SOX*&RC;\LIQ_NFY5#R]$PE1Y;
MRT7<Z(1+-D9)2W_)Q;>=@:-NJX>#X-4X!;9I9)I& L5FN[3ED?(.%"JX0O$2
M^JBLF ,@K]QWY/())QX-<,*+&Q?1K<BK*9@(H.5,-1I"-E*$D\'.BEN^"D=>
MY9AH&:_$<G/\^1>I^6$+*VT7G U\]?P5;*7#@UI)=*-VE)Z?G3<VM.F8<5%B
MX/++.O'1W9S!.1:.YT6'4E&>["^0NX-:?F]O2HUCTP#B'6 O[P-/;ZA6 C1%
MXA_<8(D<'HR) >&8";W(EW+H@H3^%'R,.44B<>/(LUL:/U$&S[;1+G@<]0[=
M5&:.SMA(V!(]KJ6SWF'&D3&-R?<. _OX!=IJY?$]\_#WT!PT9G\(O?N$[4';
M,87B0H6 YD[X&A@FD&C3N\8ZN>#4'B7?9;)@0%0PI-XP8&QY2\O-SMP.#S /
MG2 .O:^&!4HG+=*%#2P@INJZG&:ACD(2#:&RR@I!T+OJEPZOX!WS('\EWGXV
MQ-NO-]Y^-L3;!]OH4U4'9-M^NNH@KDR,R%$5]MC6[E-TP1&M<$<..^4R"B;:
MX0'GY0$9BICICY(WE;M@Q;L]CB#N._ER#B-NP)[C23A/'I"N\O_%A7DIV8,T
MORD#>OPH$1>Q+BR5DU@O3(&9,Q7&HZ2).%5?O@?<1XC^%BJ_569GIN"4>&K%
M) +=%;#Y1MS(,FET4K).B^N2!XLOT>T3:MDJJS^P8MVR$"4F]$O*>6XM]INE
M*UPP-4L0:9VC-8V8(KKXS&' G)R>4%+*<!$\!;W"RD5M9MC\LRXSGUM]^ZI(
M7%JA H,IGS2DBV)R.X4[^EQV" %Z:,KO7?%/-TU>%=,C'U66OP7T0%SO[*/)
MNWMS=;BE\.J(#\#LSQ%749)1)"L;FZA<!(_.;[,+'-]9XFJ412^<M,#B5FGG
M9%.-=_0'X[3^U0.AU97ZO2F:($\;S=S3U@ OS4Z+(R6H=1R1(V'T6F=*K[5K
M^;;>MC61\'J[F7,RK;3)6,!I,U#9RGA].U ?8.>D &= ?(I%SGT \UE#0A8O
M=[.)Q/X,_U\,H&'>%1;OH@O *W&1L3NU)8TC:2*236[M*$C@29OEL]JW=[5[
M[R]F?!B,D$\P\)[&K$8?+W7*.<W6%O;/$,#VKIADT I?9JZP87I,.G=-Z$4&
M#G)S>="WA<;#W'U7B;S#@W^YSZV Z9*@VYRYE@6^I$0D=O#K!PIE[FT#[<;%
M!6M'%VKFQB]^.I>FIMRGQHI[N!6PLC:;,IS0DL'FTUY^4R8%J0/LBUT;G\XV
M)F*6*^TT1YD^RX3L/XH+^ZZ,AND[_4C%@9(%R-CCU@CLIAD]O YEC )$XRPF
MMZMJ5U*3;8U3V77F%?2;  $QA^$HFLJ[Z]I3G=NCM<+.B%)G'%55\F%E$9A1
M!+PTQ^DT@E2(08<_6GDJD(&62F\/E4<C1/6VQU:@DWHY3T+1!+T&1]))[70S
M0EQ'I83$\I.'GW>R[LL,YN*]UAYXC']/._,X/- -6:6;B1,R)TCX-=LW<(QP
M;+J(Q(XO;[ZR[@BD>@DC$3* D1;EHLC\>:+#V%3MM-M6?D_%X)Y+\3A!] A=
MBDX>)QP4.GG&UH@8(^=V1H.YC./ZNL1%>HUXUQ#%OF5YI(>?RB.=/'A\I_)(
M=P.X+NDDHYD^/'B1-HKQ,4MHR!?=<+[HLCP\B*F?$4CN.$UI!#O:1(T4MVQ?
M !3G+K2;E8K5E/U9-J/$6,B@?-=EOEDY8Q+6"#'9O&4A$6[_&_^T+:<M)O>)
MO5(.B6I\6GMB;*.:-KZD6LRTR*A'T'U&]F4W6$ +,4^GL+I3K0:/N8CK=EVE
M8VML&1MTO@4ZO^6R[ !,R!8&,0Z6G)X?ZK C:Z+'UG8A?%[,-!FA-*,$!]/V
M:5?CD9ATOF]7U)]#LR.AEM@,,QJ(N<.>,(+WS8]F5WJKNUA1=Q09F007X&*@
M7+D?PA%LI!X^8$97=!>XVIV\L?)RY)LEK2OM' EFB"[BR'M6_W>74!&F,]GV
M.'0CH5)JRMQQD76, 1(WP_RA0(YUP8Y2)U-'WD@U;^N.I;=OMW[/A9:H%99:
M@$^_8\9Z.G [\ @6='GY$?!-OFN#RKEQ\@Y3.!QL<!S@T)HB[&30,?Y62\@9
MG+495Y=]0E%PB[(UKNU#NO#N P>C\0@POG5U"#F).Y0(T^:3:R@'AJ23'P4'
M+N/&MPR<W)5P)\E["2H%# !$)!(>Y_QX5M4-_UTH/$F"@6\G_IJ,^G3\4/AJ
M>A.$M*R<2VS9$&@$I6Y(/H?Q G00#UA3^&?C1V$AC.MN#9A[>-((!5Y58T$&
M\!IJ!X@'Y$Z=GCP$A\C?2/']_2F=1/H?WXDI:0L@+2P^O6X]Y)GKD,.PL2_C
MO%Q(QMD3?:8ZC!VO.CE)Y&7K-N&,,0 ;S/J7?A1R)!/N,EH;P^OW+_P@+IE5
M%2GH&2L>6J)+YH-1S@M9%_X]*1E_-H^2Y]'Y$SCH>);2#4CFJNNEJY7?KZW3
M\C"9(=V.UEZ\__>:$K1T>-,H.7LT?GA\]"#Y?G,?71:9')@? 75#3I V;J05
MB-M!>+XZF14H7CFX<:8>[U,]3$)YV]&,CJR</UFF_<&0:;_>3/N#(=,^J/A=
M*AZ>@B=8$0EEM;Y;*<A(I(T@U9\\I--OO%8CNJJLQB3LWSC_',E#/Y5/6?=$
M3-[D _T\E]*<GL1D,E1/OHX,B;"&L>PTJ%+A%F+\R_(A)9\V2P_ZVAK+UIQ.
MS>Z,W@ZV:?GCD^T1]2<P(MV'OY,<?W),"O#IP[_TO+Q1(&$"CZK534@[REJ+
M\26#E)?%8HS&N#Y;&<9RVAW++ -5K&8@=)FT#$3: @7K H:6<6;#XCF1I15A
M&%.C<[=(CM/OFBD-Y7WW@'#3V5JH!%DS-T:!C#^90VUIC'*B[3J17\+.M)*Y
M6B&9MEYNO!'P_'W'$)%&!/&O#P^,'5]RYF$8JCZ-0GTD0$^R_IZ_1WJ.'& E
MV>(:<C\1I16/3D[T3#HE3W><$NR"(A#LD"KKNEB0VB)TE2+]T,Y\0ZVF0O>$
MD&WW@^#\3L<JQ G?84!KCR5FCL?K5BFC9J-9CM3&0\0 0,%Y,$ZP !58RV6I
M,"+'#/41??3>BK,]E\81J/_TY,DWAP>>6XC.X'NE24Z>__S/5R_&)T\']_B&
MJ\++BER)BZP"S"S0CCXO_UD'^04PN:=:$5B9U%"S%\0B9^$*K<M5D:'W\?3X
MY.G((]VFX6TQT8FP<5M2^?  G/NXUY CA2,!4T#8IMP<O$C^U2XQ,;3@2\EY
MR20JIT%/>794B@ (N\#]A6L5DBJKA/2MWA2S"LBK>%RG$4_*VW=C6HGQJ2T%
M1*75*8=7,**.87H&-%N(=T;?M7-^E)Q/I]R-F$.H_UTN28S_4*X_ ),<;0*8
MN,JVHBD]9[M9TOV+O)PPS$D:[1T>V&-%<ZJ#*46^#QX\2N@LY%H2/<]88,I/
M&>H/,E#6%>%[E</NPH\%ZIR)X&GM7_.M?4Q&T?'IZ2!/;PHG)%T0I 065Q&M
M##Q;IR%[YH[#]-8Q"A486CC!Y(>0N6U6+_UY%'"'V$D"XH@O1E;,Q?:@<468
M(0[(SS8U7<H4E[VL5YG6CVS2?)&E6GDB5;KY-B@?4>]:LA:KC Q+H^QD^C:+
MC_@KQ@T'*M,>=$P5B7%X$# B%^ETZFE7HVQ'[2E4Y1;_3+<XQK!6;H6+2E,?
M)=-E3A?PWRTJ;,B666Y(*'S<1'\=X2*1'<N=FAK03]6K5*CF9 5A"4W*&5DT
M7*3N:]E'<7.=5S^.'W6XD'S-".<\]!]3I=D&8*#B5B\"!%-F).R.]GS11W,#
M%1Y 5O+$PR33_V0@S>/^$49[02;;TN6KK&B6^++Q,0&XL^(."WS&X*E$)3ED
M9B^$_EAY]B1$N@-6-HB)&QK^JR923EZ>LP4/98YL5FWLC.F,+QKIH27W+^'*
M)S@TYV!%(;^GS@I2? 4'?FBS7S(US#AHQO/G+X-2]$0P8U(TF9CQ8*X IBGR
M'!GPOOYA+ W"%($(7A>FA)?"(?D#37*=?7#)O7?WC:^-*=]"\4Z@>Y,W)Q.M
M,)):MM6D2L&)+8DS'-N@RMF11,O=6CE2PQ)PS1L/,T<N4G+,]C0_$@57&@N.
M.D2BO-5QY*Y6<T[ UNV$ ]2HC^P Z-^=V&?PL6DTJ9"L M3KV_KR.H=9SDL3
MUDB&;A"YG=3:V N<)[((HWBV;$34OHJP+GT[N3#Q$3(+_9UI7)EO&)*<N_1"
M._/5O"^V$N (V5XB^.&@2Z=_G\+R$VGI=V6<%E/PD<^4N"VM+:?*SEZVYB8:
MV/%X#&D-PA(I=E,N%;%#=_+YL:\-F.5%*BO#';^$.]LW]"@U8N.? RBZTQP^
MKXT_>Q7?Q=ZN:3H7.+U:=Z5=-^D'B4+XQ;6M(MU6C(S0U.,#N,42%[QU?V2K
M5<<]XJ:9@EEQNU Q !>9Q'8FO9ME#*0;N(D-4AO2PS&ZX_Y@I=G,3NZ[4YO2
M(+MOO%2(/.;M6J$ZU !%=3]M(<67G?J?P!_M/,0@&!,*'EWGI70:ES(CY3HW
MH 3B>B0CN'L5=RU<IGF_279I?=>"I#E*7AI$0B-(]<Y"(9JA+YI5>B;MSLZ&
M41T7!6D+,HS\[4_GOOH95-T0*HP7 G;"%R7]P&W$#55O.J57>;54CS, ,(!.
MK] 7TES71JB5PNRTB#H2HWK_Y5=> JK&N;=;T]V/L#)9D^Q0UZ5'\X2[^FZL
M@FBD[,:K-3X7W9 V#?E^GG>9/G,S*3$VF'EO":-9R"*J([NQ133.+- N%_S<
M^K.[441ES=&AXU/6-<?YQ S0Y=\\_&>)+OC_/N7_=WW3>99\HK#L\.#T^/0$
M[-\!K&?P/;J5W[[[\2Q1WG'MFB:AYU"%%5W_'4=!S2?P+C$QV#]=528O'_E&
M%WR<.0"/1B=1YPHE*]2@HD(KIO1%;HX<=)Y_MPH[20#"VY,(<BB<X*]OC6QJ
MIH:BV*RGAX:;M"RAV\(#Z,!0'8<&PXX+[^623=M51(8GSVFR1NGA; IUNV9H
M6%HT8B>#]#QT&'(?T32#L0PD'#J=AZ+)/Q1G6QI1^95 T+^Q%H9Q&9_*%VX_
MB=A]AT_K5R;,'Z-\CR=">_/XE.P/&##D^#=C'U=0AF4;KP0'P"#8-#E39ISL
M'+.LX*R[7 S;XZEP#0M&.7.-M9^E,9P^V#F&(XE&[UBPD^.=;Y^7N7)8A'GL
M')$IJNU-Y)(O&RV\YLYH-11@76ZN7FM6<]*\VK?1M>J4N#MJ=$=]@:S)>VF8
M&,2T=OS^]$6]8R;BKR X'@X(CNM%<#P<$!Q# <?G%5,]_B;(H7'R AY]L*=W
MR"KQ5OH-FWRX^RL76>TW5]_UCWYGB=6CH<1JOV;Q"1\AKF:W.VF17Z&2VHI@
MA-92/H0Q8EA(">YN)DVSZN"Y< IKSD<3Q8'*(.)8TVB:/EM<:@[79H)+"98;
M! :<YP\PGH*%LZ//D>^PQ'P,G.J0EX?.=\SQ[#XD"Z1@"W/'#P\D/31O"TO\
MFI76>8Z6XM\QXVI_AB^0E5<5_(77FL-(GB,.^P+Y</*[8()7R7F1TBD%P_@;
MV;$!O7+#22_:L!=NZE;231A0DTLXUR 88FAD0YM(][T-3)#BI\Y0&EHYJ;-"
MN,+O;+ I'NV,4[*#>)%6'"_3QC%IQ<PY4D:G/J3QVLTB?FMUIYAED1L@102(
MW=01C-RZ&<74,)IOX"Q%H**QSJRY,-7H+)21O=?DTP;$43J0=P T QF6JJ#\
MU,0#"A'B=/MAOC5L:) +7@1$**:ZR#PFT#F4ZR:F1DP67!12"2KEDZM/WCQ[
MYN-96<-0ES*443*U$!!'K&UL.^HL?2_>;EOJFCUJ&6Q7S&-*GJDGS"VM-1PP
M]K4RBCN(UI&5#T86&EN$FL9 0-A)7I75&JO@>T:+"H6O7R,O:T6"7-P3+:4V
MK!Q4R,VI$&_9'!Z\]Q;-H!UN6JW_3 +R(G.7>Z^K[[@'P4G07^4X)&M9,%8D
M=C\4)'Z7Y:6H1DZ$UQ%%(-O[;9%QJQT,P?, I O2. O.K'(" =']"5*54U ^
MSR3-UK0 ZM=18Z#M])SVMV;)#QP4>EV,XD;446<YZ6H2)?_9U@A? (!CLT9/
M''.,>#DFN5MI"D0YAK $6<EZNV%Z VDRQU-HTBPO59M;BZ&@FD27U&7>3M@C
M$[RJ9%^3]-^M8_IE&, >%\;H"!J(@#CP)F$QE$?-:'_2T$-#]*YD5],5[;$$
MXUEQ>[9@Q0=;R08[9D+L&\H7A?. M"L\I;)V7U>MZ1\SCC71#XY.'V;%3<>B
M'PVQZ.N-13\:8M&#GOJ\6/23;R)E],:ZI(^3%UD-?; 07I*]GNX=#"\__E1X
M^>'#TSB\?'RZY^'E/3?5V?BS;'7434[P'<8,Y"/&:E4(RM''=E,ME^QU=JZY
M6XC@ZQF%X:,^DH4O%F3)(7Q!0^3BFE1X-94W(J90TL0^FT#2VU+QHMP#)/'!
MCK)MIJ@K2FN!5[ )Y$<?0>F\L<>=,00J)RT2:$XU!PN4V8FS_> *142)V4+0
M/0%E!F":U+ ,\U>W>0F */T[SSP!DH=NOWWYS@.W=3H\ *-%<B#&3HK4#.@2
M.Q,9X!&K4\K]-\L"55Q^Q1 .P4)&T2)IW=:!O*@1:#MGQB#9_F4E[1NE.2+/
M]XY9?W=//SXELXL<$.;#95JQJBPD3E=/R_4FN??NY>O[V&>O1?=ZZGLN:W<J
MRR>?S,4^?A0IRY.'9W=16?Z*__5X\+^NU_]Z//A?@WC:Q1&*HAS\840V(!E>
MDEP/U59=$(&:(QEG;<"?M79<R;:@6]$QUY(+M+7._1_?OWXI/V;L9%G%>/FH
M;@'-EM5P9.R\Y&40)U-LL@+Z457=H6:W.J-:\/-&3^9<SEF>@CY2.TQXSKDV
M7*K&I;!@FB'SA)J?*8V]JH&KG:0UJJ'*8I:9]0A(E#PQ3"O4G&9%#2K+K5$_
M)R&0HK2IK'PHDGD]@J'G:>I]"8<T.)'.=MSJ&;W)IB7(WH6H9IDB-$K[6ENX
M,=<&=F7E%S;LG1'PEVT^BU[G>[>'%\>SU+<?'OCW\H+Q6'H-_]@T1\MP(:NW
M9@1S[K$F"[!UH.* :8^!!%^,B[>TM(2[R2 _%X>*?;\ G!E4T#'8G.Q<&ERM
MM8O&VU+"H ="F(SU!KV,,^83$*"Q?@!,+TIPYS'//L.%<;KL;300@\R@$PV-
ME^/>5BMTX9:@S!MZ9M^<;,NX@D'/1F=SM()?H.A7'$[./]>97=DY8XL$4,0Y
M:B[3YJ)S>X2<O5D">AWM\<[)=GBY*%ZJZC3W0?JH^39^*J+B\RI_7O1^K_F(
M:9[6M?4$A<=]"1':N$4)VJAO:.^RO\]0FRG-+>(G<)FN CG"GTET28N<P"B)
M$('[*/V[KW[<K&1J)[EU<BW1/=1W/O)MF9B(,NKQPY676^/04LZHD19],=/V
M)M%+4EG924MC1*E8RU_0!\;C0VZIT<S3TFI75K"_I7L1XB$)/*IZW/V50,P$
M>])6\GBN@O9E /PW;J0I7)62I2)YN.1:T8*)0E:KLJ"O(:=6,*7 ZQ=O@Q/O
M"R4JMZ C;IU#E% [0?_U;)T[HR;@Y%B0XQ+ J8V]@D,&$:!/VFSL2O>1D.]T
M. %6+@RZ79=%ISPYKC<,^\E:I@M?J=RJ0$F-_<B^8UDONSU,!;%>EA, 2&@]
M0=8RS]/B@["QZL=9#J4LGP:XAIRV.-;DPTBA6[RPWO 1H3_F[<=DW:[6L%@X
M%2G5^KE5C'B;I =*G+ANUQ1LG>?:EKG54LS3QT?C^?8WN3-#5=[-#C]"D5QM
M7_U'HV@A%J<$\[ 9KK*=^3DU2EM]!MTN2]]RHS-5 6I?^89.-!H0A*2^3*ER
M7.K)0%H-I9+M*5>YYD9^3%#3R=%'?^?*M2834TC15AA\D (QE8KFKY<I:4]M
MC,;$<;X5+Y/^80FT"9NJ2,8-^Y+H7C2WELBC-S9_Q9KE:?;Z,'J@\6;DN0=[
MY?U>- 8-S-T1&0^VPX"7='Q#KLI\Y,W U)HC>>*?N"V7)J10T!7 #* 25L[A
M3N=(OR$3,@9!8-,1O:9&G+7HL]'GZ4;3\N',7;F6V"2CAXYDI!4)1E+5M_Z.
M4!4]+$*[XN?P>LW8(1KC:$3;'$?\A<V!.UV),F7G3Y;!.,RFNWP1FSC;XD#X
MB186/9!BW8.Z8'?&"(>@4Y:>Q PQ&YN3P"'HC&!+(VX(<N7XJ5+MKEXGJ+N@
M& %DR<I9;1F)#C807Z+Y;83:68#JRCG^&>*=Q"#]4?7!X /<9*IK)[;)\P'$
MSN,$+K$TY<N=$0DH^DC\3P@:IPW !=7K[1P @C=H4*\'MVR;==N(-QQ\1J\8
M1KT&J\J#+TU6K>4<NP_,Y4,6<:8,X/BF0:V,<8''J#^7T>-Z1*T%ITB-A9$?
M'1X\]\(W=G1R8()F%KCY[L5Y\JI04/"K8H%1L'F(=C\L&?C%;,B:RP\Z]:CU
MB_8*\1(TSDR,I"[VJHR7PGBE;%?=<)^W"S=5>PC2,>CAC$?2\@]X;I)DM2?E
MFI2<^@P$+;,9MF:>NX]9&.6,W(<QWL5=0T5WQU)8Q;V%33"\VE:[]Z@H5#4M
MVW5N2P.A5+0KB18%IQ(-<Z-E\"E9B^'H>;PB&V@P9HC Z*G6_,!WKW_YYJW5
M]@DSL@TD\F9H48SK3JA,''-.&E59I/W]8FX%Q7H=&5UQD55E(77T.M05#Y4+
MY%VS+&=R%N*3(IQ\(5;DE;2?'\9CVCGN30Q['K VNY=!B_I@H[79&>3T#28X
MWU=<+']X<%ZQU8IT^BNN*<D6G*PP+-"0SORSH+R/'F;%@*#[O&"G]&>52):2
M5<!A:S@:1=[;HF15B8!.LUF#KH(D]G3IF<>Y%K3B_T$P91)7@,?>DG)1L3DL
M'6H3:8Y6<DC=026PLX;.<=P)K6T4?8.XG 1K+LVC1*Z(F;06T% -=[\)7J(I
MHE7]3?+R]?M1\L+Y#X79_*_OP8F7]/[*H_-\(];(%I$<M)#AP.9[KC4B=;J^
MA%\<K0NS[&76L;?BMO5D%$*-3#=33BA)65C<8UE>(:WC:*DP[YPT&:^(%!*I
M)?#!P8^M6#-9UDIIG2_A9I F5,]YE9#>4]JQ4NNHXKB6MG[3W(N[>A)&1BF/
M*-?PR\! E\'08->2MY0G9AXO;[4?%):3&P&RJ9$U%GDKRL(%-ZVXD!@%DD2:
M&'%R%F,3>U8.2O8&FZ!K=V,I1T T=%.DFMA3MSM89!9Q3V-AXB[*_()%B?6J
MONBVA,"&-W**4]1.T%P_N&J\:#,8TG8R.*RJ2+W0)ITET64&&QY=GWB8/AH^
MH1,(PDYI3J&--XR;)XIJO3]_-;)40#C:D8]A5N*($ZQVQY:N,Q3NSZ7'>?>U
MBYCY.%Z<I["8]9YWDA5]9N9>_N<(0R:;/UO5DEB'FP?^Z)VMY"?2ZGKC!=&X
MG(]I ..T:NB+;HWRU(KA86FPI++8DO)KH;/0U>10#XE)CD.-N8,EU^[6KKEK
MEO&OX(^>#/BCZ\4?/1GP1X-*NBH^IY[?^2LOF;_9VPGMWH]P[^-[WI<#OWF*
M'3%PI;CX7WS:(Z'P^2_8(3[^E]V=(#)^\X"/CTZ_:(T?291;.<BGCQX_O:Y1
M?N%S_ .R?Q@<QT<UDHE,.$>DR;SZ3OD05HBDG3=Y:I:C%6DA9,@Q444LC.6K
M9E!$\5OXFXR'8#IM#N^Y=:;^HPY#*"S)J9E6F;V5_4G -;B[C=JDC0OOT1&I
MA6=-9*8^71B,W\J-+[-*^4 X7CFVQJ_<8";G3A@8B+I 51=UIG;@J]?/7W0V
MF!7;+;E^M_3"W=)A?6U-,1R6KS^L.R"/C6 V>-J*%HNC4W%XS/DNB]Z!%V&H
M'FODQDK:L!)<E:*^9R3;G9.A<'^($-V2\D"+?_&+-0;FO>246WX8R2[[PHPJ
M2:L9O-@IQPZ\PR\$^EV7W#O-S_#Q<'ONPK &47L;=^5/*VI?J:3M5A4PM%J)
MYKGLL@>*ANCB\N,\^^ DIQPADW=T2NV<0@U][+^GNS?#]T&'PX.8YBCMA5!=
ML0#F6E27=:&L/Y7FX0[-_8 O:TTCOH]UK$ .@_+NX@K9XQ%4<Q3UU@.HK/H6
M.T'9?71B?0#=%56F34OBR#FWA+[ZT')\OJN*FV6+5XRKK/Y0?]U^=$,B^#=F
MZ)]SK\+HG$FG-9>RP\TXL8S<9ZG_[Z4CAJS^K=G,/<CJ(_D,V3:M,N%E"TE[
M'G$WT3\!!!T91#>+JC<D_:_=<FFXW&J]1G$>S17 KGS@VKS!"F' JK%-#,&8
M]2$8(337^V 4/F&MA8-F6(PD@F+08R&>HH(+*?AAD/4*%*W&\"<@<\\#[.LT
MMWZ:ES7#_=(UF^FDW8&Q0(,9\VO=.C/.%E;)O_@*8A.27+0FS]?Z/'EG ,LR
M8PPLAU7<EFP4VJ1)(%$;S=#?QE&AD$45996B<C7IO20_!QR21'A*HGFX #<T
M_/-&0,IUNG**KY4>S]-&^9S91/*P;SM9[8H&3-N>,A)ZLHFK7\I2ZC6@=%D6
M"S28Q?S$+3+I^M>_4XX[!>*H:#6I\#^3!>JT#K%[.9T4[07?(_F..PU:4>7G
M%9O2?$B"H]8''</H2@*R#JUDG5)U9SWIT<OOOWMKK$=CACH50 J-WSW_\3F+
M^W)2N^K"&=T_O&GZS\NT D0[X:^91M,IX)%Q;RRIN<S3HD1K:%FW_MPC? HL
M6T5R*3"JU(+NPJ&*$UF-NAG#"!9(12UJZS-7Z&)<I7/ )K@/:YU6M"NI]@$L
MBVG)T*DE&ER5B^3;DT07S'>GWN4=[MLM^3THBZ<#RN)Z419/]PEE\8?.]OXU
M /KBK(R!(NST^!MIJ/%[_;_K]9CVT,"X$0K-IY]B!3L[>1JQ@CU\^O#Z6<'V
M?I^^P)!_I N4;U"F!D]<+33UO!45CH;!>4:&1\I&.WLYZMTT8DV@M#C/E0PB
M? 9R&B;@IO=KB]1>PR*&>)KO[5UN;KF$)W40I#VZ!E_>Z(TM,BH7>59.(!-H
M[O12LZ $X&TFVK7:(,.9VA[R\Y+;Y+!=*@60<27"%R\_2*ZN/B ;]G>6'V2^
MS !ZIE]IL!$FI1X@N^QVP^Z7:XS 40MXLQ4EC'8GE^522?QJG6;77,0G_W^_
M0Y9?*^8<58 $;BQ!F/?V'EX@]P^F?WR)</.P:Y\EAW[3?B%^3!Y%MEY;@ZEB
M9HQSUM";@QKQK=Z21]NW-7F'4!AJC,<2U>#(VII\Z2G(,&H$A!=MEC?CR69L
MB34$ :)*#";Y8)Z2*=,V\%MX#J7]PW? H,62," S7V_@ER"]1LM6MU/4^P.X
MJ.1[.08:X0Y%7%J<@;[LP33&!,&T$F-4'L\DL$@2V]4: F1B"&%N\<7WT8"B
M+>"QT<IE5;+.FGG*3=#'"3"7VK/<_SZ0B$15U\ROXANC6.LO9>\BHX'&O2F5
M0R6P60F%$E3/,EMK@V]\ [1))L%)8=FQH*VSETOI2!2:G972Z_$BJ[@A'*T?
M+1.=1LY!"IE!,)>B\S *PD%CN7#ZZ5A=HL2??HG6:]+?A$%0'(0]>R'0SZR(
MUZ.G=&07UF480$1)H$.89,(/D\[G8!C;')%[S;H1!ZF@O2ZK#SK7SH5!QS.%
MO4JEG/NX-FP5:5?P"M+,;(S&P"*,E5)<1W;;&%-,ND>\G6T$RKIT^3J@O:*D
MKO')Z20/#P"+50(V/MU;T+#/3B[_%.K[4-QU=5$?W:U*.X?"MX3<,JU-6KPO
M W2D^V5H?DK.?SK.=78\Q+FN-<YU=KQ/<:X_>+ '6Z4?W3KY)GE^1;%Q"&:M
MVPIINBU;<\_F?3="6Z?'GR:\?]KI#O-H"&U]/:>M"X-+DQ= O_UHZ+>77Q;]
M-KA^-[3WT:XK2Y36:)$D94ZIF-F:; N8LHG#OS7)[3,)H%2M?6?E3O5 W6D]
M:.E8^G:1<CN=W7"2O^Z$DBA7[Z]@212=ZR->RM!EI% 3\B+!]>=1GG,D<U-?
M#=:I5I/R=TXT^^HU=DLON/X-GD0[ 1>M+VBS\C>4M;FMHK8=%6QBV#-WKAG?
M9**QZR@L^K2@9+NOZPW !VMM;(E^UNQ4ZJ+0F1AK[4:HFNN]3?U6S?,($WIX
M^?OGWY^/C.J9$T<_XM:_+!!P+-?<HA+/^U[+\[!83$']+BPU'"!]Q"@4Y@E!
MI%662'&>"RO&;_?%>XN\G(BS6E;FK-IJ_L /TB&^L0?1?_Q"OLJ(MUD^/#SP
MGTI1(E/!T,<_:>S<'O*JH(/:M(WSK:^?&Z+UC541)HR_XT[T3.Q'9D<-#O]V
M=42_IY%9[4R_[A#$X\Q6YU%Q<(WBP,AO*SV,J@[UE-419)=\N556PR?-Y@E<
M-CH\'VIM^\20O:L.(#.'TE;1C_;+&]M#?=O7M)_ F8<*VE^GD(XN_:B_O=K%
M7@\SG\P(*L<EK?YP +.6*L,K2/@VN84@,)!10*[M1/E)!,++X2BV?ZVE_*K<
M3Z_2[KUV8N.OU$WV*]3WW\HB_FM?VSVJ$OK6@FHRQ'D&FGU$K4UUS9"X9:@S
MR"H=72\ P<!2*::2:G9FND8?%D1(FPZ)E^3Y4B8J3A.2",R]JOK&<R_9Q91Q
M! -L=[T;#NN-GZ'?O0^WN.SP$U6&^[SB^WY-?Y*8O2]8IGLVKMRBU;CW#@8^
MOKQ2M2#4XV:<>T,17V4FL:MKD/=[TX=K-ERSWS;85\5,>56BQ \&ZT-%XYVA
M(@W8UE^T+/:V6HW[XJZT39;3)W6R13<H%DZK(E3!])HFK7^U;MH7W4JBF\VB
ML45 ).HR9>=$B>6Y.);L)X8E";]D1(W>.V=Q!.L#&"4-;@>:20_F2];EVG>'
M%@?9I=$0D5"646?^A'^%Q.47;XO\.^#Z9R=#&O-ZTY@G0QKS3Q9WC].8I]_$
MQ?N[DRN+/Y);^0IK<S-R:O_RGR>?AO8_[N0_!VC_S>0_5^ABS$S.$8\Z6PH!
MDRTI"VD^,IYE:,XHMD].QH,T1"XEH//O%IUF@-B_<(BHIC491U!T9>$ZO^3>
M84,F].;-7&Y24UM;N77N/GYRFWW*,Z)1^Q0A&_Z1K&#&-B4@H=QA*:NMMV2[
M@OWIZ<CE^'3(*KVDCY.L'!SD'DI5BEQ866TB4A@?LMB=;*BXBV::K,H9H_L5
M&U@YY%5A;-/PMI8@*R#8TM"-,-TZTO'9UUI=?_SYN&L6BY;N JA.)5_?,;\,
M[5&[2=#$3'<D02V7N&O.;3')V,-0=**VM+J@AP,@5&H9L+4-[!&>*VMHW:,-
M9;CIK^ ?M%NK$>=AG-S2&FE1+KW#"'K:.\Q9RRGZS/FCI%L-$76?MI$"B"D0
MYGDK;;%]!%HRB;477]<7CN8%B>/1G Y"*AW=:4/::(M7$'L) "M*FSY5MC(D
M)K^B47H6&Z4[%6)0A5X"_DZ--VB[&Z@1WFF>GG[*/#T]?;2[\G38OYNW67ND
M;[_2.D0H0J0MGK(_D>1>H>R0A3AI%C9CT EV2EKK#ENEOQ+K.AUB7=<;ZSH=
M8EU_%GOB:O$4R1YTPH;5O>**J3+-1P'9%GM1(28/:55!)?TZ\:KO% 5K-Y#K
M'![\@RL"_ !'L9,F!HL4RAL<DV&8?^UA,+D_%=(:=2/]U.F*K++".J/O]&.D
MD6NPW?4%-FE^)/VX"#U)Q<U*T@ES\6WEH/O$VZ@G9P?EKQ%-DN\\>R4GMT)(
MJW(2U<(%)R+FCGJ-9#C]M. S8T2@#$[<H6M&D1V9UNNLTF3?3NVC/D1?_3 )
M'#"[DNL).-XH;Y30T#&<+I2WT] J;#+ K^(+BB;<W2M+:OEV-LN*^5;!L-!Q
MMWP,MU-Q9WX@@SZWN/.8XDU8&)0./8;4<F-S)8EBU.U<FVY<-Q_<X!9]VBUZ
M\,W51+N?MKGVS46X(P'WLT\6'#T]V?N ^U[[,-SUZYV4[W^=1-4^79$OU68-
M5I::5[.LKMJUV%2DJZ+>F"' #<;*0$.T10!3<VT^"!M2KMY@ME98=0;)&*NN
MWX0F[EZ%6Z?)SO.@D_& ]U$CN+C^""*7X[ %\'DKUXBAP(@3-Z/9LP)-:?;3
MEJM\O/$B5 !2AL(=0R<T-'<A<'LR/C#JL 1+K5SR!#L8!"#V7-W?(9EDTVG6
M>FX%HVWH_E;LUPJ&JC=GV1\W J?F2[2?'^[!%?=@ LY]/E J@:S*J+[66H6A
MU>#MJ5+X"GNQ1V!-B2*^\,)=VYV@A(=DY"R;,6?=#^^^'9^<GCP:,0@.,:T@
MI7IAP2^'V;SI,.&7G /=HZL8A:]O<B_2)CT\T+2?=U#665Z"G!#L,J 7) TF
M@8_OP?1<;*#;H<;^47!-K,8%?G#D N435RT2L!FVTCM:4W_^O$@*\=5/+\8>
MIXD7<;=YUM!X,-LB'&J8K+)&.*8*_(CU)7WANQ?G&,\I3'EM;]]Y9%-EJ?9$
M6%=N[&=&OQ$R*:5<DO+1IOR8346[<Y)]O4QIGM/R0R;5L@(PY5$$#B4RC%)4
M?C;:'KU.-[%GQX:$=2Y '"BKR>ZH&4GJYQFF<2P\[Q_19)VIJFHGO.(/CQ_>
MF]R_=W*?O\Q)W8M0CZ#)4MXBVL$W2]12G\CT\9AR H+Q!&1%^$M_8ASG$!Z,
M;MX^=% _//B7XY)#Z53DZ.4M#)T=#=&C+4Y*)JID=( 88S#"F.Z:ESF"RXZB
M5I]D@/%X)X >C!)$=.M&]Z0J)<,L=EH],M*L:;F:9(4,G!=67JU5Q6)"(C:S
MIUF*08T/:OP:U3B<F?C&[%+K3YX\42(VU/:3+)D::_UNY:YKL-<JGI;*;MI7
M3VI^%4VO&\M)EZS8J2U_C_I]8.KW-VE<Q*YCE;NEF'Z?QOTV1/XS:_',!!\"
MO6,ER#ZZ5\61S1'-R;=D$9T'?L,_J(IQFT07BZ[=J8X/#WC(DGR0K)&\N%PW
MW*R-E;7KJ.>DHYUG;H4.4)4IZ#J=.^MH,T=L9 K5ZT=W*N99NI(_3M+Z W(^
M,F175"3ON7^4)=1XK2HW;2ON4Z*:6.DP!28'!)X)BUBSO[RD_QO24_*-45(M
MT\FL7&U*:XO!0Z7;D9$$.3P@E>_\1W[.^^^&_PJ\X&R %UPOO.!L@!<,QN=@
M?'YMX_-''_\/QJ<F2NFN6D(]>17GT]]H:/\.AI'NO(WYWK,7 ;_M^U$D'<!$
MR-U\(=I V$2'!TS1 /:ZKTM>%RR>T$*0D1J_A<[NLSHC_GXV.\;3_#J=7?*%
MV>S(W'6_@<XN^:-L=G? ;AQ4[Z!Z?U_<1XMJ5JZ"RF5VMRCQSF%4VF3:^BB0
M:H)0W53.PZ,;(KI:%A)2O9O!H+N;[WF%@CGMW,SY@;:2=@-%KQ9  P. 33B!
MCP(\6SOW(6K<HQ0MX>@X'R(H%X5TVR6)?L7Q8;6H[^R<Q6E9K4OMEQ7W%%JG
MF[Q,9UJFINTOJI+4E.,R,05;)!C>G-S@LA\>B;!X\6FW*!!4; T231Q\!#98
M_V@;D6G_&I35@J;QG_3Z.3^&[,*@9?9#R^QR\ 0*%B.T[(ZGR3I;.Z[+)0,4
MN<$$V40777[<O %!L$\:Y3TXA$D;1 4"/<!<FN?E9:UX  Y#P_HG;>(^K@W4
M%Q\,?QI&BAJ4<I#RL@@IWRU;A9.^-??+DZ9X%VF5H7PY2G;5H9,/::87/YTG
MY)"6,VUP@^K4L5(_;1J.R2OGTPX59)495ELMDUO1T6=\ WE8G(1.D<#F)='$
M=QP2SU:KMBC'/B=^2;]PDPT4[K1L\UFOA=^T8E^3>XASPR9TSG;2R/[5\U=?
M505]E9,UZ*9!-_VA?H,=;T?Y;R-S,6@=J0,RK&Y\1P/*+:J\,NP3I,@[Z0</
M.<%R*(@FKLEIFQI-N\(/9!CRJ\%_VCN9A,@B%)&'.ID"$WG?\49,I76!7:N4
M% 0P3MK93XH6?6ZUMN]M/S"<UTN'V!D;53T/AZ-^!G*/ 5=U*KT2@\\B@ZD^
MN*8;"-@^W.1+D0;'=8CSWD?)SW*Z!:?6^0E[C6'.%7S'LNA=#O8<PQUUG<G*
M6^B!?FR#BS6HL3^E&F/^)Z_!8$-_Y.ONVS?0)6,;6L,?L>E=1!?(]XNVH _W
MF4;W35P\VM=-B)P,JFDO51/'YP1U[8]%WQ_70_"/HW=''N=4%6G@.9<NW0%V
M]:$H+\?+\M+2+&3/U [T3W7B2Y<5%R:%KU(U3F-NYREZK6KSFJY;*/AHKR*4
MYHR!1"#SU8% #^2&%)9!\9\V?2<33<AIJ:)6KIWR,>^XH3-/8A%05E.AV,LE
M4@+J4+JK+/"@ *O0U[ARH52,J[VTTQ%#S:*!K-(-8H:N6'#!/K?8T>V TDW1
MOF@FK6L_[QY^X9S5#;IRMSK_9G6H[UVZ&FI0O_20/W$*>1>>+S,W3UY^=-.6
M60-_1A@) 19FDZN8V5#;8K-V9*JYF@--0)F,)!W<(:#H9\3$*(9$(AN4\^O3
MJJQK$(.39))\=5:CZ7A6=!+]9F,_2^I52B)3NUR[$?UTW7#/9M;6338IT:X9
M(^D*1WS^;Q( :,L2T01\WI"/#@]HB9+?L$)+='VV^)AQ7HRNX.D(Q!<=&,?(
MET>.$LO7!*_$TTE!GGG54@HS'+<>D];IG\@.V>&]MCLQHAL0/^S* Z=0AV[A
MLQ^7[$)KE4](@=&B8A?!:@]X21.^# :0)=36B_8-C2=Y33OWX?#@36?.],CS
M%2TJ>L8=C;"%>?8QH[_*O]_13G],MGXB'WXO3?&T:=U;XR_QW>OP\Z*<9SSH
M?SS_\3QY-UV6)=#=AP>OE4@%GMQO.D 3:6G/W)$S\QEQ.4H4=(^Z!VC[J&\=
M80:D>/BP.*5Q\;3>1#NRL5[G"&L4L9'N@L"C6(_XID3SPDFY<LWFX]_J=@WI
M^/C!,[)?\8][4_KL/[B=13:Y3X?DK4/CO9F+OBK?3.YEQ1Q;LTHG]WDBS_.2
MSO&N9^;E/ 48M7#W@PK?&VG\^U#+#P;4\O6BEA\,J.7;Y>9]#:/S.>D.U["B
MW+OAWR6SD_.:/>,$,K]K%BADA/&IE8O;9XJ+A]K3&7FKZ>R"5#1[RA%?V$@B
MM[4PBNNNBX&1PKX"E;);T2!J=(PEZW0'VJ7V3OR6&\DN-JG>SN,%/+.Z=O,J
M_:4D.YV5> @F7&';C0(2Q_57-/H2\^&E.?SAJQ]D[8$%JT/6ZKA='QY$W^B8
M:FR3<F3=<[UE:BNQ9<H)YRLS/)U024[K>UYL>A64RO1RZ3KD;]XPWK)_G)#[
MR08I?,J1]1>!GVS<'-_P?U'2^ T98U.T,TXOTBQG3:G#G[>HNKL+H-=;/>37
M:;%A^U4K:_F>>4LY(B4".AK4/G3VYG1%"G:IZ!32[Z:ZP^Q\-IF4^/7("*^R
MJ$>=<LO# SJ"#?]92Q$[#(Q2I#F*2A&C,)<E=F0L8H7SS;)43$QF5."(S\HC
MN#0+P\JETW^WF3IYW/%;V,'CNSOJ77?Q+M)%40);'\M3G&U: Q(H6 V:?T&>
M-<G8L&03QY,C_]L5[(S2"%9"/\^>.*UTT:XFZ,&ZO3]6MQIO&3<E[US%MI:M
MF%9MUIB8J9RM'COM3.D88@VZ>@591H*DI-4IB\+E$A;UDF][8^BTF*0QAE':
MGHP=;9;<@*;TMS(*U**($SM0]?5,ETX?N,L1T/:%@X""+J$GCRR'P+#/H^1E
M6N69@TT,$R^6RNK2VA)[OP\[7?<)PZ(?8D-YA?DX,?ISTKDA\5[0L4;D88KF
M &!MU:AUA/Q!+X&J2HN%!F8%LLQAA<XZNUF$6$[>059NGP:<5BEE^+;*9@OW
M;5:JRRV>=G+O.W!KXLR8ZRD?W!\E_U/^0BL??>*]\V_3#2W0^?>^R_RW59G.
M@G>.@;Q^]9X__B&MR+^=D0/ZNIQ!R\A[^9?I!S=+>R& Y#E/:NA_\%5(P8+*
MCN#/&\5I39SV1.$:%H? 0\'2*-O6"E?; 5VJ.*$MKB*L%YT,5BES=PF&7& E
M05(&!"9NT<R^"IE@/T:##U=(6VA&H\F/H&<D1,J2'(P^W;=?.KZM'F/P<_^V
M\#W&5Y1@!L" LO*FU99.8=GE$=OR)I'F:B";2HF>V?DMK6,_=U-B8PQVV 3!
M+481,BW.>(N8M&B:HD!K J,=3,Z Y]B(FV56S<:0.!MDBO 94FF:V0)*L*T@
M!J'/6J'#UQR0G\[1X<'WO3^)2R#%\@* P.]%L<8@(^[/$U,=:K(*(^\ 33KD
M'/A51*-C&T=+ @H&6JZ6S0#6R[IFXAN$L4GZ37AJM\Q(KARS64[@@B00\]8
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M[.XRRO170"L/!]#*]8)6'@Z@E3^][CP7R?B:TY>G)R.0JIY*@JEM)%YK,LB
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M5XY"D&/34CM@3V39R ,K.H7J'/UC;(J49:.W06$QSB*]*+,9R96-A*%'0D>
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M$1%)SX%"4H)GJ/QIQ7))!P2+_?*TRBDFD-\[8*]O!\1^\7 "Q'Y00.P7#R=
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MCPX=_.Y7A1-(>[+47Q@7VNAG#J@F<M96=-:(*)&A#7;Q@6MT##[<U#"27@@
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M>5,\Q8R>G.+YM/,C%U_CQAG3B_<VU_1=KHE=-4U$2RF^)<X_?_N[,2LGZ*=
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M[TUS> 7^<6]BTR%/&8V/[RE<7A=E)3U KP+3Z^0I?/PALX]VXV@[((6Y6+0
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MAZYN5AB(R*K]Z=NHVSU&5,VYEG#.[<>?9'^;=GNBP@/_E%7W+)N1$:7XE=8
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M0S(U97O:MUIP? \ *6QKL*A%A/<&?QK3)06K+AC+JFINZ%]_/*G7-Y'7O\>
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M*QC<'VBY44];,OBFJ.'I+<KBJFXZP!2!?>ER:5$09SB/%5:5]@8RJP(3V()
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M-X^*> Q&B$IXYV?\Q=I)9GK&?0?;EEY.#V@O?=&X#8U]A/F\NOG*+?K*1=7
MB^PE_;?[M<#7A$/CY8M+Z76H"NY2YO2XM">#D#&,>=54B_,SC#,\\)@C4G ^
MWHF7HRGYB17C(P_Y3>  Q<Z)EM\^I%#W!\U7HWP7W:IIMTYF%MNH61ASAO(8
M:FN+5&Q6V&V^ P9,V[[1/6:].#\;<6]I#=+6$6Y3 3]JG_R,[^8YP%#_YDV8
M2:L=1D";3SEXBK(=4G(DJMC)6,#9LN\:&Y7CJFC7*6UG\(:9%49T7LII$7\J
M?L?+>D=+Q]MP!GPIB8()(ZJ9HTG)XQ0T!RIQV)*;G6KJJX;[ELU"!T[;/:8E
MWA&R $ 'Z ^:A9X^#+K( T<,L^X-EZ,GES5&65$^9E)#,)4)]Z#N ]-MMU[G
M[D3I.5-NSA,:N3"BT3'+S'4TXR4=@2-%:/8@4TLB&@/@4X3,M"Q)(S_K^AF6
MQH!F:M0Y4&8P.HS)Y4 ;2J1N#U[OIEWKQ4-M._HS+3UTS'"S2S(\3TY)OL"Z
M)*=AQY33/?BGQ< KB2=XIL7V*<TQ%\+/SPZTZ.>@4X*K( 1PV:L?7_#6H[U0
M%3'G;+8LH: UV<Y/M(3?S>IG3M^0QF^4WOJVY7V8K^_\+%K7,6/?"%O?/AE?
MEG+QP2G&O;I^;>MU2*KG"?5>U;Z1%N,\/Y,2J$2&PGHJBS:-#2(R,%S>LG3T
M @IOR1=@BL4[>O[ZIVZH)2]>L\)1HL7/%J##4=2=GQW(TE%@P=2W-T[\*W/G
M^1^>5:-3U7N!LC!177QCW>=9Y]KK<HZ%8I<S4EBR%A7S'= :N1;!N1($Y2(A
MX%JV)?0QO<3EV!TL]N&>$GXSQ34%W49FV3-ZVJ2A*GJ7,T08_.U#+V0,N$A_
M Y\(O1]0PO9MUX/67A5<HK=A)+'K7-[I2.>S;SX,OG&UDW,;O+Z^8_O\S"*K
MD6;L.'IK6'(A_I3? P0.4 UG8EU>@Z[DI8%GV!^>QK#L9IAO@> 2FR8.\RR5
M@;T:(=YEH\+>8CU]_^;;!X\>/_J*'P?_>/KT:>0RXS23^'*OAQ*/KZZ.=*6+
M+5B#HMIKPF+-F[W84%S08F!Z/,IFW.]+5Y_M;S4ONS=;#].*XD;9.GL;X9<0
MCX("V;KE#TS-Z$%J-QJ<TOI*RJU$()U>]>!)#[ %7^C\C%ZUT;EC0=%,\/3$
MJT #JCI,J+JMG<80;%K'"5#]<KT#1^0["&T>3X0V'Y;0YO%$:'-?_+O?%!7_
M[K W/2JC*'4D&0NE%K)O!_.B<4)T--_)CEW:J' XA0F_0E.8OPR>72BDTZ<?
MXT^>.7_X2YXR\"6,((?U7;,J.1_($U7KP;M/Y"8?HR [D9O$( KXA8NRXQ"
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MX.=3COV:EA]"H"Z/I)'F13](-<8I2&WWE$"^Q="#G'?\J-$206*-!JI+CGQ
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M"_6J3LMTO <S^#O:C+Z:VHP^;)O15U.;T?TDN9<',%J[@3TCYQ$,IS$],#0
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M.G8?(A!K4?4"HA'S1TOT+AW%UR$T8BYC(VAK+'T*M1<&,CK:CY*(Q[R1\6%
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M/\GZ*<7UY07;5(ZM)[4@;*N_\C$.^'EEV(T37' EJ\G2:JS[=0!IG'-YW)<
MK&(0T7T78D8$$>U%&R&]EE?#SG^#'%Z.M9+ KC$H:P'-<]_AI52;?G0D&=7-
M#5WR[U6D4NC"HF.(G4  <?Q2^"KRQ_VH:3N'E-%XVJ8)FUS!S;GB#GF_X1_R
MS*$%?\\8 $-4N-Z#\'-8#/LPPNHS=1&>22A3^<$0X(P62)P-8!7R?G%MQ0Y-
MUX)9U8#A(_" $[<<E1K1V4%6)&'$V%F:>SP_^I!%C&XJ'CPDV@CI;$''8V#
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MX\>>7-CPL-R$O&AW(7: @8N/%4HYG !,D#O).$'$J?Z8"T/U%KD:<?GU6'!
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M?I@WEQ=_XEG=K[MVN%ES&:BK=H?,&7%UP%/U.#OT-Z&"VV"YKN*7I+J0 EJ
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MU;^4Z?E' _=\DL91_$3JW(=GLF$A]2G12-3ZC,=PNB2_&PTS3I58[RPC(#D
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M\;NYK>)QVRI^]W+;*IY)<N%LAL_*EEH!@=+K$5GW:N@411>3<JWK?>M/07&
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M*PMIHCT>*7.>J%HWVIIYM_2]'O[(-\"^G.X[A/KYZ)TYQG5Y^BG#(>*DE83
M7;4#3(\Q[TO;H5E2U39ZVH#_]K_^\/GKWW_1&PT)7KD:YWN?F9R9OBWN>6XW
M?G9GR,"EVT]V:M-02V4(!.>:7N=D!_/UH=1<Q]2;D?3GR-J(/*3Z/P$-:/ #
M-8^,=;UME_!KZ)_Q&]+E>M ,%;U2; -.#O>UY*J8&KKA)"S:IF'*Y=?LDK8_
MUPLE8M#E2 MW77%_*FT=VJ<+1UM"JT3 F,@N15=SJJ6M\T*EDIIV;"4#)[)Y
M=R^X0]98&E<=RCH@Q>E"7"J@5]D(VG9'D\87W;6[2/F"X<7S@%GQ6CPI[YDF
MM1'+*D3G+K[,$E"[GC-<W]PG*\L;""=(/_&<I3HK@C-%5RJ\A%%"7KY.0QKZ
MO!O1=O)=-1)[E=^R\]#KN2N^TGS ?#).+YH!LP8\A?>L?KK,-6VETPY8==VU
MU;(<17R\9E =VO)J/-"1T0LMH6VJNH\Y1!$4WVS$*G%[T2V?6-ITOI<0YQK4
M1.B.S93=V62UW8C"B6S'81=*TXJOU> VM&XW^ZAU=K0YZN:VW=SR+GJ[9DPZ
M3J>I(+?=U/!*EV(LQ[!Y87.@VZ>K:-@:&AJNY(A7>9&IV@_2Q\M[U#%3<;(V
M72;C4+NM:<;CP91\1R%-2FZ S,:BX@V;IZ^]B>O"7]-A4/%9DJYP5?PP?2RJ
MCG2<J!'P/KN'+;A4:%CQB-BR035:VM>=TRN' 7.$+.JE]I_!VO I7O-#. 5K
MN+_QS$0R6>H8[BU[QZ#,R*>T04T2'B->,EZ,0OO&A3VZQMY\'EU&/)R8#X?C
M_[YIE%P-6^RD.VVFSJ(5LX+F*_>J> ,Q]J,OW]'9N=G76SEE8T2#,]C<2C"!
M&9%:S@3'(VE[,D1V/2%PU4X-3$<70$R4G0L8' @IXAE)=[^M^?Q^9B;_ >#,
M[V?@S.,"9W[_<H$S<TK[],,XD$MJ\S6JN)ZL=2]>PD&=4#F!S%R"0$V#G:P$
M@OJ'4$@=%3_F8L<3?YB81&G:4>K$'92<"2"KR?_&;"9F4I^5@_G".F!?Q=,J
M634B)D;3M5N+PP1O=!*.>F[O]?Q#'X[&V50 .%.8SR_Y^)C"L4W.:+6'C,85
M2R#3(JLXV$"FO1OJN,  '\-_Z(5HT?!")!<JQDORQ:,B6<8*YDAX*"X?FL4:
MP7Y>#-._8/6-4]2\6"4LOPLVR*+B6D$:%=)2,8TU_;CL>F-(XCTN6_H(])@+
MIK^R-+20TDLQ3 E<)#5'WN@@*49.Y5B"LF9(-PBT@"\$L>9QC4]Q@P9W2HV\
M78B=N$:T!VVQ,I(;"9V><&497>R&OE-H/528R-BYKQODQ;M SJ]@4_CW4XN
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M&X0W]>]W[;NJO[P@@]PV44U,?4>]-,,IV  )5/-O ZN.M>_[3LAATZ1^T+-
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MQ*_;:-S6<;D(^QKYIHCYL5*K?P\BN3/]#M))%S90E-WG+BC?J\+G2+,(+]%
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M,5ULV$FQCR(>],706SRT6I2AX+-.^=?TT.)#%!M07>1_&M^ASAKZ]OFO&#F
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MF_!SK:5U>6RT*4A]FXOA<#BY<VW8QN'4#7\--?+8&']5Z*;BH2F9BW-Q#4'
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M#7DK&#D_;"T?W;.XN4(E-73K.-#80WJ^XQ(76Y^M<AIK8XT**&L!/9W@VW3
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ME%>B;J4 KN/D9C&=V\2GRLB:9TJG,YX*8:"%0ZLQWYT]]O T?\ZOPM7-%<W
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MLWH*W5L?3(Z*Y&(X**F18YE#K_.=K,R@7T(X2 (..N;6^N; %A(=+."XV%!
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M\OD>V!B%/.,#E>J]!%<D*<ET/!E73Z7!CB4'6T,6!B8,""W+2_1*GZ!>(;R
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MH=4&6"1Q,JL1X0>NI9Q&A89'V3@0/$0I,IKF5U+DUDDL():P(I0[#UQ4!-=
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MMQ)<01*]) #'"_LSL#Q*;LGJ9!3LVN*I1241>A/F@/UD?*[#@0D458!7SCI
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M+1>+:K$H&]1)%,\NBC\UOSFO*'YWA(Z;4HN!NGE!>EWR^_L7W^LMQY(&:,(
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MP=,;33TKIXM28^(-R;C[Q#[O7$^)[1$O,1VA9_[6^K]/1I?NNJ>GK;F5RA/
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M'6P_9U(H[!$R(<:>>6D:Q#:^3AU[CPS]SK4^UNQS,I@U=X:>]JEF_?R4LY[
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M""\1/O,(OY;6I,V=NEJM5B0!2 )XQA#4(RE@37'<JMH ,Z9>S%<YFR2 -T,
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M$)X*N<99<T12>&XH_+XMGBNRQ;-$N><HG;Z#4Z_:')NSPG:::KFXEK+,EY"
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ML8QWRHEV3M[# WX'Q-;IC=7WRC?-"O"S4B@(EFB8EV))=W?0F=MJG6(V)3)
M#<OBDXBHY,*_87FZ^#OY#M#D+&WJP5K$I_?*E6GX8UQH\8^4+<<R=N<U13B*
M5)82\:8TLHV];NO#?B$..P&U]\K9S116T'*UH:F_5XY!"V"0/780A/7X37^+
MN_"7B!$))O3/WP#I-*"[1+LH# EH!/#L*3VU.(J]'A@+I+T5,G& (J 9ICZ%
M>"E%1O]=.QERU?$XF,!=^KTU0N+IVA3!Z 9@HB:S='8#S[2)Y^W!1:XY19VO
M91N[FF=ZO=&)"]S0!JX'WY[!FW8M1[^ 74Y#.VXGT6G_X0\;S#H?OU;.6Y\^
MU[R=K16=PWUYY#O% VW8*@!TO'N\#9XPY _![8\&Q6)]2Z@LZ 78W #NI\0V
MCQ)%P(36,QV:OP/3,/V;?_X>?EB9#'GD]I^*FR$D*"*46X/9Y:>=H_9TTM9N
MAN%9&J8WM31X"R NV?JPU^FW3[LG9]W>\>9&;U_9_=KO'G?Z?:5UO*<<=K]\
M[>YUSW[,JX-Y@]"!"=S3!_8[V=S8-9V3L08VF:IT;7U;^?/__G>G7"Z^/]CM
MTD^E]W\I5YJ'\Q <=^JX5.D W#G27'VLE'=4I5PL-50%+M$ N2SM"I67=D%<
M#7BVK;1\^$DGDR%QE4H);RG#_]ZVC+%F*/Z5HUR-@8/?%)PK&U[K!4,/\%-S
ML<Y..=A5V"U*&]X57WFX<$3J?<U%,]6'-8/*Y0*K"8"_>\KA83N\);J&WPJ:
MF8T.^7,"*I<+W-P?P_NZ]($'NRHJ8@J_M\T4./'.U>E>+T0W>5T^U:?Y82@F
M8N/4)07=,FV4YLK0!!:HCVW'<LYO%*YU*P:Y))8S1>W;=N C'JQ $46'TZ9:
MMJ?XL"5"ZS[1^>%,?0>$AHHZ.FC<N-MSFB&AV;X)_!I4(7=S8T*PB;WI3100
M+8%%[S:!);F B1,":(R4A(H,K$(#_!+(V#UJ[X48#,J1@B3BHV*/#S)!S8=/
M["7>-N*T$D/!4N.]ITP<SU<TXQ*O,38WIJYC!+H?[0?!<]#?!0%<JM--X"OA
M+B.P--]QU=AV->42R<V_06%!=6'%#R:.>#.M>R6*X09T;^*AE&/0 !<&M5P"
MKX?#H3<JPP!T-+1MX-GAZ4Q-RP%=VP^,&_SE(P&RMNG'6S:O(E-BW3W@,G,*
M>J)-SC6Z(E0N/7$E)5LR!2(FEHD5OCHP+],&M%H"P','U@1 PC"=:7%;C%;^
MGE..!K_B<=-M:].I!7N@ C4\PN/H!"GO0'[Q=;N_K>P[CL&8RQ[>W#(F  $L
MT$[<O[_7"N\'& "[K- ]P/;!$(S!C4&,L2<!>W[#>V7L7 %ZPW':#K!G+W 1
M& B2S8TAB>:9^F/-IPN<AP+L AX-^#G$@];)U&?33_%:6*%X$1S#2(%'@*ZR
MK72ID4IO11I<O(OQ3K%8.(KYK<#[1HX>>"ADR/44<1;.EQ9\X)VI* .J)F(X
MO"A"GG M<9Z M@0<*H-C_'&;&[> 4DT\!XE<-Z>,+R#LX D^&N! 6IHR DT7
M!!7(1D!)^%( T"46CK@ /#2I2.$PYUW&Z D[P#2(YEHW^&<U@9E*X,';O@0:
M8 HP'#BBZD[Y/5L7'.04251S;QAMQL@7=!L?/:XJ[IK88XH!>%,P];4+6ML>
MWRS^0A\!W,O478?8E\BN*/E1R"##N_9AT; 1(^!8"P_ASF+$441HT%O1^5]@
M"X%W7P/$?#P2N :L.+P8&+J+>8X^&)D@"TSJP\#,# M$!%J3='<A2P^Q4HNN
M-F-7([?73<_DS!7(F\1V#V<?>"S$3M\)L@<E DBJ"V DE"W[7@RW7.<< $T9
M -L#X,<4G@\O!DO5-W'9'CEGWA9Z4-@P '-)**-TR3FRTB1_AX?JH&FC#*/X
M@1K3E(L2"CDM %MSK)W?J*#^>'!<B*Z&$$Q\&=%[4#10#L2%&"X&&$Q"/E%W
M.ZX(.3P%0UQDW;9,T+Q,6*08B(4PPC82<!W< OA!Q1CB&NS]4!LBE^SB5R>.
M8X5\[+![$NI%2IOQ8FJZ1^.UZ/W=$["J-<;('26PYQ9V[CI7%/D NP#/AR"&
MO,FVPL?&P%T@6]AC4"2@L/&HF"T@^. 2)J2<ZQO %(6>(^8Q,JDHT-8RIR#;
MIL0%7#4TAJ"H@%Z0&S@-RT)4\1"2,07@;X3J=HR9#>'M[-6"FO0;.%-+\^@A
MZ'$(X$LCZ(;K1^9 AC=L'W,*Q]_L%&.@2CO![<V-%CX5WQ@F<X[X4<5P)4'\
MU..(2E,D;^<$_KVEK;JY$5P2H*()6 ,H9%7EW#*=(4#!A[^4">I"B)= X6/8
M"H6$3?0+Q?L=:!,'6#_=3"BDZ04.Y9JW: .,08W-\S$@T 1)Q2;$R*\Z#M:\
MT,AS;(S#+D*O JP[SUMY#?91(MYP9QP!&!\2-P&N"=)UJKG,]$<^,D2OV8+J
MR.RN<X<_'<@2UL4$"?4&3E BPR)A(1,'QW$PHA[#]1Y39H"^+7,6Z14@+WW&
M*SWXTAMQ10-^ DT>I [MN2.8K8VQ96 <3N!Z5+<9<N\6ZMV,_V$[5X7I+\(C
ML;D1N202>['U@*4QL/: L%[+\;SH=<BK&)\$&P#EQ@0V!]K;?Y*^IV:BQ+LG
M'M:UX2C((3QQ8!X/IG;-K@\,<Z#C0HKPG\$ /Y7*E=)@=M"I?#D9D4_C3]6[
MZAI3GK_BX'P!"R5 2X*7UI=.(ZQL+S8\1/I/.,Y6AMMPER4$^9A*%#0]@@F7
MC09!A1$DPMU'U8D=U2GH&H ^1D=S<7B,UXH>N<>>""?7G3LZ=F"MD:YYY?..
M]EV_Z\#N?LL*&L'>Z\SJV\WE"1;T'SC!U9]9BF\P:?LPUH3&';""*\>]H!J?
MKH%!#]3N$A O+F=8_MAU M  %IX(# Q X<)*PVN0A+&= +6)4#MC27,FVHB
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M5L1M*]CP SNT\_SJJ$Z(.@;-N*,CI0<L=Y+0X'@,)_"<0BAHYRXA;.Y!XF6
M*0][6S'V-M92A[=^0E>A+<;<S)7JP5)0A7CV'*Y7K0YT[1/FJ4R7[*D*0=R2
MN]?]@]EH=W)TZL\^?=VI9T4EV!G,.O:P=-/7O)%MK$PE:.FB*,^T"\(+O,PE
M*M6$/.TK8?*A1:7QLQ:.^)O00\X<]?QWE4W/]EBO1WKX87LP9O7 2V@Q\<+H
M,"H$_PY;I40HA4[T):H'\X.SX3]S*;C[H<D9JUSH8SZ/YAJ>LDO3CL*I6*U^
M--HO[7H$AL$2I.+3M%K]=GA;HU(LE(J%<JT C/\?\T-"7XKQ"158W0<^*:D
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M8YZV.^X<S"Y^CR;'QH_VY6E6_&WUP:QS<O&E=]'=/SPNK<S?=DR %5!? FA
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M@#'C!B20@EO:@/(H!H!HQC9F^77]$(7YIOP)@T@6&3I6-$'$E#<2=3S<M&]
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MKDB4,;5BX X'P1)/D"A:%R*5&_C:*P S,W3H@'*F)PN_)99-UJ2X3(' )4:
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M2FHY:%PP$1TI/"=W4A3E(.&19E@H8""G'4%:L:+*O+.2(0!,E0:$1ZUKA@6
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M!764[?'Z,^DSFZV=S%P76V]/[_73]E;35M9M)G"8R2#[_N$-%0C2TU<0VHD
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M<*TMM#RSKC<)VYFC=?#ZEA.DKZ!Z9G]SC[^;K=_EWRL18_CKW*6 \M;U[%A
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M_WDSFX9^ M\_($WI7.J7[SJ4WIK$/E)XPG[  2ZXPAF-@:E^414N823$K*K
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MPFE!R ZI'PJXB(Q'A0070?\@K=V7P&H#(</ARI>! H!UY@1@& %J&ETP%=2
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M0'\ NS*]8Z(S0$ \6L"3ONUA>E,R3; 7^FX,&[=# (V;@(Y449C?^XLY6K9
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M\:E.]ZHIO''&&; ,!UK'"UA/#E2L $.=)C--;>[(JE=SAIFVR=]F,2[NPKW
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M1M4G>^\[K!V05@$GCSS:Q2?[I,.QZ .IGL@;7+@G243?>61#*/=MS_>_%/>
M1\%+ #(;'ORF//AF!+8?Z )'][;CDJ3]8Y:KY/GQV/[JC..Q\&)RAB$YT2+X
M+]3C?4\Q6<([1G7 ]#!F')]D&'V!A8$44)9*=]?:[^ZC*MC["[4L4EWQ$)!'
M$3,"1DRV,BB00 1HD0!%>G>HI3)J*3<>PV8I#3=4H(43D#I@Z?#V<Z_QE,Y<
MJD/@FU6%S4AJ[1*(&)N[N,A^X(&A=!*V-'%P>?L.(>T!<8SA1\E)XV)$N>6L
MO%XK@RY+T_#F4$81O!BY%7"6$<L)I$;]3E9[GOS2RJ+S9E CZR"7K,G\I*FN
MLKNJ^J4XO_PJP6*TW9\ ;+B,5'$;*7$^:W(G043D=7$ 7"F4&0Z9D8.)'9?C
MFBA4$[60'B\RVL3GLW =5"?0TW*OO3W2!K;%P%G*^%7*PB1PN#=5YA&VDJF@
M$11)WA%^Y(*AR%HBP&&#H>[TB:\D!G6J@.1>"/:Z&Y-&FEDP:[5EUAK* 1XZ
M^88B9.VA[,=PR X<H6L_A);R,) ' )4D4 ]!-0XY-AR(U-M06=2K/N6<*DP@
M;,UR--!@-8XIY2!1WT%KI,Q],/-!K@^H95JBJ++O&G$P@T&YW $0>H&4I"*@
MBAEBV-T)1X3^[)-CXK4C7A#VH!<@TF7+3,,&IY('#F@()"N22M[';A&X^$^'
MGYK84P)"K9VGLP;:NE/.)%#[UYX)DN!^8&D %21J&8+=(ANA'\5,'D@!41"3
M)HV^%,R0F"Y2R1APMBT2/J+>PZ9O/%&J^]!V D2?+S(2]]@Q30.BU\ZWP-.[
M-#3WEC0'"J>."P3B-K5=D?!^TF1(%C$JB9- WCM^' +194QHTB%9=]67+).%
M^;[SM"7FD5:]1G3U06#XS1E(I;>2+H[DC(HSPB&_]B5^*3V*MRMW=?Y1MFC3
MH%K6Z9/X E".*.S&'U"P =:!XVAQ+3SZ\.]]E36$"^0A&.+*!$)#'Q8?AW8#
MH&]^R*O.GDHQ$B!U+A.:Z=E@C8+:88L\Y3#(ZX /=%0ZD2:XK ^"7J0<&KS1
MU!VLDAB(8\9A"G-8#G2]AHOEF1XP),Z0TE E1D,XD7UGB!R.$Y_0T$('B#;$
M,D 2X J:K.3//8+>'>5KH7,92#L:H6L-7DD^0?;Y1X"%R"PS*5R M<Q..0%+
MY6RD9MD\X<(:T7S4]0;U6B"'RI6E_#^I2)&(P5Y?&Y9DAVT8LWNL=^:!Z9VY
M[-Z9!]]I[TPCS9_B$+A. A>)-PA%8_JQ2F3Y ^,9+./18<"1%:"HG+--,41B
M7-II3*RZ/#QB*98:2&"XH9)HP"&QV3WR4AV-R-NV)3:HTDM1OHVD-_L4"LF0
MQ5#&Z3TG9D/2&/W2&!+P$IV4H*+?V5GW>='S'(/NH*+=K*($]-\DC1;L(PW*
ME_HQZS40%NR)R^K]+"%F0O5YXSYW0[#LP\@?)[9W 4;=W6?^S=5K?$J)*U]=
MME5P)/!3?#T:'\B].,T"9!4= *@'J-QHJP1 I;ZHG"CVN'*H2J%>QI.I'*5Q
MH#.?>".L/0"2P!;#H0K6<X!ND?W'KVF(4YL0MNQ0U)G (>)_,<"H#JC\;F7B
M*!6NU/9!=",D*<610IRFLHQG(_CF)6*,SO+\2';M$:$(\4ADD84\E"2"%DK,
M:"*$TT'@3!@#%$"?=6IR\(.A3XJ+ W 1FI#:""3L2I4L@=1$J0U)HA*@F"5T
MU/D!]5BVNW62BZM2?JP">@6 E"KA2 /D>$.7U06R-32>$N$Q-VN(,T^@1D5.
MN*P/)-UT[&4)AID@!K[+9(A!ZW5 ZW.=SGF%9C7E#J5XS7C.<A+Y&ULM;.S8
MXB' !+*,IXSR#@AC@"./40YJ-4'GS&:-),(GLB+OI<=VV[T=H LA";\I#MJW
M)TX$Y_&W#IV3Z9UXS,K"<9;ZBQ(JI*>RUD('3LQ&RMC)KXEN8(_!G,!I1!+3
MS)(8H=X_^=9R=IX"<"9\F7&5^W&4)E#P>?K!C(L[<9MG)!V)^WJ-WX0IEV[H
MHZ%*>7OT;C:'DXRNF0MA7PDGA!&E*]])/NJI#EL;J9DT-[X:<K[8ZCEV WI1
MX+LS%Y%:YW8?8YA!<E]*T(-0_=J7$W*IICPK46+*_3^YIMY6DH681"<Q44Y)
M>&2@EA;Q "ZN1\]Q<08Y_"GA4H9]\NQB? 2S%%7*<P.HP.';R:2S9!X /59B
MAG.]EKL'4'GB/K%\5%M0713VV(]1L0ICS/31&8!8$A0..1\Q*2+1OR%O@/T5
ML/,_L?)4A%F5C^Y_)EB$)\(YCZB'6 2.$^(5.9@&DSBD*3UOF$6MA<O2&;CH
ME,$@".5XEJ;\9-!;![LQ,Q?H/G5SS61THLX6!W1-K']:!:\>9NC@.Q/R8Y<-
MO(RA)'YB)QB837*Q4(/N@Q4;ED>\,O'KLJ@\$@8C.FG4G-^8"C#*'5R8,I4"
MCB(2]6S*!+('U)T3<U%ULF<);V 64P97WTXC\-FC4#D_6F5,3964D1A!NV[%
M UPZU'WKTB%3#+8>)43=1TN(NC,E1-1BO;W+1<D;4D'4-15$U>'-CU40=<LK
MB+IO64'4?9,*HFX%*XBZ&U!!U'W["J+N*BN(NM]I!5&W6$%TQ,[QEY8-%3)[
MEEDVU#5E0VL&_F-E0UILB;S<VI"RH<I>6\6Q+N/0FU.N)9Y=K=5]>K563AQI
M=TU9N99XY6JM>FUNN99X[6HMBL 64Z7T3U^Q6JN8FDWE6N(MJK7JM4*YEC#5
M6L_.=SHT^4[+SG<Z-/E.1LI^:SEBF7_BF\H1TY2DA16)W;0BL6-UFRUKK]5^
M@Z)$K+05)46)W5<L2NR^15%BUQ0EK@%-FJ+$=0+?%"6.3%&BH1Q3E%A2E(B&
M[;-J$84N1437]EO6(B;][TTMXL:0FJE%-+6(IA;1U")N/+.K:*G6$S3UY91N
MZ:JDI'9+O%WI%J4W9<Y:O%'I%I)W:73QE4NWX#QF:K?$&Y1NU6NEM5O"E&Y]
M9WS4E&Z9TJW-16M3NF5*MTSIEBG=>GKI5O=;2[>Z:UVZU7U1Z59W9:5;W>^X
M=&M1O<]CJ3)=DRJS[%29KDF5>7T\K]0N>#%G\(]W_?]MMEOO]&;.;D_/Z[56
MNR%N3H__N#Z[_;>X_//B]/KFM[,K<?E)')]>WQZ=78B/IQ>GG\Z.SXX^J^_%
MT<6).#^Z./KU]/STXI;^O#[]?'1[>B)N;B^/?__M\O/)Z34\<GL+CU?]_#8
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M( 8G<= ?V2'^%O_<;5G[^X>O*FK7@=BJ1%T&UE>;*6#0:GE<NE-1+LT=,Y?
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MKZIJN/0&8,4WCY-"2(3<&8_EP+$C*1AO\',%'WZ-C/W.Q\.?P'O@W.NUD3W
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MGHM)!5?\?Y%/>C#IP:0'DQZ\1@]6XD*G:BB9D?L-@,AZ V3E"67O<@&(K#=
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M8(L00VZ?@;VSX&OX<_D@VF=P&.0N>XU?6@R[YQF$K,&LSA>N8:Q/-HCB!I=
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M3"\!W/PDC[)OSKQVJU(Z^MU>@R=%K].^*BQJJU3@M .:D>JMP> <H,LQH#2
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M)UW@^Q= NE'UT\B!02\\Z'I/H\#H=9YD%HIZ"@I8[6@^2; J;,Q'#F;&54'
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M5,2[G.(CHA#\\8 PV43NC%-/5?#!X?ZA8,]<0U7XDN07#92U4:1!YF)'3OZ
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MFYMEP#,SK3771R/],$Q"P"[NI?!7ARL@.Q4WT;S]*#IQ6,;$>!DB55H&GOU
M 2TM1"@D*80&65>0@2P 1C##G;<>2<>-L6"R\<;J47%-#$\.VMRHS[=28T"#
M-N?F\6B[%V37W%?\A37WP[\;PQ^?YC9H*27-K2PO&.BM/>T),+84JB%0R^JT
MQPMV.O^%63 "M7/B+.1E@7T*#LB>S*V(D*K#G:APU6NI1@UPU0WO%70IW:>%
MPKLU%#<[1-^+?V D]"K \-E,>[#?=Q?.3_KRDW3"=")9)D;A>TGBD#]F&_-Y
M]R":6$-,U.),+39$X#/.&-7D]N0"J.:!<:0*A!X*C&0 *R?(J!Y3HVM/%%*V
MY%[<<]DM\,SH/?"Q%-]U(SX!)#]PBL4!0QTW4_&:"ES6O;H]ZQW&+<BK*"GZ
MS2M&>*)T48WUREK_>\^^5?'&!E4M8ZAMN\9YM$F:BV+5?W>N#ZF1^J@7%?.A
M@NB0YR-/G@N11I8&PQG<AQB]T[@A=$@;<@HW[V.-@D=1+M6EG#(Z*[>?W^G3
M,<S]H)Z%UU^ L6X/U[!+/22E6<IDY3-H=:Q G ^,$-0.[IM/8/KS4I*E(^=2
MX6T3!FP-MKX=_ Y_Z%FQ,]SCA2X22O\+^>1A'^MX]@6I.S^VDRN<26IW!GR:
MS.G;^.61P34J[FL-2W>KJ@Q0["=A([XG!Q'$7-S&M39",Q=METH/IX>#=SA4
M5-"&H:8TH41.O"4+P](C'[]=)Q&YPCU(\.$D"06$2NF4L8U-#S8*,JP_L8\^
M2)B,UQ(ZSV_3^O=SA%[B48:&?U/5'M3?TLU>#V/1.SU.,#?FNFT92Q)'Y_QD
MK9+B[1F^Z2#NG"8R<2GW_D2!OZXAR9%1%D.;J;M'0MY3@V<]3$7V(\)O-\,/
M\98%UIOJGD%PQE2K=NP@H0;(.D$Y%K\6-:Z<V:3A*29;_'?DH:$[<"F%E]EZ
MA!>0Y5T*K.8>,*E9C$VF?9'+^%"VGS-52>7Y1L$=%;4?(?8])!+MP4+3(=V0
MQ\9A_9\YPF'I>T.O0I">T!3&.'FWN-6->%)IR>JPO6'=A4!O&\"'#Q$J&M"'
M,AZI]=[.S7LM*KGFI>X\OS<N(-\1P@NK"\'I>UD*=+N6FVX<2:QCXIK9=&8;
M\GZ"@,T\U>G-OJWK>;X7(Z[1N:F;L(\ELQ,:YO@8C*+3D^!J:=?1L;Z+15_8
M)^8M!;? >=CX+.J%<H*B8R',=D9OJ1V[LCLCKJ^3!8D6$YF-1[(SI@X.>M2T
M;?ET7Y9(%_H.6OW<IQ] UTG73>]H)I8XZ'CSD\1/K'ZFS(J1\J'?%LGDXTV0
M2IJ[<%[+11<_<YRE,^*NQL7R.\5$ N-?ZJ.B[4<J2#Q%A$V29O47RX\$/QN;
MDD!;YG?NFI4B+?K;$=]!-A66'G[U\:<]A=L^T2'^G\&B=^KBM4\Y8$2;&HF4
ML/>@P1)/-$HW(?MP[RD2Z.F-,686:RXJE\F3C?.M3^R*YQR7O\B>L5.\9A+L
M?A8LU(^UL*T/\RBFBR6=6JBW]TWHL3'1\9&E7/,*AGYN61W*12,NGF"T^<*W
M6LJ@S$]].9]ZM7X8X?!)@J]''F@?47#4A8U;6QC64:V=7.\W3Z'CW6WK D/$
MJ*'6_\:_E/?6:A'(2P#8:D-X7P G]3AQ9#IHC$Z\#HE,50^ E5Y[TS/I+P]H
M)5GN\U\9IN*(VO;3GR;?;32.NN$,WDH,5?8/O@"[)K7.8=JS8A,VSC+;SG5U
M<N?8REUHG_AG1+Q1OU#;"%%%@C=ZDL\(\&V$22SM?F$-,BR@%Q+$F_ 1 P<J
M:-\)/HN$L*CD+[:@=%*M(M\<O(LB=,&7G_3_M7=5SMTX5E;V*+J1_&!I+E^*
M3<N9F$XF2:D-PT3BAJP '2'K4M)P9$7UP'KZ,]G5ZO-$6?;TA365<5# )L@5
MXN='CK0=_QVX)'8A)_YJ'&0$XG="#%#J9\[Q,47<*==-WX<'=$+R<>M*::4&
MV?UY;U1Z]1D23I^#FTRR5Y.3=?#)DC9DHYP1(%G92>G9H?,;45)L-AV#FPO-
MDUIWN@;S)Z_@)@WY.6EO2(TQCY\NV^CC5UE'/*^(%.&,30OF+7"Y9^MB>IEJ
M!^"^_UK[A8]7C+S_8['=AA>?M_^RG+9YK$8.\?X%D)NI.2A.QCLDJQ]7B+P@
MP:@O,88;9/L*6DTIXR5BLU9&D'RDJ>/AJ1*.,,=)9!6\_2&Q[%"HZ#+T$4X0
MJP<-&V(/XX"U+<AT'%H9(;,F_+"_9Z+L.,-CAQ;,/YX\=$YU7KEM+>!X,-]
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M(2^ \+]4,_/[WY1SHOQ[C=K.H?37LM[[\2-TAS0#VYSDQF_<IX)5I&M*Z2^
MF@>I_Q<V5/\P>S+UELA/%;M^8V 5G9GK^.NHPWH?BH\?%.D]@N1:8;,_9073
M(_ZQ=<1L_$CXT6+>))UX.YD]1VK!1 7/!DULM(TTS%E-_WB"80%DG:\X+OT=
MSY- 64-=?"(I=#*Z27"CG6>^MOO<_$SVC8(W9W0$(Z:#&_Z-2-]L/HM\G-^:
M+5IY0,VL3ZI1&@A)T*]A-_O\"51ZIB+'12QGKT:I7&RW<'&!FYFVSF#ISOPV
M2ADOMKF9"$:1'?1(;['UDR*>%.TJ-?&7'Z;ALWL\X0MPMC1MRE=I4**Y+_-F
MK@PG3<:I43-Y*_+#"^ <G/:.5\B+7J -W6P&?91K.=\26E&6+&XS%HA&QR._
MY"7;6&Z\-:VKNZTL<(\1QTS%_,V\C<BV(S/1\&2>^R;)ISZ<S_0%^#8_.0@B
MM:AVQ_B$Y>=SXO>.)/D%0"")HBXM'>(Y';5VMJNK'(9R#]KF$:<R0D[C.WYW
MHH.SK7T<Y&ZX9HNS?Q]4'WZAY.D:/C\4+Y436M0CAH[$9]W(2PP<Z2?_Y1$<
MNKL5S<6'L'H;9--,H<#+')GOYYU#R$1'7=]0O[;N=[.-&RF79<9>(;.CO#DF
MOU2%?7L1-R.A!D6BV3,IA]D7?"3HJ<:/37V#EL<A[KLMD;F&0JK<9!ED/<^G
MNS6/CV@KG(/*<3)3PSG\ME>JGDUS(3 N7/-<*Z*0)D8]WFP.Q\^;]'@G]-F9
M225E?LM6E+;G1DJ"6C$2"9W#9VK:'N&'.-6 VMCQ[Q([-*O[]2AD#0[&OB%U
M]@&V&]"QUT/$2.G$;\_OV+V?LP5 Q&<SWZ*H]?I^!=221_PY<\V-]4O@IL:@
M"O+\D=GA*>=3_^E937^'J+,URE'.3 )&$'DB 1]&$WN4KPBERO@[O.R.>0;M
M^5_.>?,KA&[J>%LMW]_&6(0B5R,GM3ZE&H$,32'>&@C+RCQ7 %"7#^T QVQP
MHSA@NJ^M5U=25^C<&KV\QJR&4X$_&;<HX&UGOP]C]G_)*)(XDV06[%+_U;?(
MX0?:%-^Y6]:^:^AY= PNM"PQKZ^?55>OG[G0G2?2_1 -.4YZ'6 3!^:TP,7]
M([NC:-BB;-G(."OA86_VC!AM0[T@ ]7B0KNQNBT<GX '@W09[P4();7ITA##
M+A248;3"QS/"D/H4%,2$B>D1G9564-"L]C[B'2LMQ+2^3EC^YT]U[#)$,/=3
MFV=)0QH10T.W#YFG$J),*Z>K*L&-["X(2-BN2<Y24T<F4=?EFVSW2:K?I!?>
M2]83^A5!XMF'FC38!EY/Y'8G]V-'FQ=C;;VA8FP-^8KWZYJK]/29[H@S),^>
M7_-NKE9KRG_!I\%G5T&AIXF805D-ZPZ/;CF?4E*&NB 8<\,2![^GO?&Q26F;
MT]"#(_#BYL?QQS/(,@;&2G^B8H]@*U_VK+?D8G891*0=%6V.^OH=DL+;YYMZ
M$;]=1,34&1ACS;5Y.\,:F1HN*;-1'=-WM-G8W*+Z?GU"H6/ >6/?6ZK>UOA
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M*\[\F@2+HCENU[-KSOI;HY%"O%"?Y4BV5Q<6]FG5XE:HQ;#A''HTT8E"G6B
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M:E%:!>93)JAJ9!(*_+C[\2]$H"*9-)C]PFRD+'I2QRX*\C NPOWY<2T%[";
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M-5_)U>DHV>9!]JFS!<+7@LQ^4 A5//\G,_+5_KY?[:6.Z68:['>"6H#8(R5
M)@88(:N+:JFD]"'$?!0@M R2:;;[Y]V'TZY?G8LO^UPNL8 AAYCB'"&1Y^XX
MSU;XTS2:[S CU55[W"8L$CK,5E>\#MKXFE]+T 7@ZJX;.1*QLPMJS?/YT\;Q
MQEJ6!JNN76FED53H\I55_8U!RKWIAJ1@+<$4%J!:=D[J>P?GLWY._QVI"&2;
M"*(#9JTP67[ 29@!WD+\LHK142O>0HU/];3_@95G'QAG3<^$18<AUQ80:(&'
MUZ&:$:KUC1EJ@1NXE^X) <UA  7[?"S 7E[HXNW]B21#"[19_Q0\+=2(&776
M'.,]3AS6NJ3?ALMQZP.X:0&>R'D+Q:^ZT0)L7* P?PASQ$P0C<'H_21!*OW]
M%0'M/=N647)#1^\6V"ZJTT"2#J/3DJ4[ G?T5W)J_0B;0KSY.;84H,6.^"K;
M'#-O+5AJAIN!.WITEDW*Q*"AP=?KOJ2^Z@';VCNEEK-G,1Y[PMU-S@5U6O\^
MT= \=5SX@6/?*#HP$VS>TR/)[<GUTN>CM$KV(UM0=:+L6%YS%4&7%:PYHB2K
MS&%KCV^EN59E^5,>V6\6>:VZVJAM@G!K4@82<C!0>616S0]^@HMAPR-SC?Z[
MLL/_D +8$A8>MD[(,V !3=DC\O9XC4^B!/*C'^_I#O_O->_]#X(%._U_ %!+
M P04    " !83X%4S#39K6!7  #L7   $    &9O<FTQ,"UK7S P,RYJ<&>\
MNP50)=VR+KC1C=/0N&MCC4OC[HV[->[N[C30N&OC[M*XNSL;=W=WY_'_YYT[
MY]SWYMT[$Q.S=F15U+(=62OSRR^K5KTOO&\ /DF*2H@"P,#  +H?/\#[,D (
M  ,-#82&@@$"@;"P,' (:(@(\/ (V*B?D='P<0@)\''P\(C(Z"B(2+Z2XN%1
M?J/ZRL#(PL)"2,'!P\[$3<?,PO37)&"PL+ (\ A8B(A83,1XQ$S_C\M[)P %
M!HP,W!8"C 0 C@(&@0+VW@L@! # H,#^+H#_6<# (2"AH($PL'#P'QWJ/@'
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MPK/V;>M-R<WLM>^E>+;S(6F++BGOF),UH: R[\^$M]4M(JC8]!/5$+M-_!G
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MY%J*>Y$)EKK\D5C-I*FM0:;X#261*SY3:CNTY&B$AH8*%<*?<9 UW&A:>T[
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M#6KBU7DYY+'$C8P%I/KAR)+E-CX6CFI"3#5475H; 3>EV%D0^JEFOW"<3<<
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M!PT4W:)U-J1J@9B_I^IRL>I/OMV\ UJ4'51HD<_? 1"*M'[6]AUH/CM@9N\
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M4%8!Z&93"X@R#]4TW8OPE5-*L[(6>'D'<-)C-L-+6(YD[1@JS+/"MP=P%DB
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M.5D'_JFOA;"7VEXN.S5)?N1I1QCD(T>,E8E)?H(I(K;+&>ZONO3H.%\M1D[
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MDA2'56(;'UE#SJ<>*1J \U1S'[A"G4F?-1NX'+CPN<>-H5Z>97Z",]5S+5=
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M02D)O?[L< 566#(C^$+7(XS1[SE;;GD-^$5?O863<WG-U3'\2[3\P*Q6&%+
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M9X_2 M(+M*_&S H(+6D"H%P;@]C2=#W#)#%VP\>^B+>6(_8_(CN0N]^#'C#
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MS>#N[BZ;W[O??OO^L5NUNU_M<^M4=54_W56G;M_N<ZKO\SKWN@9XJRRO) ]
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MI\?]BM+-+'2MTFA39\I:94BU2:_VAY$6M[4)JAXM.).2QL5QV)V##O8*Z,4
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M/W&@S*-E0K8CXSXO? <!92.#-57&Q=)HOA;-,<RLW9>W[]W2@\7$,T).XUT
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M;R2#7 *TBE-7/*U1D?'B?4--8"V \ .)!-8/VK'EP>H^+\ER_A:NN&.4]+X
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M)GB[VMFA 01;WL<97_A;MF&S;91!"RE%YSZ%.BZR5;R\X]07<82\_=;9SF)
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M,&;GW=E_$$2JE&]D3[SJ&";XG/,AN,!-*:2WD;OG%* A8^1K&[&1L1&>4^2
M=*PE0Z]ERC]UO[BE\FG*B:EDN1^WB+EA^:F"09G59,BCZ? ^[LXC[\[+- I3
M+4BK1E_)VL"]('4D:=R;EV=0+!C K([*!VN)57)?EASL%JQ/!3WG<@Q_@/U1
M"E2P2QS-$6'55,(,<5M$;5V4D)SNDR(X^<)>\26HMJ==J[)L@R&$E_M G\*D
MMHH,/+&IVVZ[CGOW0=QRH;#S*R@@?XQ41<S)O][EJR)X)B%D[H739U" 2))*
M_0%#9WK6-Q,>P5&O,B9_@#DF=X34/T+4K5I&3-ISAILB<\!3#W&L@EW[;<WP
MC^$<G*K60_X \!WQ=A;D*R].DF)^+:&]D3Z$=UC=T76_F\5_,5;Q^P', J7#
M%$,C1^)Q>$6#]:E$T,3U_^KYZL7]G->XH<!48?,G8[RP1$='@KJ(;+24]A.H
M2XB^ A(Y.PGF'ZL_>SOEK'.(F<"+4S8N%B9Z>,9_,5RWR^,V#BO^X3R*L17Y
M/4#]Y!>6N"^JRFUWTR3X]YZ5+FII5 @B3,I$?WM;C7'.%>7<[I!*8E>.'?.6
M/T6PS*W#OR_V1XP'0JV&Q>\7H&$Z8Q/I5 ,I%].\JZ5TX1+4>MV@408Y"+]9
M+.E1Q\]#_>#-#97H&Q9WCKN,C^WU&?JU2:8J7CAW5<X+F^#-O')!11I!T4^4
MF[!2N5R'+^E4O;YR2UWV"1;A<S+;!34H''6)$VI]$ 4R_MAU6,BT^LR*G0<%
M6WE24XO8G.K4EI,6:;8!03C9X:+ 2:?H6<DY5YA9_R"[5^-F0!J6IBQ IQ1X
MIPPM\(.[]<(J'=N8%X:,C4%NN+94V@H1X=E7 2E4']5:,F4=;Z3[!;1CG)C*
MKI@$]B0QSZHC/I_U;3JT"C2,]44,T0?7L)=]_4UY)J^!1!7K<Z1WZ:VMV3S%
M5!NGWI7"W)A6):U>[$EJS?)/]%_WF==D&_M468"4T?F-HY-RM)NF57 Y:7U]
MTCA6LX](%MIV1>!YQ41><-/*Z=&-HGSY\IBL5#6A+E/^"V8Y*S?P1CD;0\[1
M7P?V=XU1*^LU#ICN]$\#I$S.?Z\JQ][W*,ZT.X$^U:4'2*H,YD7?CM7J:)6L
MJ[M*6JJOPZG >OZVN7?ZRC">(K7M.OOCK<KZXW>&W=0?S328@'&JV;QL4^UB
M:Z9"2M"I9Y@]U[OH6R6^$V/7WTZ8 S/66QLU^=\=<CI/IIJ2'[-<BUHZIB@F
MPHVPKP)-JDN0]W1,H&0!Z"*#SXXU$/IP!HC F^^()50 *A0E.2N6X2""EK(H
MR* 1<U[!?\I#$,FW VGGE\V\)??9X7[R(^P)M^[:*4BK,2]$LW_EA-O$HI0/
M!K+OBLT;9L2IB@]2IIGK4SX==\7'E/6BO@(\@H5/]-H[8:?JG;7>Z5.F*CI=
MF4L*;HS[]$TZPEH_]OC@]"R//RDI?16B.VGL@1]FJHZKN#@04"V<"=-"1X%.
MRG@G@6F;1#L+E"12\VZFBST2A3%3][RFO0!0^44!NM*]"ZK2(12\TN+(93NF
MQ;WC-!38&9121$1_DN_G85->_[TZP<MER!7N.?0%I)%"6C]<RX*4]>@&R7'?
M<A_/B;KJX'8PBC(T$9E,8>>.(69Q-4 $,D'E$3;%USPW,=IC<T#1$[\ZWL?+
M6%NNS \MOO/<#&)"QFY&=AKG2?.H-%UT?/ HVE]Q&4$6_/NR3J?_9VNW_*V+
MR._=Q#'F::T8+66NLH/*%UL!H[JLDKZ5AU6UKO$'DZE9NFFG:PM0GL36.7IW
M^([MLGA8X&5,V)L6>K>L7GQ4%*V:OQ2&\$\1AN?(L(_KC3Z_@*1+5.W'7P!!
M'3/6U@"9J@CER8WI)P4O]K&W,Z,6GT-8_">_I"$ .85MQ92$UUR$RVY]L[,D
MJG(*%@ZH XZ?-X?X),KIC!D-VNA_;/<#4-3Y8*T.&S;*.:W5U*V+ZM5C]YC8
MX^?:A22.]'#'SNQL&VRK/[O=))(VQWV-U45CC=I4'2/R-CVLQY\P:-\^U^*@
M..=0+4YL9 &USUXBP"@S8($D6(TB>O-WEKD,0MMM)[>88&RS::XG,NS(&:=Z
MS+:T_%#W$DUKB,SPZ9LQ:#&4+],6UEC1KK^>A7@Y'/>'SSZ<3A4J]SFX+Q-1
M7>2%86)&1P5//<\$NOA0<S!5*#"Z2V6><^V7_,3;VM[UMO[Q%)^_^&/'](IU
MT\4-PX\A1&Z^_<SL%KH.M4VE?+MEW<FO>EJ\Z!(R1+UW@2=2;[T?M6&@C+&:
MAD85888!K-X32ZD)\*'IK(XGE>G4A1RS>Y;@["9T5:,^<I-",S],IV0_6'JC
M6E-.K_^_UT8A41%_8#X@,_A4CA6JVM04#D,)61&(HB?5D0F6#"GZWTL[\6N>
MU)R]W'(GB%(V6?IUU3$Y?1 ;61N><-V*EV0([EV5*%B;<NDR3=,MH:TUP][R
MXZ^ (VT,1IZ!KFUY5T6).[2H%3F(",F7FB':8TKCC,NA@5V3H C^FUI845-'
M<]1RLN"/]CZ&"?/B7=.OCNYJ)1.LKP"?@KF<'*0+U*;2<](!*\V1L&'&S3UU
MUK;VG\?V *M)()E46O'B+^@2H*>(-^WWP^<""'V,A8)9<4N55VXKLZF!DI?3
M9":+>,BHP>Z]WMM@0_.\9<HO[[[';#WJ:S+\B?G6@S>S^T:RJ.7PD**XU0?*
ME$ O@E7^S(Q$T"N%>]PP3Z$U6:6U8J]D#_20-!9R&V!U_"&%Y:^* 3!,.&"2
M6C>++700O.$A+5Q-\8>BOK^IBC7@#=>.EY<A//DS$!47;L:$]@Z$-A7TTD!S
M5O&D\;PH]?@*> 7 JK_D03ZS43.] MZ,]-ZC@8H4-%:OGIG_63;;#4B@L;KO
MRW_2*LWFY2A'V;W+GGC/^;K&;GBR*VR9'O0U\N^XU,^FGO.U,E?,6Q-(Y?[T
MG?R\O1587EH:<,1(T0ZCSE*ZJG)Z67/PLOLK_]AX/ =.A'CG'7E26!5W7&;5
MTN7E_$@<?&++)3XE_8.#=DM:^M2JYY3J"+:>X"_?/B5%:*4I/39&W)87_ST8
M,$"314L[2'-(WQSWO#FPPSI_;_4"_'K-F&QJ8F. =^30L1CVG855B-)_Z^L]
M)&FJC6"NR/H"OALBI/F\%T6S)>=JQMXUO0-%1\GP&;KDZU]WP76*D(I3/L+H
MB#@!\CX0XTA)XEY6,6G-K,VV*Q'J>R*-*'U P^I>S'2[N^ESUS9:O>;)AHE5
M4K/9N6?HUND9NY%:8\/1L@/NRV=ZY:($8@E9F1&D]P#%<+'9I7F[L+PH%JQJ
M[ +B";8>+'!]A9F\;O=GB:%3O?]6H(S?&72>Z<L8?8Y_G1^A66-LD-OVW;Z:
M7-Y)T=(P=%L?:#<,X<EVW'MS/N;<+7H:>4TE:SJ=9'@@J\?]VQE^:SD)O!CQ
ML5'\TJ@XN!^C_4%-L%ZD@W)B'41\VM=:,%54+:Y&G>Y$P:MLSJ@TKT&/,$CO
M%@<V\J4)OU8#_GF 1UYKO<OX6"OX5U:$@RXRTRE%=AXB,^!TW65_IC?)]:$U
MO,[-!Y!L[<X3?+FVBR]"GY"C"C;U@CR)N6W$O3&Q]_1"Q,A*AGLM!Q2+:5P^
M?/VP:#^73CB5[F;T;RGAO-@F[TGA.UTQ<[@?>M?O'Z^9 [<;[9 S7)"<3$(T
MIHD6EKS[%S:&"<\_IX&((P(CAF8L6BXK;Q'B2==XA=#09CSIVB=,)T^NT(_,
M^XS0/Z4<(FN]/]RRX,M<>[Z$*EE-K!M.5V?Q)]@A1ZOXX*O\L #!+HDH^A$&
M1KG=OJYVN)9!H[>3GS7,#+S5*:\6-&I;IKQ==]3H-LC",K--G 6VZQSP[T&L
M8GB$U?T&H(EB6IT7EG/!N@TU<D/ZCJ9HU=@D?I=^72>1[JT:#DA/KM37:OF.
M<_.PJF/:Q+'&KA:+QQ)+G11K>ELQC>5^D0E C'[FGI"1VDWZI9F]6DD971_R
M9POR][_]CQ1%L+/7J$4]!,;TEU+9K:&^78>CK6IZH:ZAKLHC#Q<';F5&]@4Q
MQB:]\?RI;W_$)0JTYEQ'[1UH;HJ(9^+X'$;])6>*J!;G"?#B+&J\S35BKOA4
M)^=#83OL O@\).&MN9^0WK5V3+F\M&"O?XLO&>TA-OAKL21VUV.$*WMS)P&
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M'#>L/P72*NSC"N:J*.#Y";C+VOATW%E>+MN=8ICS\H5,PP^#XBW:KT;OQ;7
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MK"BV*]3*%L"[5_KI0[5",QF.*;H5\ETRN[ 1$5HO6GS8;5)('6?E"R,#63.
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M8/-3JZ)S76/(*4SZJEHR+KXVT&BP:SX\@Q.VM>9M.]9=ZJWL^O!57-F_" Z
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M[]7YJ*R@'X"74_X,OWB54U\51^)J2F6.O=,LJA@IO?20\A7KV9M7 (,-]:^
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M@R(ABM_+&6JE.8CAA@U F.6_/J52?GS>+?.4D=!/XRB4+6DT>7O"[NA0\HZ
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M6UN^4'L@$W;Q:U>(7YSX'X[&>3G_/,E 4NXT9:09PE\!EBNFXM+]D5*:0 C
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MU._QY2C>LM"^%X;SE[C? _F'2E(%R[*-NLS;_S)>^BKY\N?S_F:\/+GG&[2
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MCC?"KJ\,#1S3(V9ZL17BL^-N'#T%%$X R^ZU;U UQW5C4+6&7>Q*($4AF#1
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MB#B42&(*0M*[YH1 -Q(3!] MW;HJ%N _/7C;DTN_!CQ0Z_;)M%.;*G8&HVT
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M[N1M @BE-\4']R7S3$YT>@.)'[;P UEO!/,MK-Z!U2+X\T^$AK].M&\W)H?
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MKV2(1.6 RQD0FX-,+5'3C:<\=4[SZ9MC( HJ/@$A$3$M'3T#(Q,7-P\O'[_
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M!93P&!0&2EG<UFB"EK9P$(:+I;8RT<P>-.RX":<<O%Z+LGZKJWTL>P-0":Z
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M)<32Z*XX1+T\^N*6E?4+#&4Z@6!6W5P>(3,8 _&4S%;%2Q,DQ4A[T*XMI*!
MQD1/W &Y^750OF&FY(.2C\\14^U>6>% C))B&^/OXB])Y;PY%AQ-Z1QP,\*?
M-(2^GY[X>6^*:58;=I.OKJ;?])NNN)ODSU%FN#6B(B^%H*-\0$&*32>>]?*H
M/_+Z7HB0*K3SV<33M1+RA5$J,RW8>&DJM94U,OL#Z8#8D*9^&87VP/PU<Y!O
M*"]3[,[ U,#R#9R0,S=&: E-+6X<%4]D]TRZA@9/?@VTRY"1J^K="C7Z<_,;
M@'PN!'7Y>T1U7,:"<CZ^(]@BR4Y(1MT8#7*C_DAQ<+] 4:FS8G% RO+JTM;Z
MGB7+EY*47.'"^6C6+'U!.[6WW(ZTCB;6(&RYZYU(1VG=(D\9(3X'S7GU&P#L
MF"QY0W'B2ZJJ&E]\&E'P5 496MB+4$"RG!Y2_D";EK R%VV"5U-NA5*T[VO2
M_R/8&>6]-$/D'::XY)&_O31?I4I?C?:]OLR<\U*)W-)8$7Z#(^=4S8-WM2##
M4]?-(.F%]D&AKJX<WFM[H9S,@80V.&'4GE[9]3%@B+P]/3--J8C^=-!O:*=?
MM0AI0C2L**OH^?U'X/G-7OA.\SRWG)BXC>.]FR+O*-!$K_=HGZ_RUT17ZOM@
M*S46HSU.#NLLJ0,-KC:NIGG:Q78/M [W'NR>ZU.@]L'QB?*[<0(L.C1?.-C&
M6_L('ZU^(37M>#D1S5MM4K]@KL7U]H5@'&D+*LNH7.YO4[$[@T?S;=][@TF&
M6)<C]MH9QQ;"/[T!Q,-%KU75IF=I&*4[>OYF')3_647X-V!J?7H552__&C5*
MU*^1BV>R<LZ8PEC?!%4 9JA=Y&&0&6-]=D,0.C\>.6\HD)+][.A,;K4+A6/X
MO"<CW%KE"B&V-:@AK(")@LZ(0'>YJJD"4[4%)I1&?SZUBXN#G<_ZII!J#G?6
M9I_D"O<P;JC2-KO.?\R)4_+=X;B]2 +P%0>##S!!4_/A@*9:@/[E6HJ1Q5 7
MJ-K2V?R0"%5!J.7]LG27=2@OY8,@@N%(THFMNS^ !$O8K96&0&LKU$=^2"[T
M!N@XMM#!0# 8)@(Q28DC449H#]=!+%K[H-[>VB,$4$KYJ?2-62]'3$'C^0K
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MSKH>/E(^&).G'/<NOB;,*XEMT1.XU^V=6/6(L)X7NR8N6WEJO@$2)]F,U=X
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M;@ML]U_I80TFYCVNYUBZAO2QD]U7%^J5W9XIYML/3>#C47Q:+,0B(TR[M+1
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MB/S[S(U/XV7451_K_/O ?D$MCTS9\V>T+9\;9I@+[5:VE.I&LOSX96 &V[
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M0\():2CAD-N$XX:)M5.$U&#Q;-0/[TR]/7TM79PLD=@"&IN$"JD1[)1*A[S
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MU'WV>6[YS3++Z5S5EI"[TQ8I%;-9!50\SC^XP>PAYODA\*L,]$/-0'$0(ST
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M+!&-B/T%<*RW";9XC]\\&^2]VDIJX]T.N/CJ9]G(7W9E9!]F+)R;DW3J 4Y
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M.Q41[KH-;8?-.UMH6#>"!*BYS9[6FIIRL>_\%N9Q8,">D:$GX=/5L-=T%#4
M],S\@ :O@<,S'5-.=G"L+B!!3+!VJ"IF!!U=1O;UL>J??@?\5W8&N[]A.E$8
M-TY_HL<%Q=F_P.27;TW/H7:P!G]I]-8# E_D<9#U:2HA?2T1+KS!\54^8EC[
MZS%],^:TQF]_^6E.W168F__;[_$5YV[*2LO_\GDC+NK27;%1B;^\;-)&;O1[
M4ERZ7SZ.H4,:'U:04?67)]/TBV*%]]#*_.5_G];H7Y]>HUQ/@#;Z/0V.NL9_
M'BW_Q9^'# 'O6J34=-8\5I"=32#$*-4*!<FOO%DF?.3G,0(1):FS!Q]:BFA0
MG "54JG1A:S=!L]OL]'#T^7@8654%0Y.'6^<FJ;&A8,^]L@*)(8[0N/%(L 8
M/9]8XTJ'J<M;([>6NO02U'#-A%Q=Q9_\IA#EI=TCE!<:XWE@^LQEOQE2[Y+Y
MW K'RO%XJ]1W-K4V)UQ^F] =Z(/?"H2;G:WBAJGX;_-F_U%QX2^F_Y_/3/JW
M[=]>29T.>9K:YECL2 -:+8%!:K=Q_=+O"?5X[B-!^+&\UH@M<-PPZ8?%K[%\
M&;?9LSDKU_NCT65-.#*?,Z]S>,"%UD8NN^8J^'#D#[R!J!K$ZW(2H8TV\5G)
M8"G8]DL9'Q'^PE'ODE[&/G7CCQGY4@&.SCM5A%T"I^GP<OC:9J6#(<TDR=<[
M!6RI97CP<@!"NK/-1I]!<F_R&,/JE&WMU%,DK;+X3M:UJ!;QL4_1;P\/&#I?
M^4;)#1&JC;@*7:]#;[;S4UC$1TYQEG9/7S<Y<S9/$AZVUA=GH_ILS:<%OG5K
MJ!;]:OKN5N1VQK"[I(^<V9?U!W-[#;,XB:L ;ITTP.+.;S%%#N)]#3@]O'*_
M>>@XUEA28)E2<6<5M7S_]&M+_?.HS#_N,WN#/^Z^()K_<*[>?V1_=%0K)?!
MO)J'$(5)U."^%@>,DY?]!'P9^ D@$OWK(2 ]*N)D^K[SZ='E(N\O!]G(Q?__
M[8#T/Q!)_@-W0-5/0"#Q(^AK-!&"^ON;<8#H?["=_+]B&#^7_P]02P,$%
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M+C/J]C5?4 QQLG.C2_<(NL7"3KA@'R:Y/8SM^L;S[SK[Z_&[O?*;.T&Q_33
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M+2[BDL'0 9$H+@BG5:ZFK XB0"(D1*: (<"+DI#?@",XR1#O"5\ XK0#H(*
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M\Z;ASJ;D+^HJWOXAEB6*D[O'RO#G0-[6_@T:D #]U3Q\ <@Z'$+O@F];A%\
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M\::RM 72V<;>!IUF=H_LB[$C-# .KV/DHCYK6 !0\1%0">UR'WS'G-903<C
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MHV/?7OGMB?%:$P/F#T3/QH:%?8\0RTPQ<$-6@' ANC%^JA_4L5667 X;.:^
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MT2723]?5&O_W5_F_ ?EIF1:-R,6+,UQ/54YF9$*$7C$-<HX;8=M!2HE]ECA
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M$@@NP2&XN[M+<'=W[TO6V;+6/N?<>_9YOOOCWNIG_.BN.4>-=\B<[^BJ@LY
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M]5<.*H;H=8W9_,PD6.^DD]FLU'8=K%0],%KMNJ_(W+!8MC8,Z2MF_KL9<^K
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M\O"0_OA(7Q@/9E!'.K=;N-"_,0Q_+GA&1I3+_MF,([@Y6 >"EED@HSH(YDM
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MD_?=6@>P#P/Y X%"[A1H'F.?D\@9*MP'I9^)2ZC6S5912$5\P"]6H/W]X&I
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MQ?#S&":\T$S2@"F#P/29&_![%\Q%1FI"_A@"U2O(^+;#1Y7 @V*+<#6TTOT
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M09_0%7U9! $7@W.B&N&+G1;:MKT:G7C.6O<9GELE*K==_?P5-:GF>@,V5T\
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MPHH7SG^6&O$Z TA>P!/I3[&4?%<1RA]\TT"SQ))O%M)&#IV2PDN=04);2S6
M3_^*!1K_K+0-=^AA@W,;8KTPTD2P:PR6:G>)MK+T9.E^3B U4!#;G!<%G18>
M#-!)GU8)?CG/_6X,-9\ F1H='30MA%JXLS3[T=SJ.S!&GU%N_O>6?QZPG)%
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M(N =Q:Y"[SV&O1KW_P"$_:N%]C3[OP!02P,$%     @ 64^!5#S-B)VM+0
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MXD%!;X.H*<[^XXK\!9:&]Z2,2@#@V$K4<?^(/*XV[V#8#OS#O,RC6\GLZQ6
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MS0(#?>!]FBO U.>U\ZDE*Y+#]4WA_,O1LD.K%V)AMU\\CGVKS6 9I:[-8$:
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M2-2' 5^6LIT3\WLU'XB?!L6O_MEB1_^]Q0JEH/\Y_KN'4:B_""]37?SG\,_
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M#_Y\O?/@GZ]W_G_I9%=S_P-02P,$%     @ 64^!5! X? $H)   L2@  !
M  !F;W)M,3 M:U\P,3 N:G!GK7IE6)3=VO8]U( 2DM(@(2W=+5)*2DI(#$@H
M##@*# I#2)> = I(B(1*"H*@,'0J.71)M_3,.^.SG_T^S_[V\1[?]W[[YEB_
MUJQ[7>>YKO-<UW4?8,8PL\"5VQK:&@ (! )LL7\ 9A)0 XB)B,!$A,1@,)B$
MA/@2*0T9Z>7+I Q4U!0T+(QLK"R,S,SL7#=XV#D$.9F9>:7Y!$5$)20DV'AD
M%67$%&Z(2XCA7@(B(2$AO4Q*3T9&+W:-^9K8__.#^0)0$@,CH!A\$ > 1PG"
MIP1AO@%L   B!/U^@'\\(#Q\ D(B,#')I<O8'U1? ?! ^/AX!/B$A 0$V%D_
M[#Q 0$E(=4U4E8C:T [,X4DC%AC_FICSYOL6VKN#.USB]H^#2"[17:5G8.2^
MSL/+QR\A*24M(RNG=DM=0U-+^[:1L8FIF?D]"XB#XP,G9Q=7V).G7MX^<-_@
M%R&A8>$1D0F)KY*24U+3TO/R"]X4%A67O/WPL:JZIK:N_E/KUV]M[<B.SJZA
MX>\_1D;'QB?FYA<6EY97?JZN[>[M'QS^.CH^.<7A @'XH#^??XN+$HL+CX
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MTKF=9\F-P+>:1#DT-<L_/HI;;7+&^EL7%8U\(KX3SCZ1&Y3OV2<B>CJ"B,0
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MS'@5>1_ADY(/(PE@]KK@P>M4MJ8&E?>6=1V.\AP_.Z/=@A]B^L05:>%F 5@
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MKQN54JV9<6IT&M;6S&I,M1Z68Y.4V$H@)!3*&&@HMQCR!J$>HC:PY97?&ED
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MK6 &;V$QKTNO8PNU1A'"G,.22<3M*)R,)GXIET=W,@.@R7_"32[+QY^\QR&
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MMDSZ[BS#K*(!9T!I/6P,"/N1CS4A%;I'C[E=0?M1)8\$)S>GS4\0T3[Y.4&
MAYMH""".>WGH/7U5F56K< _LOZ[F,?E+ !WT];]8#,G,*MS65_7QIEH_.!8N
M'2$;>"/+1)TXN&((-]Y4]'39]=AND(HP@I(K#%4H9+DDW]G^W-L6*AJS$V;7
M"0VO<!965XN[_#1SK3;%O!'<8X'%B*!\]&X_K1$.D<R_M.),J54$8WHLAT5B
M\KW^\<=D>8WU>@\L-OLEOF,QXMJ_E%E$MC\J%$)5?MF*KZ8<^F=0/+&"X*_P
MU161JZD&Y, #W[?Q8#\N,0" !RK4_Q."*9NO<E7YHNXG/5P_1T;V'8F8#OR0
M+$PC;8G^5+SN.6S]0>]<=33M7$><YLJ$.BR0$9U>"M:;#J;Z'X%7Z-T7"$#!
MK/[2?2LZHFZO(]J=>0]EV7&#W_1BV!(.[/J\2N@AX;E7P;8  =C5A8@A *5:
M* 30PX  ?Z"+GUZK1YQG^2M[K7HQK'#[6YP")+:$W9^$L[AGE*BK6[]C,66Z
MT@K%KOFY5? ,;]8MJX4W",@N\U';UH6%OWS@XRX^#WR1\$3WED=_3FGQ!&DP
M;6" >TC8T<*(@LECRI:-=SS_F.?C$FM_&4O='-DA8 GT(@@,W.8';HY5GI V
MWZ@I$$B BG3&AKU)HHR2$8=@^($HQMG#D#G?[6HWUY=6&]'8[.D6^4?HHCC+
MI?11#C7CL$5\3SAJ.F&%?)'PB9&^L_[2(LL;CM'B_5$CRD%5Q0!>=!TR[Q)=
MO9N;U^CEPW_3I(Z[8E'Q+/L%1:<BD,R52W&=:Q?<YTO/&)^X /9#AS*,C!P'
M,O(V2FJZ431>LL5O0K2#L5H_?L-4MQ-$&E+F&$XC/;!C#Q"8RPR]7EJ"O *M
M9*8C%,GDCT2^B^3[=)? \:\<@O/B;W;*^X6^?S,9HK"R<Y!2&MCX8IB,P Q?
MYS2?HEMZ@/E<8?R&28XH)V$8>OE"IA-*O0!)2 7SL+G,M5YQ6;JLK$\S]GUR
MZKCQ6Y7 -#IE.TFH,7G&7YU7.7YX?T?.T=,K?+=.?!_^K(W,J-+\;Y$4]:JS
M\V&$7+/>^*);F'UI94"&$V]J2+/7[8L.M3[:0;4V3/P<T-L$9;]@[%K)%6X6
M5ETF?HU;AU=8I@OFTR[6Q'"0=9R>?\6VJ1[KG58*\$<:=><%6;)6:$]5A9K?
M18:IU$5H_LL8@O9WZJ19;BG>E/L-B>;&FXKL+00#L/,?'X[K2J2K5YABAI(:
M,*K(-*E.>00OW++>]-;[YT2RZO&K_@C^*+25YG\7OMZJZ6YA[Q8P)F.,V/A.
M H@6'ZBS@ #=!B8PR50UIBEL7LDRR"I;C:0M\Z3VG#KR%TW#[-0IP-*TD.0<
MCR$ZJR/+^U]6 +I.U/7D\EWHYY:SPUH3JE;&@"#':X2YUDNNEDA UM&19B9_
MQ^'(,\7*/O0PLSLW7]V$_TLX0!L];*IS4YG%]3>XP]B%AY#"3[T>3++;=OH1
M L3@O2IDO<G7-*'T8_U7'Z5O-VB1CG]CU=OKUL-OG# UZL]G[M$RRVC_M&?W
M$'[5AC7W,"Q5WS#+"G>\;1%FAM+@/EXX#7-61@KJ%7C2HVR<=B+E^'VFK97?
M6\[=%1'0YZ>7+C_];"\5T&IDOZD\J0<6ART "S9F(+7VNBU7KV]#ER''2 #.
M?\$1;E*YFZ/\.1#X*$E/LA0WR>4H9()$0(U+<57^J=+3UZ)@B;OO>81G@AX8
MX@Q2NDL!AL_6@JV>^+.U]TM?XBB'.#[S8BGH0,M/3OOWF;F)XXEBW=4IJ:KH
M2_GEPCQ_4E>R=H3;:=;1&B69&.2(D^Q*"*TB!26?93Y%DK&\,ID["'#U21%!
M_6^8)@+N)BNVI0@1QXBL3FA,'Y:,U1#1A;PK!, G^>K\Q"C5G<%DBZ%!-6[!
MY&C+7B-%3-!(.'82^$?.$E0_L6+N&KO\,2XK.!44$>$GS<V2#(++2+5]4RN#
M(PZ%& B3;V;AN/I VCX5.NON+OQXZK""HZ1%(H5^5OA*E2N?@T]\?U9L-OH&
MBUY S_H>L3H^];GB0(W\$[#[<A?]7Y.R/1'65^)7:0 !#/A$;RQ/00%W':\P
MVA;Z'+0. 19+V[*@&ZW-7F1I0WT/^[?NB4Y ?PM;66B[*3T.,4BP$<8NA5]T
MY_@6ES=4L&2.Z* 3XPME"I9:'73:NLR8FUI4];'-+P^UW )6<M5Z(IH&5B65
M%FZY1<(J%]Q"P#)7^YI3O M+/XH1_GB7R$DI\3@LB:.^\_R>R$AD V:#EZ%M
MP(F7TWU3D)Z<9+)QF"KG>VS-,8J?2IUAE+G*9JP*^+'WK[;_/-7%=4P280*9
MV+-DG+=^QA-G*BD)RO+"VX89@W<3R6E&S!P)(X&& >SL!W8^?_CSC^C9W-Z+
MR!X$J(A\&F6#!BUF;JR%IB^F3,F-R)*OB7ZYF\ZY\]ZXTQ%8K)>2FZHB'_,3
MT@F@@V^KV.KT>#,)KRTY>%+-]B*9#0&"'3?6[J_B7R! Q]T$0J19AJ5Y)4W(
M.^GE8!M$A'*/VR?&:#0(,)Z7>?L, ?JC[]3)2"% IHSHZ2,$B 3<5N4=)3<]
MYZM?$:/I[/3I008"^*X]F?\??AW,NZXJS15"V\D^]*7Z<%2]U':<^;GY(CR_
M:8( !>4O7%";04IZ8SZD;J^L9#@5 JR]!D?TX6RKI_!%E_K5R>EKERT<]9K7
M@1K/]OYV(/N-\?O+_QB($/$]_[Z^F/G?/!]5HWUB]$4COW?\GYWF96VAM98D
M8#]@]OKCF/$!7Q5A?_Q?'OW^N[EW1%[%;^KCU"5FYBW(N9I9QNDH.#LST6R9
M6E%@QBBL"&7 @W+/N 1T^T/AJPKVATQHCNBJ*>N/V_44Z40"$0@.Y^+U)YX8
M-_F5K36T%+@^J>KH'%GY.B48Q!Z]8B[Z-?RLT)M\72$V,3U*6,5W,V($18#Q
MEA\=3.Y?/*-"?1,^WRC?_.967<OU)GC$,= "4])$TT[RIM\-R%C[=%"4A8;=
MHZ66Y<5LW$X\;Q B/-5ZRI/6*T,E(C]KF*^")490_(2 NRPP'VXTPZ*\NV-K
MM,8@L1,BH@P!T.3Y!CR.&7_\ETBB<NIL+2KOK'UXJ&UJGX#]N4CZ9J@T87>5
M9[J<VS:\':]FAGEJ$ZQ!NT9\945/=0WM)] FV]M,G:(+EBJS&#E&"59M>B\#
M=B.9J5]]-S$W1V-M)@]+ 4N<MQ5=;F))CB[$")_NR*1%FC-$\OEW)QDB;.!<
MINW987><=N]QMA:>,6P:6>/#U('%C8C9!Y,2C0/MERY/:^<:XJ=DU9N] CNW
M?;72\5:H0O"^#]]Y0GH$$ERKLC9LI #=PL!]O%[@YY&-E_\D&I?5_S-&^?%G
M?H, %PK.'0\WHB.JX_"OG1->DV,^2/0!*/'%A #;&8>^UT>^/TLSWD" 6,97
M1*I$]+V"$B/9ZX, ][A'HD>T""^CNL=V^OBOG=5_O0Z41O[([5H+J+\I>^5^
MQF>GSV[+OE2ZHW;@\:=$A=><FH\<N.""6I["C!$GA$\,!\I-#$"%'PVK&\)7
M>0S[C!2SXM?"95=$4*ZCQ]#(WJV0Q#9)?8@@P1RGB%4KROW*@1["-1%L)),[
M"/[LV)Q(_'X]QAT6*NUVK]Q2@N@#E@11\$?%DMPLF*S"R7_(V@E3ML%I>%4B
M\="C=/%[[\5H7.(0J-&TS47\4O:\I$K<XL;%:GA,^;@9TV6'ODF7N/:[5I<Z
M S%9QNH@U9,RZ\K/\+NX,5UT*<QKG>L8!)X7YC#CS*WV1:":;U>/X]42WL5]
M())*K,1Z_9HP4C9)E%,X]U&;-PY['\Y1ZU,JLIEW\MO3XKG"0$D61*8ZQQ'8
M$U"= X2;=;MG8\%,O'CQ%G/!K":\6/TJ/A?RI]>W9'5&"A.U*_231TR;_G&L
M;S^AA376KSW^B7_->-RBNVF5 %U+ LH6D^]*]>$H^?Y"14:^C SW_$.KGN2M
M#'Q/^N4ZJY9("&"?6<[5#P7B.WW;@A]B:S,[6F!<^6#3U)W?A19^3J*GR?O<
MH%PV#2TZ)[ %(K>O\V7PN].6X$U2]UVLAP#F+9(RVTO#(8]KF5[.66A$"L0'
M:EKRY6_ZCB;E&USFZAMXZTOB/AJ+C>GB?#V&2BWP4"$*C7;6?!+-6M'2E8^3
MA9M?>I/?ZL ?AR%B7<&&+\I^P_U'S8=DBNNTACD_")/8S-T0S*]F4)>Z'-LO
MQ^#F*QUU73'5#V5G'/?^;L_)CS&S&!GJ01%6"^[Y>2<_NUW6=,T$=52((X!,
M$L$.Y7DUB.0RTW*KOZ%\]0Y=^9SWIBOH9X50*;4_X%>*J]1"W/"FB?]Z7W<T
M*K+0PJK<!$3"]*L,6;TH4N:MCU_5TT'NG:A8W,'!3FVI$?=4]<B2SYUM6V:E
MHQC!%[>+AXDA$Y&87!7MNGJ-W.3\]T2L7#RJ*-ZK;#B7QY_;[X)]+0ABS-&$
M&IEW&\-!T2S2(U,$W7",0\L"KV27^3;TRC.;*ZG>CC>=4OID&>N )WO<$ $&
M9V[BBM-JH[P\XBU5\) -$-9 &9^Y8>-3"Q5,'GE-"!:D<_HF6A?9U\N*O7(<
M_/&MYC?O)GXL%GAA;T8CL7/=I&^4]1=4C5$6Y8GKN=V/*AA\:Y%YEPO3)ZWL
MV9:QLJ3]F=8"M<><V\;W><  58PT0#070G"\(6T0:13.C?PM$$KL#Y"%\$_.
M._X/0KGG:K1AG7 (7A[(R3OHTW0QLSA!@H%NB61 0;%F616F,=#&: H2CTQ5
MX"<X'G4G4;?-MU"+^4.4U5S3C#5D"TS"WM)C.!!FQL804]&6>Y@%'!]9>[TM
MZ,M?3BUEQS-*#IFZI\X0=% @;5:$W_DK08WN"K]T3'$1?V]C&;6IP"3\=8)+
M!27#LG@ +X F[TNT4 (.3CD@<IY-K:'4^7B.IY?%1D5UF87F@DYFX>$;Z@3J
MP- K;^O/-H]_^M4"3R-N98U DM)UUA#Y)(C6LBF;["QM%'YP3H9-8;*:0P.[
M'G$-W[)")2]')54SG>/B=OQ66C6U% Z ]F7H_+N"  L!SGX],0D<N@0>##S1
MO5;?X W;AS=@'[,G!EM2W\'0BE=<B^AX0"J\8WSY&/D?(E;M/WJ^F#W1B6(\
M,0@<)O[E@C&O@G@S\\G-S?>EQV7MD1NP?"WPW6<-S_#'OIPON/V@5<9)EG8Z
M-Y!2H%+PT;%ALNE/,ROCXGYYP?G223&2C-RM4U2Y@A4ILCI+W0UG1:3M&.\2
M6=]O9/BRY@EUI8JJ@%"F0K[-0<<%8MLK64)_)9(IB=,OPJ^SJ@ ]%3NS'GF-
M<YT-?'<2%"5QJ[[84PX0!#4QC[9&IDGC(O)M554TO.#A!W?\X07=9YY5Q(4;
MD^F?'?:!R>+S+-GU#Q2UA]X5"A55QF@21+!M95?4_.?.P.4:R=UTST-20!U(
MEEEM%126Q4AB$:?Q@,8P'_SDN#',BFS!,R_05NO88X8E'2'-T 50G"_,V[_R
M#/W>-3SSE('0H_7I.@(;&KGWA)I&0V\E'3R<""MZ_FZ470BP8>"F_1+HTI$,
M 9"WZQ3PS1V]E":N":[IM,909.(T0UQR2=:QHZX/N!01>"$ "DKWVA5QW=/X
MG=I<>C'8\D;&M7 L">]$6A,[NZNK5.6?/KE&$-X23)=<^EQ#]'GJ@]#MA-B%
M%('#M]$0/HHH!.X1J9*[*%9,O:71DGMZ*Y-@JHS%S)%(P]^?H >&F"^QB&>L
M2=0>[YJ-XR0>*0V08).$H8K+GA2X1\Z+ZQ#C' CB^*X?%!'>@HHMY]GWY[%D
MV%H"2-^+-BQKA^&P2=\TXT:0)H_!+Z=ACM%-GUY3E5EX)*RLUGXYPK?8^3;;
M>Y$; 16D^ $U@9I>4*K=H_><YBG#=(D.,?IT\\O%P\W>62$Z]CA-4PJQ&S*2
M4&MKL(-]IKPH$;#-->K9J^7W**2>$F0OXVL99L^$?,'D(+DKGLFL'I#;\-LS
MI2YGM&1T,QUY3Z5C!@!YEAI]LXOG<CS676>!,H8*VSJ),.I0@ !('RCI$F$U
MC1EP98\///<*Z&RQQN$FM;]_Q*"C22>G1NM%>Z49UI\$OWFY>SP(H P?UL5^
MD -1#AEN0N,F*O/\'!H@*Q_P&)&88GZB,;WAX:VRC)$S?<BMJUT:9BK1J:+:
MY4=U&R>LN+I+B*BB!MET?R7BT(B(]N$K0O]^)WI^V.B+_G-M' =J?&4\]T"$
MM;%MOMSFI&PO /THZ9%I)!?V%(!*\%XX#(Q06VTIUA??8B3^X.IJ]G6"<6!;
MVSU@UY83GM>Z$,9&6&!/2#F38 S]R>.C5%',UOU?Q]$_UB[WR9]O?+O]^'$[
MYJ^]L<XL&]Z9F36X,WF%H,,&' CY/_Z"]L_@Y?V\1UB.4BHSWJ. (W'C_CFZ
M>+FZH"<1?AU#[+3/UK?;A/?I@?8O/]%WGPM>580T!#BM>7F=LZQ(?4K=;$$Z
MUPW&J'?1$'4,N$+;V)Z#)*%?AC;CZ06]:OY)UK/2(M.\&<^^EL?&( X>Q8X4
M*HG@PZ4-M??.4I2$S2MJ_.7]55IZ9Y[E0X"@WU:^ WGN$,#K%7D YQ_J[[Q,
MV,C/_V<8S=^H.;4'WA*P9%?MQXIA_6M%@ 9PC_+/LYA[,,W?1'^E;]WBVP,X
M<XGG".J7&#&NW<2_#'O-&H74+=8W"M&1+#H6QJD6?M80?W+8HTYD?ID[VEMM
MG6+%?O<=V\*#/.+88&HV3>HFDL,U945F;.+]QB^9+NY]'[1 ^?JSQ'2T:,Y1
MP]A-?MU/2=O;,6)4M%Q0#7^=&;T.+$<KU=I0-V.[T9"Q]:S%OWT9D2F>P6''
M^>6@N2TJS' ^)?VWMG8QLK%/LC#<:_!1M8=[<]QYW^6:6XCJ4W'+2WLPG67P
M/L0,W"&\K79[ AGU[C)+R82##\;U& OU^MJU"<YV$ARH]?(GL&<E':^RT')E
M9\OJ2G%;IVVP-A>'4"C-8 ,#YWX)T4( *JGO'8<OHL]8"=KBTT^R17\PN)IG
M=].&F=KUTZV)1YD$.UR,E_FL?*_O\\^HL9= /O3A)\<5N]I_;C\/%NG<RRZZ
MD64& Y9WAR\?A5\5NLEKF9!3G& ].?+"W5BKT9;@$ [27MS5N$G_'M7F^:+J
M.Z!_\?:PXWJ+]27 0N@M[!<W\O?8'Z/@@OC0LB  D.WN5Z_'/LU:!V-!+$#F
M,D2!'!G](7-/0Q^'U'BZ56BPZ\>AV@+%-GF;5HI^<.VCKLN!A)0]WC01_^^*
M=<?KF[*.<,2J_79R%<42[M*O  ',J=I=L(R,)R-XY6/ES,FK .\TD5-_$<?O
MN.YZK8/8RN#7S25Z/>J;(%'R*A4H;U\:15\"++45[JY"7YHJ+_)G.JHNW^6$
MT\?\*ZKR;\U.//'/*NO)%LJ["96KX?7XA]EG8993,KYC%N83IBU!4ZPL?H3,
M'P]&U\7*_0-'M[SQW4.$1DW8:3$>T9^JK)@E+B7,8&.(A;"R["F$(8!>@1^=
M[J(F<]]Q>9H#G@::O/QJ+@74F%O)O)91>R1L_21AR/&+3F&,A^/@?H1JZK&!
M,T[L#$Z]_^]QS$Y.#XR59N>26W.1X79!T;?Y4*[W+5MD67X*.LA ZN^H6Y6:
M*)!;^D^[HMXR=Y(X 3(+O2DP=:/<)Q=BG3)VJ3J%=F&H\0]:>!A!DR,\6$4Q
MT!KPPW@GPI'*<82*Y7DWQW4Q\2YHFP2HL0]&.%#)CCSI--LV-[PEZB@[ W3W
M[Z\Z#^#>U]=?ZMRS+;_E9]YA'PEG[^P7G/7G$&Z]&,8I9C3 ,Q2QBH-G$RZA
MB<-IQM(M#8U(X.SE^S+!=N(^L".&&Z3 LAN,CQ)GI/3;__@SZAL=MST.IFF1
MI5ZHW(QWG6DN(AD=6A8AGHV+NTJD0S2QTBAM/AFU4-KG>5G8@U\_H&7-A&%+
M+RC%BV'NX?AP&WK2!FALN)!Y)3-B\%LY#UV5=&XK0F<D[//HGV_90@"=^7OU
M5!?NO_FJ"/M_>YOL/YM.4@2WM_(;?;FIVN]Y-7&[Q-_#:,V#@A!G,++(^&DS
M+8%#\PJ;X2^SW&M06I9X6%K@ WRU_;=Q7S_;FQ$OD?50PQRG[,;WZM$VG2U/
M[4?SY,@7U=_<3FA6[%,,C%-\"*9@HR#Q\S:'F0+]G<)7]>8=<,'3@OL!SM_9
MF9E.QFG\9?+U]X*)B=C[_U'*5X7%P2S;SN!.L."20( P0' &&#2X!W<)!&=P
M)S )KH,3W-V":Y#@;H,$#^X$U\#)O_?#^?;YSKU[__<^U%L]]%?=O:I65Z^*
MG:X2MFX'(DQFW.#$1GJWF8J-U8GG],RK^PG.^/0% #>]RC2\Z@)#Z^M7LY3%
MJ4S,CIT<7?W?G E\F:=_AKV,,#PEE(:QY*Z:,%,#*&U;<F%@C';*!04O)ZC;
M^#/F$"BUP]?1)LOX:*=H%K<;S<*/A0O6EQ^==P[/60?BET,,AYS!($.E$F1M
M!":8#'Y+T29 HKYZ_ #38\[-QU/I>V2,EYG<E+5_99D126,>*@$0'QSWMPGI
M6CC.J22#6BPE#12BA8.COW?B\!TOWUQ75AZ/K3PN9[<&"^1 BP]BK.TK3&H;
M==A,9=^+!TD: &^T?&MVOET(47O3:EWY9OX^\8E_)T62T_=WKZ^SUL*WF?1D
MKM5\U?F\&!@P6.#RLDBE7+G%MP;RUC=2W%SQ\S>!)P#5C("Y/J6+I6/TY"!K
M7-Q!GTLG^5ZD7SW:WJ$)M^[P:PDQIT8AF4*?RVRD-Q>MD^^1L/D"1YNJ.&.X
MF[*J2/),-ZVUSH>WH%&=J4*.'&+OKL.$QPU\9CU)17^  JT2TWTC@E[)0!YY
M\W![!Z:VXSQ"Q[]!^MUN V4^_V%8:D.:GJ]\I)P$B5A9M'$P]UTF(MUHY>OS
M:[I+BQ%LYOJ-XR=\&3G5HYIA:[J!26?<B](5Y$Q(D@.;GU:+B_:E;0.$F#G'
M;0[N!SXMF0ES"<L8/5  &BOTWRRR,S9E\>6NCNJHGR"!ET2:>\WB(>&J?7#R
MA4$&68Y;*G,:_[OU+)XP+^+3\AC],E3M+W%R74O@'61>_BO=INXN'L*A#L%<
MOK?A -D-F>:ZZF;+\+,?6-7*)$^ 4("_(B)V+VM!SGE;<I7GT4XMC,O#0P7*
MJ1HV/%:S++7-+ST@$!9BY+U>I=/-6SXN7/VI@F18*)UYG"X@,]!R"L;Y.#9'
M3MCFN"*YJ1C=":7^XO].:W9?B'[S!_#5^*D2/%$X&7$_X_($H#4]>:BW,$N6
M(Z@].1KE\J]FB'E[5=3"%75K!PL DPG?$@-MQE54OY_YP)E*HM)>%0B/3V?6
MJ]GB?N6Y.I>!,/LYMQ'?!4S5I7*UI"Z-G7G)2TC^DF8(K>3\++ZQ4JSD8)-T
MIK]7*-?6-]\;+&>P(]+I%+ ">WUTZ#V7K_L$Z$^@_2NI.*K)4(_,#=OTI!D6
MB%/5N(I6>#3\/T(+2<0Z+?:"9^@BY'Q97\6^8RAS02R:I&_.2)R,/OQ;Z?ZL
M-UN$X3Z1EVH)=DQ!!"<8 (R3$PYB3RG5LQ7T]6CQ_6[KQ5T/HX]Q%$>/$5\+
M$"/G]\/^VCJY*'\O=<&':T_=&$M\HQKJTD^M(N$3'@8AL*=)H4[=;VGBD*]9
M'('Z>P&QZU W*)T>& BT\2,N..V+E_RMI#:M*^F;$\Q+.7>!?]":?"<\XI'H
M(X8UH8V]Y[ ]U7=,8%!W?DAN0M^:/Q:@(W=WM@4O-4G+SS1*-[TMJGGYRU8*
MW%FN7 7S3^:=7%^]>X0_ 20+'/:\"RIK3:F/(FJ[&"5JI0<\P1 .].)R_'^Z
MG=P] ?[A!W!S0QU))BA-\WQNP10S9=>_:^/-+.;U+6.VK&)_3HL_IBUVR0FB
M<W:%NG=NLD$M?#!AE\?QXRT18S<%ZF*K.P?G7"0"4?_->[(,U/?:&Q.$2OQ.
M!^=_^T#QG]B&G9J/O69V4PR+@L "M0=48$S\HO^\I$V\J**Z]IX;7\@%M^E^
M0Z"+6I1(]6/KO?(I*VZ;3>D(_8OQH>Z<,9=1K;8SAA<.5,'B71(_+N\F4 @9
MSD:)KV(5&(K=16:6/)!_^Q<8:JJ7U<VMF-NI$X*J0/UDOU^W?UBJ23FBCC&0
MYBAI-J8SN>P[>?RFC0U1ECKDRF-B.7LQWL%4G(UI]JQ5P<$!AU-?#A8W3*?]
M7G:#=J=(SR_/ZE2\1N%P)/]CUI!02GS1FJA@L,KA8IFH(.:($"5.W O6_/L[
MGZFPAZRO+?,*CE>!00GMX(/I;P"=MI;:=FD%(;MEL2\$#4@=Q31%!WN:G&S=
M^FTO[+=T8+&46POBD$<QC3$,G\%ZKAH(*PUQ4$/MQX^ 0KU#!*M#YJ,E(4_X
MHPE55>,T,9 OC]Y@OK/1(].HGR&=>B3?4:9*93;;*UY'(LK>#;>F<D_Q=98
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M)C*UB<6%AR*0T+,A606J(0JV67@5?05YGL$^?8BDX].-WK8^I4#T*/%!J3$
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M,H5): S^*O-(B"\U[FW7Z&^Z:FDEEM  94).AJ[1BM]=Y@K)42H3ZMB'B[_
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MXG2.=J)E0M>EM ;5XP0>-."=$^A4OIPE_N,D3X".SX4JN*L8#+ITN*W()C&
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M"@  )["8LU%SPYF!P0Q<F%CLOS@HJ3[MI7[\]U)D]*<?_P502P,$%     @
M64^!5'AZ_XJ>2   "U$  !    !F;W)M,3 M:U\P,3,N:G!GS+L%4%S=MBZZ
M"-(0( 2'X!8([BX!@M.X:[!@ 8([C00)00($2'!W28([! L>W-V=1AOKOOS[
M['/.GU-WGWOOJ_OJO=4UBRIZK3GL&V-\<Z[9B!G$"O!4459!%D!"0@)>/WP
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M$JA_3%:@\K9,B"HH"SN29<A/<H7"\_;QL<K)=L11P BWV=L+4@-)4A"S^9<
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MT$B!_L+"QP]9.JDDR_$X0*#7$3(_CGJ"2HAJ;>V[T5Q+EZ8-Z[EWQ'3TZ]2
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MZ5YCXG#YD]PGHPXN&J1XLVO1XVFH' -/@1' \D2^7 (FS]:V/:Z) #K\EN_
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M5!GZC6F-%KT?V7QO%.N/?CKG0@5DR)+55Q39ZYC586++>2PVP(>3!<]O6YC
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M:J7HR?/0-4RR#LCS'+9JH2RT97EBL,]3W$0SGL"7O5:_*J6S'D5N._D9%\[
MPB@PLELS+B7)J*KFFC\\]6#.G\%BZL]0-4OA52796:)IS1A7R="-9^!^X:5/
M9--)P$%*]Z0IB)1BYU'! TMDH.O.O#@T0P!9 \8.+@:,=Y]CB2#3->'P$#;W
MZO]X-YI>:JN3LO65/1V"&S_U&B6"(OD=2/ 7]64%M_]CG'#N: NI8.U1YVB5
M01&%&E^5K_2;D A/TWP?7((I&7?F=D(Z%-Q/,DY*N,+VB4W=1XT2,+%,*2/-
MZ6(5&]::=$&ZMQE3;EAEA31!&YP217R9!<;@PB7VN")Y2Q>,VGJGZ[>YWQ'
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MVNWO;N\W5;%A82/=S^B?)7ZEEAB@5PZPR:/R)EL(R 5EEV>;N)?L3HNC3S-
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M]]MWW'/>>'>\6SV^O]9:-7I63?GFK%EO2V^_ .\59.1E %!04 "3/S_ VPI
M"H  !P</!XL #P^/B(B A(*-BH*,C$* B86.34)(1DI"2$Q,3LU*1T[)3$5,
M3,_'P,S.P<W-348G(,+/*<S*Q<WYUR10B(B(*,@H^*BH^)P4Q!2<_^WQ]A.
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MU$#(%_\)'<0T=7K#SZWD)/^CN<W<P7U7W"6NC0":YT"ST9*V:U,SC/+WD/M
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M=R?>^\-F1^J$Q!.NE-L!:>O-:Z;.#."@"_L&/O6FDM.'K/P/4$%+/]$*&M6
M_N/G=#LFL4J.KYND?E,,M)$I1D.':J41^]XL'S+"PI.E<E0.#17T:I%3H>$I
M<QR2O-EF,T2*F]$4SUR3'[Y<\3L"!<."<R2"Y _5K?L) V:8V%M#$.HESM\
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M.F%'\'\L3$1$MO[BA=I=K(67>EXAS=G:'_WML99J^VSFUN2NJ+*22,MFX,?
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M^K8P$)WWGEF>;,UQJZ&L/9O?A\7,S8TA58Q^!ZVMZI \A\&S;!U=DG''*\B
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M&+VI35V6LS!YGB2LHJ%0P:] MT7X)GL].[VY]I22XE*;*U#7=V1.&4GF3M<
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MT\MN,3FL.%)F0!\=#QEX@'2L8]PWL"IKR@0JZO6&*#VI9L(M%4U%<]ER2U^
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MB!1&4]OT/EY^P Y!D\"_+YJ](8IJ"IN[1>YQ$5;UP8!1RD/;><X '/PK#\B
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M-\J*O@V*8W18/Q<4%P21/TN1)LKGNL10Q(5R)Y-E=PDAY?R?W^'_V_"V_#\
M4$L#!!0    ( %E/@52\Y7V1ST4  )1(   0    9F]R;3$P+6M?,#$U+FIP
M9YR[=5A<S9<NNCNX!(*[6Q+<W9+@(4!P#<%)X]8X!'>7A! @P0GNTKAT<(?@
MT W!I=%& B??S/S.F3ESSGWNO;6?]=>N9U>M6E+ONZKVPZ^'=>")JJ**(@ "
M@0#SOP_PL 2\!+ Q,;$P,;"QL+!P<+!Q\4D?X^/AX5,1DQ"2TE$ST--1T](R
MLO)P,#)SL=#2/A5]QL7'+R0DQ, A+BTF(,4C*"3PST= .#@X^'CXE(\?4PHP
MT3()_']N#UT $3:0^L@%#<0,/"("H1&!'OH !@  88#^K0'_T4"/T- Q,+&P
M<7#Q_G9H> (\ J&A/4)'P\! 1__[-N#O>P"="(.8B5\>DT3K/1:S*ZG Q^1O
MV"PO:KK)WDZ>L I:N(7@X))34%)1L[%S/'WV7$A81%1,7.+E*P5%)64556T=
M73U] T,C2RMK&UL[^P_N'IY>$&\?W]"P\(C(J.B8E-2T](S,3Y^SON<7%!85
MEY26U=;5-S0V-;>T]O3V]0_ ?@X.34W/S,[-_UI8W( C-K=^;^_L[B%/S\XO
M+J]0US?_Z 4"T$#_:O]'O8C^ZO4('1T-'>L?O4"/(/]T($+'8.+'));7PGKO
M2L(L\!&;]$7RMYIN'!;!MR=D%FZ3N.2L0AMLR']4^S?-_M\I%O+_2[/_J=C_
MTFL1P$<#_34>&A$@"US=//T>C-L_#U4I1KDR@L>E5S=B^DF)J.@:XVH +[14
MPW@$SF_H9Z$UPG=[Y!,B"QP1!CI_=*EZB6!8:-)U6MX_>FJ\X;T:S?KD4Z]2
M'(R'U5&&VF!K''2Q]=!?,4!&4)011L/*,HF&!)Z5FS6?",P*U_ )(I-FGO/8
MF%JQS;K"?CS R2J>&1)CU?R2IF<GT-K%E\C$Z@' S0B20"L?O>3_K>90@6W/
M\K7GT<'U]8#E&)\,\G=K!9J<Q)NO$(R#?3_IB[XF48TM!R7;O4>;&RY -WLP
M2<\J,SUK74>+,D+Y\/AWO6*"^CYSOKF8S$6GB5*OLD7#U$6;-XOR^U@3Z*MX
MB@_?(]=!O_2=Y3!(M?[OHM/9'OJF-NMR=\BX)WS3O+ :JQH]MZ?&7[)JCWJ@
MN'S1;#=ID>>K"R-!IHSS)]6(W7K++>L[%;H?@=OWTD4/@&MG.J ]Z=DNV2?Q
MX0.UZ?@BMTFZX2.!$"43)V NW6V-0';S"RKH'IIZK:_][P.2X9\I.:*GCG0S
MQZNUT<< @\*#03V#DPE9F3\<2P5^;EG&.YZ>/M7@^YDO]IPD=4SIM6T,<+!3
M:?L&V9A<NJ]69%1_-(5)9.+SZB7G<\Y:3HAY.0YB?BJW!)4CR4N^LXBOAE_[
M[GK5B8UF _M+-^?Q<0RPL_,]!GCZ_R0E/!QJQCX<Z3$PXDPWD!A@=2(NG/H-
M5:6,I$WE275G&^IQ90W!TL&:=@=PUL_S'B_^XUN<6'T=; TG<SEU(^_M"QRK
M^]EZ7M!>27XZIT.F'GSH2"S?GT]](?R8>%72<-X#XJ7?X]TUH+C^(IM!*UF.
MS%.6P6 WAY.:-(G<(TY%JL.--P.W#I])/) T->$S'5B"-[K'#I$@C7FP-D9L
M[/=2R'P0[=54M*@MVI;BM89X5X6C?M>B34W% V"W/.Q"_I+&Q.@'(8]7'%_\
ME_A>FL07@@-@&=D((W^7IXDZ,W-[TK&/?Y^?,4=;VO6]W!I82>A-SG'/GL <
MO8HIYX92/  X3,W*W-8-AAL^D52>0X^P_).>CX<W/+M(Q-F52)^0EUXIT%9^
M\OZE0(B+M'B)L!KX,6'7E<C'%!I.2<QH_'*^LM)ZJ]R>?%30 \!ZW-MY21#Z
M ,B1@J:T%$B!_[NXZ5W=P.ZX?GSE4=MY]]H8HTT9HX.6W.W36HYK?<Y7Y&*P
MQ'17.2$!JFBI+]&_\5+_<F#H'?.[ANZMNS\S;FY*5#<Q:Y4:W0Q()#SQED#C
M <A3DJ.S_L?#7KH^,EE2<W[*+JZ9#[BX*!(*"Y."-A^ #PTGD0G&JI/P:6X=
M>4>2!EB6F?F("N.K+R_]:K830MHMH%_ZYGMXHQ/Q]7/?ISI6?;G_ZI9K-RA&
MP_P6ZB9C(9BK>I$%/,-&?^)+;?1" %MZ!RT29>E(EI-<8=15:!%I#(TGK;$
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M,H26YVC3$TUX1[@+%7OP[J012E<W>.LUW"E(>2;5R;DU'M"RDK P"D!FM!0
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M?X\<:0$V?5PO=-?]816 ]9TL*GJ]G4)IEL6O+\9'F#,Z/X+&YHPMOH"=+X_
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M$\5N#I<<<S?7)HX<Q>=5\<*C+^6FR?=Z:!2OO_B9M+FYG@[$= I*-@)HQ4;
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MV=N,D<9\=)^8PSQN&C%B6WLJD/OXA_$36%\%9,"(BSL/%<#>@>:X,MK7H5Y
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MJ@G3IV_$7+6"P2*I/]'13&?_[<8/*!W.UA2$OU?JN1WP:?$O%<&T6JK>MKN
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M;VP2J:GVB%#N5C#G3Y()F\"*\2=&OK2[)VEI2.R5&-W[4F3;6AVE6G!(^\3
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MKE/\N+*?9,IBX_/%OF>=X8'82.GD&9[*.[;WGDX;.O+EO&G]'Z6*M#HUL81
M1T;;<1ZRA':G>YE-DU_L?F(-RE@2>P,@_?,56XW9^J6 %U-;]*MP?E:'P+<Z
MY^NGG-O.<8V\U@6[+2>F1:&M7FO2/U[M\P[W',EA'[DHR8:#_7ED,!Z ,)$5
M?VW+#YDV]B(F9D:U^47>?<V+KC_WY>C[*[RGY4[^'(;G%)8HD,Y/^;C$;1)Z
M24>X".Z!WZK;JD7^<2JTR3U^DW\S'XSZ:Z(U@DTD67DTO,V4AS,J3<'YO0U[
M/&;@K4 CID95H1_]Y_4@O)?%2Y8OIW@H7[5D&\)NIS^>>1S/(_,('.Z4&QM1
MR9 B,^]$%75J&BV)9(81$^36]9<H5I=E O>$V2;>O@#"(1^';[/"V(BW1Y<9
MQ&FZM"F&P2:!PILW'!%2S^R1Y0&I_3LV,8<%"9/<C;_?()T'>@=9 (]U]W<O
M-+8"<C1D;5/KK[\@FYS$Q_PL@J5(-L;[R*#(H"C&22E^]$SJM-^_T0TMFYB%
M 3+6! VD.80+W(@,BH&Z%GA_V#OT%[:ELCY-4O"Z(OXA"@HI]T94<33HHSS]
MUEONM'Y41I8'M-[;"AQDS#)C8PV]?L5\U]S5=7/%WI9+ND?M]'FC;>FKT8T:
M#3^5?@X')_/VQ^H$B*]%L%A5"/767.FZ6'F5HVV,NE04(D5YJ+R&-NVYAHF;
MV#E]P^[%P)WXC+^XSX9':*_H%86>WICEDLN!5>RDLI/<^:'I7R:X+4MJ*^*V
M _E^=O"=R@8CY532GF!S@&S%P'+&\EH_7_\K*M]XEAW)-I8()FAD;@QY!EVA
MI[2RL%K%'?Q]@C7$_W$_"]CW%Q5=A(H6OV'W>97$Z1,O,&3,4NH)B,Z C"X2
M-[XH'TB)%B_VDBUK]>.6))R$"MS*B(U/Q_S*>P3-A0>V%:(D!W+(D=RC-5EV
M&;^?O1([,\5]C\619R-; 4GRSE5NF2^89&EEO\9[U&&,P95'KHE:-,!$#W83
M- M .G<W=O @_^Y:2"X]",1BB_K8YO=B=+O.J< _!4K*U@=@X%8]2#5K6-%Z
MFES-ZU9A]B;"ZB>+E58EI&8WM6O41[:7VXB.$';C]4VX<&5*T03;D>6,S4+S
M8_CQ7$?*"6%O/$<WM4GC(9=$^,R43Z([UW-L2K0/%UW[:^VF$_?TWAJ]OLM9
M'9D63%"77I_/GYXZM<G_W=U^OO/_T$GBHQ=(,.,(N[N:25&>"7C!0ETFP[3V
M019YBVAG4< J,]HE:2-$D7813K5_&4V\W;^>-MQX'V$W/A,#7#O#&WZ'0XKM
M3XV\!V[[C)+3FZA,_4M2:3<>!1=D!^KN,.!X)$9>Y1#6M&1,O\[5P0B'+7E)
MA<CY<7I0#O!QUB!AO5\)89I+W)L5]L)MQ*G&A_CR>\4LR5U"]N_PI6B*=B;L
MIW;U1#N4Q9M;PZGU6;?9:N3H(4B!_5[R'*G)M&6[N=_=;U_B&4A]K-4@T Q?
M%&/TNJ&^BOK*&DTOHA<?_'S(#?LPYOIJH!.MN VIV7PRXE5M[U9&96D?<JV4
M[X!5TC4N/>HKW1G:L$(P]U2(D&8YZIM<J6-)-UV/.3XHN2'XS@ZML^Q*^<QH
ME%9;B&='UUH3YX42/@B1 )T?OJ=#$O:%(D5M;H?CY8LY7>TE:^5T/+%J2^BP
M+ZN,D+QQ4CZ%WLZ:4'K2NG!X6'5SK)8AM/.RT1&C9IX4-.TMVU/KK;=XBCGG
MU$#:\K52-H":!V:AEEP?1"1^KSNC/Q:$=\\-+M:$)O:]???!R$[]T)6L)KUB
M2<K6?&QZ?*I=[QC>&7(H5#2#V8+^LX W_0F[18 (+=_?"3=]K_&7A']EZ9=X
M^\%(=R)C)5J[V='J_0R?]&-K[WRX4H0_DP]&T0_?8:DN!AY6'BWW^-&$T(L\
M@HZ84OL2HW>&O1!'5]+&,\84<;((*N6?PD.[N:10CA_>R?4TZAJ>O^%1(V%*
MG 3?C+_)CC< 7O6Z=$JZ-5,>UU7'E98QBQB\K''>6@:!)*C0C6-JX1Z[*Z?3
M[N'^YZ0!G:O !2EH]A_T/8R"<QLA%)M"%:/4I)J2E9[+^#>&I= J*S'QSY.]
MZPZD;CFY-:.)YU6H/0MY7S^7_!F90]D\AND-*ZWL^0>(5$LIP7D/* _?<E)5
M.1VM9-!X?]5)BC*-YN[J*;W)Q@5R^ZY<%KS?Z;1D5T=S6RUKX='K)(3F7)P=
M1\H(>R<+?97ME9 )!TLO>^V"/W35\5N;8"Y-G C&7*F_ZS-R/<%?W$R])M?7
M,T;X@,:/2;;0":X9]3^C"-Z%W=!_S=^;>F?PLI*MC,I,)3LMK8AA2PHMQ4_S
M+Z':[Z47REB=?COK09//M176A*E1/\[Y #12A&G*[ 4#VZ65B&X9 $DJPS!=
M>005_;8Z6N>O]L/TM1$;QW.IBD*21/E<,_#4 [!A[\UP'P$FO#UX ,(93NJA
MA _ 2^'(/Y=!/<&,"?MP,BB8UA<K\M4'OA]T=S' );VI[*T^G/KBI"-N[6BO
M7#;;D^..FQ?M 9@8??\ !.2>Y-^39WY\ '9LJA^ CG&4)E;H&BIR(!;9*ADQ
M_0+,*=&7Y5O#7VM)N;),=B\+:_ +&&A!7#2EP=:7Z/;"*H4UEQ$)(OA_GF,B
M<WO)9^<-'+45):(H*124LC#YKVIRLO4B_^MP>81,* CB 8C*7.5K#0&KM5OP
M53IQK3G(J-#QC0#:.7R^\SX(PJC6N>0-Z1<^_DP_=L]\ HU,/C/;P6W6^:TM
M% 5A=*ZFV*C<=5W61&+[]9P"_NWSLM;</L+(F\;/[L4KJ)3!BB,+NP+03S$6
M+"Q::F"]@\S?H"55K;T12?RA:5KIJ6=;Q,(17[G,/CH##W_R?JJI<U2@D+>S
MXM0B?,6ILG(80TV_,>611JFM)L 0+]C3P8RR7A\549=51I*5R;,6Z9VQ\Z@]
MP3+Q@.?"$TGN!)"!*1XK[\QJ4^@V9E->5-$0[+G"7%$3:%!19'&/[U@:C_,Q
MB5H+ONYA$5O4%3X6XRPAF;_7R5'4Y>2NRI_J4^L"?MF,DLZWXAS39.Z],FRH
M=QO<K/:+>FT624<\HRP9$,N5!/$R>JXVE#I"J2E3=]Y1ZA<(AU60\E>5:7&"
M N!L<&=\TO\GCN*)2-[Q<TR^_O="<9&M*67R++_FT[SS$9A5%'TE5M6FBG0\
MLP@5H5U!&HWEE#!KE7&-]V8-Q?[R*+^"W0D#0_"-AT@UHW*^GIBF+&[7S 5#
M>%93K*.4NB=<S;W$R.&T9S1,TCVN<M5W DM92@.^7W,?OJZ2KSU9=8']_6X6
M0HW\0I,8G8C,D,-/_C#R*YUMV)BM$1&'*+>4LLR^G6_XBXJF3F3_X,\Q7"T\
M +@CL?T/ #[3/.M<_FQ]^LRF:94;SFHO8)[;I8G>FA"*^*/VNK4IB,R^<5R(
MYU/#]- %Y>W!9F()%=GO!^ 1E//'+^\FG?:,/8R&!D*P*ZD^'L<7=GDL7 VT
M$DL4I$KO;V04K@?=4)7+'M?=DY5N#$*E_:RN[FF-R1L_-]8WNI9%L-1TT<9=
M7>0]'OI/_[7PW6GG=T9)"?L5O7S>SS54).J:CE].:4M7FT==M;&""8>ISIC/
M4N/8SC@5M30G/%HUNLYV>.NBW+4/\]U]WK W<BF*Y]#MA/^:Q7*AVO5F HND
M^([QY&M2"[&1&E\&Y#.H)1E=U36,QL"*4'O4,'-#/\PJ?%)H%\%5@*6V4-M"
MI_BN0A-E^3[(BO?5I?Z<"PU8UP.*CY_Y(8[#M3D[Q.NN-S3FW B ,Z)T-RC-
ME3>KFS\GO_C,VO[%/4DBFX]*IN=;.TIMP^_3A@%C<_TS >51NN6"UM AVJ:7
MT]+@]BIQI%E\Q6 56)1:N</==>/:,BKZ3?^7$1-F]W"+O/.\QQHHW4""!R#/
MI!-%(_L 4.B.]P3A!-1PW++]5'@1 ?+C&6!-_'2W\'-WGO;\APRH(6/ZS4S(
MPHJA_;COZ'M'C_(J6N,G#.G1C!0$<C(=%[\FL&C^FKFJ>^T<+_,!0+-] .![
M!>]P_'GI_HP<8_0E#96P-(%+7_3(B3-&#*X,N.^:$L:2BH8WD(ED-@7W)]89
MBAM:;_KG)2CZDNQFG7J?JWLH65C6S,;%H1D\C5%&3&^+,JVXP#@I$X-'9S#I
MD'+TX7^'J_O7<!S_#-?>U).(TXN38&S\(V-9XS/W05OU&[F-X*X=F?05+3E:
MS-*3T![JA*_"90;#Z"G/</B:TT<<_ZQ318W/E1?W!&$45C=)J%'V'')>EH;D
M]@9RB@YDB,X'<D_]GO;X(U]ED4&<R=G<N[75%-]=0R^ 9T6' +3OJ79OPM.:
M(N!#-U,L]@ZI%;_,K:$T=[L4K)NT52-BLN& ^SW;G]QZ1PWMIERE-L?G2R";
M)FQK++J9U"37_613#UF<.RI\_N)+D_B:%YLKHZD?#RZ69OWJ7!K=&\KREZ-^
M]56Z%"*[.*;%\@@9&_[D>GR"&GCB".-83;V*>%7339@S9#7F(BL;>/%+_22W
M.Z67-6C!#=C32?8140RL,L&_H8A.&;N4UE>=J;00G1> XQCII4 :M6A#*:_1
MOU3[/I/^R[\#V'CR)\LM.QSG8YVIQQ;&K'!%&<:%0%LR5"BT GMJZ+Q1X5U6
M>@=N-_9C@N4K&[U!L?.NBA6_]?'P!E-ZL+&D#Y<3#:9XWZE*3619W1,%7VF?
MJ[X5F:/+>0V1QGD(-Y[J/KY(A[^;2AUV+=!5EIK[)>\R#Z>#^DXB<N/R"^1)
MNVBFOE,%5YL(#X6D')5,<:[OT?ZPOW#1O@OJSL1DP71IN&.W:MMB (?)/.<%
M"TG$HOS?.*:]J'J;]RB?B-'+)4\2P ,-PE13_KT@ 3^XHW$'(TC*A,_5+>EF
MKJI[6)@U1*QTS$>S'0%BL7&9F17(1F?$W4MX;(#MVV 5V;1!5HPHDI-'-=T_
MGV,YFX$;JT20,J%EIJA3O&:A:R>!2W6P?X%CG<&6339M=OR0DAS$XU".>NVD
M%/KX 7AQ)WMUJ7'__ ?L)++[F=345UK9+)VH55M.>DP9K1S!F8O?;:U/T6)D
M<?UQ\U+SY("]U[5!2%TU-93\^C G905/_69'BYR:!E<"7;>%/*.H ^*D(I=A
MYPR<@S?#=6B1 ?[^[5N"."ZYN9*9HI(9(=EX96A94,_8+>32/_^/U#*=FLLO
M1YD1EB<78_YC7@BZG4<7\SV$Z,N+4,[\@*^?7+D$Q3QOB#5.?S#\U]FV23Q%
M&^>Y?X(2 -^J,%6K>339^.2I4$;/E (BQHQHX_3IGC*D**(9 3OR@^*D5U-/
M@I![FU"%C79M[?F+%BX/R26+M_*T.^L/@)W3 E0R\Z=ZB2X)Y> @B_"R-XE&
MR_2Y<4/6F!HE>V<.6$V%CQK;X*Y,CI77_>.T$"B[$]N?M"E1?/**\WM5BDU
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M!\DFW>X6DYPO7>3M]+Q_O2!=QWQ:E>,"H??3Q%S]?!+:K7>CVP!M-3)33L8
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MY(Q\4W-GE&C)Y)_,DIC/F)YBV4C]G@TTC0Z"KU;X_%$-O6HQS)UGTD+Q=5
MY2H@&&RP>P-;5G\)"VD=:_F%HP\%O/H@>"DG8;\:PAYDF$$GQ+]-!P>&307X
M[V[\N,)?&D).-@?C%H2/C'!=Y<YQ7/.!].C/P;#+<B#Z!.1_&>:.[?')/X9
M_GZA."'U]_3\O^;VZ])WF"7I_F')C-\.001SB)[?#J$H_@1^[1'O<OS/X6+O
MX27^,;&*XH3HP DD$+3]MWR##R)C#@4IW^LQ*G:=.*6N;"NX--.H-TIDZ%.?
M)OP>%_+U3QEA*P<%$I0(!0S5C"%-O\7PJFV!*=%R\0\[1BS(E97V5917U["*
M&&#(Q-VM*HH#VO_-6[+PT+G_ 5!+ P04    " !93X%4U=ZKQBUJ  ",=P
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M:E>M063&F:;?:>3:<+F\ _VODT(QJ)G,0=I(HZE4E""4!2VX:OL=@0-%/L6
MZ-!OK%X=O1\'^M*B,CPKF/##>D=ROYA5"0[NJO@UU:];N8K<G6O:@V=DV3,=
MRLG#+M+WUQ=I:@^K(A;C.'*A[RN+K\LRLV6Z2O38\ID]9.QN7Q:Z!Z<JZ:%I
MD-3H3S':<[SYY@P.PQ_&NG8K>93D(P@O(41K\V']U&%PPTK&W4T:M2MDAC'H
M!$W.<S?[HZ5#_OZ&9B%6G%T&*NG@*DPEP20"2Y8?)@A!6GEK1-*IW>'<W^]C
M@T&[K/%[.]5X@5)<^(6'P0!_6K,';#G&7KBZL$&X9?_HD,1+'S[Q3- 4\W2D
MA,-W>,X\+%,9O./(G1YBQO)12=+0E=U<_@#,7#L?&Q<')SH6L0V"K7+G3>(?
M,S;K'4R[$7HDU5_2,57#<':KO[$E/2.A:BZ+V[@_&P<[M!NX!F40N+P AXKN
M-77LB8T@\J#,4:9+B)CM^YDR^-'8<B+P$[(E\F=O7Y<QON!*4#JL395;/^HP
MS8,J\E$6BF)$S(.91JW58?IW)?6WK,MMJG"\,0X!CZ6@!ZCCEIF*RK=H(P7V
M[=&%,;=X.GU='%0HX[S('XBG(W;7SRCJ>DULWO(XC@HZPB D!&BSW[C.)T^]
M_OM# #\P8Y/XR6];LAS<C?)<;N]44(74G3>4\@H\I;"W;1.-$8 X6/O))*N<
M0J3V81C$CY[P[%.FS%*JY.$&&<P;3@+V[+./6,F#*EO\E!K+->(H2"AFSU^H
MU/*#GO);(]8Q16M7F\2G3;+JW:'=U88F$8W  DA><?UO3YX\^<FP/VOQ)?<$
M*<F?-8H=-';[/,>:0#N:;UN:8MZ1&UQP\*",?)I7^F 0_PS2UF/-# X1'&#V
M<1BSE:@@6<"HDC3D)Z!ZUDMDWYC#']Z,T(B7,-K#,7:8OT<9+T]1H^WG4:[:
M*U#'@=GF+*7EO:3UJ+9UP2F,Q^ZFPOAI.PAS1^ U:]P^X_P=,ULUW#BL69!<
MG'XM88E N1F?LW!,T,X)<T::C@$7Q]COODSG3\[X.EP#N%E-T]-89!#F_!R>
M&XP:5+X^5%]AVC68T'_71A#%4(G\1X?T@BILR@_-+\!J^4;=E5X;]LRT=A#+
M:^;+(F893IC&(CO&+JF$,QK/E?=>S<B?.N"=9=1<G9D)8[2:*>==GQ&%> >[
M\;=9.C4;SB1N,PHM,7(.'6,OU=W3IY#;JCDR\JBHI>'>#X025^1.5T65,_)#
M$]_.A/?G;>RL3 .PB7D6OY]E/-$*S??;9[(<NS6>]SY,T%GK=H^SQ&EQ3/8[
M$5@K:N LE](@\VFQ41FTUFA;H.)(03-_4."DOU79.\ZQQ'-M,BHSL2F\&WS'
M@6/M0S57KRWKVGW\'IW&0YS8 W]&G1<[5"YK4S5PO<_>U !.+_.+4^1#C.7\
MCT=)K*IC!-%M':J5)DY$WBAJ\3(\GPG>R4<.MP+W%T"^KE4O4;<P6H%/$U.0
MD[A(W/+*Z[M[U3%%H/OCT**'GI:76,Q;;BJ&5%"?8\O/C<)2JDV>]V52.[)\
M""I1ZLS@S!*[,*[R>GY3K:)JDKYN2*1'?*:#YQ"G54Y:TH>$#@QYJ?36!290
M,\$P#TO^6UD-K3&V>SQ)+-"X2 GU#V=S]9X'8;KAY#*U@GC<X,@:=F0_XMTQ
M1V^CQ_%I;UVH3W2WS'1Z<8#,]J>3M4079G #I;%Z9^YPQ3OXL=G<KS8,=LS0
MF8G2)"0ERS"VV86HGD%L%79DW[Y&') (2;0 5T2SIBW5L):.'T'2MOMXGWUR
M$8T@8'A\$Z=5)#47"DX"_Z,5@B(NNC#%&>:LW!#!XDD!W.F]:VQU22>VKZPE
MC/AQ@[9<:HBKJ/&@J9\:NMS2[P!DUZC489V8WO.J-@Q5:E9*C/&W&E=/G-9T
M<7CF@Z.N53\E*;<I?Z#LJE6VJT*V)O;JB!B&8')+<'+"X)#-;,UKJU35?Z=M
M?A>A@8[N<YZ/*&\4MYK-Y97KV!GB4U5JQ9?! #G"<[. &8WR48P?_2ZB\T!8
M%-G7%;+VAE=^.VVP_=2E?6?19L?<,.S-B-C&(N>XC^5GT6J+9([Y(YFA,J$3
MF^X GC>\P;Q$HUJ5XQE2PI)-)^_D4'@_0%Q 3CT??PG!!QLQ=B9Q7)M1?P\3
MKK7: UMUO"S/8FL* 6%JCT\<NJ]]J@M:7?5)@YL2!'_\2>SW7/-D\6$!G8['
MVHB444S:X<#35QCFM*B5;IK<G4C)&287HO3QE)]+U'&8?'&0TM:OW7WB)]/]
M3.1!ET>8K\%2U?(IROQ4[.CW*')+O)3V0 _Z5!6&O;.+]_J"CWZ(JA(N8<]K
M%(DC=RPP;UD>F1%/!2N'40,Q"4J-,HATLM>OB;Y)E7J9UVD.6V%-VQ^HCR'<
MP!%V\&4&*QF::[%HL,\K[V-_+]3ER"H#8S$#@^9]0-Z:FW$DKPTG<W&V%:8>
M8A,B_\L(!LRU[X)R79U;%1_BHOFZ?*6<TU9K08LJK\! %$,![!\1S=:F^^:8
M!['Z<GY5'5"Y)V.1__#K('@6UW;T_I.G-53<UOH.Q),>H<]!? O]0M*%8LA8
M'.Q[V@R:]\KJQY>+^IT>=EO1&S"ZI3CR<6).\2C*<E/U]5/K\7-N%V[L+P!K
MI'X6,R__0#VF#O6GG]8\'#?R1I?\&]1[_M8.E2WF0CMH7,@CGJB/,3\M1<+"
MKMN,R!W6[#F'[C=9<P/?U 8T&R->\\XO@?+(ZTWF?PUXP)1"Y/)M%N\J0:9O
MP,6F^X^#\:_BOG:12O4.WUL\"2!Y7@!87GZ\B=;9"AOCNY,W="/D0IP0,%GB
MF^I<98VNE*K$?:O/:Q]GCL!'R9OM:('WSD<P#WKK.HV%F-]"[ S;:V-&XVZH
MT3B&LIH'G>[5U=8Z@NSU8<Z\%_1*>0\:^FCIZV-[X=NKBJVX$*F/'!:4962Q
MK1DZEPR@YGJR+*%!7J85\_@Y>I)%!\S[R0G#+&W!([4F8H/R.MFVT+0Y;;,_
MFU*ZT7C[AW"91)C5#SR10ZL+I3]WQ,XD-M"ZI\MK'W/8!TH6?=IAC:J1<^</
M%LQ=D69(*NE!,$ ]OR;S[D)1'(8NLNHP%'(M_$)H7U ?FGO"R(TRGC)U$,?=
MW%2;D=4F*&9M1NB4-2O%,$?1X)7F$!/7@\6)2U<>F5W*1@QZ&W8&^WZY/D)^
M-]ZR,BL?XV(8HL_FQ#5[I5W?]@:2.,5AJ4'G8I5BXXWX ]7W)VK6Z1DWSFRD
M@X3.#M[B9#Q!4M?S2?!/9/NZE0X@Y&+"W7!;J45Q=*D*X1+N$!3?Y1> Z\A"
MWF%0/R^"1NI_S^_13PO+W+2B"B,2G)P(Q"U\*I9CN6*YTL:2^T$R!B/?R=-5
MM;<B,T+V9<7DC2G)FTR/,4,Z::>TY.F+G>U81NXV#29NU3(KGPJW+*]O4$<J
M,S"M+P^%(Y/V,!(6&D0QE'!^SPPI;<K7MZ9Q%C=%2[Y]B.PE5^=T6><D:<RL
M7]QBD>JE.6[:&I?:\MH\KVI,2DL0LF )TQ56F&;X6=,N>YTTW*H)CMYLQ#FQ
M&;%4,TLZHWR,BD81&T<@&]6%S&'84$42<0 3:(R"'\F<M=&"9"3;.ED%M1H?
MGY1,TX_NEO2A)R ZZ\JB%&U:7*9RNRDY?C 7X3'TFZ.Y"77;=XB'=M<7P-A/
M67..*[&M*XZN;'X;2,2.#VTFCCF<JQ=D/!;RX%5QJO=$4?+QK4_#5;N>9*@P
MGIY_UCH]X29J]^&?>-=2RC>YOE1?UZ3LA!Y[TN^0, TQC;F02(J;C],%$KK2
MNQ;_QFL)9P0-DC;!]1 4)VL4%WS-LHK>13CH"-O#!1HG"G93.;(HF;8LE5O%
M(([7:B383X-U1'H,H, #^_.5=DL32#_YS9(XX@16PQ9!/C39#M@5T"9&>PWY
M*M9D)LA'L!,0;.YS2LL--:\XA_RC>P4PD?K>;L!$9AC;^R#)B@(.BN,N^-?3
M^A8D"8A$:O+-XM9><RO!:8N:X@:DPS$!I(3#$UM^][.%O*TRQ?[XM8,7)8K2
M-*G<A#E-RDL65_>S:[)P-31U)&AOP#->8P-[MH(%ARV?TF,S#OS*D\H+((6
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M7(!0+HR>W7-S9,3 WKHG.M%&509EMAQGZ[T NH[):D[N6J)>[UB&&4';":0
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M+TV%%Z!O4$N3[Q)+DZ(V=BHN$B5G0FXG;+^4^<CN?]]*":=S$\& FQ,D\VG
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M\C>/Z^\/' ]R$W1CD.=")]DKAI$<*$9:(-=TDP*+,PT-[4$[*_ACB1_Z5"\
M[Q[X]C]L[>JTY;<W0E,N5KJ$5;Z3I3JCL94-G81?:@=T+A6O=D'^'-5'^=\:
MF3AIND[$"17;4#7>Z'XT3_#),N\.CX'+@/B%R^/7)>NB2C ISF/*::0N/*MA
MC&>I-GGTKO5+WCP=!3%;3\_*G%ULS'CVN]KB/N;YV&P3F\%S3,U'7G._69[3
MF)/\;;]W8^S\R$OO5YN;#?9P7A49%"@^^;Q*HV?EI,NQ>)2?R'&6X7OV;86X
M]XK-2V)*](NO=5FG%\,RLHC5T^3AB=?LDA6^%06M'?Q@5@&R_,P5FVDH/5T
M0\7O[1TY_\33P'\3B/2SAGHW(M09GF/338GPM\R\RTB!.<BA,T0ID.B''[%/
M'WJT.JK[^)&7+;F<3[4G6L^IC3\20)(;7]N&PF19+?PZ?DV16,]@:WV]^0M&
M\7:G3O8]4!_R7.S4NHZL&OK_>\ZH*TO3Q.+Z3\BDN?RWG7G'3"@?LQ]JQ$+Y
M>K!)(AUY!_>HY"-NL!RWQ%:I4$#S59+RK)-YM3?GWB\\!Y;U$,&'H0>?5F4)
M4KI!<.LAWBO>4?)$5O>_Z6B?%4WKL0DBBB&+2K;,Q\9Y=%#3$[-W]=/Y(G&A
M7IX_XY8=JJ9CW.*!8L /IJ8OSUY?7H#-!C5Y/(MK,]M:.Z\"=H$5#[#SX>M$
M-\I#73:V+\R)^K \;[Q^0'G1/LB*@?$FSF S$<4@!LQ?8%+T][$WGLL[T(@B
M6FJN+,'GSV3-CNL]\IUN'^WLT(I-5Z-(9W()VU ^<_K[O;$:YZ/JKW;7[AF8
MTL.4+-F_C\PV>^#=0MC=_$4@T3ST$R)NU9^W^4W7&T&86'%/%W?Q'GE\JZ0)
MK'"?8DOL5DU2_18)PK&F'$J"XO-[YQO/_Q04-)S&J"+G'"NB='[P\6DCN%(U
M0V20"C"I>Y[LN1MK\,7A)VQ/2DMJG5$G]+YCSL-0)</G/T3XU  CUY^2NVGS
MITW1Q-J?>V/'K#YGJLMZM5"H]>2+J6I 75*$$\QI[_.QGU:'V%[J@J_)?_L:
M3([%PC/:Q"36%YL."SIJ(2'L(D"<N5[%FV&];:<OO;6=Q7_@E_/BJ)]9K-PR
MM@]U(-6V"ODHQIT&S!$Q-C?7SNQ\G=QIR9I0\6$S1/.O4(<<.1(?\B>20V9:
M8PLO=3]43>[]2*VMC4,R5__9C@V$WY!$$AGYG89]+26J>(O$^:9$KYN()%V@
M-6*]?O%D>SY=-6FT[;-5RDC -M. 0Y8'I(F8*%]O5VOY^\]S.VL2T]/:-=+F
MI#7#$CCDGR^0RK/;D05VI_S?9^-:L<]UXG_%0UNQPNNHC_^$'1%7G53FQF*S
M)VP&.$RG)>B<#13F(GPO=8;"<XGFN:/HT-C^ G"P,B7>S9B5TF80*"W<>FG9
M&/5X!M]K]H!D"_L;1H19/G G8L+'YW,N2(XS_=(@(CF%;O-=)0NAE84_/?C*
M4W/ ,3JP 4D#A(M-^S=WD?KCCK,($/+^^LS&R;:4228\B?9L3O^VC7G,G43H
MJVW/TY33^=G23/1=DA]J-</E,8>6'0J/%N%QG^NJUTIU)G[;G5=[#:,"/^Y*
MUFUE![Y@>\V9['4IY^?AYNECFT35</VS7RM97-Z]F.$V/RN5WH>T\H>F'G<N
MF7D@GC,ZU93I>(3"X(ZOV=:#F:F>/<XU:95.7Q:TUTXN%!Y-N-=R,Y>8:<0&
MM9>0_:_>WCL8#BCZ%U\AB!JBUX@5$43OG2B+1716B\Y:O:P6+41$74%TT59;
M(GH-P2):U&5UJ_<>(>27WYLW\][,>]^9]_V^F??'^??,.7/ON9]S/N?<>Z5X
M4[M&S-ZA3:23WA=-U"< +2&W>4N'D/X6J@J5%Y[**XA9%HJ[PB\U=VQ@BI9*
MBWEG>99IW!12@D>\K!@$X\1K9N%8RF0.OZ\+#,: BN!!>SHG_I_+)>;2)X))
M(<Z(AR90U6^25D-G9-[.]V+2<-D'YIM2!Z)TV1K!Z'H155^V-6H69"90\K<!
MY\T<?HXQ,MYC;;)^[P$7O6FJ0>/;T"R?1P[% /O$RMV.?MKAIJB&O5QW].[:
MLGK,(?;",=6BGI^VKY>CKK;0")#.SC-$M4P[!?^FVHKQO2'F)U-:F8)5YP_;
MXFFLD\UVR:YX*3(T+<E,<TJ?-\JSBLQM>[=:CO[ZP.A@2($6PWIWZWAZ2GO[
M])N]J'4B#+]>^$KS5<NC021E(,E]'X>A'5%?A5R,_X$YFU.*0/+6M/1-5X@B
M[)B;<<E!3G&85"7Z)4)Y]O;0//<\O@W?+9?32X2<9^"_XI"W/X#>/#V3XG,Q
M5UHC*L7IB15?-:J^V4P/[TL:P3&$*,IP7YYCES[(/Q,%6NVA^!#LG8[V@:/X
MW"8"79=,K0S\B?3^Y=.K^?<77,Q+HBS@T.^7?P%V1*&W]?8C0O@D VWJZ;H&
MB,6NBW)8"'.%RO$RZ/A&[ML\3.!QGIJ)#$G)P,<5G-3\P4PX\QH[[:Y)8QZP
M<4+4P.\U4D6L862NE>I;]L;&6Y>D;&=.*4YL;C$<<<W/V=/Z(@F9H*4/8UHZ
M=,S##28^^W'_?CZ4>EBI"[_V*>*H)X_[JSSGE_&8[!?Y*!#?&J3<$MB(>(G%
M.>NS4 M+,8R)[GF00[$$U\:?2_AS1WJ#M)E@!\5GHJYHCC1?3V2R%AG5@"@>
MWS<JSB25F /?&; :^.6.KHOL'I.2I[!&8""SIS QD10#RW1FB(,?TKG)A*GQ
MG5S#N0D5MMN#IO!E.T*;^$\Y,2!2%Q@1SS+-\(<+9>YL F!]<7W]%Z 7?*LV
MNBL,0U((;? \3L/>6_WB;9(RHM]X%5:>P'0MAAC3S;Y1(U?1_A*GGHX=6>MG
M?,PB-:H((#M19.;!\0[Q9K?)!:C1F7C-:86Y<[2>%35K](]^;BPW9F0D"!AQ
M2HJ5;L4Z8[["C:)+Z[[*/&(]K8\Q41Y@]0^O4.3VY 9XRQABK%@P%S<WN>HF
M6J0@V\D7?/LHU*:+VN^/A '>E1&GX0"V4J0'R?)?P.NKYT/#42/C3DV([2/)
M)Y)FS!XLISW5D@6$R*2[;I<:UC#M&]J9^!004$^'VRS=(O92G![1XT[,('K#
MSCS"5NSF-R(NPV-?GWZXO(_YX-=A!VAE :B$*_4_/HOJ,\2$$/G4[++QG#G%
MR<#,L2/\\T>T"#K'WQ@&7D2[4TJ6*/N#)=,ED/0V&],X-\0I408ES\G7"24C
M9#0BB<K_N)Z764#:R7+RIJ1Z! E^^I9STH]X.-D28OG^3TV&IUGXJR\IV[JR
M3/M[H_76Q%!!.%)WFKMV_+RQT82^S@4A>#?.Y2FAWF"D]L8]X*$Z6\-V_7^)
M.C0*1/%7L[)!X27P4;U60M[S,<U:5<!C!@::^G^YL,\;Z1.6I4?'?G=-]ULM
M0+"-@_>S9;#1RJFP#DLN3VO&OX#UU#WKR_Z_ '4N@&KPVA'=E7?_C4DO$V&.
M[Z<?MX404G0@A[[B<L-'=WS.<!_+<^_B\:J4+_:>C!J'Y)X22X].G-[73T]<
M?'OH,E@";CJ@FC7]"GI^CV)Q>,O=4^I>8[$N'627.E;GPVT"DV"<*.C->#T'
M5B2W953&MX <U'#+1CK(MSF];]?ZG@RA_(N8E<8;I.]-*#-YZ)?[8D3"8M<X
M62!MRQ&4IIZ1X[%^NY RIGER Z-4;KO-%Q SVS]PFN*JS]J$#AHR)J W!U\$
MCL+1H6TS[4Q6^14AH.-V\^AB>J'^U0B@UVA$!MP/L'*L0?"3J&QN";M+5^[G
MX$,^TG;Z]?OJ=.=;+T-WC\.U$];H>-NA_3H5SJ%-W<:0:J%:A5B?P0.+C*C'
M43I723A^"?#+#^"D_;I *B\6 VGQVP+/!UU DH:JOX!!^^-OMU%'"I>:@!WV
MWJ GHB18=![*4_,[TP9><E0D_3]H]EJJ;5!X-%+Z1^G+A%,>EOP%6!K:4IQ!
MVI#61>0EB9]U]HWR*D"UY8ISC72N?LC,@]$C?PS>[3DP5D<6R-"U<PO5P:(G
MK4Z:(OX"&E"XCK^ .(^Q>>DC<N[!LX=P.=!6!R!(;*F.II.Y=5H4VD;:D2*B
MRKL0@6>C\+X?$#1#<\??4G]2G8VT!MMY($>*&@YZH]'3R=*)0"!Y^YT8VI6N
M\3K$FE[T1A*!'94QY=+@U"NK/J;NQ>L:O%?S(A?I&D;5SDY8 B,?AJZ."4MN
MX7ULYDVD)(A(O;XLH%1MG7F2T=,DG9?J]]J7F@Y>$AS^F(_H1'( ?VI&;"OI
MO(/WU<_S1<W-D1<7#(.91:TJK+54[X:HE;"+-+^J'YDW-$ZZ=S[=P1I"Z?)$
M8[?2B6,XXU93ZL(E"<H(IO=RQ=$PIU6/; <81QY6B0=NU-[5&(7W5:K?[;R
M$CPEAA( :<R_FG+;GU&)'>G=8_ Y2!T!\U^4M%-IB4U1]7,8J0<"C/E_*7*7
MRW5 PX_OLI'0//F3#WOBR99+$#!M/94%FD4%MA'99GB,3]V+0WEE"*KXK 1W
M<!/"F"@92G(+TX&!;#8_>.ZV^;J8 +^8^97'],-''/SN#RO%T4<J[C+X,;+V
M02J"WF3;E9CSHZ)SZ!KW?ME&"L8IX)G\=^:/#9[N&UVLQ!MII$4^3*1/%&+_
MQD_.\R^ JII>^1WHQ./CH2BTT/'!5/?S3[-ARZJ4JXJL/E;8*F%MS,/80EN$
ME"<M \M#7;NL[U,AKUT^S[E*M'Y'H3I0/^;1^KXIR-$EY:@T*7?#4\"8YEFV
M)=-UO_YD.T?HYH_6@[[&6G\+AX!2^U:5;=)BZU_3,KWBQ^!5CUAO+3+O0.ES
M'<:?XMUW2<U).B*I.UF <YY_^HD^J&6(-J;L_ 7,V?ZQEEWA>6H9X0WO#]EL
MU2A-7*-)YZ'%>;68Z2BQ%6#R2,F9C:[:W.ZCTJ9SWK!2NMWC[<7+B2_;^9G2
MY_I'V.A#]P&!)H'@+GW*RZC"Q\V>-,%XBJQ"TZ(7G73DH6X"#/:0S(QASMN%
MS?0]@R^UZ<]J!&"H]8]KHNE&RENSCT;@CM_*7,ZV6Z,7*#_O8#C-[L,T1;.2
MLIH C$S*<\J*8\KW<AQ;M\+(5->L&07BP<F9<[(UC3A^I_7J<;I !8G,W/;#
M7WV @+TP(4RV[HUP+-VL]@O9BT';7MCIW:6@2!O2=7BJW0P**]\1-Q8Q7Q+;
M^#6[=;I%9G,[WZG!N+6.)O?,BM/VXP>+ZC8&_@4<ORVH/_.YC/<(;:L;_?-&
MZE<A3P@+]EW/QO'.9.?/)D7;!8&LVML\\'=M;XI]IP"IL7\!:9E8YEC;W-JI
M485@+(Y/;U&WK.@EY)-DW(L:V'8]*-EHN&A=,%OH\2(-G>/PW'WSULM*RN/2
MH6$BW_CT+^ +?9]T1,=9V#31(C?"_J#IWUF>X]CV%T#R%_!=_!K=Q/V.PBA/
MH($Y[.I"&*:P>W)ZB):PFY?]27B KBF=:]9"*4\0"=2YU57DSHY*R7FJLUUH
M[O7>F^^[?A-QZ3T2".7ORGYSS^VY4+Q/[E)'980P7$V!&?X7<$=M5QI_FW_O
MR/V,?0XC(S+J<[ODD^0Z,G&>?6#PZI@\]ZZH;.=7V*Q!G1:,.T,<+\D5H73'
MXI0XA;=+O;=''P_[(PL;%#$=A',O=I'LMGDE7=;E7);",R 96HFC,VC)S6DQ
MQKZ.8G>=+D^SW-K1:3U37 U^A[>Y8RR6&\TLF6T\U<#Y]+V,Q[=/&H,WVU<6
M>!$0\^6A$X7O8!XV",0:^&\I\K+M%/)^+J<4D,J+G:0U19XKA<J2^\GDUD)>
M^M=_VLB6736T3SV_J,[5V2#?%;&2.+FWW*N%O*HSFA)511 U0+4@;SNT(9![
M#V2$$*,+35]>83M4=*<1UG5S2WS&657)C"/O\KY*%\AX$^^*)(9NX^=-_'E=
MLR<A#WOW=@;,>^ -^3 SE0(R3"Y22#=1^*XC8BG>5-Y?N"T=4[%MKR7C\H($
M/[+;L%'D*.[4NY.QMFZB@9)X>5FENA/)8CUW:B65V02^V2X)KR4!O-#%9Q@-
MQL"JS98@5P$688]<P>7.IXK=J/VJD/*B^#P=E=Q9JW:*MS=Z]SN(+$_HD#[L
MEQG1Z&PGH)5-_HW24RD<OHU>X(CIB7JLNR@QGWQ?::[:Z?4!['73H]BOFG74
MII$ /'*O:Y[Q^F4VEV2X@7'P$&FV5,D4CG[$A^EY].DZUZ<#6Q!K(.-:8XB)
MUZJEX[)2AG%K6OW\AYA@Z'QP% W>Y4/\@6(;03XBV;QG]R!C5%<Q/8KY9E,A
M<JP(,TVVS07+]XL'M6>MM !"JV8YY90%$PC9^((2R[@@O%AO>V@\@I' ).?*
M/1A>/\:(G5^26XZIFOH VO@X7$$&'(Y;S_V!7, !35ZMB.7*LU\%OO#9(I<F
M[VY-2K93B ;X_D<]V/]CMB:W:ON2[?'$YJ28S&LO!_%EX2=]*C8Q+)&4>KQJ
M+<M,4 DF]I@7[E67H8W&B5@,?.#,WC-.]PM__O=PZ?MZ%31D $&>:?0@JG]5
MBB]$ HITS>JX,1?[_M'!,94,OZ[M"R#=[=HG8M;P VY1K/[^5.<(W)UI?Y9<
M9HC=^49OCTXD/OY1#HYE,UQ2SJ.K"5O5FI#SACAFZ?1:;?%-:[J;@5=_'L=H
MR+#_/"9KIX$24(W$60H=P;2O5=/C872KCD(#J426)?[)70=$*?U PZSE>(>V
MXXRXQQ#( ;OYE\GBG&XAO=T2B%OLML;K9#6EE;C.)8%@R?H#Z4EPYXR86FWB
MIC,JCI*?&+WE9".L(<DXV%U CB+JR;*.J;*:!#4\5.?,!')]:$\,JA.A-KT%
MZXJGOO:IG-_]VL5T.2,1QQC 4M@I0>;$LN)'^YXHL7ZP8**ZO2UV_^)!WOQ8
MVCU2%PSGCX^/TFR57DW9^ZV_8D] '8H:3>W7CZCM<+="H9*KL72MZ#!X^ZJ=
M)+</5=>85S*YC ?9#ITYV3571U9IKF2*0U3PP^_:1^LY9ZE+Z<L]64:HBX1U
M<=?46>QMXMROIL-5W ;:,XA"5RQV^2$?ZES._.Z7;F=#/@@A><1G9E2BPF$9
M[5]K3"#(2?@I).R):]A<TFJ"HYR:Z?!,XX;M2*_-2N/!C0&+O1!1BB*S#]Q:
MM274;+/6&&9)+8/K>)=3T6;(!N^2Q-$:&!Q+O/-+;X(>B,JF_R0-#C"S- <2
M<;H0/(3O89:SJO-D)[,5F5+-ETACVL7Q=6?)-K>IR12=W.'<4FA"'Z.MJW=.
M=L6N&5GIF6%.?J6B3W8'IYGTN&S*?AC%?47HJLPFUN.5VZV@\'5^5I]#H0"^
MFH#0<G,UIVS/;K[U0^Z3DND0UL][TK"TZ(TB!C[_V^RA3)RSIWA"=;&$CO0,
M17GEDOE($;P :^4R/N2?%7J0.YF4]8#9S9N6(/S'AFXU8T3U=;A4![2;B?";
M'^OB1?9M.>=I^Q4W@I%1H7GX+1T;NBJ?U/D=J'X" W[OYK8!*H@ &:FKI+E3
M<LN>83I@X_^#-Q?6F##D><+[>;=*F%P^#A"/CE%-KLC04[25 EQL'9=FP\WL
M#:AI,^1ML()_[/+-L^( -;2H=HZ0LB=)MFZ6L833YPP'!]IY4+#T7$F6*<R&
MB.^PFX8Z.+7_*0J3^T<[[;"Z7:I(I52^U%T@86I&0R]P7+$M5F; PMU^- A'
M@S=K_J]J=_7@G_Y<VQ; #$SG1U#+/6"?*3VMOWVIZFG;U$J%L/U8T3E!03$Y
MN^Y?PU/7T3!^$48+3^2GIJ0<*W*1!TU,TS#FWOFF#(=Q$)2]BM1=&I6L3@*W
MS+P ZI([Y]M,A-7Q<\#45OGQGRQHM/UI+B3 FZH%YK<363GC=YSBSD(6/VQ2
M-?E+]9>&/H^K3H66<WTMR3%I8D::?J\8?+K$>#*%\V3\5<VM>Y+>4C'KTFKY
MU9S<>W=W=_&(S+XK!=*)R7GJ[>T?WH+&8>[5(C%'LG)KNE1[07V]3+GHM/N=
MJ;8GO:^IAX3.3(4C9SEY$!T9I? "2G.H,Q/]VQ[&]V<=).2HO!;6'=C!2D/T
MZZ8825OKUI0R(W9%WF'?OX#8 ..,IE0K5SW7:U]IWZ;4AHZWZ<M.*2013!DW
MW4TV3CEQW\21."URE9[*@&!D8-:_LIT_TCP'BZ89N+$.&%8NU]?8]7Z&7U1[
MC$(UME6Y9K 9C4\YQADEFBJ=DJ@]BO3)P4FM-6F_RC36C[/74_26 ER.!!Z\
M>R^K%%SJ*L\5J@Z*4HL+_K3_N5F%/:MB4]2%:[!KX<'W<FYD4"42?GHY:=II
MJ6+PX=4DJAXYY<XJNL//1&>,9X2?T^SN=;ZGR)84()8;+VR]V"ZH3F#??IK\
M^5'Y$%MD7<,MH]\\LP]Y=^0AUJ&EKM5H<6- FB6,.EDS94&HFJBW?"W7!#1^
M( 9M [[KI?^I))Y)VT+N01<R<P^\+$3R5EQ-2K)/:^T;RVZ6;U8T.K_29=U,
MYTN/'7EQQCUOTQ=SC@RFLPBU\<D6[CC ^:\$A]CB@>HJP1]J2G_(U=GG'%L"
M[4ZMX'6/A%>^^LJ =F583![([&*^T0$5YGGH,HM,4;U?8B4-A+K59%ID[/@8
M$D4F*IS9'D^+\8+%A[2:)O<;8"Y<T]75][\-WF\)+=O 8[./%T_4M=75!)P[
MU#9 &ML@IO>'R!C?V@6R9;=.9YTQY]-??0#78D3[$3-GIO53,#>^ZEXNSDPD
M29?P/4_#1SGLFO,38OS^ FP+SD%I%PW[['.50=KB: &.X6SE4%SS0X:S,1J\
M:<@LUNS=C5C5PP<4%JH,EOU3.!1/70-4]VM#_=-E]V5@P5P2N.-Y'PU>-&K[
M0>4.U0[)&D;7A<:BA\8FL)9"VX[=5ZB+>Y*S$^IB]$JYC*3 !B (0([_IUO*
M_XMXLU,=E.1_%[948?YQ'3I,CQ9E?%&K4=T5?$#^V\1:%1"(KJRPX.X]>'JC
M40LSU?JLW<V1^; >QO=2.)U#UUU84JKLR7%-+&=C4N^]4?:#Z)GU:9W<K?A
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M4&>!GH#(F&N4>](&"";$K0ZP1AO\?,-AZCJ3-;VQ+[PS@[4<3FEOHI+F2=
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MKZ6CJ49642>I_1X"H5 HM !:7%!07$T:*ZWV/XO[$HCP@2A @T$R@$<$@HE
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MA#0WOJC7PYL;B5E _Z&0W(&_ 5!+ P04    " !93X%4X?QFJ_26  #(FP
M$    &9O<FTQ,"UK7S Q.2YJ<&?$NU50G<'W)7K@0 B!X.[!W=U.@.#!W=W=
M+7"00(#@">ZN!W<GN+N[6SAP<.?F]Z^Y=^[#/,Q,W;JSOUI/NZOK6]6[=Z]5
MU?VV]+8%P)"3DI4"P,'! 8S_?8"W58 $X/V[=TCO$-\C(2$A([__@(KS$14%
M!940"QL=AY2(G(R4B(2$@IJ5CH*2F8J$A)Z/@9F=@YN;FYQ.0(2?4YB5BYOS
M/Y/ (2,CHZ*@$GS\2,#YB>03Y_]RO'4#,-_#@>!5@7"4 'A,." FW%L?@!P
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M7$L^%R"\.'S 'UNA?NNR;-VE]4@V0!9++;"QMZC6,'_368&,UYA,R2]MJ?E
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M!J'2C0UU^T2M" R^&@0RD1*@!L\9I791FHCF\$Y0\-=3YU S4V<@R87;TNQ
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MC[3;$\K<4G9JQ.[W4$@)".6_[$FO=]Y=0@S8#.;=R3>7UL=M0\78,%B )&^
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M ($/6B(F_[=^C26:#86NR_6.&&ST@)1#*<:DW%KTV=&6>QN]PU<%VL\&,EJ
MXEX3\^]>- ?SK31H@R?6'TST@!)<M*2#7TAG?^X"6>%J%_&[P- /J6FJDI"U
M<FH!<8*ASX.32 -"S>2SD7CT,164F#*=NZF415*MIL[3_UDBI4]GY<D4-&1'
M8XDH=_@#SFF8<?S3WF7G_1 74_6>?));?S1<6HASU/-9E3KZG00OXZ.P*=WR
M)H,S^P <U<N!( S@0V_,)^R:7NSH!PALU.=_(0BGOQ-4:[Q]\?W3< _K@&6Q
M:U/%).37IX$CT@Y&<<4$?M,_1DVJ;6/\I#".795A"-#$X)8B@%T:C[Y(@I E
M_608Y?U$V5G9A79_(YX0[!R"=#UB2650U.K[^X:'I+5^%MJ.>+SSCGO0#'5A
MLSWO@)6>3SIDG!62.1/?Z3.,3E$(L0X60C_%&8""7*]R%9FYB/TI]9NZ-%X!
MFFN\"!D=>0M?/NDW<;O3,DJH3^ @[!<ZB?SQCOPIP%=^NN\M8&8=Y&OJ*O 7
M;DX'#/P"J?AECIS(_J=(8]G(RX?H!AFW4"RG5&G;R-DHUF":_Q6 ^Z!#%5,Q
MFU0=#2H%NM&*]%^<>FM]L1=,_:, <'HG959+OR\.&ZPFB7O4,M@JMQU%Q=?1
M-EP_Q/DMPOX[TM3$:]=)!/-(J>528\RK;D:7_Y,2^9;,8W*D"B@9G.^AS32^
M2<>$9GZZ<SG\4G3:82W>B>VOG5PFB6L@G#7R!$T9S(LY G,*2$<%!W&1I%^J
MH]]W9E"KR'PH).WK\TQB2UY$B]G91T:?X1,:QQ:['+;W<>C.C[BK KIQVB$!
M(_D*K;&3;4,"?XT6#:5RDC;<,A^RQ5P8Z;Z16A2-N!ZS?AUH876%L$3NNI?$
M9N1P<^3D%<"T8Q^?50P&RL^5ICF^9%%C?C8(A< M5E+=XLS62=8DDN\M;\EX
M*FF:O-T;)B^3TOSNV=RP]UO<"$ZBAZ#F6Z&7CGK]!J_S$>6ISS<;3U!,YK1/
M!WIW1M$5%&J'7HT[,X="QY_S8P5^5(=V3FLLDX.:2GQ? ;N20L=Z,J9UM1G4
M JIS2[Y_YT!B[^7^6;DWMLS^,W[9F_Y(6@WIP8_(>T$2/N!*\(H_G+E+^#&*
M6VJ?PX!C(.,D8;C"\@J8=C>M6Q,6+WX%6"R)Z?P0I43KBB2(>R19,#&=@:(7
M*OCPXO.'E_HAHL!B"G,.KKG,S[?!/?RF-'4FVX])#JH.^L^9O9-:"*[%':5\
M<Q745M$D7YOVI00=!+S@;KD@D5S7QQG&@4J*D6[0'*\KY='VB[#2C9(H*)[F
M[*^O]E_(8)!-G^9NC9!7P&@)R.6+VRM@,JK>S+(1;]W[&$L2RRH9B=+!UPT\
MVGP5R:X3Z15S)%,LH+_Z%YWM7:R==6AMS^>M%>$P80VHM=O\N]K&,"3;7MDK
M3[>[B^G/H+97@&'A[)5AW9%8N@:1[%34-Z<1S;_% LURX,)'O/U R@9N$K"G
M\W6KRV/GP3\A/W+30T"A]M=&[G&:&<Y&>2+"C#<,OJ&0DB!]N"UB&M,5E[%V
M9)%#O9+M9?Y\J$4JHS;IA2E=:X@J,\^[$R"0<(T_\3[-:9,,;H>*]%GS9\K(
M[NFTE_W;<UHP\9@[OZ$+;(Z7G (:G'2]?.5<69#+X)_>F]-!B6F%9T>RCW\%
M'&J@4-ZMPUSDZFRW+'J[N&-]U29W78 97VO/IBM.[=0E3:VP^!!7Z2X^_Z<E
M.@#BK__(;,-,/'4+'<4<<1FWPM)R;VP*H:R]WL.U@Q/J7O-3DBUU"")EDJV^
MR%)JIF5K)06^ YH4/FJ4]B1],A;X;+E'@R346Z@TIJ$-AZ V\R.Z+0*8ALVZ
M%U_!)S3$"-[299#YV4"CWMY:ZHL&OIXM+Z&4MSL_V[G&DE8U#P^_$(WN)<NN
MO,9-9[)GRJ"L;9:J,SWH)REN_64&S^H5F^X()J!LH# /5J[-<H"PY%+%38LA
M? >U!_@VWY888^$T!APPHVA](;%/QQD>6+T;4/]]BUN2;VZK6&MX/.?SLK">
MRF&A:5##62VK_6-9T#_N]"L5EWS3N"MF6964<(8C\418:VXBU[L_)HX)MX@S
MR\6BIA;N&/36#A:JJA)&,1K!Q7:9G1&>O.$YN1E'MX=/H)0G395!G-Q@]2NK
M8LF1(P.NJ0N7YQ1,E-B^+2GJ)^3C,J:$,P2EH5CVZLI[S&"Z8V^8!EZ,24B
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M&>^D8HBJK9";IIMA;UP5"T\B?!KB^CY,^ZYW]*N&-_>&LH?PANP\-ZS,_*W
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M?Z*];J 13 M$<B$L&L;(A=:Y4HU[@F2Y1;S0")XS"):];26E;=='2FE@NON
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M#4VQ1_,K*ID$1'LI&R/O<!_3$DFB/X)QIZ?^JQ5D\5-7,:MTI0[_SE%?4I3
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M/Y+"\0F5^%T=!!&P&IA@?:5^CR+W??/L?W1V7D%->&T:#T4"TGL)37H)O4-
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M3SQ<XFA+-HQ26NN:(GDD:KUB5PT*L/3F9N80TQ-N"F?97#_6CB%9_>BOPR[
M Y<5JBY8E6-E3;0O5_82>O$[)F*ZX1=?&>UCUFY=R2K6GH="$9*#;WI'Q9T)
M,F(_(R!&R@-)H.^WS#%8WX'2Q"4KNK$:V>1OC?ZV)-L.+G4BB45C5Z(@F.'L
MI(+%9-C31#G%=S.(,MB8\%A/P2_70W+);_M]Q1V,F$'R>I-+6^_5C9MTLL$;
MC%D.?Z*8C$E(-CR9/-=3'L'3'MBFGI3M8T^*71O]BP'V"S!3PU EVSQ2_9.M
MTQ>!/O%C_LY%RM_P[(AYS79Y"**4,'ZU))#S]D<+6Y/H3]581%<7ND&#%800
MK^0RL:-+^4)IJ >DGX*&R8V?M!:EUB3>.J2(BHQW3TA<,BWZ#:JT;BK0>U\;
M%6G)K(J5?Z[]+\68VF=BTW,FB,.\5@AWFX6<*ZHG^]_$^3HXSE8?#J?623EQ
MK]Y3VZA1^L'FI([EF3RYX!Y?#RF7KGH1!9O@\4L7M_)T8G]N%4[,VZ4G89/L
MM"S";R#[>?J/ LM2B1F6D&9(<EN-F1"?@H)"B'9Y#T]EI./%6])22NJ->SJS
M3+FO"_+PY('- !_L/'O;,]TO7%AM.X]3<I4MOB0Z<&K5%P?F49_['51AG>L(
MW*-NZV R%]I/%>P5O.B!^K8 7:CYT#,<BK50_6<BOA1.YB<'M0N!.8M.SSO;
MM":-M!%[)5],@ (N=R776.&U4V&"ZU9ACPXZ5T0ZCHJGH:)/>/"[U("FZH$J
MZ\';3BGO8BN8AS\F#"UWYC<!U9/(2)-X3^%[S!HS:.7[7&TI).%7P!34PB7G
M"S3G_1%)A,-//DB#9A"PV6\Z#(RIY8Y?1=/))MN)C:#Y!M7Y.213>]G;=BXQ
MF $5#D3O?)(A-2#[)>\;01HYH5+M(7X4ZUD!A=RSP_D*O(E21=^OY>3L^U]%
MOU7)5.-BWULWIN!'X3'OP$\KED3X7*VA),@3A1,85[VX31QS^&397.O+9OCU
MRSL +$CIKT<N$J-R,=I$5VF%4]<_C?T@?U^MCY!=;8QI)R>RT[J -\I6MHP)
MA3#"K__OZ@WPE@T#=:693+U4I,W:%]F?=JG%=VC,+3@V[@DK60%A!0#KY?,7
MGL9M=1,KMR/M\1-^)4UF-*."#LVM9(&M1!K4]9?:*4YE\@>;<NSBXWM-.->S
MJ9='HOV@ &85Q_E.O!2\183\0?RWJ6N?/X'1G0]K9.([@W/KXB8<[@!&H,(
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M"D*R?3;BS5!-H?'#W"-G&V:,!P\JU6^R!\JD],KVP;)=C^'-E7'L[^Z<!-@
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M[#3^:B-$I3@$(YQ\PPY7^^*DTU)F[JXL'S#0YV5*#+@??/T4>R. T0"S)M*
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M[V:&>,O\APJ=,@U97PY5&](7>V-9)6O3J];6?MYEBAR6?43RDQ%G9[A*D&;
MRHF)R$XH!20.T.CQ\;'K-+&Q5:6 ?\#MI?6MN"2#)]>XRLC0(V5G1:3;IR.Q
M0!!LU.I4K&]Q!#'\W=QL$@CO^_9E<LM\7YWO>\/'Y9R%0//B/MI&K[+75)I=
MAAM$94/16P9KNR2SQW%HX+T]GKVQ;(PI/=7,'\7S6%79?'SB!7XU:FG$C:58
M>D#QV5^=2+_75Q;?!6YSFRS3JO2L1]+*S.%STOD?GO0"!MZ*Y2<SXW,X;3JJ
MLCB[Y:=Q/"6=@'C7J)?.K:_N\I _'SM:&MLCR6?Y?DPPV>\O?A'IG)A^V[]"
M*]B[JU 5\YS$>Y^B_/ J(#>DN/I%.>IGC[\TU ;D_DQ.TB#Z^_-6 PIP:5@[
M*\I/?PSOW9[Q</0O4H'=WB6" F)3A2GY0V2!+A=8"3GMZ20;+=?5[:2YI,'K
M-/5U0>YVMMB(21\7VS9W&+U;,,J=6W"3K=:?*2H+[=+[=F1/V#4=,CJS=@W0
MZRL,#@73U;DH%,P@*&=MCJ,@MJG\<^-PO-XS?;U]O[Z2KW+4PLCX4;Z>Z!X5
MJ6\S&AJD8XMQ/)SU"5([0Z[), W;3DRC5L5: @V.Q84VFV\+!OL7E=X3(4%V
M,%L$-$S<)^2PM]@/]RP;DEAMOKV3>Q?#WD7N @4.P>E<S4FRG]"_JO^]< T[
M<MZD7TA?69'_L5@YFFWCX+(1WG14_[8OP#E$<(/Z"D;CB]5,X=0I*_=-_06<
MES7IHH/]XKPO=O0GS/0LO4M#VHD=CS!;79V0^VT88?.K2O-:OW+K#;\\"ST>
M%,,HN0HIJ3Y6FX7]&6<Z(V/M3I:DY^.2F8ME.ET%:M/ 8Y;"[UHK)\//!A3.
M^"LH/^>:>)K7O9G&9ZWM$OEDS%']*G[4A'-U(+PC=2TB42YW8[&PH\XTT>^=
M>-[PS1HO*-9PT=XS+;),\_) SPEC<LK[WRLR1J)P=]OL[^:A-*']!-0JPSZ_
M9V94X/45W@K!F=;6!RWK; >H!L(];M2R7;7F=0H&_;)),D%,V&<VQ_C91%Q,
MO$MU7@ZAAYUP(7E[7/W==:ADR([6Z.[33[$V;>U[S2A@!/.J5'N_Q)(4OUVG
M7J4E@*OMW:=)MO&N-9NNX6IB4U(T!9:7Z.<2\%QL>2\[=^Q RWR+G9L!N;7-
MN&.[=ZG/@+).@R(U1Z\V)3X50$W^8!(YT/S4WEUH[M3]Q&6S8</62\G"7I#Q
M8QQ\!/&O\I=S:!UV%*PFH+I$S/1&LB)[=]0T4U:^J0K65WCOG!4G3P8%2"H:
M^WA55^]\W*D;K0)9B+!5%+X8RE$1;P'*Q ^:-C@JEA=I']OTJ9"6=T/?I/ Y
M1'.E;TY#<MZI:,EH<1$P&RI;T.<=)84M$B]GEA<=MM3*"$1K!:U@I!+);E=S
M"/'!@[7AXF &"D7K*W/<4U=(R+USOE-JQ(D7N[@74U;<0-!/,(A=1)A^MTY%
MSNZUA%UX6;15$^'WQ'1AR:!B?%#>U>43)0[JU1&)C&G!'7V<DB&P&79<Y1M)
MO_!T*15 NLXBM6A1\G,H^;6529_,2,DX0F4.(*J)[[;;\X'PCETZ80[?NN2-
MH(U@U/S:2&/\6-+%;NT001P!$KR*%/K@;^4M;JGG#,-&8[(E2LQLIFGOT#6.
MO FN$998&Z-3.J.M-,_9XQT?>R^?M*[@$0?3+;P5NYAZ\&?8?\K!9MG*RV(6
MU$VSFGUQ?P&?RV&!-N40J%JM?;Z5M6TL_@,#7.^M+-52U_9\DF&VW6<AH")$
M7""STC4PS;,VAVG(S&#%$RZ]M4'K3F DF=6ZZ";L3-L1?J>^UJ[<0^ARE)I^
M?I\<2&"S\55+&'9H7-0D:ZJ]#&S_T)YW2GO5VKD$AKAQ%K0?8\B^+M^=L6'"
MAA32R@+%+]PU,L1-(Q_%O_AC$,"Y7I7M"S.9<8[;FC=G>H7DA>DN=[FBO[D!
M4&'\_**4B<'W_^K54-2LFRFS^T/$-.(5T[3T)=&8X+K[-[K197?-T(](M*N.
M3X5\3G)LI]^(9L/>X1')JO O^F7FANWO5@5Y+2HT\]G5LYH YTGXU"\$3V,&
M);=X20V9QA#6+\&C-J$[_(9C>UPS?Q%YO M6AKSM]ZV/RBG((QP95U+,G%#5
M0BG,:/P('K3?EC]]G*M[]GP9)ZOQ4%$Z+]@+Y4>,N-2ZBB8YU&YXK\BWX);7
MC3 ?@L^H7&Y!6%%Z(UO\99G^4;OQ/J-]N>S4G)/YDVZ,+Z+G3F?U-=G]9?)5
M@<PFB6:>IIAY-S\4T +U5T"!'L4BT#39XR84J-0%Y^USYVD21N78TN%MV+VU
M:DQM&;$K4*3V^6C5[#!C3E5N=0?[YZ$AS:-(Y#K@+W-,3O8/1TES<(M3Y4I
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MY_B^QTD&Y2P:Q=*NLIIM&RHA/<G(S^;E37F%YMT*_/I!ASJW[UW4JDS]0X;
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M"Y    0,Q-\%^%>!@(2"AGD'"P>/@/C'H0X-@(2 @H*$AH*!@8;^T^O]IQ^
M1H?!(&,1>?=>R0#V@STFJW]L%ARY:%47EO+D.06;H4, / (V#BX>/B45-0TM
M'3L')Q<W#Z_8)W$)22EI&94OJFKJ&II:1L8FIF;F%I:.3LXNKF[N'M\"@X)#
MOH>&Q<4G)";]^)F<DIV3FY=?4%A47%U36U??T-C4W-W3V]<_,#@T/#4],SLW
MO[ (WMC<VM[9W=L_.+RXO+J^N;V[?WC\2Q<$  7Q[_+_J O]CRY(:&@H:-B_
M=$% NO[E@ X-0\;R#D-$"=; _OT'5G\X3-'8K*HN>'(VY7,L0X=)!&P*]@W*
MB[^D_:WL_YNP@/^1LO]+V/_6!0:0H"#^+!X4.B $W'9P*IPU[)I?&;\^^9@F
MB]L:H;]:9:S9_I[<'7JY?1YU!&=$U#*2]*II(=\LB?MZ8':W:]*Y8I0D[;-*
MT#IWX)JG$\U:L:_('.2T='RME*A*.EP2L7+"VTSR+YIPK_;U[F"3_$5]MW3%
M/I5+^'6WZ6J+B(Y14K>VV:5>%TUT7OT]DF2HA#KNT.W!:B2PW[HHU+Z6G#,:
M_W3RD#(:KQ8FH#<NCWUG,V]7.V07$X_@/X;W]'Y!S0_Z&J\@$^4?RM%_\[=H
MT9Z8P$SW2V& ^@^0*(G+S3A1^"_* \0]'&D;*S9KO6"8_!H3PB);A[Q8$^!C
M#]8>=%3F9"9^^W]5;61)3%HW[26>:QXOSJ9SF&X;-_QN]G+>?F7,YV>QQU[D
MM3[*H?W!_(G3O(/87F!#O7ME,CFUK;Q(7J:ETW\ F>Z#^],VD7DXD.D.F,IT
M8HA8X<@+22_AKCF8\@H7#[ Q] _5:4$6V%RCU A-I*@S_A)^NO^A*Q.#%8)T
MLC:]_^=_ZLV2WD?^HBLQ5*<^U3=,<!VHP]%Q 3?4:9MO/H'X'PS8BXA$,!,T
MX+-B?_MAVX1TU)G/&9,<24Z\ 733I?DZ" W>V,6J+>WAJO0IONCSJ($TV6$!
MW6'TL>=KT>_[<- 0F5$/+Q:'QP(>-::'8!Q38Q8/6::+"@QTC@H+/[37ILH8
MM#3$B/6V4*I=O@&K75L7N=I'G&-+(XX!F9NJW(S#46U/'E/HAF'EX* XK?#\
MMGIM4^[W> ED@OXU89[+2_V%X_8()44FC*00?G@4'GX\HQ .6O3D7RX$HW,T
MP;JK>@/;NF-)Y])X*'B_"L@;BO;I14%'?$Z1NZT-H92;G.ZJ8B_P_*^8QWS9
M'G1XY2=E5WO+7=BSJUY#D!N.$9<>9FUT*]K\!Y#+G2;.JX44,,F^K>\<)-O(
M,"8UM4RK;<N8F6P945*3YE%1S)+A3'2\'F !PFO^V2$.1-S,*'=;ZS@\>?+8
M?,5R[R@[7P2C)M.PHF)+M4?!6->BE2KLV\K:*?09/S;_4P^$[BE^[YS#U?<M
M%WA798P,BU.;/#/NL8G %G I10X9#C,YHZ3S>Y6U%K\A^/CD \['HP QPB-2
M8L5/J(,W/ ?]]#[T2[*AVP$$+>ZFT6<#A,6_.Q11Q+$1_ZC"K6 T2Y<B:PZ0
MSGX#-/&E\.(/(0:+BI#^K!- +R/42,]9F_,44%O0E*C[G>0L(_/UR[!7ZM"#
M.KI0;QN'LVR)+".]YLS7FA]#+6U5=5=D05<!\&/R?.MJ_=06XBP%0=0:^&Y)
MICM&3%!<$\[LT?;09JC\4JXP/5*POSU0*^H :?&/<N_YOU?W:PG=A!%B9.@K
M],=2!TOSUZ93>V?=E@2XI(<0IU]#4&)V\5.J!DYB&=5I</>0"'NFC$VUBN6!
M5/3[#%RJVR).;.U0"70]M@0D!20Q(8K$59IFK1B=EM(D9!LC\ZK9XX8(0A P
MC:_/3C0/-LUM-B=/G98T*\J<.0&%]W3?,0O)4M^GO_!.O-O!(LE 3;=^WF\]
M9]NQ);BX/I($DR(5FX4[LJCJ?S2N/ 1N;C/A:0K!F]!I7RTV-7^=]D\! _N\
M*?W3_++$>9LGCL+::I'7B?XIANNA7GTKG0.XF<A@>A*)"\:H!L=B$1N*T-JC
M'A/:7PC$(B^K[B1E&C,WHUR24TS.LBVYV"Z=R7IL'<0+1 IU@+F2ZF9';4H_
MWTQ3^/$4C4EB*DS7MH/GDYI\Q:;;=0:&.:](O454I>DBZR 0/2*\PC+F*$PP
MHTZY44%(@K%@WA!CWL#24XS7PYVH:=U:+3DZD;:P!=GLW%IO\1O1$4H&!<E0
ME0$UGRT%2 DS'$4<OJ"8K(U]N5:'^7'(I\S8BW(8RO_YN"5135@659$O#(@+
M,TO#R=AVGWQ86-DY(Z@ZBJJEF!@B[XV7F)*\F]3!UB\\$7[?<]>G63SQ<J%F
M#O4AC*;LM\*'B].PQ[M> =$QP&<F'>])O(99B<'Q3,='XQD$N7NZU<>9E,[>
M%MA_Y[&;8605<F\4@;'MR1Z8T=UV9GFZ4N=J1% U)L FO3-0RYST2V10-P=X
MW"Q(<.7GZN-]]O )OT"5;&Q-%U"VUI$#P:VU#"\7V)%GKY/8I->>85L<%<I=
ML-?:7&KW%,C_DL8EXZ$FDIA:\:D[12:TZDMA-R6WH!2A\""QU/V.B!:>M!$%
M*Z2OQ2.ZEVAQ":8.?29'#2K'UI:8LL7'2K+ I_H%RS<TU&GUPJ<:C2=9H=NW
MH2WGH>VI65[7&Q05RQ^&]/DGN>/7;T,5LAK9PED?(ETBF&:@S&^O"[#4^G=4
MOL7&II(HB0?L^1\V4_#Z!&V%AX-&Q0EZ'@-!^<Q+%/3O=G5[D2[E/5+G*L*8
MKH^B,=V^N]7?[BYW%8A1!9>PQP;T\]=(X 1[WQ,^/:K7X&Z1^4?"V;8B1/\Z
M.A+K(PSZ'"NQ@_*E^EOMDUD>899CSVFY>']6[L!6R8KHK&2(FK9 G%3$W:<8
MA9&A>-SU5PYYQ#;N^_?=6B8WM92KP[M?TB]O09Y.']1Q(07U=*Y)MO0>A\N'
MQ\)^%]!I0(K<$"=,8WZB89$0)2RD$50Y%*#904SGVOC5\NOH#0A261F^DC><
MP4H7E44K%AYZ!.A==>>=UE">K>K;9RLPQA;V/P>HP\)$%$#YN:_/Y\)M$=CC
M(W>X(G _>BBS*[6\<\MQ(4*DH5"IU+D0JEOJRKR/ULJ0S7@BT)[_@&TOS0:6
M;-A]IRGS/()'G:'?76WV[4ER(R.2<:+T%FR3@S1G ;)GB.DM@ C#V8FW4>!W
MO:O((E+[1/NAI B7KH?T%3. '?#'!R3@$#Y*RELXA+!LIM.VGX]H6S2;)F,J
M+T8R:9XP,W/0!P82'2/TXE!)-^Q55!8WMSW*KK\!");-^06V/N<6@2-YNBNR
MB,L[PZ'D3D+LWW#W!-CT#K:[(2&0-*)/D;]M/WKX8.*262<'D]<D#*/^.#BX
M5QK&^?-\OE^V%*2?55%IKY^:M#K)D/66OW3#7_G\-2F"M(?;AH!_V[!N:D"F
M^K[+S+%TN;*Y>7(]'3'S$B;]C!1;:<T_K2#:\J;I0YAAOD9.3-'PF?""X.*!
MS&#$\._OOU-+L* K)FYS$IC<%7K@3QB?Y5SS!SC:R^RLD4Y*P<O#1ZS)W)JQ
M8]@*GUVPCC![P[@;W)4DB;>2%K(<O.5YIP_R#%BEA.:BLUY5"S1C?,M(Q)Y+
MY&N2[>A6KK6*U$X?&;^46SQ+Z@BB98?1(4+=*4S,1][+=C^NW^MZ"N3GE8I[
M4W!9H/SLI= ._0JG#/6./\9Q9KY:45K HL!0JVEC%6\J$Z0=:JUG?D8VP<18
M4!7R*6X&P^B (3"6_'3?(Z7*=0-10Q#=S8? F^I32UM+->CE^RKH<I%Q^2O+
MHVE;896 ]//^T)B#H^IO)K$1?H7L UZ<B%JC0G-KH4#K8],P C=&+;>L1C.*
M))%T*?[W:P<ZX9K(O -=\)O(=(=R G4$!SG38"IWY84@NCS>&,$+??G9:S@*
M)PHUY]-PHT++%)<\1P*.N=33VS%"O[Q^ O(.XEI:^,X+^FA4>"\BQR*F$#OV
MP NZ9;"V0 L>>0V_=. A5F6KI]I<E6U.WZ;V4YEVSYVZ!^-8+*8'H87A:>5S
M:S\FZDJ[MYVX)Y6\8WR&%A?Z1+KY+HI8/[LMO()G^;W62"\8M%S6$9*'45HL
M4_(0H81[O8P9A2HJ4!P=U,IIY:0/',8>./85$QDDG1H1A$)KFD#43+KX"0CQ
MWGU.-:IC4BC:C7(A# E*X]UEI*6:<6HIB<0GP5I1*-1F0.K;(H5V2-.$&*_3
MOM#AY5J\+I,5FS+]WH,T8I:[NC\E:^M40;8,N75G)2_%;R<I<YN:ND?-;F/C
MSO\T^5M0;-R'5++X<)5@DI_/P*#Z2"V)S)[@]#(SB@-E\#C'/P:V'=FA 4S5
M0;07P9ZF+EW[Z\E,GC>H>H%\"%*G'ZX["0]%0E[ /NRV-=4P(M6(/:$4A8O?
M5S8 MN7>E3,V5T<,N;(91^DE.?OE#5B<8;&*WK3A<GVF9^X^$!B(?&;Q1HDD
M3MMI^^UJIWG@L!1N9V1%$<_R<D1H)A!Z5^',H*!LOJR@;'$%2[;]!B!_E1/J
MO5HXN/4%32>M2O*F/H*6=$6/'RY-7*!^"SQ=5ZCG4:3GIL@DG;*7!H31Y"JJ
M)?C:J5E;2-[!6"@XTK6@<3V.-:X['O2YX_@[WYQ3!JT%.[>QJ>!'N%[6"IG6
MN(N#FW!-# 9V/0S;G%\?'E%WY)8[O[Z/+K,R]'H#RC7%/MSG]RA/V9[R6S@7
MXTSMR;H:&B[GLQ%^"U*$&!<:"?<X"_ZAU'H?[>Y;,&3O:6UM.1=W;.7>KK@Z
M% 4_?$,RUS9O#X7'?9U#':5 1 /5-RT2(CIO#>X>EG6KX"?G6^WX_:D&:XA)
M06V\@B-R75N;ODRL,T1LFME@=IV9JLCI@K=$6)VP:2,A"H>(5[UM181H)_4V
M?KN'WYK0C]!$X^MK<.:4TXCN>ZFZJ6/5N:E9:'MZSDW@1F ?JMNI*9^8Y#PD
M../SC-J3[ 7=D'OS;*\];>)%4C_/RB/^9%7-=*O &X#X;DH(D:!,W#3QI.QU
M;(.BAB&#QOF5.+*6,(9^N8&3I?'5R88;BCH,.+>&E<&O&P^WSIP^V:ENF?C6
MAY6?1EG6,E:PLQ ]9&*[>2JN.<%X0J!P;\<^RJM!O*9D,L-F>? :0Z;X>Y'P
M]J'9_D1O72,]-Z,_\K='_,,$['B2AYTG'S*_A6O.)@)(%!1>4=/X-=V \G>'
MZ\AB%)O\G!=GG)OK@,?@M!EO7<?WGXN_L>ZRW8L=ODUL7\+R>R \PMKWL]H?
M2&S%.+AEHF:\_IE-2_"E6':7=6&7/50/J\65K*O#N^7A&M0D#L ):JG,@SF8
M-%F0T0UL%B8>)57JPD>+T"LYANIQVO,1%TER2SH^PNR/3&\CN:;&J58E1"V=
MQ!]]%^A5N!AIB) \ XTE6F>!92?E@F06O'I1W4,,C#;67Z,XC=_3I59[U",Z
MW578+GLK%&BQNFU?3/GQDZ@&]QT_D[F:62:UXX?!*]L[Y@[90[L: Z,4I '2
M^P2Q\U@YN182TRKWCD1EHV-9%IC@4.V0VCC@NTH0>)&N:8QMQJG";'EQ;"NC
MC"!TG#J]%F+=!ZNNI;;ZWIV]?A[=.P59-]<P",F+!8\Z2#!PUC9D+ND'#ECG
M\B5N7/UU--4B4V.$8%5^6"HVS[XNV?O+549WNU]S0]CME*=V D87+^Y.9#-O
M; #J.BAMBA\F<[]AKB'IX ^RN?)O7=TAUB5:W \<1D%;T7F NV_/"Q-9F;F/
M]4;M7!GTYN$LNT5.BO+P4N!5$GBKD;I#IF(C X4J8Z,#.$([F.XKD2[_?FI*
M\]3+MV(G:=))O.(MY_FZ2X['_3C9N)V:;@[5WTIK;8:25:2E?Z#N>Y[&L;/4
MXW%[ZA(76?6\UOR>$,4^CKOT#0CQL!+KQ8>2=;'F^"7$K:M%%<FN(MM(U.T^
M8FV__'[US[[Z>_5WR:%3O<TASO^DG9:U0EZJ*4#!+<NKPAN@%5T5?>G[..L0
M5FZJ0$?[$N$;_P;,Y1P;/6>\UNED1YD2%A;<BAP]O@$WA4^D;P#U&U#VA5]N
MDT !R5S%TC7LM%"40OHNS\&NN'W[58RZSCVOHU].F;Z+*2M[R?N;$*_VYU%V
MT-%@3^Q!GX5\FE9H(WVNB7(9G35M"Z?'_,+ @]"+I6"_T- ;</0EJ4%1#RSF
M:DTW KU?+?GAVH2<-+J[5,WK]WPBYNL_/DK_(EVN),F&\D7E"?<?0I+_ )D6
ME1XT4U8VSIR5E6Y00^PED%)/F!45L;_(#*C6:9<)GB(6$OA38,"JW(?Q_'S@
M#?WO,\#SLTE)X1_E)$8D?P[5F^(=3,>/.^)"?WO,>/\S.24)2K][_F^4"I(T
MUD/S4CY%<>"9N0 0IW(.@E075O4@0W:^<(*&=%O:;M;?Z[&70<);/ +R;EG2
ME3N2"O])8&]>D.E"-U[8QFHSTCCYP[O-A4^!\1,=*2X7Z?9Z_K;%!W=Q#VH-
MMS5#$<=A)D;1.E!R3:0[8E-+1F9_K4[Q+.:7!OL\0UI##/]X)>\$3Q_]%X\Z
M<;$PDR)VM2>:&Y(?;X!>='6TTH/OS>$831]A+(H[5ONP@.3.&S"?<YPS\Y=_
M31B+)(58NKCM/W[[_QY7NAFA-(2V%ZO]+S_!?XTKX<[!=/C$L_U_(  ]JO*%
M?'0NJ-DF^D]BWC83BGT18]?KD?Z-VO_0?/N[X^#T_X"3[<@;4*&&:8V;@UD[
MH[P@+W<J80B]%Z9 X>G3L:4\^?F3GM3MBV]_]+_JPNCNY$LW;P ^?^S)GS6(
ME!4'Q+>C;>>?S2\E&XY>.1@Q(7#B!#KT+W*&B-<J[F?J,*MST5JK/VI,RK(1
M=SK( <3"?\.1_@4G$\<06_I=C!SX$A6('_!XPF"5WQR?&(KXU5G0SS,]03OS
M_7\&<UB%G&?FB*1SFG&\;32UBE]!)/3YQ/H&=(+*1GG$N^49E+R&]Z/_#CSY
M-RF+(D?,>%E(*:38+8_HC7&9])C!UG^@B/]6E9?M]^%OWNS_"I04!H3_E_&6
M6C20S'\KE_Q;5)%YYCL& RERS$>:3,BPOXP.+R]L%2?%[$L8!\/Q (3P=IPY
MU+@/BY:"4-")+3G2I,9JZ;0?6R#-0>,39.<34LK% 544S>?R+3,KQY8)5&70
MI/,;$.[J&DG9$,)PTE= ?SNRS;@;_26:/-J%_U$]0T-']Z"Y<)9A7DZV<FDF
MC5?@N[>JY,HSB]X<C"'ME.7'9H^2%F(JGHU#57F5&BT^^@R1>Q*%IBDO]!R-
M55KM[V6*4B'%[\?6>KB?Z;,J/IX7]"GY>MKF@VZKP#ICW=PVF10]].EA(COP
M FPQWJ"B"Y)(]C< I56M GETY[FDC9$Q 6<QU<90"J%IB^)JB6-;-:)HJ#AL
MH$(^EYK8G"\G/[O)%]D-W-/KRFQ:J;.HWY]NI+5"BJ3"O9R+@6LV<9$.*J"@
MH8@!#N5,4RSW:\^JKFRC*G;G^-V+1QQD&7-WYU9P+_"9(#I/XN,4&J]+_N0<
MSO#7X\1@L'85]F.8-.$%U&5<H:X^<8X%WK6E?JC^>=3()OP-(XYN7<JE(LQL
M"D,</3?N:@5^I8H?!.Q4K2 V5W#IC;VW;_D29Q6%CP[V[[A/L5!WE5,PJWL%
M1#41NXVJ/"]&*8\>K[#S"GA![D)5BEYSK^J@N[8.E16:[+ S0:F_?MOZR_:>
M34!8:X$<4KNO!"Z)]HOQNRH/_CKBN]_,<JE"BPE: GP6K<9WH1&X'!2&,^=]
M-V/? ,S\LH'GIC^[*3/EO*1-_G7SM1L,6MSV8Z<>,:-T@"544=GA^_B3.G37
M8E%B].4%Y:FW.2F^7" X&>:Q-<Z2)5BC_1S*16JP3V?2BP=4<+\Y0U$SLK,P
M9)=N.EDW$C@^_,Z-^IN>0N$H8WO>GABY))V.B:X\0H:27OCYZNWA7:_G:3EE
M6O]/80L""I]KI1.>6C-3@X12?ETIF0-M[]/)PQDE<?(!])_,6F8IZ067'$3S
M*R1: [/.:6QB]=J1RK<$&LGU9#&7)_N9#@,+",#RE<K,JT0TAX#"-@A5>JYV
MQ6%E;YK9L#F2P"AAD&;%KM-/Y#&L31BG=>9&*#9G5$'E 3]''-#[WZ,L(]73
M'\%SNW-@"Q<YI^,8IBG72MU>8R046 ]@[K^Z84)X_CV<_R^D8G9%F+._VLW_
M=BF<_'^/T*[=,'V*W2V5W6J^('Q%:ZP^ .-WR":,?<.H-2(]O=O1T2C%:*![
M*?4 H%[<5OSR(;W/T+ZH6&B5ANE8N*:7W6F8ZBFG3%<9LG\#O% -.K=WR]W2
M>S9M*@HUM-RB13+4IH]_4=%CPQ,-O5ZQ[J6OP!(%6Q*9WX_TMW^<:*5E2C;9
M>&"8/^&LO[BLI,%#6J#.7WT'J^\!/&H:/[P[_A;EHS+WXV_>#^GF_ :>6]^O
MF5'OEY1GZ^!"N1IH3HCJ&OBOXE#X+N;]X_6BUSMP0+2;/,\$F]L1H(\#NTNZ
M^9 K T<#>/WRDCJ$?N* 1TJE3<)A!6AB]I\GE":[*>CB+'A)M&6N/Q<Y*+<?
M/O<R@^X!BL"^\88(!G"Z5C6W92R'UM,9_EP5JN083.-!Z-Q'O70"+6KD"IN@
M_=7WX]>&?&_O0LA9+ V]I??1M>+I;DQ\SL\MTT$S,#E*[.*Y8YV$)E7SQ(V9
M\/N%6FY&B8;N2L9?9;*^PD,50=9<"[B,]'(ZZ%GLI"^:NB5)Z,#2V<D\F?%/
MO"M3GI-GE[TZL*9^#; \49Q[ [9A"GWG:SL>X;-L F]IW+0DHF5T!249&7]J
M= EHL6;%O %KU"2J'$SY/O-%"P<YIS9/7[9> LG-A=3_9%^=<L)"$\S7(V.Q
M.MWU-;YMD9,9XPY_FH/D<C+J.$Z+[7RF=LC^W,>D8SJ2E]?.Z29/UVX<U.9X
M*I!,QQ6J9B27<92U/_LNQ/HK^T0WO#YRK(S0B;V7)8?YI/Q[(!.JJ%RVNSYV
M[5Y^=TP/P]2$PF68=O .;U0K[E).7;IZ>GMS=U<%9H*DFURH[1F%Y0V PCQD
MLNA0$@%_<-,>C5><.<T?3-KOL?OR!@ F?.KGBCE7Y?E5Q^_XQ4L@IJU('A'5
MVCZMK Q'?=>B*1?KUTH<S5L-,FXH*UA<T_MI<SH11)/-:2+<:R#[$4K FW<F
MP?E:/4GWOMD;2F4> UG[)"S#)&K\Y-/O<J]DHJK:0NCC[6VG4S=.G$VJ'$Y-
MJ]+8<O:9EJJ@_/'47793-2^_7[);((B6 %3N3%39[%8QC8O@@C(Q\H.[=ND4
M DIWK#QQ@M,4*H1?[6*7ZS$.$L("R!;[JTQM#;,$GZ.T-529F%:ES\J)OI4Z
MPMU*2(^=.GZ+X5Z?@"U7TOOD0W[X6)8CF&9O8/-AAD'E1 '1RLW,%-?$=#CZ
M1[D(Z;6*RK+;[9TL;ZH=HN'<Y2$.PUT#R@A=UX>*>&P%I*5&PJ M8-=/0"ML
MW6F-P))KE:JA.F5JCH_G;+=*$=%]<+*3:L1E7R;V_DG=6Q@&4TD87D>_CW[:
M[/Q)Z1.W9UM2>-2K49#MLZNS2^*./MY9AVN6A7_'G +E=+3YO/F+\0N]%MI>
M">Z=>7_K ZV,=SQ_2\2ZT<&)N-E2,HE^DV&NQ(<O8H<B0R]RYH_SLU,I*=:N
MH%-!^5)"_ [CUTN"[-TYM:"07[BK@2XF#R&',*X_?F2 !:EGSWZ=Z81;9(\_
MGYNCY0M4ZU^,ND?@G(,/P8&N;)+X?$6ZHVM00O*S"V!+YC(W;;F&VJE%YNL9
MT*=9F/-PFE*[%M'ZF_Y57&_ZW:L!A-J$\J0R[]^W=E]VX(8Q)ODXKB0E\VS?
M@,#QGG0)G\G;AH,W@+^UX(KM),*'.^^^JV)%NKAK8]"&F$^H)O0TB2V:O0:M
M<. IDY;[+#8EI-NCQ4UKY_2&",%SJ0AG).X5L8N_.'D,^T,AY%X<3OR9CEDX
MQSW'&B8(OZ\VZ&2Q6[Q))JTJD_#;X#9+UTT%8K)*SV6WNH^>V9S=*7&BCHZJ
M+'<?YY.Y:7$QS1?%8E[@(PS&!ZD\8W%G 3&D,.O68&VW/"O(0WBH>G%)3SMK
M:XID8</&]1?0F-(/CN:,(MZ$MF\9BW6W!S8#%5YD%X2[1&(2,\SA7>:Q(U97
M[3+D&*6_HK^*;@EP&4VU&6CJBM&_4^8FW<9_4) /GO)%T_ NABL(4[P(BA5#
M2EPN@'U9FVM3Z'1ESK[/)J);##MH#E1&MXY3PU-\M_SM7D0G !;O3W8LAI82
M0=GTH.<J@^O5[919FI9R8EKN<8*II%N0BJDD#ABYY60@6+YF&/W)@T4XUO]D
MAX.&/2_[OM?XCZQ[QU/=M_-4K/&THA'"RZC0ZK^HNU<X]S33*2XPQ^I;'*UQ
MQ=CQ\(1'K[>-'6"H*HRF1JJ<SB]2TEYV"E;=RRO> )+H-T#W:,('^P]JM^\Q
MKN^U>4F<%ZGT[RD=4 W[3L.G(9OB8F\-LXS?ZF(;T0A:;IS@S=O#-V#,'INR
MZ2?<%,T/:L"%2)IB2JF&CPUI+.I#1!;T*?@9?4%)L8?!L3NN]_"B.5A=):;S
M$DXPD4-I/?&T??]Q'J)PE*B@CYNR/0FW=84H9\JDB3O2AK_;&.HENX7W:\Q'
M^@FF+]41D.XGF@U@W?(B2^LZ1#B;DZ&A,+=OY=YVDEK 59I*G\?:K5H-E/17
MII,ZD"R\;>TM"VV4<-XOSR2PQ,FO*)?='TKQO5H*03=3\U-: WN:+]_? '/$
MII,1F1(J'3^7V  HL_L6]2SM_13O_/1'[_H?(.3X .(5QAF)Q:/$?M0M)6TW
M1^F:VKBY><G:X%4)E M)FRQ=_T$*HSA4!1E@P_G7BTJWJQY=;=5,A<W<FF38
M(W9;_)BYL0414;_D9^0E#V.G$M91JO"R);!%RLUI'LQNK+.C'77SU6\3K,^.
M1:_(O;'^7<?<Y=>+GVSTUL%9Z5+/!3$#5ZS&:;EW>-31'B4FF18IAI^3\.7*
MBD=[LQ&=_QQ+W(11"I@0>V"3\AQ[YF\8^AA'#!PCL'%OP OYV4DHA6ZJSUDY
MO X&WUY*5;;E8[S.O<.8G.BFLZZM8G5LVN5T'\90)<_KAX\\MZ,>"!83$M9A
MFOWYLS(BWSLO$R+0VK\!*+1%>>#^_0,#A%H']D(U4H06,T<4;FIJZG9SJ)#S
MW]6'Z<1R#K;OQ]_5N!,-_S1M)O[$BKS.'.=&K >QE<[JF#)Y+O?[^]VCZI&^
MKR68@=F)NNWIBVTKH33!+7)M7"Z2?9\35 ]8>57!C3U<J$Z'5CK_B?4LAAC.
M*,IQ;2YO^MJ3D>I=B/QT9DWH+T<*M$#HQU04<\A1S#/&-Z!Q+9%8^PVP[Z #
MK/\'#6XD$8Q>(D(#B"=LDHVRLFF&8]P8NQ)=4IRTW@7SV^11'OYZ+SL==P27
MY0H#Q!#?^K%C9&IDC4HTT^9<)Z&:V>9A"6/3O44.A EO3F[]SVU[T ZT=$BL
MY\HO=D3?F33'7+1=#.I<D_B=@D*GKN4\YK>H@T[KCOHS=-K7W)W1^+4'@B$$
M&F'].P_4C]L)O>0K+SX]+C1/57#@2<S.,*4.3D8E*ZKO<&\58(T?@*'<?NA>
M,-5MV;Z73P*S(5I4,)ZW@R E>K<*" &>4<";V8R?%?M3"K7!K&H7^65)W17)
M-Q_L9;?FTR/MJ=S6\]>XS$A>3<+:R\;][0C[]%QOV#)OG.S%58M'CKSR+*_Y
M>7L);.TDQ7R)F\Y,9'R:;#^$2Z=[]2+&2K\U,%S*L$D260MH95,U6#X-<G2\
M.0K9H\]1D'V^W(LO9TE7JQ9N6E_$:DKNO5153CVBM3(\J<LHX$C>R1N4W\"9
M>^=RUCT$'?$&'*9J?Q?%7/SQ>7O+#5?(E7\.\AY'\XGA>-IB\U:VMBFHQ^<4
M&QUNX6>O""$AR0_SDS$)4&;=17OQ$>T<PZ:_BH*L/_H'Y-\V%!&"QN3F)JI?
M"V+3;Z %^6M;HTBJ%L:F% SO[.'3R)$;7 =9?0P1"$_&6)$!XU4W'+5&G G*
MT>\!XC/\/RA[DIK!$AL1 -P ]-RR#Y3%LXBUN_4V902\)3;N]F5D4V@X1D:+
M53!%'!25@V/J+*("X>#DPK(>6";:O:"+7TTQR/IRA*EWB>H4XEH EF(O;$(?
M]]##I^SVR]2J:;QB0ZTYA;$8;#*Z ]0[LO&1U',80'_V^;UGH5N[G)Q)+<B]
MG&'OR@1Y;^D[BA;W??_\V>#3:%?9&NP^\T8'BEC^(./S3)RZ$>2&_ %>B,$S
M!6IWR7XZ6^V\,^5TV4DY>9/&KF>0=\?^+H]76<6WV>^&+ NFS::Z(Q&QIR@T
M$" A7>[SUVS?@SG]%^C9&CBA_I>GQUE&-^OSW;PAH?WJ/_=OIVGM+(%DL5Z$
M:3==JQR2 QQ1;L8'<@Q"M$4BSO6&YW?E!_%]7"&9<33/M6C6EW_VRI>O%>LB
M)$'J#>^N],3>  :G>\AH]U2D5^GHI].?(<=<X+S8SB@W\"E)KZ'(&^!MT+'N
M[,UX15TVR(_1PAZJ/J7Z!DRRS'B !MX ^+SG%K@P9Y;.OD96JDE.6*OG#-W@
M[$E;E+2-I<595YDRM$BAUA,D$<E-J9)Y#T^+5>)Z<T?*_E3Q?DE-N/'D/^B0
M;T!H\8_>YR%MY@\KT<\1'@U/,;Y498X:*59%G!U%(P3O)(-7$D-$X:SPY^,$
MMM-.65DN4]5L'>9Z$Y'[6KD4:[G0<B>%D.)H3(04+5;5>59?'"-F$BD)2[7V
M IFMR[U"KY]^?H4SCJ+Y% @L89X <1#K:!_IE9\^5S_Q)5;5CQ1&_IG!#E8(
MOX(H27GZD>LUB/OT)?D4(8H![EK.SC9PZAN06YKYZ8L)CKGU(G^JA^K1&_#.
M+7W]T)"E?E.C0O6T?<%WVFL12ICS#8!-RB%>V.)AAYCW#H-1%!R" ^C\=Y
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M9HGONHD$Q4ED(N3U("VLMDAQ/KU^C@-/<VZ]>7Y3DP!Z74R&*OXK#6E'UI*
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M,BBB*G,%&7V-FO^A3*%86E(GQM+)L)IZ.ZKHZ?@NXU8:CIFPF]J8PCCTHY2
M>X4M3Q2>3&IAGN>1[9'C_KWZ^ZA;C12WI =W;>F[RP[1WE?3A/5!-J9?SG6=
M I]MZSJ$00L^A.)F14=R)4-%%N..F(Q899%M4R,4,KTX[BS/DL!7NW?NNZVG
M=UW5 L>38!UQE#3ZN'T19EPA-V:C='<!MM5FOC3>L6/J7Y"G"C<.S",?2%0-
M!H7$]!CH50J80/KJMO2I3?5&8EATJF2NE)AYAQULJ[2@P'OO\M75 =_<0W5&
M9P'_R,U&@ZLAQ&\-KB60I6QK43<KZD5XM.+2SMSQ<KJ(XIBJ$1?,X7.3RVZ5
M\#YC+=?2&._2^TX197>]2M#UF\B.E[>F8L]NPNE73 ]4%*?)FWY(R4DX18QP
MY+Y;> C$**#@Q*Q'896G7RK,1,7%?VUXR3!L>!RKL-Y89#Z-=?YY8N](05?\
M=>6IQN^WC@V8RYJ(31.\6[4)6D,> %7H6=8;;HFF96I["MH6,!UB***=_-:&
MU_]!$#K8Y]F'"?%CHXY^PYM2)O'#,)K(R27"3'88( IQ")&[T+%"DL@;!MCT
MO>X_%_X?J\W^J97LGL'?$SE7A#;OA=P\-:F-*+1XGAV?P^&(_T+8?K2F/PON
M/-.7GG6N]V=*WS"(-(L5;?47-H7BAKXA-7YU O8-PE8I@G&GN&-%LS_X8:+X
M04Q\F5'Z^_8-HSSC-"*@1"H[Z#4)?;$LP85>_XE';6MB%DP#A:-RWA];LD+P
M:TDB;CW7G$)3%Q=NN1GM2P1:;VJ4>^G&N@#VNSK.N5S*S ]PZ6;&GT^A3R@"
M%DSQ^*_FFIMIH"*B-TZ_5^;5@%F"R#3>.YUJHNM[!/$,@I<#4"2G:CLV4"=9
MOEF0&;&K/ 1ORKT:@^I(7([WH*.]4N?%Q(&OYJ\$]9,W9;9?))#M2^3CI ,1
MT.A@$,^6XY?K;"?% :SD"HJX??P(>XFIP;DIF$@>!I=4B%.03.'R8:76L%$,
MC\$^[/VT%E_HL2,^=@.?5KA;9C#]@6Y>QLF5N]PNRQ"DH(9_)Q$W9.E1BLE&
M0[1B^PR^B-5B'+WQY8]A&PJ\(9O4FU?\R<:9ZY'&YY9P6QZA%@K+GAN.7Q1:
M"DE#%HPGQ8VDN:PF< (^$I2^,I/2>D=B?!8&\UKL*J!*[8.[]]H,+&6_6P@\
M;  *?7IC,P3?LUAUICID26G=^2D-G9YIUU^WKD+GV)0*N_0?AL>FYAV&BBU5
M;!!PR32JL40+*>U68"LJRBS LEF:#<G(WS4]'B+\_[Q8.T.I;[+:'P.>PO00
MW:DRE.UM[8F*?V[66\3;W,^[L!SY"0]>8RV$#>.?)),:RGN'W,^E5)H@\1*#
M>/A:?A!AA2B)8X8A_)76_G?;;G5AD(B'Z1LKL\C7!<M3UZ0?=(JN_UGIG<3$
ML!B>/8$2A3[>VA22X#-G."R]#4P*A!=\R:_?4>MWL887S;'G&A@]70849_5?
MK&\&D;8?F8WUQ740@'6./[G*#V83J@Q;"ZS4> FE&P@V:0RH+I;G'.II[CX[
M%V#<#$&:3<[:FB)[C-,J5T9CN_"&PC@CSYNTMSK1-EE!T1UK3X__/#C#(D\'
MU&R,:&%OH[H71O9]5[23A7[BXYB# $]I%9U*WA R\6N[9$&\>EYP?W^9\RA1
M$IASKMT,XG,*W)YB>5/7<.5ZT0UL5<$LD>C)"1A3&6=T^%2HV[ZK B$E(3?!
M54BA?R9+)K! 4T_ J:E]E;S.%E97S-.;0#_7X9-J]"B9RF7\J01=?!_EI>&E
M)&<?6*H,ZP)3Y&>E'DL'WJ$W_4KM"JK\5&W"U$D9V1-=_IR:\*IM":?/A8 \
MJ*\.Y&E-WI=2'PK*H *+4-#/2$05+[$=:_B?A-UQ^]3CUW_X4H#LJKYT*O1^
M=%\^D4LYO-:VP?AV?C#3J04)J%=$<NH&)+>^<!!039>"/<U,_7'Y.O>X(?PI
M%92N.6KA":,2-8?UQ-TM(99SC* .1V*?CXZJ-&2P#$9H2JYO^!F(^=Z+>DW\
MDC4K/]B??AIK9Y394HPUG+I>K+!!DF8H+B^,"<:#2&L<XT/QG,%I/I^V+D<^
M29B;5SLA^65-B[=PC,E;.6BR5W@]@%5P7K])'_TN,M<[SX;DA+Q]*S+WR7HI
M.D_Y/MX$NZQPWT.+Y#IT^W)G:>;3I42.8-]%=%;%^$N$=T&-^6/15XM2WB)O
M^5]=#4)&%R_-OC W"94DKA(H'5D>-\7G<E0/)VL]'J7)FHRGZ^]]:SKN6'WW
MS2XK/,N/J<\?]&5STL/OK!?H@HN*17+!!,D]F(.X(G'2)?>;C1G$+5"&.:?/
M)R<9/YY!U72G WK$<26J(L>6/9LGK-+#MDYZG$UZJ/6\8=6KU),3E: 9&'F4
M/RDZPA6,?=K"& __38$,FER;"IT48[Q_A%.9=XH [<[U]&3-U*\^#[HB(X]6
M-);:O0=5:2_G',D&T#@9-:Y&-(G.?(:><&?%3PK%YT#;MF,Z9O)8H3-(%'B;
MQM>FFX+C;)DNY</% [%^?/<$"0S=WBU<XF2BH^Q#^G[&9%7K+DK1'7_<(:MS
MEE>/^1KF%:PTJ<)C^\W"_GB=G,+\&IBCYX-V0X_HWVIFM)18)#_3<ZXPW4,/
MA5B$,924'O[Z(OEW&\3_H%-ZCQ2/ 2"2-A#&4)ZG%XIB[W&S9M"TI=(YU=A1
MFI[F*,H]JO=HYNW6X_O>,;<TS#E$,N/A>5WLM)T(II3F,@8I:8++RZQSEA##
M8\F4ET1[@Q8R,F]+JF1J/L61#7,C%<S@QZ[H]28DJ/E4%%$EYH^Z#!K3"&IT
M 8,K"69S?M:4+N9*BEJZXNX66+\E68:S$EY K-,Z7+PK.]^TFBD0,[@K>09T
MHE;<;C+E9178+,.Z)H^9<F9L;F#;+$Y.Y8W$R+[RK*^?-Q)^54L;RS$Q[K*Q
MR8[\:4S_$?H%5HLH9LMUHD'2<I-?UJC(K9GZF_C,1H.VJ<I5@)KR2&H<#X'#
M1P''E".G)Q43 UO+*3PDI>+:D)(8'J-3!7;D,D0G)7$ \[\85K?;W.SI5G,4
MS>+NY:]AA 6^VZ^.&1ZGQ=0- 6)-&Y&_9A/P[5U<,1,GM\#Y\=X?-%Z"X7%&
M@B(RI6M/APFAT@F"N[:1GF8:YG"FY0I;7:824S9GMP@ZA\NY[K8ZB([FV@>L
MWP#!"]\UR.BJ)=_Q5OV[SC*!$O*82UJG49$XU&79'<2A7'0;)*/ +(0"!HB]
M5+.(IR]3%H\AMPT9&$*+QHW?1Q [5A!R4%H?=Z3.NBI4M4'JT.%NS;'#* .8
M9_^&S %7;O./RTVGK&FT)70>H+N]CO55L]2^VQ)LKSM$]RU6N!-G.W99NSK#
M>3FG^_J118G6$0MW08LF.S?SS\T#^&\&%7TQXGZYSVO#RL2!E2+RVDLWY;LO
M(L3[NV$.8Z^W.3BJZ$ISJ8=MJ*4HIF$D^BO$L^5<#?62(%D?VI"ND!SC,;$[
MR\/)]U?GH7LE_C7\^V_*%&] @40UE6]CO"S":^S>12;*7-.62SIUU85@A"'<
MW#AEZ$--A]/7$D\'7YE]4/CYC)S1UAF:E+$1<1Y[1+$'K%\F]S,E22*4_-A>
MDM;0KE;O7I%2AM%JC7,6 2Y_)P$>N&UAQXWX?M3)%?QIXDB0NB%8(UN.1LZU
M+B9MWUBW^*,$=XS'=87XO?/&"($NRK1V"LP/Y58%=EG2H5!X/E6AEGY628J4
M"[J*$EFP+*B%Q#9JC-;PHTP$1V*.SXC9%4\96[\>3^T4QAP)RK+^ +Y5V"-(
MTQ4&*G+DV=CC(OVF;RFWH)?+E:MF>'Z>+\6X48RP"=JK3YXE-1551%]JNT%,
M4^LNQ.D-P%@DT+Z'XB9I3G.+PSX>7I&\%-@?N?)PTRJV25E3:WAMSB"+[N;_
M;)Q0YI.&OGD3;7R<3MX>S2\;X?V%^=IRTK]\*QC"'<1N M8(+,VDB$8'W^]5
MW198M..WS8R5E"Q2Q(];N.(S-E<2&^*^>D'UGRI&YWGO4N,IQ*69,+LF^]"_
MPE\V?B9</E2*NVO2;5.9OF2^=Q2;XZ QXY6;;<^@S#V#:'XO5=T<WTJKBDO'
M99\R3TPR?^V>V90RQBB)4W^'PZ4VW?H#J6JPU*%BQ X%,J.[[AD^]Q ;[9"+
M:^X,=-N$-@#]<Q6R'/$C$?RX@HBN[U0['XX:/;J@+/>:0OO>O$%EF)M;<5&1
MIKY>>P@]3A SOQC[48ZLF:"_M\L5XB29>H-:O&>_(3G9;#7L9_M4]5IUF U:
MF(R(.L^/D .>(*Q#_WY=Z2BQ&_*1\MOF(IK+*W';HB%>F=1ET:9H[/T&C\IZ
MD'"$(0J>9OT>]Y]S_V"_;+JF\>!+(FW1@)/[YU62V1,-V.K8A(A=_H\D.BH&
MP::(!'T?(.U4<RAB7[&*C"[H9,?Q!?VL&%U>FCT_3J[:I'EE*OR\L,85BVHI
M]B0)Q?^,CYWF7/3[#@<'._]4K;(Z.8Y&#.M*TTZ&&G?HFL-G,JV")34Q#R/R
M)F<E4*,WE#?ZQPYY[$WI5KY^H.DE$Y&JJ)3HMA%_#/ &\)0W'VU2AUASP-;$
M;;JPM-)33"ZU].#^A")@][-&6 J&YR"_OQ.+T!\<=6(L-463<[Q5OQ1["&"%
MVH(%H:$6Z"6\E'QBL(JKB_)9ZVE 3VC$GF[$_<KYXN'C?$!J(&YF\=B77N3H
M"U-24Q?X!IBEU<=DRV5]AVV'0II+_)2[TS2N5E,"BM'UGKPI]U2]8$K+6>LQ
MLFN(6Y%[_SE6"]QZ4HF6]UW1CE6X/'CO-+K,O2',1GE^4^+GV29<[4<GBQ"P
ML<:@[QKUT-.8P(M;$2M?BV;02JXZ>FYQ7*&))CG-ED!8NL@M^U#Y'.((2"W*
MX0XFH/J3)H[YT&I/T.VX2I]=RLU<M.L6,@*1D1:L=./4KM&'E9\&S78' ;\#
MD9S)8]@>5!50UG2'N+XUZ.K*6M[Q9FOSU; IV(2M2EN]O $)2&85F! '2]IX
M8/NC,(085I&!,K<]?^-P]=GK7[.-(4\RJW/NU%?.5'':!X,/"HD9/VQY8//M
M!_%*?.">='>SLO3K:_('"J5.7K+>6V*TS0[1+6VYX5HKEPT.K"P-8$(<$6@@
MK6\=2$Q'K&_-M?Z0:.!LI@[BF&EMLQ;=T\&N'J*<KJYE9B@T LNO- )1;.D6
M];:%^B!7'+;#1Y.D&I3JH=?X0IF:4A 3-M8W AEV-ZAY%\<4X 9VYD0-\<#(
M)>.8HJS7CBQV,B!XJ=9!&QH-MK"$A2L-029L0U<,&!8!(B[Y2"PO-RSR#GS/
MJP7'21MF/[ROI;W]<04ML4)@I[S"9;8[0%S'CH,O-]?AU$X[2U'_Q)$8?E!\
M%PV )P,NJ::XFN*_S9S# !XN*&S?HK5DKEYX-\'CFVP4/SY:UASBL'VW(6TS
MXOBI2M'#P -&=XDAF,?#XZD0SH3,;*_&CXRXE2,+-1,-ZH0N/)6P]"@KE*;0
M<A[Y!!\_0O?SAA]U3T[O$?[8P*+>I=FZ+%>-Q5V1L6UTCC>5&(>ZB#]EI*.F
MM49;=I214T]3LX^5QRH$EBS;5I74V,/Q1!=IOVK94D9P)S^A"K4(2>$@+.Q2
MBO%K"ZBIER6-B93H%ZY!"^[=J"T>W_(8&)MB_EI7H1NQ3#<3)->20H7G'&-?
MB7IF%NV1X[N%4SEM_ :(Q5$OA"+WT+#DL'2BCH]$%300@;Y7US0V-]==8&)S
MO0&+M"Z7B%8;NGY@:O%]MW%"3S/(%B+\OKJ1)U!H&56T?"W2P GZ"0X&%H!<
M$(?#/'0H-2#C4 #'=_U:2ZAMPG'A4V9 T?H&F&MV"\?M9(X1F%O_BO>3VJ/X
MB@'C>GL%/N2,'4>DF)#BHD<1*6V35:B:?J;UMK8&(6$/0<5BF@TKVBDH3>RU
M*9\''7.^H@7LGIIO1;2&C,;#Z>_Q5QZOYLQ5)^:6QYK/:.96S^34)>=<ED-'
M$\^",<M1>!]))E(J2O06I:')F,3PS*3\([8%Y:4H[/T@J!?4F++*+)IO*^OK
M[^Q'L7[\H'-7")BN(ON2\=F9J(=$9J*C-F 5MF6)L$&*2V;;^X9(G2B8]\^Y
M,,K36!]I!'ULM;RJ95'_W?AK;!PVASB#1KJ_\'9&GOO+0)A!RAN@C*/E-<ZO
MC#M+&1%0$B<A<A#;<%DVBKV+.([QDKZX>%*:Q0K(B[:L P*".JF>3W.[)1ME
M.#K&WK)R#4U.^Y>25T;3 O8G:IMY6$[PEU*[/@0Z.FM=Q6OCY%)QR]#J#+C8
M(M\">+?\% H%$U>_8,]-:&KGM=6R]$ ;64KB!ZD2^R%4??F4MM(=1I,I(HZI
M"/%O^[SZ2]:&0%(EG?9FO<K-J)=^XZ@-S>)'CL),3N,,$V:.B6G$,+3&34RX
M"U0[,N YR[(M-3#6:3;7VCV\U8_=/$Q/"5[4%L,-6Q#M,_NNC53(QUF:;N-N
M!HT>F8O?I:O?K[(PSA>I#^]*T&=E8,MIS.(U^9"NL11RJFXC@M?_!_"S0\^=
MVN?M^*&;QYF;S8;F'^%;H 7KK9G>"U_SZN:N!')@"<;*X/L>X(T,REW]&*)7
M61/U>BK[)6HE:5-#-O1G$ULHI(1P)RE2 L)'"7ESJ)E#W'*RGXUAYMLL]0-P
MZR>V8E$AX$9=RZT^J'Y&K(*EN64Y<T9L7)&&.&RCVWCZ]0V_,1[8H'X'D.S&
M7")3[ 9%V :3LCM3.85S(ZZ/B=?[SL./[C>9*,UA__[GXG\:"H'VI)<(['=;
M#B+LU;$##K@<R:=/NVRV'R"A[%"VN\;>H4BVF6I8T&??9SGEQ0S=6B-,<<9$
MV-KR6H_>QRELZ27K<&:] 91T5Z]=G&N/O); P!2_B&?AH86M?8$83.V0P^T5
M99>+ 5(WU7*+Q')\>GYU'4^&]&0=";IP.&-_6L5@ !4W1NX(H573R:R\[V()
M,<D;$/V"\]IHN?:H0U<1*K2==I_I.],I=$UC:7R"/6HN(E]*>FO-W)9K?ZZG
M VKP86M+I]E(?Y)&+Y5QP+FK^H!T)\!SPW&(TQPSP=S*EB4<&^NRNWQZ6#6
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M3JUU02_T.QQBW]6AJ:8A<R_@ /:E2<%E>7@R?/)?(5?)4HK,W*-;HJN$=8^
MC!.$5-2U%(OH=A,HIBSS./>XG/8."7GNX6#_]L'N$1 @(?G;EU-!7IM4/^'7
MII>3+(28KMR$H;^'4%D23PPW.#L_3_@5P*>^#-0[5/((F#E8OB4J^"2SJS0C
MNO%U"K1_:?^ .>DX$S>5F0T:*+IE[<-/TFBIJH^6<-K+;MGE)X\I%S]^!$01
M=[>_%!S 3:0R;'V'9Z?H>>!UI_EK =0SV:HS7_L(T,@\C-K4:7<*<[-(#^T8
M!Z/1]V3O7V90CUZ\9G>:/O2<YX _2./E 8EE.J,KY8)S*>U03\M)0Z%,Y79
M/>&FTT]+19V::NS8Q6L: Y27I%$2L;PJ$O0O7$M&EBI+[[7]2G V3>N5+F<R
M!S6J!;H3/!$U_,"%"XI#PY.R7YIA"V<E*WL=@QLLHNNG^XC&UC/PK=*]1^N#
M&VCWRXAMY=+B+VIMU(SK[1?AM^H0EB6SWS$I/ #%=;YUJ+U"(65LCI6US -#
MXU3R,Z(7)F!AMT^;,4C3=OE7'QX!H%OB<:^AR98-PZ,G<ZF3RY)/!UK?8KUJ
MS08/J1D_]<NOUB5$4#DW\#(YON;3UP9RY$= ;Q?Y7<1]A'/WOZ8D[5?E1]5
M(>2J$T]Z]3C*]F]'@X=?1WBZ6N1JO=.=@V#6[KX=0.\ ,MR09]V#J\K>K=D
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M*\R8;']]G8EHJ#V#0 @00LM/O\XA#63 N,1"Y<O4EQ5AJ=0JH%#6I,Q\"98
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M-2C6+26 .370MOXRS)$[LC!/*CAS2:<AYL"I!Z5.UN6(=+^%H3I65L.X4*Y
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ME%I#MU$S%@L@E<$]"!Q2;M15B1[_2MZ9^1=F[CQ1SZZ%5GF2XOF-A2>N^$3
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ML]61U1B<V@+>A[GPY1V-UCD9+C<W06XC*YL#6MAL".O")1^B[!H'7N7_"'?
M7O_BX76(=&+?;5X086KC35&FA6SR>ANU56>-.RIH26"J;"6#E/=S17QLK+0]
MQ\^/)10:/7JQAD*NAODB2L$MS'4M-3PPA29=<6V?2^5WA+E:IV@C6-IICL,+
M&=:^CP#63MBLP>E=TDU&P(G UF(+\7XQWJ"*S/2J^IL 6I;F$O(WNI:W2>U'
MU[_"O+];%3"=2)EWH*NPL$<Z9X@2;Y4+H:\1VD* >>.V9MK U8D!;;ROD9(N
MS&X'ZDK#V6W=,NME"O*%UZJ=M\L_<#A7C[!W1[A;8\D\%NUF1%E3_ P3_KQ8
M;_$*+1HNI<I'_=K\<=9BZJ$7?B[XBES^V&B""_R3Z<=E9Q#.9J*THE:LDR(H
MP>D1@.VB[:+@=;IUIE[Y)N<7&5\9DIUI$-%V.):OY^T4/X+L.M%;LO8.*]2_
M!VOZ(Z_4L9.LX#-[OG7A>*^I(=XV+WA!OJ<3@G24MG:2I#?QBL-LED<& ^TC
M$8^_ _L9\<0^'H3JX*:V99/>>)T =ZE%YL)?'/ -31BM4,V1I3>&#0P5:P]_
M=GY9S( E]B]G0#QCY-2IJ6NH5(=J+:FET..9.67!'3K-D")1\ZW&9,'@5[(%
M*7Q#JAU>D27=>Z[^,N/%/&!V-&7E>/-+DAJMS,:)**_!3+'F5)4[3#?C6<:M
M6[$;P/RO=GO*A 5I)]^&E',]LW&OM?R)SSN1+%:Z2I01<>V<CP#;Y!7+U6 C
MK722XN]OXF%%J)2T[DM(<3&:38)9>E8ZKI,X>$&R\726^1Q&@=TGT74BLP<<
M"BZS6:/9N(>?*[BIR33.)X[YP$KHPV\T;&P($T2&,;KEF?*I%L9YU'PZS=R%
MTE+&05@OTU4NU[;6[*L&56W9>S_6J0."26_(FD*IIUR1W!U)F*UCNN@C)-H'
M/9#2@LA:$G+S#)2\S<S3I+>8RHGHT%!MWJ3A^ I;JX;Y%&5"%%46-C7;O5+V
M\*MXY[2-';HZ W7M#!FOG)P;[_YX6Z3(-)'[U7PD9QE!&V>2TWI+7"W)V42Q
MX/R]=U@@UJ9YB(C;8)BFG$C]DA_W>!$VY/@+PG$*3DT?VNH5FO0M90^G>X&E
M9)<VY2LH5@>=K+X3?RYMCT/$\MGRDYWR;-?W@#/S$,H:5*A;?99K8>_/V\&#
M"5))7'7"OYWV]5^DI@H6PF$@$:3'\,6B0^)1>KWK.&QLDZ%>4_6"6OR<EK!P
MR2:1V&<?K[.4-&[PW9?:@?T_EV5VPE*"K-@ON2V-&WY4#@"%J)LZ,E +A9PU
M3%M")_0KZEK,:Q<+BHRK_0EK/[N5%4K25NV?5?2#>:=<;O06$7._$2-W#G6J
M* Z$2&FWIF6^Q=->T/2=I+ZD!\UE395\O_HRX\"FFJ2D6*8!*^:U)H[.NM/>
MD2/VW9$;KIV-^F9]N6FBV&O?U ^;'S Z-_P.,FZ(\G:Z1VX/R&":O"LSY_/@
MP&^,X8TXN/$4[.<OPC7RG1,;RI*96U*MHSW/GI=0H@]28>+S[X;N[#/$;'IS
M[P'1G9F/=I@UZ^LBQV'R8<%:JR'RC15_OJ#(<HO::I"'G=]%:+:G1"24*73^
M?OV=;T&:[]XQJKL2F ?C+23LM^9P4X!\GF?]2:P.WZQFM@<!\>8/H/5UM?2X
M\%E&[\MA^MO,R/-%EEL;<2#( QAD9P;U;Q!'W(S@)>==0^Q,Q\[!"CA[\EWT
MI(-.G::Z;.!O\S][2/WW#SQ*!-Q*A=XYK[T4EFL_U#XL-VN$GF99Z.8[L&7Y
M2WFTC4#,A^&MPTO2V1=:SM#>PQK-95W#PYF3V0/C$ZE4QR*KRVC!?M@/9BXL
M\&F"<ES<)+FMJI#$FHTA5G.. M#3F7N>HPNO5'<NU%^)B S:;YV2_?O$, @*
M_-AN(],5WV*K+#5^P]01>"-]7M+"/F5[T7<O#++GR;6WPAL<8.Y\+2!+WLL/
M*/..=-R7G;02>00<=P1A<!2_(F=4O+W0''\$4.^YZ] T/M1N91X,2?7T]]S[
M_3%=3GM8\NSFOPV%E4FW:;JI]+CB%127+"<P#,*^_69,\\=-($N8<8/D')8Y
M:'X+E,:%/'@&.@L<A7\89;E/C:!43>3H#Q%BIX^8"\9 -QZQW@7'GRPV70G8
MI?R68"IMB,=JYV;Z^,U)45 EU4J?L+F:2<^C9FE"/NAP6VGR?<J:*BZ/PNNS
MQ>9XLHR;0JLEYM\MNFU"FL0^E[);>EUNJ41ORPXYT$H? ?CBSC9E.SKG;A/Z
MNK-"Q4)?"K;57;N/!=>;)3V=?==?$>A65T\4U-1:J@,+ZU!XTGNH@,*HA"/-
M2IR*[8U,'>L#]&:U5EQPQ:7^S4Z'I2&4#TY>SFG^WB3JCX#7UV"EXY$YY*M?
M"@,)^OZD6:9,3EZ8H>NL%Q#KO?[V&>E@S:K)M4]!\NQ?A;*DD<-^KQ@Y^"68
MJH]?C.!<1VDD3L/&@)2U CY?[V7J1YAV V:$$?'UB]4$G,)4K\4H-HAUMH4(
MG#U%@U:^*P=IE3.CU\3+Y-G-_3'.R IWOB@+K5;<VX1(YH32^_^WE_R_$?N&
M#.*NY$$!(!(:/+QX]69^F9 <0MYJOZ9&UN&8A5Y4Y!-HI__DK"P)^>DS-.<!
M=#?1(VI;%3,]GK"!5ZA_4\C5#.5=+^<MZ';ODVN,.R4*68X_^;^&[?\KJ9>S
M4E34V(0%T^.L,U>G6>QJ6$6&?<!UQ2QE$R=ZH>(GYL0N5Z7DSF$W>U9%;\X8
M$S",S>TN-LF<@]*V.+UZ2&,N\<Z)]VW:.F&7A'NAWN[I#^@W>; [7XCX38[H
MH@GH^W*MDMS4!%>;2037(%5#M-_I9P?4*\TQZ?W)&6&^OL_]]&?$U<J2+BF!
M_Z88_YLPV7/YG$*U7*B<Z"S'(K5Q,QV5<L("?_SI9F/?5?@D,V/-4'2.A$<Z
M-<GC%J>O)T/Y#=>*RGE,#3/N1@/C^JH#AX-A[S@6CD,'6ZCVCR<5]+=$RGF3
M4V$42GA!X61U(2TW9>L*$6"64*K3AIL/]^&^QD)'+:_C]O+'H"OAM$YT.ZU6
M413JNNLOT8HJ0\5]Y@YPPS4BR]( 74[Y/P(21QX!?IGW=(CYB>N'.^>)*Z61
M7<D FXKL@!VZ/^=XF0_0PB>$:O$(:%5"X(* 5H^ L[DG]W3B$1"(-#GVA[2H
M] @.QK08!MV=/P)6-8!E*TWA33C@(CZ^/>QLTJ(W)J%T0__V80&'[ M3FNP[
MN3N$X8.7;GF#R)/FN#TL!*XQ @GD)IC+#FFJO+MMPG(Q2L E1L:ZM$QT2"7_
M*"TRWO((^.N:JGJ@:!?,YY+@K;6Y2VJ8?&:E?IOK!\2>GAV ;36 Y/N"1D(D
MM,#:VZ_#%[G-4O(/VL*O/@9RLN07?KC/RB\3KNY;;\]]\_]"<XAF([WK7/&J
MRIJ6NBGX!VB#RK'<2&>HP.^>+\)>&+'ZUJ/73MNZE3$L<).:V%5BGC6Q4,5G
M]^QB[T!6AJ"_+L"2AFDNGSX"]F>(<J\K;X]4QDM=%6@8I:9*87O#\M[E?'CJ
M&N8.ZG)I;-LQNO@&[\>@C+NVI:[RNF%% :RX3L_%4%]$?<%&)>H" !_^42'R
M?W#6>NV1*=X0>JC%[2U+6?VNC-1P,\(Y/&XW)CR205_0<.S"<_N[XB3<+K_V
M$: 3(T.8M9M96+?FS]/RSTZ*JBYO_>ONKE)FP<X4FG)WZK)TL(Z^GM1++D<9
M]#\K,7O"W58U!G2CKN\V*BNGF<I8TGGSE.5>LNWWE).L0P#V_Z-"TRF'<2 0
M=T1!KKWP)!%'9U1L'9_( AF6@*K+T6O+V\[3MH(]MUJG3HY=W&0*"Z(KHG7*
M4,#\/\;.:9CT6_@9_*D^)0E4Y/N)_K1U(60?!K,JGZO=$D<^(^&)Z9U7W4!.
MKH,O3":AE=M3&,=47_58GP&=_Q PY_8("0R>26,*IKQ+NGD>D"&(Q4"SD7L(
M;OD36?7EI#:X>E1#7X[>3'G0@9P-D>;G.F!-CI_[N2R]H/%6UN%.^N&4\WY_
MF.6 A2GO="O,HM#T"Y#R^\QX4\ILPU"+0F,^XFLHO9U+2G#4O6P13L'5P5CF
M:HU^YO45[471N?V[_11&NLB#A;:T:MX7=??8RGJK+W $56=>&&5X.W<YT:^1
MG-OMWYXS]/=4[63BN "5S#3-=J]>==.(OA<9F3CK<DVEC/GTTY/R_>A?D20W
MO\4&T94;TQR'7!"D]2>2<7G$GR=83C+?'P]$?2D4S?=R<53'3]"4OSD"-D2O
M^T;9?I.RHHGHI>%!<F-/\P=!M,J\.UA+9$EWIW+8%VXZ*'R7ZUK=XT[O?&VR
MRR5WQ/Y2OFI.<I1"DPDZ^^6;#Y: _Q0=L";MVI!29\JG2Z?=B5U1L\;F;WTX
M:TM2+E98O#@DSY]M$V9AS< 9C_YVX]S?_[NQW/7:L@WHNCN@3\FPH >;[:^I
M2!*EL.!_F199V&I=X;BV2#ROG2F;N";N;O_=X06+"O)<JW<=H7J/D]>)&"GM
M/T1D[.^2=S&PB^!XDH,9:&#9NDO-G;9WJNQ[)5J$EYT1RL3W[Y]$.,993-.S
M>,W7:WB5NR]C*95>(_@"]!HV(C-R_ 7^.:ES_U[%_?!Q'_?"Y>NO UI_!89[
MY_Q,' !2-L5R',Z_GD]&>2883**>B6-3J>LA(@_G]6AJ0K<WJI12;MK5-3'7
M,GLM2_7FGL9?H/P_F Y!H_#VB841%3:DA]$F8[8K\1#$*O<9!\Z\C!$23AVA
M:A_>6(0?UV2.;N,OVQ4!S<L?TV?=[3)!JXD6PZ,$?(SAVRF W?\AAV4V2B=N
M4<7R5%\&'$G"GM6KU=?$OF6B!!>L\+).3*K3(3YX6-O3#C34VXN(<LSC/[EN
M>2[()C=^;B_" R:.L[ &_GU4M@FZO-12U%MR[>P.C>O<(OG@<*I8E?WH_B^8
MQ83\PPST3399;06SR]"%".0S(;<U/M+T1;]36Z3WE6AM1$, 5_+_U&!O;-:N
M<Z9=H9/49E5!-GRE)J_)^5,LO]O"4-;F^'MLR>4F07@[)WM?V\JHEUB0P9\I
M0.\MA#]PK%OZB75[G4S["XC^1S?&B0@<7R>>B$SQW[VK5FV8EU&GPJX:6$!Y
MF4B)P<^/5U6XW%6L\_*G:5V(.QZ]\\M/>])?U/VYGA7^8YX(\&RB5.W=&^X%
MC__=]!M(GFQM>0.Q92QI8C_8Z>&$:XJR0KW@#JTX36\]UX$"W;#AO9=NM0EY
MIFQ\%.&. 6)D[]<,27A_4HX:51.X08SM$L_8?R$N@E .1=+W*PC<18_''@$6
M=Y^6E&"@J2-!T*1%OHL(X[6J=YGN#KV5NZD=S+6D@YU.^M<?S-]_+H^43@K;
M&Q?M.UN/HW=T*F<-6R8HG ;.  !S\PT' 9. -/=OT)?EUUI+C,M"E=)X^6=,
M]CQ3J]W\=@1['G@+LWLU9]*6I_H2N&73J;D$QS7C7U8L2)YFQY1N^S)F_G%D
M*L1P<3'U06-O6"M>'/_^.8<8]M5LM,"*VY%F$T&N9VTMDNKX)B,)?A3!/%=O
M]G/)CQSY7K]'E%;A.A]S P_*G&>RB:>!4+M.#NLD =;@<A\EH*NCHPU^2A\F
MR%H6>+_,^^QW;F+?QJVC@4V>AT7G_RGM.H.:X)9VZ%T$@1<0! &EA4@G=!"!
M)(AT4$(5!$*/(%6*](Z !J57D=X)+71!NH02")$J79 FTKGOJW/GN]^/^^O^
M.#/GQ]EG9I^=G=D].[-/EMCN:N'2QDLUGD%G6ZMDR.R[O B%T+"%O;X52Y71
MG UO=EK\O>FE1!V4=%PW=9@N/3_ 4W9MRT+M7L>%'QZZ+3G**(1(R<Z2 85'
MGL':A0T'S/97ZV/S=68Z-7ZA/8J.I9;*U7H";S773Q3Z%E4EZ=G;H#RMW*EV
M-.B58=-3DK%:F5P&$^\^@ZQER& 0E8%:&YZ*8^%.5"#U&%U\7:4DMOV]PG=1
M\^H$"BMYZL!<NIFQGXI*\K*%OCV]@KS"=3_ZV?I)K3("F3WM%O6@\HYM6Z5)
MT9&*LAJXL8NC+X6+PTKX/I7$)^0VR",O>\*WT+BC<Z&L^!S^J,/L;<7[.XL5
M:W8"1I\9K%Z+*E//8!7.%(GG=9K&7=^C1)+)*%5'@O!E-_W=F#98L-.(AO!M
MUE7^-P(^G5L=SL9O2SPF4E:WB@IGYM\4:M'UD^<J<LXO5V!>! R>?L+T9N8A
MIGZARV6A1W6-W&\[MW!@S@W4/KRBW2Y-\J#_)M>\L+V#9=^L<B%]D>45X-FT
M:;K3['NK-PHU,,.U"5HT;+J]%6,NOB+Y%;3BBA?G(3 8BG$P>GMM66C#&#,1
M6L\^-. >X2_6#/>NAXGLR0PWQ)I@R@_@M[R7:"Y@5X >]M3H,CLD(E>'B8H]
M)5K%IOVGPAF#16HAH=L_2&JEB8[N4WGKQP#5^= 3$ZK"E_+CJ9!H*>U[^LGG
MQ1)0CE(TDK]H> 1\7EJP>RVQ9!VOUEFR_'P)K*'*(_HX;OEBV?RZOHY%T=N;
M\P854IW==+B8<ZW2/J5"?P2BZ'-5)UU9VY.OH:E/Y0Z76H9,)/P7[TD\SM8?
MKY?/E/,/IP&'"3X1^[)PJ/1S' :UV!G-EXZ%K?%6SBE61KN6[;S(-&*?ZU*N
M#<B<%Q]^%3*0SY&%(=,N-W5$Y#N8_/)#%;D%>"/),#U( NL$.>F-.D]GHNR7
M.'N;Q?7O]:D3E^.26$P-/%N"]'7C2?3.(R%S)_584RU)E'T<W/S.P#9@1SB+
M'BU5V1"#U'K6_G7=1*X9''2C_\4SH)]29MG7!_B @M1*(([--]M[D(TO;B]+
M4<Q4KJ()6=X>\=UYYUMMI+$&"I'G#*9N$BBJ'M%<@8=VL<,W37"XJ3U++<_%
M6B0C&@7H,!K6OP*$,8YYICOQ81KCM_D1Y?8/*2*1_7J;$H8E^C5M6X/-%ZP>
MFFI.FEB-)*9JFMG! CM"MF/*D.WR:WHSXT([!+OSZ4O]V$R-I5/H3:1O%?%>
MG  'D>F+07Y?-P^9/_/P):E\_Z+CHVZ36$C[A(A&JDCI33YC85Y8'!&AFX3:
MMV+5T_XAO6GH]WT_?8;5%!\GPW:/XGE$B]U$_9E\D[,W,$N]3JO*39&JHY]$
M$3GLM!G]<2-+-MT(C075T_@/"[K<^-X2"$5I6'$A;QI&G!$.I? !63HPI5'^
M0H#/9'U$$T+Z52$>_B@MO#V2]J_JWB0H'V3?AA0RD+^3<5U'+2EFNVRXHF@7
M/? %ZRLR#TV>F[S+U?JTNLY:QV6&]?!<V-M@=^1M63]'6E:JB]<>,</*PYK0
M647D-K:RVU9D$6(5SA,C19V4%VY$D@/P9"):/;4,<ZV3+P=IR^$=K@!UGA[6
M@5B(K9-LF%5!</4=$Z^5VX\D$@051/)TJ,:X)\I>JA^5\WP=LWFG(L+<FA?'
M,$$\T)TSFJLH//Z/!USV*=A@A43=4(/:7?YH9T:<7F3W+@+NDC_)JY[&)N/!
M^%;6H6LYY?B&J7>S1?&2?Z^_-L^RQF-)X4Q9BP4A-Y1NKIYTRAOS@IT%CT]^
MG'/OF2\R&E)1&XIU@S60 C832S4#&F\ H)4:<'!&XW1A8K#;R$XV\B:-S^TH
MFM_0:)4+J,Z@[UW,[^7#JC>7@VU5#$(LCA*I2*Y&+'7KWK 0T*6%Z>L.3?\$
M-IW&' ;5]F]HSGP[S*&7#(5.W8TT^7(8:P[K@S15M^C=*HC*PZ^J[4>90^TT
M@#UKW,A0?(6/B5;0MK;TTCZN1\]\X\B%^*+)"NX3*A2A+D"$W(][P6'7<@7X
M-RAE"409)W+O[VO1)YJR$LB"+DG%TWDV-W%U?%&X,TF?']R*KD!V[9<3;D,'
M)2'D0C#!<5Z4O-%TVV%M[>)FCME+ '_^<6P7#&Z/.G4_X_-[VZHYG$@C7"H
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M0' ;2/P3<8O_ *=6^A/^ENL\HO3DJ7\XP @0.>3% *YF_@502P,$%     @
M64^!5"]&\^UW2P  D5,  !    !F;W)M,3 M:U\P,C(N:G!GW+L%5!W-MB[:
M! *!$ @)!&<1W GN+!*".\$U2((%=UU( L%=@TMP".ZN"W=W=W<6:SW^?>YY
M]]_[[7/&NW>,-]X;KWK,,;J[9E?5K%E5WS>[NQ SB!7@I;2XE#B A(0$?'X\
M ,0\( H\0T5%0WWZ# T-#1W]&08F[@O,Y\\Q"5^]QL8E)0*1D1*1D)!3L="2
M4S!1DI#0\= SO6/CY.0$T?()\;(+LG!PLO]5"!(Z.CKF<TR"%R\(V-^2O&7_
M7TZ(5@#G&;#VY!,R$@7P! <)&0<)T0F   #I*=(_$O _$M(39)2GJ&C/T#&>
M/RI4O02>("$C/T%!?OH4!>4QU_,Q'T#!>?KJ+=M[U-=*!F@4MKCL/I$9SR@_
ME+7A*8^>4'$8VOFB8[S!)R DHJ:AI:-GX.3BYN'EXQ?]*"8N(2DE_4E%54U=
M0U/+R/C+5Q-3,W-[!T<G9Q=7-[_O/_P#?@8&147'Q,;%)R0F969EY_S.S<LO
M**^HK*JNJ:VK;^_H[.KNZ87VC8U/3$Y-S\S.K:ZM;VQN;>_L[IV>G5]<7EW?
MW-[]91<2@(STG^G?VH7S:-<3%!1D%+2_[$)ZXOR7 @[*T[=LJ*_>*Z$9V+ZF
M8/=YAOLA,J.L#9V20_D$S]!N%.,-%><J]>E?IOW#LO][AOG^;UGV?QKV/^V:
M S"1D1Z=AXP#@('K.[I,;XS_MV6H;LIA7^"'[]8970ZO@&Z9MYO)^&DQT097
ML'M9GKY03O&> C^=Z$LIRR-A'22&FL4+(=X>SK5HMVB:L9'] IY8RCG22>?J
M26BW0OIUB?B9D+QVBGP?.K6P7%'\\PUI.^I(C"*C<10![(()^UU\'',ZP5_0
M8O*&FA0.#C:4P@"#N"&.RLC+ZX)-W:ZA>]+0IDX>1:H3R?*/ZPQ[=L\RI3)_
MYCFK,J>DI\JCR@NYX+7W9%MP:^G0&[*L)\F\WJ:/2.:-Y%74 .:?^_@*5U%I
M6<*9MEV.C7%T9#8V-8G(1S^3YLQ6'X,Z(:(*D<[X @?..+WEF?4DA4#KG9^R
M.NGO-@A9ANFTTUQ(]&'PMV97'"HO12P2DZ<U1[V45!'V/:2A'V.#@FN5Q'"#
M_KL^Y+5^ Q,)Z+BVS)WMKEAF./)<=N0=PN)/MM=,);O)CJ\YF3,W>X7^4XGI
MLW>1 B%*JM#^D#"CIIZ9'E=CD@.$XN#VCU08P6=CDYG36W76U7V9!W?=JO$#
MU25-8^3P5=*9.X#O]Z$E$DAW5$ZI2@3*2P#-508R@^C^GQ9DEO9-JHE+ 8>:
M,$J4_+KIHA\1W JDKCVKJBPPU=SY.1V=CU^2VW^U%\D*=BW@QE 9>%,9ATRT
MS/+8FD_SQ%V?9O.PA#*QHJZ?Y>F@+K!%"#%R+[<Y74V-S_?P,W R8\I7]Y*^
M)_<=G.QM):U8IDVJZI\8/'=@G7.)FEK;TS:K$:60/_FM%%0]N=AOA%067<.W
M%J> ,\<.R4*+4F#'8Z2R)IRE_([%@Q0Y';DKAP"^>^ 2EU)A7U77LWC3+QC1
M^^Q.4Q1HWKRWW&1OVHT2/Q/%></CJFR-LA$EM2-O>BVZQ)]$EYD^0I<9!/Q7
M(AH$3=.I\-,,EC'<6E.*K++#O4(;G\J=O.2]*.:7J>.;;R^]3KC &W81E8LS
MHYXZ;K8(CI)U/<C-A[EA&VBU)VW8QRT*R9KP#&60WMV1OLG*T=B;^CVO5.&[
M]WH(JO@.;<(DH\31>,2#H;PC?>=4:%1 CU&QH!,!.)0=+Y,VK%5ZR)0@ ..Y
M@Q^:V[;)$KZ]B6V?L3]% :30*ZZ^##EN=^V\.#Z6H^YN5<%O@OG,.\2$1OUO
MN%:V-*,[O(ZB&I<7POI4DB_=25_D!K$8LU4-Q>R2K%0RH_2_)<=<"7OG=C$L
MJEVM/C476KZ@U5?>O6!%&FXC871@,9P=MDO>L.S.T%34;Q.,45#@=T[R!+UG
MF21)=<*Z\H6X5$11!%/!^3LDT>[;H=,1@W)1K&1?-AT-IK7"-&IWSKMB9OC7
MZ([*DG#9S()9/5&(!6DG=D*RC7M8)^@#-IX%UT7^HBY)AACNI__=<8E$EU5E
M+\Q^:JSW:GREUO3[F-R[4"/F\/A"GA5P0B[NQD'-:S/&BMS,#%_3(\OUU#<O
M2 I("9Q1C(F2(MJ#Z-*?_!M!*:$8.])VKV7)J4U:XRLA55Y;VBGOORXC%EFV
M!XPV-W N2Y;*4O=%*B>H$IM[\(XD7;D!^"WOH [+453=Z_(*JVX2,L9)VHKS
MKAB,KY+9WBT8/+V!?O[4_J!C@(^403L<QSR",B-H!OJT,W*8@O+=7$$1@40M
MM["7)"W!CKT6V]*-%<?;T**7?6UIYG0+[WMIP^1=<Y*N.^+) ^>Z%?4'WHYJ
M,X=8;3BVDDR>-<"PCSBVU&XB4[B+';GS<:I2N:IYJ'B6A,T?8B0%8$WN1F67
M?:"7.@C@R_>775L/X8<?K;S>GCF;\ TYP^J&6[0FHI5.8+GL,E^W7:*W%+T^
MOR/.U;%-D]8_U$6V6N8?MQIF)!;GACCG*EC%V/7?ZB\(FR( =@ZC:98#HKN]
M,XW-<IE(LI%<!Y'6HBP^(0V?2_-=2R*GRA\EJFIV0<:J.\0D/C=3[AJ[]>5,
M?Q(&Q#^:>>3H+W_;5 UC%^'E*M,<6JQBX3EBQE52UGA<5X%_E9BO05N-VD7<
M*8;,EM![U>%>'[>\'87I/P7?238R?R9/4&P,%&Y;OW&)93*@O1<>V1(G)9Z
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MDHYV=:*EXL]QAVMU3SN5?#.*UIBIC#87[*'DOL3+>XR[[ O2,4(Q.4[5%PC
MV[4VR<D#2A8N9M\R W^+ #(*%&!(P3 Z>,\I]L,+9<@*IOZJ7EF?@XJZT$/X
M&NB.R!@!M!*TM(<?0%XB@)%Q6CC0!<=%&AG5N;X"_X3LF$4C , 0 6" RV"B
M"$!4-NT&&?]&$4U4S'[Y/RKX_?<*V/]1@0CI"[QAB-%- -P_$7R"RGJ2=0_J
M!%]P0A\;R ;Y 3AP_O^[]D"3WQ:*BSW4PS_UMO#N1WY)CCNO\>'5B+S461"S
M0(\S>\/;!E20 %*M#Y+YA;$W05T>: 5X5.]4VDC#+@N;7T^A-JS^8ERSIY2H
M5DK]&-QA<DH(,Z\3&H((O!X\MOLUH20F]4'='R;7'*UZ2OQ]JZ^5JSRU6[=A
M^6S%"^^ Z"J?+#AC:4_9H>;G'[+B&2_:)XV_.MUDDYQ_.!"4\#74X3L[4UVR
M<[J';[;"&'.?9]>E9?RP5 V;7RW)8NX) %=8U=:/SWQL3<WKL /UKI^43#7N
M=;7\N3S&,A?=K)X\H*A(&Y'.PS0YW=4+UE33NV;?,Y/;M6H?%<-+-,;'?Z>E
MW7C]JDB)=LF)%[E*3L_Q5$:3^\2L_J.L\Z).=M1ZI7D'X5TUF.%":2R_>U2A
MCD$]6O='9H&^J+VMZ:F6[B^I,.X!2NR:5!=!=S6%?W9"5)A_T';+WSVA]$]>
M].8G8DS]NR<D_OEY8,>TQ/V?1H+]TKN3W.!+73SFBV5<\%SS*'%A0M0+;Y*X
M!3]G,K]BP.V%*SBP9<.@$0&4^#=A=UQIQ?J'/ZTNSD< 9GKI'0NW%,S+WG#/
M_>%&:?!:^C^T&FQ Q!>\92U/+MEV<@U#U OM!__, = N 3R(6,6]59D%$J&:
MC?8.'SB=BSV>P3*6H/H@7'+D4+@K1TM$G/"3/;83E*M0U=!SFG4'?'=IWH@N
M!:T>MF+;E'IKFADD]A172>1?Y:6N3I>)!7/GP!NZB0J0^7JCD"5-4_%@J6[I
M499E]8[;$WXOT4O.X]>Z_47F?UR\H+4+1$ZD:%Z>WMO[0?O?#BG**H.FGLZ3
MR%2).4 PTJYS;EAO:'E.S5TESA\[22Q_N2UGMP9_FKF:[F6#^SVV_5ACP?-Q
M>^;N#%XCX6-A%0._+=YV%J%X @3@5MUH7=+F6$3S,YHUVASE6IHX[ILQC9 _
M^(V^=-N<T02SLT^#0(F\R](M'1CY@7'S7*LDNREJUMRIO2"W16GW]0MV.:IW
MY\GU'%A]XFO+-R=*"& J/W77,$"V%CW.CE)CVM>9]OW!,Y!TT)320Q;7^!^-
M[0"[Z-F7ES#1KX4?GFLHV*T$^'_:?'1.G"D)+T@92V%SKC'M\_ST)&P$WF#I
M);,AP\ET-=V]V=@=I/1.1"&N;FX!Z^$6G,.\&%M?G;'926E )!L*ZA/GV(7O
MY)<8^S,6_MR,5+)BANM<&J*38#V(O2>%O1*J@&X5#)LK)73.#*.-+XQD\11]
M^I-B51[7G&'/>37HU$G\LS5HXUVK8]O&>I9-4]W=N)HK$Y?"H26[W"%>]UIA
MKV,$]MX["4@>[KTF9:.,8A3C;77Q\T.^-H+]NTFG']N22_AG.;55;:V]SA_X
MP_7<+M=J<M (Z27$?Z;2%U,7"%E_G&)V?*!X(3Z1QO*^CRROHR#-QD*ZT43T
M%&7N3?5TEH.3LWGYHA:9Z)-WQC^OOPA&+KSN%BG]7%/G?[8D$.RJ)FE,'#FR
M\:XTMV/RZD_#Z"4%A_),:A!=B:_O?\'1_IU@*:SQ]?APO<369X*L[ZO !"%E
M@B9Y.]F6U2VAUH?O!5%;7]'!7 OU7T$V))K(2A\7U]Y@Q9LEVK**<0^Q)]'<
MT>R-WHZFVL_)884N FT230A@A:!_K<6H,C/37R45-X[F!4D0H88S6H39P0=?
M*0!+BLNGK/NF DXK_';4@[NQ<\RS^@3[=A.TB+:WW%<A3%-RWT0C".EOVO=2
MG$KS0[NJSBER216Q=>69/;2?>W:#XBFOL*HB_/;%W51,VL6V%^3LA4.'=)!0
M"P>AQ9O[>*O*W*EF LT.I*X))\5AJXZ\2%R\GLWP[AH87^'ONM5[9C$7CH_/
M2Z]U;#I.R"?T<"R7L$>''_AZ$$!Z4/=)#TQ*4+7HQK765_S>,P$!&,#OPK,@
M_('N?3(5+;<QE6;7 M)T)<[=]95)"OY6>@M?S];?3/7Q)X)\;NT@&'ULEMG!
M5GW;R"5L4Y:7I2]K!I_K:\]J@>Y,2/QL06JE^J2,P[!/.1(9,*[*\:Q=:^;R
M,OBYJY\M3%[.#>V]UF24K=J\_LA/1A[;1U0P-,55$@/^4XQO_%TM+XCSTR.S
M8D7F]B<\6M6CS:.&YF(VCVB<%KR^?HO6@T),WF1\8<[N^FX'H(OZ30MZJ6XF
M347C$E5U6C -X/7VOX,^,#:@3"Y.#NFH'E2]:X1"M@OA#JY1"&!8';9W?>4!
M68X^!SVNM/_C1._'.BP7?R!K2P8!".F?%UN^*'FE:?5JRZ6/!9GR\\8DY. &
M ;30;H';ZQ\$VJ^@F6),\?@R5+-V!>L$.P*>+XSTLM^^4-NJ)-\4(DSF>O%>
MV417^N3E]_ E-^2PR9TI^6$CJP.[P5=1"O8^.E5I/XIRF4+M77W?V5*<\2&
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MM13'VJ6&F)2V9_# [1'CY;@"?MVH>>]+' I)+3T+#$U$W;&:Y<$B0!WB(T$
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M)E]B0:BI/.5D;#[=?QBC C4HQ):-1\: DK;/BHZ%#XG6) U\U@4+!@9RC<@
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M$/FFONO>;U<1 ?@W:<JL&>45U!2[5(=],_25">,N.E+"%MSP5E P[S^':2(
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M48;GY1 Y!C(C5=?TR>9(_K OF]X4XFL#Y39]D7+WDHUL_-/ QJ32Y8NU\ H
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M!8N%&(^8Y?]Q>^L"H,(!.C_H0$.1 #Z@0D&C0KWU 0@! *B/4/]J@/_1H#Y
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MPBYX40_:L@7H/@+^;L=1,P#> !F2&]5/2)_O/K5]4C;/014JNY8*"%0Z9\U
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M2KWW_DA0@/!N !L'S%Z)YG(6U_R<#A\KK_(F@5L_BRTTIW;)XT_F!R')8MW
M\'=^^Q;E$OVEEMK>B4+8<O?UG)6_$W&^P(\^./CFTO1=)T"$3EZ:01V.DG+W
M--ZZF7;.U5+]>I>;1M[L"#ZO\(W1:T#-[DN]%_^R-\ )L>V[II^_?!X\UI!Z
ML'^,M.E[MW'$@?_VWA[5+=152_V5#&)0Q:'2;JG-\B= (^W[%<4YF]=*U.)6
M36<]+L3;YXKR/2_;R_A_%),-IW.LCNKJU3N9Y8#$&H-]ITU47]P(LRI4Z276
M5!3,'.1>WHW=L<JI<)\U^W!_C,IW5+7Q"<#V=.%7U<L:SIZ9NHIQ/9:64=)4
M*KGG#VV@9_LWP/[,&X#DO7"7EDZWB<]H/5+,C#*3..[93#B>\-/&4:IH:0D7
MYU2E:OY]G16\A7TQ#U9O)HU SL(0I104<315:@5>S4*$GY2M/>U>C7VZ(P'.
MZ--'[>K(Q17*(%KO?<ICZ96N'32!/U"48<ZCX6H-53/[X@5-8K'[\OBY(C0"
M\F[#=$RRW[LW%O 2J3&>CU"UURBRMBUUPH-8F&ZX-Z(-F$^5O7YZV\4=U6H-
M]9CE^$U3@$0-VZ-W>J_*O_RH.5P(XJ#:^@Q?=80TX_]]8K#W%XGEJ&4(XXYJ
M:WV,Z$1HXYAB=D+U)($XUS;1S:'6ES*M2A''1Y](]^@ FS7STYT_D*MKV<B\
M^T0*\/H3X:&.&Q%>=4]4(=B7Y3;=XUZULZ6AL3EQ?F#U)8Z(5]>TBS[I"##!
MU,2'ES&74- OX!?\C+8E9?NW,V;,*$CT#6 N<7Z4A]/7T)8AHR4A8H!V:&-+
M2;C&(/'=!Q&B8JO3FC+L=)CC4,*8B[9Q&Q'T)7/_01%Z\L1+@B*[8%EG$(<$
MA#9<%[%-&KM0O95N7SZ*B#9V6D\JZM*%#Q@^/=5>#XH:Y[#4>[QM220"+M&W
M^XBAOP'0N'4^[)%S>48V'+\!H/4+;RC^8G,JZKK%C7$T.M)5RV;WIW ,Y<+&
M,#&I1RMZW&'P5^3ZY(Y;5*_+461<Y2'#3.B-( J5DA)\AXE"$N6G991J2=Q7
MGA=FOC)H4M_0[18"O*^0#U^4;ZE-XS4Z:A&]&F=^5%5X2$:-#QX^*D*_^T"3
M6L5!BO)YEW">57/,>^I[$Y$8;RSH5TO1OQ%2E:A:&@^!=:DAJ\Q&MGS7D0$?
MNBHK[/)>H8K8UK^9)]W-,](%36]="M.WK;NS]'\WX())(#*Z$OUD(:/6R]%2
M?M&28A[;'1Q ]*&Z-KV=ARDVH;TDXA=*C=TP_FNO%BM52P Z+7/D:)%A1,7G
M[FYL@/S'OVV&N:..?.8"!]GBZ^,J!GBM3/"YV+9-XD0H8K()AA"T=*Q$!*\R
M5;:81S-0[^N*/E[\HO/&9;^1Q :M1(Y(!F3/$"Z*5X^=]">\6!O5<N.7OHC/
M5O&#PJK(?J>)_:=$;<T!K$)]6=^1$^&ZY0%$.W',$5N^])3A-^;D"8J[860*
MDF2HU1HP@7Z!7:.<(VYX$#%,&S[AO*6E99U1#[^UXU=A(L8]._4-@,3&UP><
M=UD>Z&U 3U2O-3RF>N1'3&;?A!@DA.77Q"=Y),H\>2&BTW(Q5HH4;ENPQIYS
M>'9BHBRS:+;DIM/J3G] ]6'[(5<D>NS3*W*B/"&]QI6.:Q$6K#WMM;YIE(<R
M1P?]-.6L2<VSD<60\L#.+KEJB#B<3:93!FM\74H8(RQX:?E'(J<KQW0W4^)G
MT04JKX2 ""8BO]+UYG&U\*Z[6 .L>H2;VH]X/\IRT>@,V.V674VA7;5-8<&^
M=*!M'1S,QOY>K-W87%/4!D-BSH@*3OU*HFVL_7P9SM!3DE94XJ@?Q"')QK@
M @5LKC,*;4-@N8F6&Q+NMVMK9\LAF\9S5AJQX:N7VFYM[S5OQW%-.9A%43^N
M@B;QV8\*,78 7U?"F[/.Y+LL!+!KJ-.XXHH,^CCA^0\M<J'(N)/P[EMCKB?5
M.8=)-_W>BB5M]_S3<J_#3UN<O$,[)3&?F%+3_-->UB.=V0 *(B*,?W_:HWZ0
M*?S)SPKVY>/L3YJ1VCS_JK=\QKJN,Q:+XDZ#]2//IXMTW(G9IRCZM1^B$L#6
MNN0$6Y\JU^YKCF,\UFAM_UGD6J0UI\BP-VYB/&&H:\(=(]NQ!'PXU=7XP4'W
MG3E; O/ I768UEFG@)HK;W/$B=:FQ/7!)WVHE^03X]"0Y^Q&&^WGEX(F;UGV
MZOE;7FT.DJ:X[QA2UJ+$-79<T&[8[ <M$2SL_;=]YBU2"'#G]ADN@P+[T"L%
MEP\+Y SYMD5'$)I9NA\=PFXVQJLD?QA&+HTVKB.L"0-_ZJ99B(C4SHY4)]@Y
MD^NBMB=DW,W=OL*W4 ;:.,\]&S42&E=36K!0F1O1#,9FH)N24G+?E/=>K OC
M@KEMXTQAV')4R""X]II/1C&'F"D,D13G=5)6+AOV?^0GY+8L#8O+J065),2R
MQR/ZE?N5TX[XR<YM,C0)3'URM1\<U']F*&?,F_S\TA,9[$JGLI#%-0QC9P^N
MXONN=3+?H?G-D7$(ZKQN8R'/(HF#IR.FT=:F5M"PF&8<?0@+/\[=-G;E9V@E
M-^GK-TE%WNA7S+EC86S.P&)L[P0GB-EEL3XQW4"8)G4K,/WL&PGXZ&G:H)@R
M&9K@NQ6B'_*1")]&3TW>%%&0V2*/U+>1D:X=%+%L[ (-K!U6/GN2+:%FE8$3
M5[;G47]+BQD THJI0("O3[K7 "L&GRCQ!,WXLM0C8?'.HRSNQR1/GG)9FK-3
MI]:7:.6'7U;U?YKF&:SH?1KU__;R;XG5YX_X$>)#H]B)XVTL..K^O*APA:S-
MEBE_O0M73O^.O8MK_HKW2^5HW:CI#9#!XK-.4>_O&!9[P5V!_;.ZGEK$+",C
M6N4Q1D'I-6X;XC;\!O!*$1A^+Z1\1F^ #AF53$-0+5%.X3/YX,ME/.21S?N_
M>M$]?TS^B %<8@#N1V3>#^>>)!%>#\@][TR9+M(-415#_N<@A/_UT^$"W2:.
MOW#? 'H5A#J2<CO4':3C-T^_@@HA0/)KRD$SI<27B8_J%_UM94_SLX[O\HA;
M\%$.-LPDV):AN.S(8R@23+1NV$ L@8ORTN>M]:BF)".K=/H('@HW-Z %/22Z
M-4Q<?&EX"O..TW9"8V3.'"5I/,H,8=-*E_K1Y$>U(ILE!6W-)]Y6><3\,-O"
MWI<R$&M>)/85E>5#%_5F"],+''O:S!_E5G.(L$2A860\1*# YRGYZQM \$-K
M_'Q3*$F,H#W%P';?2#OO#ORIS:X6K?N9Z:-!($+S#<"DKH_RK/(X*^>GQ/M3
M [%%OFEYTS"RMR.">J*['7QP^(#O]/?\*O7#!O.SP-2[UM+.VR?T-U+N^-88
MRQ;O;L?L[$/<DL0O>MX"_-@O4NG3UZHXXYS=(T*Y5"'WRA+O*S=5969SY91D
MR:A2N45@V*;Q!B!JU7OWL(UO@,EC]X[+IWG8\*;I\LYCR/H;0+C\[EW(J8_^
M]T(.6[,R>,4ZV?;34H88V."YF9\UPY+S&4GN\8GP_IV8*W6B\IKKZY^ UQBI
M->V:$@ZTB<LL92] "HHFSK <=/I,2F[^X+7[LH*9E6J@!2QDZ5V/'9?,[F)J
M8LE"KP#W2M\ "R3-F9QKS<=2:S7\=.2X,WO>XIVUJ9!?8J_/[XIOP3#?S<.L
M7-&Y6</K8"8RU65;8)_?,O[:^WB&S3^=9/(-,$,.46%R_1E:D(L^E0B6F;Z1
MAI"^6+ 6ZB!5$W:9M%C0"D?LRI1M7'^-+HE5J+/I=#-H.1)B_8Z7.  Y?"EN
M(JUW#L)*/1<-/LKY:W4*>JD6O,'*0J:_1 K$JI]C)ZP;4AIU[^^8JI.J-3E=
MM8]::YN7.5T=U3EJ&"=)=:Y/LK#"AA$-YFU]O1ZL][ -.[%^ VQ^G5L>W=$4
M%QOS"&3?6YC,2E**@6[J=4">%/X$3,XR%<PW4]#4[O=J1*MY-,[U+4+ %8=R
M0%:*XX(MD+$:"J>3PXW(+5;%'H31G^\OB(:J;NSM?,H_OD&_FU)^7:I^ T#]
M\WX;-E4NIR+6M2#>X9YA[#+8":&!+;2A G9VYW[<5-T]90R3R0+M,\R"*(>1
M?":M5N+VBLWQ"6WMI4F:=05;T!HNJR20*_6%-O%B]4^D>UX7_!FGV:JG=PSG
M5192KN0,L);D+_M8$JOT\T["+(,XE!CT[R[T4R4YG(2</@HSLBB5%&X,86OC
MPQ@WTOA^ZX8$IW92T!9P(-=:8%>,F7/C<Q8R=_OO&]?.AMJT4(SRI(E8:#1U
MX[]1R629$V7F3^[S-CM)IXS6=HD-TWG565:8:)]PY6!0?!(80[9BV74DL+$X
M4\V[L4[5O&B0P07O:PQ!;N<&ZL#C2YV+)GU]F<;59J2ASB E ,"JZ2PG#:-!
M18KA\!NOH(Y]IG+P#EC_R.5_ I'0(_/:G[BN!:T, &4M"C)S+3@$T*>=GEU:
M&V/6@EJ,G:]AC/\V:*WO#A^/N\S*PZ:*?(M(F;BM*&R7J$F=IQ+$;9OPJNWD
ME;P%0PWP[B@NZSRD[*LR"S%NMP?QVJX,#=U-[7Z.'^>"J=ZX7,<ZUXV5@8<B
M WP^\C:#]J^NO\0X7A9D'ZBT-9NF!!LE;&MX=:-WF$RSAMP_JM]/<!6A/XR)
MX["WQ)W)< '(%V-%...X-Q(,C/"1IC^?Y;1CA@'V7JA:<A:EV;D9"%D@^Z>H
MIW:MHH[7S*0N'F\ .C4)$?1W#?!? 16ZC?R(YOP&>(;5]CEHJ&28_;4+>O6M
M -Y8UWM$1P!W)!;>+1O^>X'- ;>U*CPG$=Y!OY?8J899J%S*]4O.U_ DPO'2
M<:?/#4?(EKXRKX5+3)Y!*6CK#T?U'LHKG*&=)]K-$&M=PQS1.&V=]7XJK71&
MZ92[3YN^SFY!6*XPK-"W%9J=_<&@*_ZQ3TUXDN>CC^GLJ^>9E[9R=80NX![A
M&U.8S$EZ%]*B2OJ+\;'&3C3]MJ8$XZ:,SRFB@K_O[0#XO@#X<VL;QE1UD42W
ME'D-AE@2E,WX86: E&G:8W#5H5:/A<*>6%)(-AV_F*Q6J=Y9\[B;M< J<GB=
M"^7]PM>AS N6]T*4353!O'M5U\XB"L$8]?XADW)X@]X6/R"$BUMM2;_[<E=)
M^H,,5SIJ:3EVB#3*<VJ#GF=&^5(NZ-1V0RL$>TU5[&",V!7FZ:67ZU W)6>.
M)_:0JO!^\6HS;+=/H:0Q(G/3D>%9"H>AT+G0\ M4I-[K.37"K[QI#;!8T5&*
M]Y\LK#-;HL#?-^88<M?E<K@EH]OC-AP3"QTJ7%Q<-+Y7-%SE!E67+ZHNC^K6
MMS=A1!(&)8U$4/'#71C7:(7/:[:\A$6* V^ *L]/]4XK%3H/SO8,R=NOY&1#
M#E<:TOQW5<"')^21CN@/S<\^L >8&<3>+E\XV&;3:K&%.: YU_2;P5@[.[_C
MXX\L?=H]E'\.$^AQ>(D",:M5,*0TEBCW%A1F%40L[/]]5QV!NVVQ1(&;;5]M
MU^>65+4FOU4Q)=($E<'K%]KJ*:>A&V],D%PTC#"6HM@EIRHP=+B2?;J>%G4K
MO*@>MZB\G.U4].CT91X@0<LQ"W F \AA+!%BM9_C4(3[%.V?C0SO"/ELV$(P
MVL4ES&U9J21L)G*:\0G<ZI!1+'%D^HJ_E&8V+K-%U@LU]T9D +Z\'-G6N#4J
MO@&B(X5FI +> *.\XB]+S <:3; 'M,A]OS"JIW_6SE?@;"L^T_>\%JV+&Z\C
M>!5&I:'!;16@1HV?+Y*M'5K)6X;@?F]N_TK<*$!Y'=#:H9,Z.)XI[9ARZ*7$
MQS-]F$*?5SW1$K Q-E6E3R27_$C0!G^H.#T)1G!J##[9L<<2K(HNE-QDJT0X
M?!JH+[50_663CLCJG3AW0CC"+7C=B(<B1Y"F0BUR=--X$[ UGSZQ>[/LB@6G
M%.%5F&]\U($;KCC#4+8T,+Q-#<*Z 69\47W^%LXV8<W.JZ.(^IZOYZ17.X-9
MSAN91;D0M$<KM_D;J6,\[\-</0'&YT/W5UI"HTJWXP.EW:,R^_LX[=4'AN%"
M[57-(Y1E;:2M'S'03_H0]B4)W-(89?\%C'Y+<$.:<TV+\XH:1TM^?]WVJ-6C
M(ZGO$KZHLC\HWV-*Q3Y(7FTR8DHWK*8AM;-M K75(ZT>8TKBIRVE\N!TR7 >
M]7.<X6+8CI-1F)T)/X:'#,,F#V!=6$7W,RF7$>D1+2=F(WE!R$%6A'-.S#_[
M_! :<SGFWP"B$&<)PY4N_?G(R?$\PO<C_)J2(:-?:,SMT5EX;P#)F^)609Q\
MQX1+XPW(M)0(*>9E(/"<0.+51[+KNOVH_?599UW.X7$L2HL@F9^F,UV;)7T5
ME)\K' ?/'XG,N]:N]X-[\B3ZE5EO5Y=Y7ZW&#%: L$J@BO*JG*JUP7X/93?
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M?FA*F.=8+1_PO-[UBL\ZY0NU;+GQ?XZD!J+/Z,AS&"P((GPA5YOGLR0@Z&R
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M4#+N)N6LZX&'2N'LK.YB-R*%625&.J48[G=HLNWBC3#0+-DW51P)#DY15H?
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M1\0U)M!1+CB+0.6*S,3&)4(TY44X]!%K*2<D2VNFN%NJC<M,P)P7MYW$7Q#
MI34@A9 K(1,\%P5S)T6D@XRT]+/-<I%GXN=TP'$2\^[[AS;U"+-%GW"\X+RC
M)>\C,FAR-64"[U+W$\J+:!HEF>>(5?D8YRQ?RT\ZHGP!9!(#3^/VG=9'[CU'
MOKIE '+M95(-J7N0DQ(V_ MS3BW?IH-9RL=NTZD7"2GR,79!R=61R3P8K0]:
M>P)^-^R9M!O>UIKC1#]'K)4=\4[^=MD72:ZS3 *C5+ATVEIY6TL5P@^#)#B]
M<B*F@KU6%DVNR$P"([WY5 -.K\"K"<ZV_"#LM!_7.ND0QH/7\_LHLAR27(V9
M]$5:C1U5'RF?U.XD^#;^H)TT63Z=D6]-RP!*-795,L5Q,IEY^RS(:@P"^:LF
M2*5X<TD@Y?K)9C]2.RK,A Q";>&MU*?3!MI2D?9 N<D$'7)FTA&^92W04#&@
M7$'9MP8I!6E?M%%+-S2(Q_06V#NU_UX[Z2>MGZ9-S&\U8<ZA680;!#4 ,7'/
MM:C]F;+;.;B'*CB-Y):FG(T"-3YZ/+FVLV\=4MIN=M76QQJT#+K@9D;;$C6/
MX75OT-:ZRF=-?_\!G5$5W%05%D/:MSDMC(),<O[A5Q)6KM!,"J4XNWPZ Z7/
MAR1*V@$HUU F32)Y7G124H&CLDXZXEYQG>@G)/"9."M4#.6<6F/R !:1>D7&
M]=!AY J6)E[2R4K<CH-^\!(D2,GTAFK_:[0"#%P"V@B\5[RE0+.JC4\6==,5
MFLTH^IXTN0[2'M!L%GI$N^#E:LT^+DD[1IV.AOZJEKI: F\)K>W)0=J\R,NW
MJS( N5XRJ9;-R[V3 =W]PK H&"\)+==/)H=2_ +QI*V2KQ*+<M'E$:0Z>YGS
MRPK)J\63VF0O&0O\R%U0<@5ETRC;+QW_OY6"_V'UD1&=*4'5DFLLBW%S)AC6
MC3F+VN:<SD!=((1:7*SB-V#M_&%AQR XM*1J2:#1;6E$$\=#$&YF1LE458%!
MW"4-[H3J,?'Q ![S$#U]PZ[@/.#!U)^"99M,]V494*C]C+QV<?PG91)6W[Y,
M;BW89V*UM9[E21F&K;,OPYN[[9GX;2>3I-F-RL'4U_5@HN_;-6/> >,N]Q0G
M4X%&5E,HK(;4=<U@* D*?JO%>#5LJC4N:U>-\P=AK2G=AXBU&/8C(L8[@(C"
MRD9Y%(AB!/Q8"S^6G5I:)4DZ?2YFG=J>B%MJZ[$.(2=;4^D1] 2#'4#0[G)-
M143MP@R^BX.62/ LBZ\"#DLNDC1*_"40Q]Z:V:Z/54XI,5:H$"R9]8C%D5]Q
MZU!"=BR-J+Y6X.5A4:[?.N!_@2/NN4Z/+J98S I)O3G+:0>/$M^BWIQYW$>[
MBC75KL'>,M<:!\>"Y?/HQZ3A,9'4"[NVW 5ACN[1!4("=^!@@D7V$?H]=_WE
MS5DX' ,0&;G:@QG42%%O.0VZ-JDN[JX"\:GG.$/N+I@0+E_APYR$7+')SCX(
M56!PP-DM<X@=/#;:9"6_JPI$QVLFA^C\KBH0W8&(*:!J2%9(S-;F+>JM ND&
M77H!/1+![X"I ALCU[8A$H3]N4EZ3GNUR-6=L=NG]SE2WP%3!3;&]_!U95!,
M2U :5N/2P5EV,(4PM,G6*58>O#K,]9E#R_-6 KH*K&T\^!@X=-O.%O16CO3Q
MO2LA/=U;/=(A3I?)?;._<N1W7)]+J-_HKA[QL"=EQ*>[*T>\P1XDM*=[JT<Z
M6GX9\1O]E2-?P_=3$O(W^ZM /FQ#QZ(<;WCFC.([/]/' VDPFP&]6QNX+' 5
M& O>6 Q]#NZH*(H^=\!4@0UML;3=%2V,GPN[JT#\B HLSFF%5&)? 1ME *O
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M1VKFO%)6V02ZMN _*F\5RXW3CG^I_#:R]% -^I]*+U."_5DDFYZUI;JH<8J
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MC1"NL.%D&M"+1@QH[\?M1YM.%2IW7S?%><[*"EBMWH_QB$VSQ;_5FV3E,F>
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M*4<^#:?*073*5CM:4DE]+Y,B[6BGFFZEN("I%"L:CHGVGG'1-<:;.,E6B@-
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MA%1HA2 VOR?_><"?Q;_Y?U!+ P04    " !93X%4!'+/LLM0  ! D00 %0
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MK5\:TPBFE/;').T8I1 %RB73*'2^O/YQ?GNW.+N:H^OEW7R%3M'M_&IV-[]
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M ]<AZV.MN^"9/>%![VUW_/.1/6^D-3]=;%*1Y7UIE"F G68*?JT[V7GCB"8
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M$TI,ZK0LZH2?]O5D9<PS04<4V$!="TN026T/WX;N)ZBU1\=B;A$U)E%MTU,
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M"UM( -#JH]8 ?:\<H]8$^ID;<1TTP8IXBR.\86R[BH/[."%\$UI/(@.KG=0
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M3.Q8AE<+2PT_?R8+NKC -WDLF4GW91@@K_97*MF<O$XR,O.2!6Z > 9N?F6
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MD;^&H%TI# 3\&TS )1(B8I[MWC/+-03T:FD@ZM^B;D@D,B+"/G\BOK\Y<$.
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M'M)]!"?E#.E:;%IR3YJQ;>YZ$U:[W>Q.ENR_?,D+8^%I(7_"65L//?;Z>'J
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M+2%G>S ;O/('KQ6D5 IB7_L:D2$1TS(2-G<0VAA367GPT=(J3L12O[D=,E;
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MTYVSXW1O<C<=C.?=[,C=V/--EQ,U5OP#),?<D:$.!I^PPRD2):K! "6[ Q@
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M-TIW/\6LU]E9%[IJ&S2('=)V[*)MC)VMLX4FYXFL/':<6@,CMIF4(@EW#[3
M&Z0B'G>OSNGP_?"S.B855!D[T*T!RN68F//_0\Y_0!ZY3=!&#1@3DX4\*XT=
M6M8 QP6I&QW4R);3P7))W&1G:V;B;E8:I8GT.Y6)='![.^@MAI\&G>&X-[D;
M9 ;0P;_X2S>#BP6T16FXWWC@4I]FBE(F=+-1[":WQ.,Y5KEI)V5]6N_K*Q\B
M;/@S9V<U;07F]F+317V=DFCE9%>\E U[AI*KW8S7:NF,3**U9;1J^RV1X,!Z
MNRNCRE9IW- 964GKBG@.3.],2P#3FT$39V13-1?NS>S0)3)G$U77^Y\T3K)@
M!V.-J#9P?D980VSL'N6])QX#, R..I0WT?;Y&5:;0]0V%3G<=P)X+U<X(YNI
M3I2W<CXO[#]@83+?EP_D^Z/W8&Y;7,S;.G[+[]DU03+:BG8X:YL/3ZU@ML3%
MR#LZTH?"@"K;02%01<$TCNR+<=EIZ<:O.5E#GJFKEC]GPF0R61+!4NT>[+4Y
M40T[:%(KG98=NV)8MJZ>O3 -DFBMBV.1%+?F9"!1LO(UCTIH2W;Z!Y:I_TXC
M&GO4Y7CJ*-)6M&;G#R,+"(0EM%5/D.5#YO;PV5UQ[9/S:-X2\N6*P;ZJ1'%=
MT"SAO'J;RB][#DT.M2_@&FD<^VJFOFHTB*TEVB+'PL2>9]8*]GU-??[KH&4]
MT75HQ;^6:8-$RRC[XSJZUR?W>(?WLPU%G9$LA'?J1,EZ$3E![&0;4Z#U]H>R
M]78V&'47@WYGVITM?NDL9MWQO-M;#"=CZVRY,L'U!EU]3=1#U\Y#;JO5DFQ<
M/]/D:1AX](5ZJ>,/7ET_Y>D/*RFZN.O(-.2JD] HS^.U\=R_62^X-DR6^V:X
M7_^:OZ8J_KS&L'P.?;?#@ /5WO)!] P ML7&WCI" %/]*?M@AV*?@X8J]Q"G
MH*JENXLX2@K#@_U4'AKL5[]6,1-?5["RDJ(71:NG:')$V[DGJ:<.'*YL=>++
MT1-]7H2#(%%=F8C$TC6"K$)R)O2,Z40[]DY%[%=]&Z;L9! QM>L]4;(<O!(W
MY5OPR7))71))#?*\,K NFH&N#LJ'/!E(V>99'S3@S/AC-9H@K7FKVO&DZ42S
MRRJ3DD58V+13$O?2*!)GC]CN*!1UD.])3K\W+N^VM'BB)C27!)SS3F_FF1Y_
M@"!BO5^$XS A#!#)T3B+M@94Q+X?P5,)*$+2"0'%\,;S&M)D*S)_7(+!00*7
M CTGO_ZJ;'OK3>[NAHN[+*U;=]QG/X\7P_''P;@WM,^54B6^@7.E83.82T!F
ME2YV4&,,DY6WX_A4B[_2)"Z3T!8+4*5_ (N-JHX=S*GU4$=1^U8(8YKR8W1A
MK5$[4$J*GR$Y$DDL\9HL/E?#IHAQ&#C[WQ1MUCIO,..&[*!2J9;E%/VF(K9C
M)<@N/Z=IY#ZQ'5GW,2+9]Y7& 745[$UI31T\2'<'P*2E8/CMZWPP)J2EL9TN
M&B!!@T1+^,](S!TWO?SKV1 &,0&HAYU7I@%.P.@@&LO>RF4%;%N@O2!X?[D@
MN%P0G)GIN?EEZ;Q-SR"F9GPJE\]UA3^?V?Q6Z'E!/U#@52G^00'\N:BB#F5$
MFSI6U(?TC@9TE:Y4H):*H&7<+(-6@50HBR4743+'L9MU\2]J"XI)&^<TO]00
MK^#3; NKNMA445D[6#+7305S=L6H#K/GQD/Y;FD76'A8#CO'K%RQ*D'"(@';
M>IB!VV0*CT/U2>Q&-'OZ6F6FDM5 ODS77S-4[%%JV2U9:K8WNHMP\V3$- J]
M-(N$RZ,LY,, 4!7;M AG#2Y3JX/FCOI\A 9DTQ')2*D6PXZ\,QL?,C$M&12;
MK/ASQW>BO=-*;H)S=1Y!H,K8YE[C@6$ B5TD;JW26P\5K4>7KAYV!%U=ZC1
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M_'\>6#?9;_X74$L! A0#%     @ 6$^!5(/BLTS\'0  #/P   H
M     ( !     &5X,30M,2YH=&U02P$"% ,4    " !83X%4$KYCA78"   &
M#P  "@              @ $D'@  97@R,2TQ+FAT;5!+ 0(4 Q0    ( %A/
M@51'%Z+_]0(  , -   *              "  <(@  !E>#(S+3$N:'1M4$L!
M A0#%     @ 6$^!5!R1&ZWU!P  SD$   H              ( !WR,  &5X
M,S$M,2YH=&U02P$"% ,4    " !83X%4R3\KD@4(   &0@  "@
M    @ '\*P  97@S,2TR+FAT;5!+ 0(4 Q0    ( %A/@50),,SA@@0  # B
M   *              "  2DT  !E>#,R+3$N:'1M4$L! A0#%     @ 6$^!
M5/2!;R66#@   U@   D              ( !TS@  &5X-"TS+FAT;5!+ 0(4
M Q0    ( %A/@51!%@?.+Y0# (]?(@ ,              "  9!'  !F;W)M
M,3 M:RYH=&U02P$"% ,4    " !83X%4_:9Q'#X[  #$4P  $
M    @ 'IVP, 9F]R;3$P+6M?,# Q+FIP9U!+ 0(4 Q0    ( %A/@53:JDD-
M!%L  'AL   0              "  547! !F;W)M,3 M:U\P,#(N:G!G4$L!
M A0#%     @ 6$^!5,PTV:U@5P  [%P  !               ( !AW($ &9O
M<FTQ,"UK7S P,RYJ<&=02P$"% ,4    " !83X%4QQ)YV2YR  !N=P  $
M            @ $5R@0 9F]R;3$P+6M?,# T+FIP9U!+ 0(4 Q0    ( %A/
M@53:/&SBR%,  )%8   0              "  7$\!0!F;W)M,3 M:U\P,#4N
M:G!G4$L! A0#%     @ 64^!5$-8:%8$;P  ]W@  !               ( !
M9Y % &9O<FTQ,"UK7S P-BYJ<&=02P$"% ,4    " !93X%4\<2;FWY(  ![
M2P  $               @ &9_P4 9F]R;3$P+6M?,# W+FIP9U!+ 0(4 Q0
M   ( %E/@50@X0"/>F(  ,1M   0              "  45(!@!F;W)M,3 M
M:U\P,#@N:G!G4$L! A0#%     @ 64^!5#S-B)VM+0  X"\  !
M     ( ![:H& &9O<FTQ,"UK7S P.2YJ<&=02P$"% ,4    " !93X%4$#A\
M 2@D  "Q*   $               @ '(V 8 9F]R;3$P+6M?,#$P+FIP9U!+
M 0(4 Q0    ( %E/@51*Y(>/6C0  ',^   0              "  1[]!@!F
M;W)M,3 M:U\P,3$N:G!G4$L! A0#%     @ 64^!5(#)90S(7   PV0  !
M             ( !IC$' &9O<FTQ,"UK7S Q,BYJ<&=02P$"% ,4    " !9
M3X%4>'K_BIY(   +40  $               @ &<C@< 9F]R;3$P+6M?,#$S
M+FIP9U!+ 0(4 Q0    ( %E/@51F1U6_#4$  ,]'   0              "
M 6C7!P!F;W)M,3 M:U\P,30N:G!G4$L! A0#%     @ 64^!5+SE?9'/10
ME$@  !               ( !HQ@( &9O<FTQ,"UK7S Q-2YJ<&=02P$"% ,4
M    " !93X%449QTKPH]   T0P  $               @ &@7@@ 9F]R;3$P
M+6M?,#$V+FIP9U!+ 0(4 Q0    ( %E/@535WJO&+6H  (QW   0
M      "  =B;" !F;W)M,3 M:U\P,3<N:G!G4$L! A0#%     @ 64^!5/4T
MU_#Q"P  G P  !               ( !,P8) &9O<FTQ,"UK7S Q."YJ<&=0
M2P$"% ,4    " !93X%4X?QFJ_26  #(FP  $               @ %2$@D
M9F]R;3$P+6M?,#$Y+FIP9U!+ 0(4 Q0    ( %E/@52:^AZ),$D  !=,   0
M              "  72I"0!F;W)M,3 M:U\P,C N:G!G4$L! A0#%     @
M64^!5*/1\_V&D   6)8  !               ( !TO() &9O<FTQ,"UK7S R
M,2YJ<&=02P$"% ,4    " !93X%4+T;S[7=+  "14P  $
M@ &&@PH 9F]R;3$P+6M?,#(R+FIP9U!+ 0(4 Q0    ( %E/@51#KPZC"4<
M $5*   0              "  2O/"@!F;W)M,3 M:U\P,C,N:G!G4$L! A0#
M%     @ 64^!5!L_<L.Z#@  E(D  !$              ( !8A8+ &AI;',M
M,C R,3$R,S$N>'-D4$L! A0#%     @ 64^!5'[S8/^[#@  OZH  !4
M         ( !2R4+ &AI;',M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M %E/@51^LZ8NJR(  .0V @ 5              "  3DT"P!H:6QS+3(P,C$Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " !93X%4!'+/LLM0  ! D00 %0
M        @ $75PL :&EL<RTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @
M64^!5(,#-N 1.   5K0# !4              ( !%:@+ &AI;',M,C R,3$R
@,S%?<')E+GAM;%!+!08     )  D )X(  !9X L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
